nct_id,start_date,primary_completion__date,study_type,brief_title,overall_status,phase,sponsor,why_stopped,ctg_links,Abstract,Registry,Total_pubs,vaccine_trial_flag,Number_of_updates,US_site_flag,country,Has_Results,mapped_intervention,ArticleType
NCT04326790,2020-04-03,8/31/2020,Interventional,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,Phase 2,National and Kapodistrian University of Athens,NA,https://clinicaltrials.gov/ct2/show/NCT04326790,2,0,2,0,4,0,Gibraltar,0,colchicine|standard care,Clinical Trial Protocol|Journal Article/Journal Article|Randomized Controlled Trial
NCT04292964,2020-03-01,3/13/2020,Observational,Prognostic Factors of Patients With COVID-19,Completed,NA,Chongqing Medical University,NA,https://clinicaltrials.gov/ct2/show/NCT04292964,2,0,2,0,3,0,China,0,"NA",Journal Article|Observational Study/Journal Article|Multicenter Study|Observational Study
NCT04315948,2020-03-22,3/31/2023,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,"Active, not recruiting",Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicaltrials.gov/ct2/show/NCT04315948,3,0,3,0,7,0,Austria|Belgium|France|Luxembourg|Portugal,0,remdesivir|lopinavir/ritonavir|interferon|hydroxychloroquine|standard care|lopinavir|ritonavir,"Journal Article/Adaptive Clinical Trial|Clinical Trial Protocol|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04323527,2020-03-23,5/7/2020,Interventional,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicaltrials.gov/ct2/show/NCT04323527,1,0,1,0,3,0,Brazil,0,chloroquine,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04279782,2020-01-20,1/31/2021,Observational,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Recruiting,NA,"Third Affiliated Hospital, Sun Yat-Sen University",NA,https://clinicaltrials.gov/ct2/show/NCT04279782,1,0,1,0,1,0,China,0,comprehensive treatment,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04318366,2020-03-19,3/19/2022,Observational,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor",Recruiting,NA,UniversitÃ  Vita-Salute San Raffaele,NA,https://clinicaltrials.gov/ct2/show/NCT04318366,7,0,7,0,3,0,Italy,0,observational,Journal Article/Journal Article/Journal Article|Observational Study/Journal Article/Journal Article/Clinical Trial|Journal Article|Multicenter Study/Journal Article
NCT04355936,2020-05-19,11/2/2020,Interventional,Telmisartan for Treatment of COVID-19 Patients,Completed,Phase 4,Laboratorio Elea Phoenix S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04355936,1,0,1,0,8,0,Argentina,0,telmisartan|standard care,Journal Article
NCT04308668,2020-03-17,5/20/2020,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04308668,4,1,5,0,9,1,United States|Canada,0,hydroxychloroquine|placebo,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04321278,2020-03-28,6/14/2020,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Phase 3,Hospital Israelita Albert Einstein,NA,https://clinicaltrials.gov/ct2/show/NCT04321278,2,0,2,0,6,0,Brazil,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,"Editorial/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04261517,2020-02-06,2/25/2020,Interventional,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Phase 3,Shanghai Public Health Clinical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04261517,1,0,1,0,3,0,China,0,hydroxychloroquine,Journal Article|Randomized Controlled Trial
NCT04276688,2020-02-10,3/30/2020,Interventional,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Phase 2,The University of Hong Kong,NA,https://clinicaltrials.gov/ct2/show/NCT04276688,2,0,2,0,2,0,Hong Kong,0,lopinavir/ritonavir|ribavirin|interferon|lopinavir|ritonavir,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04367831,2020-05-02,11/30/2020,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Phase 4,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04367831,2,0,2,0,2,1,United States,0,enoxaparin|heparin|enoxaparin/lovenox|lovenox,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04372589,2020-05-20,1/31/2021,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Active, not recruiting",Phase 2/Phase 3,University of Manitoba,NA,https://clinicaltrials.gov/ct2/show/NCT04372589,3,0,3,1,4,1,United States|Brazil|Canada|Mexico,0,heparin,"Journal Article/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04366960,2020-05-14,8/31/2021,Interventional,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Phase 3,Niguarda Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04366960,2,0,2,0,3,0,Italy,0,enoxaparin,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04345848,2020-04-28,3/31/2021,Interventional,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Phase 3,"University Hospital, Geneva",NA,https://clinicaltrials.gov/ct2/show/NCT04345848,2,0,2,0,3,0,Switzerland,0,enoxaparin,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04257656,2020-02-06,3/30/2020,Interventional,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Phase 3,Capital Medical University,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be
    enrolled at present.",https://clinicaltrials.gov/ct2/show/NCT04257656,2,0,2,0,3,0,China,0,remdesivir|placebo,Journal Article|Multicenter Study|Randomized Controlled Trial/Clinical Trial Protocol|Journal Article
NCT04329832,2020-03-30,12/18/2020,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,"Intermountain Health Care, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04329832,2,0,2,0,3,1,United States,0,hydroxychloroquine|azithromycin,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article"
NCT04374071,2020-03-12,3/27/2020,Observational,Early Short Course Corticosteroids in COVID-19,Completed,NA,Henry Ford Health System,NA,https://clinicaltrials.gov/ct2/show/NCT04374071,1,0,1,0,0,1,United States,0,methylprednisolone,Journal Article
NCT04280705,2020-02-21,5/21/2020,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04280705,2,0,2,0,24,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04313127,2020-03-16,12/30/2020,Interventional,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"Active, not recruiting",Phase 1,CanSino Biologics Inc.,NA,https://clinicaltrials.gov/ct2/show/NCT04313127,1,0,1,1,4,0,China,0,adenovirus type 5 vector,"Clinical Trial, Phase I|Journal Article"
NCT04292899,2020-03-06,4/9/2020,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Phase 3,Gilead Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04292899,1,0,1,0,20,1,"United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard care,"Clinical Trial, Phase III|Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04321421,2020-03-17,4/28/2020,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,N/A,Foundation IRCCS San Matteo Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04321421,3,0,3,0,2,0,Italy,0,convalescent plasma,"Clinical Trial Protocol|Journal Article|Multicenter Study/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04324736,2020-03-10,4/10/2020,Observational,"""COVID-19 and Diabetes Outcomes""","Active, not recruiting",NA,Nantes University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04324736,3,0,3,0,6,0,France,0,no interventional study,"Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Letter|Comment/Journal Article"
NCT04354701,2020-03-17,12/31/2021,Observational [Patient Registry],COVID-19 and Cancer Consortium Registry,Recruiting,NA,Vanderbilt-Ingram Cancer Center,NA,https://clinicaltrials.gov/ct2/show/NCT04354701,1,0,1,0,4,1,United States,0,web-based redcap survey,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04332991,2020-04-02,6/19/2020,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Phase 3,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04332991,2,0,2,0,6,1,United States,0,hydroxychloroquine|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04330638,2020-04-03,1/31/2021,Interventional,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"Active, not recruiting",Phase 3,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04330638,1,0,1,0,6,0,Belgium,0,standard care|anakinra|siltuximab|tocilizumab,Clinical Trial Protocol|Letter
NCT04343768,2020-04-09,4/27/2020,Interventional,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04343768,1,0,1,0,3,0,"Iran, Islamic Republic of",0,hydroxychloroquine|lopinavir/ritonavir|interferon|lopinavir|ritonavir,Clinical Trial Protocol|Letter
NCT04328961,2020-03-31,9/24/2020,Interventional,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Phase 2/Phase 3,University of Washington,NA,https://clinicaltrials.gov/ct2/show/NCT04328961,2,0,2,0,5,1,United States,0,hydroxychloroquine|vitamin c,Clinical Trial Protocol|Letter/Journal Article
NCT04331171,2020-03-17,11/15/2020,Observational [Patient Registry],Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,Recruiting,NA,Weprom,NA,https://clinicaltrials.gov/ct2/show/NCT04331171,2,0,2,0,3,0,France,0,web application users,Journal Article/Journal Article|Observational Study
NCT04328441,2020-03-25,3/31/2021,Interventional,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Phase 3,UMC Utrecht,NA,https://clinicaltrials.gov/ct2/show/NCT04328441,1,0,1,1,3,0,Netherlands,0,bcg|placebo,Clinical Trial Protocol|Letter
NCT04360980,2020-03-20,9/1/2021,Interventional,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04360980,1,0,1,0,3,0,"Iran, Islamic Republic of",0,colchicine,Clinical Trial Protocol|Letter
NCT04333589,2020-04-01,6/1/2020,Interventional,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,N/A,Peking University First Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04333589,1,0,1,0,2,0,China,0,favipiravir,Clinical Trial Protocol|Letter
NCT04316377,2020-03-25,5/25/2020,Interventional,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Phase 4,"University Hospital, Akershus",NA,https://clinicaltrials.gov/ct2/show/NCT04316377,2,0,2,0,3,0,Norway,0,hydroxychloroquine,"Clinical Trial Protocol|Letter/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04326920,2020-03-24,1/31/2021,Interventional,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"Active, not recruiting",Phase 4,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04326920,2,0,2,0,4,0,Belgium,0,sargramostim|control,"Clinical Trial Protocol|Letter/Journal Article|Research Support, Non-U.S. Gov't|Review"
NCT04306393,2020-03-21,3/21/2021,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04306393,1,0,1,0,7,1,United States,0,nitric oxide,Preprint
NCT04335786,2020-04-17,12/31/2020,Interventional,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Recruiting,Phase 4,Radboud University,NA,https://clinicaltrials.gov/ct2/show/NCT04335786,1,0,1,0,6,0,Netherlands,0,diovan|placebo,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04341493,2020-04-06,8/30/2020,Interventional,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Recruiting,Phase 4,Materno-Perinatal Hospital of the State of Mexico,NA,https://clinicaltrials.gov/ct2/show/NCT04341493,1,0,1,0,2,0,Mexico,0,nitazoxanide|hydroxychloroquine,Clinical Trial Protocol|Letter
NCT04334265,2020-04-01,6/1/2020,Interventional,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04334265,1,0,1,0,1,0,China,0,anluohuaxian,Clinical Trial Protocol|Letter
NCT04359810,2020-04-21,12/31/2020,Interventional,Plasma Therapy of COVID-19 in Severely Ill Patients,Recruiting,Phase 2,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04359810,1,0,1,0,3,1,United States|Brazil,0,convalescent plasma|plasma,Clinical Trial Protocol|Letter
NCT04338958,2020-04-22,7/31/2021,Interventional,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Recruiting,Phase 2,University of Jena,NA,https://clinicaltrials.gov/ct2/show/NCT04338958,1,0,1,0,4,0,Germany,0,ruxolitinib,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04368338,2020-04-28,1/28/2021,Observational,Lung Ultrasound to Diagnose COVID-19,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicaltrials.gov/ct2/show/NCT04368338,1,0,1,0,1,0,France,0,pcr|lung ultrasound,Journal Article|Observational Study
NCT04322396,2020-04-06,10/31/2020,Interventional,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04322396,2,0,2,0,3,0,Denmark,0,azithromycin|hydroxychloroquine|placebo,Clinical Trial Protocol|Letter/Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04352517,2020-03-16,8/31/2020,Observational,Influence Physical Activity Psychological Responses COVID-19 Pandemic,Recruiting,NA,University of Extremadura,NA,https://clinicaltrials.gov/ct2/show/NCT04352517,1,0,1,0,1,0,Brazil|Chile|Uruguay,0,online survey,Journal Article|Multicenter Study|Observational Study
NCT04336254,2020-04-06,12/31/2020,Interventional,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Phase 1/Phase 2,Renmin Hospital of Wuhan University,NA,https://clinicaltrials.gov/ct2/show/NCT04336254,1,0,1,0,0,0,China,0,mesenchymal stem cells|placebo|utooth btc),"Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter"
NCT04369469,2020-05-11,5/31/2021,Interventional,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,"Active, not recruiting",Phase 3,Alexion Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04369469,2,0,2,0,8,1,United States|France|Japan|Spain|United Kingdom,0,ravulizumab|best supportive care,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review/Clinical Trial Protocol|Letter"
NCT04354259,2020-05-13,8/1/2020,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04354259,3,0,3,0,1,0,Canada,0,peginterferon|placebo,"Journal Article|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04343781,2020-03-22,4/5/2020,Observational,National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19,Completed,NA,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04343781,1,0,1,0,2,0,France,0,observation,Journal Article
NCT04355364,2020-04-21,11/21/2020,Interventional,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicaltrials.gov/ct2/show/NCT04355364,1,0,1,0,7,0,France,0,pulmozyme|standard care,Clinical Trial Protocol|Letter|Multicenter Study
NCT04331574,2020-03-10,4/10/2020,Observational [Patient Registry],Renin-Angiotensin System Inhibitors and COVID-19,Recruiting,NA,Societa Italiana dell'Ipertensione Arteriosa,NA,https://clinicaltrials.gov/ct2/show/NCT04331574,2,0,2,0,0,0,Italy,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't/Clinical Trial|Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04365959,2020-03-20,4/9/2020,Observational,The Prone Position in Covid-19 Affected Patients,"Active, not recruiting",NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04365959,1,0,1,0,1,0,Italy,0,prone positioning,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04368156,2020-04-20,7/31/2020,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,N/A,Hospital ClÃ­nico Universitario de Valencia,NA,https://clinicaltrials.gov/ct2/show/NCT04368156,1,0,1,0,0,0,Spain,0,gammacoreâ® (vagus nerve stimulation),Clinical Trial Protocol|Letter
NCT04348513,2020-05-29,5/2/2021,Interventional,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04348513,1,0,1,0,1,0,Greece,0,t3 solution|placebo,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter|Multicenter Study"
NCT04338672,2020-04-05,4/1/2021,Observational,The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients,Recruiting,NA,Sheba Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04338672,1,0,1,0,1,0,Israel,0,covid-19 pandemic,Journal Article|Observational Study
NCT04334291,2020-03-23,5/1/2020,Observational [Patient Registry],"International COVID19 Clinical Evaluation Registry,",Completed,NA,"St Carlos Hospital, Madrid, Spain",NA,https://clinicaltrials.gov/ct2/show/NCT04334291,6,7,13,0,2,0,Spain,0,observational,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article/Journal Article/Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study/Journal Article/Journal Article/Journal Article/Journal Article/Journal Article"
NCT04327531,2020-03-26,5/22/2020,Observational,"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04327531,1,0,1,0,4,0,Turkey,0,turkish physicians,Journal Article
NCT04339608,2020-04-02,5/30/2020,Observational,Max COVID19- Study,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04339608,1,0,1,0,0,0,India,0,"NA",Journal Article
NCT04380818,2020-06-05,5/4/2021,Interventional,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,N/A,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,NA,https://clinicaltrials.gov/ct2/show/NCT04380818,1,0,1,0,2,0,Spain,0,radiotherapy|hydroxychloroquine|lopinavir/ritonavir|tocilizumab|azithromycin|corticosteroid|heparin|oxygen|ritonavir|lopinavir,Journal Article
NCT04410562,2020-05-13,5/13/2021,Interventional,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Recruiting,Phase 3,Barcelona Institute for Global Health,NA,https://clinicaltrials.gov/ct2/show/NCT04410562,1,0,1,0,1,0,Spain,0,hydroxychloroquine|placebo,Clinical Trial Protocol|Letter
NCT04307693,2020-03-11,4/30/2020,Interventional,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Phase 2,Asan Medical Center,Terminated early because no patients were further enrolled since mid-Apr 2020.,https://clinicaltrials.gov/ct2/show/NCT04307693,1,0,1,0,2,0,"Korea, Republic of",0,lopinavir/ritonavir|hydroxychloroquine|lopinavir|ritonavir,Journal Article|Comment
NCT04368676,2020-06-25,6/30/2021,Interventional,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,Recruiting,Early Phase 1,Lawson Health Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04368676,2,0,2,0,1,0,Canada,0,sudarshan kriya yoga (sky)|health enhancement program,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter"
NCT04331106,2020-03-27,4/30/2022,Observational,Survey of the Anxiety Associated With the COVID-19 Pandemic,Recruiting,NA,"Charite University, Berlin, Germany",NA,https://clinicaltrials.gov/ct2/show/NCT04331106,1,0,1,0,4,0,Germany,0,online survey,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04390464,2020-05-08,5/7/2021,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Phase 4,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04390464,1,0,1,0,1,0,United Kingdom,0,ravulizumab|baricitinib|standard care,"Clinical Trial Protocol|Clinical Trial, Phase IV|Letter"
NCT04339816,2020-05-13,11/4/2020,Interventional,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Phase 3,"Charles University, Czech Republic",Steering Committee decision in accordance with stopping rule 1: Emergence of new data,https://clinicaltrials.gov/ct2/show/NCT04339816,1,0,1,0,3,0,Czechia,0,azithromycin|hydroxychloroquine|placebo,Clinical Trial Protocol|Journal Article|Multicenter Study
NCT04264533,2020-02-14,3/2/2020,Interventional,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Phase 2,Zhongnan Hospital,"the study was started in the second half of the outbreak, and the number of qualifying COVID-19
    patients decreased with the control of the epidemic so that we had to stop our trial before
    reaching the predefined sample size.",https://clinicaltrials.gov/ct2/show/NCT04264533,1,0,1,0,2,0,China,0,vitamin c|water,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04321265,2020-03-19,9/30/2021,Observational,Outcomes and Prognostic Factors in COVID-19,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",NA,https://clinicaltrials.gov/ct2/show/NCT04321265,1,0,1,0,4,0,Denmark|France|Germany|Norway,0,"NA",Journal Article|Multicenter Study
NCT04471701,2020-04-13,7/31/2020,Observational,Italian Web-based Cross-sectional Survey on COVID-19,Recruiting,NA,"Institute of Biomedical Technologies-National Research Council, Italy",NA,https://clinicaltrials.gov/ct2/show/NCT04471701,2,0,2,0,1,0,Italy,0,environmental exposure/clinical features|environmental exposure|clinical features,Journal Article/Journal Article
NCT04335123,2020-04-04,6/21/2020,Interventional,Study of Open Label Losartan in COVID-19,Completed,Phase 1,University of Kansas Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04335123,1,0,1,0,3,1,United States,0,losartan,Journal Article
NCT04311177,2020-04-09,4/1/2021,Interventional,Losartan for Patients With COVID-19 Not Requiring Hospitalization,"Active, not recruiting",Phase 2,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04311177,1,0,1,0,9,1,United States,0,losartan|placebo,Journal Article
NCT04312009,2020-04-13,4/1/2021,Interventional,Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,Phase 2,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04312009,1,0,1,0,12,1,United States,0,losartan|placebo,Journal Article
NCT04283461,2020-03-16,11/22/2021,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04283461,2,0,2,1,12,1,United States,0,mrna-1273,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04252274,2020-01-30,8/31/2020,Interventional,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Phase 3,Shanghai Public Health Clinical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04252274,1,0,1,0,2,0,China,0,darunavir/cobicistat|darunavir|cobicistat,Journal Article
NCT04251871,2020-01-22,1/22/2021,Interventional,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,N/A,Beijing 302 Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04251871,2,0,2,0,1,0,China,0,"conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,|lopinavir|ritonavir|traditional chinese medicine",Journal Article|Randomized Controlled Trial/Journal Article
NCT04370067,2020-05-01,5/1/2021,Observational [Patient Registry],HUNgarian COronaVirus Disease-19 Epidemiological Research,Recruiting,NA,Semmelweis University Heart and Vascular Center,NA,https://clinicaltrials.gov/ct2/show/NCT04370067,1,0,1,0,2,0,Hungary,0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04381936,2020-03-19,12/31/2021,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04381936,2,2,4,0,6,0,United Kingdom,0,lopinavir/ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine|baricitinib|anakinra,Journal Article/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04368390,2020-04-03,4/30/2021,Observational,Neuroradiolological Analysis of COVID-19 Patients,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04368390,1,0,1,0,2,0,France,0,"NA",Journal Article|Multicenter Study
NCT04361474,2020-05-18,11/24/2020,Interventional,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,"Active, not recruiting",Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicaltrials.gov/ct2/show/NCT04361474,1,0,1,0,4,0,France,0,budesonide|serum,Clinical Trial Protocol|Letter|Multicenter Study
NCT04279899,2020-02-01,11/30/2020,Observational,The Investigation of the Neonates With or With Risk of COVID-19,Recruiting,NA,Children's Hospital of Fudan University,NA,https://clinicaltrials.gov/ct2/show/NCT04279899,1,0,1,0,0,0,China,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04403607,2020-05-22,9/30/2020,Observational,Cardiac Imaging in SARS-CoV-2 (COVID-19),Recruiting,NA,NHS Greater Glasgow and Clyde,NA,https://clinicaltrials.gov/ct2/show/NCT04403607,1,0,1,0,2,0,United Kingdom,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04324606,2020-04-23,10/31/2021,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04324606,3,0,3,1,12,0,United Kingdom,0,chadox1|menacwy|paracetamol,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04341389,2020-04-12,1/31/2021,Interventional,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Phase 2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://clinicaltrials.gov/ct2/show/NCT04341389,1,0,1,1,3,0,China,0,adenovirus type 5 vector|placebo,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04322123,2020-04-01,8/30/2020,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Phase 3,Hospital do Coracao,NA,https://clinicaltrials.gov/ct2/show/NCT04322123,1,0,1,0,6,0,Brazil,0,hydroxychloroquine|hydroxychloroquine / azithromycin|azithromycin,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04441489,2020-03-27,5/3/2020,Observational,Assessment of Lung Inflammation With FDG PET/CT in COVID-19,Completed,NA,Centre Hospitalier Princesse Grace,NA,https://clinicaltrials.gov/ct2/show/NCT04441489,1,0,1,0,0,0,Monaco,0,"NA",Clinical Trial|Journal Article
NCT04323644,2020-01-01,9/30/2020,Observational,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Recruiting,NA,University of Birmingham,NA,https://clinicaltrials.gov/ct2/show/NCT04323644,1,0,1,0,1,0,Spain,0,surgery,Journal Article
NCT04368975,2020-03-12,4/21/2020,Observational [Patient Registry],ARDS Caused by COVID-19,Recruiting,NA,Hospital Clinic of Barcelona,NA,https://clinicaltrials.gov/ct2/show/NCT04368975,1,0,1,0,0,0,Spain,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04393246,2020-07-03,2/15/2021,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04393246,1,0,1,0,2,0,United Kingdom,0,edp1815|dapagliflozin|ambrisentan|standard care,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Letter"
NCT04363827,2020-05-14,9/30/2020,Interventional,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),Recruiting,Phase 2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,https://clinicaltrials.gov/ct2/show/NCT04363827,1,0,1,0,2,0,Italy,0,hydroxychloroquine,Clinical Trial Protocol|Comparative Study|Journal Article|Observational Study
NCT04433910,2020-08-30,1/21/2021,Interventional,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,"Active, not recruiting",Phase 2,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,NA,https://clinicaltrials.gov/ct2/show/NCT04433910,1,0,1,0,3,0,Germany,0,convalescent plasma,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04416399,2020-07-16,11/15/2020,Interventional,STerOids in COVID-19 Study,Recruiting,Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04416399,1,0,1,0,4,0,United Kingdom,0,budesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04331470,2020-04-04,4/20/2020,Interventional,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Fasa University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04331470,1,0,1,0,2,0,"Iran, Islamic Republic of",0,levamisole / budesonide/formoterol|lopinavir/ritonavir / hydoxychloroquine|levamisole|budesonide|formoterol|lopinavir|ritonavir|hydroxychloroquine,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04377711,2020-06-08,9/1/2020,Interventional,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Recruiting,Phase 3,Covis Pharma S.Ã .r.l.,NA,https://clinicaltrials.gov/ct2/show/NCT04377711,1,0,1,0,2,1,United States,0,ciclesonide|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04330586,2020-04-01,3/31/2021,Interventional,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Recruiting,Phase 2,Korea University Guro Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04330586,1,0,1,0,2,0,"Korea, Republic of",0,ciclesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04355637,2020-04-21,8/31/2021,Interventional,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Recruiting,Phase 4,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicaltrials.gov/ct2/show/NCT04355637,1,0,1,0,4,0,Argentina|Spain,0,budesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04331509,2020-03-23,3/23/2022,Observational,COVID-19 Symptom Tracker,Recruiting,NA,King's College London,NA,https://clinicaltrials.gov/ct2/show/NCT04331509,1,0,1,0,2,1,United States|United Kingdom,0,no intervention,"Journal Article|Observational Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04346186,2020-04-15,10/1/2020,Observational,COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff,Enrolling by invitation,NA,Herlev Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04346186,1,0,1,0,1,0,Denmark,0,igm/igg rapid test|igm|igg antibody test|igg,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04296643,2020-04-01,2/1/2021,Interventional,Medical Masks vs N95 Respirators for COVID-19,Recruiting,N/A,McMaster University,NA,https://clinicaltrials.gov/ct2/show/NCT04296643,1,0,1,0,1,0,Canada|Israel,0,medical mask|n95 respirator,Journal Article
NCT04392245,2020-04-15,4/26/2020,Observational,Proctologic Practice and Covid-19,Completed,NA,Societa Italiana di Chirurgia ColoRettale,NA,https://clinicaltrials.gov/ct2/show/NCT04392245,1,0,1,0,0,0,Italy,0,"NA",Journal Article
NCT04338698,2020-04-22,9/1/2020,Interventional,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Phase 3,University of Health Sciences Lahore,NA,https://clinicaltrials.gov/ct2/show/NCT04338698,1,0,1,0,2,0,Pakistan,0,hydroxychloroquine|oseltamivir|azithromycin,Clinical Trial Protocol|Letter|Multicenter Study|Observational Study|Randomized Controlled Trial
NCT04401202,2020-05-21,12/31/2020,Interventional,Nigella Sativa in COVID-19,Recruiting,Phase 2,King Abdulaziz University,NA,https://clinicaltrials.gov/ct2/show/NCT04401202,1,0,1,0,0,0,Saudi Arabia,0,nigella sativa,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter"
NCT04401540,2020-05-01,10/30/2020,Observational [Patient Registry],Characteristics of Neonatal Covid-19 in Turkey,Recruiting,NA,Recep Tayyip Erdogan University Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04401540,1,3,4,0,2,0,Turkey,0,"NA",Journal Article/Journal Article|Review/Journal Article
NCT04434131,2020-04-28,4/28/2021,Interventional,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Phase 2,University of New Mexico,NA,https://clinicaltrials.gov/ct2/show/NCT04434131,2,0,2,0,0,1,United States,0,convalescent plasma,"Clinical Trial|Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04316949,2020-03-20,4/30/2020,Observational,Predictors of Respiratory Failure in SARS-Cov-2 Infection,Recruiting,NA,University of Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04316949,1,0,1,0,4,0,Italy,0,"NA",Journal Article|Multicenter Study
NCT04368728,2020-04-29,8/3/2021,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","Active, not recruiting",Phase 2/Phase 3,BioNTech SE,NA,https://clinicaltrials.gov/ct2/show/NCT04368728,4,0,4,1,23,1,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,bnt162b1|bnt162b2|placebo,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial/Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article"
NCT04343729,2020-04-18,6/16/2020,Interventional,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Active, not recruiting",Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicaltrials.gov/ct2/show/NCT04343729,1,0,1,0,6,0,Brazil,0,methylprednisolone|placebo,Journal Article
NCT04394000,2020-05-04,5/15/2020,Observational [Patient Registry],Impact of an Intensified Thromboprofylaxis Protocol in COVID-19,Completed,NA,Jessa Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04394000,1,0,1,0,0,0,Belgium,0,thromboprofylaxis protocol|standard care,Journal Article
NCT04385095,2020-03-16,2/1/2021,Interventional,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Synairgen Research Ltd.,NA,https://clinicaltrials.gov/ct2/show/NCT04385095,2,0,2,0,1,0,United Kingdom,0,sng001|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04343976,2020-06-22,4/1/2021,Interventional,Pegylated Interferon Lambda Treatment for COVID-19,Enrolling by invitation,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04343976,1,0,1,0,3,1,United States,0,peginterferon,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04344600,2020-05-29,6/30/2021,Interventional,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicaltrials.gov/ct2/show/NCT04344600,1,0,1,0,3,1,United States,0,peginterferon|saline,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04347993,2020-03-27,4/30/2021,Observational [Patient Registry],"A Prospective ""Universal"" Observational Database for COVID-19",Recruiting,NA,Hackensack Meridian Health,NA,https://clinicaltrials.gov/ct2/show/NCT04347993,2,0,2,0,1,1,United States,0,"NA",Journal Article|Multicenter Study|Observational Study/Journal Article
NCT04345614,2020-04-08,3/31/2021,Interventional,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04345614,1,0,1,0,15,1,United States|Puerto Rico,0,auxora|placebo,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04352556,2020-04-07,4/30/2021,Observational,COVID19-hematological Malignancies: the Italian Hematology Alliance,Recruiting,NA,Ospedale di Circolo - Fondazione Macchi,NA,https://clinicaltrials.gov/ct2/show/NCT04352556,1,0,1,0,1,0,Italy,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04325061,2020-04-03,6/19/2020,Interventional,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Terminated,Phase 4,Dr. Negrin University Hospital,Lack of enrollment,https://clinicaltrials.gov/ct2/show/NCT04325061,1,2,3,0,8,0,Spain,0,dexamethasone,"Clinical Trial Protocol|Journal Article|Multicenter Study/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04375410,2020-04-22,4/30/2020,Observational,Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic,Enrolling by invitation,NA,Vendsyssel Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04375410,1,0,1,0,0,0,Denmark,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04381962,2020-05-29,9/13/2020,Interventional,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Recruiting,Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04381962,1,0,1,0,1,0,United Kingdom,0,azithromycin,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study"
NCT04438629,2020-03-26,6/10/2020,Observational,Evaluation of Immune Response in COVID-19 Patients,Recruiting,NA,Azienda Ospedaliera Universitaria Integrata Verona,NA,https://clinicaltrials.gov/ct2/show/NCT04438629,1,0,1,0,1,0,Italy,0,covid-19 treatment,Clinical Trial|Journal Article|Multicenter Study|Observational Study
NCT04412057,2020-06-09,10/31/2020,Interventional,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Recruiting,Phase 2,Cerecor Inc,NA,https://clinicaltrials.gov/ct2/show/NCT04412057,1,0,1,0,5,1,United States,0,cerc-002|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04292730,2020-03-15,4/29/2020,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Phase 3,Gilead Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04292730,1,1,2,0,20,1,"Japan|United States|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard care,"Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04370288,2020-04-19,9/20/2020,Interventional,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,Phase 1,Mashhad University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04370288,1,0,1,0,1,0,"Iran, Islamic Republic of",0,methylene blue/ vitamin c/n-acetyl cysteine,Case Reports|Journal Article
NCT04262921,2020-02-08,8/7/2020,Observational,French COVID Cohort,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicaltrials.gov/ct2/show/NCT04262921,2,0,2,0,2,0,France,0,"NA","Case Reports|Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04337541,2020-04-02,6/2/2020,Interventional,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,N/A,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04337541,2,0,2,0,1,0,Denmark,0,surgical facial mask,Journal Article|Randomized Controlled Trial/Journal Article
NCT04357730,2020-05-14,9/30/2021,Interventional,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Recruiting,Phase 2,Denver Health and Hospital Authority,NA,https://clinicaltrials.gov/ct2/show/NCT04357730,1,0,1,0,8,1,United States,0,activase,Journal Article
NCT04252885,2020-01-28,4/30/2020,Interventional,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Completed,Phase 4,Guangzhou 8th People's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04252885,1,0,1,0,1,0,China,0,lopinavir/ritonavir|arbidol|lopinavir|ritonavir,Journal Article
NCT04395105,2020-05-21,12/31/2020,Interventional,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicaltrials.gov/ct2/show/NCT04395105,1,0,1,0,3,0,Argentina,0,dexamethasone,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial
NCT04420741,2020-06-15,5/31/2021,Interventional,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04420741,1,0,1,0,5,0,Denmark,0,iloprost|saline,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial
NCT04378595,2020-04-10,12/30/2020,Observational,Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin,Recruiting,NA,University of Texas at Austin,NA,https://clinicaltrials.gov/ct2/show/NCT04378595,1,0,1,0,1,1,United States,0,during covid-19 pandemic|after covid-19 pandemic,Journal Article
NCT04378582,2020-05-07,7/28/2020,Observational,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Completed,NA,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04378582,1,0,1,0,3,0,Brazil,0,risk factors,Journal Article
NCT04327401,2020-04-13,7/22/2020,Interventional,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Phase 3,Hospital Sirio-Libanes,"The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial
    results, which was accepted by the CoDEX Steering Committee.",https://clinicaltrials.gov/ct2/show/NCT04327401,1,0,1,0,5,0,Brazil,0,dexamethasone,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04305574,2020-03-07,4/21/2020,Observational,Social Media Use During COVID-19,Completed,NA,Yale-NUS College,NA,https://clinicaltrials.gov/ct2/show/NCT04305574,1,0,1,0,2,0,Singapore,0,use of social media during covid-19,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04368988,2020-05-25,12/1/2020,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,https://clinicaltrials.gov/ct2/show/NCT04368988,3,0,3,1,5,1,United States|Australia,0,sars-cov-2 rs|sars-cov-2 rs/matrix-m1 adjuvant|placebo|adjuvant|21 - phase 2,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04338841,2020-04-09,6/17/2020,Interventional,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,N/A,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04338841,1,0,1,0,2,0,Belgium|France|Monaco,0,home-cov rule implementation,Journal Article
NCT04445935,2020-06-28,9/28/2020,Interventional,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Phase 4,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04445935,1,0,1,0,0,0,Qatar,0,bivalirudin|standard care,Clinical Trial Protocol|Equivalence Trial|Letter
NCT04436471,2020-06-17,8/3/2020,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04436471,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04437875,2020-06-17,8/3/2020,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04437875,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac lyo,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04333849,2020-03-25,5/11/2020,Observational,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Completed,NA,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04333849,1,0,1,0,2,0,France,0,"NA",Clinical Trial|Journal Article
NCT04347681,2020-04-18,12/31/2020,Interventional,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Phase 2,King Fahad Specialist Hospital Dammam,NA,https://clinicaltrials.gov/ct2/show/NCT04347681,2,0,2,0,3,0,Saudi Arabia,0,convalescent plasma,Journal Article/Journal Article
NCT04400799,2020-06-15,3/14/2021,Interventional,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Phase 3,University of Zurich,NA,https://clinicaltrials.gov/ct2/show/NCT04400799,1,0,1,0,1,0,Switzerland,0,enoxaparin|0.4ml inj syringe 0.4ml,Clinical Trial Protocol|Letter
NCT04357808,2020-04-13,12/31/2020,Interventional,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),"Active, not recruiting",Phase 2,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,NA,https://clinicaltrials.gov/ct2/show/NCT04357808,1,0,1,0,2,0,Spain,0,sarilumab|standard care,Clinical Trial Protocol|Letter
NCT04396197,2020-03-01,5/8/2020,Observational,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care,Completed,NA,University Hospital Birmingham NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04396197,1,0,1,0,0,0,United Kingdom,0,physiotherapy,Journal Article|Observational Study
NCT04399317,2020-05-28,7/31/2020,Interventional,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,N/A,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04399317,1,0,1,0,1,0,Qatar,0,flow controlled ventilation (evone-ventilator),Clinical Trial Protocol|Letter
NCT04327206,2020-03-30,6/30/2021,Interventional,BCG Vaccination to Protect Healthcare Workers Against COVID-19,Recruiting,Phase 3,Murdoch Childrens Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04327206,1,0,1,1,10,0,Australia|Brazil|Netherlands|Spain|United Kingdom,0,bcg|saline,"Journal Article|Research Support, Non-U.S. Gov't|Review"
NCT04352959,2020-04-27,12/11/2020,Interventional,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Completed,N/A,Claude Bernard University,NA,https://clinicaltrials.gov/ct2/show/NCT04352959,2,0,2,0,3,0,France,0,mouthrinse with bãªta-cyclodextrin/citrox|mouthrinse without bãªta-cyclodextrin/citrox|mouthrinse with bãªta-cyclodextrin|citrox|mouthrinse without bãªta-cyclodextrin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Letter"
NCT04364802,2020-04-29,5/31/2021,Interventional,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Phase 2,University of Kentucky,NA,https://clinicaltrials.gov/ct2/show/NCT04364802,1,0,1,0,2,1,United States,0,povidone/iodine|gargle,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04373291,2020-05-18,7/31/2021,Interventional,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,"Active, not recruiting",Phase 3,Bandim Health Project,NA,https://clinicaltrials.gov/ct2/show/NCT04373291,1,0,1,1,4,0,Denmark,0,bcg-denmark|saline,Clinical Trial Protocol|Letter
NCT04367129,2020-04-14,12/1/2020,Observational,Electrocardiogram Analysis in COVID-19 Patients,Recruiting,NA,University Hospital of Ferrara,NA,https://clinicaltrials.gov/ct2/show/NCT04367129,1,0,1,0,0,0,Italy,0,ecg,Journal Article|Multicenter Study
NCT04439084,2020-03-06,6/30/2021,Observational,COVID-19 in Patients With Chronic Liver Diseases,Enrolling by invitation,NA,Stanford University,NA,https://clinicaltrials.gov/ct2/show/NCT04439084,1,0,1,0,1,1,United States,0,prospective chart review,Journal Article
NCT04343261,2020-04-10,7/23/2020,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma,"Journal Article/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial, Phase II|Journal Article/Journal Article"
NCT04335162,2020-02-28,8/31/2021,Observational,Cardiovascular Complications and COVID-19 (CovCardioVasc-Study),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicaltrials.gov/ct2/show/NCT04335162,1,0,1,0,4,0,France,0,"NA",Journal Article
NCT04321928,2020-04-01,4/21/2021,Interventional,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,N/A,University of Pecs,NA,https://clinicaltrials.gov/ct2/show/NCT04321928,1,0,1,0,2,0,Hungary,0,personalized health education|general health education,Clinical Trial Protocol|Journal Article
NCT04394416,2020-06-02,6/1/2022,Interventional,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 3,"University of Maryland, Baltimore",NA,https://clinicaltrials.gov/ct2/show/NCT04394416,2,0,2,0,1,1,United States,0,imatinib|placebo,"Letter|Research Support, N.I.H., Extramural/Clinical Trial Protocol|Letter"
NCT04329923,2020-04-09,11/11/2020,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Phase 2,University of Pennsylvania,"Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met
    pre-specificied futility analysis at planned second interim analysis",https://clinicaltrials.gov/ct2/show/NCT04329923,1,1,2,0,7,1,United States,1,hydroxychloroquine|placebo,Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04377815,2020-04-23,5/14/2020,Observational,Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,Completed,NA,"University College, London",NA,https://clinicaltrials.gov/ct2/show/NCT04377815,1,0,1,0,1,0,United Kingdom,0,general public cohort,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04352764,2020-03-27,12/31/2020,Observational [Patient Registry],ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,Recruiting,NA,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicaltrials.gov/ct2/show/NCT04352764,1,0,1,0,2,1,United States,0,igm/igg rapid test|igg antibody test|igm,Journal Article
NCT04333420,2020-03-31,5/31/2021,Interventional,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,InflaRx GmbH,NA,https://clinicaltrials.gov/ct2/show/NCT04333420,1,0,1,0,5,0,Germany|Netherlands,0,soc / ifx-1|soc / placebo|standard care|ifx-1|placebo,Journal Article
NCT04384926,2020-03-30,12/31/2020,Observational,Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,Recruiting,NA,University of Birmingham,NA,https://clinicaltrials.gov/ct2/show/NCT04384926,1,0,1,0,0,0,Spain,0,elective cancer surgery,"Comparative Study|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04358029,2020-04-09,5/31/2021,Observational,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),Recruiting,NA,Icahn School of Medicine at Mount Sinai,NA,https://clinicaltrials.gov/ct2/show/NCT04358029,1,0,1,0,1,1,United States,0,"NA",Comparative Study|Journal Article
NCT04323839,2020-03-20,3/31/2024,Observational [Patient Registry],COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),Enrolling by invitation,NA,"University of California, San Francisco",NA,https://clinicaltrials.gov/ct2/show/NCT04323839,1,0,1,0,4,1,United States,0,pregnant women under investigation for coronavirus/diagnosed with covid-19|postpartum women under investigation for coronavirus/diagnosed with covid-19|pregnant women under investigation for coronavirus|diagnosed with covid-19|postpartum,"Journal Article|Observational Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04317092,2020-03-19,12/19/2020,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",NA,https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,0,3,0,Italy,0,tocilizumab,"Clinical Trial Protocol|Journal Article/Journal Article/Clinical Trial, Phase II|Journal Article|Multicenter Study"
NCT04307459,2020-03-19,9/1/2020,Observational,Acute Respiratory Failure and COVID-19 in Real Life,Recruiting,NA,University of Milan,NA,https://clinicaltrials.gov/ct2/show/NCT04307459,1,0,1,0,3,0,Italy,0,SOP,Journal Article|Multicenter Study|Observational Study
NCT04342182,2020-04-08,7/1/2021,Interventional,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Phase 2/Phase 3,Erasmus Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04342182,1,0,1,0,11,0,Netherlands,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04357106,2020-04-13,7/31/2020,Interventional,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Phase 2,Centro de HematologÃ­a y Medicina Interna,NA,https://clinicaltrials.gov/ct2/show/NCT04357106,1,0,1,0,0,0,Mexico,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04441424,2020-04-03,6/1/2020,Interventional,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,N/A,Alkarkh Health Directorate-Baghdad,NA,https://clinicaltrials.gov/ct2/show/NCT04441424,1,0,1,0,1,0,Iraq,0,convalescent plasma|hydroxychloroquine / azithromycin,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04340050,2020-04-10,12/23/2020,Interventional,COVID-19 Convalescent Plasma,Completed,Early Phase 1,University of Chicago,NA,https://clinicaltrials.gov/ct2/show/NCT04340050,1,0,1,0,4,1,United States,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04507282,2020-05-15,7/1/2020,Observational,Eosinophil and Anticoagulation in COVID-19 Patients,Completed,NA,Bursa Postgraduate Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04507282,1,0,1,0,1,0,Turkey,0,lmwh,Journal Article
NCT04555096,2020-09-09,11/30/2021,Interventional,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Recruiting,Phase 2,"Galera Therapeutics, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04555096,1,0,1,0,3,1,United States,0,gc4419|placebo,Journal Article
NCT04356495,2020-07-29,8/15/2021,Interventional,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Phase 2/Phase 3,"University Hospital, Bordeaux",NA,https://clinicaltrials.gov/ct2/show/NCT04356495,1,0,1,0,6,0,France,0,vitamins|telmisartan|ciclesonide|interferon î²-1b,"Clinical Trial, Phase III|Letter|Randomized Controlled Trial"
NCT04445467,2020-08-01,11/30/2020,Interventional,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,Recruiting,Phase 2,Bayside Health,NA,https://clinicaltrials.gov/ct2/show/NCT04445467,1,0,1,0,1,0,Australia,0,favipiravir,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04314232,2020-03-18,12/31/2021,Observational,Mechanisms for Covid-19 Disease Complications,Recruiting,NA,"University Hospital, Akershus",NA,https://clinicaltrials.gov/ct2/show/NCT04314232,1,0,1,0,1,0,Norway,0,"NA",Journal Article
NCT04448717,2020-06-16,3/31/2021,Observational,Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children,Recruiting,NA,University of Zurich,NA,https://clinicaltrials.gov/ct2/show/NCT04448717,1,0,1,0,1,0,Switzerland,0,covid-19 antibody testing,Journal Article
NCT04343963,2020-04-04,9/30/2020,Interventional,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04343963,1,0,1,0,2,0,Mexico,0,pyridostigmine bromide|placebo,Clinical Trial Protocol|Journal Article
NCT04423770,2020-06-08,6/8/2021,Observational,COVID-19 Related Health and Infection Control Practices Among Dentists,"Active, not recruiting",NA,American Dental Association,NA,https://clinicaltrials.gov/ct2/show/NCT04423770,1,0,1,0,3,1,United States,0,no intervention,Journal Article
NCT04323592,2020-03-23,5/10/2020,Observational [Patient Registry],Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Completed,NA,University of Trieste,NA,https://clinicaltrials.gov/ct2/show/NCT04323592,1,0,1,0,6,0,Italy,1,methylprednisolone|standard care,Journal Article
NCT04411459,2020-02-01,6/30/2020,Observational,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,Azienda Usl di Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04411459,2,3,5,0,2,0,Italy,0,invasive mechanical ventilation,"Journal Article/Journal Article/Journal Article|Multicenter Study|Research Support, N.I.H., Extramural/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, N.I.H., Extramural"
NCT04346355,2020-03-31,6/6/2020,Interventional,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Phase 2,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,Based on interim analysis for futility and given an enrolment rate almost nil,https://clinicaltrials.gov/ct2/show/NCT04346355,1,0,1,0,2,0,Italy,0,tocilizumab,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04331808,2020-03-30,3/31/2021,Interventional,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicaltrials.gov/ct2/show/NCT04331808,1,0,1,0,2,0,France,0,tocilizumab,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04436276,2020-07-15,12/3/2021,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),Recruiting,Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,NA,https://clinicaltrials.gov/ct2/show/NCT04436276,2,0,2,0,7,1,United States|Belgium,0,ad26.cov2.s|placebo,Journal Article/Journal Article
NCT04356937,2020-04-20,7/13/2020,Interventional,Efficacy of Tocilizumab on Patients With COVID-19,Completed,Phase 3,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04356937,1,0,1,0,4,1,United States,0,tocilizumab|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04416100,2020-04-29,4/28/2022,Observational,Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Medical University Innsbruck,NA,https://clinicaltrials.gov/ct2/show/NCT04416100,1,0,1,0,1,0,Austria,0,pulmonary function tests|imaging|blood sample,Journal Article|Multicenter Study|Observational Study
NCT04282135,2020-02-15,5/8/2020,Observational,Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling,Completed,NA,Klinikum Bayreuth GmbH,NA,https://clinicaltrials.gov/ct2/show/NCT04282135,1,0,1,0,1,0,Germany,0,mcc ims,Evaluation Study|Journal Article
NCT04374526,2020-05-27,4/30/2021,Interventional,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Recruiting,Phase 2/Phase 3,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicaltrials.gov/ct2/show/NCT04374526,1,0,1,0,2,0,Italy,0,convalescent plasma,"Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Letter|Randomized Controlled Trial"
NCT04290780,2020-03-09,12/31/2021,Observational,COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicaltrials.gov/ct2/show/NCT04290780,1,0,1,0,6,0,France,0,nosocomial|hospital acquired infection,Journal Article|Multicenter Study|Observational Study
NCT04403477,2020-05-20,7/20/2020,Interventional,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://clinicaltrials.gov/ct2/show/NCT04403477,1,0,1,0,0,0,Bangladesh,0,convalescent plasma,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04389840,2020-06-03,2/28/2021,Interventional,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,Phase 2/Phase 3,Chimerix,NA,https://clinicaltrials.gov/ct2/show/NCT04389840,1,0,1,0,10,1,United States,0,dociparstat sodium|placebo,Journal Article
NCT04344197,2020-04-02,4/8/2020,Observational,"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",Completed,NA,University of Rome Tor Vergata,NA,https://clinicaltrials.gov/ct2/show/NCT04344197,1,0,1,0,1,0,Italy,0,global survey,Journal Article
NCT04328493,2020-04-07,4/1/2021,Interventional,The Vietnam Chloroquine Treatment on COVID-19,Recruiting,Phase 2,"Oxford University Clinical Research Unit, Vietnam",NA,https://clinicaltrials.gov/ct2/show/NCT04328493,1,0,1,0,3,0,Vietnam,0,chloroquine,Journal Article
NCT04427501,2019-11-17,9/20/2020,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2/Phase 3,Eli Lilly and Company,NA,https://clinicaltrials.gov/ct2/show/NCT04427501,2,0,2,0,31,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04407156,2020-06-01,6/7/2020,Observational,Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom,Completed,NA,University Hospitals of Derby and Burton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04407156,1,0,1,0,2,0,United Kingdom,0,acute kidney injury,Journal Article
NCT04392973,2020-05-21,11/30/2021,Interventional,FAvipiravir and HydroxyChloroquine Combination Therapy,Recruiting,N/A,King Abdullah International Medical Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04392973,1,0,1,0,2,0,Saudi Arabia,0,favipiravir/hydroxychloroquine|favipiravir|hydroxychloroquine,Clinical Trial Protocol|Letter
NCT04521309,2020-06-19,1/31/2021,Interventional,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Recruiting,Phase 1,Dow University of Health Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04521309,2,0,2,0,2,0,Pakistan,0,sars-cov-2 antibody based ivig therapy,"Clinical Trial Protocol|Letter/Journal Article|Research Support, Non-U.S. Gov't"
NCT04336345,2020-04-01,4/30/2020,Observational [Patient Registry],Outcomes of Patients With COVID-19 in the Intensive Care Unit,Completed,NA,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04336345,1,0,1,0,6,0,Mexico,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04492475,2020-08-04,12/15/2020,Interventional,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"Active, not recruiting",Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04492475,1,0,1,0,28,1,"United States|Japan|Korea, Republic of|Mexico|Singapore",0,interferon|placebo|remdesivir,Journal Article|Review
NCT04401579,2020-05-08,7/31/2020,Interventional,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04401579,2,0,2,0,13,1,"United States|Denmark|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",0,placebo|remdesivir|baricitinib,Journal Article|Review/Journal Article
NCT04349202,2020-04-10,6/30/2021,Observational,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Recruiting,NA,William Beaumont Hospitals,NA,https://clinicaltrials.gov/ct2/show/NCT04349202,1,0,1,0,2,1,United States,0,euroimmun assay,Journal Article
NCT04557605,2020-09-14,10/15/2020,Interventional,Effects of a Face Mask on Oxygenation During Exercise,Completed,N/A,University of Saskatchewan,NA,https://clinicaltrials.gov/ct2/show/NCT04557605,1,0,1,0,1,0,Canada,0,progressive cycling exercise test to exhaustion,Journal Article|Randomized Controlled Trial
NCT04351152,2020-05-05,3/31/2021,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,Recruiting,Phase 3,"Humanigen, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04351152,1,0,1,0,10,1,United States|Brazil,0,lenzilumab|standard care,"Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04428099,2020-01-13,1/12/2022,Interventional,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,N/A,University of the Balearic Islands,NA,https://clinicaltrials.gov/ct2/show/NCT04428099,1,0,1,0,0,0,Spain,0,lifestyle change promotion program|mindfulness|information,Clinical Trial Protocol|Journal Article
NCT04412538,2020-05-15,9/30/2020,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04412538,1,0,1,1,1,0,China,0,inactivated sars-cov-2 vaccine|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-/14-day schedule|placebo|28-day schedule|14-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-,Journal Article
NCT04346342,2020-03-06,9/1/2020,Observational,PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID),Completed,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicaltrials.gov/ct2/show/NCT04346342,2,0,2,0,3,0,Netherlands,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04486404,2020-04-01,6/30/2020,Observational,"Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America",Enrolling by invitation,NA,Universidad Miguel Hernandez de Elche,NA,https://clinicaltrials.gov/ct2/show/NCT04486404,1,0,1,0,3,0,Argentina|Chile|Colombia|Ecuador|Spain,0,online survey,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04366882,2020-04-14,12/31/2020,Interventional,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,N/A,Jessa Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04366882,1,0,1,0,0,0,Belgium,0,ct-scan,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04487990,2020-06-29,12/31/2020,Interventional,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04487990,1,0,1,0,0,0,Brazil,0,heparin,Clinical Trial Protocol|Letter
NCT04395144,2020-05-15,3/30/2021,Interventional,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Recruiting,N/A,HÃ´pital de Verdun,NA,https://clinicaltrials.gov/ct2/show/NCT04395144,1,0,1,0,2,0,Canada,0,prone positioning|standard care,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04391140,2020-05-13,12/31/2020,Interventional,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,N/A,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04391140,1,0,1,0,2,0,Spain,0,prone positioning,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04347941,2020-07-11,6/11/2021,Interventional,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,N/A,University College Hospital Galway,NA,https://clinicaltrials.gov/ct2/show/NCT04347941,1,0,1,0,1,0,Ireland,0,prone positioning|standard care,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04358939,2020-04-27,11/10/2021,Interventional,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Recruiting,N/A,"University Hospital, Tours",NA,https://clinicaltrials.gov/ct2/show/NCT04358939,1,0,1,0,7,0,France,0,prone positioning,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04386395,2020-03-30,5/1/2020,Observational,Immune Changes in Severe COVID-19 Pulmonary Infections,"Active, not recruiting",NA,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04386395,1,0,1,0,0,0,France,0,"NA",Clinical Trial|Journal Article
NCT04342663,2020-04-10,8/20/2020,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,Phase 2,Washington University School of Medicine,NA,https://clinicaltrials.gov/ct2/show/NCT04342663,2,0,2,0,5,1,United States,0,fluvoxamine|placebo,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04412655,2020-05-05,5/30/2020,Observational,Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry,"Active, not recruiting",NA,"UniversitÃ  degli Studi del Piemonte Orientale ""Amedeo Avogadro""",NA,https://clinicaltrials.gov/ct2/show/NCT04412655,2,0,2,0,1,0,Italy,0,percutaneous coronary revascularization for stemi,"Journal Article|Multicenter Study/Comparative Study|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04364022,2020-04-23,3/31/2021,Interventional,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Recruiting,Phase 3,"University Hospital, Geneva",NA,https://clinicaltrials.gov/ct2/show/NCT04364022,1,0,1,0,1,0,Switzerland,0,lopinavir/ritonavir|lopinavir|ritonavir,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04435041,2020-06-01,5/31/2021,Observational [Patient Registry],Remote-by-Default Care in the COVID-19 Pandemic,"Active, not recruiting",NA,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04435041,2,0,2,0,0,0,United Kingdom,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04459247,2020-06-15,8/30/2020,Interventional,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Active, not recruiting",N/A,Postgraduate Institute of Medical Education and Research,NA,https://clinicaltrials.gov/ct2/show/NCT04459247,1,0,1,0,1,0,India,0,vitamin d,Journal Article
NCT04435184,2020-07-09,11/28/2020,Interventional,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,Phase 2,Johns Hopkins University,NA,https://clinicaltrials.gov/ct2/show/NCT04435184,1,0,1,0,5,1,United States,0,crizanlizumab|saline,"Comparative Study|Journal Article|Research Support, N.I.H., Extramural"
NCT04374149,2020-04-30,9/25/2020,Interventional,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Active, not recruiting",Phase 2,Prisma Health-Upstate,NA,https://clinicaltrials.gov/ct2/show/NCT04374149,1,0,1,0,1,1,United States,0,therapeutic plasma exchange (tpe)|ruxolitinib,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04487964,2020-01-01,12/1/2020,Interventional,Complementary Intervention for COVID-19,Recruiting,N/A,Egyptian Biomedical Research Network,NA,https://clinicaltrials.gov/ct2/show/NCT04487964,1,0,1,0,1,0,Egypt,0,licorice extract,Journal Article
NCT04468893,2020-05-20,12/31/2020,Interventional,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,https://clinicaltrials.gov/ct2/show/NCT04468893,1,5,6,0,1,0,Mexico,0,online intervention mental health covid-19,Journal Article/Journal Article
NCT04455360,2020-10-01,3/31/2021,Interventional,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04455360,1,0,1,0,1,0,United Kingdom,0,eye movement desensitisation/reprocessing recent traumatic event protocol|eye movement desensitisation|reprocessing recent traumatic event protocol,Clinical Trial Protocol|Letter
NCT04328467,2020-04-06,8/31/2020,Interventional,Pre-exposure Prophylaxis for SARS-Coronavirus-2,"Active, not recruiting",Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04328467,1,0,1,0,5,1,United States,0,hydroxychloroquine|placebo,Journal Article
NCT04341922,2020-05-09,8/20/2020,Interventional,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",N/A,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04341922,1,0,1,0,5,0,Sweden,0,internet-delivered cognitive behavior therapy (icbt) for dysfunctional worry related to the covid-19 pandemic,Journal Article
NCT04382755,2020-05-22,2/28/2021,Interventional,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"Active, not recruiting",Phase 2,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04382755,1,0,1,0,2,0,Belgium,0,placebo|zilucoplanâ®,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04352608,2020-04-16,7/10/2020,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicaltrials.gov/ct2/show/NCT04352608,1,0,1,1,3,0,China,0,placebo|inactivated sars-cov-2 vaccine,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04400838,2020-05-28,9/30/2021,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04400838,3,0,3,1,9,0,United Kingdom,0,chadox1|menacwy|menacwy vaccine|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04406090,2020-04-01,6/30/2020,Observational,Endovascular Thrombectomy in COVID-19 Infected Patients,Completed,NA,"University Hospital, Montpellier",NA,https://clinicaltrials.gov/ct2/show/NCT04406090,1,0,1,0,1,0,France,0,mechanical trombectomy,Journal Article|Multicenter Study
NCT04412304,2020-03-06,4/30/2020,Observational,Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients,Completed,NA,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04412304,1,0,1,0,2,0,Sweden,0,tinzaparin/dalteparin|tinzaparin|dalteparin,Journal Article
NCT04449380,2020-11-02,4/30/2021,Interventional,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,Recruiting,Phase 2,IRCCS San Raffaele,NA,https://clinicaltrials.gov/ct2/show/NCT04449380,1,0,1,0,4,0,Italy,0,interferon-ãÿ-1a|standard care,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial"
NCT04495816,2020-07-15,4/30/2021,Interventional,COVID-19 Anosmia Study,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,NA,https://clinicaltrials.gov/ct2/show/NCT04495816,1,0,1,0,2,1,United States,0,omega-3|placebo/control|placebo|control,Letter|Randomized Controlled Trial
NCT04477655,2020-05-03,11/30/2020,Interventional,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Recruiting,N/A,Hospital Civil de Guadalajara,NA,https://clinicaltrials.gov/ct2/show/NCT04477655,1,0,1,0,2,0,Mexico,0,prone positioning|oxygen,Letter|Randomized Controlled Trial
NCT04438070,2020-04-10,6/30/2020,Interventional,COVID Screening Strategies in Homeless Shelters,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicaltrials.gov/ct2/show/NCT04438070,1,0,1,0,0,0,Canada,0,covid-19 swab,Comparative Study|Letter|Randomized Controlled Trial
NCT04357535,2020-05-10,7/1/2020,Observational,Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,Completed,NA,King Faisal Specialist Hospital & Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04357535,1,0,1,0,8,0,Saudi Arabia,0,angiotensin-converting enzyme inhibitors (ace-i)/angiotensin ii receptor blockers (arb)|ace inhibitor|arb blocker,Journal Article
NCT04383535,2020-05-15,9/27/2020,Interventional,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,N/A,Hospital Italiano de Buenos Aires,NA,https://clinicaltrials.gov/ct2/show/NCT04383535,1,1,2,0,4,0,Argentina,0,convalescent plasma|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04529525,2020-08-19,12/31/2020,Interventional,Ivermectin to Prevent Hospitalizations in COVID-19,Recruiting,Phase 2/Phase 3,Instituto de CardiologÃ­a de Corrientes,NA,https://clinicaltrials.gov/ct2/show/NCT04529525,1,11,12,0,3,0,Argentina,0,ivermectin|placebo,Letter|Randomized Controlled Trial
NCT04341142,2020-04-09,4/9/2023,Interventional,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicaltrials.gov/ct2/show/NCT04341142,1,0,1,0,5,0,France,0,serology test,Clinical Study|Journal Article|Multicenter Study
NCT04380987,2020-05-04,7/31/2021,Observational,Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis,Recruiting,NA,Luxembourg Institute of Health,NA,https://clinicaltrials.gov/ct2/show/NCT04380987,1,0,1,0,0,0,Luxembourg,0,biological samples,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04344119,2020-04-09,4/30/2021,Observational,Assessment of Chilbains Occuring During Covid-19 Infection,Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicaltrials.gov/ct2/show/NCT04344119,1,0,1,0,2,0,France,0,"NA",Journal Article
NCT04430608,2020-05-25,4/25/2021,Interventional,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,N/A,Nordsjaellands Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04430608,1,0,1,0,0,0,Denmark,0,dexcom,Letter|Randomized Controlled Trial
NCT04244591,2020-01-26,4/13/2020,Interventional,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Phase 2/Phase 3,Peking Union Medical College Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04244591,1,0,1,0,6,0,China,0,methylprednisolone|standard care,Journal Article|Review
NCT04348695,2020-04-12,5/13/2020,Interventional,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,https://clinicaltrials.gov/ct2/show/NCT04348695,1,0,1,0,1,0,Spain,0,ruxolitinib|standard care|simvastatin,Journal Article|Review
NCT04321174,2020-04-17,3/31/2021,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04321174,2,0,2,0,1,0,Canada,0,lopinavir/ritonavir|lopinavir|ritonavir,Journal Article|Review/Journal Article
NCT04359329,2020-04-20,11/15/2020,Interventional,Estrogen Patch for COVID-19 Symptoms,Recruiting,Phase 2,Stony Brook University,NA,https://clinicaltrials.gov/ct2/show/NCT04359329,1,0,1,0,0,1,United States,0,estradiol,Journal Article|Review
NCT04304313,2020-02-09,3/1/2020,Interventional,A Pilot Study of Sildenafil in COVID-19,Recruiting,Phase 3,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04304313,1,0,1,0,1,0,China,0,sildenafil citrate,Journal Article|Review
NCT04429854,2020-05-02,11/2/2021,Interventional,Donated Antibodies Working Against nCoV,Recruiting,Phase 2,Universitaire Ziekenhuizen Leuven,NA,https://clinicaltrials.gov/ct2/show/NCT04429854,1,0,1,0,0,0,Belgium,0,convalescent plasma|standard care,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial"
NCT04447534,2020-06-23,10/1/2030,Interventional,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Phase 3,Tanta University,NA,https://clinicaltrials.gov/ct2/show/NCT04447534,1,0,1,0,3,0,Egypt,0,chloroquine|zinc,Journal Article
NCT04444661,2020-06-10,11/11/2020,Observational,Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise,"Active, not recruiting",NA,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicaltrials.gov/ct2/show/NCT04444661,1,0,1,0,3,0,Germany,0,"NA",Journal Article
NCT04349592,2020-04-14,8/14/2020,Interventional,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Recruiting,N/A,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04349592,1,0,1,0,1,0,Qatar,0,hydroxychloroquine|azithromycin|placebo,Journal Article
NCT04386083,2020-06-10,12/31/2020,Observational,Neurologic Manifestations of COVID-19,Recruiting,NA,University of the Philippines,NA,https://clinicaltrials.gov/ct2/show/NCT04386083,1,0,1,0,1,0,Philippines,0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04361877,2020-03-30,4/20/2020,Observational,Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial),Recruiting,NA,Klinikum der Universitaet Muenchen,NA,https://clinicaltrials.gov/ct2/show/NCT04361877,1,0,1,0,1,0,Germany,0,"NA",Journal Article
NCT04445324,2020-08-25,8/25/2020,Interventional,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting",N/A,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,NA,https://clinicaltrials.gov/ct2/show/NCT04445324,1,0,1,0,4,0,Canada,0,"online support group|control|or psychotherapy, n=10)",Journal Article
NCT04405726,2020-03-27,3/31/2022,Observational,Prognostic Factors of COVID19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04405726,1,0,1,0,2,0,France,0,"NA",Journal Article
NCT04402970,2020-06-19,12/31/2020,Interventional,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Completed,Phase 3,University of Missouri-Columbia,NA,https://clinicaltrials.gov/ct2/show/NCT04402970,1,0,1,0,3,1,United States,0,dornase alfa,Journal Article
NCT04402944,2020-07-05,5/31/2021,Interventional,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Phase 2,Boston Children's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04402944,1,0,1,0,2,1,United States,0,pulmozyme|placebo,Journal Article
NCT04541979,2020-06-04,11/1/2020,Interventional,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Phase 2,Region Skane,NA,https://clinicaltrials.gov/ct2/show/NCT04541979,1,0,1,0,0,0,Sweden,0,aerosolized dnase|sodium,Journal Article
NCT04432987,2020-05-25,8/25/2020,Interventional,Dornase Alpha for the Treatment of COVID-19,Recruiting,Phase 2,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04432987,1,0,1,0,0,0,Turkey,0,pulmozyme,Journal Article
NCT04445285,2020-04-28,11/30/2020,Interventional,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,University of South Alabama,NA,https://clinicaltrials.gov/ct2/show/NCT04445285,1,0,1,0,2,1,United States,0,pulmozyme/ recombinant human deoxyribonuclease (rh-dnase)|saline|pulmozyme|rh-dnase,Journal Article
NCT04343053,2020-04-08,6/9/2020,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",N/A,University Hospital of Ferrara,NA,https://clinicaltrials.gov/ct2/show/NCT04343053,1,0,1,0,2,0,Italy,0,sars-cov-2 infection,Journal Article
NCT04395807,2020-06-03,12/31/2020,Interventional,Helmet CPAP Versus HFNC in COVID-19,Recruiting,N/A,Lund University,NA,https://clinicaltrials.gov/ct2/show/NCT04395807,1,0,1,0,1,0,Sweden,0,cpap|oxygen,Comparative Study|Journal Article|Randomized Controlled Trial
NCT04405570,2020-06-16,1/30/2021,Interventional,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","Active, not recruiting",Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://clinicaltrials.gov/ct2/show/NCT04405570,1,0,1,0,16,1,United States,0,eidd-2801|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04405739,2020-06-16,2/12/2021,Interventional,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://clinicaltrials.gov/ct2/show/NCT04405739,1,0,1,0,14,1,United States,0,eidd-2801|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04645563,2020-03-11,5/30/2020,Observational,Using Whatsapp for the Consultation,Completed,NA,Kafkas University,NA,https://clinicaltrials.gov/ct2/show/NCT04645563,1,0,1,0,0,0,Turkey,0,sending thorax ct video images via smartphone applications,Journal Article
NCT04558476,2020-09-01,9/1/2022,Interventional,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Phase 2,University of Liege,NA,https://clinicaltrials.gov/ct2/show/NCT04558476,1,0,1,0,0,0,Belgium,0,convalescent plasma|standard care,Clinical Trial Protocol|Journal Article
NCT04304053,2020-03-18,6/15/2020,Interventional,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Phase 3,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicaltrials.gov/ct2/show/NCT04304053,2,0,2,0,9,0,Spain,0,treatment/prophylaxis|standard care|treatment|prophylaxis,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article"
NCT04476667,2020-06-15,5/31/2021,Interventional,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,N/A,Queen's University,NA,https://clinicaltrials.gov/ct2/show/NCT04476667,1,0,1,0,0,0,Canada,0,psychotherapy,Journal Article
NCT04510623,2020-03-17,6/30/2021,Observational,Host Response Mediators in Coronavirus (COVID-19) Infection,Recruiting,NA,University of British Columbia,NA,https://clinicaltrials.gov/ct2/show/NCT04510623,1,0,1,0,0,0,Canada,0,ace/arb|standard care|arb|ace inhibitor,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04502108,2020-04-01,12/31/2022,Observational,Behavior During and After COVID-19 Crisis,Recruiting,NA,Bern University of Applied Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04502108,1,0,1,0,1,0,Switzerland,0,covid-19,Journal Article
NCT04369378,2020-08-19,2/28/2021,Interventional,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,N/A,Lake Erie College of Osteopathic Medicine,NA,https://clinicaltrials.gov/ct2/show/NCT04369378,1,0,1,0,2,1,United States,0,meditation app usage,Letter|Randomized Controlled Trial
NCT04362059,2020-06-18,7/27/2021,Interventional,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04362059,1,14,15,0,3,0,United Kingdom,0,covsurf drug delivery system|standard care,Letter|Randomized Controlled Trial
NCT04348929,2020-04-16,8/16/2021,Interventional,Birth Experience During COVID-19 Confinement,Recruiting,N/A,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04348929,1,0,1,0,3,0,France,0,questionnaire,Comparative Study|Journal Article|Multicenter Study
NCT04351906,2020-05-03,6/1/2021,Interventional,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,N/A,University of Giessen,NA,https://clinicaltrials.gov/ct2/show/NCT04351906,1,1,2,0,5,0,Germany,0,ecco2r,Journal Article
NCT04444674,2020-06-24,12/31/2020,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04444674,1,0,1,1,4,0,South Africa,0,chadox1|saline,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04315480,2020-03-12,4/9/2020,Interventional,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Phase 2,UniversitÃ  Politecnica delle Marche,NA,https://clinicaltrials.gov/ct2/show/NCT04315480,1,0,1,0,2,0,Italy,0,tocilizumab,"Clinical Trial, Phase II|Journal Article|Multicenter Study"
NCT04444531,2020-03-20,5/19/2020,Observational,Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia,Completed,NA,Institut d'InvestigaciÃ³ BiomÃ¨dica de Girona Dr. Josep Trueta,NA,https://clinicaltrials.gov/ct2/show/NCT04444531,1,0,1,0,3,0,Spain,0,"NA",Controlled Clinical Trial|Journal Article
NCT04369690,2020-04-03,4/3/2021,Observational,"The Psychological, Social, and Economic Impacts of COVID-19",Recruiting,NA,University of Ottawa,NA,https://clinicaltrials.gov/ct2/show/NCT04369690,1,0,1,0,0,0,Canada,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04555005,2020-03-10,4/26/2020,Interventional,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,N/A,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicaltrials.gov/ct2/show/NCT04555005,1,0,1,0,0,0,Spain,0,mindfulness,Journal Article
NCT04425629,2020-06-16,4/10/2021,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",Recruiting,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04425629,1,0,1,0,16,1,United States|Chile|Mexico|Romania,0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04372186,2020-05-14,8/18/2020,Interventional,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"Active, not recruiting",Phase 3,"Genentech, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04372186,1,0,1,0,7,1,United States|Brazil|Kenya|Mexico|Peru|South Africa,0,placebo|tocilizumab,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04371419,2020-05-13,5/24/2020,Interventional,COVID-19 Health Messaging to Underserved Communities,Completed,N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04371419,1,0,1,0,2,1,United States,0,messaging,Journal Article
NCT04492904,2020-07-23,3/31/2021,Observational,Singapore COVID-19 Chemosensory Tracking (SCCT) Study,Recruiting,NA,"Clinical Nutrition Research Centre, Singapore",NA,https://clinicaltrials.gov/ct2/show/NCT04492904,1,0,1,0,0,0,Singapore,0,questionnaire|home-use test,Journal Article
NCT04501978,2020-08-04,7/31/2022,Interventional,ACTIV-3: Therapeutics for Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04501978,1,0,1,0,21,1,United States|Denmark|India|Poland|Singapore|Spain|Switzerland,0,ly3819253|placebo|remdesivir|vir-7831|brii-196/brii-198|azd7442|brii-196|brii-198,Journal Article
NCT04358380,2020-04-15,12/31/2020,Observational,Liver Injury in Patients With COVID-19,Enrolling by invitation,NA,"Austral University, Argentina",NA,https://clinicaltrials.gov/ct2/show/NCT04358380,1,0,1,0,2,0,Argentina,0,liver,Journal Article
NCT04344041,2020-04-15,5/31/2021,Interventional,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,Phase 3,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04344041,1,0,1,0,4,0,France,0,cholecalciferol,Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04635241,2020-06-01,4/1/2021,Interventional,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Phase 2/Phase 3,Australian National University,NA,https://clinicaltrials.gov/ct2/show/NCT04635241,1,0,1,0,1,0,Argentina|Egypt,0,heparin,Journal Article
NCT04470427,2020-07-27,10/27/2022,Interventional,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Phase 3,"ModernaTX, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04470427,1,0,1,1,13,1,United States,0,mrna-1273|placebo,"Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04540029,2020-05-06,10/31/2022,Observational,Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure,Recruiting,NA,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",NA,https://clinicaltrials.gov/ct2/show/NCT04540029,1,0,1,0,0,0,Italy,0,maternal stress,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04344327,2020-04-10,4/21/2020,Observational,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,Completed,NA,French Cardiology Society,NA,https://clinicaltrials.gov/ct2/show/NCT04344327,1,0,1,0,1,0,France,0,"NA",Journal Article
NCT04336410,2020-04-03,1/31/2022,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Phase 1,Inovio Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04336410,1,0,1,1,8,1,United States,0,ino-4800|cellectraâ® 2000,Journal Article
NCT04382235,2020-03-26,12/30/2020,Observational,Non-invasive Ventilatory Support of Patients Affected by COVID-19,"Active, not recruiting",NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04382235,1,0,1,0,1,0,Italy,0,non-invasive ventilatory support,Journal Article
NCT04549376,2020-07-01,10/20/2020,Interventional,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Phase 2,"Pi Research Consultancy Center, Bangladesh",NA,https://clinicaltrials.gov/ct2/show/NCT04549376,1,0,1,0,0,0,Bangladesh,0,povidone-iodine|placebo,Clinical Trial Protocol|Letter
NCT04414631,2020-08-06,6/30/2021,Interventional,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"University Hospital, Basel, Switzerland",NA,https://clinicaltrials.gov/ct2/show/NCT04414631,1,0,1,0,4,0,Brazil|Mexico|Switzerland,0,conestat alfa,Clinical Trial Protocol|Letter
NCT04459286,2020-10-09,3/31/2021,Interventional,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Recruiting,Phase 2,Obafemi Awolowo University,NA,https://clinicaltrials.gov/ct2/show/NCT04459286,1,0,1,0,3,0,Nigeria,0,nitazoxanide/atazanavir/ritonavir|standard care|nitazoxanide|atazanavir|ritonavir,Clinical Trial Protocol|Comparative Study|Letter
NCT04463706,2020-06-01,6/30/2021,Observational,COVID19 Severity Prediction and Health Services Research Evaluation,Recruiting,NA,Hospital Galdakao-Usansolo,NA,https://clinicaltrials.gov/ct2/show/NCT04463706,1,0,1,0,1,0,Spain,0,predictors adverse evolution|predictors of health care provide,Journal Article
NCT04345536,2020-03-15,1/1/2021,Observational [Patient Registry],Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital,Recruiting,NA,Oslo University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04345536,1,0,1,0,0,0,Norway,0,"NA",Journal Article
NCT04479163,2020-06-04,10/25/2020,Interventional,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,N/A,Fundacion Infant,NA,https://clinicaltrials.gov/ct2/show/NCT04479163,1,0,1,0,3,0,Argentina,0,convalescent plasma|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04615429,2020-09-15,1/31/2021,Interventional,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,Recruiting,Phase 2,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04615429,1,0,1,0,2,0,Spain,0,mesenchymal stem cells|placebo,Clinical Trial Protocol|Letter
NCT04422418,2020-07-01,12/14/2020,Observational,Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi,Recruiting,NA,Khalifa University for Science and Technology,NA,https://clinicaltrials.gov/ct2/show/NCT04422418,1,0,1,0,1,0,United Arab Emirates,0,"NA",Journal Article
NCT04385121,2020-04-16,4/16/2020,Observational,Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04385121,1,0,1,0,1,0,France,0,questionnaire,Journal Article
NCT04338009,2020-03-31,12/31/2020,Interventional,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Enrolling by invitation,N/A,University of Pennsylvania,NA,https://clinicaltrials.gov/ct2/show/NCT04338009,1,0,1,0,2,1,United States,0,discontinuation of arb|continuation of arb|ace inhibitor,Journal Article
NCT04484493,2020-08-08,10/25/2020,Interventional,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Phase 3,Benha University,NA,https://clinicaltrials.gov/ct2/show/NCT04484493,1,0,1,0,5,0,Egypt,0,mometasone furoate nasal spray,Journal Article
NCT04438980,2020-05-15,12/31/2020,Interventional,Glucocorticoids in COVID-19 (CORTIVID),Recruiting,Phase 3,Fundacion Miguel Servet,NA,https://clinicaltrials.gov/ct2/show/NCT04438980,1,0,1,0,1,0,Spain,0,methylprednisolone|placebo,Clinical Trial Protocol|Letter
NCT04472728,2020-06-16,7/31/2021,Interventional,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Biophytis,NA,https://clinicaltrials.gov/ct2/show/NCT04472728,1,0,1,0,5,1,United States|Belgium|Brazil|France|Puerto Rico,0,bio101|placebo,Clinical Trial Protocol|Letter
NCT04389645,2020-04-07,5/12/2020,Observational,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,Completed,NA,MeMed Diagnostics Ltd.,NA,https://clinicaltrials.gov/ct2/show/NCT04389645,1,0,1,0,0,0,Israel,0,ip-10,Clinical Trial|Journal Article|Observational Study
NCT04458337,2020-03-13,3/13/2021,Observational,SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19),Recruiting,NA,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,https://clinicaltrials.gov/ct2/show/NCT04458337,1,0,1,0,3,0,Canada,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04357938,2020-04-15,4/20/2021,Observational,Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections,"Active, not recruiting",NA,Jena University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04357938,1,0,1,0,1,0,Germany,0,ct-scan,Journal Article|Observational Study
NCT04330261,2020-03-18,3/17/2021,Observational,Clinical Characteristics and Outcomes of Pediatric COVID-19,Recruiting,NA,University of Calgary,NA,https://clinicaltrials.gov/ct2/show/NCT04330261,1,0,1,0,0,0,Canada,0,exposure,"Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04385771,2020-09-01,5/31/2021,Interventional,Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,N/A,University Hospital Freiburg,NA,https://clinicaltrials.gov/ct2/show/NCT04385771,1,0,1,0,2,0,Germany,0,vv-ecmo / cytokine adsorption|vv-ecmo|cytokine adsorption,Clinical Trial Protocol|Journal Article
NCT04364893,2020-04-09,10/1/2020,Interventional,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,N/A,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04364893,1,0,1,0,2,0,Brazil,0,suspension/maintenance of angiotensin receptor blockers/angiotensin-converting enzyme inhibitors|suspension|maintenance|ace inhibitor,Journal Article|Multicenter Study|Pragmatic Clinical Trial|Randomized Controlled Trial
NCT04344145,2020-04-16,5/25/2020,Observational,Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population,Completed,NA,UniversitÃ© Libre de Bruxelles,NA,https://clinicaltrials.gov/ct2/show/NCT04344145,1,16,17,0,4,0,Belgium,0,"NA",Journal Article/Journal Article|Practice Guideline
NCT04346602,2020-02-01,6/1/2020,Observational,A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019,Recruiting,NA,Jilin University,NA,https://clinicaltrials.gov/ct2/show/NCT04346602,1,0,1,0,0,0,China,0,all treatment about covid-2019,Journal Article
NCT04345523,2020-04-03,2/28/2021,Interventional,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,Recruiting,Phase 2,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04345523,1,0,1,0,2,0,Spain,0,blood/derivatives|standard care|blood|derivatives.,Clinical Trial Protocol|Journal Article
NCT04403685,2020-05-08,7/8/2020,Interventional,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Phase 3,BeneficÃªncia Portuguesa de SÃ£o Paulo,Safety,https://clinicaltrials.gov/ct2/show/NCT04403685,1,0,1,0,3,0,Brazil,0,tocilizumab,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04319731,2020-03-20,3/20/2021,Interventional,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Early Phase 1,University of Utah,NA,https://clinicaltrials.gov/ct2/show/NCT04319731,1,0,1,0,1,1,United States,0,human amniotic fluid,Clinical Trial|Journal Article
NCT04471519,2020-07-13,6/30/2021,Interventional,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,Bharat Biotech International Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04471519,1,0,1,1,2,0,India,0,bbv152c - phase i|bbv152b - phase i|bbv152a - phase i|placebo - phase i|bbv152a - phase ii|bbv152b - phase ii,Journal Article
NCT04273321,2020-02-14,4/15/2020,Interventional,Efficacy and Safety of Corticosteroids in COVID-19,Completed,N/A,Beijing Chao Yang Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04273321,1,0,1,0,4,0,China,0,methylprednisolone,Journal Article
NCT04351295,2020-04-20,12/1/2020,Interventional,Efficacy of Faviprevir in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicaltrials.gov/ct2/show/NCT04351295,1,0,1,0,2,0,Egypt,0,favipiravir|placebo,Journal Article
NCT04341038,2020-04-01,6/1/2020,Interventional,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Recruiting,Phase 3,Hospital Universitari de Bellvitge,NA,https://clinicaltrials.gov/ct2/show/NCT04341038,1,0,1,0,0,0,Spain,0,tacrolimus|methylprednisolone,Journal Article|Review
NCT04390022,2020-07-31,9/17/2020,Interventional,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Completed,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicaltrials.gov/ct2/show/NCT04390022,1,0,1,0,6,0,Spain,1,ivermectin|placebo,Journal Article
NCT04451174,2020-06-23,11/30/2020,Interventional,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Recruiting,Phase 3,University of Chile,NA,https://clinicaltrials.gov/ct2/show/NCT04451174,1,0,1,0,3,0,Chile,0,prednisone,Letter
NCT04394182,2020-04-21,12/31/2020,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,radiotherapy|oxygen|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|heparin|corticosteroid|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam,Journal Article/Journal Article/Journal Article|Review/Editorial|Comment/Journal Article
NCT04373707,2020-05-13,11/30/2021,Interventional,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Recruiting,Phase 4,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04373707,1,0,1,0,5,0,France,0,enoxaparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04354155,2020-06-02,9/30/2022,Interventional,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Recruiting,Phase 2,Johns Hopkins All Children's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04354155,1,0,1,0,2,1,United States,0,enoxaparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04359277,2020-04-21,9/20/2020,Interventional,A Randomized Trial of Anticoagulation Strategies in COVID-19,Terminated,Phase 3,NYU Langone Health,the PROTECT study is being transitioned to ACTIV4 ACUTE anticoagulation inpatient study,https://clinicaltrials.gov/ct2/show/NCT04359277,1,0,1,0,3,1,United States,0,enoxaparin|anticoagulation,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04368377,2020-04-06,4/23/2020,Interventional,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Completed,Phase 2,University of Milan,NA,https://clinicaltrials.gov/ct2/show/NCT04368377,1,0,1,0,0,0,Italy,0,tirofiban|clopidogrel|acetylsalicylic acid|fondaparinux,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04362085,2020-05-11,3/31/2022,Interventional,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04362085,1,0,1,0,3,0,Canada,0,anticoagulation,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04360824,2020-05-06,4/16/2021,Interventional,Covid-19 Associated Coagulopathy,Recruiting,Phase 4,University of Iowa,NA,https://clinicaltrials.gov/ct2/show/NCT04360824,1,0,1,0,4,1,United States,0,thromboprophylaxis|standard of care thromboprophylaxis,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04394377,2020-06-21,3/31/2021,Interventional,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Recruiting,Phase 4,Brazilian Clinical Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04394377,1,0,1,0,6,0,Brazil,0,group 1: rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|enoxaparin|rivaroxaban|d followed by enoxaparin|heparin|d,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04401293,2020-04-26,4/26/2021,Interventional,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Recruiting,Phase 3,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04401293,1,0,1,0,2,1,United States,0,enoxaparin|prophylactic,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04393805,2020-06-01,12/31/2020,Observational,Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto,Recruiting,NA,Quovadis Associazione,NA,https://clinicaltrials.gov/ct2/show/NCT04393805,1,0,1,0,2,0,Italy,0,heparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04397510,2020-06-01,12/31/2020,Interventional,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,Phase 4,Frederick Health,NA,https://clinicaltrials.gov/ct2/show/NCT04397510,1,0,1,0,6,1,United States,0,heparin|saline,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04359212,2020-05-01,6/30/2020,Observational,Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19,Completed,NA,Quovadis Associazione,NA,https://clinicaltrials.gov/ct2/show/NCT04359212,1,0,1,0,3,0,Italy,0,thromboprophylaxis|fondaparinux,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04647604,2020-06-23,4/30/2021,Interventional,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,Recruiting,Phase 2,Karolinska University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04647604,1,0,1,0,0,0,Sweden,0,omegavenâ®|sodium chloride,Journal Article|Review
NCT04359836,2020-04-16,4/30/2021,Observational,A Study to Explore the Role of Gut Flora in COVID-19 Infection,Recruiting,NA,ProgenaBiome,NA,https://clinicaltrials.gov/ct2/show/NCT04359836,1,0,1,0,1,1,United States,0,there is no intervention in this study,Journal Article
NCT04411446,2020-08-11,12/15/2020,Interventional,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Recruiting,Phase 4,Vitamin D Study Group,NA,https://clinicaltrials.gov/ct2/show/NCT04411446,1,1,2,0,3,0,Argentina,0,vitamin d|placebo,Clinical Trial Protocol|Letter
NCT04405908,2020-06-19,10/16/2020,Interventional,SCB-2019 as COVID-19 Vaccine,"Active, not recruiting",Phase 1,Clover Biopharmaceuticals AUS Pty Ltd,NA,https://clinicaltrials.gov/ct2/show/NCT04405908,1,0,1,1,4,0,Australia,0,scb-2019|scb-2019 with as03 adjuvant|scb-2019 with cpg 1018 adjuvant/alum adjuvant|scb-2019 with cpg 1018 adjuvant|alum adjuvant,Journal Article
NCT04371744,2020-04-17,6/4/2020,Observational [Patient Registry],QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19,Completed,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicaltrials.gov/ct2/show/NCT04371744,1,0,1,0,1,0,France,0,"NA",Journal Article
NCT04380701,2020-04-23,4/30/2023,Interventional,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,Recruiting,Phase 1/Phase 2,BioNTech SE,NA,https://clinicaltrials.gov/ct2/show/NCT04380701,1,0,1,1,4,0,Germany,0,bnt162a1|bnt162b1|bnt162b2|bnt162c2,Journal Article
NCT04334954,2020-08-26,3/31/2022,Observational,SARS-COV2 Pandemic Serosurvey and Blood Sampling,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicaltrials.gov/ct2/show/NCT04334954,1,0,1,0,96,1,United States,0,"NA",Preprint
NCT04462393,2020-03-06,5/6/2020,Observational,Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19,Completed,NA,Linkoeping University,NA,https://clinicaltrials.gov/ct2/show/NCT04462393,1,0,1,0,1,0,Sweden,0,admission to icu for covid-19,Journal Article
NCT04411784,2020-05-20,7/31/2020,Observational,"PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis","Active, not recruiting",NA,Hull University Teaching Hospitals NHS Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04411784,1,0,1,0,0,0,United Kingdom,0,"NA",Journal Article
NCT04530396,2020-09-07,5/1/2021,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04530396,1,0,1,1,8,0,Russian Federation,0,gam-covid-vac|placebo,Journal Article
NCT04275414,2020-02-15,4/5/2020,Interventional,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Completed,Phase 2,Qilu Hospital of Shandong University,NA,https://clinicaltrials.gov/ct2/show/NCT04275414,1,0,1,0,2,0,China|Italy,0,bevacizumab,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04383574,2020-05-22,8/28/2020,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicaltrials.gov/ct2/show/NCT04383574,1,0,1,1,2,0,China,0,"two doses of low dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of medium dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of high dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|placebo",Journal Article
NCT04568525,2020-07-01,7/25/2020,Interventional,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Completed,N/A,Kyrgyz State Medical Academy,NA,https://clinicaltrials.gov/ct2/show/NCT04568525,1,0,1,0,0,0,Kyrgyzstan,0,passive microwave radiometry,Journal Article
NCT04533360,2020-09-28,10/9/2020,Observational [Patient Registry],Prevalence of COVID-19 Antibodies Kingman AZ,Enrolling by invitation,NA,Kingman Regional Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04533360,1,0,1,0,2,1,United States,0,vitros anti-sars-cov-2 igg test,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04473261,2020-07-14,7/15/2021,Interventional,Efficacy of Iodine Complex Against COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04473261,1,0,1,0,1,0,Pakistan,0,iodine|placebo|idoine complex,Clinical Trial Protocol|Letter
NCT04288102,2020-03-05,5/12/2020,Interventional,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),Completed,Phase 2,Beijing 302 Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04288102,1,0,1,0,5,0,China,0,mesenchymal stem cells|saline containing 1% human serum albuminï¼ˆsolution without uc-mscsï¼‰,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04318444,2020-03-29,3/31/2021,Interventional,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Recruiting,Phase 2/Phase 3,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04318444,1,0,1,0,2,1,United States,0,hydroxychloroquine|placebo,Journal Article
NCT04312243,2020-04-07,4/7/2021,Interventional,NO Prevention of COVID-19 for Healthcare Providers,Recruiting,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04312243,1,0,1,0,2,1,United States,0,nitric oxide,Journal Article
NCT04303507,2020-04-29,4/30/2021,Interventional,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,Recruiting,N/A,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04303507,1,0,1,0,7,0,Indonesia|Italy|Lao People's Democratic Republic|Pakistan|Thailand|United Kingdom,0,chloroquine/hydroxychloroquine|placebo|chloroquine|hydroxychloroquine,Journal Article
NCT04413968,2020-06-02,7/2/2020,Interventional,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",Completed,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicaltrials.gov/ct2/show/NCT04413968,1,0,1,0,3,0,France,0,rapid test|nasopharyngeal swab|stool collection,Journal Article
NCT04609865,2020-11-04,12/31/2021,Interventional,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04609865,1,0,1,0,2,0,France,0,lidocaine 2%|control,Clinical Trial Protocol|Letter
NCT04379440,2020-04-25,9/30/2020,Observational [Patient Registry],Geriatric Population COVID-19 Observational Study (GEROCOVIDobs),Recruiting,NA,Campus Bio-Medico University,NA,https://clinicaltrials.gov/ct2/show/NCT04379440,1,0,1,0,0,0,Italy,0,"NA",Journal Article
NCT04383678,2020-03-01,12/31/2020,Observational,Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome,Recruiting,NA,Helsinki University Central Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04383678,1,0,1,0,2,0,Finland|France|Germany|Italy|Sweden|United Kingdom,0,extracorporeal membrane oxygenation,Journal Article
NCT04497389,2020-10-28,9/15/2021,Interventional,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,Phase 1/Phase 2,University of Utah,NA,https://clinicaltrials.gov/ct2/show/NCT04497389,1,0,1,0,2,1,United States,0,human amniotic fluid,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04342728,2020-04-08,12/30/2020,Interventional,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,Enrolling by invitation,N/A,The Cleveland Clinic,NA,https://clinicaltrials.gov/ct2/show/NCT04342728,1,0,1,0,5,1,United States,0,vitamin c|zinc|ascorbic acid/zinc gluconate|standard care,Journal Article
NCT04411576,2020-04-23,7/1/2020,Observational,Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare,Recruiting,NA,Karolinska University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04411576,1,0,1,0,0,0,Sweden,0,throat swab sample for measuring current infection with sars-cov-2|blood sample,Journal Article
NCT04730323,2020-05-12,6/12/2020,Interventional,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,https://clinicaltrials.gov/ct2/show/NCT04730323,1,0,1,0,0,0,Pakistan,0,tocilizumab,Journal Article
NCT04479150,2020-03-01,8/31/2020,Observational [Patient Registry],Complications and Mortality Following Emergency Digestive Surgery During the COVID-19 Pandemic,Recruiting,NA,Hospital Universitari de Bellvitge,NA,https://clinicaltrials.gov/ct2/show/NCT04479150,1,0,1,0,1,0,Spain,0,"NA",Journal Article
NCT04449718,2020-06-01,10/7/2020,Interventional,Vitamin D Supplementation in Patients With COVID-19,Completed,N/A,University of Sao Paulo,NA,https://clinicaltrials.gov/ct2/show/NCT04449718,1,0,1,0,1,0,Brazil,0,vitamin d|placebo,Journal Article
NCT04363333,2020-04-27,11/30/2020,Observational,Obstructive Sleep Apnea & Covid-19 Outcomes,"Active, not recruiting",NA,KoÃ§ University,NA,https://clinicaltrials.gov/ct2/show/NCT04363333,1,0,1,0,4,0,Turkey,0,home sleep apnea testing/in-hospital polysomnography|home sleep apnea testing|polysomnography,Journal Article
NCT04595123,2020-06-15,11/1/2020,Observational,Impact of COVID-19 Pandemic in Perinatal Mental Health (RISEUP-PPD-COVID-19),Recruiting,NA,University of Minho,NA,https://clinicaltrials.gov/ct2/show/NCT04595123,1,0,1,0,1,0,Albania|Brazil|Bulgaria|Chile|Cyprus|France|Greece|Israel|Malta|Portugal|Spain|Turkey|United Kingdom,0,"NA",Journal Article
NCT04426084,2020-03-01,5/11/2020,Observational [Patient Registry],Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study,"Active, not recruiting",NA,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04426084,1,0,1,0,0,0,Sweden,0,hypertension|diabetes type 2|obesity|antihypertensives|statins,Journal Article
NCT04433260,2020-07-25,5/31/2021,Observational,COVID19 and Physical and Emotional Wellbeing of HCP,Recruiting,NA,Queen Mary University of London,NA,https://clinicaltrials.gov/ct2/show/NCT04433260,1,0,1,0,2,0,United Kingdom,0,questionnaire|informed consent,Journal Article
NCT04466670,2020-07-08,12/30/2020,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,heparin|acetylsalicylic acid|enoxaparin,"Journal Article|Review/Journal Article/Letter|Comment/Journal Article|Multicenter Study/Journal Article|Review/Comparative Study|Journal Article/Letter/Comparative Study|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article/Clinical Trial, Phase II|Controlled Clinical Trial|Journal Article/Journal Article|Observational Study/Letter"
NCT04333550,2020-04-30,9/30/2020,Interventional,Application of Desferal to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04333550,0,17,17,0,2,0,"Iran, Islamic Republic of",0,deferoxamine,Journal Article
NCT04382768,2020-05-01,1/31/2021,Interventional,Inhaled Ibuprofen to Treat COVID-19,Recruiting,N/A,QuÃ­mica Luar SRL,NA,https://clinicaltrials.gov/ct2/show/NCT04382768,0,3,3,0,3,0,Argentina,0,ibuprofen,Journal Article/Journal Article
NCT04503434,2020-05-15,5/31/2020,Observational [Patient Registry],Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,Completed,NA,Hospital Clinic of Barcelona,NA,https://clinicaltrials.gov/ct2/show/NCT04503434,0,3,3,0,0,0,Spain,0,"NA",Journal Article
NCT04424953,2020-06-01,12/31/2020,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,"Active, not recruiting",N/A,Singapore General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04424953,0,17,17,0,2,0,Singapore,0,mcgrath videolaryngoscope|laryngoscope,"Journal Article/Journal Article/Comparative Study|Letter/Journal Article|Research Support, Non-U.S. Gov't"
NCT04445961,2020-05-01,8/14/2020,Observational,Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure,Completed,NA,I.M. Sechenov First Moscow State Medical University,NA,https://clinicaltrials.gov/ct2/show/NCT04445961,0,3,3,0,1,0,Russian Federation,0,respiratory mechanics measurement|gas exchange measurement,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Editorial"
NCT04632615,2020-05-22,2/28/2021,Observational,Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak,Recruiting,NA,Istituto Ortopedico Galeazzi,NA,https://clinicaltrials.gov/ct2/show/NCT04632615,0,8,8,0,0,0,Italy,0,"NA","Journal Article|Observational Study/Journal Article/Journal Article/Journal Article|Research Support, Non-U.S. Gov't"
NCT04369807,2020-04-21,5/31/2023,Observational,Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection,Recruiting,NA,Perspectum,NA,https://clinicaltrials.gov/ct2/show/NCT04369807,0,19,19,0,0,0,United Kingdom,0,mri,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04542512,2020-10-01,5/31/2021,Observational [Patient Registry],Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic.,Recruiting,NA,Poissy-Saint Germain Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04542512,0,6,6,0,2,0,France,0,"NA",Journal Article
NCT04482634,2020-09-01,8/31/2022,Interventional,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,N/A,KoÃ§ University,NA,https://clinicaltrials.gov/ct2/show/NCT04482634,0,10,10,0,1,0,Turkey,0,remote controlled exercise|home exercise,Journal Article|Review
NCT04359095,2020-08-18,11/30/2020,Interventional,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Recruiting,Phase 2/Phase 3,Universidad Nacional de Colombia,NA,https://clinicaltrials.gov/ct2/show/NCT04359095,0,21,21,0,2,0,Colombia,0,emtricitabine/tenofovir|colchicine pill|rosuvastatin|standard care|emtricitabine|tenofovir,Journal Article
NCT04668404,2020-08-24,1/1/2021,Observational [Patient Registry],Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19,Recruiting,NA,Postgraduate Institute of Medical Education and Research,NA,https://clinicaltrials.gov/ct2/show/NCT04668404,0,12,12,0,0,0,India,0,sonoclot,Journal Article/Journal Article/Journal Article
NCT04441814,2019-07-23,7/31/2021,Observational,FOUND - Ancillary Study to Smile Protocol NCT03654105,Enrolling by invitation,NA,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",NA,https://clinicaltrials.gov/ct2/show/NCT04441814,0,8,8,0,1,0,Italy,0,"NA","Journal Article|Published Erratum/Journal Article/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04511429,2020-06-30,10/31/2020,Observational [Patient Registry],COVID-19 in Immunosuppressed Children,Recruiting,NA,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04511429,0,9,9,0,0,0,Brazil,0,"NA",Journal Article/Editorial/Letter
NCT04610554,2020-05-14,10/12/2020,Observational,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19,Completed,NA,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",NA,https://clinicaltrials.gov/ct2/show/NCT04610554,0,1,1,0,0,0,Italy,0,"NA",Evaluation Study|Journal Article
NCT04410328,2020-10-21,3/15/2021,Interventional,Aggrenox To Treat Acute Covid-19,Recruiting,Phase 3,"Rutgers, The State University of New Jersey",NA,https://clinicaltrials.gov/ct2/show/NCT04410328,0,5,5,0,4,1,United States,0,dipyridamole er 200mg/ aspirin 25mg orally/enterally/standard of care|standard care|dipyridamole er 200mg|aspirin 25mg orally|enterally,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04338568,2020-04-16,11/30/2020,Interventional,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,N/A,Hasselt University,NA,https://clinicaltrials.gov/ct2/show/NCT04338568,0,2,2,0,3,0,Belgium,0,lung ultrasound,Journal Article/Evaluation Study|Journal Article
NCT04642326,2020-06-26,7/1/2020,Interventional,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",N/A,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,NA,https://clinicaltrials.gov/ct2/show/NCT04642326,0,7,7,0,0,0,Turkey,0,test group: experimental - uvc therapy applied,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04374786,2020-05-15,9/1/2020,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,N/A,University of Arizona,NA,https://clinicaltrials.gov/ct2/show/NCT04374786,0,4,4,0,2,1,United States,0,meditation,Journal Article/Journal Article
NCT04282902,2020-02-04,4/30/2020,Interventional,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Recruiting,Phase 3,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04282902,0,4,4,0,0,0,China,0,pirfenidone,Journal Article
NCT04673214,2020-12-16,2/2/2021,Interventional,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicaltrials.gov/ct2/show/NCT04673214,0,6,6,0,2,0,Mexico,0,azithromycin / ivermectin / ribaroxaban / paracetamol|azithromycin / ribaroxaban / paracetamol|azithromycin|ivermectin|ribaroxaban|paracetamol,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04594356,2020-11-19,1/31/2021,Observational,"Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist",Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04594356,0,10,10,0,1,0,France,0,"NA",Journal Article|Review
NCT04480034,2020-07-15,1/31/2021,Observational,Obesity Surgery During 2020 Italian Pandemic,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicaltrials.gov/ct2/show/NCT04480034,0,25,25,0,1,0,Italy,0,bariatric procedures,Journal Article/Journal Article|Video-Audio Media/Journal Article/Journal Article|Observational Study
NCT04501965,2020-06-01,8/30/2020,Interventional,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,https://clinicaltrials.gov/ct2/show/NCT04501965,0,19,19,0,1,0,Guinea,0,hydroxychloroquine / azithromycin|quinquina-stevia/azythromycin|4plants/azythromycin|hydroxychloroquine|azithromycin|quinquina-stevia|4plants,Journal Article|Review/Journal Article|Published Erratum
NCT04459819,2020-03-01,9/30/2020,Observational,Respiratory Physiotherapy in Severe COVID-19 Patients,Recruiting,NA,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",NA,https://clinicaltrials.gov/ct2/show/NCT04459819,0,5,5,0,1,0,Italy,0,respiratory physiotherapy,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Practice Guideline"
NCT04567927,2020-03-03,5/28/2020,Observational,Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19,Completed,NA,"Ente Ospedaliero Cantonale, Bellinzona",NA,https://clinicaltrials.gov/ct2/show/NCT04567927,0,6,6,0,0,0,Switzerland,0,ultrasonography,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Observational Study/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04631861,2014-01-01,7/31/2020,Observational,Physical Activity and the Risk of COVID-19 Infection and Mortality,Completed,NA,Wonju Severance Christian Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04631861,0,4,4,0,0,0,NA,0,"NA","Journal Article/Journal Article/Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Observational Study"
NCT04407468,2020-05-01,7/13/2020,Observational,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19,Completed,NA,Hospital General San Juan del Rio,NA,https://clinicaltrials.gov/ct2/show/NCT04407468,0,9,9,0,1,0,Mexico,0,prone positioning,Journal Article|Multicenter Study|Observational Study/Comparative Study|Journal Article/Letter/Journal Article/Case Reports|Letter/Journal Article
NCT04374422,2020-04-10,4/12/2020,Observational,COVID-19 Pandemic and Female Sexual Behavior,Completed,NA,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04374422,0,2,2,0,0,0,Turkey,0,fsfi survey,Journal Article
NCT04442178,2020-09-15,12/30/2020,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Phase 2,Revimmune,NA,https://clinicaltrials.gov/ct2/show/NCT04442178,0,4,4,0,1,1,United States,0,cyt107|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04407689,2020-06-08,7/30/2021,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Phase 2,Revimmune,NA,https://clinicaltrials.gov/ct2/show/NCT04407689,0,2,2,0,2,0,France,0,interleukin|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04340921,2020-05-14,11/10/2021,Observational,The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury,Recruiting,NA,Barts & The London NHS Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04340921,0,7,7,0,1,0,United Kingdom,0,exposure,"Journal Article|Research Support, Non-U.S. Gov't/Letter"
NCT04422535,2020-05-29,9/1/2020,Observational,Effects on the Qt Interval of COVID-19 Coronavirus Infection,Recruiting,NA,Hospital General Universitario Gregorio MaraÃ±on,NA,https://clinicaltrials.gov/ct2/show/NCT04422535,0,5,5,0,0,0,Spain,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04497311,2020-06-15,4/30/2021,Observational,Tomographic Findings in COVID-19 and Influenza,Recruiting,NA,Universidad de Guanajuato,NA,https://clinicaltrials.gov/ct2/show/NCT04497311,0,13,13,0,1,0,Mexico,0,thoraxic computed tomography,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article"
NCT04367883,2020-03-01,9/30/2022,Observational,"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection",Recruiting,NA,Consorci Sanitari de Terrassa,NA,https://clinicaltrials.gov/ct2/show/NCT04367883,0,1,1,0,3,0,Spain,0,ace inhibitor|arb,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04407169,2020-06-01,11/17/2020,Observational,Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04407169,0,4,4,0,1,0,France,0,no intervention,Journal Article
NCT04661631,2020-05-08,7/31/2021,Observational [Patient Registry],Surgery and Lung Ultrasound in COVID-19 Infection,Recruiting,NA,Fundacion Clinica Valle del Lili,NA,https://clinicaltrials.gov/ct2/show/NCT04661631,0,30,30,0,1,0,Colombia,0,lung ultrasound,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Comparative Study|Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Letter/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Multicenter Study/Letter|Comment/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article/Journal Article"
NCT04353674,2020-04-28,12/31/2020,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,5,0,Canada,0,control|sledd with a l-mod,"Journal Article|Research Support, Non-U.S. Gov't/Letter/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article"
NCT04475471,2020-06-11,6/30/2021,Observational,WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey,Recruiting,NA,Public Health Foundation of India,NA,https://clinicaltrials.gov/ct2/show/NCT04475471,0,8,8,0,1,0,"Argentina|Bosnia and Herzegovina|Ghana|India|Iran, Islamic Republic of|Sudan",0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04366232,2020-08-19,10/2/2020,Interventional,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation,Terminated,Phase 2,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,investigator decision,https://clinicaltrials.gov/ct2/show/NCT04366232,0,3,3,0,5,0,France,0,anakinra|anakinra/ruxolitinib|standard care|3)|ruxolitinib,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04368351,2020-03-01,6/30/2020,Observational,Bacteriotherapy in the Treatment of COVID-19,"Active, not recruiting",NA,University of Roma La Sapienza,NA,https://clinicaltrials.gov/ct2/show/NCT04368351,0,4,4,0,1,0,Italy,0,sivomixx|azithromycin|hydroxychloroquine,Journal Article/Journal Article|Systematic Review
NCT04611269,2020-03-20,10/31/2020,Observational [Patient Registry],Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina,Completed,NA,Argentinian Intensive Care Society,NA,https://clinicaltrials.gov/ct2/show/NCT04611269,0,7,7,0,3,0,Argentina,0,"NA","Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Editorial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Observational Study/Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04577105,2020-04-01,8/31/2020,Observational,Risk Factors and Computed Tomography Findings in COVID-19.,Completed,NA,Instituto Nacional de Cardiologia Ignacio Chavez,NA,https://clinicaltrials.gov/ct2/show/NCT04577105,0,12,12,0,1,0,Mexico,0,simple chest tomography,"Journal Article/Journal Article/Journal Article/Journal Article|Multicenter Study|Observational Study/Journal Article|Research Support, Non-U.S. Gov't|Validation Study"
NCT04627467,2020-03-28,7/9/2020,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Systematic Review/Journal Article/Journal Article/Letter|Comment/Clinical Trial|Journal Article/Historical Article|Journal Article|Review"
NCT04344951,2020-04-06,4/1/2021,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04344951,0,3,3,0,1,0,Greece,0,chloroquine,Journal Article/Journal Article/Clinical Trial|Journal Article
NCT04385043,2020-05-01,10/15/2020,Interventional,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,https://clinicaltrials.gov/ct2/show/NCT04385043,0,3,3,0,0,0,Italy,0,convalescent plasma|standard care,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural"
NCT04517162,2020-08-19,2/19/2021,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04517162,0,31,31,0,2,0,Mexico,0,collagen-polyvinylpyrrolidone,"Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Validation Study"
NCT04321369,2020-03-09,3/23/2020,Observational,Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals,Completed,NA,UnitedHealth Group,NA,https://clinicaltrials.gov/ct2/show/NCT04321369,0,2,2,0,1,1,United States,0,testing sensitivity for sars-cov-2 virus in symptomatic individuals,Journal Article
NCT04494724,2020-07-13,12/31/2020,Interventional,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Phase 2,The Methodist Hospital System,NA,https://clinicaltrials.gov/ct2/show/NCT04494724,0,8,8,0,0,1,United States,0,clazakizumab|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Published Erratum"
NCT04333875,2020-03-20,12/31/2020,Observational [Patient Registry],Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis,"Active, not recruiting",NA,"University Hospital Inselspital, Berne",NA,https://clinicaltrials.gov/ct2/show/NCT04333875,0,4,4,0,2,0,Switzerland,0,tavr/savr|tavr|savr,Journal Article/Journal Article
NCT04479202,2020-02-08,4/18/2020,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,NA,https://clinicaltrials.gov/ct2/show/NCT04479202,0,3,3,0,0,0,China,0,berberine|montmorrillonite,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Letter"
NCT04340349,2020-05-11,3/20/2021,Interventional,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Early Phase 1,Instituto Nacional de Rehabilitacion,NA,https://clinicaltrials.gov/ct2/show/NCT04340349,0,4,4,0,2,0,Mexico,0,hydroxychloroquine|bromhexine hydrochloride|hydroxychloroquine sulfate placebo|bromhexine 8 mg placebo,Journal Article
NCT04384380,2020-04-01,5/31/2020,Interventional,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,N/A,Taoyuan General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04384380,0,5,5,0,1,0,Taiwan,0,hydroxychloroquine,Journal Article|Systematic Review/Clinical Trial|Journal Article
NCT04342637,2020-04-10,4/25/2020,Observational,COVID-19 Endoscopy Survey,Completed,NA,Al-Azhar University,NA,https://clinicaltrials.gov/ct2/show/NCT04342637,0,6,6,0,3,1,"United States|Egypt|Iran, Islamic Republic of",0,practice details,Journal Article|Review/Journal Article/Journal Article|Review
NCT04516811,2020-09-21,12/30/2021,Interventional,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Phase 3,South African National Blood Service,NA,https://clinicaltrials.gov/ct2/show/NCT04516811,0,1,1,0,2,0,South Africa,0,convalescent plasma/standard care|standard care/placebo|convalescent plasma|standard care|placebo,Journal Article
NCT04567979,2020-06-11,9/30/2020,Observational,Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.,"Active, not recruiting",NA,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04567979,0,12,12,0,0,0,Mexico,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Video-Audio Media/Journal Article/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Letter|Comment"
NCT04712292,2020-09-08,1/31/2021,Observational,Effects of COVID-19 Pandemic on the Diagnosis and Outcomes of Colorectal Cancer (COVID-CRC),Recruiting,NA,University of Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04712292,0,5,5,0,0,0,Italy,0,surgical procedure for cancer,Journal Article|Video-Audio Media/Journal Article/Journal Article/Editorial
NCT04353583,2020-04-21,3/31/2021,Observational [Patient Registry],Renal Outcome in Patients With COVID-19,Recruiting,NA,University of Giessen,NA,https://clinicaltrials.gov/ct2/show/NCT04353583,0,1,1,0,8,0,Germany,0,"NA",Editorial
NCT04392323,2020-05-13,7/1/2020,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,pcr/serology|pcr|serology test,"Journal Article/Journal Article|Observational Study|Research Support, Non-U.S. Gov't/Journal Article/Case Reports|Journal Article/Journal Article/Journal Article/Journal Article"
NCT04418557,2020-04-28,7/31/2021,Observational [Patient Registry],COVID-19 and Obstetric Transmission,Recruiting,NA,University Hospitals Cleveland Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04418557,0,2,2,0,1,1,United States,0,pcr/serology|pcr|serology test,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04515108,2020-03-10,8/5/2020,Observational,Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies,Completed,NA,Ankara City Hospital Bilkent,NA,https://clinicaltrials.gov/ct2/show/NCT04515108,0,4,4,0,0,0,Turkey,0,clinical assessment,Journal Article|Review/Journal Article/Journal Article|Multicenter Study/Journal Article
NCT04356482,2020-05-20,11/30/2020,Interventional,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,https://clinicaltrials.gov/ct2/show/NCT04356482,0,6,6,0,3,0,Mexico,0,convalescent plasma,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04393727,2020-05-01,9/30/2020,Interventional,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Phase 2,"Azienda Ospedaliero, Universitaria Pisana","Study was stopped because the Promoter was changed and a new study on convalescent plasma
    promoted by AIFA was started in Italy.",https://clinicaltrials.gov/ct2/show/NCT04393727,0,1,1,0,2,0,Italy,0,convalescent plasma,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04366089,2020-03-26,10/30/2020,Interventional,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,Phase 2,Azienda Policlinico Umberto I,NA,https://clinicaltrials.gov/ct2/show/NCT04366089,0,3,3,0,0,0,Italy,0,oxygen-ozone|sivomixx|azithromycin|hydroxychloroquine|standard care,Editorial/Journal Article
NCT04374123,2020-04-20,5/20/2020,Observational,COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit,Completed,NA,Instituto Ecuatoriano de Enfermedades Digestivas,NA,https://clinicaltrials.gov/ct2/show/NCT04374123,0,3,3,0,1,0,Ecuador,0,igm/igg rapid test|igg antibody test|igm antibodytest,Letter|Comment/Letter|Comment/Journal Article|Multicenter Study
NCT04368897,2020-05-01,4/1/2021,Observational,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,Recruiting,NA,"Applied Biology, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04368897,0,4,4,0,3,0,Spain,0,cag,Letter/Journal Article/Letter/Letter
NCT04437940,2020-06-15,7/10/2020,Observational,Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,Completed,NA,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04437940,0,1,1,0,1,0,Turkey,0,pcr,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04378738,2020-05-01,5/7/2020,Interventional,Social Media and Covid19 Pandemic,Enrolling by invitation,N/A,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04378738,0,1,1,0,0,0,Turkey,0,questionnaire,"Journal Article|Research Support, N.I.H., Extramural"
NCT04424836,2020-05-15,6/4/2020,Observational,HFNC Treatment in COVID-19 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04424836,0,3,3,0,2,0,Turkey,0,high flow nasal cannula,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04360837,2020-05-06,6/1/2021,Interventional,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,N/A,Szeged University,NA,https://clinicaltrials.gov/ct2/show/NCT04360837,0,1,1,0,2,0,Hungary,0,alveolar,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04346264,2020-04-27,6/1/2020,Observational,CoVid-19 - Infection and Antibody Formation in the Viennese Population,Enrolling by invitation,NA,Ludwig Boltzmann Institute for Lung Health,NA,https://clinicaltrials.gov/ct2/show/NCT04346264,0,1,1,0,1,0,Austria,0,no intervention planned due to the observational study design only a diagnostic testing,"Comparative Study|Letter|Research Support, Non-U.S. Gov't"
NCT04361942,2020-05-01,11/30/2020,Interventional,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Phase 2,Red de Terapia Celular,NA,https://clinicaltrials.gov/ct2/show/NCT04361942,0,4,4,0,2,0,Spain,0,mesenchymal stem cells|placebo,Journal Article
NCT04480593,2020-06-02,8/30/2020,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04480593,0,8,8,0,1,0,Brazil,0,brazilian green propolis extract (epp-af)|standard care,Journal Article|Review/Journal Article|Review/Journal Article|Review
NCT04392713,2020-04-15,7/31/2020,Interventional,Efficacy of Ivermectin in COVID-19,Recruiting,N/A,"Combined Military Hospital, Pakistan",NA,https://clinicaltrials.gov/ct2/show/NCT04392713,0,1,1,0,0,0,Pakistan,0,ivermectin,Journal Article|Review
NCT04453579,2020-03-09,5/4/2020,Observational [Patient Registry],"Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health",Completed,NA,University of Rome Tor Vergata,NA,https://clinicaltrials.gov/ct2/show/NCT04453579,0,1,1,0,0,0,Italy,0,telehealth,Journal Article|Comment
NCT04468035,2020-06-01,12/31/2021,Observational,Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04468035,0,4,4,0,2,0,France,0,"NA",Letter/Case Reports|Journal Article
NCT04530617,2020-10-05,1/31/2021,Interventional,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04530617,0,28,28,0,3,0,Mexico,0,camostat mesilate|artemisia annua leaf,Published Erratum
NCT04526405,2020-07-14,11/3/2020,Observational,Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases,Completed,NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04526405,0,4,4,0,1,0,Italy,0,sars-cov-2 s1/s2 igg|sars-cov-2 s1|igg test,Letter/Letter
NCT04568356,2020-04-24,6/12/2020,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19,"Comparative Study|Journal Article/Journal Article/Evaluation Study|Letter/Journal Article|Research Support, N.I.H., Extramural|Research Support, N.I.H., Intramural|Review/Journal Article/Evaluation Study|Journal Article/Journal Article|Comment/Journal Article|Research Support, Non-U.S. Gov't|Review/Preprint/Evaluation Study|Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Comparative Study|Journal Article|Validation Study/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04367896,2020-03-24,4/17/2020,Observational,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,Completed,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicaltrials.gov/ct2/show/NCT04367896,0,3,3,0,0,0,Italy,0,questionnaire,"Journal Article/Letter|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04402853,2020-02-01,3/1/2020,Observational,SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients,Completed,NA,UniversitÃ  degli Studi dell'Insubria,NA,https://clinicaltrials.gov/ct2/show/NCT04402853,0,1,1,0,1,0,Italy,0,tears swab,Journal Article
NCT04616950,2020-12-01,6/30/2021,Observational,Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04616950,0,5,5,0,2,0,France,0,"NA",Journal Article|Review/Journal Article
NCT04488484,2020-07-01,12/31/2021,Interventional,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04488484,0,5,5,0,1,0,France,0,serology test follow-up,"Journal Article|Systematic Review/Journal Article|Research Support, Non-U.S. Gov't"
NCT04522492,2020-08-11,3/31/2021,Interventional,Impact of COVID-19 on Mental Health of Patients With Skin Picking,"Active, not recruiting",N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicaltrials.gov/ct2/show/NCT04522492,0,2,2,0,1,0,Brazil,0,internet-based cognitive behavioral therapy|quality of life promotion,Journal Article|Randomized Controlled Trial
NCT04689672,2020-12-16,5/10/2021,Observational,Predictivity of Hemogasanalysis and Lung UltraSound in Determining COVID-19 Severity,Recruiting,NA,IRCCS San Raffaele,NA,https://clinicaltrials.gov/ct2/show/NCT04689672,0,5,5,0,0,0,Italy,0,lung ultrasound,Letter
NCT04647695,2020-11-20,7/31/2021,Interventional,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicaltrials.gov/ct2/show/NCT04647695,0,2,2,0,2,0,Hong Kong,0,interferon|remdesivir,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04454606,2020-05-01,5/15/2020,Interventional,The New Silicone N99 Half-Piece Respirator,Completed,N/A,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04454606,0,1,1,0,0,0,Thailand,0,fit test|filtration test,Journal Article|Published Erratum
NCT04733729,2020-03-01,1/30/2021,Observational [Patient Registry],Covid-19 in Hematological Malignancies,Recruiting,NA,Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne,NA,https://clinicaltrials.gov/ct2/show/NCT04733729,0,3,3,0,1,0,Italy,0,"NA","Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study|Observational Study/Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04443140,2020-03-15,7/1/2020,Observational [Patient Registry],Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?,Completed,NA,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04443140,0,1,1,0,2,0,Turkey,0,pcr,Journal Article|Observational Study
NCT04558996,2020-03-01,12/31/2020,Observational [Patient Registry],Spanish Registry of Pregnant Women With COVID-19,Recruiting,NA,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04558996,0,1,1,0,0,0,Spain,0,"NA",Letter
NCT04449731,2020-03-20,8/30/2020,Observational,Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int),Recruiting,NA,Universidad de Granada,NA,https://clinicaltrials.gov/ct2/show/NCT04449731,0,2,2,0,3,0,Spain,0,"NA",Journal Article/Journal Article
NCT04643522,2020-01-07,10/5/2020,Observational,Semen Parameters and COVID-19 in Infertile Men,Completed,NA,Ankara City Hospital Bilkent,NA,https://clinicaltrials.gov/ct2/show/NCT04643522,0,4,4,0,1,0,Turkey,0,clinical assessment,Journal Article/Journal Article/Journal Article/Journal Article
NCT04517422,2020-08-19,1/31/2021,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,"Active, not recruiting",N/A,"AB Biotics, SA",NA,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,5,0,Mexico,0,probiotics|placebo,Journal Article/Journal Article/Journal Article|Review/Journal Article/Journal Article/Journal Article
NCT04343898,2020-04-01,8/1/2020,Observational,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,"Active, not recruiting",NA,Brigham and Women's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04343898,0,8,8,0,8,1,United States,0,no intervention,"Clinical Trial|Letter|Multicenter Study|Research Support, N.I.H., Extramural/Journal Article/Journal Article|Multicenter Study/Journal Article|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Letter|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Research Support, N.I.H., Extramural"
NCT04476589,2020-07-01,6/30/2022,Observational,Prognostication of Recovery in Early Disorders of Consciousness After COVID-19,Recruiting,NA,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04476589,0,1,1,0,1,1,United States,0,functional mri,"Case Reports|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04679168,2020-06-01,12/31/2021,Observational [Patient Registry],Study on Kidney Disease and EnviromenTal Chemical,Recruiting,NA,Seoul National University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04679168,0,3,3,0,1,0,"Korea, Republic of",0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04685512,2020-11-18,4/1/2021,Interventional,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Recruiting,Phase 2/Phase 3,"University Hospital, Caen",NA,https://clinicaltrials.gov/ct2/show/NCT04685512,0,5,5,0,0,0,France,0,tenofovir disoproxil/emtricitabine|tenofovir disoproxil|emtricitabine,"Journal Article|Research Support, N.I.H., Extramural"
NCT04514705,2020-08-11,12/31/2021,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise,"Editorial/Case Reports|Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article/Journal Article"
NCT04662437,2020-09-10,12/1/2020,Observational,The Status of Parathyroid Hormone Secretion in Covid-19 Patients,Completed,NA,Bezmialem Vakif University,NA,https://clinicaltrials.gov/ct2/show/NCT04662437,0,3,3,0,0,0,Turkey,0,venous blood was collected for biochemistry testing,Journal Article|Review/Letter
NCT04578158,2020-09-29,4/28/2021,Interventional,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Liaquat University of Medical & Health Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04578158,0,3,3,0,7,0,Pakistan,0,standard covid-19 care|quercetin phytosome,Journal Article/Journal Article
NCT04604249,2020-10-26,11/30/2021,Observational,Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World,"Active, not recruiting",NA,Centre d'Expertise sur l'Altitude EXALT,NA,https://clinicaltrials.gov/ct2/show/NCT04604249,0,6,6,0,1,0,Peru,0,"sars-cov-2 rapid diagnostic test (covid-prestoâ® igm/igg, aaz, boulogne-billancourt, france)|sars-cov-2 rapid diagnostic test (covid-prestoâ® igm|igg, aaz, boulogne-billancourt, france)",Letter|Comment/Journal Article/Journal Article/Letter|Comment
NCT04700254,2020-12-28,1/11/2021,Observational,"Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in Greece",Completed,NA,"Chania General Hospital ""St. George""",NA,https://clinicaltrials.gov/ct2/show/NCT04700254,0,5,5,0,4,0,Greece,0,dass questionnaire|eat-26 questionnaire,Journal Article
NCT04486508,2020-07-30,11/19/2020,Interventional,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Recruiting,Phase 3,Rajaie Cardiovascular Medical and Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04486508,0,1,1,0,5,0,"Iran, Islamic Republic of",0,intermediate dose enoxaparin/ unfractionated heparin|standard prophylactic dose enoxaparin/ unfractionated heparin|atorvastatin|placebo|enoxaparin|heparin|standard prophylactic dose enoxaparin,Clinical Trial Protocol|Journal Article
NCT04659200,2020-09-01,12/5/2020,Observational,Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients,Completed,NA,Bezmialem Vakif University,NA,https://clinicaltrials.gov/ct2/show/NCT04659200,0,1,1,0,2,0,Turkey,0,venous blood was collected for biochemistry testing.,Journal Article
NCT04721457,2021-01-03,2/28/2021,Interventional,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,Recruiting,Phase 4,King Abdulaziz University,NA,https://clinicaltrials.gov/ct2/show/NCT04721457,0,17,17,0,1,0,Saudi Arabia,0,distilled water|1% povidone iodine (pvp-i)|1.5% hydrogen peroxide (h2o2)|0.075% cetylpyridinium chloride (cpc)|0.1% sodium hypochlorite,Journal Article
NCT04705753,2020-04-01,10/15/2020,Interventional,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",Completed,Phase 2/Phase 3,University of Crete,NA,https://clinicaltrials.gov/ct2/show/NCT04705753,0,4,4,0,0,0,Greece,0,cretan iama,Journal Article|Review
NCT04245631,2020-01-01,12/31/2020,Observational,"Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV",Recruiting,NA,Beijing Ditan Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04245631,0,0,0,0,1,0,China,0,recombinase,NA
NCT04252118,2020-01-27,12/31/2020,Interventional,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Recruiting,Phase 1,Beijing 302 Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04252118,0,0,0,0,4,0,China,0,mesenchymal stem cells,NA
NCT04256395,2020-02-01,7/1/2020,Observational,Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19,Completed,NA,Beijing Tsinghua Chang Gung Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04256395,0,0,0,0,4,0,China,0,mobile internet survey on self-test,NA
NCT04263402,2020-02-01,6/1/2020,Interventional,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04263402,0,0,0,0,3,0,China,0,methylprednisolone,NA
NCT04255017,2020-02-01,6/1/2020,Interventional,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04255017,0,0,0,0,3,0,China,0,arbidol|oseltamivir|lopinavir/ritonavir|lopinavir|ritonavir,NA
NCT04254874,2020-02-01,6/1/2020,Interventional,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04254874,0,0,0,0,3,0,China,0,arbidol|arbidol hydrochloride/interferon atomization|interferon,NA
NCT04260308,2020-02-03,4/15/2020,Observational,A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia,Recruiting,NA,Huazhong University of Science and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04260308,0,0,0,0,0,0,China,0,"NA",NA
NCT04255940,2020-01-20,4/30/2020,Observational,2019-nCoV Outbreak and Cardiovascular Diseases,Recruiting,NA,Qilu Hospital of Shandong University,NA,https://clinicalzeros.gov/ct2/show/NCT04255940,0,0,0,0,0,0,China,0,"NA",NA
NCT04261270,2020-02-01,5/1/2020,Interventional,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",Recruiting,Phase 3,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04261270,0,0,0,0,2,0,China,0,asc09f/oseltamivir|ritonavir/oseltamivir|oseltamivir|asc09|ritonavir,NA
NCT04259892,2020-02-04,10/4/2020,Observational,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicalzeros.gov/ct2/show/NCT04259892,0,0,0,0,4,0,France|French Guiana,0,pcr,NA
NCT04331613,2020-01-27,12/31/2020,Interventional,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Recruiting,Phase 1/Phase 2,Chinese Academy of Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04331613,0,0,0,0,0,0,China,0,castem,NA
NCT04275245,2020-02-03,12/31/2020,Interventional,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Recruiting,Phase 1/Phase 2,Tang-Du Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04275245,0,0,0,0,0,0,China,0,meplazumab,NA
NCT04269525,2020-02-06,12/1/2020,Interventional,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Recruiting,Phase 2,Zhongnan Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04269525,0,0,0,0,3,0,China,0,mesenchymal stem cells,NA
NCT04273763,2020-02-16,5/10/2020,Interventional,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",N/A,Second Affiliated Hospital of Wenzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04273763,0,0,0,0,4,0,China,0,bromhexine hydrochloride|arbidol|recombinant human interferon î±2b spray,NA
NCT04645407,2020-02-01,4/15/2020,Interventional,Effects of Fuzheng Huayu Tablets on COVID-19,Completed,Phase 4,ShuGuang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04645407,0,0,0,0,0,0,China,0,fuzheng huayu,NA
NCT04279197,2020-04-23,12/31/2021,Interventional,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,Recruiting,Phase 2,ShuGuang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04279197,0,0,0,0,2,0,China,0,fuzheng huayu|vitamin c tablets|placebo|respiratory function rehabilitation training,NA
NCT04276987,2020-02-15,5/31/2020,Interventional,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,Completed,Phase 1,Ruijin Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04276987,0,0,0,0,3,0,China,0,mesenchymal stem cells,NA
NCT04274322,2020-02-19,4/4/2020,Observational,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool,"Active, not recruiting",NA,Peking University Third Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04274322,0,0,0,0,1,0,China,0,nutrition,NA
NCT04276896,2020-03-24,7/31/2023,Interventional,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Recruiting,Phase 1/Phase 2,Shenzhen Geno-Immune Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04276896,0,0,0,1,2,0,China,0,lv-smenp-dc vaccine/antigen-specific ctls|injection|lv-smenp-dc vaccine|control,NA
NCT04283396,2020-02-21,5/30/2020,Observational,Study for Novel Coronavirus Pneumonia (NCP),Recruiting,NA,"Wuhan Union Hospital, China",NA,https://clinicalzeros.gov/ct2/show/NCT04283396,0,0,0,0,2,0,China,0,systemic,NA
NCT04280224,2020-02-15,9/30/2020,Interventional,NK Cells Treatment for COVID-19,Recruiting,Phase 1,Xinxiang medical university,NA,https://clinicalzeros.gov/ct2/show/NCT04280224,0,0,0,0,1,0,China,0,nk cells,NA
NCT04275947,2020-02-14,4/30/2020,Observational,The COVID-19 Mobile Health Study (CMHS),Recruiting,NA,Chinese Alliance Against Lung Cancer,NA,https://clinicalzeros.gov/ct2/show/NCT04275947,0,0,0,0,0,0,China,0,ncapp,NA
NCT04284046,2020-01-31,2/18/2020,Observational,CT Scores Predict Mortality in 2019-nCoV Pneumonia,Completed,NA,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",NA,https://clinicalzeros.gov/ct2/show/NCT04284046,0,0,0,0,0,0,China,0,ct-scan,NA
NCT04279795,2020-01-20,1/31/2021,Observational,Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations,Recruiting,NA,"Third Affiliated Hospital, Sun Yat-Sen University",NA,https://clinicalzeros.gov/ct2/show/NCT04279795,0,0,0,0,0,0,China,0,"NA",NA
NCT04292327,2020-01-01,4/30/2020,Observational,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus,"Active, not recruiting",NA,Fujian Provincial Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04292327,0,0,0,0,0,0,China,0,"NA",NA
NCT04303299,2020-08-19,12/31/2021,Interventional,"Favipiravir, Protease Inhibitors, Oseltamivir -Gpo, Hydroxychloroquine for Treatment of COVID-19",Recruiting,Phase 3,Rajavithi Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04303299,0,0,0,0,6,0,Thailand,0,oral,NA
NCT04343794,2020-04-01,12/31/2021,Interventional,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04343794,0,0,0,0,1,0,Hong Kong,0,biovitals,NA
NCT04285801,2020-02-14,2/25/2020,Observational,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,Completed,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04285801,0,0,0,0,3,0,Hong Kong,0,"NA",NA
NCT04292340,2020-02-01,7/31/2020,Observational,Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,Recruiting,NA,Shanghai Public Health Clinical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04292340,0,0,0,0,0,0,China,0,"NA",NA
NCT04306497,2020-01-22,4/30/2020,Observational,TCM Differentiation and Treatment Protocol of COVID-19,Completed,NA,"Jiangsu Famous Medical Technology Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04306497,0,0,0,0,2,0,China,0,tcm,NA
NCT04291729,2020-02-17,3/19/2020,Interventional,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Phase 4,The Ninth Hospital of Nanchang,NA,https://clinicalzeros.gov/ct2/show/NCT04291729,0,0,0,0,3,0,China,0,ganovo/ritonavir//-interferon nebulization|ganovo|ritonavir|NA|-interferon nebulization,NA
NCT04312464,2020-01-01,3/15/2020,Observational,Myocardial Damage in COVID-19,Enrolling by invitation,NA,"Wuhan Union Hospital, China",NA,https://clinicalzeros.gov/ct2/show/NCT04312464,0,0,0,0,0,0,China,0,non,NA
NCT04308317,2020-03-05,3/1/2021,Interventional,Tetrandrine Tablets Used in the Treatment of COVID-19,Enrolling by invitation,Phase 4,Henan Provincial People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04308317,0,0,0,0,0,0,China,0,tetrandrine,NA
NCT04306055,2020-03-13,3/13/2020,Interventional,Blood Donor Recruitment During Epidemic of COVID-19,Completed,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04306055,0,0,0,0,1,0,China,0,questionnaire|experimental: questionnaire without precaution information,NA
NCT04310228,2020-03-08,5/31/2020,Interventional,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04310228,0,0,0,0,1,0,China,0,favipiravir/tocilizumab|favipiravir|tocilizumab,NA
NCT04299724,2020-02-15,7/31/2023,Interventional,Safety and Immunity of Covid-19 aAPC Vaccine,Recruiting,Phase 1,Shenzhen Geno-Immune Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04299724,0,0,0,1,0,0,China,0,aapc,NA
NCT04305457,2020-03-21,4/1/2021,Interventional,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04305457,0,0,0,0,12,1,United States,0,nitric oxide,NA
NCT04305106,2020-03-17,6/30/2020,Interventional,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,Recruiting,N/A,Qilu Hospital of Shandong University,NA,https://clinicalzeros.gov/ct2/show/NCT04305106,0,0,0,0,2,0,China,0,bevacizumab,NA
NCT04304690,2020-03-16,5/16/2021,Interventional,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Active, not recruiting",N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04304690,0,0,0,0,4,0,France,0,blood sample,NA
NCT04302688,2019-12-10,2/10/2020,Observational,Accurate Classification System for Patients With COVID-19 Pneumonitis,Completed,NA,Renmin Hospital of Wuhan University,NA,https://clinicalzeros.gov/ct2/show/NCT04302688,0,0,0,0,0,0,China,0,"NA",NA
NCT04306705,2020-02-20,5/30/2020,Observational,Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,Recruiting,NA,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04306705,0,0,0,0,1,0,China,0,tocilizumab|standard care|continuous renal replacement therapy,NA
NCT04314271,2020-03-20,5/1/2020,Observational [Patient Registry],The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,Recruiting,NA,Xiangya Hospital of Central South University,NA,https://clinicalzeros.gov/ct2/show/NCT04314271,0,0,0,0,0,0,China,0,"NA",NA
NCT04313023,2020-06-09,4/30/2021,Interventional,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Recruiting,Phase 2,"Pulmotect, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04313023,0,0,0,0,9,1,United States,0,pul-042|placebo,NA
NCT04312997,2020-06-16,3/31/2021,Interventional,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Recruiting,Phase 2,"Pulmotect, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04312997,0,0,0,0,12,1,United States,0,pul-042|placebo,NA
NCT04318314,2020-03-18,12/31/2020,Observational [Patient Registry],COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,Recruiting,NA,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04318314,0,0,0,0,2,0,United Kingdom,0,copan swabbing/blood sample collection|copan swabbing|blood sample,NA
NCT04316884,2020-03-12,12/31/2020,Observational,Mechanisms for Organ Dysfunction in Covid-19,Recruiting,NA,Uppsala University,NA,https://clinicalzeros.gov/ct2/show/NCT04316884,0,0,0,0,0,0,Sweden,0,"NA",NA
NCT04312100,2020-02-01,10/31/2020,Observational,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Recruiting,NA,Henan Provincial People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04312100,0,0,0,0,0,0,China,0,oxygen,NA
NCT04316299,2020-02-26,2/28/2020,Observational,Acute Kidney Injury in Patients Hospitalized With COVID-19,Completed,NA,Nanfang Hospital of Southern Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04316299,0,0,0,0,2,0,China,0,"NA",NA
NCT04314817,2020-03-17,1/1/2021,Observational,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Recruiting,NA,Groupe Hospitalier Pitie-Salpetriere,NA,https://clinicalzeros.gov/ct2/show/NCT04314817,0,0,0,0,1,0,France,0,any drug used to treat covid-19,NA
NCT04311697,2020-05-15,1/21/2021,Interventional,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,"Active, not recruiting",Phase 2/Phase 3,"NeuroRx, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04311697,0,0,0,0,18,1,United States,0,aviptadil/standard care|saline/standard care|aviptadil|standard care|saline,NA
NCT04315298,2020-03-18,7/24/2020,Interventional,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,Completed,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04315298,0,0,0,0,7,1,United States,0,sarilumab|placebo,NA
NCT04313322,2020-03-16,6/30/2020,Interventional,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,Phase 1,Stem Cells Arabia,NA,https://clinicalzeros.gov/ct2/show/NCT04313322,0,0,0,0,0,0,Jordan,0,mesenchymal stem cells,NA
NCT04313946,2020-03-18,8/16/2020,Observational,Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays,Recruiting,NA,Grigore T. Popa University of Medicine and Pharmacy,NA,https://clinicalzeros.gov/ct2/show/NCT04313946,0,0,0,0,3,0,Italy|Romania|United Kingdom,0,scanning chest x-rays/performing ai algorithms on images|x-ray|performing ai algorithms on images,NA
NCT04347369,2020-01-17,8/30/2020,Observational,A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease,Recruiting,NA,Xinqiao Hospital of Chongqing,NA,https://clinicalzeros.gov/ct2/show/NCT04347369,0,0,0,0,1,0,China,0,other,NA
NCT04323514,2020-03-13,3/13/2021,Interventional,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,N/A,University of Palermo,NA,https://clinicalzeros.gov/ct2/show/NCT04323514,0,0,0,0,0,0,Italy,0,vitamin c,NA
NCT04319315,2020-03-11,4/1/2020,Observational,Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04319315,0,0,0,0,1,0,Egypt,0,questionnaire,NA
NCT04315896,2020-04-14,7/1/2020,Interventional,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),"Active, not recruiting",Phase 3,"National Institute of Respiratory Diseases, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04315896,0,0,0,0,2,0,Mexico,0,hydroxychloroquine|placebo,NA
NCT04315870,2020-01-01,4/20/2020,Observational [Patient Registry],Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.,Recruiting,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04315870,0,0,0,0,0,0,Italy,0,pregnant women with laboratory-confirmed 2019-n-cov,NA
NCT04320017,2020-03-20,5/20/2020,Observational,Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19,Recruiting,NA,Groupe Hospitalier Pitie-Salpetriere,NA,https://clinicalzeros.gov/ct2/show/NCT04320017,0,0,0,0,1,0,France,0,"electrocardiogram, transthoracic echocardiography/clinico-biological parameters in routine care|electrocardiogram, transthoracic echocardiography|clinico-biological parameters in routine care",NA
NCT04319900,2020-03-05,4/30/2020,Interventional,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,Phase 2/Phase 3,Beijing Chao Yang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04319900,0,0,0,0,0,0,China,0,favipiravir/chloroquine|favipiravir|placebo|chloroquine,NA
NCT04319445,2020-03-22,8/31/2020,Interventional,Mindfulness During COVID-19,"Active, not recruiting",N/A,Wake Forest University Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04319445,0,0,0,0,3,1,United States,0,mindfulness session(s),NA
NCT04319172,2020-03-12,3/31/2021,Observational,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Recruiting,NA,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,NA,https://clinicalzeros.gov/ct2/show/NCT04319172,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04320056,2020-04-20,4/30/2021,Interventional,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Recruiting,N/A,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04320056,0,0,0,0,2,0,Canada,0,oxygen,NA
NCT04319016,2020-01-01,4/30/2020,Observational [Patient Registry],Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy,Recruiting,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04319016,0,0,0,0,3,0,Italy,0,pregnant women with laboratory-confirmed 2019-n-cov,NA
NCT04318418,2020-03-23,5/10/2020,Observational,"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",Completed,NA,Neuromed IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04318418,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04318015,2020-04-14,12/31/2020,Interventional,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Recruiting,Phase 3,"National Institute of Respiratory Diseases, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04318015,0,0,0,0,1,0,Mexico,0,hydroxychloroquine|placebo,NA
NCT04318431,2020-04-14,5/12/2020,Interventional,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,Completed,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04318431,0,0,0,0,7,0,France,0,data collection/rhinopharyngeal swab|data collection|rhinopharyngeal,NA
NCT04318301,2020-03-21,3/28/2020,Observational,Hypertension in Patients Hospitalized With COVID-19,Completed,NA,Nanfang Hospital of Southern Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04318301,0,0,0,0,3,0,China,0,"NA",NA
NCT04320953,2020-03-16,3/26/2020,Interventional,Non-contact Endoscopy at Covid-19 Outbreak,Completed,N/A,Changhai Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04320953,0,0,0,0,1,0,China,0,non-contact mce system,NA
NCT04325867,2020-03-31,10/1/2020,Interventional,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,Recruiting,N/A,Grigore T. Popa University of Medicine and Pharmacy,NA,https://clinicalzeros.gov/ct2/show/NCT04325867,0,0,0,0,1,0,Romania,0,telehealth,NA
NCT04320238,2020-01-21,5/31/2020,Interventional,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,Recruiting,Phase 3,Shanghai Jiao Tong University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04320238,0,0,0,0,1,0,China,0,interferon|thymosin,NA
NCT04317040,2020-04-08,10/20/2020,Interventional,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"Active, not recruiting",Phase 3,"OncoImmune, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04317040,0,0,0,0,10,1,United States,0,cd24fc|placebo,NA
NCT04322773,2020-04-05,10/8/2020,Interventional,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,Terminated,Phase 2,Frederiksberg University Hospital,The study has been terminated due to changed clinical conditions and too few patients available,https://clinicalzeros.gov/ct2/show/NCT04322773,0,0,0,0,4,0,Denmark,0,roactemra|sarilumab|standard care,NA
NCT04320472,2020-03-23,9/30/2020,Observational [Patient Registry],Acute Encephalopathy in Critically Ill Patients With COVID-19,"Active, not recruiting",NA,Ictal Group,NA,https://clinicalzeros.gov/ct2/show/NCT04320472,0,0,0,0,13,1,United States|Brazil|Colombia|Egypt|France|Mexico|Spain,0,follow up,NA
NCT04322565,2020-04-20,12/20/2020,Interventional,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Recruiting,Phase 2,Azienda Ospedaliero-Universitaria di Parma,NA,https://clinicalzeros.gov/ct2/show/NCT04322565,0,0,0,0,3,0,Italy,0,colchicine,NA
NCT04320862,2020-04-03,12/31/2021,Observational,COVID-19 Pandemic Response Network,Recruiting,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04320862,0,0,0,0,4,1,United States,0,"NA",NA
NCT04322279,2020-03-09,3/1/2021,Observational,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicalzeros.gov/ct2/show/NCT04322279,0,0,0,0,1,0,France|French Guiana,0,serology test|sequencing,NA
NCT04322188,2020-03-19,5/8/2020,Observational,An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,Completed,NA,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04322188,0,0,0,0,3,0,Italy,0,"NA",NA
NCT04321993,2020-04-17,2/28/2022,Interventional,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,Phase 2,Nova Scotia Health Authority,NA,https://clinicalzeros.gov/ct2/show/NCT04321993,0,0,0,0,6,0,Canada,0,baricitinib,NA
NCT04371601,2020-03-01,12/31/2021,Interventional,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",Early Phase 1,Fuzhou General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04371601,0,0,0,0,0,0,China,0,oseltamivir|hormones|oxygen|mesenchymal stem cells,NA
NCT04330690,2020-03-18,3/18/2022,Interventional,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Recruiting,Phase 2,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04330690,0,0,0,0,32,0,Canada,0,interferon|remdesivir,NA
NCT04353271,2020-04-17,7/8/2020,Interventional,Trial of Hydroxychloroquine In Covid-19 Kinetics,Terminated,Phase 2/Phase 3,University of South Alabama,"FDA recommendations to not use outside of the hospital setting or in a clinical trial due to
    the risk of cardiac arrhythmias",https://clinicalzeros.gov/ct2/show/NCT04353271,0,0,0,0,3,1,United States,0,hydroxychloroquine|placebo,NA
NCT04328129,2020-03-23,3/23/2022,Interventional,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Recruiting,N/A,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04328129,0,0,0,0,3,0,French Guiana|Guadeloupe|New Caledonia,0,biological samples,NA
NCT04323345,2020-04-15,12/15/2020,Interventional,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,Recruiting,Phase 3,Misr University for Science and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04323345,0,0,0,0,1,0,Egypt,0,honey|standard care,NA
NCT04323228,2020-09-01,12/1/2020,Interventional,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Recruiting,Phase 2/Phase 3,King Saud University,NA,https://clinicalzeros.gov/ct2/show/NCT04323228,0,0,0,0,6,0,Saudi Arabia,0,antioxidants|placebo,NA
NCT04322682,2020-03-23,1/21/2021,Interventional,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Completed,Phase 3,Montreal Heart Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04322682,0,0,0,0,12,1,United States|Brazil|Canada|South Africa|Spain,0,colchicine|placebo,NA
NCT04322513,2020-03-24,6/30/2020,Observational,Biomarkers for Identification of COVID-19 Infection,Recruiting,NA,University of Catanzaro,NA,https://clinicalzeros.gov/ct2/show/NCT04322513,0,0,0,0,4,0,Italy,0,biomarkers expression,NA
NCT04322487,2020-04-08,12/31/2020,Observational,"Simple, Safe, Same: Lung Ultrasound for COVID-19",Recruiting,NA,Catholic University of the Sacred Heart,NA,https://clinicalzeros.gov/ct2/show/NCT04322487,0,0,0,0,2,0,Italy,0,lung ultrasound,NA
NCT04322344,2020-03-23,6/30/2020,Interventional,Escin in Patients With Covid-19 Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,https://clinicalzeros.gov/ct2/show/NCT04322344,0,0,0,0,2,0,Italy,0,escin|standard care,NA
NCT04321811,2020-03-21,3/20/2021,Observational [Patient Registry],"Behavior, Environment And Treatments for Covid-19",Recruiting,NA,xCures,NA,https://clinicalzeros.gov/ct2/show/NCT04321811,0,0,0,0,2,1,United States,0,observation|at risk for covid-19 infection,NA
NCT04321616,2020-03-28,8/31/2020,Interventional,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,Recruiting,Phase 2/Phase 3,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04321616,0,0,0,0,2,0,Norway,0,hydroxychloroquine|remdesivir|standard care,NA
NCT04321096,2020-04-04,1/31/2021,Interventional,The Impact of Camostat Mesilate on COVID-19 Infection,"Active, not recruiting",Phase 1/Phase 2,University of Aarhus,NA,https://clinicalzeros.gov/ct2/show/NCT04321096,0,0,0,0,4,0,Denmark|Sweden,0,camostat mesilate|placebo,NA
NCT04320732,2020-03-27,3/27/2022,Observational,Risk Factors for Community- and Workplace Transmission of COVID-19,Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04320732,0,0,0,0,3,0,Norway,0,observation|covid-19 infection will be conducted.,NA
NCT04320615,2020-04-03,6/24/2020,Interventional,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Completed,Phase 3,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04320615,0,0,0,0,10,1,United States|Canada|Denmark|France|Germany|Italy|Netherlands|Spain|United Kingdom,0,tocilizumab|placebo,NA
NCT04320511,2020-06-24,6/30/2021,Observational,Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,Recruiting,NA,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04320511,0,0,0,0,4,1,United States,0,ct-scan,NA
NCT04327349,2020-03-28,5/20/2020,Interventional,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,N/A,Mazandaran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04327349,0,0,0,0,0,0,"Iran, Islamic Republic of",0,convalescent plasma,NA
NCT04325919,2020-02-24,2/28/2021,Observational,Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong,Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04325919,0,0,0,0,0,0,Hong Kong,0,no intervention,NA
NCT04323800,2020-06-10,12/31/2022,Interventional,Convalescent Plasma to Stem Coronavirus (CSSC-001),Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04323800,0,0,0,0,18,1,United States,0,convalescent plasma|plasma,NA
NCT04323787,2020-03-30,4/30/2021,Observational,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04323787,0,0,0,0,4,1,United States,0,observational,NA
NCT04329195,2020-04-09,5/9/2020,Interventional,ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04329195,0,0,0,0,3,0,France,0,discontinuation of ras blocker|continuation of ras blocker,NA
NCT04333368,2020-04-06,1/30/2021,Interventional,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,"Active, not recruiting",Phase 1/Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04333368,0,0,0,0,4,0,France,0,mesenchymal stem cells|saline,NA
NCT04331054,2020-04-13,1/13/2022,Interventional,Protective Role of Inhaled Steroids for Covid-19 Infection,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04331054,0,0,0,0,3,0,France,0,usual practice / symbicort rapihaler|standard care|symbicort,NA
NCT04329611,2020-04-13,7/20/2020,Interventional,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,Terminated,Phase 3,University of Calgary,"Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack
    of Covid19 cases.",https://clinicalzeros.gov/ct2/show/NCT04329611,0,0,0,0,8,0,Canada,0,hydroxychloroquine,NA
NCT04329559,2020-03-30,6/29/2020,Observational [Patient Registry],COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study,Recruiting,NA,Hepatopancreatobiliary Surgery Institute of Gansu Province,NA,https://clinicalzeros.gov/ct2/show/NCT04329559,0,0,0,0,0,0,China,0,"NA",NA
NCT04329546,2020-03-27,1/31/2022,Observational,Understanding COVID-19,Recruiting,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04329546,0,0,0,0,1,0,Switzerland,0,na (no intervention),NA
NCT04336462,2020-02-15,2/21/2020,Interventional,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,Recruiting,N/A,Shanghai Asclepius Meditec Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04336462,0,0,0,0,0,0,China,0,oxyhydrogen|oxygen,NA
NCT04337983,2020-03-13,10/31/2020,Observational,Hemodynamic Characteristics of Patients With SARS-CoV-2,Recruiting,NA,Bicetre Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337983,0,0,0,0,1,0,France,0,transpulmonary thermodilution|echocardiography,NA
NCT04328285,2020-04-14,3/30/2021,Interventional,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,"Active, not recruiting",Phase 3,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04328285,0,0,0,0,7,0,France,0,hydroxychloroquine|placebo|lopinavir/ritonavir|lopinavir|ritonavir|r tablets,NA
NCT04348370,2020-04-20,5/31/2021,Interventional,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Recruiting,Phase 4,Texas A&M University,NA,https://clinicalzeros.gov/ct2/show/NCT04348370,0,0,0,1,5,1,United States,0,bcg|placebo,NA
NCT04327505,2020-06-03,12/31/2021,Interventional,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04327505,0,0,0,0,5,0,Germany|Romania|Sweden,0,oxygen,NA
NCT04327180,2020-03-30,9/30/2021,Observational,PREdiction of DIagnosed Covid-19 infecTion in IUC Patients,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04327180,0,0,0,0,2,0,France,0,"NA",NA
NCT04326452,2020-03-27,3/27/2021,Interventional,Treating COVID-19 With a Bidirectional Oxygenation Valve,Recruiting,N/A,TMC HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04326452,0,0,0,0,2,1,United States,0,bidirectional oxygenation mouthpiece,NA
NCT04336956,2020-04-07,6/30/2021,Observational [Patient Registry],Covid-19 Pediatric Observatory,Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04336956,0,0,0,0,5,0,France,0,hospitalized children with covid19,NA
NCT04325893,2020-04-01,6/18/2020,Interventional,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,Terminated,Phase 3,"University Hospital, Angers",decrease in number of eligible patients,https://clinicalzeros.gov/ct2/show/NCT04325893,0,0,0,0,4,0,France|Monaco,0,hydroxychloroquine|placebo,NA
NCT04325412,2020-03-23,3/23/2021,Observational [Patient Registry],Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY,Recruiting,NA,UMC Utrecht,NA,https://clinicalzeros.gov/ct2/show/NCT04325412,0,0,0,0,1,0,Netherlands,0,"NA",NA
NCT04332380,2020-05-01,7/28/2020,Interventional,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,Phase 2,Universidad del Rosario,NA,https://clinicalzeros.gov/ct2/show/NCT04332380,0,0,0,0,2,0,Colombia,0,plasma,NA
NCT04332107,2020-05-22,9/30/2021,Interventional,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Recruiting,Phase 3,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04332107,0,0,0,0,8,1,United States,0,azithromycin|placebo,NA
NCT04332081,2020-04-06,5/29/2020,Interventional,Hyperbaric Oxygen for COVID-19 Patients,Terminated,N/A,NYU Langone Health,"The IRB has determined that the design of this trial should be changed to a randomized
    controlled trial. A new record will be created for the redesigned study.",https://clinicalzeros.gov/ct2/show/NCT04332081,0,0,0,0,5,1,United States,0,hyperbaric oxygen,NA
NCT04332016,2020-04-02,3/31/2023,Observational,COVID-19 Biological Samples Collection,Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04332016,0,0,0,0,1,0,France,0,biological samples,NA
NCT04324996,2020-02-21,2/20/2022,Interventional,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,Recruiting,Phase 1/Phase 2,Chongqing Public Health Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04324996,0,0,0,0,1,0,China,0,nk cells,NA
NCT04331600,2020-04-16,9/30/2020,Interventional,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,Recruiting,Phase 4,Wroclaw Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04331600,0,0,0,0,1,0,Poland,0,chloroquine|telehealth,NA
NCT04324684,2020-03-31,5/7/2020,Observational,Prognostic Factors Keeping Track for COVID-19 Pneumonia,Completed,NA,Catholic University of the Sacred Heart,NA,https://clinicalzeros.gov/ct2/show/NCT04324684,0,0,0,0,6,0,Italy,0,"NA",NA
NCT04324528,2020-03-27,9/26/2020,Interventional,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,N/A,University Hospital Freiburg,NA,https://clinicalzeros.gov/ct2/show/NCT04324528,0,0,0,0,2,0,Germany,0,vv-ecmo / cytokine adsorption|vv-ecmo|cytokine adsorption,NA
NCT04330521,2020-04-08,5/31/2022,Observational,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Recruiting,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04330521,0,0,0,0,2,1,United States,0,"NA",NA
NCT04324489,2020-03-06,4/16/2020,Interventional,DAS181 for Severe COVID-19: Compassionate Use,Completed,N/A,Renmin Hospital of Wuhan University,NA,https://clinicalzeros.gov/ct2/show/NCT04324489,0,0,0,0,2,0,China,0,das181,NA
NCT04324463,2020-04-21,12/31/2020,Interventional,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,Recruiting,Phase 3,Population Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04324463,0,0,0,0,5,0,Brazil|Canada|Chile|Colombia|Ecuador|Egypt|India|Pakistan|Philippines|Russian Federation|Saudi Arabia|United Arab Emirates,0,colchicine|interferon|aspirin|rivaroxaban,NA
NCT04324073,2020-03-27,3/27/2021,Interventional,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",Phase 2/Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04324073,0,0,0,0,2,0,France,0,sarilumab,NA
NCT04324047,2020-03-27,3/27/2021,Observational,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04324047,0,0,0,0,1,0,France,0,"NA",NA
NCT04324021,2020-04-02,11/13/2020,Interventional,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,Terminated,Phase 2/Phase 3,Swedish Orphan Biovitrum,"Standard of care evolved during the timeframe of the study and had critical impact on
    recruitment.

    Early termination is not based on safety reasons but because of recruitment issues.

    Patients ongoing will be completed. Planned LPLV 25Jan2021",https://clinicalzeros.gov/ct2/show/NCT04324021,0,0,0,0,7,1,United States|Italy,0,emapalumab|anakinra,NA
NCT04323878,2020-06-01,3/31/2021,Observational,Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.,Recruiting,NA,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04323878,0,0,0,0,3,0,Italy,0,"NA",NA
NCT04355962,2020-04-23,3/31/2022,Interventional,Sevoflurane in COVID-19 ARDS (SevCov),Recruiting,Phase 3,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04355962,0,0,0,0,5,0,Switzerland,0,sevoflurane|intravenous drug,NA
NCT04332913,2020-04-01,12/31/2020,Observational,Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia,Recruiting,NA,University of L'Aquila,NA,https://clinicalzeros.gov/ct2/show/NCT04332913,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04328480,2020-04-17,3/30/2021,Interventional,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Recruiting,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,NA,https://clinicalzeros.gov/ct2/show/NCT04328480,0,0,0,0,4,0,Argentina,0,colchicine|standard care,NA
NCT04336384,2020-03-01,12/1/2020,Observational,Impact of Covid-19 in Congenital Heart Disease,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04336384,0,0,0,0,2,0,France,0,"NA",NA
NCT04376515,2020-03-20,6/1/2021,Interventional,Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),"Active, not recruiting",N/A,"University of California, Irvine",NA,https://clinicalzeros.gov/ct2/show/NCT04376515,0,0,0,0,1,1,United States,0,hope intervention,NA
NCT04329533,2020-04-13,11/1/2020,Interventional,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Completed,N/A,University of Arizona,NA,https://clinicalzeros.gov/ct2/show/NCT04329533,0,0,0,0,8,1,United States,0,"""calm"" is a mindfulness meditation mobile app",NA
NCT04352348,2020-03-31,5/31/2021,Interventional,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04352348,0,0,0,0,4,0,France,0,blood sample|fecal sample|sweat samples (covidog ancillary study)|saliva|6 minutes walk test|phone call|urine samples,NA
NCT04347174,2020-04-30,8/10/2020,Interventional,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,Completed,N/A,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04347174,0,0,0,0,6,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04343651,2020-04-01,7/21/2020,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"Active, not recruiting",Phase 2,"CytoDyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04343651,0,0,0,0,7,1,United States,0,placebo|lenzilumab,NA
NCT04340219,2020-03-30,4/10/2020,Observational,"Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic",Completed,NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04340219,0,0,0,0,2,0,Belgium,0,questionnaire,NA
NCT04329507,2020-03-25,3/25/2021,Observational,Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS),Recruiting,NA,NHS Lothian,NA,https://clinicalzeros.gov/ct2/show/NCT04329507,0,0,0,0,1,0,United Kingdom,0,breath test,NA
NCT04327804,2020-03-25,4/3/2020,Observational,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,Recruiting,NA,UnitedHealth Group,NA,https://clinicalzeros.gov/ct2/show/NCT04327804,0,0,0,0,1,1,United States,0,odd/even birth year intervention groups|odd|even birth year intervention groups,NA
NCT04327570,2020-03-27,9/30/2020,Observational [Patient Registry],In-depth Immunological Investigation of COVID-19.,Recruiting,NA,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04327570,0,0,0,0,1,0,Belgium,0,patient sampling,NA
NCT04327479,2020-03-26,3/25/2026,Observational [Patient Registry],Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection,Recruiting,NA,"University Hospital, Essen",NA,https://clinicalzeros.gov/ct2/show/NCT04327479,0,0,0,0,2,0,Germany,0,assessment of cardiovascular diseases/cardiovascular risk factors|assessment of cardiovascular diseases|cardiovascular risk factors,NA
NCT04336332,2020-04-01,4/30/2021,Interventional,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Recruiting,Phase 2,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04336332,0,0,0,0,3,1,United States,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,NA
NCT04327388,2020-03-28,7/30/2020,Interventional,Sarilumab COVID-19,Completed,Phase 3,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04327388,0,0,0,0,17,0,Argentina|Brazil|Canada|Chile|France|Germany|Israel|Italy|Japan|Russian Federation|Spain,0,sarilumab|placebo,NA
NCT04335305,2020-04-09,12/31/2020,Interventional,Checkpoint Blockade in COVID-19 Pandemic,Recruiting,Phase 2,MedSIR,NA,https://clinicalzeros.gov/ct2/show/NCT04335305,0,0,0,0,8,0,Spain,0,tocilizumab|pembrolizumab,NA
NCT04335188,2020-04-06,7/31/2021,Observational,COVID-19 Registry Rhineland-Palatinate (Germany),Recruiting,NA,IHF GmbH - Institut fÃ¼r Herzinfarktforschung,NA,https://clinicalzeros.gov/ct2/show/NCT04335188,0,0,0,0,2,0,Germany,0,prospective oberservational registry,NA
NCT04334980,2020-11-02,2/8/2022,Interventional,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19",Recruiting,Phase 1,Symvivo Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04334980,0,0,0,1,7,0,Australia,0,bactrl-spike,NA
NCT04326725,2020-03-20,7/1/2020,Observational,Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia,"Active, not recruiting",NA,Istinye University,NA,https://clinicalzeros.gov/ct2/show/NCT04326725,0,0,0,0,2,0,Turkey,0,hydroxychloroquine,NA
NCT04333953,2020-04-01,10/1/2020,Observational [Patient Registry],COVID-19 in Patients With HIV,Recruiting,NA,University of Missouri-Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04333953,0,0,0,0,1,1,United States,0,no intervention,NA
NCT04326426,2020-04-13,8/1/2020,Interventional,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,Enrolling by invitation,Phase 3,Vanda Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04326426,0,0,0,0,2,1,United States,0,tradipitant|placebo,NA
NCT04333355,2020-05-08,12/20/2020,Interventional,Safety in Convalescent Plasma Transfusion to COVID-19,Recruiting,Phase 1,Hospital San Jose Tec de Monterrey,NA,https://clinicalzeros.gov/ct2/show/NCT04333355,0,0,0,0,2,0,Mexico,0,convalescent plasma,NA
NCT04332835,2020-08-08,10/31/2020,Interventional,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,Phase 2/Phase 3,Universidad del Rosario,NA,https://clinicalzeros.gov/ct2/show/NCT04332835,0,0,0,0,4,0,Colombia,0,plasma|standard care,NA
NCT04326387,2020-04-06,4/7/2021,Observational,Evaluation of Novel Diagnostic Tests for COVID-19,Recruiting,NA,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04326387,0,0,0,0,2,0,United Kingdom,0,samba ii|public health england gold standard|cambridge validated viral detection|radiological,NA
NCT04332094,2020-04-02,9/30/2020,Interventional,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",Recruiting,Phase 2,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,https://clinicalzeros.gov/ct2/show/NCT04332094,0,0,0,0,3,0,Spain,0,tocilizumab|hydroxychloroquine|azithromycin,NA
NCT04326075,2020-12-01,3/31/2021,Interventional,Early CPAP in COVID-19 Patients With Respiratory Failure.,Recruiting,N/A,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04326075,0,0,0,0,3,0,Italy,0,cpap,NA
NCT04326036,2020-03-25,11/1/2021,Interventional,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Recruiting,Early Phase 1,"Black Tie Medical, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04326036,0,0,0,0,2,1,United States,0,tsvf|centricyte 1000|csvf|liberase enzyme|saline,NA
NCT04325906,2020-04-02,3/30/2021,Interventional,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Recruiting,N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04325906,0,0,0,0,5,1,United States,0,high flow nasal cannula (hfnc)|prone positioning,NA
NCT04331886,2020-04-13,3/31/2021,Observational,An Observational Study of Patients With Coronavirus Disease 2019,Recruiting,NA,"Target PharmaSolutions, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04331886,0,0,0,0,4,1,United States,0,"NA",NA
NCT04325646,2020-03-13,2/28/2021,Observational,Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France,Recruiting,NA,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04325646,0,0,0,0,5,0,France,0,biological samples,NA
NCT04324190,2020-04-08,6/30/2020,Interventional,DIgital Online SuPport for COVID-19 StrEss,Recruiting,N/A,International Psychoanalytic University Berlin,NA,https://clinicalzeros.gov/ct2/show/NCT04324190,0,0,0,0,3,0,Germany,0,guided online support program|who recommendations (waiting condition),NA
NCT04331366,2020-04-08,8/31/2020,Interventional,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,N/A,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04331366,0,0,0,0,3,1,United States,0,go2 peep mouthpiece,NA
NCT04330599,2020-05-01,4/1/2025,Observational,Longitudinal Population-based Observational Study of COVID-19 in the UK Population,Recruiting,NA,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04330599,0,0,0,0,3,0,United Kingdom,0,"NA",NA
NCT04329650,2020-04-15,5/20/2020,Interventional,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04329650,0,0,0,0,3,0,Spain,0,siltuximab|methylprednisolone,NA
NCT04333732,2020-09-04,8/31/2021,Interventional,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,Recruiting,Phase 3,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04333732,0,0,0,0,11,1,United States|Ghana|South Africa|United Kingdom|Zambia|Zimbabwe,0,mr/m-m-r ii â® vaccine|placebo|mr|m-m-r ii â® vaccine,NA
NCT04337996,2020-07-13,1/13/2021,Interventional,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337996,0,0,0,0,3,0,France,0,covid-19 diagnostic test,NA
NCT04331899,2020-04-24,8/14/2020,Interventional,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"Active, not recruiting",Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04331899,0,0,0,0,3,1,United States,0,peginterferon|placebo,NA
NCT04328454,2020-01-30,4/2/2020,Observational,Clinical Characteristics and Prognostic Factors of Patients With COVID-19,Recruiting,NA,Shanghai 10th People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04328454,0,0,0,0,0,0,China,0,retrospective,NA
NCT04328012,2020-04-06,1/1/2021,Interventional,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,Recruiting,Phase 2/Phase 3,Bassett Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04328012,0,0,0,0,2,1,United States,0,losartan|placebo,NA
NCT04341766,2020-03-31,5/27/2020,Observational [Patient Registry],Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19,Completed,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04341766,0,0,0,0,2,0,France,0,no special intervention,NA
NCT04339712,2020-04-02,12/1/2020,Interventional,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Completed,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04339712,0,0,0,0,5,0,Greece,0,anakinra|tocilizumab,NA
NCT04327674,2020-03-14,5/15/2020,Observational [Patient Registry],The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19,Recruiting,NA,University of Aarhus,NA,https://clinicalzeros.gov/ct2/show/NCT04327674,0,0,0,0,0,0,Denmark,0,"NA",NA
NCT04333472,2021-01-06,3/6/2021,Interventional,Piclidenoson for Treatment of COVID-19,Recruiting,Phase 2,Can-Fite BioPharma,NA,https://clinicalzeros.gov/ct2/show/NCT04333472,0,0,0,0,7,0,Israel,0,piclidenoson|placebo,NA
NCT04343092,2020-04-18,5/31/2020,Interventional,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Completed,Phase 1,University of Baghdad,NA,https://clinicalzeros.gov/ct2/show/NCT04343092,0,0,0,0,4,0,Iraq,1,ivermectin,NA
NCT04335279,2020-04-09,6/3/2020,Interventional,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,Completed,N/A,Lady Davis Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04335279,0,0,0,0,7,0,Canada,0,spin-chat program,NA
NCT04341675,2020-04-24,7/31/2020,Interventional,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,University of Cincinnati,NA,https://clinicalzeros.gov/ct2/show/NCT04341675,0,0,0,0,4,1,United States,0,sirolimus|placebo,NA
NCT04335136,2020-04-30,12/26/2020,Interventional,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,Phase 2,Apeiron Biologics,NA,https://clinicalzeros.gov/ct2/show/NCT04335136,0,0,0,0,6,0,Austria|Denmark|Germany|Russian Federation|United Kingdom,0,rhace2|saline,NA
NCT04335097,2020-04-22,4/8/2021,Interventional,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Recruiting,N/A,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04335097,0,0,0,0,3,0,Norway,0,biosensor,NA
NCT04338828,2020-04-18,4/30/2021,Interventional,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,Recruiting,Phase 2,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04338828,0,0,0,0,1,1,United States,0,nitric oxide|oxygen,NA
NCT04337424,2020-04-13,10/7/2020,Observational,Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04337424,0,0,0,0,4,0,France,0,salivary,NA
NCT04333914,2020-04-15,6/30/2021,Interventional,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,Recruiting,Phase 2,Centre Leon Berard,NA,https://clinicalzeros.gov/ct2/show/NCT04333914,0,0,0,0,7,0,France,0,avdoralimab|autophagy inhibitor (gns651)|standard care|monalizumab,NA
NCT04333862,2020-03-19,1/31/2022,Observational,Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04333862,0,0,0,0,1,0,Switzerland,0,"NA",NA
NCT04337346,2020-04-05,4/20/2020,Observational [Patient Registry],Evaluation of Covid 19 Anxiety in Endometriosis Patients,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337346,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04337320,2020-03-15,5/25/2020,Observational,"Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study",Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337320,0,0,0,0,1,0,Turkey,0,newborns,NA
NCT04366765,2020-03-19,6/30/2021,Observational,COVID-19 Survival - The COVIVA Study,Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04366765,0,0,0,0,1,0,Switzerland,0,"NA",NA
NCT04333654,2020-04-12,5/26/2020,Interventional,Hydroxychloroquine in Outpatient Adults With COVID-19,Terminated,Phase 1,Sanofi,Rate of enrollment too slow to allow completion in a reasonable timeframe,https://clinicalzeros.gov/ct2/show/NCT04333654,0,0,0,0,7,1,United States|Belgium|France|Netherlands,0,hydroxychloroquine|placebo,NA
NCT04333628,2020-06-01,9/1/2020,Interventional,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,Terminated,Phase 2/Phase 3,"HaEmek Medical Center, Israel",Teminated due to changes in treatment guidelines .,https://clinicalzeros.gov/ct2/show/NCT04333628,0,0,0,0,3,0,Israel,0,chloroquine|standard care,NA
NCT04354558,2020-07-01,7/31/2021,Observational,French Single Centre Experience of Critically Ill Patients With Covid 19,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04354558,0,0,0,0,2,0,France,0,"NA",NA
NCT04333407,2020-04-03,3/30/2021,Interventional,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,N/A,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04333407,0,0,0,0,2,0,United Kingdom,0,aspirin|clopidogrel|rivaroxaban|atorvastatin|omeprazole,NA
NCT04333225,2020-04-03,6/30/2020,Interventional,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,Completed,Phase 2,Baylor Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04333225,0,0,0,0,4,1,United States,0,hydroxychloroquine,NA
NCT04354519,2020-03-14,7/14/2021,Observational [Patient Registry],The United Kingdom Multiple Sclerosis Register Covid-19 Substudy,Recruiting,NA,Swansea University,NA,https://clinicalzeros.gov/ct2/show/NCT04354519,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04349631,2020-04-22,12/31/2020,Interventional,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"Active, not recruiting",Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04349631,0,0,0,0,4,1,United States,0,mesenchymal stem cells,NA
NCT04346797,2020-04-16,9/30/2020,Interventional,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04346797,0,0,0,0,1,0,France,0,eculizumab,NA
NCT04331795,2020-04-04,6/5/2020,Interventional,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Completed,Phase 2,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04331795,0,0,0,0,6,1,United States,0,tocilizumab,NA
NCT04334044,2020-09-01,3/1/2021,Interventional,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Recruiting,Phase 1/Phase 2,Grupo Cooperativo de HemopatÃ­as Malignas,NA,https://clinicalzeros.gov/ct2/show/NCT04334044,0,0,0,0,2,0,Mexico,0,ruxolitinib,NA
NCT04340557,2020-03-27,10/6/2020,Interventional,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Recruiting,Phase 4,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04340557,0,0,0,0,1,1,United States,0,losartan,NA
NCT04340479,2020-07-30,5/31/2022,Observational [Patient Registry],The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation,Recruiting,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04340479,0,0,0,0,4,1,United States,0,ultrasound|evaluation,NA
NCT04339998,2020-04-15,10/31/2020,Observational,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Recruiting,NA,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04339998,0,0,0,0,2,1,United States,0,ultrasonography,NA
NCT04347226,2020-04-16,9/30/2021,Interventional,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04347226,0,0,0,0,3,1,United States,0,bms-986253,NA
NCT04339881,2020-04-17,7/10/2020,Observational [Patient Registry],NOsocomial Dissemination Risk of SARS-Cov2,Completed,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04339881,0,0,0,0,1,0,France,0,"NA",NA
NCT04339387,2020-03-01,4/26/2020,Observational,COVID-19 Risk Stratification,Completed,NA,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04339387,0,0,0,0,1,1,United States,0,"NA",NA
NCT04339660,2020-02-01,6/30/2020,Interventional,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,Phase 1/Phase 2,Puren Hospital Affiliated to Wuhan University of Science and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04339660,0,0,0,0,0,0,China,0,mesenchymal stem cells|placebo,NA
NCT04336215,2020-04-07,9/1/2020,Observational,Rutgers COVID-19 Cohort Study,Recruiting,NA,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04336215,0,0,0,0,1,1,United States,0,non-interventional,NA
NCT04335851,2020-04-06,5/15/2020,Interventional,Video-Based Exercises and Well-Being During Social Isolation,Completed,N/A,Biruni University,NA,https://clinicalzeros.gov/ct2/show/NCT04335851,0,0,0,0,1,0,Turkey,0,exercise,NA
NCT04335630,2020-03-30,3/31/2021,Observational,Cardiovascular Manifestations of COVID-19,Recruiting,NA,Memorial Hermann Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04335630,0,0,0,0,1,1,United States,0,"electrocardiogram, telemetry, echocardiogram, laboratory values",NA
NCT04335084,2020-06-22,6/30/2021,Interventional,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04335084,0,0,0,0,5,1,United States,0,hydroxychloroquine|vitamin c|vitamin d|zinc,NA
NCT04335071,2020-04-26,9/27/2020,Interventional,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Terminated,Phase 2,"University Hospital Inselspital, Berne","1.) Not possible to recruit the planned number of patients during the planned study period; 2.)
    ""Dexamethason"" was included in the standard of care for the study population during the course
    of the study and inclusion criteria could no longer be met.",https://clinicalzeros.gov/ct2/show/NCT04335071,0,0,0,0,4,0,Switzerland,0,tocilizumab|placebo,NA
NCT04334928,2020-04-15,12/31/2020,Interventional,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Recruiting,Phase 3,Plan Nacional sobre el Sida (PNS),NA,https://clinicalzeros.gov/ct2/show/NCT04334928,0,0,0,0,5,0,Spain,0,emtricitabine/tenofovir disoproxil|hydroxychloroquine|placebo|emtricitabine|tenofovir disoproxil,NA
NCT04338074,2020-06-01,12/15/2020,Interventional,TXA and Corona Virus 2019 (COVID19) in Outpatients,Recruiting,Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04338074,0,0,0,0,2,1,United States,0,placebo|tranexamic acid,NA
NCT04337918,2020-05-08,1/31/2021,Interventional,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Active, not recruiting",Phase 2,Sanotize Research and Development corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04337918,0,0,0,0,6,0,Canada,0,nitric oxide,NA
NCT04337762,2020-04-06,12/31/2020,Observational,Beat COVID-19 - Observational Trial,Recruiting,NA,Beat COVID LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04337762,0,0,0,0,1,1,United States,0,"NA",NA
NCT04337502,2019-12-23,1/20/2020,Observational,Clinical and Radiomic Model of COVID-19,Completed,NA,Maastricht University,NA,https://clinicalzeros.gov/ct2/show/NCT04337502,0,0,0,0,0,0,China,0,machine learning model,NA
NCT04334850,2020-04-20,7/31/2020,Interventional,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04334850,0,0,0,0,1,0,France,0,pcr|usual antibiotic treatment|procalcitonin,NA
NCT04334629,2020-05-26,5/25/2021,Interventional,LIBERATE Trial in COVID-19,Recruiting,Phase 4,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04334629,0,0,0,0,4,0,United Kingdom,0,ibuprofen,NA
NCT04334512,2020-06-22,6/30/2021,Interventional,A Study of Quintuple Therapy to Treat COVID-19 Infection,Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04334512,0,0,0,0,4,1,United States,0,hydroxychloroquine|azithromycin|vitamin c|vitamin d|zinc,NA
NCT04334460,2020-05-04,10/9/2020,Interventional,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Active, not recruiting",Phase 2,Blade Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04334460,0,0,0,0,9,1,United States|Brazil,0,bld-2660,NA
NCT04334382,2020-04-02,12/31/2020,Interventional,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Recruiting,Phase 3,"Intermountain Health Care, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04334382,0,0,0,0,1,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04334252,2020-04-17,12/20/2020,Observational,Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia,Completed,NA,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04334252,0,0,0,0,4,0,Belgium,0,questionnaire,NA
NCT04352933,2020-05-11,10/31/2020,Interventional,PROLIFIC ChemoprophylaxisTrial (COVID-19),Recruiting,Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04352933,0,0,0,0,1,0,United Kingdom,0,hydroxychloroquine|placebo,NA
NCT04334434,2020-07-30,9/15/2020,Interventional,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Completed,N/A,Istanbul University-Cerrahpasa,NA,https://clinicalzeros.gov/ct2/show/NCT04334434,0,0,0,0,4,0,Turkey,0,telehealth,NA
NCT04347408,2020-05-06,12/13/2020,Observational,Seroprevalence of SARS-Cov-2 Antibodies in Children,Recruiting,NA,"Queen's University, Belfast",NA,https://clinicalzeros.gov/ct2/show/NCT04347408,0,0,0,0,5,0,United Kingdom,0,igm/igg rapid test|igm,NA
NCT04347031,2020-04-08,11/1/2020,Interventional,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,Completed,Phase 2/Phase 3,Burnasyan Federal Medical Biophysical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04347031,0,0,0,0,2,0,Russian Federation,0,mefloquine|hydroxychloroquine|mefloquine/azithromycin/ tocilizumab|hydroxychloroquine/azithromycin/ tocilizumab|azithromycin|NA|- tocilizumab,NA
NCT04346147,2020-04-13,3/31/2021,Interventional,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,Recruiting,Phase 2,Hospital Universitario de Fuenlabrada,NA,https://clinicalzeros.gov/ct2/show/NCT04346147,0,0,0,0,3,0,Spain,0,imatinib|baricitinib|supportive tratment,NA
NCT04344210,2020-04-17,9/20/2020,Interventional,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Completed,N/A,Federal University of Rio Grande do Sul,NA,https://clinicalzeros.gov/ct2/show/NCT04344210,0,0,0,0,1,0,Brazil,0,tele-interventions related to diabetes management/mental well-being|tele-interventions related to diabetes management|mental well-being,NA
NCT04343742,2020-04-01,4/7/2020,Observational,Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19,Recruiting,NA,Genesis Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04343742,0,0,0,0,1,0,Colombia,0,chlorine dioxide,NA
NCT04348409,2020-05-25,7/31/2020,Interventional,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,Recruiting,N/A,Azidus Brasil,NA,https://clinicalzeros.gov/ct2/show/NCT04348409,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04347278,2020-04-22,10/15/2020,Observational [Patient Registry],Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry,Recruiting,NA,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,NA,https://clinicalzeros.gov/ct2/show/NCT04347278,0,0,0,0,1,0,Spain,0,patients with the treatment agains covid19,NA
NCT04344925,2020-04-18,11/30/2021,Observational,Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19,Recruiting,NA,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04344925,0,0,0,0,4,0,Canada,0,mask,NA
NCT04342169,2020-04-04,4/30/2021,Interventional,University of Utah COVID-19 Hydrochloroquine Trial,Recruiting,Phase 2,University of Utah,NA,https://clinicalzeros.gov/ct2/show/NCT04342169,0,0,0,0,3,1,United States,0,hydroxychloroquine|placebo,NA
NCT04341792,2020-04-11,4/30/2021,Observational,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04341792,0,0,0,0,2,0,France,0,"NA",NA
NCT04340544,2020-04-22,10/12/2020,Interventional,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Terminated,Phase 2,University Hospital Tuebingen,"It appeared to be impossible for the study centres to recruit the targeted number of patients,
    due to reduced incidence and reduced acceptance to IMP",https://clinicalzeros.gov/ct2/show/NCT04340544,0,0,0,0,2,0,Germany,0,hydroxychloroquine|placebo,NA
NCT04341415,2020-04-09,3/31/2021,Interventional,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Recruiting,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04341415,0,0,0,0,2,0,France,0,auricular neuromodulation|control,NA
NCT04341519,2020-04-06,11/30/2020,Observational,"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers",Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04341519,0,0,0,0,1,0,France,0,ptsd|burnout,NA
NCT04339491,2020-04-01,5/31/2020,Observational,Physical Activity During Social Isolation,Completed,NA,Istanbul University-Cerrahpasa,NA,https://clinicalzeros.gov/ct2/show/NCT04339491,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04341506,2020-09-08,7/15/2021,Observational,Non-contact ECG Sensor System for COVID19,Recruiting,NA,Northwestern Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04341506,0,0,0,0,1,1,United States,0,ecg,NA
NCT04341480,2020-07-01,12/10/2020,Observational,The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19,"Active, not recruiting",NA,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04341480,0,0,0,0,1,0,China,0,chemotherapy,NA
NCT04341441,2020-04-07,12/15/2020,Interventional,Will Hydroxychloroquine Impede or Prevent COVID-19,Terminated,Phase 3,Henry Ford Health System,"Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not
    provide support to continue. Event rate did not meet projected magnitude; given low recruitment
    potential, it is unlikely that a positive result will occur.",https://clinicalzeros.gov/ct2/show/NCT04341441,0,0,0,0,5,1,United States,0,hydroxychloroquine|placebo|monitoring visit|weekly assessment,NA
NCT04341012,2019-09-10,12/31/2021,Observational,Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04341012,0,0,0,0,1,1,United States,0,collection of breath sample,NA
NCT04340466,2020-04-03,7/3/2020,Observational [Patient Registry],French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study,Completed,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04340466,0,0,0,0,2,0,France,0,no intervention,NA
NCT04337190,2020-04-03,10/6/2020,Observational,Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2),Recruiting,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04337190,0,0,0,0,1,0,France,0,blood sample,NA
NCT04337151,2020-04-30,1/31/2021,Observational,Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment,Recruiting,NA,Royal National Orthopaedic Hospital NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04337151,0,0,0,0,0,0,United Kingdom,0,magec spine rod|titanium blood test,NA
NCT04337047,2020-03-31,4/30/2020,Observational,Distress in Crisis Situations During COVID-19,Completed,NA,Wefight,NA,https://clinicalzeros.gov/ct2/show/NCT04337047,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04337008,2020-04-03,6/3/2020,Interventional,Renin Angiotensin System - CoronaVirus,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04337008,0,0,0,0,1,0,France,0,blood sample,NA
NCT04336904,2020-03-25,7/31/2020,Interventional,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"Active, not recruiting",Phase 3,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04336904,0,0,0,0,1,0,Italy,0,favipiravir|placebo,NA
NCT04336761,2020-04-15,1/31/2021,Observational,Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04336761,0,0,0,0,2,0,France,0,nasopharyngeal swab,NA
NCT04336657,2020-04-30,5/31/2020,Observational,Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04336657,0,0,0,0,0,0,Egypt,0,questionnaire|igg,NA
NCT04339634,2020-04-07,7/7/2020,Observational,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy,"Active, not recruiting",NA,Tabula Rasa HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04339634,0,0,0,0,1,1,United States,0,simulation of repurposed drugs for covid-19,NA
NCT04339426,2020-04-20,7/31/2021,Interventional,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,Recruiting,Phase 2,HonorHealth Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04339426,0,0,0,0,5,1,United States,0,atovaquone/azithromycin|atovaquone|azithromycin,NA
NCT04338945,2020-03-15,4/15/2020,Observational,Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy,Completed,NA,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,NA,https://clinicalzeros.gov/ct2/show/NCT04338945,0,0,0,0,3,0,Italy,0,covid-surgres questionaire,NA
NCT04338932,2020-04-17,5/15/2020,Observational,COVID-19 and Deep Venous Thrombosis,Completed,NA,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04338932,0,0,0,0,2,0,Belgium,0,"NA",NA
NCT04335773,2020-04-03,12/31/2030,Observational [Patient Registry],"COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",Recruiting,NA,"University Hospital, Akershus",NA,https://clinicalzeros.gov/ct2/show/NCT04335773,0,0,0,0,1,0,Norway,0,"NA",NA
NCT04335747,2020-04-23,8/1/2021,Observational,COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases,Recruiting,NA,Aalborg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04335747,0,0,0,0,2,0,Denmark,0,covid-19 infection,NA
NCT04341584,2020-04-08,5/10/2020,Interventional,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,Completed,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04341584,0,0,0,0,2,0,France,0,anakinra,NA
NCT04335552,2020-04-17,6/17/2020,Interventional,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,Phase 2,Duke University,"Poor recruitment, strong evidence from larger trials of no therapeutic benefit",https://clinicalzeros.gov/ct2/show/NCT04335552,0,0,0,0,3,1,United States,0,standard care|hydroxychloroquine|azithromycin,NA
NCT04358081,2020-05-01,7/27/2020,Interventional,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Completed,Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04358081,0,0,0,0,6,1,United States,0,hydroxychloroquine|hydroxychloroquine / azithromycin|placebo|zidovudine,NA
NCT04358042,2020-04-24,1/1/2022,Observational [Patient Registry],PSYCHIATRIC Disorders and Covid-19,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04358042,0,0,0,0,1,0,France,0,"brief psychiatric rating scale|depression, anxiety/stress scale|impact of event scale-revised|connor-davidson resilience scale 10 items (cd-risc 10)|depression, anxiety|stress scale",NA
NCT04352634,2020-04-26,12/31/2021,Observational,The Covid-19 HEalth caRe wOrkErS (HEROES) Study,Recruiting,NA,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04352634,0,0,0,0,6,1,United States|Argentina|Armenia|Australia|Bolivia|Chile|Costa Rica|Czechia|Germany|Guatemala|Italy|Lebanon|Mexico|Netherlands|Nigeria|Puerto Rico|Saudi Arabia|Spain|Tunisia|Turkey|Venezuela,0,exposure|its,NA
NCT04342702,2020-03-16,3/31/2021,Observational,A Study on the Prospective Cohort Library of COVID-19 in Southeran,"Active, not recruiting",NA,Second Affiliated Hospital of Wenzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04342702,0,0,0,0,2,0,China,0,"NA",NA
NCT04342650,2020-04-08,5/14/2020,Interventional,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicalzeros.gov/ct2/show/NCT04342650,0,0,0,0,2,0,Brazil,0,chloroquine|placebo,NA
NCT04341116,2020-04-11,12/31/2021,Interventional,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2/Phase 3,I-Mab Biopharma Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04341116,0,0,0,0,14,1,United States,0,tj003234|placebo,NA
NCT04350580,2020-04-11,4/30/2021,Interventional,Polyvalent Immunoglobulin in COVID-19 Related ARds,Recruiting,Phase 3,Centre Hospitalier St Anne,NA,https://clinicalzeros.gov/ct2/show/NCT04350580,0,0,0,0,2,0,France,0,immunoglobulin|placebo,NA
NCT04347928,2020-04-20,11/6/2020,Observational,Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04347928,0,0,0,0,2,0,France,0,"NA",NA
NCT04347460,2020-03-27,7/1/2020,Observational,Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH,Recruiting,NA,Technische UniversitÃ¤t MÃ¼nchen,NA,https://clinicalzeros.gov/ct2/show/NCT04347460,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04346693,2020-04-08,11/1/2020,Interventional,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,Completed,Phase 3,Burnasyan Federal Medical Biophysical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04346693,0,0,0,0,2,0,Russian Federation,0,standard care|dalargin,NA
NCT04346420,2020-04-09,5/1/2020,Interventional,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Completed,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04346420,0,0,0,0,1,0,Belgium,0,standard interface|mask,NA
NCT04345653,2020-04-14,6/5/2020,Interventional,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Active, not recruiting",Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04345653,0,0,0,0,2,1,United States,0,hydroxychloroquine,NA
NCT04345861,2020-04-11,6/8/2020,Interventional,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Terminated,Phase 2/Phase 3,"University Hospital, Montpellier",halted prematurely.,https://clinicalzeros.gov/ct2/show/NCT04345861,0,0,0,0,3,0,France,0,hydroxychloroquine/placebo|hydroxychloroquine / azithromycin|hydroxychloroquine|placebo|azithromycin,NA
NCT04344587,2020-04-23,4/30/2021,Interventional,Awake Prone Position for Early Hypoxemia in COVID-19,Enrolling by invitation,N/A,Boston University,NA,https://clinicalzeros.gov/ct2/show/NCT04344587,0,0,0,0,11,1,United States|Spain,0,prone positioning|standard care,NA
NCT04344457,2020-04-16,6/20/2020,Interventional,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",Recruiting,Phase 1/Phase 2,"Perseverance Research Center, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04344457,0,0,0,0,3,1,United States,0,hydroxychloroquine|indomethacin|zithromax,NA
NCT04344249,2020-04-10,9/30/2020,Observational [Patient Registry],Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04344249,0,0,0,0,1,0,France,0,"NA",NA
NCT04344236,2020-04-09,5/1/2020,Interventional,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,Recruiting,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04344236,0,0,0,0,0,1,United States,0,saline|povidone/iodine|chlorhexidine|nasal rinse|povidone|iodine,NA
NCT04344106,2020-04-01,4/15/2020,Interventional,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Recruiting,N/A,Centre Hospitalier Intercommunal Aix-Pertuis,NA,https://clinicalzeros.gov/ct2/show/NCT04344106,0,0,0,0,0,0,France,0,prone positioning,NA
NCT04343755,2020-04-09,4/30/2021,Interventional,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,"Active, not recruiting",Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04343755,0,0,0,0,5,1,United States,0,convalescent plasma,NA
NCT04343404,2020-04-01,4/15/2020,Observational,Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19,Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04343404,0,0,0,0,1,0,France,0,"NA",NA
NCT04342221,2020-03-29,3/31/2021,Interventional,Hydroxychloroquine for COVID-19,Recruiting,Phase 3,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04342221,0,0,0,0,2,0,Germany,0,hydroxychloroquine|placebo,NA
NCT04342195,2020-03-25,3/31/2021,Observational,Acquiring Convalescent Specimens for COVID-19 Antibodies,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04342195,0,0,0,0,2,1,United States,0,blood sample,NA
NCT04342104,2020-04-01,8/31/2020,Observational,NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure,Recruiting,NA,Hospital General Universitario Morales Meseguer,NA,https://clinicalzeros.gov/ct2/show/NCT04342104,0,0,0,0,2,0,Spain,0,monitoring for aggravation|evaluate hacor score effectivity in this patients,NA
NCT04343339,2020-04-08,7/30/2020,Observational,Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04343339,0,0,0,0,2,0,France,0,"NA",NA
NCT04343248,2020-05-12,12/31/2020,Interventional,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),Recruiting,Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04343248,0,0,0,0,5,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04341714,2020-03-16,5/30/2020,Observational,Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic,Recruiting,NA,Pierre and Marie Curie University,NA,https://clinicalzeros.gov/ct2/show/NCT04341714,0,0,0,0,1,0,France,0,satisfaction evaluation,NA
NCT04342884,2020-04-08,12/31/2021,Observational,COVID-19 Community Research Partnership,Recruiting,NA,Wake Forest University Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04342884,0,0,0,0,2,1,United States,0,"NA",NA
NCT04342806,2020-04-10,12/31/2099,Observational [Patient Registry],"Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19",Recruiting,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04342806,0,0,0,0,2,1,United States,0,"NA",NA
NCT04342689,2020-06-03,6/1/2021,Interventional,The Role of Resistant Starch in COVID-19 Infection,Recruiting,Phase 2/Phase 3,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04342689,0,0,0,0,5,1,United States,0,dietary supplement containing resistant starch|placebo,NA
NCT04341207,2020-04-03,4/30/2022,Interventional,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,Recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris",NA,https://clinicalzeros.gov/ct2/show/NCT04341207,0,0,0,0,0,0,France,0,hydroxychloroquine|azithromycin,NA
NCT04339790,2020-04-07,3/1/2022,Observational,Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers,"Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04339790,0,0,0,0,139,1,United States,0,"NA",NA
NCT04339686,2020-04-20,9/30/2020,Observational,Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.,Recruiting,NA,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04339686,0,0,0,0,2,0,France,0,thoracic ct,NA
NCT04349618,2020-04-15,4/15/2023,Interventional,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04349618,0,0,0,0,1,0,France,0,protective ventilation|ultraprotective ventilation,NA
NCT04348383,2020-04-08,4/15/2021,Interventional,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,Recruiting,Phase 2,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04348383,0,0,0,0,3,0,Spain,0,defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|placebo|defibrotide|kg 24 hours continuous infusion for 15 days,NA
NCT04359251,2020-03-05,3/25/2020,Interventional,Different PEEP Settings of COVID-19 Induced ARDS,Completed,N/A,"Southeast University, China",NA,https://clinicalzeros.gov/ct2/show/NCT04359251,0,0,0,0,0,0,China,0,gas exchanges at different peep|lung mechanics at different peep|hemodynamics changes at different peep,NA
NCT04358952,2020-04-04,11/4/2020,Observational,Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04358952,0,0,0,0,0,0,France,0,global longitudinal strain,NA
NCT04355728,2020-04-25,10/31/2020,Interventional,Use of UC-MSCs for COVID-19 Patients,Completed,Phase 1/Phase 2,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04355728,0,0,0,0,5,1,United States,0,mesenchymalÂ stem cells/heparin|vehicle / heparin along with best supportive care|mesenchymal stem cells|heparin|vehicle,NA
NCT04357340,2020-04-02,4/30/2020,Interventional,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Completed,N/A,Tehran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04357340,0,0,0,0,1,0,"Iran, Islamic Republic of",0,pulmonary physiotherapy techniques,NA
NCT04357847,2020-04-09,7/31/2021,Observational,Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection,Recruiting,NA,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04357847,0,0,0,0,1,0,France,0,"NA",NA
NCT04353037,2020-04-07,4/30/2021,Interventional,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,Recruiting,Phase 2,UnitedHealth Group,NA,https://clinicalzeros.gov/ct2/show/NCT04353037,0,0,0,0,1,1,United States,0,hydroxychloroquine|control,NA
NCT04350710,2020-03-18,4/20/2020,Observational,Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS,Recruiting,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04350710,0,0,0,0,0,0,France,0,peep,NA
NCT04347980,2020-04-30,6/30/2020,Interventional,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,Recruiting,Phase 3,Centre Chirurgical Marie Lannelongue,NA,https://clinicalzeros.gov/ct2/show/NCT04347980,0,0,0,0,1,0,France,0,dexamethasone/hydroxychloroquine|hydroxychloroquine|dexamethasone,NA
NCT04347850,2020-02-01,12/1/2022,Observational,A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19),Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04347850,0,0,0,0,2,0,France,0,blood sample,NA
NCT04347824,2020-04-27,12/31/2020,Observational,Predict Adverse Events by Covid-19 Nephritis,Recruiting,NA,University Hospital Goettingen,NA,https://clinicalzeros.gov/ct2/show/NCT04347824,0,0,0,0,3,0,Germany,0,"NA",NA
NCT04346615,2020-04-25,4/30/2021,Interventional,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,Recruiting,Phase 2/Phase 3,"Biohaven Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04346615,0,0,0,0,12,1,United States,0,zavegepant (bhv-3500)|placebo,NA
NCT04346589,2020-04-15,8/31/2020,Interventional,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,Recruiting,N/A,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04346589,0,0,0,0,3,0,Italy,0,anti-coronavirus antibodies (immunoglobulins)obtained with dfpp from convalescent patients,NA
NCT04345692,2020-03-26,8/31/2020,Interventional,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,Terminated,Phase 3,Queen's Medical Centre,RECOVERY Trial results - no efficacy,https://clinicalzeros.gov/ct2/show/NCT04345692,0,0,0,0,2,1,United States,0,hydroxychloroquine,NA
NCT04344730,2020-04-10,12/31/2021,Interventional,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04344730,0,0,0,0,1,0,France,0,dexamethasone|placebo|oxygen|cpap|mechanical ventilation,NA
NCT04344431,2020-04-14,4/30/2022,Interventional,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,Phase 2/Phase 3,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04344431,0,0,0,0,2,0,France,0,hyperbaric oxygen|device),NA
NCT04344080,2020-04-01,12/31/2020,Interventional,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Recruiting,N/A,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04344080,0,0,0,0,0,0,Germany,0,cytosorb,NA
NCT04344015,2020-04-13,4/12/2021,Interventional,COVID-19 Plasma Collection,Recruiting,N/A,Thomas Jefferson University,NA,https://clinicalzeros.gov/ct2/show/NCT04344015,0,0,0,0,2,1,United States,0,plasma,NA
NCT04343989,2020-03-31,1/30/2021,Interventional,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,"Active, not recruiting",Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04343989,0,0,0,0,4,1,United States,0,clazakizumab|placebo,NA
NCT04346199,2020-06-12,11/17/2020,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04346199,0,0,0,0,5,0,Argentina|Brazil|Chile|France|Germany|India|Italy|Japan|Mexico|Peru|Russian Federation|South Africa|Turkey,0,acalabrutinib,NA
NCT04344002,2020-04-21,6/30/2021,Observational [Patient Registry],LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID),Recruiting,NA,Spanish Lung Cancer Group,NA,https://clinicalzeros.gov/ct2/show/NCT04344002,0,0,0,0,5,0,Spain,0,"NA",NA
NCT04524663,2020-12-19,6/30/2021,Interventional,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,Recruiting,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04524663,0,0,0,0,4,1,United States,0,camostat mesilate|placebo|standard care,NA
NCT04438850,2020-07-31,2/28/2021,Interventional,COVidIVERmectin: Ivermectin for Treatment of Covid-19,Recruiting,Phase 2,IRCCS Sacro Cuore Don Calabria di Negrar,NA,https://clinicalzeros.gov/ct2/show/NCT04438850,0,0,0,0,3,0,Italy|Spain,0,ivermectin|placebo,NA
NCT04390178,2020-04-10,6/30/2020,Interventional,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04390178,0,0,0,0,0,0,Sweden,0,convalescent plasma,NA
NCT04381312,2020-04-09,7/9/2021,Observational,Direct and Indirect Impact of COVID-19 In Older Populations,Recruiting,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04381312,0,0,0,0,0,0,France,0,"NA",NA
NCT04357444,2020-10-23,11/2/2020,Interventional,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04357444,0,0,0,0,2,0,France,0,human recombinant interleukin 2|placebo,NA
NCT04351711,2020-04-09,4/30/2022,Observational,Immunological Profiling of Patients With COVID-19 in Respiratory Distress,Recruiting,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04351711,0,0,0,0,4,0,France,0,immunological,NA
NCT04349982,2020-04-08,6/30/2022,Observational [Patient Registry],ICU Trial in Critical Ill COVID-19 Patients,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04349982,0,0,0,0,1,0,Austria,0,"biomarker (tropt, myoglobin, ck, ck-mb, ldh, d-dimer, crp, pct)",NA
NCT04348396,2020-04-03,12/31/2020,Observational,Clinical and Biological Predictors of COVID-19 Disease in Older Patients,Recruiting,NA,Istituto Nazionale di Ricovero e Cura per Anziani,NA,https://clinicalzeros.gov/ct2/show/NCT04348396,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04348227,2019-01-01,1/1/2020,Observational [Patient Registry],How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?,"Active, not recruiting",NA,HÃ´pital Universitaire Fattouma Bourguiba,NA,https://clinicalzeros.gov/ct2/show/NCT04348227,0,0,0,0,1,0,Tunisia,0,enhanced hygiene measures,NA
NCT04347070,2017-04-01,9/1/2020,Observational,Implementation of Physiotherapy on COVID-19 Patients in ICU,"Active, not recruiting",NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04347070,0,0,0,0,2,0,France,0,phsyiotherapy,NA
NCT04346628,2020-07-12,7/31/2021,Interventional,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,Enrolling by invitation,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04346628,0,0,0,0,5,1,United States,0,favipiravir|placebo|standard care,NA
NCT04345640,2020-04-10,12/31/2020,Observational,The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.,Recruiting,NA,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04345640,0,0,0,0,2,0,India,0,no intervention,NA
NCT04346212,2020-04-14,12/31/2020,Observational,Oropharyngeal Dysphagia in Patients With COVID-19,Recruiting,NA,Hospital de MatarÃ³,NA,https://clinicalzeros.gov/ct2/show/NCT04346212,0,0,0,0,2,0,Spain,0,swallowing evaluation with the eat-10/the volume-viscosity swallowing test (v-vst)|swallowing evaluation with the eat-10|volume rapid test,NA
NCT04346121,2020-04-28,6/29/2020,Observational,Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis,Completed,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04346121,0,0,0,0,3,0,France,0,"gps reports of potential patient safety incidents, non-covid-19 related",NA
NCT04345991,2020-04-15,5/15/2020,Interventional,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04345991,0,0,0,0,1,0,France,0,convalescent plasma,NA
NCT04345549,2020-02-26,3/30/2020,Interventional,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04345549,0,0,0,0,0,0,United Kingdom,0,ayurveda,NA
NCT04345315,2020-03-27,3/31/2021,Observational,"Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.",Recruiting,NA,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,https://clinicalzeros.gov/ct2/show/NCT04345315,0,0,0,0,1,0,Italy,0,serology test|rapid molecular test|next generation sequencing (ngs) analysis|serum test,NA
NCT04345289,2020-05-01,6/15/2021,Interventional,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,Recruiting,Phase 3,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04345289,0,0,0,0,2,0,Denmark,0,convalescent plasma|placebo,NA
NCT04345276,2020-03-18,4/15/2020,Interventional,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Phase 4,Huoshenshan Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04345276,0,0,0,0,1,0,China,0,danoprevir/ritonavir|danoprevir|ritonavir,NA
NCT04345159,2020-04-17,11/30/2020,Observational,Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease,Completed,NA,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04345159,0,0,0,0,4,0,France,0,questionnaire,NA
NCT04344964,2020-04-15,5/29/2020,Observational,Endoscopy-related Phone Consultation During the COVID-19 Outbreak,Completed,NA,Austin Health,NA,https://clinicalzeros.gov/ct2/show/NCT04344964,0,0,0,0,2,0,Australia,0,none - na,NA
NCT04344912,2020-03-20,6/30/2020,Observational [Patient Registry],Impact of COVID19 Outbreak in Cardiac Acute Care,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04344912,0,0,0,0,1,0,France,0,data collection,NA
NCT04344561,2020-05-25,5/1/2021,Interventional,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,Recruiting,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04344561,0,0,0,0,3,1,United States,0,postural positioning,NA
NCT04344535,2020-04-08,4/30/2021,Interventional,Convalescent Plasma vs. Standard Plasma for COVID-19,Enrolling by invitation,Phase 1/Phase 2,Stony Brook University,NA,https://clinicalzeros.gov/ct2/show/NCT04344535,0,0,0,0,1,1,United States,0,convalescent plasma|plasma,NA
NCT04344444,2020-04-13,4/10/2021,Interventional,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,"Active, not recruiting",Phase 3,LCMC Health,NA,https://clinicalzeros.gov/ct2/show/NCT04344444,0,0,0,0,1,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04344288,2020-04-21,8/18/2020,Interventional,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Terminated,Phase 2,Hospices Civils de Lyon,Competent Authority's decision,https://clinicalzeros.gov/ct2/show/NCT04344288,0,0,0,0,4,0,France,0,control|prednisone,NA
NCT04344171,2020-03-30,12/31/2022,Observational,CovidDB: The Covid-19 Inpatient Database,Recruiting,NA,ClarData,NA,https://clinicalzeros.gov/ct2/show/NCT04344171,0,0,0,0,1,0,Germany|Romania,0,"NA",NA
NCT04342897,2020-04-20,10/12/2020,Interventional,A Study of LY3127804 in Participants With COVID-19,Terminated,Phase 2,Eli Lilly and Company,Trial terminated for futility.,https://clinicalzeros.gov/ct2/show/NCT04342897,0,0,0,0,19,1,United States,0,ly3127804|placebo,NA
NCT04345601,2021-01-31,10/31/2022,Interventional,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),Recruiting,Phase 1/Phase 2,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04345601,0,0,0,0,7,1,United States,0,mesenchymal stem cells|supportive care,NA
NCT04351724,2020-04-16,12/1/2021,Interventional,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),Recruiting,Phase 2/Phase 3,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04351724,0,0,0,0,2,0,Austria,0,chloroquine/hydroxychloroquine|lopinavir/ritonavir|standard care|rivaroxaban|thromboprophylaxis|candesartan|antihypertensives|remdesivir|asunercept 400mg|asunercept 100mg|asunercept 25mg|pentaglobin|chloroquine|hydroxychloroquine|lopinavir|ritonavir,NA
NCT04569851,2020-01-01,10/1/2021,Observational,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019),Enrolling by invitation,NA,Medsavana,NA,https://clinicalzeros.gov/ct2/show/NCT04569851,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04351789,2020-05-01,4/30/2023,Interventional,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Recruiting,N/A,"Copenhagen University Hospital, Hvidovre",NA,https://clinicalzeros.gov/ct2/show/NCT04351789,0,0,0,0,1,0,Denmark,0,psychoeducational intervention,NA
NCT04350099,2020-04-15,2/15/2021,Observational,Emotional Burden of Healthcare Professionals and Covid Infection 19,Recruiting,NA,"University Hospital, Limoges",NA,https://clinicalzeros.gov/ct2/show/NCT04350099,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04349410,2020-04-11,9/14/2020,Interventional,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,Phase 2/Phase 3,The Camelot Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04349410,0,0,0,0,8,1,United States,0,hydroxychloroquine / azithromycin|hydroxychloroquine/doxycycline|hydroxychloroquine/clindamycin|hydroxychloroquine/clindamycin/primaquine|remdesivir|tocilizumab|methylprednisolone|interferon|losartan|convalescent plasma,NA
NCT04348305,2020-04-17,9/10/2020,Interventional,Hydrocortisone for COVID-19 and Severe Hypoxia,"Active, not recruiting",Phase 3,Scandinavian Critical Care Trials Group,NA,https://clinicalzeros.gov/ct2/show/NCT04348305,0,0,0,0,12,0,Denmark,0,hydrocortisone|saline|methylprednisolone,NA
NCT04347382,2020-04-30,8/30/2020,Interventional,Honey & Nigella Sativa Trial Against COVID-19,Completed,Phase 3,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04347382,0,0,0,0,6,0,Pakistan,0,honey|nigella sativa / black cumin|placebo|nigella sativa|cumin,NA
NCT04347538,2020-05-01,6/30/2021,Interventional,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,"Active, not recruiting",N/A,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04347538,0,0,0,0,5,1,United States,0,saline|saline with baby shampoo nasal irrigation,NA
NCT04345419,2020-06-16,12/31/2029,Interventional,Remdesivir vs Chloroquine in Coronavirus Disease,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04345419,0,0,0,0,4,0,Egypt,0,chloroquine/hydroxychloroquine|remdesivir|chloroquine|hydroxychloroquine,NA
NCT04463433,2020-02-01,12/31/2021,Interventional,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,N/A,Beijing Normal University,NA,https://clinicalzeros.gov/ct2/show/NCT04463433,0,0,0,0,0,0,China,0,behavior|problem-solving/relationship improvement intervention.|cognitive|problem-solving|relationship improvement intervention.,NA
NCT04353934,2020-03-31,5/1/2021,Observational,The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic,Recruiting,NA,Ariel University,NA,https://clinicalzeros.gov/ct2/show/NCT04353934,0,0,0,0,1,0,Israel,0,"NA",NA
NCT04349371,2020-04-30,4/30/2021,Interventional,Saved From COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04349371,0,0,0,0,1,1,United States,0,chloroquine|placebo,NA
NCT04347694,2020-04-11,4/11/2021,Observational,Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.,Recruiting,NA,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04347694,0,0,0,0,2,0,Austria,0,"NA",NA
NCT04356560,2020-03-23,9/30/2020,Observational,COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department,Enrolling by invitation,NA,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04356560,0,0,0,0,1,0,Denmark,0,pcr,NA
NCT04354584,2020-04-06,4/6/2021,Observational,Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19,Recruiting,NA,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04354584,0,0,0,0,0,0,Denmark,0,"NA",NA
NCT04352582,2020-04-14,4/30/2020,Observational,COVID-19 and Vaccination Attitudes,Completed,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04352582,0,0,0,0,1,0,United Kingdom,0,questionnaire,NA
NCT04351243,2020-04-12,12/1/2020,Interventional,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"Active, not recruiting",Phase 2,Kinevant Sciences GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04351243,0,0,0,0,11,1,United States,0,gimsilumab|placebo,NA
NCT04350281,2020-04-09,7/1/2020,Interventional,Double Therapy With IFN-beta 1b and Hydroxychloroquine,Completed,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04350281,0,0,0,0,2,0,Hong Kong,0,interferon|hydroxychloroquine,NA
NCT04351139,2020-05-06,11/30/2020,Observational,Impact of the COVID-19 Pandemic in Gynecological Oncology,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04351139,0,0,0,0,5,0,France,0,modification,NA
NCT04349241,2020-04-18,6/1/2020,Interventional,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,Phase 3,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04349241,0,0,0,0,2,0,Egypt,0,favipiravir|standard care,NA
NCT04349163,2020-05-10,6/15/2020,Observational,Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.,Completed,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04349163,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04348942,2020-05-29,5/1/2021,Observational [Patient Registry],"A COVID-19 Symptom, Exposure and Immune Response Registry","Active, not recruiting",NA,ObvioHealth,NA,https://clinicalzeros.gov/ct2/show/NCT04348942,0,0,0,0,4,1,United States,0,"NA",NA
NCT04348240,2020-04-16,7/1/2021,Observational,Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04348240,0,0,0,0,16,1,United States,0,"NA",NA
NCT04378452,2020-03-31,6/30/2021,Observational [Patient Registry],Assessment of the Psycho-social Impact of COVID-19 Outbreak,"Active, not recruiting",NA,FundaciÃ³ Institut Germans Trias i Pujol,NA,https://clinicalzeros.gov/ct2/show/NCT04378452,0,0,0,0,3,0,Spain,0,survey,NA
NCT04348656,2020-05-14,10/31/2020,Interventional,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),Recruiting,Phase 3,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04348656,0,0,0,0,10,1,United States|Canada,0,convalescent plasma,NA
NCT04348552,2020-04-28,6/28/2020,Observational,Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04348552,0,0,0,0,2,0,France,0,"primary care professionals reports of potential patient safety incidents, non-covid-19 related",NA
NCT04348500,2020-04-24,12/31/2020,Interventional,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,"Active, not recruiting",Phase 2,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04348500,0,0,0,0,2,1,United States,0,clazakizumab,NA
NCT04348422,2020-05-01,12/1/2020,Observational,Evaluating the Immune Response for COVID-19,Recruiting,NA,Assaf-Harofeh Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04348422,0,0,0,0,2,0,Israel,0,pcr|serology test|symptoms,NA
NCT04348214,2020-04-22,10/1/2020,Observational,Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04348214,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04347954,2020-08-15,12/13/2020,Interventional,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Completed,Phase 1/Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04347954,0,0,0,0,6,1,United States,0,povidone/iodine|saline,NA
NCT04347798,2020-09-30,4/30/2021,Observational [Patient Registry],IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT,Enrolling by invitation,NA,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04347798,0,0,0,0,2,0,Canada,0,chloroquine/hydroxychloroquine|hydroxychloroquine|chloroquine,NA
NCT04419610,2020-10-09,12/31/2020,Interventional,RAS and Coagulopathy in COVID19,Recruiting,Early Phase 1,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04419610,0,0,0,0,6,0,United Kingdom,0,trv027|saline,NA
NCT04347239,2020-04-15,12/31/2020,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,"CytoDyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04347239,0,0,0,0,11,1,United States,0,placebo|lenzilumab,NA
NCT04376905,2020-04-01,9/1/2020,Observational,Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04376905,0,0,0,0,2,0,France,0,"NA",NA
NCT04373109,2020-04-16,10/12/2020,Observational,Stroke Rehabilitation Outcome During COVID-19 Lockdown,Completed,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04373109,0,0,0,0,1,0,Switzerland,0,observation,NA
NCT04346667,2020-04-14,5/30/2020,Interventional,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Recruiting,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",NA,https://clinicalzeros.gov/ct2/show/NCT04346667,0,0,0,0,1,0,Pakistan,0,hydroxychloroquine|chloroquine|placebo,NA
NCT04367662,2020-04-09,5/14/2020,Interventional,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04367662,0,0,0,0,1,0,France,0,blood sample,NA
NCT04346056,2020-04-14,10/1/2020,Observational,Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04346056,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04366154,2020-04-15,7/15/2020,Observational,Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers,"Active, not recruiting",NA,Centre Francois Baclesse,NA,https://clinicalzeros.gov/ct2/show/NCT04366154,0,0,0,0,2,0,France,0,questionnaire,NA
NCT04346017,2020-03-20,12/31/2020,Interventional,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04346017,0,0,0,0,0,0,Belgium,0,cytokines|complement dosage,NA
NCT04344977,2020-06-01,7/1/2024,Observational,Collection of Anti-SARS-CoV-2 Immune Plasma,"Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04344977,0,0,0,0,14,1,United States,0,"NA",NA
NCT04373889,2020-04-22,4/30/2021,Observational,COVID-19 Among Healthcare Workers in Belgian Hospitals,"Active, not recruiting",NA,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04373889,0,0,0,0,2,0,Belgium,0,"NA",NA
NCT04348864,2020-04-16,4/30/2021,Interventional,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,N/A,Neuroganics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04348864,0,0,0,0,9,1,United States,0,"covid-19 antigen/antibody rapid testing, mobile device image capture/telemedicine support|telehealth|covid-19 antigen|rapid test",NA
NCT04498936,2020-07-15,10/30/2020,Interventional,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,Completed,Phase 4,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04498936,0,0,0,0,1,0,Egypt,0,sofosbuvir/ledipasvir|nitazoxanide|sofosbuvir|ledipasvir,NA
NCT04361838,2020-06-01,8/31/2020,Interventional,The COVID-19 ICU PRAYER Study,Recruiting,N/A,Kansas City Heart Rhythm Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04361838,0,0,0,0,1,1,United States,0,prayer,NA
NCT04360538,2020-04-08,7/1/2021,Observational,Long Term Outcomes of Patients With COVID-19,Recruiting,NA,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04360538,0,0,0,0,0,1,United States,0,quality of life|impact event score|hospital anxiety/depression scale|hospital anxiety|depression scale,NA
NCT04359667,2020-06-16,4/16/2021,Observational,Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,Recruiting,NA,"University Hospital for Infectious Diseases, Croatia",NA,https://clinicalzeros.gov/ct2/show/NCT04359667,0,0,0,0,2,0,Croatia,0,tocilizumab|methylprednisolone,NA
NCT04359264,2020-04-20,5/29/2020,Interventional,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,"Active, not recruiting",N/A,"St. Michael's Hospital, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04359264,0,0,0,0,2,0,Canada,0,cash transfer,NA
NCT04386369,2020-04-15,6/1/2020,Observational,Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04386369,0,0,0,0,2,0,France,0,airway pressure release ventilation,NA
NCT04357418,2020-04-01,6/30/2020,Observational,Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives,Completed,NA,"Centre hospitalier de Ville-Evrard, France",NA,https://clinicalzeros.gov/ct2/show/NCT04357418,0,0,0,0,2,0,France,0,survey,NA
NCT04356950,2020-04-28,4/30/2022,Observational,Analysis of the Coagulopathy Developed by COVID-19 Infected Patients,"Active, not recruiting",NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04356950,0,0,0,0,5,0,France,0,thrombin|fibrin generation markers assays,NA
NCT04382391,2020-05-08,3/1/2021,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,N/A,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),NA,https://clinicalzeros.gov/ct2/show/NCT04382391,0,0,0,0,2,1,United States,0,gammacoreâ® sapphire (non-invasive vagus nerve stimulator)|standard care,NA
NCT04356443,2020-04-15,12/31/2020,Observational,Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,Recruiting,NA,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04356443,0,0,0,0,0,1,United States,0,respiratory monitor,NA
NCT04355442,2020-04-01,5/1/2020,Observational,Evolution of Facial Trauma During COVID Containment Measures,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04355442,0,0,0,0,3,0,France,0,facial fractures reduction/osteosynthesis|facial fractures reduction|osteosynthesis,NA
NCT04354870,2020-04-03,9/15/2020,Interventional,COVID-19 PrEP HCW HCQ Study,Completed,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04354870,0,0,0,0,3,1,United States,0,hydroxychloroquine,NA
NCT04354818,2020-05-11,4/27/2022,Observational [Patient Registry],Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA),Recruiting,NA,Kirby Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04354818,0,0,0,0,3,0,Australia,0,"NA",NA
NCT04354792,2020-05-01,6/10/2020,Observational,Asymptomatic COVID-19 Infection Among Healthcare Workers,Completed,NA,Kasr El Aini Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04354792,0,0,0,0,4,0,Egypt,0,igg antibody test,NA
NCT04361916,2020-04-21,6/30/2020,Interventional,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Terminated,N/A,Mario Negri Institute for Pharmacological Research,interrupted early due to the drastic reduction in the number of cases,https://clinicalzeros.gov/ct2/show/NCT04361916,0,0,0,0,2,0,Italy,0,home care monitoring,NA
NCT04354428,2020-04-16,12/31/2020,Interventional,Treatment for COVID-19 in High-Risk Adult Outpatients,"Active, not recruiting",Phase 2/Phase 3,University of Washington,NA,https://clinicalzeros.gov/ct2/show/NCT04354428,0,0,0,0,6,1,United States,0,vitamin c|hydroxychloroquine|azithromycin|folic acid|lopinavir 200 mg / ritonavir 50 mg [kaletra]|lopinavir 200 mg|ritonavir 50 mg [kaletra],NA
NCT04353518,2020-06-30,3/30/2021,Interventional,Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19,Recruiting,Phase 3,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04353518,0,0,0,0,2,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04356833,2020-04-22,1/14/2021,Interventional,Nebulised Rt-PA for ARDS Due to COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04356833,0,0,0,0,1,0,United Kingdom,0,nebulised recombinant tissue-plasminogen activator (rt-pa),NA
NCT04355143,2020-05-01,4/25/2021,Interventional,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),Recruiting,Phase 2,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04355143,0,0,0,0,3,1,United States,0,colchicine|current care per ucla treating physicians,NA
NCT04354831,2020-05-11,5/1/2022,Interventional,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,"Active, not recruiting",Phase 2,Medical College of Wisconsin,NA,https://clinicalzeros.gov/ct2/show/NCT04354831,0,0,0,0,4,1,United States,0,convalescent plasma,NA
NCT04354610,2020-04-27,12/19/2020,Interventional,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,"Active, not recruiting",N/A,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04354610,0,0,0,0,4,0,France,0,biological samples|clinical examination|telephone follow-up,NA
NCT04353596,2020-04-15,5/15/2021,Interventional,Stopping ACE-inhibitors in COVID-19,Recruiting,Phase 4,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04353596,0,0,0,0,2,0,Austria|Germany,0,"ace inhibitor, angiotensin receptor blocker",NA
NCT04352699,2020-03-15,4/17/2020,Observational,Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?,Completed,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04352699,0,0,0,0,2,0,France,0,"NA",NA
NCT04353284,2020-06-19,5/31/2021,Interventional,Camostat Mesylate in COVID-19 Outpatients,Recruiting,Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04353284,0,0,0,0,7,1,United States,0,camostat mesilate|placebo,NA
NCT04353206,2020-06-27,5/31/2021,Interventional,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,Recruiting,Early Phase 1,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04353206,0,0,0,0,3,1,United States,0,convalescent plasma,NA
NCT04353141,2020-04-28,5/31/2020,Observational,International Lung UltraSound Analysis (ILUSA) Study,Recruiting,NA,KU Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04353141,0,0,0,0,1,0,Belgium|Italy|United Kingdom,0,standard care,NA
NCT04353128,2020-04-20,10/31/2020,Interventional,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Recruiting,Phase 2/Phase 3,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicalzeros.gov/ct2/show/NCT04353128,0,0,0,0,2,0,Spain,0,melatonin|placebo,NA
NCT04352491,2020-04-24,5/31/2020,Observational,An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease,Completed,NA,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04352491,0,0,0,0,3,0,India,0,no intervention,NA
NCT04352842,2020-01-21,4/8/2020,Observational,Echocardiographic Manifestation in Patient With COVID-19 ï¼ˆEARLY-MYO COVID-19ï¼‰,Completed,NA,RenJi Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04352842,0,0,0,0,2,0,China,0,echocardiography,NA
NCT04351763,2020-04-27,3/2/2021,Interventional,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Recruiting,Phase 2/Phase 3,Nicolaus Copernicus University,NA,https://clinicalzeros.gov/ct2/show/NCT04351763,0,0,0,0,0,0,Poland,0,amiodarone|verapamil,NA
NCT04352751,2020-05-01,4/30/2021,Interventional,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,N/A,Hilton Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04352751,0,0,0,0,4,0,Pakistan,0,convalescent plasma,NA
NCT04351620,2020-04-30,6/30/2020,Interventional,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,Phase 1,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04351620,0,0,0,0,0,1,United States,0,hydroxychloroquine,NA
NCT04351581,2020-05-18,12/31/2020,Interventional,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Recruiting,N/A,"University Hospital, Gentofte, Copenhagen",NA,https://clinicalzeros.gov/ct2/show/NCT04351581,0,0,0,0,3,0,Denmark,0,discontinuation of acei/arb|continuation of acei/arb|discontinuation of acei|arb|continuation of acei,NA
NCT04351568,2020-04-01,7/31/2020,Observational,Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04351568,0,0,0,0,1,0,Egypt,0,questionnaire,NA
NCT04351542,2020-03-06,4/6/2020,Interventional,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04351542,0,0,0,0,0,0,United Kingdom,0,ayurveda|standard care,NA
NCT04351399,2020-04-27,5/4/2020,Observational,Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04351399,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04351191,2020-04-15,5/30/2020,Interventional,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Recruiting,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",NA,https://clinicalzeros.gov/ct2/show/NCT04351191,0,0,0,0,1,0,Pakistan,0,hydroxychloroquine|chloroquine|placebo,NA
NCT04350736,2020-04-23,6/24/2020,Interventional,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,Phase 1,Theravance Biopharma,NA,https://clinicalzeros.gov/ct2/show/NCT04350736,0,0,0,0,4,0,United Kingdom,0,td-0903|placebo,NA
NCT04351854,2020-04-20,12/31/2025,Observational,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Recruiting,NA,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04351854,0,0,0,0,2,0,Germany,0,retrospective data collection,NA
NCT04351802,2020-05-11,1/20/2021,Observational,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,Recruiting,NA,University Hospital Plymouth NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04351802,0,0,0,0,1,0,United Kingdom,0,lung ultrasound,NA
NCT04351659,2020-04-14,8/31/2020,Observational,Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,NA,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04351659,0,0,0,0,1,0,Singapore,0,convalescent plasma,NA
NCT04351529,2020-04-01,12/31/2021,Observational [Patient Registry],Austrian COVID-19 Registry,Recruiting,NA,Arbeitsgemeinschaft medikamentoese Tumortherapie,NA,https://clinicalzeros.gov/ct2/show/NCT04351529,0,0,0,0,2,0,Austria,0,"NA",NA
NCT04358406,2020-07-30,5/1/2021,Interventional,Rhu-pGSN for Severe Covid-19 Pneumonia,Recruiting,Phase 2,BioAegis Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04358406,0,0,0,0,3,0,Romania|Spain,0,recombinant human plasma gelsolin (rhu-pgsn)|placebo,NA
NCT04350723,2020-06-10,7/30/2021,Interventional,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicalzeros.gov/ct2/show/NCT04350723,0,0,0,0,1,0,Canada|Saudi Arabia,0,prone positioning,NA
NCT04350684,2020-04-15,4/22/2020,Interventional,Umifenovir in Hospitalized COVID-19 Patients,Enrolling by invitation,Phase 4,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04350684,0,0,0,0,1,0,"Iran, Islamic Republic of",0,umifenovir|interferon-î² 1a|lopinavir/ritonavir|hydroxychloroquine|standard care|lopinavir|ritonavir,NA
NCT04350671,2020-04-15,4/20/2020,Interventional,Interferon Beta 1a in Hospitalized COVID-19 Patients,Enrolling by invitation,Phase 4,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04350671,0,0,0,0,1,0,"Iran, Islamic Republic of",0,interferon|lopinavir/ritonavir|hydroxychloroquine|lopinavir|ritonavir,NA
NCT04350320,2020-04-30,10/20/2020,Interventional,Trial to Study the Benefit of Colchicine in Patients With COVID-19,Completed,Phase 3,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04350320,0,0,0,0,3,0,Spain,0,colchicine|standard care,NA
NCT04361344,2020-05-19,10/25/2020,Interventional,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Terminated,N/A,Centre Hospitalier de PAU,objective of the study demonstrated by other research teams,https://clinicalzeros.gov/ct2/show/NCT04361344,0,0,0,0,2,0,France,0,blood sample,NA
NCT04358549,2020-04-17,11/1/2020,Interventional,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Active, not recruiting",Phase 2,"Fujifilm Pharmaceuticals U.S.A., Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04358549,0,0,0,0,9,1,United States,0,favipiravir / standard care|standard care|favipiravir,NA
NCT04357769,2020-04-10,4/20/2020,Observational,COVID-19 Pandemic Burden in Severe Mental Disease Patients,Completed,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04357769,0,0,0,0,1,0,Italy,0,pss|gad-7 (7-item generalized anxiety disorder)|phq|speq (specific psychotic experiences questionnaire) - paranoia/grandiosity subscales|zaritt burden interview|speq (specific psychotic experiences questionnaire) - paranoia|grandiosity subscales,NA
NCT04350073,2020-04-20,10/1/2021,Observational,Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Recruiting,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04350073,0,0,0,0,3,1,United States,0,q-nrg metobolic cart device|musclesound ultrasound|multifrequency bioimpedance spectroscopy,NA
NCT04349540,2020-04-15,10/15/2020,Observational,Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19,"Active, not recruiting",NA,Great Ormond Street Hospital for Children NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04349540,0,0,0,0,0,0,United Kingdom,0,no intervention,NA
NCT04375774,2020-05-31,5/31/2020,Interventional,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Recruiting,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04375774,0,0,0,0,0,0,Belgium,0,ffp2|facial mask|mfs,NA
NCT04349098,2020-04-17,10/5/2020,Interventional,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Completed,Phase 2,Karyopharm Therapeutics Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04349098,0,0,0,0,5,1,United States|Austria|France|Israel|Spain|United Kingdom,0,selinexor|placebo,NA
NCT04373044,2020-05-01,5/1/2021,Interventional,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",Recruiting,Phase 2,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04373044,0,0,0,0,3,1,United States,0,baricitinib|hydroxychloroquine|placebo,NA
NCT04348435,2020-05-14,12/31/2020,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",Enrolling by invitation,Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04348435,0,0,0,0,4,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04367402,2020-03-30,4/24/2020,Observational,"COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)",Recruiting,NA,Azienda Ospedaliera San Paolo,NA,https://clinicalzeros.gov/ct2/show/NCT04367402,0,0,0,0,1,0,Italy,0,igm/igg rapid test,NA
NCT04367363,2020-03-17,5/7/2020,Observational,Social Media and COVID-19,Completed,NA,Yale-NUS College,NA,https://clinicalzeros.gov/ct2/show/NCT04367363,0,0,0,0,2,0,Singapore,0,social media/news consumption|social media|news,NA
NCT04366921,2020-04-10,4/30/2021,Observational,European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO,Recruiting,NA,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04366921,0,0,0,0,0,0,Germany|Austria|Belgium|Czechia|Denmark|France|Greece|Hungary|Israel|Italy|Lithuania|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|United Kingdom,0,"NA",NA
NCT04364009,2020-04-27,10/20/2020,Interventional,Anakinra for COVID-19 Respiratory Symptoms,Terminated,Phase 3,"University Hospital, Tours",Efficiency and safety reasons,https://clinicalzeros.gov/ct2/show/NCT04364009,0,0,0,0,5,0,France,0,anakinra/osoc|osoc|anakinra,NA
NCT04363853,2020-06-01,6/1/2021,Interventional,Tocilizumab Treatment in Patients With COVID-19,"Active, not recruiting",Phase 2,Instituto Nacional de Cancerologia de Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04363853,0,0,0,0,3,0,Mexico,0,tocilizumab,NA
NCT04347876,2020-04-11,6/16/2020,Observational,Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04347876,0,0,0,0,0,0,Egypt,0,tuberculin,NA
NCT04347915,2020-05-06,1/30/2021,Interventional,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,Recruiting,Phase 2,Bukwang Pharmaceutical,NA,https://clinicalzeros.gov/ct2/show/NCT04347915,0,0,0,0,4,0,"Korea, Republic of",0,clevudine|placebo,NA
NCT04346446,2020-04-20,5/30/2020,Interventional,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Completed,Phase 2,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04346446,0,0,0,0,7,0,India,0,convalescent plasma|supportive care|plasma,NA
NCT04350593,2020-04-22,4/30/2021,Interventional,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"Active, not recruiting",Phase 3,Saint Luke's Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04350593,0,0,0,0,4,1,United States|Argentina|Brazil|Canada|India|Mexico|United Kingdom,0,dapagliflozin|placebo,NA
NCT04568148,2020-04-15,12/31/2021,Observational,COVID-19 Biorepository,Recruiting,NA,University of Kansas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04568148,0,0,0,0,0,1,United States,0,"NA",NA
NCT04361786,2020-04-01,6/30/2020,Observational,Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04361786,0,0,0,0,2,0,France,0,"NA",NA
NCT04386109,2020-04-01,3/31/2021,Observational,Neonatal Complications of Coronavirus Disease (COVID-19),Recruiting,NA,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04386109,0,0,0,0,0,0,United Kingdom,0,no intervention,NA
NCT04359953,2020-04-25,6/1/2021,Interventional,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04359953,0,0,0,0,1,0,France,0,hydroxychloroquine|azithromycin|telmisartan,NA
NCT04357834,2020-05-01,12/31/2021,Observational,WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04357834,0,0,0,0,2,0,Switzerland,0,equipment with smartwatch throughout hospital stay on the general ward,NA
NCT04357782,2020-04-16,10/13/2020,Interventional,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,Completed,Phase 1/Phase 2,Hunter Holmes Mcguire Veteran Affairs Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04357782,0,0,0,0,3,1,United States,0,vitamin c,NA
NCT04357041,2020-04-17,4/30/2021,Observational,"COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being","Active, not recruiting",NA,"Clinical Nutrition Research Center, Illinois Institute of Technology",NA,https://clinicalzeros.gov/ct2/show/NCT04357041,0,0,0,0,3,1,United States,0,"NA",NA
NCT04356690,2020-05-08,12/31/2021,Interventional,Etoposide in Patients With COVID-19 Infection,Recruiting,Phase 2,Boston Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04356690,0,0,0,0,5,1,United States,0,etoposide,NA
NCT04356586,2020-05-04,8/21/2020,Observational [Patient Registry],Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms,Completed,NA,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04356586,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04356378,2020-06-02,10/2/2021,Observational,Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04356378,0,0,0,0,1,0,France,0,data record,NA
NCT04355767,2020-08-11,12/31/2022,Interventional,Convalescent Plasma in Outpatients With COVID-19,Enrolling by invitation,Phase 3,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04355767,0,0,0,0,9,1,United States,0,convalescent plasma|saline,NA
NCT04355715,2019-04-01,10/1/2020,Observational,Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04355715,0,0,0,0,2,0,France,0,"NA",NA
NCT04355702,2020-03-01,12/1/2020,Observational,Covid-19 in Lupus Patients,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04355702,0,0,0,0,2,0,France,0,"NA",NA
NCT04355624,2020-04-15,4/30/2020,Observational,Kidney Involvement in COVID-19 Disease (COVKID),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04355624,0,0,0,0,1,0,France,0,"NA",NA
NCT04355611,2020-04-20,4/20/2022,Observational,Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355611,0,0,0,0,2,0,France,0,evaluation of the epidemiological characteristics of coronavirus infection (sars-cov-2),NA
NCT04355533,2020-07-29,7/31/2022,Interventional,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355533,0,0,0,0,5,0,France,0,serology test|nasopharyngeal swab|rectal swab|saliva,NA
NCT04355507,2020-03-01,10/16/2020,Observational,Computed Tomography for COVID-19 Diagnosis,Completed,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355507,0,0,0,0,2,0,France,0,chest ct|pcr,NA
NCT04355481,2020-04-17,10/17/2020,Observational,Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355481,0,0,0,0,1,0,France,0,"NA",NA
NCT04355351,2020-05-05,10/22/2020,Interventional,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04355351,0,0,0,0,2,0,France,0,blood sample|blood,NA
NCT04355338,2020-10-25,5/30/2021,Observational,Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA),Recruiting,NA,Butantan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04355338,0,0,0,0,3,0,Brazil,0,"NA",NA
NCT04359290,2020-07-01,12/31/2020,Interventional,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Active, not recruiting",Phase 2,Philipps University Marburg Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04359290,0,0,0,0,5,0,Germany,0,ruxolitinib,NA
NCT04355247,2020-04-14,7/31/2020,Interventional,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,Phase 2,Auxilio Mutuo Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04355247,0,0,0,0,0,0,Puerto Rico,0,methylprednisolone,NA
NCT04355234,2020-05-04,8/31/2021,Interventional,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns",Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355234,0,0,0,0,2,0,France,0,serology test|biological samples,NA
NCT04357327,2020-04-16,5/31/2020,Interventional,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Completed,N/A,UniversitÃ  degli Studi dell'Insubria,NA,https://clinicalzeros.gov/ct2/show/NCT04357327,0,0,0,0,2,0,Italy,0,rapid salivary test,NA
NCT04357275,2020-03-13,3/31/2021,Observational [Patient Registry],The RIsk Stratification in COVID-19 Patients in the ICU Registry,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04357275,0,0,0,0,0,0,Switzerland,0,icu treatment,NA
NCT04356534,2020-04-19,6/15/2020,Interventional,Convalescent Plasma Trial in COVID -19 Patients,Completed,N/A,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04356534,0,0,0,0,3,0,Bahrain,0,convalescent plasma|standard care,NA
NCT04354857,2020-03-27,7/31/2020,Observational,Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection,Recruiting,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04354857,0,0,0,0,0,0,France,0,olfactory/gustatory tests|olfactory|gustatory tests,NA
NCT04354779,2020-05-11,8/23/2020,Observational,Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,Completed,NA,AUVA,NA,https://clinicalzeros.gov/ct2/show/NCT04354779,0,0,0,0,4,0,Austria,0,self-administered questionnaire,NA
NCT04354766,2020-04-29,7/31/2020,Observational,COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04354766,0,0,0,0,1,0,France,0,blood sample,NA
NCT04354753,2020-03-28,4/14/2020,Observational,AiM COVID for Covid 19 Tracking and Prediction,Completed,NA,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04354753,0,0,0,0,0,0,United Kingdom,0,no intervention,NA
NCT04355741,2020-04-20,7/1/2020,Observational,"Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease",Completed,NA,Universidade Nova de Lisboa,NA,https://clinicalzeros.gov/ct2/show/NCT04355741,0,0,0,0,2,0,Portugal,0,exposure,NA
NCT04355897,2020-04-28,7/31/2020,Interventional,CoVID-19 Plasma in Treatment of COVID-19 Patients,Recruiting,Early Phase 1,The Christ Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04355897,0,0,0,0,3,1,United States,0,convalescent plasma,NA
NCT04355026,2020-04-10,6/30/2020,Interventional,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,Phase 4,General and Teaching Hospital Celje,NA,https://clinicalzeros.gov/ct2/show/NCT04355026,0,0,0,0,0,0,Slovenia,0,bromhexine oral tablet and/or hydroxychloroquine tablet|bromhexine hydrochloride|hydroxychloroquine,NA
NCT04353609,2020-04-18,12/31/2020,Observational,"Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases",Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04353609,0,0,0,0,1,0,France,0,"NA",NA
NCT04353401,2020-08-03,4/30/2021,Observational,WGS Analysis of COVID-19 Positive Patients,Enrolling by invitation,NA,Vanda Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04353401,0,0,0,0,2,1,United States,0,"NA",NA
NCT04353336,2020-03-23,9/23/2030,Interventional,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04353336,0,0,0,0,5,0,Egypt,0,chloroquine/hydroxychloroquine|chloroquine|hydroxychloroquine,NA
NCT04377308,2020-05-01,4/20/2021,Interventional,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,Phase 4,University of Toledo Health Science Campus,NA,https://clinicalzeros.gov/ct2/show/NCT04377308,0,0,0,0,0,1,United States,0,fluoxetine,NA
NCT04353011,2020-04-20,4/27/2020,Observational,Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04353011,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04351633,2020-04-23,4/30/2020,Observational,Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04351633,0,0,0,0,4,0,France,0,questionnaire,NA
NCT04351503,2020-04-09,4/30/2022,Observational,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19,Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04351503,0,0,0,0,2,0,Switzerland,0,study a|study b|study c|study d,NA
NCT04351347,2020-06-16,12/1/2030,Interventional,The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04351347,0,0,0,0,4,0,Egypt,0,ivermectin|nitazoxanide / ivermectin,NA
NCT04366206,2020-03-14,7/31/2020,Observational [Patient Registry],Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,Recruiting,NA,Centre Hospitalier Intercommunal Robert Ballanger,NA,https://clinicalzeros.gov/ct2/show/NCT04366206,0,0,0,0,0,0,France,0,"NA",NA
NCT04365166,2020-04-21,4/21/2022,Observational,Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19),Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04365166,0,0,0,0,2,0,France,0,"NA",NA
NCT04363814,2020-06-10,7/1/2021,Interventional,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,Recruiting,Phase 3,Inmunotek S.L.,NA,https://clinicalzeros.gov/ct2/show/NCT04363814,0,0,0,0,3,0,Dominican Republic,0,bactek-r,NA
NCT04358614,2020-03-16,4/5/2020,Interventional,Baricitinib Therapy in COVID-19,Completed,Phase 2/Phase 3,Hospital of Prato,NA,https://clinicalzeros.gov/ct2/show/NCT04358614,0,0,0,0,0,0,Italy,0,baricitinib,NA
NCT04359914,2020-04-15,12/31/2020,Observational,Neurocognitive Impairment in Patients With COVID-19,Recruiting,NA,University of Rostock,NA,https://clinicalzeros.gov/ct2/show/NCT04359914,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04376034,2020-04-16,3/30/2021,Interventional,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Recruiting,Phase 3,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04376034,0,0,0,0,0,1,United States,0,convalescent plasma|standard care,NA
NCT04357314,2020-03-01,5/31/2020,Observational,Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study,Completed,NA,French Cardiology Society,NA,https://clinicalzeros.gov/ct2/show/NCT04357314,0,0,0,0,2,0,France,0,"NA",NA
NCT04371250,2020-04-30,5/31/2020,Observational,Study of Resilience and Loneliness in Youth (18 - 25 Years Old) During the COVID-19 Pandemic Lock-down Measures.,"Active, not recruiting",NA,Erasme University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04371250,0,0,0,0,2,0,Belgium,0,survey/questionnaire|questionnaire,NA
NCT04356885,2020-04-01,7/30/2020,Observational,COVID-19 and Psychotic Symptoms in France,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04356885,0,0,0,0,2,0,France,0,"NA",NA
NCT04366323,2020-04-27,10/31/2021,Interventional,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Active, not recruiting",Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,NA,https://clinicalzeros.gov/ct2/show/NCT04366323,0,0,0,0,2,0,Spain,0,mesenchymal stem cells|allogeneic,NA
NCT04366245,2020-04-23,12/31/2021,Interventional,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Recruiting,Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,NA,https://clinicalzeros.gov/ct2/show/NCT04366245,0,0,0,0,3,0,Spain,0,convalescent plasma|standard care,NA
NCT04365101,2020-05-13,12/30/2020,Interventional,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,Recruiting,Phase 1/Phase 2,Celularity Incorporated,NA,https://clinicalzeros.gov/ct2/show/NCT04365101,0,0,0,0,13,1,United States,0,nk cells,NA
NCT04364594,2020-03-26,4/24/2020,Interventional,COVID-19 Search in Conjunctival Cells,Completed,N/A,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04364594,0,0,0,0,2,0,Italy,0,conjunctival swab,NA
NCT04363463,2020-08-28,8/28/2022,Interventional,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,N/A,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04363463,0,0,0,0,2,0,France,0,prone positioning,NA
NCT04362943,2020-04-20,5/15/2020,Observational,Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults,Recruiting,NA,Complejo Hospitalario Universitario de Albacete,NA,https://clinicalzeros.gov/ct2/show/NCT04362943,0,0,0,0,0,0,Spain,0,baricitinib/anakinra|baricitinib|anakinra,NA
NCT04362137,2020-05-02,10/17/2020,Interventional,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04362137,0,0,0,0,17,1,United States|Argentina|Brazil|Colombia|France|Germany|Mexico|Peru|Russian Federation|Spain|Turkey|United Kingdom,0,ruxolitinib|placebo,NA
NCT04355871,2020-03-18,4/15/2020,Observational,Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain,Completed,NA,Fundacion SEIMC-GESIDA,NA,https://clinicalzeros.gov/ct2/show/NCT04355871,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04534673,2020-08-05,12/31/2021,Interventional,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Recruiting,Phase 2,Soroka University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04534673,0,0,0,0,0,0,Israel,0,lambda 180 mcg s.c,NA
NCT04385069,2020-04-16,7/5/2020,Observational,COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study,Recruiting,NA,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04385069,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04384029,2020-03-24,3/31/2021,Observational,The Geneva Covid-19 CVD Study,"Active, not recruiting",NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04384029,0,0,0,0,0,0,Switzerland,0,covid-19 / patients|covid-19|patients,NA
NCT04376853,2020-04-15,6/30/2020,Observational,CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch,Recruiting,NA,University Hospital Heidelberg,NA,https://clinicalzeros.gov/ct2/show/NCT04376853,0,0,0,0,0,0,Germany,0,apple watch,NA
NCT04361591,2020-03-01,3/1/2021,Observational [Patient Registry],COVID-19 in Liver Transplant Recipients,Recruiting,NA,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04361591,0,0,0,0,0,0,Spain,0,observational,NA
NCT04361565,2020-03-20,4/10/2020,Observational,Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients,Enrolling by invitation,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04361565,0,0,0,0,2,0,France,0,"NA",NA
NCT04361500,2020-04-15,10/1/2020,Observational [Patient Registry],Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter,Recruiting,NA,Hannover Medical School,NA,https://clinicalzeros.gov/ct2/show/NCT04361500,0,0,0,0,0,0,Germany,0,seraph,NA
NCT04374084,2020-05-10,12/31/2021,Interventional,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Recruiting,N/A,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04374084,0,0,0,0,2,0,China,0,moxibustion/cupping|moxibustion|cupping,NA
NCT04361396,2020-06-16,6/30/2021,Interventional,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Recruiting,N/A,Centre Hospitalier RenÃ© Dubos,NA,https://clinicalzeros.gov/ct2/show/NCT04361396,0,0,0,0,5,0,France,0,biological samples,NA
NCT04361214,2020-05-05,2/28/2021,Interventional,Leflunomide in Mild COVID-19 Patients,Recruiting,Phase 1,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04361214,0,0,0,0,5,1,United States,0,leflunomide,NA
NCT04361123,2020-05-06,12/31/2021,Observational,Atrium COVID-19 Syndromic and Serologic Surveillance,Enrolling by invitation,NA,Atrium Health,NA,https://clinicalzeros.gov/ct2/show/NCT04361123,0,0,0,0,2,1,United States,0,daily syndromic surveillance|igm/igg rapid test|igm test,NA
NCT04361019,2020-04-16,10/20/2020,Observational,Physical Activity in University Students Around COVID-19 Confinement,Recruiting,NA,Basque Country University,NA,https://clinicalzeros.gov/ct2/show/NCT04361019,0,0,0,0,1,0,Spain,0,online survey,NA
NCT04360863,2020-04-24,12/30/2021,Observational,The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong,Recruiting,NA,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04360863,0,0,0,0,2,0,Hong Kong,0,questionnaire,NA
NCT04360811,2020-04-17,4/30/2021,Interventional,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04360811,0,0,0,0,0,0,France,0,pcr,NA
NCT04360733,2020-04-20,4/30/2022,Observational,Precision Immunology to Determine the Immune Response in Patients With COVID-19,Recruiting,NA,University of Bonn,NA,https://clinicalzeros.gov/ct2/show/NCT04360733,0,0,0,0,0,0,Germany,0,blood sample,NA
NCT04360707,2020-04-08,4/8/2021,Observational,Solid Organ Transplant Recipients With SARS-CoV-2 French Registry,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04360707,0,0,0,0,1,0,France,0,"NA",NA
NCT04366063,2020-04-05,6/6/2020,Interventional,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Recruiting,Phase 2/Phase 3,Royan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04366063,0,0,0,0,1,0,"Iran, Islamic Republic of",0,cell therapy protocol 1|cell therapy protocol 2,NA
NCT04360278,2020-04-21,4/14/2030,Observational,Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04360278,0,0,0,0,11,1,United States,0,"NA",NA
NCT04364763,2020-08-05,6/30/2021,Interventional,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),Recruiting,Phase 2,"Renibus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04364763,0,0,0,0,13,1,United States,0,rbt-9 (90 mg)|saline,NA
NCT04366934,2020-05-04,10/29/2020,Observational,Study of the Pathogenesis of Olfactory Disorders in COVID-19,Completed,NA,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04366934,0,0,0,0,2,0,France,0,nasal|taste/olfactory function evaluation|taste|olfactory function evaluation,NA
NCT04364737,2020-04-17,1/31/2023,Interventional,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,Recruiting,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04364737,0,0,0,0,9,1,United States,0,saline|convalescent plasma,NA
NCT04362995,2020-04-23,4/30/2022,Observational,St. Jude Tracking of Viral and Host Factors Associated With COVID-19,Recruiting,NA,St. Jude Children's Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04362995,0,0,0,0,4,1,United States,0,"NA",NA
NCT04363047,2020-10-01,5/1/2021,Observational,"Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19",Enrolling by invitation,NA,University of Manchester,NA,https://clinicalzeros.gov/ct2/show/NCT04363047,0,0,0,0,2,0,United Kingdom,0,40ml blood sample,NA
NCT04362345,2020-04-09,1/9/2021,Observational,Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04362345,0,0,0,0,2,0,France,0,"NA",NA
NCT04362332,2020-04-14,6/8/2020,Interventional,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Terminated,Phase 4,UMC Utrecht,"Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be
    expected we need more than 1000 inclusions",https://clinicalzeros.gov/ct2/show/NCT04362332,0,0,0,0,1,0,Netherlands,0,chloroquine|hydroxychloroquine|standard care,NA
NCT04396600,2020-06-08,5/25/2022,Observational,The Professional Peer Resilience Initiative,Enrolling by invitation,NA,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04396600,0,0,0,0,2,1,United States,0,peer support,NA
NCT04360954,2020-04-23,7/8/2020,Observational,Evaluation of Antibody Tests for COVID-19,Completed,NA,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04360954,0,0,0,0,3,1,United States,0,diagnostic test,NA
NCT04381286,2019-04-01,4/1/2021,Observational,Transpulmonary Driving Pressure in ARDS COVID19 Patients,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04381286,0,0,0,0,1,0,France,0,"NA",NA
NCT04359901,2020-04-10,4/30/2022,Interventional,Sarilumab for Patients With Moderate COVID-19 Disease,Recruiting,Phase 2,VA Boston Healthcare System,NA,https://clinicalzeros.gov/ct2/show/NCT04359901,0,0,0,0,5,1,United States,0,sarilumab,NA
NCT04377750,2020-04-08,4/29/2020,Interventional,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,Phase 4,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04377750,0,0,0,0,0,0,Israel,0,tocilizumab,NA
NCT04359849,2020-05-31,5/31/2022,Observational,Sequencing and Tracking of Phylogeny in COVID-19 Study,Recruiting,NA,Portsmouth Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04359849,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04359797,2020-04-27,12/17/2020,Interventional,COVID-19 Patient Positioning Pragmatic Trial,"Active, not recruiting",N/A,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04359797,0,0,0,0,12,1,United States,0,prone positioning|standard care,NA
NCT04359680,2020-05-13,4/30/2021,Interventional,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,Recruiting,Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04359680,0,0,0,0,5,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04359537,2020-05-01,8/25/2020,Interventional,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Recruiting,Phase 2,Shaheed Zulfiqar Ali Bhutto Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04359537,0,0,0,0,2,0,Pakistan,0,hydroxychloroquine|placebo,NA
NCT04359407,2020-04-27,12/31/2020,Observational,Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients,Recruiting,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04359407,0,0,0,0,1,0,Switzerland,0,prone positioning,NA
NCT04358536,2020-04-01,4/17/2020,Observational,Classification of COVID-19 Infection in Posteroanterior Chest X-rays,Completed,NA,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04358536,0,0,0,0,0,1,United States,0,covx,NA
NCT04368793,2020-04-06,12/31/2020,Observational,Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge,Recruiting,NA,China-Japan Friendship Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04368793,0,0,0,0,2,0,China,0,remote pulmonary rehabilitation,NA
NCT04358510,2020-04-01,4/17/2020,Observational,COVID-19 Mortality Prediction Model,Completed,NA,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04358510,0,0,0,0,0,1,United States,0,coviage,NA
NCT04358068,2020-05-01,7/7/2020,Interventional,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Completed,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04358068,0,0,0,0,12,1,United States,0,hydroxychloroquine|azithromycin|placebo,NA
NCT04358003,2020-05-20,8/1/2021,Interventional,Plasma Adsorption in Patients With Confirmed COVID-19,Recruiting,N/A,Marker Therapeutics AG,NA,https://clinicalzeros.gov/ct2/show/NCT04358003,0,0,0,0,7,1,United States,0,marker therapeutics d2000 cartridge (d2000) for use with the spectra optiaâ® apheresis system (optia spd protocol),NA
NCT04357990,2020-09-04,3/31/2021,Interventional,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,Recruiting,N/A,Kerecis Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04357990,0,0,0,0,2,0,Iceland,0,viruxal oral/nasal spray|placebo|viruxal oral|nasal rinse,NA
NCT04357639,2020-05-28,1/31/2021,Observational [Patient Registry],Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP ),Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04357639,0,0,0,0,6,0,France,0,no intervention,NA
NCT04366986,2020-06-23,4/30/2024,Observational [Patient Registry],International Registry of Coronavirus (COVID-19) Exposure in Pregnancy,Recruiting,NA,Pregistry,NA,https://clinicalzeros.gov/ct2/show/NCT04366986,0,0,0,0,1,1,United States,0,tested for sars-cov-2 (regardless of the result)|clinical diagnosis of covid-19 by a health care professional,NA
NCT04366947,2020-04-14,9/20/2020,Interventional,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04366947,0,0,0,0,1,0,Poland,0,nioâ® (intraosseous access)|standard care,NA
NCT04366778,2020-05-01,1/1/2021,Observational,Thrombosis and Covid-19,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04366778,0,0,0,0,4,0,France,0,tem-tpa,NA
NCT04357574,2020-04-14,4/30/2021,Observational,Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19,Enrolling by invitation,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04357574,0,0,0,0,0,1,United States,0,telehealth,NA
NCT04366297,2020-01-12,2/25/2020,Interventional,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04366297,0,0,0,0,0,0,Poland,0,intravenous|intraosseous,NA
NCT04366271,2020-05-07,7/31/2020,Interventional,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,Recruiting,Phase 2,"Hospital Infantil Universitario NiÃ±o JesÃºs, Madrid, Spain",NA,https://clinicalzeros.gov/ct2/show/NCT04366271,0,0,0,0,1,0,Spain,0,mesenchymal stem cells|standard care,NA
NCT04357457,2020-09-03,12/31/2020,Interventional,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04357457,0,0,0,0,2,0,France,0,almitrine|placebo,NA
NCT04357366,2020-04-15,4/15/2022,Interventional,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),Recruiting,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04357366,0,0,0,0,5,0,Greece,0,anakinra,NA
NCT04364984,2020-04-01,4/1/2021,Observational [Patient Registry],"ARB, ACEi, DRi in COVID-19",Recruiting,NA,Medical Practice Prof D. Ivanov,NA,https://clinicalzeros.gov/ct2/show/NCT04364984,0,0,0,0,1,0,Ukraine,0,ace inhibitor,NA
NCT04368845,2020-05-11,3/31/2021,Interventional,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,Recruiting,N/A,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,https://clinicalzeros.gov/ct2/show/NCT04368845,0,0,0,0,2,0,Greece,0,telehealth,NA
NCT04363788,2020-02-28,4/24/2020,Observational,Needle Stick Injuries in Emergency Medical Service Practice,Completed,NA,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04363788,0,0,0,0,1,0,Poland,0,gloves,NA
NCT04363541,2020-08-27,4/30/2022,Interventional,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,Recruiting,N/A,Instituto Nacional de Perinatologia,NA,https://clinicalzeros.gov/ct2/show/NCT04363541,0,0,0,0,2,0,Mexico,0,electric pad for human external pain therapy,NA
NCT04413864,2020-04-24,2/28/2021,Interventional,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04413864,0,0,0,0,0,0,France,0,inflammatory cytokines/chemokines profiles of patients with dexmedetomidine administration|inflammatory cytokines|chemokines profiles of patients with dexmedetomidine administration,NA
NCT04363632,2020-04-02,6/30/2020,Observational [Patient Registry],Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection,Completed,NA,Centre Leon Berard,NA,https://clinicalzeros.gov/ct2/show/NCT04363632,0,0,0,0,3,0,France,0,"NA",NA
NCT04363528,2020-04-24,10/30/2020,Interventional,Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,Recruiting,N/A,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04363528,0,0,0,0,1,0,France,0,doppler echo,NA
NCT04363502,2020-05-07,2/28/2021,Interventional,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04363502,0,0,0,0,5,1,United States,0,clazakizumab|placebo,NA
NCT04363450,2020-04-27,3/31/2021,Interventional,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,Phase 3,Louisiana State University Health Sciences Center in New Orleans,NA,https://clinicalzeros.gov/ct2/show/NCT04363450,0,0,0,0,2,1,United States,0,hydroxychloroquine|placebo,NA
NCT04363437,2020-04-26,5/31/2020,Interventional,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Recruiting,Phase 2,Maimonides Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04363437,0,0,0,0,2,1,United States,0,standard care|colchicine,NA
NCT04363268,2020-04-20,4/20/2030,Observational,ACCESS A Master Digital Surveillance Protocol for COVID-19,Recruiting,NA,Medable Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04363268,0,0,0,0,1,1,United States,0,"NA",NA
NCT04403009,2020-02-01,6/6/2020,Observational,The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19,Recruiting,NA,The First Affiliated Hospital of Guangzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04403009,0,0,0,0,0,0,China,0,no intervention,NA
NCT04397835,2020-04-17,4/20/2021,Observational,Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04397835,0,0,0,0,0,0,France,0,"NA",NA
NCT04363099,2020-03-01,6/30/2020,Observational,Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.,Recruiting,NA,Maison de Sante Pluridisciplinaire de Creil,NA,https://clinicalzeros.gov/ct2/show/NCT04363099,0,0,0,0,0,0,France,0,observational,NA
NCT04380766,2019-01-01,7/31/2020,Observational [Patient Registry],Covid-19 Pandemic and Pancreatic Surgery in Italy,Completed,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04380766,0,0,0,0,3,0,Italy,0,evaluation of changes in the diagnostic-therapeutic pathway,NA
NCT04362319,2020-05-15,5/31/2020,Observational,Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic,Completed,NA,University of Malaya,NA,https://clinicalzeros.gov/ct2/show/NCT04362319,0,0,0,0,1,0,Malaysia,0,questionnaire,NA
NCT04362267,2020-06-15,9/30/2020,Observational,Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04362267,0,0,0,0,2,0,France,0,questionnaire|sars-cov2 testing,NA
NCT04362150,2020-04-21,12/31/2022,Observational,Long-term Impact of Infection With Novel Coronavirus (COVID-19),"Active, not recruiting",NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04362150,0,0,0,0,3,1,United States,0,"NA",NA
NCT04361253,2020-04-30,6/30/2021,Interventional,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04361253,0,0,0,0,2,1,United States,0,convalescent plasma|plasma,NA
NCT04363346,2020-05-14,1/31/2022,Interventional,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,"Active, not recruiting",Phase 1,"Masonic Cancer Center, University of Minnesota",NA,https://clinicalzeros.gov/ct2/show/NCT04363346,0,0,0,0,3,1,United States,0,nk cells,NA
NCT04375748,2020-04-15,10/15/2021,Observational,Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04375748,0,0,0,0,1,0,France|Martinique|Mayotte|RÃ©union,0,standard care|examinations for the research:|paraclinical test,NA
NCT04492943,2020-04-20,6/30/2020,Observational,To Observe Whether Isoflurane Can Treat COVID-19 Patients,Completed,NA,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04492943,0,0,0,0,1,1,United States,0,"NA",NA
NCT04366024,2020-01-17,8/30/2020,Observational,A Novel Nomogram to Predict Severity of COVID-19,Recruiting,NA,Xinqiao Hospital of Chongqing,NA,https://clinicalzeros.gov/ct2/show/NCT04366024,0,0,0,0,1,0,China,0,other,NA
NCT04433871,2020-04-27,4/27/2022,Observational [Patient Registry],COVID-19 in Pediatric Oncology and Hematology Centers in France,Recruiting,NA,"University Hospital, Caen",NA,https://clinicalzeros.gov/ct2/show/NCT04433871,0,0,0,0,0,0,France,0,no intervention,NA
NCT04393961,2020-04-05,7/29/2020,Interventional,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,N/A,ProofPilot,NA,https://clinicalzeros.gov/ct2/show/NCT04393961,0,0,0,0,0,1,United States,0,igm/igg rapid test|igg|igm antibodytest,NA
NCT04359602,2020-04-08,4/20/2022,Observational [Patient Registry],COVID-19 Recovered Volunteer Research Participant Pool Registry,Recruiting,NA,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04359602,0,0,0,0,2,1,United States,0,"NA",NA
NCT04372979,2020-09-14,5/31/2021,Interventional,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Recruiting,Phase 3,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04372979,0,0,0,0,3,0,France,0,transfusion of sars-cov-2 convalescent plasma.|transfusion of standard plasma.,NA
NCT04363736,2020-05-05,8/12/2020,Interventional,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Completed,Phase 2,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04363736,0,0,0,0,3,1,United States,0,tociliuzumab,NA
NCT04371315,2020-04-27,6/1/2021,Observational,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",Recruiting,NA,St. Jude Children's Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04371315,0,0,0,0,1,1,United States,0,"NA",NA
NCT04370678,2020-04-17,4/24/2020,Observational,Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures,Completed,NA,Region Zealand,NA,https://clinicalzeros.gov/ct2/show/NCT04370678,0,0,0,0,1,0,Denmark,0,change in preference to surgery under covid-19 pandemic.,NA
NCT04363385,2020-05-31,5/31/2021,Interventional,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Recruiting,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04363385,0,0,0,0,4,0,France,0,biological test,NA
NCT04363008,2020-03-30,4/30/2020,Observational,COVID 19 Biomarkers,Recruiting,NA,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04363008,0,0,0,0,1,0,Canada,0,serum test,NA
NCT04362956,2020-07-10,9/30/2020,Observational,Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection,Recruiting,NA,Fundacion Infant,NA,https://clinicalzeros.gov/ct2/show/NCT04362956,0,0,0,0,2,0,Argentina,0,"NA",NA
NCT04368923,2020-03-15,6/21/2020,Interventional,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04368923,0,0,0,0,1,0,Egypt,0,oxygen|physical therapy,NA
NCT04362189,2020-06-30,10/31/2021,Interventional,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"Active, not recruiting",Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04362189,0,0,0,0,6,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04362176,2020-04-24,4/30/2021,Interventional,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Recruiting,Phase 3,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04362176,0,0,0,0,5,1,United States,0,convalescent plasma|placebo,NA
NCT04368260,2020-04-24,7/31/2020,Interventional,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,N/A,University of Virginia,NA,https://clinicalzeros.gov/ct2/show/NCT04368260,0,0,0,0,0,1,United States,0,control swab|prototype,NA
NCT04368221,2020-05-04,5/31/2021,Observational,Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU,"Active, not recruiting",NA,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04368221,0,0,0,0,3,0,France,0,"NA",NA
NCT04368000,2020-04-29,8/6/2020,Interventional,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Terminated,N/A,University of Utah,Study was terminated due to lack of adherence to the protocol in the intervention arm.,https://clinicalzeros.gov/ct2/show/NCT04368000,0,0,0,0,3,1,United States,0,intermittent|usual care positioning with no instructions,NA
NCT04362111,2020-07-29,1/31/2021,Interventional,Early Treatment of Cytokine Storm Syndrome in Covid-19,Recruiting,Phase 3,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04362111,0,0,0,0,1,1,United States,0,anakinra|saline,NA
NCT04361526,2020-04-17,7/31/2020,Interventional,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Recruiting,N/A,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04361526,0,0,0,0,0,0,Spain,0,cytokine adsorption,NA
NCT04367168,2020-05-27,4/27/2021,Interventional,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04367168,0,0,0,0,2,0,Mexico,0,colchicine|placebo,NA
NCT04360850,2020-04-24,10/31/2025,Observational,Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic,Recruiting,NA,University of Washington,NA,https://clinicalzeros.gov/ct2/show/NCT04360850,0,0,0,0,1,1,United States,0,online survey,NA
NCT04366167,2020-04-18,4/19/2021,Observational,Patient Recovery From Heart Surgery During the Covid-19 Pandemic,Recruiting,NA,Barts & The London NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04366167,0,0,0,0,0,0,United Kingdom,0,cardiac surgery,NA
NCT04366141,2020-05-01,1/1/2021,Interventional,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,Recruiting,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04366141,0,0,0,0,2,0,Canada,0,covid-19 barrier box,NA
NCT04366050,2020-05-11,5/31/2021,Interventional,Ramipril for the Treatment of COVID-19,Recruiting,Phase 2,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04366050,0,0,0,0,2,1,United States,0,ramipril|placebo,NA
NCT04365972,2020-04-23,4/30/2020,Interventional,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Completed,N/A,Tel Aviv University,NA,https://clinicalzeros.gov/ct2/show/NCT04365972,0,0,0,0,1,0,Israel,0,attention bias modification (abm),NA
NCT04365816,2020-04-30,7/10/2020,Observational,NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30,Completed,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04365816,0,0,0,0,2,0,France,0,interview,NA
NCT04360551,2020-07-01,6/30/2021,Interventional,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,Recruiting,Phase 2,University of Hawaii,NA,https://clinicalzeros.gov/ct2/show/NCT04360551,0,0,0,0,1,1,United States,0,telmisartan|placebo,NA
NCT04365608,2020-03-20,11/30/2020,Interventional,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04365608,0,0,0,0,2,0,Poland,0,laryngoscopy,NA
NCT04365595,2020-06-03,12/31/2020,Observational,SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir),Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04365595,0,0,0,0,2,0,Switzerland,0,questionnaire,NA
NCT04359927,2020-04-20,8/31/2021,Observational [Patient Registry],Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry,Recruiting,NA,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04359927,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04365335,2020-04-25,6/12/2020,Observational,Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic,Completed,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04365335,0,0,0,0,3,0,France,0,assessment of work-related stress|saliva|cardiac/electrodermal recordings|emotional stimulation|cardiac|electrodermal recordings,NA
NCT04365309,2020-02-10,4/30/2020,Interventional,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,Phase 2/Phase 3,Xijing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04365309,0,0,0,0,0,0,China,0,aspirin,NA
NCT04365257,2020-05-13,6/30/2021,Interventional,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04365257,0,0,0,0,3,1,United States,0,prazosin|standard care,NA
NCT04365127,2020-04-27,8/20/2020,Interventional,Progesterone for the Treatment of COVID-19 in Hospitalized Men,Completed,Phase 1,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04365127,0,0,0,0,2,1,United States,0,progesterone,NA
NCT04359862,2020-04-16,3/31/2021,Interventional,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Recruiting,Phase 4,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04359862,0,0,0,0,3,0,Spain,0,sevoflurane|propofol,NA
NCT04359706,2020-05-08,9/30/2020,Observational,Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04359706,0,0,0,0,2,0,France,0,"NA",NA
NCT04359693,2020-04-22,7/1/2020,Observational,Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04359693,0,0,0,0,3,0,France,0,"NA",NA
NCT04359654,2020-06-16,8/1/2021,Interventional,Nebulised Dornase Alfa for Treatment of COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04359654,0,0,0,0,2,0,United Kingdom,0,pulmozyme,NA
NCT04364698,2020-05-07,6/30/2020,Observational,Observational Cohort of COVID-19 Patients at Raymond-Poincare,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04364698,0,0,0,0,1,0,France,0,"NA",NA
NCT04359121,2020-04-15,4/15/2023,Observational,COVID-19 and the Developement of Phobic Fears of Disease,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04359121,0,0,0,0,1,0,Austria,0,phobia questionairre,NA
NCT04363606,2020-05-27,4/30/2021,Interventional,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Recruiting,N/A,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04363606,0,0,0,0,3,0,France,0,questionnaire|blood test|maximal effort test|actigraphy|neuromuscular,NA
NCT04363593,2020-05-04,11/16/2020,Interventional,Serology COVID-19 From the Cornwall Hospital Union,Completed,N/A,Centre Hospitalier de Cornouaille,NA,https://clinicalzeros.gov/ct2/show/NCT04363593,0,0,0,0,2,0,France,0,serology test|serum test,NA
NCT04363372,2020-06-30,8/31/2020,Interventional,A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19,Recruiting,Phase 2,4D pharma plc,NA,https://clinicalzeros.gov/ct2/show/NCT04363372,0,0,0,0,1,0,United Kingdom,0,mrx-4dp0004|placebo,NA
NCT04362930,2020-04-27,4/24/2022,Observational,Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences),Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04362930,0,0,0,0,2,0,France,0,"NA",NA
NCT04362865,2020-04-27,12/1/2023,Observational,Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04362865,0,0,0,0,20,1,United States,0,"NA",NA
NCT04362813,2020-04-30,9/16/2020,Interventional,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Active, not recruiting",Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04362813,0,0,0,0,10,1,United States|France|Italy|Russian Federation|Spain|United Kingdom,0,canakinumab|placebo,NA
NCT04365153,2020-04-24,2/28/2021,Interventional,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),"Active, not recruiting",Phase 2,The Cleveland Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04365153,0,0,0,0,5,1,United States,0,canakinumab|placebo,NA
NCT04666116,2020-04-01,12/31/2020,Interventional,Changes in Viral Load in COVID-19 After Probiotics,Recruiting,N/A,Hospital de Sagunto,NA,https://clinicalzeros.gov/ct2/show/NCT04666116,0,0,0,0,1,0,Spain,0,dietary supplementation in patients with covid disease admitted to hospital,NA
NCT04358809,2020-06-30,2/28/2021,Interventional,"Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill",Recruiting,Phase 3,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04358809,0,0,0,0,1,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04518969,2020-05-03,12/1/2020,Interventional,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04518969,0,0,0,0,0,0,Belgium,0,cytosorb,NA
NCT04392778,2020-04-01,7/31/2020,Interventional,Clinical Use of Stem Cells for the Treatment of Covid-19,Recruiting,Phase 1/Phase 2,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,https://clinicalzeros.gov/ct2/show/NCT04392778,0,0,0,0,0,0,Turkey,0,mesenchymal stem cells|saline,NA
NCT04358783,2020-04-27,2/1/2021,Interventional,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,Recruiting,Phase 2,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04358783,0,0,0,0,1,0,Mexico,0,plasma|best available therapy,NA
NCT04358640,2020-04-09,4/27/2020,Observational,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Completed,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04358640,0,0,0,0,1,0,France,0,"NA",NA
NCT04357431,2020-04-22,5/26/2020,Observational,COVID-19 Among Egyptian Health Care Providers,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04357431,0,0,0,0,2,0,Egypt,0,questionnaire,NA
NCT04372017,2020-05-14,6/4/2020,Interventional,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Active, not recruiting",Phase 3,Sanford Health,NA,https://clinicalzeros.gov/ct2/show/NCT04372017,0,0,0,0,2,1,United States,0,hydroxychloroquine|vitamin d,NA
NCT04356365,2020-03-31,4/7/2020,Observational,The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's),Completed,NA,University of Oslo,NA,https://clinicalzeros.gov/ct2/show/NCT04356365,0,0,0,0,1,0,Norway,0,cross-sectional study investigating the association of npis with mental health,NA
NCT04358926,2020-04-30,10/15/2020,Interventional,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,N/A,Assaf-Harofeh Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04358926,0,0,0,0,5,0,Israel,0,oxygen,NA
NCT04368299,2020-05-01,10/31/2021,Interventional,Telemedicine for Follow-up of Systemic Lupus Erythematosus,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04368299,0,0,0,0,1,0,Hong Kong,0,telehealth|standard care,NA
NCT04365764,2020-03-14,12/31/2020,Observational,Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Recruiting,NA,Groupe Hospitalier Pitie-Salpetriere,NA,https://clinicalzeros.gov/ct2/show/NCT04365764,0,0,0,0,2,0,France,0,"NA",NA
NCT04365725,2020-05-05,6/30/2020,Observational,"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04365725,0,0,0,0,1,0,France,0,remdesivir,NA
NCT04365699,2020-04-08,12/31/2020,Interventional,Cardiovascular Effects of COVID-19,Recruiting,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04365699,0,0,0,0,0,1,United States,0,at-001,NA
NCT04365634,2020-02-02,3/15/2020,Observational,A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.,Completed,NA,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04365634,0,0,0,0,0,0,China,0,"NA",NA
NCT04365361,2020-04-26,12/30/2020,Observational,The Psychological Impact of the COVID-19 on Students.,Recruiting,NA,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04365361,0,0,0,0,2,0,Hong Kong,0,"NA",NA
NCT04365348,2020-04-27,3/31/2021,Observational,The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families,Recruiting,NA,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04365348,0,0,0,0,1,0,Hong Kong,0,"NA",NA
NCT04365322,2020-04-20,9/1/2020,Observational [Patient Registry],Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19),Recruiting,NA,Centre Hospitalier Universitaire de Besancon,NA,https://clinicalzeros.gov/ct2/show/NCT04365322,0,0,0,0,3,0,France,0,biological samples,NA
NCT04393233,2020-04-23,5/23/2020,Observational,Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation,Recruiting,NA,"University Hospital, Brest",NA,https://clinicalzeros.gov/ct2/show/NCT04393233,0,0,0,0,1,0,France,0,"NA",NA
NCT04428268,2020-03-10,6/10/2020,Interventional,Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia,Recruiting,Phase 2,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04428268,0,0,0,0,2,0,Mexico,0,NA,NA
NCT04393142,2020-05-05,6/13/2020,Observational [Patient Registry],Serologic Testing of Household Contacts of Confirmed Cases of COVID-19,Recruiting,NA,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04393142,0,0,0,0,1,0,Mexico,0,"NA",NA
NCT04382534,2020-03-10,9/30/2020,Observational,A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction,Recruiting,NA,Peking University Third Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04382534,0,0,0,0,0,0,China,0,respiratory rehabilitation,NA
NCT04373824,2020-04-25,7/25/2020,Interventional,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,N/A,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04373824,0,0,0,0,0,0,India,0,ivermectin,NA
NCT04373811,2020-04-16,7/13/2021,Observational,One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04373811,0,0,0,0,2,0,France,0,lung ultrasound|muscle,NA
NCT04370782,2020-04-28,9/30/2020,Interventional,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,Completed,Phase 4,"St. Francis Hospital, New York",NA,https://clinicalzeros.gov/ct2/show/NCT04370782,0,0,0,0,2,1,United States,0,hydroxychloroquine|azithromycin|zinc|doxycycline,NA
NCT04368637,2020-05-03,7/30/2020,Observational,Acute Cardiovascular Events Triggered by COVID-19-Related Stress,Recruiting,NA,Jordan Collaborating Cardiology Group,NA,https://clinicalzeros.gov/ct2/show/NCT04368637,0,0,0,0,1,0,Jordan,0,"NA",NA
NCT04367064,2020-04-25,11/25/2020,Observational,To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study),Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04367064,0,0,0,0,1,0,India,0,"NA",NA
NCT04366856,2020-06-26,12/31/2020,Interventional,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04366856,0,0,0,0,1,0,France,0,prone positioning|no instruction regarding positioning,NA
NCT04365985,2020-04-29,5/31/2021,Interventional,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Recruiting,Phase 2,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04365985,0,0,0,0,3,1,United States,0,naltrexone|ketamine|placebo,NA
NCT04365881,2020-03-31,4/7/2020,Observational,Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology,Completed,NA,Modum Bad,NA,https://clinicalzeros.gov/ct2/show/NCT04365881,0,0,0,0,0,0,Norway,0,cross-sectional observational study,NA
NCT04365738,2020-03-11,4/10/2020,Interventional,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Completed,N/A,Istanbul Bilgi University,NA,https://clinicalzeros.gov/ct2/show/NCT04365738,0,0,0,0,0,0,Turkey,0,rehabilitation,NA
NCT04365530,2020-04-01,4/1/2022,Observational,Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04365530,0,0,0,0,1,0,France,0,"NA",NA
NCT04604769,2019-06-26,9/1/2020,Observational,Perceived Stress Among ICU Medical Staff During COVID-19 Crisis,Completed,NA,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04604769,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04400032,2020-05-15,1/31/2021,Interventional,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard,Recruiting,Phase 1,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04400032,0,0,0,0,1,0,Canada,0,mesenchymal stem cells,NA
NCT04389710,2020-04-15,4/14/2021,Interventional,Convalescent Plasma for the Treatment of COVID-19,Recruiting,Phase 2,Thomas Jefferson University,NA,https://clinicalzeros.gov/ct2/show/NCT04389710,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04383470,2020-04-26,12/31/2021,Observational,Collaborative Outcomes Study on Health and Functioning During Infection Times During COVID-19 Pandemic,Recruiting,NA,University of Padova,NA,https://clinicalzeros.gov/ct2/show/NCT04383470,0,0,0,0,1,0,Greece,0,"NA",NA
NCT04379453,2020-04-27,4/27/2020,Interventional,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,N/A,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04379453,0,0,0,0,1,0,Brazil,0,robot assisted percutaneous cardiovascular intervention,NA
NCT04374565,2020-05-05,4/5/2021,Interventional,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,"Active, not recruiting",Phase 2,University of Virginia,NA,https://clinicalzeros.gov/ct2/show/NCT04374565,0,0,0,0,3,1,United States,0,convalescent plasma,NA
NCT04372693,2020-09-01,1/30/2021,Interventional,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Enrolling by invitation,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04372693,0,0,0,0,5,0,Egypt,0,distance learning,NA
NCT04370821,2020-05-09,4/27/2040,Observational [Patient Registry],"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers",Recruiting,NA,Villanova University,NA,https://clinicalzeros.gov/ct2/show/NCT04370821,0,0,0,0,3,1,United States,0,"NA",NA
NCT04370262,2020-04-07,9/7/2020,Interventional,Multi-site Adaptive Trials for COVID-19,Completed,Phase 3,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04370262,0,0,0,0,3,1,United States,0,soc / intravenous famotidine|soc / placebo|standard care|famotidine|placebo,NA
NCT04370171,2020-05-04,5/29/2020,Observational,Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic,Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04370171,0,0,0,0,2,0,France,0,care modalities|teleconsultation either by phone/by computer consultation|teleconsultation either by phone|by computer consultation,NA
NCT04369794,2020-08-10,6/30/2021,Interventional,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,Phase 4,"University of Campinas, Brazil",NA,https://clinicalzeros.gov/ct2/show/NCT04369794,0,0,0,1,1,0,Brazil,0,bcg|placebo,NA
NCT04369456,2020-04-22,10/22/2020,Interventional,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04369456,0,0,0,0,1,0,France,0,blood sample,NA
NCT04369365,2020-04-27,8/27/2020,Interventional,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,Phase 2,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04369365,0,0,0,0,1,0,Austria,0,azithromycin|placebo,NA
NCT04368234,2020-04-18,4/30/2025,Observational [Patient Registry],Duke COVID-19 Shared Data and Specimen Repository,Recruiting,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04368234,0,0,0,0,1,1,United States,0,"NA",NA
NCT04368143,2020-04-01,12/30/2020,Observational [Patient Registry],COVID-19 Immune Repertoire Sequencing,Recruiting,NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04368143,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04368026,2020-03-30,12/1/2020,Observational,SARS-CoV-2 (COVID-19) and Surgery,Recruiting,NA,Jagiellonian University,NA,https://clinicalzeros.gov/ct2/show/NCT04368026,0,0,0,0,1,0,Poland,0,no intervention (survey study for medical doctors).,NA
NCT04367805,2020-04-27,10/31/2020,Observational,COVID-19 Infection in Patients With Hepatocellular Carcinoma,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04367805,0,0,0,0,0,0,France,0,pcr,NA
NCT04367792,2020-04-23,10/31/2020,Observational,Cardiac Injury in COVID-19: a Pathology Study,"Active, not recruiting",NA,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04367792,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04367740,2020-04-28,4/30/2021,Observational,"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19",Enrolling by invitation,NA,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04367740,0,0,0,0,1,1,United States,0,igg antibody test,NA
NCT04367714,2020-03-15,12/1/2021,Observational [Patient Registry],Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19,Recruiting,NA,Region MidtJylland Denmark,NA,https://clinicalzeros.gov/ct2/show/NCT04367714,0,0,0,0,1,0,Denmark,0,"NA",NA
NCT04367545,2020-04-16,5/17/2020,Interventional,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04367545,0,0,0,0,2,0,France,0,saliva,NA
NCT04367207,2020-05-01,12/1/2020,Observational [Patient Registry],African Covid-19 Critical Care Outcomes Study,Recruiting,NA,University of Cape Town,NA,https://clinicalzeros.gov/ct2/show/NCT04367207,0,0,0,0,2,0,South Africa,0,"NA",NA
NCT04367077,2020-04-28,9/30/2021,Interventional,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),Recruiting,Phase 2/Phase 3,"Athersys, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04367077,0,0,0,0,5,1,United States,0,multistem|placebo,NA
NCT04366752,2020-04-22,8/22/2020,Observational,Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04366752,0,0,0,0,0,0,France,0,ultrasound|blood sample,NA
NCT04366180,2020-04-24,6/30/2020,Interventional,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Recruiting,N/A,Biosearch S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04366180,0,0,0,0,1,0,Spain,0,probiotic|control,NA
NCT04369066,2020-04-28,4/28/2021,Interventional,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur",Recruiting,N/A,Institut Curie,NA,https://clinicalzeros.gov/ct2/show/NCT04369066,0,0,0,0,5,0,France,0,blood sample|nasopharyngeal swabs,NA
NCT04410354,2020-06-16,12/1/2020,Interventional,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Terminated,Phase 2,"ViralClear Pharmaceuticals, Inc.",Failure to meet primary endpoint,https://clinicalzeros.gov/ct2/show/NCT04410354,0,0,0,0,6,1,United States,0,merimepodib|placebo|remdesivir,NA
NCT04406181,2020-05-18,12/31/2020,Interventional,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04406181,0,0,0,0,1,0,Belgium,0,hads|survey,NA
NCT04380727,2020-03-20,4/14/2020,Observational [Patient Registry],Almitrine and COVID-19 Related Hypoxemia,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04380727,0,0,0,0,1,0,France,0,"NA",NA
NCT04379154,2020-04-14,2/28/2021,Interventional,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04379154,0,0,0,0,2,0,France,0,volatile organic compounds analysis,NA
NCT04376476,2020-05-05,6/5/2021,Interventional,Host-pathogen Interactions During SARS-CoV-2 Infection,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04376476,0,0,0,0,1,0,France,0,blood sample|low/upper respiratory tract sample|stool collection|phone call|low|respiratory tract sample|swab,NA
NCT04375670,2020-05-11,12/31/2020,Observational,COVID19-FOIE National Observatory,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04375670,0,0,0,0,1,0,France,0,"NA",NA
NCT04371835,2020-08-12,12/31/2021,Observational,COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings,Recruiting,NA,Kirby Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04371835,0,0,0,0,1,0,Nigeria,0,"NA",NA
NCT04371510,2020-04-22,10/22/2020,Interventional,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04371510,0,0,0,0,0,0,France,0,blood sample,NA
NCT04371393,2020-04-30,2/28/2021,Interventional,MSCs in COVID-19 ARDS,"Active, not recruiting",Phase 3,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04371393,0,0,0,0,17,1,United States,0,remestemcel-l|placebo,NA
NCT04371354,2020-04-27,6/14/2020,Observational,Outcomes of Covid-19 Protective Measures in Endoscopy,Recruiting,NA,Fundacion Miguel Servet,NA,https://clinicalzeros.gov/ct2/show/NCT04371354,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04371029,2020-04-28,9/28/2020,Interventional,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04371029,0,0,0,0,2,0,France,0,psg,NA
NCT04370886,2020-04-30,4/30/2020,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Completed,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04370886,0,0,0,0,2,0,China,0,blood donation sms,NA
NCT04370249,2020-04-09,12/31/2020,Observational,Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04370249,0,0,0,0,1,0,France,0,ultrasound,NA
NCT04369989,2020-04-14,4/14/2021,Observational,Observational Study of COVID-19 Treatment Efficacy,Enrolling by invitation,NA,OSF Healthcare System,NA,https://clinicalzeros.gov/ct2/show/NCT04369989,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04369300,2020-04-24,11/24/2020,Observational [Patient Registry],Anxiety And Depression During COVID-19 IN INDIA,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04369300,0,0,0,0,1,0,India,0,registery data collection,NA
NCT04368208,2020-04-29,10/21/2020,Observational,Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression,Completed,NA,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04368208,0,0,0,0,3,0,France,0,assessment of postnatal depression using the the edinburgh questionnaire between 4/6 weeks after delivery|assessment of postnatal depression using the the edinburgh questionnaire between 4|6 weeks after delivery,NA
NCT04368065,2020-04-02,12/31/2022,Observational [Patient Registry],COVID-19 Active Research Experience (CARE),Recruiting,NA,Iqvia Pty Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04368065,0,0,0,0,4,1,United States|United Kingdom,0,"NA",NA
NCT04367870,2020-05-23,8/31/2020,Observational,COVID-19 Detection Test in Oncology,Recruiting,NA,UNICANCER,NA,https://clinicalzeros.gov/ct2/show/NCT04367870,0,0,0,0,1,0,France,0,"NA",NA
NCT04367857,2020-04-18,10/31/2021,Observational [Patient Registry],ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04367857,0,0,0,0,1,1,United States,0,serology test|health care worker survey,NA
NCT04367350,2020-03-20,3/31/2021,Observational [Patient Registry],Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04367350,0,0,0,0,0,0,Germany,0,laboratory|muscle,NA
NCT04367337,2020-03-25,3/24/2021,Observational,Health Behavior Change During COVID-19 Pandemic,"Active, not recruiting",NA,"University of Social Sciences and Humanities, Warsaw",NA,https://clinicalzeros.gov/ct2/show/NCT04367337,0,0,0,0,4,0,China|Australia|Canada|France|Gambia|Germany|Israel|Italy|Malaysia|Poland|Portugal|Romania|Singapore|Switzerland,0,no intervention,NA
NCT04392219,2020-04-10,8/11/2020,Interventional,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",Completed,Phase 1,"Ridgeback Biotherapeutics, LP",NA,https://clinicalzeros.gov/ct2/show/NCT04392219,0,0,0,0,3,0,United Kingdom,0,eidd-2801|placebo,NA
NCT04387955,2020-04-30,5/31/2021,Interventional,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Recruiting,N/A,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04387955,0,0,0,0,1,0,France,0,biological samples,NA
NCT04385810,2020-04-27,7/29/2020,Interventional,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04385810,0,0,0,0,1,0,France,0,ophthalmologic exam,NA
NCT04385212,2020-03-13,4/14/2020,Observational,Outcomes in Hospitalized Older Patients With COVID-19,Completed,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04385212,0,0,0,0,0,0,Switzerland,0,"NA",NA
NCT04384588,2020-04-07,4/6/2021,Interventional,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Recruiting,Phase 2/Phase 3,Fundacion Arturo Lopez Perez,NA,https://clinicalzeros.gov/ct2/show/NCT04384588,0,0,0,0,0,0,Chile,0,convalescent plasma,NA
NCT04380532,2020-05-15,5/15/2021,Interventional,Tableted COVID-19 Therapeutic Vaccine,"Active, not recruiting",Phase 1/Phase 2,Immunitor LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04380532,0,0,0,1,1,0,Canada|Mongolia,0,v-sars,NA
NCT04378712,2020-01-21,3/23/2020,Interventional,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Completed,N/A,Guangzhou Institute of Respiratory Disease,NA,https://clinicalzeros.gov/ct2/show/NCT04378712,0,0,0,0,2,0,China,0,hydrogen oxygen generator with nebulizer|standard care,NA
NCT04375202,2020-04-18,6/30/2021,Interventional,Colchicine in COVID-19: a Pilot Study,Recruiting,Phase 2,University Of Perugia,NA,https://clinicalzeros.gov/ct2/show/NCT04375202,0,0,0,0,1,0,Italy,0,colchicine,NA
NCT04374487,2020-05-09,8/9/2021,Interventional,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"Active, not recruiting",Phase 2,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04374487,0,0,0,0,1,0,India,0,convalescent plasma|standard care,NA
NCT04374110,2020-05-05,6/24/2020,Observational [Patient Registry],Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19,Recruiting,NA,"Institute of Cardiology, Warsaw, Poland",NA,https://clinicalzeros.gov/ct2/show/NCT04374110,0,0,0,0,1,0,Poland,0,clinical data,NA
NCT04373200,2020-05-25,11/25/2020,Interventional,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04373200,0,0,0,0,3,0,France,0,blood sample|saliva,NA
NCT04372576,2020-04-16,8/31/2020,Observational,Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients,Recruiting,NA,Semmelweis University,NA,https://clinicalzeros.gov/ct2/show/NCT04372576,0,0,0,0,0,0,Hungary,0,assessment of ventilator-associated pneumonia criteria,NA
NCT04372472,2020-04-07,5/29/2020,Observational,SQuISH-COVID: A Pilot Study,"Active, not recruiting",NA,"Cytovale, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04372472,0,0,0,0,0,1,United States,0,"NA",NA
NCT04371848,2020-04-16,5/7/2020,Observational,Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQuÃ©bec Sub-study,"Active, not recruiting",NA,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04371848,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04374461,2020-05-01,5/31/2022,Interventional,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04374461,0,0,0,0,8,1,United States,0,n-acetylcysteine|blood,NA
NCT04374058,2020-03-20,3/31/2021,Observational,Less Frequency Hemodialysis and COVID-19,"Active, not recruiting",NA,Dialisis Madariaga,NA,https://clinicalzeros.gov/ct2/show/NCT04374058,0,0,0,0,0,0,Argentina,0,dialysis,NA
NCT04373798,2020-05-04,11/30/2020,Observational,C-reactive Protein Levels Among Individuals With COVID-19,Recruiting,NA,Frederiksberg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04373798,0,0,0,0,1,0,Denmark,0,c-reactive protein,NA
NCT04373733,2020-05-01,3/31/2021,Interventional,Early Intervention in COVID-19: Favipiravir Verses Standard Care,Recruiting,Phase 3,Chelsea and Westminster NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04373733,0,0,0,0,2,0,United Kingdom,0,favipiravir|standard care,NA
NCT04372199,2020-04-29,5/27/2020,Observational [Patient Registry],SEVERITY SCORE FOR COVID-19 PNEUMONIA,Recruiting,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04372199,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04372056,2020-05-06,5/6/2021,Observational,The COVID-ICU Healthcare Professional Study,Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04372056,0,0,0,0,2,0,Norway,0,views|experiences of health care professionals working in intensive care units during the covid-19 pandemic,NA
NCT04372004,2020-05-08,5/31/2021,Interventional,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,Phase 1,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04372004,0,0,0,0,2,1,United States,0,diagnostic tests for covid-19 infection,NA
NCT04371965,2020-09-01,10/23/2020,Interventional,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",Completed,Phase 2,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04371965,0,0,0,0,3,0,France,0,povidone/iodine,NA
NCT04371367,2020-04-27,3/1/2021,Interventional,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","Active, not recruiting",Phase 2,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04371367,0,0,0,0,2,0,France,0,avdoralimab|placebo,NA
NCT04371328,2020-03-13,6/5/2020,Observational [Patient Registry],Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID-19 Infection,"Active, not recruiting",NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04371328,0,0,0,0,1,0,France,0,recop unit patient,NA
NCT04377412,2020-05-01,8/31/2020,Observational,Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic,Recruiting,NA,"Å»elazna Medical Centre, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04377412,0,0,0,0,0,1,United States|Albania|Australia|Czechia|France|Germany|Hong Kong|Israel|Italy|Lebanon|Norway|Poland|Spain|Sweden|Taiwan,0,pandemic control measures,NA
NCT04374617,2020-04-01,4/25/2020,Observational,Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19,Completed,NA,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04374617,0,0,0,0,1,0,Spain,0,duplex ultrasound/computed tomography angiography|ultrasound|tomography angiography,NA
NCT04370275,2020-04-23,5/23/2020,Observational,Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia,Recruiting,NA,Ospedale di Latisana,NA,https://clinicalzeros.gov/ct2/show/NCT04370275,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04370210,2020-05-04,6/4/2020,Observational,Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry,Completed,NA,Centre Hospitalier RenÃ© Dubos,NA,https://clinicalzeros.gov/ct2/show/NCT04370210,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04370197,2020-03-03,4/30/2020,Observational,Covid-19 Epidemic on Acute Stroke Management,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04370197,0,0,0,0,0,0,France,0,"NA",NA
NCT04370119,2020-04-27,5/31/2021,Observational,Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers,Recruiting,NA,University Medicine Greifswald,NA,https://clinicalzeros.gov/ct2/show/NCT04370119,0,0,0,0,1,0,Germany,0,nasal|serum test,NA
NCT04369859,2020-04-23,4/22/2021,Observational,Obstetric and Perinatal Outcomes of Women With COVID-19,Recruiting,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04369859,0,0,0,0,1,0,France,0,examine the impact of covid-19 during pregnancy,NA
NCT04369820,2020-03-31,9/30/2020,Interventional,C5a Receptor Expression - COVID-19 (C5-COV),Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04369820,0,0,0,0,1,0,France,0,blood draw,NA
NCT04368884,2020-04-22,6/30/2021,Observational,Assess the Seroconversion Status of Health Care Workers Suspected or Confirmed Cases of COVID-19 Patients,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04368884,0,0,0,0,1,0,India,0,"NA",NA
NCT04368871,2020-04-28,6/30/2020,Observational,Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04368871,0,0,0,0,2,0,India,0,"NA",NA
NCT04374591,2020-08-01,11/1/2020,Interventional,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,"Active, not recruiting",N/A,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04374591,0,0,0,0,3,0,Egypt,0,sodium bicarbonate,NA
NCT04374539,2020-04-29,5/5/2021,Interventional,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,Phase 2,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04374539,0,0,0,0,1,0,Spain,0,plasma|standard care,NA
NCT04374097,2020-03-31,4/7/2020,Observational,Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak,Completed,NA,University of Oslo,NA,https://clinicalzeros.gov/ct2/show/NCT04374097,0,0,0,0,1,0,Norway,0,"NA",NA
NCT04374513,2020-04-02,6/1/2020,Observational,Community Pharmacists Behaviour During Covid-19,Completed,NA,Damanhour University,NA,https://clinicalzeros.gov/ct2/show/NCT04374513,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04407221,2020-06-16,5/1/2024,Observational,COVID-19 Research in Organ Transplant Recipients,Enrolling by invitation,NA,Vastra Gotaland Region,NA,https://clinicalzeros.gov/ct2/show/NCT04407221,0,0,0,0,1,0,Sweden,0,"NA",NA
NCT04371432,2021-02-10,6/1/2025,Observational,Genetics of COVID-19 Susceptibility and Manifestations,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04371432,0,0,0,0,177,1,United States,0,"NA",NA
NCT04370236,2020-10-21,2/28/2021,Interventional,INB03 for the Treatment of Pulmonary Complications From COVID-19,Recruiting,Phase 2/Phase 3,"Inmune Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04370236,0,0,0,0,3,1,United States,0,inb03|placebo,NA
NCT04394455,2020-06-30,11/30/2020,Interventional,Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,Enrolling by invitation,N/A,Universidad Nacional Autonoma de Honduras,NA,https://clinicalzeros.gov/ct2/show/NCT04394455,0,0,0,0,2,0,Honduras,0,behavioral|crisis intervention therapy,NA
NCT04392531,2020-04-16,12/31/2020,Interventional,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,Recruiting,Phase 4,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,https://clinicalzeros.gov/ct2/show/NCT04392531,0,0,0,0,1,0,Spain,0,cyclosporine|standard care,NA
NCT04408066,2020-04-30,4/30/2022,Interventional,COVID-19: A POC Test Under Research & Evaluation,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04408066,0,0,0,0,1,0,United Kingdom,0,sample collection/performance evaluation (a)|sample collection/performance evaluation (b)|sample collection|performance evaluation,NA
NCT04378829,2020-09-12,10/11/2020,Observational,"Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19",Recruiting,NA,Konya Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04378829,0,0,0,0,1,0,Turkey,0,"platelet count, platelet, mean platelet volume/platelet distribution width in covid-19|platelet count, platelet, mean platelet volume|platelet distribution width in covid-19",NA
NCT04376814,2020-03-29,4/5/2020,Interventional,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,Completed,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04376814,0,0,0,0,2,0,"Iran, Islamic Republic of",0,favipiravir|hydroxychloroquine|lopinavir/ritonavir|lopinavir|ritonavir,NA
NCT04376593,2020-05-01,5/31/2021,Interventional,PET/CT Imaging in COVID-19 Patients,Enrolling by invitation,Early Phase 1,"University of California, Davis",NA,https://clinicalzeros.gov/ct2/show/NCT04376593,0,0,0,0,1,1,United States,0,18f-î±vî²6-bp,NA
NCT04375176,2020-04-27,6/30/2020,Observational,Monocytes and NK Cells Activity in Covid-19 Patients,Recruiting,NA,UniversitÃ  degli Studi dell'Insubria,NA,https://clinicalzeros.gov/ct2/show/NCT04375176,0,0,0,0,0,0,Italy,0,study of immune-mediated mechanisms in patients tested positive for sars-cov-2,NA
NCT04375137,2020-04-20,4/1/2021,Observational,Correlation Between Oxidative Stress Status and COVID-19 Severity,Recruiting,NA,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04375137,0,0,0,0,3,0,"Iran, Islamic Republic of",0,oxidative stress elisa kit,NA
NCT04375098,2020-05-04,8/17/2020,Interventional,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Completed,Phase 2,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04375098,0,0,0,0,3,0,Chile,0,convalescent plasma,NA
NCT04581031,2020-07-11,2/1/2021,Interventional,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,N/A,The Christie NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04581031,0,0,0,0,0,0,United Kingdom,0,continuous vital sign monitoring - isansys patient status engine|machine learning/ai algorithm|machine learning|ai algorithm,NA
NCT04391712,2020-04-30,5/15/2020,Interventional,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,Phase 2,Lowell General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04391712,0,0,0,0,1,1,United States,0,mls laser|standard care,NA
NCT04379531,2020-04-25,5/22/2020,Interventional,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,N/A,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,https://clinicalzeros.gov/ct2/show/NCT04379531,0,0,0,0,2,0,Russian Federation,0,chest ct,NA
NCT04379089,2020-04-29,12/31/2021,Observational,Neurologic Manifestations of COVID 19 in Children,Recruiting,NA,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04379089,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04377581,2020-04-09,7/10/2020,Observational,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",Completed,NA,Milton S. Hershey Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04377581,0,0,0,0,2,1,United States,0,"NA",NA
NCT04377568,2020-10-07,12/1/2021,Interventional,Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children,Recruiting,Phase 2,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04377568,0,0,0,0,5,0,Canada,0,convalescent plasma,NA
NCT04376580,2020-04-30,10/31/2020,Observational,Use of the Nasal Cannula During COVID-19,Enrolling by invitation,NA,Tiva Group,NA,https://clinicalzeros.gov/ct2/show/NCT04376580,0,0,0,0,2,0,Argentina,0,"NA",NA
NCT04375761,2020-05-01,3/31/2021,Observational,COVID-19: Human Epidemiology and Response to SARS-CoV-2,"Active, not recruiting",NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04375761,0,0,0,0,9,1,United States,0,biological samples|symptom/exposure surveys|symptom|exposure surveys,NA
NCT04374942,2020-04-30,8/27/2020,Interventional,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,Enrolling by invitation,Phase 3,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04374942,0,0,0,0,1,0,Canada,0,hydroxychloroquine|placebo,NA
NCT04374045,2020-04-30,6/17/2020,Observational [Patient Registry],Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study,Completed,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04374045,0,0,0,0,3,0,France,0,ecg-holter,NA
NCT04374032,2020-05-01,10/7/2020,Interventional,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,Completed,Phase 2/Phase 3,Bosnalijek D.D,NA,https://clinicalzeros.gov/ct2/show/NCT04374032,0,0,0,0,3,0,Bosnia and Herzegovina,0,metenkefalin / tridecactide|standard care|metenkefalin|tridecactide,NA
NCT04373161,2020-03-20,4/22/2020,Interventional,Home Pulse Oximeter Use in Patients With COVID-19,Completed,N/A,Swedish Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04373161,0,0,0,0,2,1,United States,0,home pulse oximetry monitoring,NA
NCT04373759,2020-05-02,9/30/2020,Observational [Patient Registry],Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs,Completed,NA,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,https://clinicalzeros.gov/ct2/show/NCT04373759,0,0,0,0,9,0,France|Martinique,0,cardiopulmonary resuscitation|modified rankin score,NA
NCT04373486,2020-03-03,4/30/2020,Observational,Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels,Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04373486,0,0,0,0,1,0,France,0,"NA",NA
NCT04373460,2020-06-03,12/21/2022,Interventional,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04373460,0,0,0,0,21,1,United States,0,convalescent plasma|plasma,NA
NCT04383457,2020-06-15,10/8/2020,Observational [Patient Registry],Covid-19 Triage Using Camera-based AI,Completed,NA,Vastra Gotaland Region,NA,https://clinicalzeros.gov/ct2/show/NCT04383457,0,0,0,0,2,0,Sweden,0,ria-device (remote investigation/assessment)|ria-device (remote investigation|assessment),NA
NCT04373382,2020-07-27,2/28/2022,Interventional,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,"Active, not recruiting",N/A,"Mount Sinai Hospital, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04373382,0,0,0,0,3,0,Canada,0,peer resilience champion|enriched survey feedback,NA
NCT04382417,2020-03-26,11/12/2020,Observational,Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden,Completed,NA,Region VÃ¤stmanland,NA,https://clinicalzeros.gov/ct2/show/NCT04382417,0,0,0,0,2,0,Sweden,0,observational,NA
NCT04381819,2020-03-02,2/28/2022,Observational,"Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19",Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04381819,0,0,0,0,0,0,Norway,0,pcr,NA
NCT04373148,2020-04-08,4/30/2022,Observational,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",Recruiting,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04373148,0,0,0,0,5,1,United States,0,no intervention,NA
NCT04373135,2020-05-08,2/28/2021,Interventional,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","Active, not recruiting",N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04373135,0,0,0,0,3,1,United States,0,educational video,NA
NCT04373096,2020-12-07,8/31/2021,Interventional,Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers,Recruiting,N/A,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04373096,0,0,0,0,3,0,Canada,0,current ipac-uhn ppe|modified ipac-uhn ppe,NA
NCT04373005,2020-05-11,6/30/2021,Observational,Screening of Cancer Patients to Assess Impact of COVID-19,"Active, not recruiting",NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04373005,0,0,0,0,1,0,Canada,0,nasopharyngeal (np) swab,NA
NCT04372680,2020-04-22,9/22/2020,Interventional,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04372680,0,0,0,0,0,0,France,0,ctus examination,NA
NCT04372628,2020-06-01,4/1/2021,Interventional,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,Recruiting,Phase 2,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04372628,0,0,0,0,6,1,United States,0,lopinavir/ritonavir|placebo|lopinavir|ritonavir|100 mg,NA
NCT04372602,2020-10-12,11/30/2021,Interventional,Duvelisib to Combat COVID-19,Recruiting,Phase 2,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04372602,0,0,0,0,4,1,United States,0,duvelisib|blood draw|placebo,NA
NCT04380935,2020-05-18,10/31/2020,Interventional,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,Phase 2/Phase 3,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04380935,0,0,0,0,1,0,Indonesia,0,convalescent plasma|standard care,NA
NCT04380896,2020-04-27,7/27/2026,Observational,COVID-19 Staff Testing of Antibody Responses Study (Co-Stars),Recruiting,NA,Great Ormond Street Hospital for Children NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04380896,0,0,0,0,1,0,United Kingdom,0,blood test|standard care,NA
NCT04379544,2020-04-23,9/1/2020,Observational [Patient Registry],Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19,"Active, not recruiting",NA,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04379544,0,0,0,0,2,1,United States,0,no intervention,NA
NCT04371978,2020-10-01,6/30/2021,Interventional,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Recruiting,Phase 3,Rabin Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04371978,0,0,0,0,2,0,Israel,0,linagliptin 5 mg,NA
NCT04371679,2020-04-01,10/1/2020,Observational,Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients,Recruiting,NA,Hasselt University,NA,https://clinicalzeros.gov/ct2/show/NCT04371679,0,0,0,0,0,0,Belgium,0,no intervention,NA
NCT04371562,2020-03-01,3/31/2020,Observational,Predicting Death and ICU Admission in COVID-19 Patients in ED,Completed,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04371562,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04371471,2020-03-01,4/30/2020,Observational,Covid-19 Pandemic Triage Score,Completed,NA,Groupe Hospitalier de la Rochelle RÃ© Aunis,NA,https://clinicalzeros.gov/ct2/show/NCT04371471,0,0,0,0,1,0,France,0,stc-19,NA
NCT04370834,2020-05-28,1/14/2021,Interventional,Tocilizumab for Patients With Cancer and COVID-19 Disease,Terminated,Phase 2,National Cancer Institute (NCI),Other - Randomized data no longer support continuation,https://clinicalzeros.gov/ct2/show/NCT04370834,0,0,0,0,14,1,United States,0,tocilizumab,NA
NCT04379466,2020-05-05,10/11/2020,Observational,Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04379466,0,0,0,0,1,0,France,0,"NA",NA
NCT04379375,2020-07-27,9/30/2020,Interventional,Nudges to Improve Health Behaviors That Limit COVID-19 Spread,Terminated,N/A,Medical College of Wisconsin,Slow enrollment rate,https://clinicalzeros.gov/ct2/show/NCT04379375,0,0,0,0,6,1,United States,0,nudge,NA
NCT04379336,2020-05-04,4/28/2021,Interventional,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,Recruiting,Phase 3,TASK Applied Science,NA,https://clinicalzeros.gov/ct2/show/NCT04379336,0,0,0,1,0,0,South Africa,0,bacille calmette-guã©rin (bcg)|placebo,NA
NCT04379310,2020-05-01,5/5/2020,Observational,Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019),Completed,NA,Nisantasi University,NA,https://clinicalzeros.gov/ct2/show/NCT04379310,0,0,0,0,1,0,Turkey,0,ace inhibitors/calcium channel blockers|ace inhibitor|calcium channel blockers,NA
NCT04379284,2020-05-08,4/30/2021,Observational,Risks of COVID19 in the Pregnant Population,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04379284,0,0,0,0,2,1,United States,0,biospecimen collection|biospeciman collection,NA
NCT04379245,2020-04-30,4/30/2020,Observational,COVID-19 Infection in Patients Infected With HIV and/or on PrEP,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04379245,0,0,0,0,0,0,France,0,"data research, database analysis",NA
NCT04379232,2020-03-19,4/20/2020,Observational,Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04379232,0,0,0,0,0,0,France,0,pcr/chest ct|pcr|chest ct,NA
NCT04378803,2020-05-13,8/4/2020,Interventional,Mindfulness Training for Seniors,Completed,N/A,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04378803,0,0,0,0,3,1,United States,0,mindfullness training,NA
NCT04384471,2020-04-29,7/1/2020,Observational,Covid-19 Pandemic: Patients' Experience in T1D,Enrolling by invitation,NA,McGill University,NA,https://clinicalzeros.gov/ct2/show/NCT04384471,0,0,0,0,0,0,Canada,0,online survey,NA
NCT04383002,2020-09-02,12/31/2020,Interventional,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),Recruiting,Phase 1,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04383002,0,0,0,0,3,0,Canada,0,nitric oxide,NA
NCT04379271,2020-06-11,9/30/2020,Interventional,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",Recruiting,Phase 2/Phase 3,Immunic AG,NA,https://clinicalzeros.gov/ct2/show/NCT04379271,0,0,0,0,2,0,Bulgaria|Germany,0,imu-838|placebo,NA
NCT04378777,2020-05-01,3/31/2021,Observational,Immunophenotyping Assessment in a COVID-19 Cohort,Enrolling by invitation,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04378777,0,0,0,0,8,1,United States,0,biological samples|data collection: clinical care assessments,NA
NCT04377789,2020-03-20,7/31/2020,Interventional,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04377789,0,0,0,0,4,0,Turkey,0,quercetin,NA
NCT04377035,2020-03-31,3/1/2021,Observational,The Role of Ultrasound in COVID-19,Recruiting,NA,"University Hospital, Gentofte, Copenhagen",NA,https://clinicalzeros.gov/ct2/show/NCT04377035,0,0,0,0,2,0,Denmark,0,"NA",NA
NCT04376788,2020-05-20,7/1/2020,Interventional,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,Phase 2,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04376788,0,0,0,0,1,0,Egypt,0,plasma|convalescent plasma|methylene blue|methylprednisolone,NA
NCT04377672,2020-05-28,5/28/2021,Interventional,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Recruiting,Phase 1,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04377672,0,0,0,0,2,1,United States,0,convalescent plasma,NA
NCT04377659,2020-05-01,5/1/2022,Interventional,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,"Active, not recruiting",Phase 2,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04377659,0,0,0,0,5,1,United States,0,tocilizumab,NA
NCT04377620,2020-05-24,4/30/2021,Interventional,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),Recruiting,Phase 3,Incyte Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04377620,0,0,0,0,6,1,United States|Russian Federation,0,placebo|ruxolitinib,NA
NCT04377607,2020-11-01,11/20/2020,Observational,Haemoglobin Concentration on COVID-19,Recruiting,NA,Nevsehir Public Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04377607,0,0,0,0,2,0,Turkey,0,file scanning,NA
NCT04377477,2020-05-10,8/10/2021,Interventional,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Recruiting,N/A,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,NA,https://clinicalzeros.gov/ct2/show/NCT04377477,0,0,0,0,2,0,Italy,0,radiological,NA
NCT04377165,2020-05-06,8/26/2020,Interventional,Innovative Tool to Limit Spread of SARS-CoV-2 (COVID 19) in Residential Aged Care Facilities,Terminated,N/A,The University of Queensland,"Engagement issues, poor recruitment to study",https://clinicalzeros.gov/ct2/show/NCT04377165,0,0,0,0,2,0,NA,0,gamification|news,NA
NCT04377074,2020-03-31,4/7/2020,Observational,Parental Stress During the COVID-19 Pandemic and Its Association With Depression and Anxiety,Completed,NA,University of Oslo,NA,https://clinicalzeros.gov/ct2/show/NCT04377074,0,0,0,0,0,0,Norway,0,"NA",NA
NCT04374019,2020-05-01,5/31/2021,Interventional,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,Recruiting,Phase 2,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04374019,0,0,0,0,3,1,United States,0,ivermectin|camostat mesilate|artemesia annua|artesunate,NA
NCT04376996,2020-04-20,10/31/2020,Observational,Slovenian National COVID-19 Prevalence Study,Recruiting,NA,University of Ljubljana,NA,https://clinicalzeros.gov/ct2/show/NCT04376996,0,0,0,0,1,0,Slovenia,0,no intervention,NA
NCT04376944,2020-04-01,12/1/2020,Observational,Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04376944,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04376879,2020-05-16,5/31/2022,Observational,Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19),Recruiting,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04376879,0,0,0,0,3,0,France,0,data monitoring for 48h within the first 24 hours of admission for covid-19,NA
NCT04376840,2020-05-28,1/28/2022,Interventional,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19,Recruiting,N/A,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04376840,0,0,0,0,1,0,France,0,blood sample/data record|blood sample|data record,NA
NCT04376775,2020-05-11,12/11/2020,Observational,Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation,"Active, not recruiting",NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04376775,0,0,0,0,2,0,France,0,transplant patient,NA
NCT04376710,2020-07-01,10/1/2020,Observational,Surgical Telemedicine in the COVID-19 Pandemic Era,Completed,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04376710,0,0,0,0,2,1,United States,0,completion of pre-pandemic survey|completion of survey after peak of pandemic|completion of post telemedicine encounter survey,NA
NCT04376684,2020-05-28,1/13/2021,Interventional,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,"Active, not recruiting",Phase 2,GlaxoSmithKline,NA,https://clinicalzeros.gov/ct2/show/NCT04376684,0,0,0,0,20,1,Netherlands|United States|Argentina|Belgium|Brazil|Canada|Chile|France|India|Japan|Mexico|Peru|Poland|Russian Federation|South Africa|Spain|United Kingdom,0,otilimab|placebo|standard care,NA
NCT04376398,2020-04-06,6/30/2020,Observational [Patient Registry],Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals,Completed,NA,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04376398,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04375709,2020-03-15,6/30/2021,Observational,Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);,Recruiting,NA,Kantonsspital Winterthur KSW,NA,https://clinicalzeros.gov/ct2/show/NCT04375709,0,0,0,0,1,0,Switzerland,0,exercise|education sessions,NA
NCT04375644,2020-05-07,7/15/2020,Observational,Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT),Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04375644,0,0,0,0,1,0,France,0,questionnaires on psychological quality of life,NA
NCT04375501,2020-02-01,4/15/2020,Observational,A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic,Completed,NA,Barts & The London NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04375501,0,0,0,0,1,0,United Kingdom,0,"surgery: dynamic hip screw, hemiarthroplasty, hip replacement, intramedullary nail",NA
NCT04375397,2020-06-06,3/19/2021,Interventional,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,Recruiting,Phase 2,AbbVie,NA,https://clinicalzeros.gov/ct2/show/NCT04375397,0,0,0,0,9,1,United States,0,ibrutinib|placebo,NA
NCT04388527,2020-04-30,4/30/2021,Interventional,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04388527,0,0,0,0,4,1,United States,0,convalescent plasma,NA
NCT04375124,2020-04-25,8/31/2020,Interventional,Treatment of Angiotensin Peptide (1-7) for COVID-19,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04375124,0,0,0,0,2,0,Turkey,0,angiotensin peptide (1-7) derived plasma|biological,NA
NCT04376658,2020-07-15,4/15/2022,Observational,Quality of Life and Long-term Outcomes After Hospitalization for COVID-19,Recruiting,NA,Hospital Moinhos de Vento,NA,https://clinicalzeros.gov/ct2/show/NCT04376658,0,0,0,0,4,0,Brazil,0,covid-19,NA
NCT04388813,2020-05-28,2/28/2021,Observational,Predictors of Severe COVID-19 Outcomes,Recruiting,NA,Verily Life Sciences LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04388813,0,0,0,0,6,1,United States,0,"NA",NA
NCT04410718,2020-04-20,10/30/2020,Observational,Glycaemia and Cardiac Function in Patients With COVID-19,Recruiting,NA,Steno Diabetes Center Copenhagen,NA,https://clinicalzeros.gov/ct2/show/NCT04410718,0,0,0,0,0,0,Denmark,0,glycaemic levels,NA
NCT04374838,2020-05-15,8/1/2020,Observational,Effect of COVID-19 Pandemic on Pediatric Cancer Care,Recruiting,NA,South Egypt Cancer Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04374838,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04374656,2020-05-18,5/31/2021,Observational,Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic,Recruiting,NA,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04374656,0,0,0,0,1,1,United States,0,"NA",NA
NCT04379076,2020-05-14,10/30/2020,Interventional,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,Recruiting,Phase 2,Revimmune,NA,https://clinicalzeros.gov/ct2/show/NCT04379076,0,0,0,0,2,0,United Kingdom,0,interleukin|placebo,NA
NCT04379063,2020-05-13,5/31/2021,Observational,COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress,"Active, not recruiting",NA,Nova Scotia Health Authority,NA,https://clinicalzeros.gov/ct2/show/NCT04379063,0,0,0,0,3,0,Canada,0,covid-19 pandemic,NA
NCT04379037,2020-06-27,9/1/2020,Interventional,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Recruiting,N/A,Nemechek Technologies,NA,https://clinicalzeros.gov/ct2/show/NCT04379037,0,0,0,0,1,0,Argentina,0,transcutaneous auricular vagus nerve stimulation,NA
NCT04378881,2020-06-01,12/30/2020,Observational,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations,"Active, not recruiting",NA,Tabula Rasa HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04378881,0,0,0,0,1,1,United States,0,"NA",NA
NCT04378842,2020-05-18,5/31/2021,Observational,COVID-19 and ICU-acquired MDR Bacteria,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04378842,0,0,0,0,1,0,France,0,"NA",NA
NCT04378686,2020-04-23,5/1/2021,Observational,Serological Testing for COVID-19 (SARS-CoV-2) in ESKD,Recruiting,NA,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04378686,0,0,0,0,1,0,Belgium,0,dialysis,NA
NCT04377776,2020-05-04,5/18/2020,Observational,"Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients",Completed,NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04377776,0,0,0,0,1,0,Italy,0,practice details,NA
NCT04377763,2020-07-15,12/31/2020,Observational,Developement and Evaluation of Serological Assays for COVID-19,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04377763,0,0,0,0,2,0,France,0,"NA",NA
NCT04377724,2020-04-27,6/30/2021,Observational,Spread and Course of COVID-19 Infections,"Active, not recruiting",NA,ETH Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04377724,0,0,0,0,3,0,Switzerland,0,"NA",NA
NCT04377685,2020-03-01,6/30/2021,Observational,Prediction of Clinical Course in COVID19 Patients,Recruiting,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04377685,0,0,0,0,4,0,France,0,ct-scan,NA
NCT04377490,2020-05-04,10/31/2020,Observational,Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04377490,0,0,0,0,1,0,France,0,ultrasound|blood sample,NA
NCT04377100,2021-02-10,2/28/2021,Interventional,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Recruiting,N/A,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04377100,0,0,0,0,174,1,United States,0,questionnaire,NA
NCT04378920,2020-04-14,6/30/2021,Interventional,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Recruiting,Phase 1/Phase 2,Institut de cancÃ©rologie Strasbourg Europe,NA,https://clinicalzeros.gov/ct2/show/NCT04378920,0,0,0,0,5,0,France,0,leaf-4l6715,NA
NCT04389372,2020-03-15,3/31/2021,Interventional,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04389372,0,0,0,0,1,0,Italy,0,mindfulness,NA
NCT04385108,2020-03-04,12/31/2021,Interventional,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04385108,0,0,0,0,2,0,France,0,blood sample|blood collection on their first consultation/10 to 14 days later|longitudinally|10 to 14 days later,NA
NCT04416347,2020-06-15,4/30/2022,Observational,COVID19 Clinical Predictors and Outcome,Recruiting,NA,"St George's, University of London",NA,https://clinicalzeros.gov/ct2/show/NCT04416347,0,0,0,0,2,0,United Kingdom,0,sars-cov2 infection,NA
NCT04384419,2020-05-29,5/30/2021,Observational,"Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)",Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04384419,0,0,0,0,1,0,France,0,"NA",NA
NCT04383613,2020-05-15,12/11/2020,Interventional,Prone Positioning for Patients on General Medical Wards With COVID19,Recruiting,N/A,"St. Michael's Hospital, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04383613,0,0,0,0,3,0,Canada,0,prone positioning,NA
NCT04382560,2020-05-02,5/31/2020,Interventional,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Completed,N/A,University of Parma,NA,https://clinicalzeros.gov/ct2/show/NCT04382560,0,0,0,0,1,0,Italy,0,deep breathing training|compassion focused intervention,NA
NCT04382469,2020-02-01,4/30/2020,Observational,Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT,Completed,NA,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04382469,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04381884,2020-05-18,9/29/2020,Interventional,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Completed,Phase 2,Laboratorio Elea Phoenix S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04381884,0,0,0,0,7,0,Argentina,0,ivermectin (iver pâ®) arm will receive ivm 600 âµg / kg once daily/standard care. control arm will receive standard care.|ivermectin (iver pâ®) arm will receive ivm 600 âµg|kg once daily|standard care,NA
NCT04380870,2020-04-11,4/11/2021,Observational,Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19,Recruiting,NA,Center for Integrated Care,NA,https://clinicalzeros.gov/ct2/show/NCT04380870,0,0,0,0,0,1,United States,0,traditional chinese medicine,NA
NCT04393155,2020-04-16,9/30/2022,Observational,Longitudinal COVID-19 Cohort Study,Recruiting,NA,University of Vermont,NA,https://clinicalzeros.gov/ct2/show/NCT04393155,0,0,0,0,2,1,United States,0,covid-19/ observational|covid-19|observational,NA
NCT04379661,2020-05-07,7/7/2020,Interventional,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,Completed,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04379661,0,0,0,0,2,1,United States,0,online support group,NA
NCT04390555,2020-04-30,12/31/2020,Observational [Patient Registry],The Global PCHF-COVICAV Registry,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04390555,0,0,0,0,0,0,Switzerland,0,"NA",NA
NCT04386798,2020-07-25,12/22/2020,Interventional,Stress and Anxiety Levels of Mothers Lying in the Baby Newborn Intensive Care Unit,Recruiting,N/A,Eskisehir Osmangazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04386798,0,0,0,0,2,0,Turkey,0,survey,NA
NCT04385901,2020-05-19,4/19/2022,Interventional,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Recruiting,N/A,University of Missouri-Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04385901,0,0,0,0,3,1,United States,0,therapy intervention,NA
NCT04384705,2020-06-17,6/30/2021,Observational,HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital,Recruiting,NA,Centre Hospitalier Universitaire de la RÃ©union,NA,https://clinicalzeros.gov/ct2/show/NCT04384705,0,0,0,0,1,0,France,0,research specific blood sample,NA
NCT04384549,2020-05-20,2/20/2021,Interventional,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04384549,0,0,0,1,1,0,France,0,bcg|placebo,NA
NCT04385251,2020-06-18,6/30/2021,Observational,International SARS-CoV-2 (COVID-19) Infection Observational Study,Recruiting,NA,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04385251,0,0,0,0,3,1,United States|Argentina|Denmark|United Kingdom,0,data collection,NA
NCT04385004,2020-04-27,7/31/2020,Observational,"Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU",Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04385004,0,0,0,0,1,0,France,0,"NA",NA
NCT04384965,2020-05-12,5/1/2022,Interventional,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,Recruiting,N/A,Centre for Addiction and Mental Health,NA,https://clinicalzeros.gov/ct2/show/NCT04384965,0,0,0,0,1,0,Canada,0,"magpro x100 stimulator, b70 fluid-cooled coil",NA
NCT04384458,2020-07-20,9/10/2020,Interventional,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,N/A,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,NA,https://clinicalzeros.gov/ct2/show/NCT04384458,0,0,0,0,3,0,Brazil,0,hydroxychloroquine|ivermectin,NA
NCT04382781,2020-05-31,5/31/2020,Observational,Immunosupressive Treatment in COVID-19 Patients,Recruiting,NA,Spanish Network for Research in Infectious Diseases,NA,https://clinicalzeros.gov/ct2/show/NCT04382781,0,0,0,0,1,0,Spain,0,no-immunosuppressive|immunosuppressive|immunoglubulins,NA
NCT04382508,2020-03-22,3/21/2021,Observational,Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.,Enrolling by invitation,NA,University Hospital Southampton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04382508,0,0,0,0,1,0,United Kingdom,0,questionnaire,NA
NCT04382092,2020-03-23,4/24/2020,Interventional,Co-infection Management in COVID-19 Critically Ill,Completed,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04382092,0,0,0,0,0,0,Belgium,0,filmarray pneumonia,NA
NCT04384055,2020-03-21,12/31/2021,Observational,Predicting Outcomes for Covid-19 Using Sonography,Enrolling by invitation,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04384055,0,0,0,0,4,1,United States,0,lung ultrasound,NA
NCT04383886,2020-04-18,8/18/2020,Observational,Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04383886,0,0,0,0,0,0,France,0,stress/anxiety questionnaire|stress|anxiety questionnaire,NA
NCT04383730,2020-06-26,11/30/2020,Observational,Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19),Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04383730,0,0,0,0,3,1,United States|France|Germany|Spain|Switzerland,0,sedation,NA
NCT04382924,2020-08-05,1/31/2022,Interventional,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,"Active, not recruiting",Phase 2/Phase 3,Algernon Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04382924,0,0,0,0,4,1,United States|Australia|Philippines|Romania,0,np-120 (ifenprodil),NA
NCT04382794,2020-05-14,6/15/2020,Observational,Sitagliptin Treatment in Diabetic COVID-19 Positive Patients,Completed,NA,University of Milan,NA,https://clinicalzeros.gov/ct2/show/NCT04382794,0,0,0,0,4,0,Italy,0,retrospective case-control analysis,NA
NCT04382729,2020-04-17,7/31/2020,Interventional,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Recruiting,N/A,"University of Turin, Italy",NA,https://clinicalzeros.gov/ct2/show/NCT04382729,0,0,0,0,0,0,Italy,0,neuromuscular electrical stimulation|exercise,NA
NCT04382651,2020-06-07,1/6/2021,Interventional,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,"Active, not recruiting",Phase 2,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04382651,0,0,0,0,12,1,United States,0,mas825|placebo,NA
NCT04382547,2020-05-11,6/30/2021,Interventional,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Enrolling by invitation,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,https://clinicalzeros.gov/ct2/show/NCT04382547,0,0,0,0,1,0,Belarus,0,mesenchymal stem cells|standard care,NA
NCT04382495,2020-06-15,2/1/2021,Observational,The Impact of COVID-19 Pandemic on Cancer Care,Recruiting,NA,El Zaitoun Specialized Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04382495,0,0,0,0,8,0,Egypt,0,questionnaire,NA
NCT04382196,2020-04-17,12/31/2022,Observational,Impact of COVID-19 on Mental Health of Health Care Workers,"Active, not recruiting",NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04382196,0,0,0,0,0,0,Belgium,0,online survey,NA
NCT04382131,2020-06-23,10/31/2020,Interventional,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Recruiting,N/A,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04382131,0,0,0,0,2,0,United Kingdom,0,saline,NA
NCT04382053,2020-05-27,12/24/2020,Interventional,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,Completed,Phase 2,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04382053,0,0,0,0,27,0,Argentina|Brazil|Denmark|Germany|Hungary|India|Mexico|Netherlands|Peru|Russian Federation|South Africa|Spain,0,dfv890|standard care,NA
NCT04381988,2020-05-07,5/31/2021,Interventional,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04381988,0,0,0,0,1,1,United States,0,hydroxychloroquine|placebo|radiotherapy,NA
NCT04381858,2020-05-06,11/26/2020,Interventional,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Completed,Phase 3,Centenario Hospital Miguel Hidalgo,NA,https://clinicalzeros.gov/ct2/show/NCT04381858,0,0,0,0,2,0,Mexico,0,convalescent plasma|immunoglobulin,NA
NCT04389333,2020-03-26,4/26/2020,Interventional,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,Completed,N/A,Changhai Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389333,0,0,0,0,1,0,China,0,endoscopy,NA
NCT04381273,2020-05-08,7/31/2020,Observational,Oral Health and Psychosocial Factors During the Covid-19 Pandemic,Recruiting,NA,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04381273,0,0,0,0,0,0,Germany,0,no intervention,NA
NCT04380519,2020-04-23,7/10/2020,Interventional,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Completed,Phase 2/Phase 3,R-Pharm,NA,https://clinicalzeros.gov/ct2/show/NCT04380519,0,0,0,0,2,0,Russian Federation,0,rph-104|olokizumab|placebo,NA
NCT04380376,2020-04-30,10/30/2020,Interventional,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,Recruiting,Phase 2,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",NA,https://clinicalzeros.gov/ct2/show/NCT04380376,0,0,0,0,1,0,Russian Federation,0,standard care|melphalan,NA
NCT04387760,2020-08-11,4/14/2021,Interventional,Favipiravir vs Hydroxychloroquine in COVID -19,Recruiting,Phase 2,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04387760,0,0,0,0,3,0,Bahrain,0,hydroxychloroquine|favipiravir|standard care,NA
NCT04385199,2020-05-04,8/1/2020,Interventional,Convalescent Plasma for Patients With COVID-19,Recruiting,Phase 2,Henry Ford Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04385199,0,0,0,0,0,1,United States,0,convalescent plasma,NA
NCT04379518,2020-09-04,9/4/2021,Interventional,Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,Recruiting,Phase 1/Phase 2,Roswell Park Cancer Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04379518,0,0,0,0,6,1,United States,0,interferon|rintatolimod,NA
NCT04379297,2020-04-10,5/28/2021,Observational,COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE),"Active, not recruiting",NA,Luxembourg Institute of Health,NA,https://clinicalzeros.gov/ct2/show/NCT04379297,0,0,0,0,0,0,Luxembourg,0,"NA",NA
NCT04384445,2020-09-08,12/31/2020,Interventional,Zofin (Organicell Flow) for Patients With COVID-19,Recruiting,Phase 1/Phase 2,Organicell Regenerative Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04384445,0,0,0,0,6,1,United States,0,zofin|placebo,NA
NCT04383444,2020-07-07,8/1/2023,Observational,Surveillance of Individuals Following SARS-CoV-2 Infection,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04383444,0,0,0,0,42,1,United States,0,"NA",NA
NCT04401254,2020-07-01,12/31/2021,Observational,Recovery of Patients From COVID-19 After Critical Illness,Recruiting,NA,Australian and New Zealand Intensive Care Research Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04401254,0,0,0,0,2,0,Australia,0,"NA",NA
NCT04390477,2020-05-04,7/31/2021,Interventional,Study to Evaluate the Effect of a Probiotic in COVID-19,Recruiting,N/A,Bioithas SL,NA,https://clinicalzeros.gov/ct2/show/NCT04390477,0,0,0,0,1,0,Spain,0,probiotic,NA
NCT04390139,2020-05-13,10/31/2020,Interventional,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,Recruiting,Phase 1/Phase 2,Banc de Sang i Teixits,NA,https://clinicalzeros.gov/ct2/show/NCT04390139,0,0,0,0,0,0,Spain,0,xcel-umc-beta|placebo,NA
NCT04388605,2020-04-21,9/30/2021,Observational [Patient Registry],Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic,Recruiting,NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04388605,0,0,0,0,1,1,United States,0,"NA",NA
NCT04386239,2021-01-31,1/31/2021,Interventional,Study on the Use of Sarilumab in Patients With COVID-19 Infection,Recruiting,Early Phase 1,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04386239,0,0,0,0,1,0,Italy,0,sarilumab prefilled syringe,NA
NCT04385797,2020-05-04,12/31/2020,Observational [Patient Registry],Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia,"Active, not recruiting",NA,FundaciÃ³n PÃºblica Andaluza para la InvestigaciÃ³n de MÃ¡laga en Biomedicina y Salud,NA,https://clinicalzeros.gov/ct2/show/NCT04385797,0,0,0,0,3,0,Spain,0,telephone interview,NA
NCT04384497,2020-05-07,6/30/2020,Interventional,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Recruiting,Phase 1/Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384497,0,0,0,0,1,0,Sweden,0,convalescent plasma,NA
NCT04383899,2020-09-30,10/31/2020,Observational,Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019,Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04383899,0,0,0,0,3,0,NA,0,questionnaire,NA
NCT04385836,2020-06-01,9/1/2020,Interventional,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,Early Phase 1,"Ministry of Health, Saudi Arabia",NA,https://clinicalzeros.gov/ct2/show/NCT04385836,0,0,0,0,0,0,Saudi Arabia,0,alpha one antitrypsin,NA
NCT04385238,2020-05-15,6/20/2020,Observational,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Completed,NA,Pregistry,NA,https://clinicalzeros.gov/ct2/show/NCT04385238,0,0,0,0,5,1,United States,1,survey,NA
NCT04385017,2020-05-11,6/12/2021,Interventional,Role of Inflammasomes in COVID-19 Disease,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04385017,0,0,0,0,0,0,France,0,covid-19 patients,NA
NCT04384406,2020-04-01,5/1/2020,Observational,COVID-19 Outbreak Consequences for Outpatients Followed in PRM,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04384406,0,0,0,0,1,0,France,0,"NA",NA
NCT04384250,2020-05-10,8/31/2020,Observational,Genetic Basis of COVID-19 Infection,Recruiting,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04384250,0,0,0,0,0,0,Egypt,0,whole exome sequencing,NA
NCT04383626,2020-03-02,4/5/2020,Observational,Fear Among Dentists During COVID-19 Pandemic,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04383626,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04446104,2020-05-13,8/31/2020,Interventional,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,Completed,Phase 3,"National University Hospital, Singapore",NA,https://clinicalzeros.gov/ct2/show/NCT04446104,0,0,0,0,2,0,Singapore,0,hydroxychloroquine|ivermectin|zinc|povidone/iodine|vitamin c,NA
NCT04383652,2020-05-06,6/30/2021,Observational,Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales,Recruiting,NA,Kirby Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04383652,0,0,0,0,0,0,Australia,0,biological sample/clinical data collection|biological samples|clinical data collection,NA
NCT04383483,2020-06-15,7/31/2020,Observational,"CoV-ICU Score, Intensive Care Unit, SARS-CoV-2",Recruiting,NA,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04383483,0,0,0,0,2,0,Turkey,0,covicu,NA
NCT04442191,2020-05-05,5/5/2021,Interventional,Convalescent Plasma as a Possible Treatment for COVID-19,Recruiting,Phase 2,University of Illinois at Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04442191,0,0,0,0,0,1,United States,0,convalescent plasma|placebo,NA
NCT04431310,2020-03-27,8/1/2025,Observational,Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic,Recruiting,NA,Nordsjaellands Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04431310,0,0,0,0,0,0,Denmark,0,serial seroconversion measurements in hospital employees during the covid-19 pandemic,NA
NCT04409535,2020-05-07,2/25/2021,Observational,Effects of the COVID-19 Health Emergency on Biopsychosocial Health,"Active, not recruiting",NA,University of New Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04409535,0,0,0,0,0,1,United States,0,survey,NA
NCT04382846,2020-05-08,12/1/2030,Interventional,Novel Regimens in COVID-19 Treatment,Recruiting,Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04382846,0,0,0,0,1,0,Egypt,0,nitazoxanide,NA
NCT04382586,2020-07-06,4/30/2021,Interventional,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,Recruiting,Phase 2,BeiGene,NA,https://clinicalzeros.gov/ct2/show/NCT04382586,0,0,0,0,6,1,United States,0,zanubrutinib|supportive care|placebo,NA
NCT04382066,2020-05-12,12/23/2020,Interventional,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,Completed,Phase 1,PharmaMar,NA,https://clinicalzeros.gov/ct2/show/NCT04382066,0,0,0,0,10,0,Spain,0,plitidepsin|day,NA
NCT04382040,2020-05-08,11/30/2020,Interventional,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Recruiting,Phase 2,MGC Pharmaceuticals d.o.o,NA,https://clinicalzeros.gov/ct2/show/NCT04382040,0,0,0,0,5,0,India|Israel,0,artemic|placebo,NA
NCT04381377,2020-04-29,4/30/2021,Interventional,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,Recruiting,Phase 2/Phase 3,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04381377,0,0,0,0,1,0,Russian Federation|Slovakia,0,azoximer bromide|placebo,NA
NCT04381364,2020-05-29,12/1/2020,Interventional,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,Phase 2,St Goran's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04381364,0,0,0,0,2,0,Sweden,0,ciclesonide,NA
NCT04381351,2020-04-16,3/1/2021,Observational,Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",NA,https://clinicalzeros.gov/ct2/show/NCT04381351,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04381000,2020-04-01,5/29/2020,Interventional,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,Completed,N/A,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,https://clinicalzeros.gov/ct2/show/NCT04381000,0,0,0,0,2,0,Greece,0,exercise,NA
NCT04380961,2020-04-24,9/28/2021,Interventional,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Recruiting,Phase 2,"Janssen Pharmaceutica N.V., Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04380961,0,0,0,0,10,1,United States,0,sirukumab|placebo|standard care,NA
NCT04380909,2020-05-06,4/30/2021,Interventional,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Recruiting,N/A,University of Bern,NA,https://clinicalzeros.gov/ct2/show/NCT04380909,0,0,0,0,0,0,Switzerland,0,internet-based self-help|internet-based self-help after 3 weeks,NA
NCT04380792,2020-04-13,10/13/2020,Observational,Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital,Completed,NA,Foundation for the study of VTE diseases. (FUENTE),NA,https://clinicalzeros.gov/ct2/show/NCT04380792,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04380779,2020-04-13,10/13/2020,Observational,Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses,Completed,NA,Foundation for the study of VTE diseases. (FUENTE),NA,https://clinicalzeros.gov/ct2/show/NCT04380779,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04380714,2020-05-01,5/30/2020,Observational,Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04380714,0,0,0,0,2,0,France,0,"NA",NA
NCT04380688,2020-06-13,11/16/2020,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04380688,0,0,0,0,3,1,United States,0,acalabrutinib,NA
NCT04393636,2020-06-05,12/31/2022,Interventional,Digital Cardiac Counseling Trial: DCC Trial,Recruiting,N/A,Academisch Ziekenhuis Maastricht,NA,https://clinicalzeros.gov/ct2/show/NCT04393636,0,0,0,0,1,0,Netherlands,0,digital cardiac counseling,NA
NCT04384731,2020-05-29,5/29/2021,Interventional,CurosurfÂ® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Phase 2,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384731,0,0,0,0,2,0,France,0,poractant alfa,NA
NCT04405986,2020-05-19,11/19/2021,Interventional,Exploring Brain Damages After COVID-19 Infection,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04405986,0,0,0,0,2,0,France,0,auditory evoked potentials (aep)|blink/masseter inhibitory reflex|blink|masseter inhibitory reflex,NA
NCT04400929,2020-06-02,6/30/2021,Interventional,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Recruiting,Phase 2,Singapore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04400929,0,0,0,0,1,0,Singapore,0,sargramostim|saline,NA
NCT04393077,2020-05-10,5/15/2020,Interventional,Emotional Freedom Technique (EFT) Effect on Nurses,Completed,N/A,Istanbul Saglik Bilimleri University,NA,https://clinicalzeros.gov/ct2/show/NCT04393077,0,0,0,0,2,0,Turkey,0,emotional freedom technique,NA
NCT04389320,2020-03-15,5/1/2020,Observational,Antimalarial and Covid 19 in Rheumatoid Arthritis,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04389320,0,0,0,0,0,0,Egypt,0,hydroxychloroquine,NA
NCT04389294,2020-05-05,9/30/2020,Interventional,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Recruiting,N/A,"Hospital for Special Surgery, New York",NA,https://clinicalzeros.gov/ct2/show/NCT04389294,0,0,0,0,0,1,United States,0,antibody test,NA
NCT04388514,2020-04-08,10/8/2020,Interventional,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,N/A,Azienda Sanitaria-Universitaria Integrata di Udine,NA,https://clinicalzeros.gov/ct2/show/NCT04388514,0,0,0,0,0,0,Italy,0,ozone,NA
NCT04386694,2020-05-18,9/17/2020,Interventional,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Completed,N/A,University of Nove de Julho,NA,https://clinicalzeros.gov/ct2/show/NCT04386694,0,0,0,0,6,0,Brazil,0,pbmt/smf|placebo|pbmt|smf,NA
NCT04388436,2020-05-11,7/10/2021,Observational [Patient Registry],Post Covid-19 Cardiopulmonary and Immunological Changes,"Active, not recruiting",NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04388436,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04387786,2020-03-31,4/24/2020,Observational,Dornase Alfa Administered to Patients With COVID-19 (DACOVID),Completed,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04387786,0,0,0,0,1,1,United States,0,dornase alfa,NA
NCT04390191,2020-05-07,4/30/2021,Interventional,Early CPAP in COVID-19 Confirmed or Suspected Patients,Recruiting,N/A,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04390191,0,0,0,0,0,1,United States,0,continuous positive airway pressure,NA
NCT04390152,2020-01-13,12/31/2021,Interventional,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,Recruiting,Phase 1/Phase 2,BioXcellerator,NA,https://clinicalzeros.gov/ct2/show/NCT04390152,0,0,0,0,3,0,Colombia,0,"wharton's jelly derived mesenchymal stem cells.|hydroxychloroquine, lopinavir/ritonavir/azithromycin/placebo (standard therapy)|hydroxychloroquine, lopinavir|ritonavir|azithromycin|placebo (standard therapy)",NA
NCT04389996,2020-05-14,7/21/2020,Observational [Patient Registry],COVID-19 Pandemic Impact on Patients With Cancer - a Danish Survey,"Active, not recruiting",NA,Odense University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389996,0,0,0,0,3,0,Denmark,0,no intervention,NA
NCT04389944,2020-03-31,6/30/2020,Interventional,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Completed,N/A,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04389944,0,0,0,0,2,0,Switzerland,0,convalescent plasma,NA
NCT04387409,2020-05-25,5/1/2021,Interventional,Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,"Active, not recruiting",Phase 3,Vakzine Projekt Management GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04387409,0,0,0,0,3,0,Germany,0,vpm1002|placebo,NA
NCT04389385,2020-05-01,9/30/2020,Interventional,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),"Active, not recruiting",Phase 1,TC Erciyes University,NA,https://clinicalzeros.gov/ct2/show/NCT04389385,0,0,0,0,0,0,Turkey,0,t cell derived exosom,NA
NCT04386850,2020-04-14,11/15/2020,Interventional,Oral 25-hydroxyvitamin D3 and COVID-19,Recruiting,Phase 2/Phase 3,Tehran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04386850,0,0,0,0,1,0,"Iran, Islamic Republic of",0,hydroxyvitamin,NA
NCT04386720,2020-05-25,5/25/2021,Observational,Measurement of Airway Opening Pressure (AOP) in Patients With Acute Respiratory Distress Syndrom and With or Without Covid 19.,Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04386720,0,0,0,0,3,0,France,0,"NA",NA
NCT04386616,2020-06-02,1/2/2021,Interventional,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,"Active, not recruiting",Phase 2,"Genentech, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04386616,0,0,0,0,17,1,United States|Brazil|Mexico|Spain,0,mstt1041a|placebo|uttr1147a,NA
NCT04386564,2020-05-15,10/15/2020,Observational,Kidney Injury Severity and COVID-19,"Active, not recruiting",NA,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04386564,0,0,0,0,1,0,Russian Federation,0,mrna in urine test,NA
NCT04386551,2020-05-06,8/5/2020,Observational,Detection of COVID-19 in Saliva Collection,Completed,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04386551,0,0,0,0,3,0,France,0,"NA",NA
NCT04386291,2020-05-25,5/19/2021,Interventional,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04386291,0,0,0,0,4,1,United States,0,anxiety reduction training|kundalini yoga/anxiety reduction training|meditation/anxiety reduction training|kundalini yoga|meditation,NA
NCT04386265,2020-04-15,5/11/2022,Observational [Patient Registry],Compassionate Use of Hyperbaric Oxygen Therapy,Enrolling by invitation,NA,"SerenaGroup, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04386265,0,0,0,0,2,1,United States|Poland,0,"NA",NA
NCT04385823,2020-03-01,5/4/2020,Observational,Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure,Completed,NA,HÃ´pital Louis Mourier,NA,https://clinicalzeros.gov/ct2/show/NCT04385823,0,0,0,0,0,0,France,0,nasal high flow,NA
NCT04385160,2020-05-13,7/15/2020,Observational,Myeloproliferative Neoplasms (MPN) and COVID-19,Recruiting,NA,Fondazione per la Ricerca Ospedale Maggiore,NA,https://clinicalzeros.gov/ct2/show/NCT04385160,0,0,0,0,2,1,United States|France|Germany|Italy|Poland|Spain|United Kingdom,0,"NA",NA
NCT04385147,2020-05-18,7/1/2020,Observational,Advanced Endoscopy During COVID-19,Completed,NA,Al-Azhar University,NA,https://clinicalzeros.gov/ct2/show/NCT04385147,0,0,0,0,3,1,United States|Egypt|Germany|Peru|Singapore,0,endoscopic management according to standard of care,NA
NCT04384900,2020-05-11,11/30/2020,Interventional,Accelerated Prone Position Ventilation of Patients With COVID-19,Recruiting,N/A,Nordsjaellands Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384900,0,0,0,0,1,0,Denmark,0,prone positioning,NA
NCT04384887,2020-04-25,8/25/2020,Observational,"""Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women""",Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384887,0,0,0,0,1,0,Turkey,0,covid-19 positive pregnant women,NA
NCT04388670,2020-02-22,8/22/2020,Observational,Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19,Recruiting,NA,Policlinico Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04388670,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04388644,2020-02-20,5/20/2020,Observational,Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention,Recruiting,NA,Taipei City Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04388644,0,0,0,0,0,0,Taiwan,0,"NA",NA
NCT04388631,2020-05-10,5/1/2021,Observational [Patient Registry],Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.,Recruiting,NA,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04388631,0,0,0,0,1,0,China,0,coronavirus disease 2019,NA
NCT04388579,2020-03-20,3/27/2020,Observational,Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19,Completed,NA,University of Lisbon,NA,https://clinicalzeros.gov/ct2/show/NCT04388579,0,0,0,0,0,0,Portugal,0,pulmonary rehabilitation,NA
NCT04522128,2020-05-22,3/31/2022,Interventional,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Recruiting,N/A,University of Manchester,NA,https://clinicalzeros.gov/ct2/show/NCT04522128,0,0,0,0,0,0,United Kingdom,0,behaviour change technique intervention to improve quality of life,NA
NCT04412330,2020-05-01,5/1/2021,Interventional,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Recruiting,N/A,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04412330,0,0,0,0,2,1,United States,0,icu recovery / physical therapy|icu recovery|physical therapy,NA
NCT04388410,2020-08-25,11/30/2020,Interventional,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04388410,0,0,0,0,2,0,Mexico,0,convalescent plasma,NA
NCT04387968,2020-08-24,3/24/2021,Observational,"Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study",Recruiting,NA,OrlÃ©ans MÃ©tropole Service de MÃ©decine PrÃ©ventive,NA,https://clinicalzeros.gov/ct2/show/NCT04387968,0,0,0,0,2,0,France,0,covid-19 presto test,NA
NCT04387292,2020-09-07,5/31/2021,Interventional,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Recruiting,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04387292,0,0,0,0,2,0,France,0,ophthalmologic exam,NA
NCT04387279,2020-04-24,3/30/2021,Observational,The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease,Recruiting,NA,Keimyung University Dongsan Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04387279,0,0,0,0,0,0,"Korea, Republic of",0,interview,NA
NCT04387253,2020-05-23,7/23/2021,Interventional,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Recruiting,N/A,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04387253,0,0,0,0,3,0,France,0,pcr,NA
NCT04387214,2020-04-13,8/10/2020,Observational,COVID-19 Pandemic and Academic Performance of Veterinary Students,Completed,NA,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04387214,0,0,0,0,5,0,Egypt,0,questionnaire,NA
NCT04386668,2020-05-26,7/12/2020,Interventional,Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,Terminated,N/A,"University College, London",Interim analysis indicated adaptations to intervention may be required.,https://clinicalzeros.gov/ct2/show/NCT04386668,0,0,0,0,4,0,United Kingdom,0,let it out (lio)-c|neutral writing control,NA
NCT04386512,2020-05-15,6/1/2020,Observational,Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1),Completed,NA,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04386512,0,0,0,0,1,0,France,0,"NA",NA
NCT04386460,2020-05-11,6/5/2020,Observational,Covid-19 and Prevention of Malnutrition After Confinement by Dentists,Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04386460,0,0,0,0,0,0,France,0,"NA",NA
NCT04402957,2020-10-14,1/31/2021,Interventional,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),Recruiting,Phase 2,Arch Biopartners Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04402957,0,0,0,0,5,1,United States|Canada|Turkey,0,lsalt peptide|placebo,NA
NCT04416919,2020-07-15,5/31/2025,Interventional,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,Recruiting,N/A,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04416919,0,0,0,0,1,1,United States,0,assembled mask,NA
NCT04409925,2020-12-25,4/30/2021,Interventional,DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),Recruiting,Phase 1,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04409925,0,0,0,0,7,0,Canada,0,rhdnase i,NA
NCT04406324,2020-06-01,3/5/2021,Observational,COVID-19: Respiratory and Sleep Follow-up,Recruiting,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04406324,0,0,0,0,1,0,France,0,no intervention,NA
NCT04405076,2020-05-29,3/31/2021,Interventional,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",Phase 2,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04405076,0,0,0,1,3,1,United States,0,biological: mrna-1273|placebo,NA
NCT04397575,2020-04-03,12/1/2020,Observational [Patient Registry],The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients,"Active, not recruiting",NA,Federation Francophone de Cancerologie Digestive,NA,https://clinicalzeros.gov/ct2/show/NCT04397575,0,0,0,0,3,0,France,0,"NA",NA
NCT04391920,2020-08-28,8/31/2021,Observational [Patient Registry],Registry of CytoSorb Therapy in COVID-19 ICU Patients,Recruiting,NA,"CytoSorbents, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04391920,0,0,0,0,3,1,United States,0,cytosorb,NA
NCT04391127,2020-05-04,11/6/2020,Interventional,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Completed,Phase 3,Centenario Hospital Miguel Hidalgo,NA,https://clinicalzeros.gov/ct2/show/NCT04391127,0,0,0,0,4,0,Mexico,0,hydroxychloroquine|ivermectin|placebo,NA
NCT04394403,2020-05-14,12/31/2020,Interventional,Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,Recruiting,N/A,Hebrew University of Jerusalem,NA,https://clinicalzeros.gov/ct2/show/NCT04394403,0,0,0,0,1,0,Israel,0,internet-based guided self-help based on cbt principles,NA
NCT04394169,2020-05-25,9/25/2020,Interventional,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,Recruiting,N/A,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04394169,0,0,0,0,1,0,Spain,0,intervention program,NA
NCT04392414,2020-05-01,7/10/2020,Interventional,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,Completed,Phase 2,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04392414,0,0,0,0,2,0,Russian Federation,0,convalescent plasma|plasma,NA
NCT04392401,2020-05-11,2/28/2021,Observational,COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04392401,0,0,0,0,0,0,France,0,blood sample,NA
NCT04391946,2020-03-14,5/1/2022,Observational [Patient Registry],Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19,Recruiting,NA,French Innovative Leukemia Organisation,NA,https://clinicalzeros.gov/ct2/show/NCT04391946,0,0,0,0,1,0,France,0,data registry,NA
NCT04391829,2020-08-31,8/31/2021,Interventional,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04391829,0,0,0,0,1,0,Belgium,0,ejaculated semen sample,NA
NCT04390412,2020-05-04,8/30/2020,Interventional,Low Dose Radiotherapy in COVID-19 Pneumonia,"Active, not recruiting",Phase 1/Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04390412,0,0,0,0,2,0,"Iran, Islamic Republic of",0,radiotherapy,NA
NCT04389567,2020-05-12,5/25/2020,Observational,Famotidine Outpatient COVID-19 Treatment Study,Completed,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04389567,0,0,0,0,1,1,United States,0,famotidine,NA
NCT04388657,2020-05-01,9/1/2020,Observational,"COVID-19, bLOod Coagulation and Thrombosis",Recruiting,NA,Ramsay GÃ©nÃ©rale de SantÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04388657,0,0,0,0,0,0,France,0,echo-doppler,NA
NCT04388618,2020-06-15,10/31/2020,Observational,Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia,Recruiting,NA,Princess Nourah Bint Abdulrahman University,NA,https://clinicalzeros.gov/ct2/show/NCT04388618,0,0,0,0,5,0,Saudi Arabia,0,nhanes smell/taste tests|nhanes smell|taste,NA
NCT04387929,2020-05-04,5/30/2021,Observational [Patient Registry],Detection of Anti-COVID-19 Antibody Levels in an Hospital Population,Recruiting,NA,Istituto Clinico Humanitas,NA,https://clinicalzeros.gov/ct2/show/NCT04387929,0,0,0,0,1,0,Italy,0,antibody test,NA
NCT04387838,2020-05-14,7/31/2020,Observational,Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04387838,0,0,0,0,1,0,France,0,serology test|questionnaire,NA
NCT04387799,2020-05-13,6/12/2020,Observational,Determinants of COVID-19 Pneumonia (MC-19),Completed,NA,Catholic University of the Sacred Heart,NA,https://clinicalzeros.gov/ct2/show/NCT04387799,0,0,0,0,2,0,Italy,0,serology test,NA
NCT04387643,2020-03-01,4/2/2020,Observational,Protecting Health Care Workers During the COVID-19 Outbreak,Completed,NA,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04387643,0,0,0,0,0,0,India,0,ayurvedic kadha,NA
NCT04388826,2020-06-18,12/18/2020,Interventional,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Active, not recruiting",Phase 2,Veru Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04388826,0,0,0,0,16,1,United States,0,veru-111,NA
NCT04388683,2020-05-12,4/30/2021,Interventional,Inhaled Nitric Oxide for Preventing Progression in COVID-19,"Active, not recruiting",Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04388683,0,0,0,0,2,1,United States,0,nitric oxide,NA
NCT04387656,2020-05-21,5/31/2023,Observational,"NCI COVID-19 in Cancer Patients, NCCAPS Study",Recruiting,NA,National Cancer Institute (NCI),NA,https://clinicalzeros.gov/ct2/show/NCT04387656,0,0,0,0,107,1,United States|Canada|Puerto Rico,0,quality-of-life assessment|questionnaire|biospecimen collection|biospeciman collection|data collection,NA
NCT04420390,2020-05-01,7/31/2020,Interventional,Low Dose Radiotherapy for COVID-19 Pneumonitis,Recruiting,N/A,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04420390,0,0,0,0,0,0,Spain,0,radiotherapy,NA
NCT04410835,2020-04-28,12/31/2020,Observational,Psychological Impact of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04410835,0,0,0,0,1,0,Austria,0,online survey,NA
NCT04397718,2020-07-06,7/6/2021,Interventional,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,Recruiting,Phase 2,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04397718,0,0,0,0,10,1,United States,0,degarelix|saline,NA
NCT04393428,2020-03-01,6/1/2020,Observational,Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04393428,0,0,0,0,2,0,France,0,[timp-2]*[igfbp-7],NA
NCT04392089,2020-05-01,5/1/2021,Observational,Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS,Recruiting,NA,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04392089,0,0,0,0,0,0,Denmark,0,"masimo, lidco",NA
NCT04391881,2020-05-30,8/30/2020,Observational,Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04391881,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04391738,2020-02-01,5/15/2020,Observational,Association Between BMI and COVID-19,"Active, not recruiting",NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04391738,0,0,0,0,2,0,France,0,patients admitted to intensive care unit with sars-cov2,NA
NCT04390594,2020-08-13,2/12/2021,Interventional,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,Recruiting,Phase 3,Institut Pasteur de Dakar,NA,https://clinicalzeros.gov/ct2/show/NCT04390594,0,0,0,0,4,0,Senegal,0,nafamostat mesilate,NA
NCT04390516,2020-03-24,5/4/2020,Interventional,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Completed,N/A,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04390516,0,0,0,0,3,1,United States,0,coviage,NA
NCT04390503,2020-05-31,4/30/2021,Interventional,Convalescent Plasma for COVID-19 Close Contacts,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04390503,0,0,0,0,0,1,United States,0,convalescent plasma|control,NA
NCT04390126,2020-04-20,5/7/2021,Observational,COVID-19 Related Lockdown Effects On Chronic Diseases,"Active, not recruiting",NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04390126,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04390074,2020-05-27,6/4/2020,Observational,COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality,Completed,NA,Uppsala University,NA,https://clinicalzeros.gov/ct2/show/NCT04390074,0,0,0,0,2,0,Sweden,0,covid-19/intensive care|covid-19|intensive care,NA
NCT04389684,2020-05-27,7/27/2021,Observational,Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors,Recruiting,NA,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389684,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04389658,2020-05-07,6/10/2020,Observational,Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION),Completed,NA,Igenomix,NA,https://clinicalzeros.gov/ct2/show/NCT04389658,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04389554,2020-05-14,5/28/2020,Observational [Patient Registry],D-dimer Levels in Pregnant With COVID-19,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389554,0,0,0,0,2,0,Turkey,0,blood d-dimer assay,NA
NCT04389515,2020-05-14,9/25/2020,Observational,"Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19",Recruiting,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389515,0,0,0,0,3,0,Turkey,0,"NA",NA
NCT04389489,2020-05-14,9/25/2020,Observational,Postpartum Sexual Function in Pregnant Women With COVID-19,Recruiting,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389489,0,0,0,0,3,0,Turkey,0,"NA",NA
NCT04389463,2020-05-11,5/11/2022,Observational,Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389463,0,0,0,0,2,0,France,0,no intervention,NA
NCT04389450,2020-10-01,5/31/2021,Interventional,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",Recruiting,Phase 2,Pluristem Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04389450,0,0,0,0,8,1,United States,0,plx-pad|placebo,NA
NCT04394208,2020-08-16,1/30/2021,Interventional,Silymarin in COVID-19 Pneumonia,Recruiting,Phase 3,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04394208,0,0,0,0,3,0,Egypt,0,silymarin|placebo,NA
NCT04490837,2020-06-22,7/31/2020,Observational [Patient Registry],Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID),"Active, not recruiting",NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04490837,0,0,0,0,0,0,Spain,0,elisa/rapid test to detect antibodies against covid-19|elisa|rapid test,NA
NCT04474483,2020-11-06,3/31/2021,Interventional,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,Recruiting,Phase 2,State University of New York at Buffalo,NA,https://clinicalzeros.gov/ct2/show/NCT04474483,0,0,0,0,2,1,United States,0,melatonin|placebo (methylcellulose) capsule,NA
NCT04453670,2020-03-10,5/11/2020,Observational,Neuropathology in Adults Intensive Care Unit Patients With COVID 19,Completed,NA,University of Versailles,NA,https://clinicalzeros.gov/ct2/show/NCT04453670,0,0,0,0,0,0,France,0,autopsy,NA
NCT04408040,2020-07-14,7/31/2022,Interventional,Use of Convalescent Plasma for COVID-19,Recruiting,Phase 2,"Northside Hospital, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04408040,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04402203,2020-05-31,7/31/2020,Interventional,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,Phase 2/Phase 3,Bangladesh Medical Research Council (BMRC),NA,https://clinicalzeros.gov/ct2/show/NCT04402203,0,0,0,0,0,0,Bangladesh,0,favipiravir|standard care,NA
NCT04399967,2020-06-13,6/30/2021,Interventional,"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020",Recruiting,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04399967,0,0,0,0,5,0,China,0,chat-based support|award/covid-specific advice|award advice|covid-19 related health warning leaflet|health warning leaflet|sms-based support|referral card|cosh self-help smoking cessation booklet|award|covid-specific advice,NA
NCT04399746,2020-03-15,5/20/2020,Interventional,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Recruiting,N/A,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,https://clinicalzeros.gov/ct2/show/NCT04399746,0,0,0,0,0,0,Mexico,0,ivermectin|azithromycin|cholecalciferol,NA
NCT04399356,2020-10-01,1/1/2021,Interventional,Niclosamide for Mild to Moderate COVID-19,Recruiting,Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04399356,0,0,0,0,3,1,United States,0,niclosamide|placebo|telehealth monitoring,NA
NCT04399252,2020-06-24,5/25/2022,Interventional,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04399252,0,0,0,0,1,1,United States,0,lactobaciltus rhamnosus gg|placebo,NA
NCT04399005,2020-05-25,6/5/2020,Interventional,The Efficacy Comparing Daily and After-each-case Room Disinfection.,Completed,N/A,The First Affiliated Hospital of Zhejiang Chinese Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04399005,0,0,0,0,1,0,China,0,after-each-case room disinfection|daily room disinfection,NA
NCT04397939,2020-05-08,3/31/2021,Observational,Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19,Recruiting,NA,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04397939,0,0,0,0,1,1,United States,0,"NA",NA
NCT04397900,2020-04-09,7/1/2020,Observational,Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes,Recruiting,NA,"TScan Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04397900,0,0,0,0,1,1,United States,0,"NA",NA
NCT04397848,2020-05-14,7/3/2020,Observational,Mental Health Outcomes in Healthcare Workers During COVID-19,Completed,NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04397848,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04397822,2020-04-16,10/31/2021,Observational,COVID-19 : Study of INFLAmmasome and PLAtelets Functions,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04397822,0,0,0,0,1,0,France,0,blood sample,NA
NCT04397757,2020-05-13,4/30/2021,Interventional,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04397757,0,0,0,0,6,1,United States,0,convalescent plasma,NA
NCT04397692,2020-06-13,9/30/2020,Interventional,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,N/A,Beyond Air Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04397692,0,0,0,0,2,1,United States,0,nitric oxide delivered via lungfitâ„¢ system,NA
NCT04397588,2020-04-21,10/21/2020,Observational,Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19,Recruiting,NA,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04397588,0,0,0,0,1,0,France,0,"NA",NA
NCT04397562,2020-04-29,7/3/2020,Interventional,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,Completed,Phase 3,Biocad,NA,https://clinicalzeros.gov/ct2/show/NCT04397562,0,0,0,0,4,0,Russian Federation,0,levilimab|placebo,NA
NCT04397237,2020-06-10,12/8/2020,Observational,Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe,"Active, not recruiting",NA,PitiÃ©-SalpÃªtriÃ¨re Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04397237,0,0,0,0,1,0,France,0,"NA",NA
NCT04395924,2020-05-05,5/31/2021,Observational,Maternal-foetal Transmission of SARS-Cov-2,Recruiting,NA,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04395924,0,0,0,0,3,0,France,0,"diagnosis of sars-cov2 by rt-pcr/: igg, ig m serologies in the amniotoc fluid, the blood cord/the placenta|pcr|: igg, ig m serologies in the amniotoc fluid, the blood cord|the placenta",NA
NCT04395885,2020-06-01,8/31/2020,Observational,Sexual Function During COVID 19 Pandemic,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04395885,0,0,0,0,3,0,Egypt,0,questionnaire,NA
NCT04395794,2020-05-07,8/31/2020,Observational [Patient Registry],SARS-CoV-2 Disguise Study,Recruiting,NA,Meshalkin Research Institute of Pathology of Circulation,NA,https://clinicalzeros.gov/ct2/show/NCT04395794,0,0,0,0,0,0,Russian Federation,0,sars-cov-2-test|questionnaire,NA
NCT04395755,2020-04-01,5/15/2020,Observational,Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed,Completed,NA,Ospedale Policlinico San Martino,NA,https://clinicalzeros.gov/ct2/show/NCT04395755,0,0,0,0,1,0,Italy,0,generalized anxiety disorder-7 (gad-7)|questionnaire,NA
NCT04395664,2020-04-16,9/1/2020,Observational,Arrhythmias in Patients With COVID-19,Completed,NA,Herlev and Gentofte Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04395664,0,0,0,0,1,0,Denmark,0,c3/ holter monitor|c3|holter monitor,NA
NCT04395391,2020-05-18,5/21/2020,Observational,Home Usability Study of the SARS-CoV-2 (COVID-19) Test,Completed,NA,Exact Sciences Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04395391,0,0,0,0,2,1,United States,0,sars-cov-2,NA
NCT04395300,2020-03-30,4/30/2020,Observational,Sleep Quality in Healthcare Personnel During COVID-19,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04395300,0,0,0,0,1,0,Egypt,0,survey,NA
NCT04395833,2020-04-07,5/11/2020,Observational,National Survey on the Lockdown of Children With Disabilities,Completed,NA,"University Hospital, Brest",NA,https://clinicalzeros.gov/ct2/show/NCT04395833,0,0,0,0,0,0,France,0,"NA",NA
NCT04394884,2021-02-10,4/30/2023,Observational,Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND),Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04394884,0,0,0,0,164,1,United States,0,"NA",NA
NCT04473105,2020-05-01,12/31/2020,Observational,Optimising Resource Allocation Via Prediction of Outcomes for Covid-19,Recruiting,NA,Nottingham University Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04473105,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04441684,2020-04-17,5/7/2020,Interventional,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",Recruiting,N/A,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04441684,0,0,0,0,0,0,France,0,blood sample,NA
NCT04412460,2020-03-20,12/31/2021,Observational,Echocardiography in Patients With Covid-19,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04412460,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04411511,2020-05-06,11/6/2020,Observational,"COVID-19, Obesity and Lifestyle in Children",Recruiting,NA,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04411511,0,0,0,0,0,0,Netherlands,0,exposure to the dutch measures due to the covid-19 pandemic.,NA
NCT04394104,2020-05-27,5/31/2020,Observational,COVID-19 Wellness Survey,Terminated,NA,"Rutgers, The State University of New Jersey",Study has concluded.,https://clinicalzeros.gov/ct2/show/NCT04394104,0,0,0,0,2,1,United States,0,questionnaire,NA
NCT04394026,2020-04-16,8/31/2020,Observational,Imaging Feature of SARS-CoV2 Infection,Recruiting,NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04394026,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04393948,2020-06-30,10/31/2020,Interventional,Lung Irradiation for COVID-19 Pneumonia,Recruiting,N/A,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04393948,0,0,0,0,2,1,United States,0,phase 1|phase 2,NA
NCT04393415,2020-05-25,8/25/2020,Interventional,Using PRP and Cord Blood in Treatment of Covid -19,Recruiting,N/A,Aljazeera Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04393415,0,0,0,0,2,0,Egypt,0,mesenchymal stem cells,NA
NCT04393402,2020-03-20,12/31/2020,Observational,Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04393402,0,0,0,0,0,0,France,0,lung ultrasound (lus),NA
NCT04392388,2020-05-01,12/31/2020,Observational,"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis",Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicalzeros.gov/ct2/show/NCT04392388,0,0,0,0,1,0,France,0,no intervention,NA
NCT04392232,2020-05-05,12/31/2020,Interventional,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Recruiting,Phase 2,TriHealth Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04392232,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04392141,2020-04-01,11/1/2020,Interventional,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04392141,0,0,0,0,2,0,"Iran, Islamic Republic of",0,standard care|colchicine/herbal phenolic monoterpene fractions|colchicine|herbal phenolic monoterpene,NA
NCT04391686,2020-07-03,11/2/2021,Observational [Patient Registry],Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context,Recruiting,NA,Centre Hospitalier Arras,NA,https://clinicalzeros.gov/ct2/show/NCT04391686,0,0,0,0,3,0,France,0,indirect calorimetry,NA
NCT04391166,2020-05-20,5/1/2022,Observational,Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic,"Active, not recruiting",NA,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04391166,0,0,0,0,5,1,United States,0,non invasive visual acuity testing,NA
NCT04391179,2020-05-31,2/28/2021,Interventional,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,"Active, not recruiting",Phase 2,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04391179,0,0,0,0,6,1,United States,0,dipyridamole|placebo,NA
NCT04391816,2021-02-10,12/31/2022,Observational,COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04391816,0,0,0,0,167,1,United States,0,"NA",NA
NCT04407208,2020-05-01,6/22/2020,Interventional,Convalescent Plasma Therapy in Patients With COVID-19,Completed,Phase 1,Biofarma,NA,https://clinicalzeros.gov/ct2/show/NCT04407208,0,0,0,0,2,0,Indonesia,0,convalescent plasma,NA
NCT04396106,2020-05-26,3/31/2021,Interventional,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19),Recruiting,Phase 2,"Atea Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04396106,0,0,0,0,6,1,"United States|Belgium|Brazil|Moldova, Republic of|Romania|South Africa|Ukraine",0,at-527|placebo,NA
NCT04394195,2020-03-25,7/1/2020,Observational,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04394195,0,0,0,0,0,0,France,0,measurement of circulating sflt1 concentration,NA
NCT04393558,2020-04-20,12/31/2022,Observational,Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms,Recruiting,NA,Shirley Ryan AbilityLab,NA,https://clinicalzeros.gov/ct2/show/NCT04393558,0,0,0,0,1,1,United States,0,adam sensor,NA
NCT04398004,2020-05-06,11/30/2020,Interventional,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Completed,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04398004,0,0,0,0,3,0,Greece,0,clarithromycin,NA
NCT04400812,2020-05-19,9/30/2020,Observational,Attitude and Perception Towards COVID-19 Pandemic,Enrolling by invitation,NA,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04400812,0,0,0,0,1,0,Egypt,0,questionnaire,NA
NCT04400461,2020-05-15,9/30/2020,Observational,Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation,Recruiting,NA,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04400461,0,0,0,0,0,0,Spain,0,data collection/clinical testing of subjects|data collection|clinical testing of subjects,NA
NCT04395911,2020-09-10,1/31/2021,Interventional,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,Recruiting,N/A,SeaStar Medical,NA,https://clinicalzeros.gov/ct2/show/NCT04395911,0,0,0,0,3,1,United States,0,scd,NA
NCT04398277,2020-05-01,4/30/2021,Interventional,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,Recruiting,N/A,Kent State University,NA,https://clinicalzeros.gov/ct2/show/NCT04398277,0,0,0,0,0,1,United States,0,daily coping toolkit,NA
NCT04398264,2020-07-22,9/30/2020,Observational [Patient Registry],Characteristics of COVID-19 Infection Among PREGnant Women,Recruiting,NA,Inova Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04398264,0,0,0,0,1,1,United States,0,covid-19 positive via testing,NA
NCT04397666,2020-05-15,9/15/2020,Interventional,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,Recruiting,N/A,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04397666,0,0,0,0,1,0,France,0,pcr,NA
NCT04397614,2020-07-22,12/31/2021,Observational,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,Recruiting,NA,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04397614,0,0,0,0,2,1,United States,0,mhealth assessments,NA
NCT04397523,2020-04-30,4/29/2021,Interventional,Efficacy and Safety of COVID-19 Convalescent Plasma,Recruiting,N/A,Institute for Transfusion Medicine of RNM,NA,https://clinicalzeros.gov/ct2/show/NCT04397523,0,0,0,0,1,0,North Macedonia,0,convalescent plasma,NA
NCT04397172,2020-04-09,4/30/2021,Observational,Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04397172,0,0,0,0,1,0,Switzerland,0,study arm,NA
NCT04394793,2020-06-13,8/27/2020,Interventional,Low Dose Radiation Therapy for Covid-19 Pneumonia,"Active, not recruiting",N/A,"All India Institute of Medical Sciences, New Delhi",NA,https://clinicalzeros.gov/ct2/show/NCT04394793,0,0,0,0,4,0,India,0,low,NA
NCT04394442,2020-03-21,8/31/2020,Interventional,Hydroxychloroquine in COVID-19 Patients,Recruiting,Phase 2,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04394442,0,0,0,0,0,0,Saudi Arabia,0,hydroxychloroquine,NA
NCT04402905,2020-06-15,7/15/2020,Observational,"Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)",Completed,NA,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,https://clinicalzeros.gov/ct2/show/NCT04402905,0,0,0,0,2,0,France,0,"NA",NA
NCT04552951,2020-04-04,9/14/2020,Interventional,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Recruiting,Phase 4,FundaciÃ³n para la InvestigaciÃ³n Biosanitaria del Principado de Asturias,NA,https://clinicalzeros.gov/ct2/show/NCT04552951,0,0,0,0,0,0,Spain,0,cholecalciferol,NA
NCT04453748,2020-06-08,10/31/2021,Observational [Patient Registry],"The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications",Enrolling by invitation,NA,Silesian Centre for Heart Diseases,NA,https://clinicalzeros.gov/ct2/show/NCT04453748,0,0,0,0,1,0,Poland,0,complex diagnostic panel,NA
NCT04427280,2020-05-26,10/31/2020,Observational,Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19),Recruiting,NA,Royal Marsden NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04427280,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04425382,2020-03-01,7/31/2020,Observational,Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04425382,0,0,0,0,0,0,Qatar,0,darunavir/cobicistat|lopinavir/ritonavir|darunavir|cobicistat|lopinavir|ritonavir,NA
NCT04413006,2020-05-25,12/31/2020,Interventional,Self-compassion for Chronic Pain Virtual Group Treatment Program,Recruiting,N/A,University of Manitoba,NA,https://clinicalzeros.gov/ct2/show/NCT04413006,0,0,0,0,0,0,Canada,0,self-compassion for chronic pain virtual group treatment program,NA
NCT04410549,2020-06-01,12/31/2020,Interventional,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Recruiting,N/A,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04410549,0,0,0,0,1,0,Brazil|Italy,0,optical coherence tomography (oct),NA
NCT04408196,2020-05-26,7/31/2020,Observational,QoL and the Emotional-affective Sphere o in Rehabilitation Setting During COVID-19 Quarantine,Recruiting,NA,Fondazione Don Carlo Gnocchi Onlus,NA,https://clinicalzeros.gov/ct2/show/NCT04408196,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04403035,2020-05-10,7/1/2020,Observational,Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19,Recruiting,NA,Ascension South East Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04403035,0,0,0,0,1,1,United States,0,id now vs. accula,NA
NCT04402229,2020-05-12,7/31/2020,Observational,Psychological Impact of the Covid-19 Pandemic on Student Nurses,Completed,NA,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04402229,0,0,0,0,1,0,France,0,"NA",NA
NCT04401475,2020-11-25,4/30/2021,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19",Recruiting,Phase 2,Edesa Biotech Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04401475,0,0,0,0,4,1,United States|Canada,0,soc/15mg/kg eb05 iv|soc/placebo iv|standard care|15mg|kg eb05 iv|placebo iv,NA
NCT04401423,2020-08-31,6/30/2021,Interventional,TXA127 for the Treatment of Severe COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04401423,0,0,0,0,1,1,United States,0,txa127|placebo,NA
NCT04401371,2020-05-01,5/10/2020,Observational,Distance Learning for Dental Student During COVID-19 Pandemic,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04401371,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04401228,2020-03-01,5/1/2020,Observational,Predictive Models for Intensive Care Admission and Death of COVID-19,"Active, not recruiting",NA,Clinique Saint Pierre Ottignies,NA,https://clinicalzeros.gov/ct2/show/NCT04401228,0,0,0,0,0,0,Belgium,0,"predict admission of covid-19 patients to icu/death with routine/quickly avalaible clinical, biological/radiological variables?|predict admission of covid-19 patients to icu|death with routine|quickly avalaible clinical, biological|radiological variables?",NA
NCT04401150,2020-08-14,11/30/2021,Interventional,Lessening Organ Dysfunction With VITamin C - COVID-19,Recruiting,Phase 3,UniversitÃ© de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04401150,0,0,0,0,3,0,Canada,0,vitamin c|control,NA
NCT04401085,2020-04-23,5/1/2020,Observational,COVID-19: Herd Immunity Study in the Czech Republic,Completed,NA,Institute of Health Information and Statistics of the Czech Republic,NA,https://clinicalzeros.gov/ct2/show/NCT04401085,0,0,0,0,2,0,Czechia,0,rapid test|quantitative analysis of sars-cov-2 antibodies,NA
NCT04401033,2020-05-11,6/30/2020,Observational [Patient Registry],Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study),Completed,NA,Hospital del RÃ­o Hortega,NA,https://clinicalzeros.gov/ct2/show/NCT04401033,0,0,0,0,2,0,Spain,0,telehealth|gastrointestinal endoscopy|abdominal ultrasound,NA
NCT04400305,2020-05-20,3/31/2021,Interventional,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Recruiting,N/A,University of Victoria,NA,https://clinicalzeros.gov/ct2/show/NCT04400305,0,0,0,0,4,0,Canada,0,digital health online platform,NA
NCT04400279,2020-06-01,11/28/2020,Interventional,The COVID-19 Pandemic and Exercise Study,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04400279,0,0,0,0,4,0,Canada,0,yoga group|high intensity interval training|combination,NA
NCT04400058,2020-06-01,2/2/2021,Interventional,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,"Active, not recruiting",Phase 3,Octapharma,NA,https://clinicalzeros.gov/ct2/show/NCT04400058,0,0,0,0,15,1,United States|Russian Federation|Ukraine,0,octagam|placebo,NA
NCT04400006,2020-05-06,5/16/2020,Observational,Ozone Therapy in the Prevention of COVID-19 Infection,Completed,NA,Marmara University,NA,https://clinicalzeros.gov/ct2/show/NCT04400006,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04399980,2020-05-20,5/31/2021,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Phase 2,The Cleveland Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04399980,0,0,0,0,3,1,United States,0,mavrilimumab|placebo,NA
NCT04399889,2020-06-18,4/1/2021,Interventional,hCT-MSCs for COVID19 ARDS,Recruiting,Phase 1/Phase 2,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04399889,0,0,0,0,1,1,United States,0,mesenchymalÂ stem cells,NA
NCT04399681,2020-05-10,8/10/2020,Interventional,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04399681,0,0,0,0,0,0,Turkey,0,lung ultrasound,NA
NCT04399109,2020-05-20,5/19/2021,Interventional,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),Recruiting,N/A,"Prince of Wales Hospital, Sydney",NA,https://clinicalzeros.gov/ct2/show/NCT04399109,0,0,0,0,0,0,Australia,0,tcc-covid mhealth,NA
NCT04401410,2020-11-04,8/15/2021,Interventional,Anti-SARS Cov-2 T Cell Infusions for COVID 19,Recruiting,Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04401410,0,0,0,0,3,1,United States,0,dose finding phase (mtd)|partially hla-matched sars-covsts|routine care (no sars-covsts),NA
NCT04411602,2020-04-07,12/31/2020,Interventional,Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD,Recruiting,Phase 1,Ascension South East Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04411602,0,0,0,0,0,1,United States,0,plasma,NA
NCT04410939,2020-04-10,5/20/2020,Observational,COVID-19 PCR Test Results in Asymptomatic Pregnants,Completed,NA,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04410939,0,0,0,0,0,0,Turkey,0,reverse transcription polymerase chain reaction,NA
NCT04410016,2020-05-25,7/31/2020,Interventional,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Recruiting,N/A,University of Nottingham,NA,https://clinicalzeros.gov/ct2/show/NCT04410016,0,0,0,0,2,0,United Kingdom,0,staff wellbeing centres,NA
NCT04408183,2020-06-01,2/28/2021,Interventional,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,Recruiting,Phase 2,"GeneOne Life Science, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04408183,0,0,0,0,2,1,United States,0,gls-1200|placebo,NA
NCT04407390,2020-06-01,5/1/2021,Interventional,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,Recruiting,Phase 2,University of Copenhagen,NA,https://clinicalzeros.gov/ct2/show/NCT04407390,0,0,0,0,1,0,Denmark,0,nicotinamide riboside|placebo,NA
NCT04404361,2020-05-22,7/31/2021,Interventional,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,Recruiting,Phase 3,CTI BioPharma,NA,https://clinicalzeros.gov/ct2/show/NCT04404361,0,0,0,0,7,1,United States,0,pacritinib|placebo,NA
NCT04404062,2020-03-16,8/31/2020,Observational,Validation of COVID-19 Tests,"Active, not recruiting",NA,Richmond Pharmacology Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04404062,0,0,0,0,0,0,United Kingdom,0,rapid test|quantitative igg test,NA
NCT04403880,2020-05-13,8/31/2021,Observational,Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19,Recruiting,NA,HIV Vaccine Trials Network,NA,https://clinicalzeros.gov/ct2/show/NCT04403880,0,0,0,0,9,1,United States|Malawi|Mozambique|Peru|South Africa|Tanzania|Zambia|Zimbabwe,0,sample collection,NA
NCT04403646,2020-06-12,10/20/2020,Interventional,Tannin Specific Natural Extract for COVID-19 Infection,Terminated,N/A,Hospital de Clinicas JosÃ© de San MartÃ­n,low rate of covid patients,https://clinicalzeros.gov/ct2/show/NCT04403646,0,0,0,0,1,0,Argentina,0,arbox|placebo,NA
NCT04402983,2020-05-27,12/1/2020,Interventional,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,N/A,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04402983,0,0,0,0,2,0,Turkey,0,physiotherapy,NA
NCT04402879,2020-11-10,12/1/2021,Interventional,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,Recruiting,N/A,University of Calgary,NA,https://clinicalzeros.gov/ct2/show/NCT04402879,0,0,0,0,5,0,Canada,0,prone positioning,NA
NCT04402866,2020-06-24,12/31/2020,Interventional,TD-0903 for ALI Associated With COVID-19,Recruiting,Phase 2,Theravance Biopharma,NA,https://clinicalzeros.gov/ct2/show/NCT04402866,0,0,0,0,7,1,"United States|Brazil|Finland|Moldova, Republic of|Romania|Ukraine|United Kingdom",0,td-0903|placebo,NA
NCT04402840,2020-04-24,12/31/2021,Interventional,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,N/A,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04402840,0,0,0,0,1,1,United States,0,stellate ganglion block,NA
NCT04402814,2020-05-05,10/1/2020,Observational,IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.,Recruiting,NA,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04402814,0,0,0,0,1,1,United States,0,clungene rapid test cassette,NA
NCT04402060,2020-05-28,1/31/2021,Interventional,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,Recruiting,Phase 1/Phase 2,"Apellis Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04402060,0,0,0,0,3,1,United States|Brazil,0,apl-9|vehicle control,NA
NCT04401449,2020-01-08,5/1/2024,Observational,Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04401449,0,0,0,0,16,1,United States,0,"NA",NA
NCT04401436,2020-05-22,6/30/2022,Observational,COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO),Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04401436,0,0,0,0,12,1,United States,0,"NA",NA
NCT04401111,2020-06-16,6/15/2021,Observational,One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04401111,0,0,0,0,1,0,France,0,"NA",NA
NCT04401098,2020-05-02,10/1/2020,Observational,Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak,Recruiting,NA,Damanhour University,NA,https://clinicalzeros.gov/ct2/show/NCT04401098,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04401072,2020-04-24,5/22/2020,Observational,Attitude of Egyptian Population Toward COVID 19 in Ramadan,Recruiting,NA,Damanhour University,NA,https://clinicalzeros.gov/ct2/show/NCT04401072,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04401046,2020-05-20,10/30/2020,Interventional,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Recruiting,N/A,Institut Paoli-Calmettes,NA,https://clinicalzeros.gov/ct2/show/NCT04401046,0,0,0,0,2,0,France,0,survey|anxiety|6 months later,NA
NCT04400890,2020-09-12,11/30/2020,Interventional,Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19,Recruiting,Phase 2,Mount Carmel Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04400890,0,0,0,0,4,1,United States,0,plant polyphenol|vitamin d,NA
NCT04400877,2020-06-08,7/30/2020,Observational,Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic,Completed,NA,"University Hospital, Linkoeping",NA,https://clinicalzeros.gov/ct2/show/NCT04400877,0,0,0,0,3,0,Sweden,0,diagnostic examination for venous thromboembolism,NA
NCT04409847,2020-06-01,4/30/2021,Observational,COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX),Recruiting,NA,NHS Greater Glasgow and Clyde,NA,https://clinicalzeros.gov/ct2/show/NCT04409847,0,0,0,0,3,0,United Kingdom,0,abpm|ecg|fmd|pwv|rarefaction,NA
NCT04409821,2020-05-29,2/28/2022,Interventional,Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04409821,0,0,0,0,1,0,Denmark,0,tele-delivered psychological intervention,NA
NCT04404426,2020-11-02,9/15/2021,Interventional,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04404426,0,0,0,0,3,0,France,0,l-citrulline|placebo,NA
NCT04556149,2020-10-01,12/2/2020,Observational,"imPulseâ„¢ Una Full-spectrum, Over Clothing E-stethoscope",Completed,NA,"Level 42 AI, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04556149,0,0,0,0,3,1,United States,0,impulseâ„¢ una e-stethoscope|philips lumify ultrasound system,NA
NCT04413071,2020-05-25,6/12/2020,Observational,Cardiac COVID-19 Health Care Workers,Completed,NA,AORTICA Group,NA,https://clinicalzeros.gov/ct2/show/NCT04413071,0,0,0,0,2,0,Spain,0,passed infection of sars-cov-2,NA
NCT04407299,2020-04-20,5/10/2020,Observational,COVID-19 Impact on Rheumatic Patients,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04407299,0,0,0,0,1,0,Egypt,0,questionnaire,NA
NCT04406545,2020-05-15,8/15/2020,Observational,Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.,Recruiting,NA,"National Institute of Cardiology, Laranjeiras, Brazil",NA,https://clinicalzeros.gov/ct2/show/NCT04406545,0,0,0,0,1,0,Brazil,0,evaluation of skin microvascular flow/reactivity|evaluation of skin microvascular flow|reactivity,NA
NCT04406493,2020-04-28,4/28/2021,Interventional,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Recruiting,N/A,Hillel Yaffe Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04406493,0,0,0,0,0,0,Israel,0,lung impedance,NA
NCT04406233,2020-05-23,5/23/2022,Observational,Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19,Recruiting,NA,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04406233,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04405843,2020-07-14,12/21/2020,Interventional,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),Completed,Phase 2/Phase 3,Centro de Estudios en InfectogÃ­a Pediatrica,NA,https://clinicalzeros.gov/ct2/show/NCT04405843,0,0,0,0,8,0,Colombia,0,ivermectin|placebo,NA
NCT04403555,2020-06-01,12/1/2030,Interventional,Ivermectin as a Novel Therapy in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04403555,0,0,0,0,4,0,Egypt,0,ivermectin,NA
NCT04403438,2020-04-01,5/1/2020,Observational,Familial Mediterranean Fever and BehÃ§et: Analysis Before and After Covid19 Pandemic,Enrolling by invitation,NA,Istanbul University,NA,https://clinicalzeros.gov/ct2/show/NCT04403438,0,0,0,0,0,0,Turkey,0,"ä±t will be compared pain, sleep, fatigue, physical activity level/quality of life/questioning exercise habits before/after the covid-19 outbreak in patients with behã§et/fmf.|ä±t will be compared pain, sleep, fatigue, physical activity level|quality of life|exercise|after the covid-19 outbreak in patients with behã§et|fmf.",NA
NCT04403386,2020-06-01,5/31/2022,Observational,"Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19",Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04403386,0,0,0,0,15,1,United States,0,"NA",NA
NCT04403100,2020-06-03,2/1/2021,Interventional,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""",Recruiting,Phase 3,Cardresearch,NA,https://clinicalzeros.gov/ct2/show/NCT04403100,0,0,0,0,2,0,Brazil,0,hydroxychloroquine|lopinavir/ritonavir|hydroxychloroquine/lopinavir/ritonavir|placebo|lopinavir|ritonavir,NA
NCT04403061,2020-05-22,12/22/2020,Observational,Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome,Completed,NA,Asociacion para el Estudio de las Enfermedades Infecciosas,NA,https://clinicalzeros.gov/ct2/show/NCT04403061,0,0,0,0,1,0,Spain,0,cytokines measurement|cellular response|tlrs activation measurement|kir phenotype evaluation,NA
NCT04402827,2020-08-01,12/30/2020,Observational,Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.,Recruiting,NA,Asociacion para el Estudio de las Enfermedades Infecciosas,NA,https://clinicalzeros.gov/ct2/show/NCT04402827,0,0,0,0,2,0,Spain,0,susceptibility to infection,NA
NCT04411433,2020-05-08,12/31/2020,Interventional,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,"Active, not recruiting",Phase 3,"Ministry of Health, Turkey",NA,https://clinicalzeros.gov/ct2/show/NCT04411433,0,0,0,0,1,0,Turkey,0,favipiravir|favipiravir/hydroxychloroquine|favipiravir/azithromycin|hydroxychloroquine|hydroxychloroquine / azithromycin|1200 mg)|1600 mg)|azithromycin,NA
NCT04404179,2020-03-27,5/2/2020,Observational,Setting up a COVID-19 Care Facility at a Prison in Pakistan,Completed,NA,"Services Institute of Medical Sciences, Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04404179,0,0,0,0,1,0,Pakistan,0,covid-19 facility,NA
NCT04429711,2020-05-12,9/30/2020,Interventional,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,Recruiting,N/A,Sheba Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04429711,0,0,0,0,1,0,Israel,0,ivermectin,NA
NCT04422262,2020-06-08,5/31/2021,Observational,Analysis of Long Term Risk of Coronavirus Disease-19 Emergency,Recruiting,NA,Neuromed IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04422262,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04412356,2020-06-04,12/1/2020,Interventional,Timing of Tracheotomy in Covid-19 Patients,Recruiting,N/A,"Sahlgrenska University Hospital, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04412356,0,0,0,0,2,0,Sweden,0,tracheotomy,NA
NCT04408456,2020-03-01,7/31/2020,Interventional,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Completed,Phase 3,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04408456,0,0,0,0,2,0,India,0,hydroxychloroquine|standard care,NA
NCT04406558,2020-05-27,3/31/2021,Observational,Psychological Impact of the Health Measures Generated by the COVID19 in Adolescents,Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04406558,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04406246,2020-05-21,12/31/2020,Interventional,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Recruiting,Phase 4,Materno-Perinatal Hospital of the State of Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04406246,0,0,0,0,0,0,Mexico,0,nitazoxanide,NA
NCT04404218,2020-08-04,3/31/2021,Interventional,The AÃ§aÃ­ Berry COVID-19 Anti-Inflammation Trial,Recruiting,Phase 2,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04404218,0,0,0,0,1,0,Canada,0,aã§aã­ palm berry extract - natural product|placebo,NA
NCT04403828,2020-05-20,6/1/2020,Observational,Impact of COVID-19 on Personal Protection Among Dentist in Egypt,Completed,NA,Fayoum University,NA,https://clinicalzeros.gov/ct2/show/NCT04403828,0,0,0,0,2,0,Egypt,0,questionnaire,NA
NCT04403672,2020-05-18,7/24/2020,Observational [Patient Registry],Performance Evaluation of RealDetectâ„¢ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus,Recruiting,NA,Bangladesh Medical Research Council (BMRC),NA,https://clinicalzeros.gov/ct2/show/NCT04403672,0,0,0,0,1,0,Bangladesh,0,performance evaluation study of realdetect rt-pcr kit for covid-19 detection,NA
NCT04403932,2020-04-17,6/1/2020,Observational,Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency,Completed,NA,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04403932,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04417335,2020-04-16,5/31/2021,Interventional,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Active, not recruiting",Phase 4,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04417335,0,0,0,1,0,0,Netherlands,0,bcg|placebo,NA
NCT04413435,2020-10-30,12/15/2020,Observational,Clinical Characteristics of Critically Ill Patients With COVID-19,Completed,NA,Nevsehir Public Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04413435,0,0,0,0,3,0,Turkey,0,file scanning,NA
NCT04411563,2020-05-21,9/30/2020,Observational [Patient Registry],Epigenetic Tools as Prognostic Predictors in Covid19,Recruiting,NA,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04411563,0,0,0,0,0,0,Turkey,0,taking biological samples,NA
NCT04410536,2020-06-15,12/31/2021,Interventional,Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04410536,0,0,0,0,1,0,Italy,0,symptomatic drugs|bridge therapy|mindfulness,NA
NCT04410107,2020-05-15,12/31/2020,Observational,"Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19",Recruiting,NA,Federal University of Rio Grande do Sul,NA,https://clinicalzeros.gov/ct2/show/NCT04410107,0,0,0,0,0,0,Brazil,0,"lung function tests|exercise|health-related quality of life|respiratory symptoms, symptoms of anxiety/depression,/post-traumatic stress screening|respiratory symptoms, symptoms of anxiety|depression,|post-traumatic stress screening",NA
NCT04408222,2020-04-16,4/30/2021,Observational,Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure,"Active, not recruiting",NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04408222,0,0,0,0,0,1,United States,0,prone positioning,NA
NCT04408209,2020-04-23,8/30/2021,Interventional,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Recruiting,N/A,National and Kapodistrian University of Athens,NA,https://clinicalzeros.gov/ct2/show/NCT04408209,0,0,0,0,4,0,Greece,0,convalescent plasma,NA
NCT04407182,2020-05-04,8/1/2020,Interventional,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Completed,Phase 2,Catalysis SL,NA,https://clinicalzeros.gov/ct2/show/NCT04407182,0,0,0,0,4,0,Ecuador,0,viusid/asbrip|viusid|asbrip,NA
NCT04406844,2020-05-09,6/30/2021,Observational,Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04406844,0,0,0,0,1,0,India,0,"NA",NA
NCT04405973,2020-05-19,9/30/2020,Observational,Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO,Completed,NA,University Hospital Freiburg,NA,https://clinicalzeros.gov/ct2/show/NCT04405973,0,0,0,0,2,0,Germany,0,vv-ecmo,NA
NCT04405869,2020-04-29,4/30/2021,Observational,Thromboembolic Events in Severe COVID-19 Patients,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04405869,0,0,0,0,1,0,France,0,"NA",NA
NCT04404270,2020-05-26,2/28/2021,Observational,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110),Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04404270,0,0,0,0,1,0,France,0,serology test|questionnaire|anti-sars-cov2 serological controls/serum neutralization|anti-sars-cov2 serological controls|serum neutralization,NA
NCT04404244,2020-01-01,1/1/2021,Observational,Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04404244,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04407143,2020-04-15,9/30/2021,Observational,Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection,Recruiting,NA,FundaciÃ³n GECP,NA,https://clinicalzeros.gov/ct2/show/NCT04407143,0,0,0,0,3,0,Spain,0,igg antibody test,NA
NCT04393324,2020-04-24,5/31/2020,Observational [Patient Registry],The Critical Care Response to the COVID-19 Pandemic in Madrid,Recruiting,NA,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04393324,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04407130,2020-06-16,10/30/2020,Interventional,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,Completed,Phase 2,"International Centre for Diarrhoeal Disease Research, Bangladesh",NA,https://clinicalzeros.gov/ct2/show/NCT04407130,0,0,0,0,5,0,Bangladesh,0,ivermectin / doxycycline / placebo|ivermectin / placebo|placebo|ivermectin|doxycycline,NA
NCT04497194,2020-03-01,8/30/2020,Observational [Patient Registry],Registry of COVID-19 Patients at AOUI Verona,Recruiting,NA,Azienda Ospedaliera Universitaria Integrata Verona,NA,https://clinicalzeros.gov/ct2/show/NCT04497194,0,0,0,0,0,0,Italy,0,not applicable (observational study),NA
NCT04421625,2020-06-15,6/15/2022,Interventional,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,Recruiting,N/A,Institut Cancerologie de l'Ouest,NA,https://clinicalzeros.gov/ct2/show/NCT04421625,0,0,0,0,1,0,France,0,diagnostic test for sars-cov2 for patients/health staff|diagnostic test for sars-cov2 for patients|health staff,NA
NCT04435106,2020-04-03,5/1/2020,Observational,Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19),Completed,NA,Shaare Zedek Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04435106,0,0,0,0,0,0,Israel,0,opaganib|standard care,NA
NCT04418206,2020-06-01,12/1/2020,Interventional,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04418206,0,0,0,0,1,0,France,0,patients covid 19,NA
NCT04414319,2020-04-15,4/15/2021,Observational,Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly,Recruiting,NA,University Hospital Center of Martinique,NA,https://clinicalzeros.gov/ct2/show/NCT04414319,0,0,0,0,0,0,France|Guadeloupe|Martinique,0,"NA",NA
NCT04410263,2020-04-09,12/30/2023,Observational,Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04410263,0,0,0,0,0,0,Switzerland,0,"sampling|nose swabs, bronchoalveolar lavage ,urine)",NA
NCT04409197,2020-05-08,6/8/2020,Observational,"Evaluation of Changes in Weight, Sleep, and Other Psycho-behavioural Parameters During Covid-19 Confinement in Subjects Monitored by the RNPC Network",Completed,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04409197,0,0,0,0,1,0,France,0,"NA",NA
NCT04406688,2020-06-22,2/28/2021,Observational,Prediction of Acute Kidney Injury in Patients With COVID-19,Recruiting,NA,University Hospital Muenster,NA,https://clinicalzeros.gov/ct2/show/NCT04406688,0,0,0,0,1,0,Germany|Portugal|Spain|United Kingdom,0,"NA",NA
NCT04405999,2020-05-14,8/9/2020,Interventional,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Completed,Phase 4,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,https://clinicalzeros.gov/ct2/show/NCT04405999,0,0,0,0,1,0,Russian Federation,0,bromhexine hydrochloride,NA
NCT04403269,2020-05-05,5/5/2021,Interventional,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE",Recruiting,Phase 2,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04403269,0,0,0,0,0,0,France,0,igiv,NA
NCT04412382,2020-06-01,12/31/2020,Observational [Patient Registry],Covid-19: Possible Role of Neutrophil Extracellular Traps,Recruiting,NA,Azienda Ospedaliera Universitaria Integrata Verona,NA,https://clinicalzeros.gov/ct2/show/NCT04412382,0,0,0,0,1,0,Italy,0,netosis markers,NA
NCT04402918,2020-05-17,5/19/2020,Interventional,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Recruiting,N/A,Centre Hospitalier Universitaire de Besancon,NA,https://clinicalzeros.gov/ct2/show/NCT04402918,0,0,0,0,0,0,France,0,biological samples,NA
NCT04409899,2020-03-20,6/30/2020,Observational,The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department,"Active, not recruiting",NA,Fundacio Puigvert,NA,https://clinicalzeros.gov/ct2/show/NCT04409899,0,0,0,0,1,0,Spain,0,blood test,NA
NCT04401241,2020-02-01,5/1/2020,Observational,How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department,Completed,NA,Centre Hospitalier Princesse Grace,NA,https://clinicalzeros.gov/ct2/show/NCT04401241,0,0,0,0,0,0,Monaco,0,"NA",NA
NCT04409496,2020-06-02,3/31/2021,Interventional,Chat-based Support for Preventing Smoking Relapse,"Active, not recruiting",N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04409496,0,0,0,0,3,0,Hong Kong,0,chat-based instant messaging support|sms message support|self-help booklet,NA
NCT04408170,2020-06-19,2/28/2021,Observational,Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19),Recruiting,NA,Manchester University NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04408170,0,0,0,0,1,0,United Kingdom,0,point-of-care test for sars-cov-2,NA
NCT04408157,2020-05-20,8/22/2021,Interventional,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,Recruiting,N/A,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04408157,0,0,0,0,3,0,United Kingdom,0,self-management booklet (switch: stay well during covid-19),NA
NCT04406389,2020-10-13,6/30/2021,Interventional,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),Recruiting,Phase 4,Weill Medical College of Cornell University,NA,https://clinicalzeros.gov/ct2/show/NCT04406389,0,0,0,0,4,1,United States,0,enoxaparin|heparin|fondapariniux|argatroban,NA
NCT04405544,2020-05-22,7/22/2020,Interventional,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,N/A,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04405544,0,0,0,0,2,0,Russian Federation,0,ct-scan|eeg|ep|pulse oximetry|blood test,NA
NCT04405310,2020-05-20,11/20/2020,Interventional,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,Completed,Phase 2,Grupo Mexicano para el Estudio de la Medicina Intensiva,NA,https://clinicalzeros.gov/ct2/show/NCT04405310,0,0,0,0,2,0,Mexico,0,convalescent plasma|placebo|albumine,NA
NCT04405284,2020-06-04,6/30/2020,Observational,The Use of Disinfectants Among Women in Egypt and the Toxicity by Bleach During the Coronavirus Lock-down.,Completed,NA,Helwan University,NA,https://clinicalzeros.gov/ct2/show/NCT04405284,0,0,0,0,1,0,Egypt,0,use/exposure to disinfectants during the coronavirus pandemic|use|exposure to disinfectants during the coronavirus pandemic,NA
NCT04405232,2020-05-25,4/25/2021,Observational,Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04405232,0,0,0,0,2,0,United Kingdom,0,non-interventional,NA
NCT04405102,2020-09-16,1/1/2023,Interventional,COVID-19 Ozanimod Intervention Study,Recruiting,Phase 2,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,NA,https://clinicalzeros.gov/ct2/show/NCT04405102,0,0,0,0,2,0,Canada,0,ozanimod|standard care,NA
NCT04414618,2020-07-02,11/26/2020,Interventional,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Active, not recruiting",Phase 2,RedHill Biopharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04414618,0,0,0,0,16,1,United States|Israel,0,opaganib|placebo,NA
NCT04406038,2020-05-27,10/28/2021,Observational,"Study of the Spread of COVID-19 in Saint Petersburg, Russia","Active, not recruiting",NA,European University at St. Petersburg,NA,https://clinicalzeros.gov/ct2/show/NCT04406038,0,0,0,0,5,0,Russian Federation,0,"NA",NA
NCT04397796,2020-08-03,6/30/2021,Interventional,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,Recruiting,Phase 1,"NantKwest, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04397796,0,0,0,0,3,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04457609,2020-07-31,8/31/2020,Interventional,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,Phase 1,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04457609,0,0,0,0,0,0,Indonesia,0,oseltamivir|azithromycin|mesenchymal stem cells,NA
NCT04445259,2020-06-20,5/31/2021,Observational,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury,Recruiting,NA,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04445259,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04444271,2020-05-01,8/30/2020,Interventional,Mesenchymal Stem Cell Infusion for COVID-19 Infection,Recruiting,Phase 2,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04444271,0,0,0,0,3,0,Pakistan,0,mesenchymal stem cells|placebo,NA
NCT04396210,2020-05-14,6/18/2020,Observational,Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic,Completed,NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04396210,0,0,0,0,3,0,Belgium,0,questionnaire,NA
NCT04396353,2020-06-04,10/1/2020,Observational,EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19,Completed,NA,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04396353,0,0,0,0,5,0,Brazil,0,questionnaire,NA
NCT04395859,2020-05-27,12/31/2021,Observational,Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents,Recruiting,NA,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04395859,0,0,0,0,1,0,France,0,questionnaire|data collection up to 1 year,NA
NCT04395781,2020-05-18,12/31/2022,Observational [Patient Registry],Pediatric Acute and Critical Care COVID-19 Registry of Asia,Recruiting,NA,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04395781,0,0,0,0,3,0,China|India|Indonesia|Japan|Malaysia|Pakistan|Singapore,0,"NA",NA
NCT04395768,2020-09-09,9/30/2021,Interventional,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,Recruiting,Phase 2,"National Institute of Integrative Medicine, Australia",NA,https://clinicalzeros.gov/ct2/show/NCT04395768,0,0,0,0,1,0,Australia,0,vitamin c|hydroxychloroquine|azithromycin|zinc citrate|vitamin d|vitamin b,NA
NCT04425317,2020-06-24,6/15/2021,Interventional,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Recruiting,N/A,CRG UZ Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04425317,0,0,0,0,1,0,Belgium,0,blood sample,NA
NCT04395482,2020-05-07,6/15/2021,Observational,Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04395482,0,0,0,0,2,0,Italy|San Marino,0,lung ct scan analysis in covid-19 patients,NA
NCT04394429,2020-04-24,6/24/2021,Observational,Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04394429,0,0,0,0,1,0,France,0,"NA",NA
NCT04394390,2020-05-01,6/15/2020,Observational [Patient Registry],Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?,Enrolling by invitation,NA,Bursa City Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04394390,0,0,0,0,0,0,Turkey,0,vitamin d,NA
NCT04394117,2020-06-19,6/30/2021,Interventional,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Recruiting,Phase 4,The George Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04394117,0,0,0,0,3,0,Australia|India,0,arb|placebo,NA
NCT04394078,2020-05-06,5/18/2020,Observational,Impact of COVID-19 Pandemic on Depression and Quality of Life,Completed,NA,Okan University,NA,https://clinicalzeros.gov/ct2/show/NCT04394078,0,0,0,0,3,0,Turkey,0,online survey,NA
NCT04394013,2020-08-26,10/31/2020,Interventional,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Recruiting,N/A,Monash University Malaysia,NA,https://clinicalzeros.gov/ct2/show/NCT04394013,0,0,0,0,1,0,Malaysia,0,non-mindfulness intervention|mindfulness,NA
NCT04393974,2020-03-24,3/24/2022,Observational,COVID-19 and Cancer Patients,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04393974,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04393818,2020-05-05,8/24/2020,Interventional,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,Completed,Phase 3,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,NA,https://clinicalzeros.gov/ct2/show/NCT04393818,0,0,0,0,3,0,Spain,0,intervention app,NA
NCT04393792,2020-05-31,8/31/2020,Interventional,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Recruiting,Phase 1,Hampshire Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04393792,0,0,0,0,0,0,United Kingdom,0,povidone/iodine|saline,NA
NCT04393038,2020-05-01,12/30/2020,Interventional,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Abivax S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04393038,0,0,0,0,2,0,Belgium|Brazil|France|Germany|Italy|Mexico|Spain|United Kingdom,0,abx464|placebo,NA
NCT04517682,2020-05-21,12/15/2020,Observational,COVID-19 and SARS-CoV-2 Detection in Saliva,Enrolling by invitation,NA,Ambry Genetics,NA,https://clinicalzeros.gov/ct2/show/NCT04517682,0,0,0,0,1,1,United States,0,pcr,NA
NCT04423640,2020-04-15,6/15/2020,Observational,Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19,Recruiting,NA,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04423640,0,0,0,0,1,0,Mexico,0,active covid-19 disease,NA
NCT04416360,2020-05-05,7/31/2020,Interventional,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04416360,0,0,0,0,0,0,France,0,interview by psychologists,NA
NCT04416308,2020-05-29,7/10/2020,Interventional,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04416308,0,0,0,0,1,0,France,0,ng test|blood test|self-questionnary,NA
NCT04414410,2020-05-12,9/30/2020,Observational,Echocardiography in Critically-ill Patients With COVID-19 Pneumonia,Enrolling by invitation,NA,Hospital Ambroise ParÃ© Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04414410,0,0,0,0,0,0,France,0,"NA",NA
NCT04413955,2020-06-01,12/31/2021,Observational [Patient Registry],Registry of SeraphÂ®-100 MicrobindÂ® Affinity Blood Filter for COVID-19 Under EUA,Recruiting,NA,"Children's Hospital Medical Center, Cincinnati",NA,https://clinicalzeros.gov/ct2/show/NCT04413955,0,0,0,0,2,1,United States,0,seraphâ®-100 microbindâ® affinity blood filter,NA
NCT04408339,2020-04-15,4/14/2021,Observational [Patient Registry],COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking,Recruiting,NA,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04408339,0,0,0,0,1,0,Germany,0,no intervention,NA
NCT04413058,2020-04-10,9/10/2020,Observational,Menstrual Cycle Characteristics of Healthcare Professionals,Completed,NA,Haydarpasa Numune Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04413058,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04412473,2020-04-30,6/30/2021,Observational,COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04412473,0,0,0,0,1,0,France,0,"NA",NA
NCT04407286,2020-05-19,8/30/2020,Interventional,Vitamin D Testing and Treatment for COVID 19,Completed,Phase 1,Arizona State University,NA,https://clinicalzeros.gov/ct2/show/NCT04407286,0,0,0,0,2,1,United States,0,vitamin d,NA
NCT04405466,2020-04-22,8/28/2020,Observational,A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers,Recruiting,NA,Miltenyi Biomedicine GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04405466,0,0,0,0,2,0,Germany,0,blood sample|throat swab,NA
NCT04410692,2020-05-15,5/16/2020,Interventional,Can the Prediction Market Improve Predictions of COVID-19?,Completed,N/A,"National University, Singapore",NA,https://clinicalzeros.gov/ct2/show/NCT04410692,0,0,0,0,1,0,Singapore,0,prediction market,NA
NCT04416373,2020-03-22,12/31/2023,Observational,COVID-19 and Pregnancy Outcomes,Recruiting,NA,Universidade Nova de Lisboa,NA,https://clinicalzeros.gov/ct2/show/NCT04416373,0,0,0,0,0,0,Portugal,0,pcr,NA
NCT04410510,2020-09-30,12/31/2020,Interventional,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,Recruiting,Phase 2/Phase 3,Hospital Universitario San Ignacio,NA,https://clinicalzeros.gov/ct2/show/NCT04410510,0,0,0,0,3,0,Colombia,0,p2et (caesalpinia spinosa extract)|placebo,NA
NCT04410159,2020-06-22,6/29/2020,Interventional,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Completed,Phase 2,Universiti Sains Islam Malaysia,NA,https://clinicalzeros.gov/ct2/show/NCT04410159,0,0,0,0,5,0,Malaysia,1,povidone/iodine|essential oils|water,NA
NCT04416256,2020-02-01,2/28/2022,Observational,COVID-19 Pandemic and Worldwide Organ Procurement,Recruiting,NA,Paris Translational Research Center for Organ Transplantation,NA,https://clinicalzeros.gov/ct2/show/NCT04416256,0,0,0,0,0,0,France,0,"NA",NA
NCT04408378,2020-06-05,7/20/2020,Observational,Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients,Recruiting,NA,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04408378,0,0,0,0,0,0,Turkey,0,observation of covid 19 pneumonia,NA
NCT04408365,2020-08-05,5/31/2021,Observational,"Endothelial Function, Inflammation and Organ Dysfunction in COVID-19",Recruiting,NA,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04408365,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04408326,2020-06-01,5/1/2021,Observational,Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,NA,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04408326,0,0,0,0,3,0,United Kingdom,0,angiotensin ii|interleukin,NA
NCT04408248,2020-08-20,5/31/2021,Observational,AKI Biomarkers in Coronavirus(COVID)-19,Recruiting,NA,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04408248,0,0,0,0,4,0,United Kingdom,0,"NA",NA
NCT04407663,2020-03-03,5/4/2020,Observational,"Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near",Completed,NA,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04407663,0,0,0,0,0,0,Italy,0,telehealth,NA
NCT04407273,2020-05-14,8/20/2020,Observational,STATIN THERAPY AND COVID-19 INFECTION,"Active, not recruiting",NA,Institut Investigacio Sanitaria Pere Virgili,NA,https://clinicalzeros.gov/ct2/show/NCT04407273,0,0,0,0,1,0,Spain,0,observational,NA
NCT04407598,2020-05-01,6/8/2020,Observational,COPD in the Time of COVID-19,"Active, not recruiting",NA,University of Leicester,NA,https://clinicalzeros.gov/ct2/show/NCT04407598,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04407585,2020-06-01,5/10/2021,Observational,Testing the Accuracy of a Digital Test to Diagnose Covid-19,Recruiting,NA,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04407585,0,0,0,0,1,0,United Kingdom,0,pcr,NA
NCT04407572,2020-04-20,6/1/2020,Observational,Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04407572,0,0,0,0,1,0,Turkey,0,serum test,NA
NCT04407559,2020-05-01,9/1/2020,Observational,COVID-SErology in Rheumatoid Arthritis (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04407559,0,0,0,0,2,0,France,0,serology test,NA
NCT04407546,2020-05-27,5/28/2022,Observational,Role of Children in Transmission of COVID-19 to Immunocompromised Patients,Recruiting,NA,Jonsson Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04407546,0,0,0,0,3,1,United States,0,"NA",NA
NCT04407533,2020-05-25,8/31/2022,Observational,Dietary Intake and Eating Habits During the COVID-19 Pandemic,Recruiting,NA,McGill University,NA,https://clinicalzeros.gov/ct2/show/NCT04407533,0,0,0,0,1,0,Canada,0,survey|diet tracking|questionnaire,NA
NCT04407494,2020-03-01,4/1/2020,Observational,Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04407494,0,0,0,0,1,0,France,0,"reporting of anosmia, ageusia/other clinical symptoms|reporting of anosmia, ageusia|other clinical symptoms",NA
NCT04407429,2020-05-27,6/27/2021,Observational,Vienna Versus SARS-CoV-2 Virus Study,Recruiting,NA,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04407429,0,0,0,0,0,0,Austria,0,laboratory analyses,NA
NCT04407260,2020-03-06,5/1/2020,Observational,"The Use of Oxygen Hoods as Compared to Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study.",Completed,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04407260,0,0,0,0,2,1,United States,0,oxygen hood,NA
NCT04407195,2020-06-01,6/1/2021,Observational,COVID-19 and Mental Health,"Active, not recruiting",NA,Northeastern University,NA,https://clinicalzeros.gov/ct2/show/NCT04407195,0,0,0,0,2,1,United States,0,exposure,NA
NCT04407117,2017-03-23,4/19/2020,Observational,Appendicitis During the National Lockdown During the COVID-19 Pandemic,Completed,NA,Nordsjaellands Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04407117,0,0,0,0,1,0,Denmark,0,lock-down/social distancing|lock-down|social distancing,NA
NCT04406571,2020-04-01,11/30/2021,Observational,Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04406571,0,0,0,0,0,0,France,0,data record,NA
NCT04412343,2020-05-23,10/5/2020,Interventional,The Seniors COvid-19 Pandemic and Exercise Study,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04412343,0,0,0,0,2,0,Canada,0,virtual group intervention|exercise,NA
NCT04412031,2019-11-11,5/14/2020,Observational,Prediction of Unfavourable Outcome in Newly Covid-19 Hospitalized Patient,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04412031,0,0,0,0,0,0,France,0,no intervention,NA
NCT04412018,2020-06-04,12/31/2020,Interventional,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,Recruiting,Phase 2,Canadian Medical and Surgical Knowledge Translation Research Group,NA,https://clinicalzeros.gov/ct2/show/NCT04412018,0,0,0,0,3,0,Canada,0,icosapent ethyl,NA
NCT04411680,2020-08-18,1/31/2021,Interventional,Study of Sargramostim in Patients With COVID-19,Recruiting,Phase 2,"Partner Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04411680,0,0,0,0,12,1,United States,0,sargramostim|standard care,NA
NCT04411667,2020-04-28,11/1/2020,Interventional,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,"Active, not recruiting",Phase 4,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04411667,0,0,0,0,1,1,United States,0,octagam,NA
NCT04411628,2020-05-28,8/26/2020,Interventional,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,Completed,Phase 1,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04411628,0,0,0,0,10,1,United States,0,ly3819253|placebo,NA
NCT04410484,2020-05-22,8/31/2020,Observational,PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic,"Active, not recruiting",NA,Hull University Teaching Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04410484,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04410471,2020-05-29,5/29/2020,Observational [Patient Registry],Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients,Recruiting,NA,Hospital General Universitario Gregorio MaraÃ±on,NA,https://clinicalzeros.gov/ct2/show/NCT04410471,0,0,0,0,1,0,Spain,0,igm/igg rapid test|igg test|igm,NA
NCT04410458,2020-05-31,5/31/2020,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19 ï¼ˆRepeat Trialï¼‰,Enrolling by invitation,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04410458,0,0,0,0,0,0,China,0,blood donation sms,NA
NCT04410432,2020-09-29,8/31/2021,Observational,Immune Response and Risk of Serious Infection to SARS-Cov2,Recruiting,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04410432,0,0,0,0,4,0,France,0,blood sample,NA
NCT04416139,2020-05-01,4/30/2021,Interventional,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04416139,0,0,0,0,0,0,Mexico,0,mesenchymal stem cells,NA
NCT04433546,2020-07-15,12/2/2020,Interventional,"Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",Terminated,Phase 2,PhaseBio Pharmaceuticals Inc.,Company no longer pursing indication,https://clinicalzeros.gov/ct2/show/NCT04433546,0,0,0,0,7,1,United States,0,pemziviptadil (pb1046)|control,NA
NCT04425213,2020-05-12,5/25/2020,Observational,Obesity and Mortality of Critically Ill Patients With COVID-19,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04425213,0,0,0,0,1,0,France,0,"NA",NA
NCT04412317,2020-06-03,5/30/2021,Observational [Patient Registry],Use of PCR-Sars-CoV-2 in Children,Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04412317,0,0,0,0,1,0,France,0,"NA",NA
NCT04412278,2020-06-01,6/8/2020,Observational,Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers,Completed,NA,Okan University,NA,https://clinicalzeros.gov/ct2/show/NCT04412278,0,0,0,0,1,0,Turkey,0,online survey,NA
NCT04412265,2020-04-16,3/1/2021,Observational,Frailty in Elderly Patients With COVID-19,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04412265,0,0,0,0,3,0,Italy,0,relation between frailty/clinical outcomes in elderly patients with covid-19.|relation between frailty|clinical outcomes in elderly patients with covid-19.,NA
NCT04412239,2020-04-20,12/20/2020,Interventional,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,N/A,Health Science Center of Xi'an Jiaotong University,NA,https://clinicalzeros.gov/ct2/show/NCT04412239,0,0,0,0,1,0,Pakistan,0,patient-centred advice on telephone consultation in tb patients:,NA
NCT04411147,2020-06-17,12/31/2027,Observational,A Longitudinal Study of COVID-19 Sequelae and Immunity,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04411147,0,0,0,0,14,1,United States,0,"NA",NA
NCT04414371,2020-05-20,12/31/2020,Interventional,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04414371,0,0,0,0,0,1,United States,0,yoga,NA
NCT04418609,2020-05-01,4/30/2022,Observational,Neuro-COVID-19: Neurological Complications of COVID-19,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04418609,0,0,0,0,0,0,Switzerland,0,further processing of health data,NA
NCT04412226,2020-06-10,6/30/2020,Observational,Effect of Using Barrier Devices for Intubation in COVID-19 Patients,Completed,NA,Derince Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04412226,0,0,0,0,1,0,Turkey,0,aerosol box|transparent sheet,NA
NCT04448418,2020-05-20,6/20/2020,Observational,The Impact of COVID-19 Outbreak on Trans-population's Health in Italy,"Active, not recruiting",NA,Unita Complessa di Ostetricia e Ginecologia,NA,https://clinicalzeros.gov/ct2/show/NCT04448418,0,0,0,0,1,0,Italy,0,survey,NA
NCT04412486,2020-06-01,5/31/2022,Interventional,COVID-19 Convalescent Plasma (CCP) Transfusion,Recruiting,Early Phase 1,University of Mississippi Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04412486,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04418544,2020-06-01,12/31/2020,Observational,Vocal Feature Analysis Algorithm for COVID-19 Detection,Recruiting,NA,Soniphi LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04418544,0,0,0,0,1,1,United States,0,device used to record voice for screening,NA
NCT04409834,2020-08-05,5/31/2021,Interventional,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,Recruiting,Phase 4,The TIMI Study Group,NA,https://clinicalzeros.gov/ct2/show/NCT04409834,0,0,0,0,2,1,United States,0,unfractionated heparin iv|enoxaparin|clopidogrel|unfractionated heparin sc|kg|sodium,NA
NCT04409743,2020-06-07,5/31/2021,Interventional,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,Recruiting,N/A,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04409743,0,0,0,0,3,1,United States,0,remote cognitive behavioral therapy for insomnia,NA
NCT04409522,2020-05-12,6/5/2020,Interventional,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04409522,0,0,0,0,0,0,"Iran, Islamic Republic of",0,melatonin|standard care,NA
NCT04409509,2020-07-01,1/12/2021,Interventional,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,CSL Behring,NA,https://clinicalzeros.gov/ct2/show/NCT04409509,0,0,0,0,11,1,United States,0,"garadacimab, factor xiia antagonist monoclonal antibody|placebo",NA
NCT04409327,2020-07-11,12/31/2020,Interventional,Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,"Active, not recruiting",Phase 2,Restorbio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04409327,0,0,0,0,4,1,United States,0,rtb101|placebo,NA
NCT04409275,2020-05-21,12/31/2020,Observational,LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION,Recruiting,NA,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04409275,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04409249,2020-03-15,5/25/2020,Observational,Prognosis in Pregnant With COVID-19,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04409249,0,0,0,0,2,0,Turkey,0,"imaging, blood tests",NA
NCT04417270,2020-06-12,11/30/2020,Interventional,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Recruiting,N/A,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04417270,0,0,0,0,3,1,United States,0,freestyle libre 14 day cgm system|accuchek inform ii platform,NA
NCT04408131,2020-05-28,1/27/2021,Interventional,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04408131,0,0,0,0,0,0,France,0,blood sample,NA
NCT04408001,2020-06-04,6/4/2021,Observational,Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04408001,0,0,0,0,1,0,France,0,saliva|clinical interview|blood sample,NA
NCT04407923,2020-05-25,11/25/2020,Observational,Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment,Recruiting,NA,"University Hospital, Brest",NA,https://clinicalzeros.gov/ct2/show/NCT04407923,0,0,0,0,0,0,France,0,"NA",NA
NCT04417257,2020-06-29,4/30/2021,Interventional,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,Recruiting,Phase 2,Laurent Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04417257,0,0,0,0,10,1,United States|Canada,0,placebo|lau-7b,NA
NCT04409262,2020-06-16,2/1/2021,Interventional,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,"Active, not recruiting",Phase 3,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04409262,0,0,0,0,8,1,United States|Brazil|Russian Federation|Spain,0,remdesivir|tocilizumab|placebo,NA
NCT04581070,2020-04-29,10/9/2020,Observational,"The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic""",Terminated,NA,Cancer Trials Ireland,Study stopped due to low accrual,https://clinicalzeros.gov/ct2/show/NCT04581070,0,0,0,0,1,0,Ireland,0,"NA",NA
NCT04416061,2020-05-25,7/31/2020,Observational,The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic,"Active, not recruiting",NA,Hong Kong Sanatorium & Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04416061,0,0,0,0,0,0,Hong Kong,0,covid 19 diagnostic test,NA
NCT04416009,2020-07-05,12/20/2020,Observational [Patient Registry],Extracellular Water in Covid 19 Pneumonia,Recruiting,NA,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04416009,0,0,0,0,0,0,Turkey,0,nä°cas,NA
NCT04415086,2020-06-01,4/20/2022,Interventional,Treatment of Patients With COVID-19 With Convalescent Plasma,Recruiting,Phase 2,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04415086,0,0,0,0,2,0,Brazil,0,convalescent plasma,NA
NCT04414267,2020-05-26,5/25/2021,Interventional,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,Recruiting,Phase 4,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04414267,0,0,0,1,3,0,Greece,0,bcg|placebo,NA
NCT04414124,2020-08-02,2/28/2021,Interventional,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"Active, not recruiting",N/A,Kaleido Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04414124,0,0,0,0,2,1,United States,0,kb109 / self supportive care (ssc)|self supportive care (ssc) alone|kb109|self supportive care (ssc),NA
NCT04413045,2020-05-20,7/28/2020,Observational,"Novel COVID-19, A National Analysis",Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04413045,0,0,0,0,1,0,Egypt,0,prevalence of covid-19,NA
NCT04412785,2020-06-30,4/30/2021,Interventional,Cyclosporine in Patients With Moderate COVID-19,Recruiting,Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04412785,0,0,0,0,2,1,United States,0,cyclosporine,NA
NCT04412772,2020-06-12,12/31/2021,Interventional,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,Recruiting,Phase 3,Queen's Medical Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04412772,0,0,0,0,1,1,United States,0,tocilizumab|placebo,NA
NCT04412746,2020-04-01,6/30/2020,Observational,Covid-19 and Diabetes in West of Algeria,Recruiting,NA,"Laboratoire De Recherche Sur Le Diabete, UniversitÃ© de Tlemcen",NA,https://clinicalzeros.gov/ct2/show/NCT04412746,0,0,0,0,0,0,Algeria,0,management of covid-19,NA
NCT04412551,2020-05-20,12/31/2020,Observational [Patient Registry],Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,Recruiting,NA,"Dalarna County Council, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04412551,0,0,0,0,0,0,Sweden,0,"NA",NA
NCT04412291,2020-06-11,8/31/2020,Interventional,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04412291,0,0,0,0,2,0,Sweden,0,anakinra|tocilizumab|standard care,NA
NCT04412668,2020-06-12,12/21/2020,Interventional,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,Completed,Phase 2,"aTyr Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04412668,0,0,0,0,9,1,United States|Puerto Rico,0,atyr1923|placebo|kg,NA
NCT04427098,2020-05-22,10/30/2020,Interventional,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,Recruiting,Phase 2,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,NA,https://clinicalzeros.gov/ct2/show/NCT04427098,0,0,0,0,1,0,Italy,0,enoxaparin|sodium,NA
NCT04425720,2020-09-01,6/1/2021,Interventional,Use of Remote Monitoring for COVID-19 Patient,Recruiting,N/A,Montefiore Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04425720,0,0,0,0,4,1,United States,0,lifesignals biosensor 1ax*|standard care,NA
NCT04424901,2020-05-03,5/1/2021,Interventional,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,Recruiting,Phase 2,UConn Health,NA,https://clinicalzeros.gov/ct2/show/NCT04424901,0,0,0,0,0,1,United States,0,dipyridamole,NA
NCT04488562,2020-05-08,12/1/2021,Observational [Patient Registry],Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands,Recruiting,NA,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04488562,0,0,0,0,0,0,Netherlands,0,"NA",NA
NCT04420247,2020-04-16,8/20/2020,Interventional,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,Phase 3,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,NA,https://clinicalzeros.gov/ct2/show/NCT04420247,0,0,0,0,2,0,Brazil,0,chloroquine|hydroxychloroquine|standard care,NA
NCT04420182,2020-08-17,6/30/2021,Interventional,COVID-19 Virtual Care at Home,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04420182,0,0,0,0,3,0,Canada,0,virtual care at home,NA
NCT04418947,2020-06-15,7/17/2020,Interventional,Project Resurgence Communication Trial,Completed,N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04418947,0,0,0,0,1,1,United States,0,communication type,NA
NCT04453852,2020-06-30,7/1/2021,Interventional,Monovalent Recombinant COVID19 Vaccine,Recruiting,Phase 1,Vaxine Pty Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04453852,0,0,0,1,0,0,Australia,0,covid19 vaccine|saline,NA
NCT04443075,2020-06-24,8/3/2020,Observational,Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress,Recruiting,NA,First Affiliated Hospital Xi'an Jiaotong University,NA,https://clinicalzeros.gov/ct2/show/NCT04443075,0,0,0,0,2,0,China,0,fecal,NA
NCT04439045,2020-06-24,4/1/2021,Interventional,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,Recruiting,Phase 3,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04439045,0,0,0,0,3,0,Canada,0,vpm1002|placebo,NA
NCT04418375,2020-06-08,2/28/2021,Observational,Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP),Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04418375,0,0,0,0,1,0,France,0,"NA",NA
NCT04418193,2020-04-06,9/1/2020,Observational,Patient Preference Trial for COVID-19 (PPT-COVID),Recruiting,NA,Centre Hospitalier Princesse Grace,NA,https://clinicalzeros.gov/ct2/show/NCT04418193,0,0,0,0,1,0,Monaco,0,NA,NA
NCT04426305,2020-05-21,6/20/2020,Interventional,Community Health Workers Against COVID19,Enrolling by invitation,N/A,University Ghent,NA,https://clinicalzeros.gov/ct2/show/NCT04426305,0,0,0,0,0,0,Belgium,0,community health worker support|care as usual,NA
NCT04425616,2020-06-04,11/30/2021,Interventional,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04425616,0,0,0,0,1,0,United Kingdom,0,exercise|psychological/behaviour change support|nutrition|psychological|behavior,NA
NCT04422509,2020-10-03,8/3/2021,Interventional,Lanadelumab for Treatment of COVID-19 Disease,Recruiting,Phase 1/Phase 2,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04422509,0,0,0,0,2,0,Netherlands,0,lanadelumab|regular care,NA
NCT04421404,2020-06-09,4/30/2021,Interventional,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,"Active, not recruiting",Phase 2,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04421404,0,0,0,0,4,1,United States,0,convalescent plasma|placebo,NA
NCT04420273,2020-07-02,3/30/2021,Interventional,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,"Active, not recruiting",N/A,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04420273,0,0,0,0,2,1,United States,0,sse educational intervention|home sample collection of concerning mole with physician supervision|active control:healthy living,NA
NCT04415151,2020-07-29,3/31/2021,Interventional,Tofacitinib for Treatment of Moderate COVID-19,"Active, not recruiting",Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04415151,0,0,0,0,3,1,United States,0,tofacitinib|placebo,NA
NCT04415060,2020-06-15,6/15/2023,Interventional,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,Recruiting,Phase 3,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04415060,0,0,0,0,4,0,Canada,0,isoflurane inhalant product|sevoflurane,NA
NCT04414657,2020-04-09,4/30/2022,Observational,USZ BioResource COVID,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04414657,0,0,0,0,0,0,Switzerland,0,blood sample,NA
NCT04435457,2020-09-01,6/30/2021,Observational [Patient Registry],Cardiovascular Implications of COVID-19,Recruiting,NA,University of Texas Southwestern Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04435457,0,0,0,0,3,1,United States,0,"NA",NA
NCT04422691,2020-07-01,12/31/2020,Observational,Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection,Recruiting,NA,St. Olavs Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04422691,0,0,0,0,2,0,Norway,0,lung ultrasound,NA
NCT04419623,2020-07-09,7/31/2021,Interventional,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,Recruiting,Phase 1/Phase 2,"Telios Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04419623,0,0,0,0,2,1,United States,0,part 1 - tl-895|part 2 - tl-895|placebo,NA
NCT04422613,2020-05-28,5/31/2021,Interventional,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,"Active, not recruiting",N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04422613,0,0,0,0,1,0,France,0,pulmonary anomalies 4 months after documented covid-19 pneumonia,NA
NCT04422587,2020-03-13,6/5/2020,Observational [Patient Registry],Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea,Completed,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04422587,0,0,0,0,1,0,France,0,recop unit patient,NA
NCT04421664,2020-03-25,8/17/2020,Interventional,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Terminated,Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,Request of Health Canada after publication of https://doi.org/10.7326/M20-4207,https://clinicalzeros.gov/ct2/show/NCT04421664,0,0,0,0,1,1,United States|Canada,0,hydroxychloroquine|placebo,NA
NCT04421508,2020-07-12,12/28/2020,Interventional,A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,"Active, not recruiting",Phase 3,Bellerophon,NA,https://clinicalzeros.gov/ct2/show/NCT04421508,0,0,0,0,11,1,United States,0,inopulse|placebo,NA
NCT04421027,2020-06-12,5/19/2021,Interventional,A Study of Baricitinib (LY3009104) in Participants With COVID-19,Recruiting,Phase 3,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04421027,0,0,0,0,17,1,"United States|Argentina|Brazil|Germany|India|Italy|Japan|Korea, Republic of|Mexico|Puerto Rico|Russian Federation|Spain|United Kingdom",0,baricitinib|placebo,NA
NCT04419025,2020-09-23,1/31/2021,Interventional,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Recruiting,Phase 4,Cambridge Health Alliance,NA,https://clinicalzeros.gov/ct2/show/NCT04419025,0,0,0,0,2,1,United States,0,n-acetylcysteine,NA
NCT04420806,2020-03-14,7/30/2020,Interventional,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Completed,N/A,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicalzeros.gov/ct2/show/NCT04420806,0,0,0,0,3,0,Germany,0,exercise|placebo,NA
NCT04420338,2020-06-05,12/15/2020,Interventional,"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04420338,0,0,0,0,2,0,France,0,blood sample|serum test,NA
NCT04420312,2020-03-01,4/20/2020,Observational,Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms,Completed,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04420312,0,0,0,0,1,0,France,0,"NA",NA
NCT04420299,2020-06-04,3/31/2021,Interventional,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,https://clinicalzeros.gov/ct2/show/NCT04420299,0,0,0,0,1,0,Spain,0,bemiparin,NA
NCT04420286,2020-05-06,6/5/2021,Observational,Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France,Recruiting,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04420286,0,0,0,0,1,0,France,0,"NA",NA
NCT04419870,2021-02-10,5/1/2025,Observational,"Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity During the COVID19 Pandemic",Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04419870,0,0,0,0,154,1,United States,0,"NA",NA
NCT04418518,2020-06-24,6/30/2021,Interventional,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,Recruiting,Phase 3,Weill Medical College of Cornell University,NA,https://clinicalzeros.gov/ct2/show/NCT04418518,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04418505,2020-09-02,3/1/2021,Interventional,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,Recruiting,N/A,Vielight Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04418505,0,0,0,0,4,1,United States|Canada,0,vielight rx plus,NA
NCT04441918,2020-06-05,12/11/2020,Interventional,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects",Recruiting,Phase 1,"Shanghai Junshi Bioscience Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04441918,0,0,0,0,0,0,China,0,monoclonal antibody,NA
NCT04418284,2020-06-05,11/5/2020,Observational,Online Learning of Veterinary Anatomy During COVID-19 Pandemic,Recruiting,NA,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04418284,0,0,0,0,3,0,Egypt,0,questionnaire,NA
NCT04417374,2020-05-01,5/30/2020,Observational,"Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in the Context COVID-19",Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04417374,0,0,0,0,2,0,France,0,description of groups caracteristics,NA
NCT04416438,2020-05-18,12/31/2020,Observational,COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias,Recruiting,NA,French Innovative Leukemia Organisation,NA,https://clinicalzeros.gov/ct2/show/NCT04416438,0,0,0,0,1,0,France,0,"NA",NA
NCT04416334,2020-08-19,8/25/2021,Interventional,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,Recruiting,Phase 3,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,NA,https://clinicalzeros.gov/ct2/show/NCT04416334,0,0,0,0,3,0,Spain,0,colchicine/symptomatic treatment (paracetamol)|symptomatic treatment (paracetamol/best symptomatic treatment based on doctor recommendations)|colchicine|symptomatic treatment (paracetamol)|symptomatic treatment (paracetamol|best symptomatic treatment based on doctor recommendations),NA
NCT04434014,2020-06-08,6/18/2020,Observational,Proper Nutrition And Its Relation To Oral Diseases In Covid -19 Era,Recruiting,NA,October University for Modern Sciences and Arts,NA,https://clinicalzeros.gov/ct2/show/NCT04434014,0,0,0,0,0,0,Egypt,0,proper diet,NA
NCT04427969,2020-06-15,6/25/2020,Observational,Early Prone Position on Coronavirus Disease 2019 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04427969,0,0,0,0,2,0,Turkey,0,prone positioning,NA
NCT04435808,2020-04-14,7/15/2020,Interventional,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Terminated,Phase 1/Phase 2,University of New Mexico,Stopped for futility by DSMB,https://clinicalzeros.gov/ct2/show/NCT04435808,0,0,0,0,2,1,United States,1,hydroxychloroquine,NA
NCT04425889,2020-05-05,5/30/2020,Observational,COVID-19 Antibodies Among Healthcare Workers,Completed,NA,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04425889,0,0,0,0,1,0,Mexico,0,igm/igg rapid test|igg|igm antibodytest,NA
NCT04423289,2020-03-31,5/4/2020,Interventional,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,Completed,N/A,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04423289,0,0,0,0,0,0,Spain,0,farmalarm,NA
NCT04422561,2020-05-31,7/14/2020,Interventional,Prophylactic Ivermectin in COVID-19 Contacts,Completed,Phase 2/Phase 3,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04422561,0,0,0,0,5,0,Egypt,1,ivermectin,NA
NCT04427345,2020-04-30,4/30/2021,Observational,Predictive Factors COVID-19 Patients,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04427345,0,0,0,0,1,0,Italy,0,predictive factors for clinical response in patients with covid-19.,NA
NCT04428021,2020-06-15,6/15/2021,Interventional,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,Recruiting,Phase 2,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,https://clinicalzeros.gov/ct2/show/NCT04428021,0,0,0,0,1,0,Italy,0,standard therapy protocol (stp)|stp / standard plasma (sp)|stp / covid-19 convalescent plasma (cp)|stp|plasma|covid-19 convalescent plasma (cp),NA
NCT04424992,2020-02-28,12/31/2021,Observational,The Natural History of Hospitalized COVID-19 Patients,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04424992,0,0,0,0,1,0,Italy,0,observational cohort study on the natural history of hospitalized sars-cov-2 patients.,NA
NCT04424212,2020-06-10,8/31/2020,Interventional,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,Recruiting,N/A,Linkoeping University,NA,https://clinicalzeros.gov/ct2/show/NCT04424212,0,0,0,0,1,0,Sweden,0,intervention group coronacope,NA
NCT04428008,2021-01-12,4/30/2021,Interventional,Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients,Recruiting,Phase 2,Inova Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04428008,0,0,0,0,5,1,United States,0,thymalfasin,NA
NCT04425915,2020-06-14,5/30/2021,Interventional,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Recruiting,Phase 3,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04425915,0,0,0,0,1,0,India,0,convalescent plasma|standard care,NA
NCT04422873,2020-06-03,1/1/2021,Observational,The Impact of COVID-19 on Dialysis Users,Recruiting,NA,University of Portsmouth,NA,https://clinicalzeros.gov/ct2/show/NCT04422873,0,0,0,0,2,0,United Kingdom,0,"NA",NA
NCT04422444,2020-06-01,5/1/2021,Observational [Patient Registry],Post Intensive Care Syndrome in COVID19 Patients,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04422444,0,0,0,0,1,0,Spain,0,questionnaire,NA
NCT04422769,2020-05-22,3/31/2021,Observational,Needs of Persons With Spinal Cord Injury (SCI),"Active, not recruiting",NA,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04422769,0,0,0,0,2,1,United States,0,"NA",NA
NCT04424771,2020-03-01,6/30/2020,Observational,Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia,Completed,NA,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,NA,https://clinicalzeros.gov/ct2/show/NCT04424771,0,0,0,0,1,0,Italy,0,maslach burnout inventory (mbi),NA
NCT04424082,2020-06-09,11/7/2020,Interventional,External Dead Space in Ventilated COVID-19 Patients,Recruiting,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04424082,0,0,0,0,2,0,Sweden,0,removal of dead space filter,NA
NCT04423692,2020-06-01,8/15/2020,Observational,Knowledge About Covid-19 Infection in Pregnant Women,Recruiting,NA,Aljazeera Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04423692,0,0,0,0,1,0,Egypt,0,labs,NA
NCT04422522,2020-03-15,5/15/2020,Observational,Fibromyalgia During the COVID-19 Pandemic,"Active, not recruiting",NA,Al-Azhar University,NA,https://clinicalzeros.gov/ct2/show/NCT04422522,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04422353,2020-05-01,12/30/2020,Interventional,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Recruiting,N/A,Federal University of Rio Grande do Sul,NA,https://clinicalzeros.gov/ct2/show/NCT04422353,0,0,0,0,1,0,Brazil,0,video dance classes|unsupervised physical activities,NA
NCT04425707,2020-06-09,7/1/2020,Interventional,Ivermectin In Treatment of COVID 19 Patients,Recruiting,N/A,"Ministry of Health and Population, Egypt",NA,https://clinicalzeros.gov/ct2/show/NCT04425707,0,0,0,0,0,0,Egypt,0,ivermectin,NA
NCT04475601,2020-07-15,7/8/2021,Interventional,Enzalutamide Treatment in COVID-19,Recruiting,Phase 2,VÃ¤sterbotten County Council,NA,https://clinicalzeros.gov/ct2/show/NCT04475601,0,0,0,0,0,0,Sweden,0,enzalutamide,NA
NCT04442087,2020-06-19,9/30/2021,Interventional,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04442087,0,0,0,0,2,0,France,0,serology test|data collection,NA
NCT04421391,2020-06-08,11/1/2020,Interventional,QuadraMune(TM) for Prevention of COVID-19,Recruiting,N/A,Therapeutic Solutions International,NA,https://clinicalzeros.gov/ct2/show/NCT04421391,0,0,0,0,0,1,United States,0,quadramune(tm),NA
NCT04420676,2020-09-24,12/31/2021,Interventional,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,Recruiting,N/A,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04420676,0,0,0,0,2,0,Austria,0,omnibiotic aad|placebo,NA
NCT04420637,2020-06-15,12/31/2020,Observational,Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases,Enrolling by invitation,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04420637,0,0,0,0,1,0,Austria,0,"NA",NA
NCT04420416,2020-04-01,7/30/2020,Observational,Mental Health and Academic Performance in COVID-19,Recruiting,NA,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04420416,0,0,0,0,1,0,Mexico,0,questionnaire,NA
NCT04419571,2020-03-23,6/16/2020,Observational,Outcomes in Emergency Laparotomies During COVID-19 Pandemic,Completed,NA,"Barking, Havering and Redbridge University Hospitals NHS Trust",NA,https://clinicalzeros.gov/ct2/show/NCT04419571,0,0,0,0,3,0,United Kingdom,0,emergency laparotomy,NA
NCT04419545,2020-03-24,12/31/2020,Observational,Covid Radiographic Images Data-set for A.I,Recruiting,NA,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,https://clinicalzeros.gov/ct2/show/NCT04419545,0,0,0,0,0,0,Italy,0,neural network diagnosis algorithm,NA
NCT04418245,2020-03-01,6/30/2020,Observational,CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis,"Active, not recruiting",NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04418245,0,0,0,0,0,0,France|Martinique,0,imaging by thoracic scanner,NA
NCT04431453,2020-07-21,2/28/2021,Interventional,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)",Recruiting,Phase 2/Phase 3,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04431453,0,0,0,0,19,1,United States|Italy|Spain|United Kingdom,0,remdesivir,NA
NCT04513990,2020-04-09,4/30/2021,Interventional,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),Recruiting,N/A,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04513990,0,0,0,0,1,1,United States,0,biospecimen collection|biospeciman collection|questionnaire,NA
NCT04426292,2020-05-12,10/23/2020,Interventional,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04426292,0,0,0,0,0,0,Belgium,0,serology test,NA
NCT04427566,2020-07-23,12/31/2021,Interventional,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04427566,0,0,0,0,5,1,United States,0,radiotherapy,NA
NCT04425031,2020-08-25,12/1/2022,Interventional,Handling Oxygenation Targets in COVID-19,Recruiting,Phase 4,Aalborg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04425031,0,0,0,0,2,0,Denmark,0,oxygen,NA
NCT04424797,2020-07-13,12/31/2020,Interventional,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,N/A,Poudre Valley Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04424797,0,0,0,0,1,1,United States,0,prone positioning|supine positioning,NA
NCT04424355,2020-05-19,7/19/2021,Observational,Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.,Recruiting,NA,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,https://clinicalzeros.gov/ct2/show/NCT04424355,0,0,0,0,2,0,Russian Federation,0,chest mri,NA
NCT04426266,2020-05-01,9/28/2020,Observational,Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population,Completed,NA,Szeged University,NA,https://clinicalzeros.gov/ct2/show/NCT04426266,0,0,0,0,2,0,Hungary,0,"NA",NA
NCT04425863,2020-05-01,8/30/2020,Observational,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Completed,NA,Eurnekian Public Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04425863,0,0,0,0,4,0,Argentina,1,"ivermectin 5 mg/ml oral solution, aspirin 250 mg tablets|ivermectin/deamethisone/aspirin|ivermectin/deamethisone/exoparin|ivermectin|ml oral solution, aspirin 250 mg tablets|ml oral solution, dexamethasone 4-mg injection, aspirin 250 mg tablets|ml oral solution, dexamethasone 4-mg injection, enoxaparin injection. inpatient treatment with mechanical ventilation in icu.",NA
NCT04425850,2020-06-01,8/10/2020,Observational,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Completed,NA,Eurnekian Public Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04425850,0,0,0,0,4,0,Argentina,1,iota carrageenan nasal spray/ivermectin oral drops (used as buccal drops)|iota carrageenan nasal spray|ivermectin,NA
NCT04425759,2020-06-08,6/30/2021,Observational [Patient Registry],Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19),Recruiting,NA,Hospital de MatarÃ³,NA,https://clinicalzeros.gov/ct2/show/NCT04425759,0,0,0,0,1,0,Spain,0,blood sample,NA
NCT04425538,2020-06-01,1/22/2021,Interventional,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,"Active, not recruiting",Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04425538,0,0,0,0,1,1,United States,0,infliximab,NA
NCT04425005,2020-05-10,12/7/2020,Interventional,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Completed,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04425005,0,0,0,0,1,0,Brazil,0,exercise,NA
NCT04423315,2020-06-08,7/15/2020,Observational,Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia,Completed,NA,Nisantasi University,NA,https://clinicalzeros.gov/ct2/show/NCT04423315,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04424849,2020-03-15,6/15/2020,Observational,Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients,Recruiting,NA,Tepecik Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04424849,0,0,0,0,0,0,Turkey,0,ct-scan,NA
NCT04424017,2020-06-07,9/30/2020,Observational,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,Recruiting,NA,Egyptian Center for Research and Regenerative Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04424017,0,0,0,0,5,0,Egypt,0,specific anti-sars-cov-2 antibodies,NA
NCT04424004,2020-06-09,6/30/2021,Observational,MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study,"Active, not recruiting",NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04424004,0,0,0,0,2,1,United States,0,pct/serology|pcr|serology test,NA
NCT04423991,2020-03-10,6/4/2020,Interventional,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Completed,N/A,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04423991,0,0,0,0,0,1,United States,0,coviage,NA
NCT04423978,2020-05-04,6/15/2020,Observational,Implications of Covid-19 on the Lifestyle Changes,Completed,NA,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04423978,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04423003,2020-03-01,5/15/2020,Observational [Patient Registry],Endoscopic Interventions in Patients With COVID-19,Completed,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04423003,0,0,0,0,0,0,Germany,0,endoscopic intervention,NA
NCT04422470,2020-06-22,1/22/2021,Observational [Patient Registry],Registry of Patients With Hematologic Disease and COVID-19 in Russia,Recruiting,NA,"National Research Center for Hematology, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04422470,0,0,0,0,2,0,Russian Federation,0,non-interventional study,NA
NCT04422574,2020-05-01,5/1/2020,Observational,COVID 19 Serology in Pulmonologists,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04422574,0,0,0,0,0,0,France,0,"NA",NA
NCT04422340,2020-04-01,8/15/2020,Observational,Senior-COVID-Rea Multicentric Survey,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04422340,0,0,0,0,2,0,France,0,group1,NA
NCT04426695,2020-06-11,4/16/2021,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",Recruiting,Phase 1/Phase 2,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04426695,0,0,0,0,18,1,"United States|Brazil|Chile|Mexico|Moldova, Republic of|Romania",0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,NA
NCT04427735,2019-01-24,7/24/2021,Observational,Effect of Covid-19 Epidemic on Primary PCI in Patients With STEMI,Recruiting,NA,Beijing Friendship Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04427735,0,0,0,0,0,0,China,0,"NA",NA
NCT04458948,2020-03-24,3/24/2021,Interventional,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,"Active, not recruiting",Phase 2,University of New Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04458948,0,0,0,0,0,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04426318,2020-06-14,1/12/2021,Interventional,COVID-19 and the Healthy Minds Program for Educators,Completed,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04426318,0,0,0,0,4,1,United States,0,healthy minds program foundations training,NA
NCT04426279,2020-08-18,2/28/2021,Observational,Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04426279,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04426253,2020-06-05,12/31/2020,Observational,"Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19","Active, not recruiting",NA,Szeged University,NA,https://clinicalzeros.gov/ct2/show/NCT04426253,0,0,0,0,0,0,Hungary,0,"NA",NA
NCT04426006,2020-06-01,6/30/2021,Interventional,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut BergoniÃ© in the Context of the COVID-19 Pandemic,"Active, not recruiting",N/A,Institut BergoniÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04426006,0,0,0,0,1,0,France,0,pro-sero-cov,NA
NCT04425252,2020-08-01,12/29/2020,Interventional,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,Completed,Phase 1/Phase 2,"Clear Creek Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04425252,0,0,0,0,9,1,United States,0,brequinar|standard care,NA
NCT04425044,2020-04-12,5/18/2020,Observational,AiM Covid Self Monitoring,Completed,NA,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04425044,0,0,0,0,0,0,India,0,other,NA
NCT04424446,2020-07-13,6/1/2021,Observational,Saliva as Source of Detection for SARS-CoV-2,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04424446,0,0,0,0,27,1,United States,0,"NA",NA
NCT04445246,2020-05-23,5/31/2021,Interventional,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Recruiting,Phase 2,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04445246,0,0,0,0,0,0,Qatar,0,iloprost,NA
NCT04435275,2021-01-02,3/31/2021,Interventional,Virtual Assistant for COVID-19 PPE,Recruiting,N/A,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04435275,0,0,0,0,1,0,Canada,0,"virtual assistant first, then human coach|human coach first, then virtual assistant",NA
NCT04584541,2020-06-11,7/31/2023,Interventional,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04584541,0,0,0,0,0,0,France,0,blood test|nasopharyngeal swabs|stools,NA
NCT04429724,2020-07-06,4/30/2021,Interventional,Health Professional Exposure Assessment to Covid-19,"Active, not recruiting",N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04429724,0,0,0,0,2,0,France,0,diagnostic test covid-19,NA
NCT04558437,2020-06-12,12/31/2020,Observational,"COVID-Impact ""Psychological IMPACT of Covid-19 on AP-HP Staff""",Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04558437,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04434144,2020-05-02,6/5/2020,Observational [Patient Registry],A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh,Completed,NA,"Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar",NA,https://clinicalzeros.gov/ct2/show/NCT04434144,0,0,0,0,0,0,Bangladesh,0,ivermectin / doxycycline|hydroxychloroquine / azithromycin|ivermectin|doxycycline|hydroxychloroquine|azithromycin,NA
NCT04470258,2020-08-02,9/29/2020,Interventional,Elmo Respiratory Support Project - COVID-19,Recruiting,N/A,Escola de SaÃºde PÃºblica do CearÃ¡,NA,https://clinicalzeros.gov/ct2/show/NCT04470258,0,0,0,0,1,0,Brazil,0,elmo project at covid-19: study in humans|elmo project at covid-19: proof of concept/usability|elmo project at covid-19: proof of concept|usability,NA
NCT04431414,2020-07-20,1/31/2021,Observational,A Study of Immune Responses to the Virus That Causes COVID-19,Recruiting,NA,COVID-19 Prevention Network,NA,https://clinicalzeros.gov/ct2/show/NCT04431414,0,0,0,0,12,1,United States|Argentina|Botswana|Brazil|Kenya|Malawi|Mexico|Mozambique|Peru|South Africa|Tanzania|Zambia|Zimbabwe,0,sample collection,NA
NCT04438239,2020-06-22,12/31/2020,Observational,Rehabilitation Needs After COVID-19 Hospital Treatment,Completed,NA,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04438239,0,0,0,0,2,0,Italy,0,"none, this study is observational",NA
NCT04429555,2021-01-11,6/30/2021,Interventional,"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS",Recruiting,Phase 2,MediciNova,NA,https://clinicalzeros.gov/ct2/show/NCT04429555,0,0,0,0,4,1,United States,0,ibudilast|placebo,NA
NCT04429529,2020-06-09,11/30/2020,Interventional,"Safety of TY027, a Treatment for COVID-19, in Humans","Active, not recruiting",Phase 1,Tychan Pte Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04429529,0,0,0,0,1,0,Singapore,0,ty027|saline,NA
NCT04433078,2020-06-22,1/31/2021,Interventional,RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM,Recruiting,Phase 2,Temple University,NA,https://clinicalzeros.gov/ct2/show/NCT04433078,0,0,0,0,2,1,United States,0,doxycycline|placebo,NA
NCT04429477,2020-05-01,7/15/2020,Observational [Patient Registry],Cerebral Compliance Impairment in COVID-19,Completed,NA,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04429477,0,0,0,0,1,0,Brazil,0,cerebral compliance/hemodynamics monitoring|cerebral compliance|hemodynamics monitoring,NA
NCT04431466,2020-07-01,12/1/2020,Interventional,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Recruiting,Phase 2,Universidade Federal de Sao Carlos,NA,https://clinicalzeros.gov/ct2/show/NCT04431466,0,0,0,0,1,0,Brazil,0,ivermectin|standard care,NA
NCT04434157,2020-03-28,5/5/2020,Observational,Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients,Completed,NA,Hospital Regional de Alta especialidad de Ixtapaluca,NA,https://clinicalzeros.gov/ct2/show/NCT04434157,0,0,0,0,0,0,Mexico,0,"NA",NA
NCT04430023,2020-05-15,6/3/2020,Observational,Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04430023,0,0,0,0,1,0,Turkey,0,epidemiological/demographic characteristics|epidemiological|demographic characteristics,NA
NCT04433949,2020-06-12,5/30/2022,Interventional,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Recruiting,Phase 3,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04433949,0,0,0,0,0,1,United States,0,best available therapy|low,NA
NCT04433754,2020-03-01,6/11/2020,Observational,The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection,Completed,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04433754,0,0,0,0,0,0,Turkey,0,biochemical analysis,NA
NCT04429867,2020-05-07,12/7/2020,Interventional,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",Phase 4,WellStar Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04429867,0,0,0,0,1,1,United States,0,hydroxychloroquine|placebo,NA
NCT04429620,2020-05-30,12/31/2020,Observational,Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method,Recruiting,NA,Szeged University,NA,https://clinicalzeros.gov/ct2/show/NCT04429620,0,0,0,0,1,0,Hungary,0,immunfluorescence,NA
NCT04429594,2020-07-28,7/15/2025,Interventional,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04429594,0,0,0,0,2,0,France,0,blood sample,NA
NCT04433000,2020-03-15,6/10/2020,Observational,Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia,Recruiting,NA,University of Siena,NA,https://clinicalzeros.gov/ct2/show/NCT04433000,0,0,0,0,0,0,Italy,0,butterfly,NA
NCT04432870,2020-06-09,5/30/2021,Observational,Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study,Enrolling by invitation,NA,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04432870,0,0,0,0,2,1,United States,0,"NA",NA
NCT04432324,2020-06-02,2/28/2021,Interventional,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04432324,0,0,0,0,2,0,Spain,0,immune globulin|standard care,NA
NCT04432298,2020-06-20,12/31/2020,Interventional,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease",Recruiting,Phase 2,FibroGen,NA,https://clinicalzeros.gov/ct2/show/NCT04432298,0,0,0,0,2,1,United States,0,pamrevlumab|placebo,NA
NCT04432272,2020-07-16,6/30/2021,Interventional,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),"Active, not recruiting",Phase 2,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04432272,0,0,0,0,3,1,United States,0,convalescent plasma,NA
NCT04427358,2020-05-07,8/7/2020,Observational,RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population,Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04427358,0,0,0,0,1,0,France,0,"NA",NA
NCT04427332,2020-06-11,10/16/2020,Observational,Smell and Taste Disorders in COVID-19 Patients,Completed,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04427332,0,0,0,0,2,0,Italy,0,investigation of smell/taste disorders|investigation of smell|taste,NA
NCT04427267,2020-06-03,6/27/2020,Observational,Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients,Completed,NA,"Federal State Budgetary Scientific Institution ""Izmerov Research Institute of Occupational Health""",NA,https://clinicalzeros.gov/ct2/show/NCT04427267,0,0,0,0,3,0,Russian Federation,0,personal protective equipment from biological hazard,NA
NCT04427176,2020-04-29,5/28/2020,Observational,Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).,Completed,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04427176,0,0,0,0,1,0,France,0,mask,NA
NCT04427137,2020-06-09,6/30/2022,Interventional,Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,Recruiting,N/A,Centre for Addiction and Mental Health,NA,https://clinicalzeros.gov/ct2/show/NCT04427137,0,0,0,0,1,0,Canada,0,"magpro x100 stimulator, b70 fluid-cooled coil",NA
NCT04431284,2020-06-16,12/16/2020,Observational,Impact of COVID-19 Lockdown on Obesity and Eating Behaviors,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04431284,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04431856,2020-05-15,11/17/2020,Interventional,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,N/A,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04431856,0,0,0,0,3,1,United States,0,unified protocol for covid-19 parenting stress (up-covid)|shg,NA
NCT04430049,2020-06-22,10/22/2021,Observational,"Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients",Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04430049,0,0,0,0,3,0,France,0,covid icu containment measures,NA
NCT04623255,2020-10-16,10/15/2021,Interventional,Randomised Study of Plasma Exchange in Severe COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04623255,0,0,0,0,0,0,United Kingdom,0,octaplas,NA
NCT04431180,2020-06-13,6/13/2020,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Enrolling by invitation,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04431180,0,0,0,0,0,0,China,0,blood donation sms,NA
NCT04441502,2020-03-30,9/30/2021,Observational,Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic,Recruiting,NA,IRCCS Policlinico S. Donato,NA,https://clinicalzeros.gov/ct2/show/NCT04441502,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04434248,2020-04-23,7/31/2020,Interventional,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Active, not recruiting",Phase 2/Phase 3,Chromis LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04434248,0,0,0,0,0,0,Russian Federation,0,favipiravir|standard care,NA
NCT04434118,2020-03-20,12/30/2021,Observational,Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients,Enrolling by invitation,NA,Sadat City University,NA,https://clinicalzeros.gov/ct2/show/NCT04434118,0,0,0,0,4,0,Egypt,0,antirheumatic drugs,NA
NCT04447222,2020-05-12,7/21/2021,Observational,Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04447222,0,0,0,0,0,1,United States,0,quality-of-life assessment|questionnaire,NA
NCT04445272,2020-05-22,12/23/2020,Interventional,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,Completed,Phase 2,Fundacion SEIMC-GESIDA,NA,https://clinicalzeros.gov/ct2/show/NCT04445272,0,0,0,0,1,0,Spain,0,tocilizumab,NA
NCT04435353,2020-03-22,12/31/2020,Interventional,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Recruiting,N/A,Astana Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04435353,0,0,0,0,0,0,Kazakhstan,0,vibrolung,NA
NCT04433039,2020-05-22,6/12/2020,Observational,COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising,Completed,NA,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04433039,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04435717,2020-05-04,8/4/2020,Interventional,Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),Recruiting,Phase 2,Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04435717,0,0,0,0,0,0,Spain,0,tocilizumab 20 mg/ml intravenous solution [actemra]_#1|tocilizumab 20 mg/ml intravenous solution [actemra]_#1 (2 doses)|tocilizumab|ml intravenous solution [actemra]_#1|ml intravenous solution [actemra]_#1 (2 doses),NA
NCT04432948,2020-05-15,8/31/2020,Observational,Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.,Recruiting,NA,General and Maternity Hospital of Athens Elena Venizelou,NA,https://clinicalzeros.gov/ct2/show/NCT04432948,0,0,0,0,0,0,Greece,0,phq-9 depression scale|gad-7 general anxiety disorder scale|questionnaire,NA
NCT04456010,2020-06-01,7/30/2020,Observational,COVID-19 in ART: Perception and Experience,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04456010,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04451694,2020-04-01,7/30/2020,Observational,Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19,Recruiting,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04451694,0,0,0,0,0,0,France,0,nutritional intervention,NA
NCT04432051,2020-05-26,8/8/2020,Interventional,The Use of Lung Ultrasonography in COVID-19 Patients,Recruiting,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04432051,0,0,0,0,2,0,Turkey,0,mechanical ventilation|position,NA
NCT04431869,2020-08-18,7/31/2022,Observational [Patient Registry],In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers,Recruiting,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04431869,0,0,0,0,2,1,United States,0,"NA",NA
NCT04438967,2020-06-16,12/31/2021,Observational,Brain Health in the Time of COVID-19,Recruiting,NA,Miro Health,NA,https://clinicalzeros.gov/ct2/show/NCT04438967,0,0,0,0,3,1,United States,0,"NA",NA
NCT04430374,2020-06-02,12/31/2020,Observational [Patient Registry],Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04430374,0,0,0,0,1,0,Qatar,0,no intervention,NA
NCT04430322,2020-03-01,12/31/2020,Observational,Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study,Recruiting,NA,Centre Hospitalier RÃ©gional Metz-Thionville,NA,https://clinicalzeros.gov/ct2/show/NCT04430322,0,0,0,0,1,0,France,0,"NA",NA
NCT04430062,2020-05-01,5/20/2020,Observational,Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital,Completed,NA,Azienda Socio Sanitaria Territoriale di Lodi,NA,https://clinicalzeros.gov/ct2/show/NCT04430062,0,0,0,0,1,0,Italy,0,surgical procedures performed under general anesthesia,NA
NCT04437342,2020-06-30,8/30/2020,Observational,Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia,Completed,NA,General and Maternity Hospital of Athens Elena Venizelou,NA,https://clinicalzeros.gov/ct2/show/NCT04437342,0,0,0,0,5,0,Greece,0,questionnaire|gad-7 (general anxiety disorder) scale|epds (edinburgh postnatal depression scale),NA
NCT04459975,2020-04-01,10/31/2020,Observational,Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04459975,0,0,0,0,0,0,France,0,non interventional study,NA
NCT04437121,2020-04-30,5/24/2020,Observational,Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece,Completed,NA,University of Thessaly,NA,https://clinicalzeros.gov/ct2/show/NCT04437121,0,0,0,0,0,0,Greece,0,survey|lifestyle habits,NA
NCT04436484,2020-04-29,2/19/2021,Observational,Immune Biomarkers of Outcome From COVID-19,Recruiting,NA,University Hospital Plymouth NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04436484,0,0,0,0,2,0,United Kingdom,0,blood sample,NA
NCT04435587,2020-07-13,6/30/2021,Interventional,Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,Recruiting,Phase 4,Mahidol University,NA,https://clinicalzeros.gov/ct2/show/NCT04435587,0,0,0,0,2,0,Thailand,0,ivermectin pill|combined art/hydroxychloroquine|combined art|hydroxychloroquine,NA
NCT04435327,2020-08-17,4/30/2021,Observational,Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19),Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04435327,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04435119,2020-03-15,5/15/2020,Observational,Covid-19 and Vitamin D in Nursing-home,Completed,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04435119,0,0,0,0,0,0,France,0,"NA",NA
NCT04431908,2020-06-15,9/1/2020,Observational,Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects,Recruiting,NA,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04431908,0,0,0,0,1,1,United States,0,olfactory device,NA
NCT04435080,2020-03-15,6/11/2020,Observational,Physical Rehabilitation in ICU in ARDS Patients With COVID-19,Completed,NA,KoÃ§ University,NA,https://clinicalzeros.gov/ct2/show/NCT04435080,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04435028,2019-01-14,8/13/2019,Observational,Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy,Completed,NA,Horus University,NA,https://clinicalzeros.gov/ct2/show/NCT04435028,0,0,0,0,0,0,Egypt,0,ketotifen,NA
NCT04435795,2020-09-14,2/25/2021,Interventional,Inhaled Ciclesonide for Outpatients With COVID19,Recruiting,Phase 2/Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04435795,0,0,0,0,1,0,Canada,0,normal saline intranasal,NA
NCT04435223,2020-04-07,5/7/2020,Observational,Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen,Completed,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04435223,0,0,0,0,1,0,France,0,biological assays in particular on the lipid metabolism,NA
NCT04434261,2020-05-11,12/31/2020,Observational,Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2,"Active, not recruiting",NA,Instituto Brasileiro de Controle do Cancer,NA,https://clinicalzeros.gov/ct2/show/NCT04434261,0,0,0,0,2,0,Brazil,0,pcr,NA
NCT04435379,2020-06-18,9/30/2021,Interventional,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,"Active, not recruiting",Phase 3,Vakzine Projekt Management GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04435379,0,0,0,0,11,0,Germany,0,vpm1002|placebo,NA
NCT04433364,2020-06-02,6/2/2021,Observational [Patient Registry],COPE - COVID-19 in Pregnancy and Early Childhood,Recruiting,NA,"Sahlgrenska University Hospital, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04433364,0,0,0,0,0,0,Sweden,0,questionnaire|interview,NA
NCT04432922,2020-11-01,11/15/2020,Observational,"Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection",Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04432922,0,0,0,0,4,0,France,0,hospitalized patients for covid-19 infection,NA
NCT04432805,2020-06-15,6/15/2021,Interventional,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04432805,0,0,0,0,0,0,France,0,performing of lung ultrasound,NA
NCT04432779,2020-05-25,6/30/2024,Observational,Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children,Recruiting,NA,Centre Hospitalier Universitaire Saint Pierre,NA,https://clinicalzeros.gov/ct2/show/NCT04432779,0,0,0,0,2,0,Belgium,0,no intervention,NA
NCT04435522,2020-10-01,12/31/2020,Interventional,Maraviroc in Patients With Moderate and Severe COVID-19,Completed,Phase 1,Rhode Island Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04435522,0,0,0,0,3,1,United States,0,maraviroc,NA
NCT04624997,2020-06-08,12/31/2020,Observational,Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04624997,0,0,0,0,0,0,France,0,biological samples,NA
NCT04499677,2020-09-24,12/11/2020,Interventional,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04499677,0,0,0,0,2,0,United Kingdom,0,favipiravir|lopinavir/ ritonavir|placebo|lopinavir|ritonavir,NA
NCT04497948,2020-09-21,11/18/2020,Interventional,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,Terminated,Phase 1,Acerta Pharma BV,"Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19
    did not meet their primary efficacy endpoints.

    Based on this higher management made the decision to prematurely terminate the D822FC00005 PK
    study.",https://clinicalzeros.gov/ct2/show/NCT04497948,0,0,0,0,2,1,Brazil|United States,0,acalabrutinib,NA
NCT04448782,2020-03-09,6/30/2020,Observational,Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation,Completed,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04448782,0,0,0,0,1,0,Spain,0,asynchronies detection,NA
NCT04447131,2020-04-29,6/30/2021,Observational,Effect of COVID-19 on Platelet Aggregation,Recruiting,NA,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04447131,0,0,0,0,1,0,Brazil,0,venipuncture in peripheral vein,NA
NCT04447209,2020-06-06,12/31/2020,Observational,Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study,Recruiting,NA,University of Malaya,NA,https://clinicalzeros.gov/ct2/show/NCT04447209,0,0,0,0,0,0,Malaysia,0,"dietary counselling on food groups according to iyc feeding practices, who",NA
NCT04447781,2020-07-15,2/22/2022,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19",Recruiting,Phase 1/Phase 2,International Vaccine Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04447781,0,0,0,1,1,0,"Korea, Republic of",0,ino-4800|cellectraâ® 2000|saline-sodium citrate (ssc) buffer,NA
NCT04445194,2020-06-22,10/22/2020,Interventional,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04445194,0,0,0,1,3,0,China,0,recombinant new coronavirus vaccine (cho cell) low-dose group|recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,NA
NCT04442958,2020-05-15,6/15/2020,Interventional,Effectiveness of Convalescent Immune Plasma Therapy,Completed,N/A,Bagcilar Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04442958,0,0,0,0,1,0,Turkey,0,convalescent plasma,NA
NCT04442230,2020-10-10,2/28/2021,Interventional,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),Recruiting,Phase 2,"Altimmune, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04442230,0,0,0,0,4,1,United States,0,nasovax|placebo,NA
NCT04444609,2020-06-18,6/30/2021,Observational,PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04444609,0,0,0,0,1,0,United Kingdom,0,"blood tests sputum, nasal lavage/brushing|blood tests sputum, nasal lavage|brushing",NA
NCT04443712,2020-05-29,6/1/2021,Observational,Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19),Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04443712,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04438694,2020-06-01,5/31/2021,Interventional,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,Phase 1/Phase 2,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04438694,0,0,0,0,1,0,Egypt,0,convalescent plasma|standard care,NA
NCT04439071,2020-07-09,7/31/2021,Interventional,A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19),Recruiting,Phase 2/Phase 3,PTC Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04439071,0,0,0,0,4,1,United States|Australia|Brazil|Spain,0,ptc299|standard care|placebo,NA
NCT04439006,2020-07-22,12/31/2021,Interventional,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04439006,0,0,0,0,3,1,United States,0,best available therapy|ibrutinib,NA
NCT04438954,2020-05-05,6/5/2020,Observational,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels",Completed,NA,Ankara Yildirim BeyazÄ±t University,NA,https://clinicalzeros.gov/ct2/show/NCT04438954,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04438941,2020-03-25,6/20/2020,Observational,Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04438941,0,0,0,0,1,0,France,0,"NA",NA
NCT04438057,2020-08-12,8/12/2020,Interventional,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,Phase 2,Metro Infectious Disease Consultants,NA,https://clinicalzeros.gov/ct2/show/NCT04438057,0,0,0,0,2,1,United States,0,ccp,NA
NCT04437823,2020-06-01,5/31/2021,Interventional,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,Phase 2,Jinnah Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04437823,0,0,0,0,0,0,Pakistan,0,mesenchymal stem cells,NA
NCT04437719,2020-06-29,12/29/2021,Interventional,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",Recruiting,N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04437719,0,0,0,0,2,0,France,0,obvio-19 app,NA
NCT04437706,2020-12-11,6/30/2022,Observational,Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling,Enrolling by invitation,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04437706,0,0,0,0,6,1,United States,0,"NA",NA
NCT04441476,2020-04-21,7/31/2021,Observational,Ethical and Psychological Support for Health Care Professions in Intensive Care Units in the COVID19 Pandemic Context: Adequacy With Needs and Psychological Impact Crisis and Post-crisis,"Active, not recruiting",NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04441476,0,0,0,0,1,0,France,0,questionnaire|psychological/sociological interviews|psychological|interview,NA
NCT04440007,2020-10-09,3/31/2021,Interventional,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04440007,0,0,0,0,6,1,United States,0,abivertinib|standard care,NA
NCT04438863,2020-08-08,9/1/2021,Observational,Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19,Recruiting,NA,Sheba Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04438863,0,0,0,0,2,0,Israel,0,home spirometry,NA
NCT04587375,2020-03-01,5/1/2020,Observational,Diagnosis of Endocrine Dysfunctions in Covid-19,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04587375,0,0,0,0,0,0,France,0,"NA",NA
NCT04459351,2020-06-19,5/31/2023,Observational,PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs,Recruiting,NA,Chelsea and Westminster NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04459351,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04450004,2020-07-10,9/20/2021,Interventional,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","Active, not recruiting",Phase 1,Medicago,NA,https://clinicalzeros.gov/ct2/show/NCT04450004,0,0,0,1,3,0,Canada,0,intramuscular vaccine,NA
NCT04449276,2020-06-18,12/31/2021,Interventional,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","Active, not recruiting",Phase 1,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04449276,0,0,0,1,3,0,Belgium|Germany,0,cvncov vaccine|placebo,NA
NCT04442152,2020-06-30,8/31/2020,Interventional,Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,Enrolling by invitation,N/A,"Promundo, United States",NA,https://clinicalzeros.gov/ct2/show/NCT04442152,0,0,0,0,0,0,Rwanda,0,mencare//bandebereho fathers'/couples' group education|mencare|NA|bandebereho fathers'|couples' group education,NA
NCT04442048,2020-06-25,12/31/2021,Interventional,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,Recruiting,Phase 3,Canadian Cancer Trials Group,NA,https://clinicalzeros.gov/ct2/show/NCT04442048,0,0,0,0,8,0,Canada,0,imm-101|observation,NA
NCT04441996,2020-07-17,2/28/2021,Interventional,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,"Active, not recruiting",Phase 4,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04441996,0,0,0,0,2,1,United States,0,therapeutic plasma exchange (tpe)|standard care,NA
NCT04490811,2020-04-09,12/31/2021,Observational,Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children,Recruiting,NA,HÃ´pital Necker-Enfants Malades,NA,https://clinicalzeros.gov/ct2/show/NCT04490811,0,0,0,0,0,0,France,0,no intervention,NA
NCT04444596,2020-06-17,3/31/2021,Interventional,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,N/A,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04444596,0,0,0,0,0,0,Austria,0,conjunctival swab/nasopharyngeal swab|conjunctival swab|nasopharyngeal swab,NA
NCT04443881,2020-05-08,12/31/2020,Interventional,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),Recruiting,Phase 2/Phase 3,Fundacion Miguel Servet,NA,https://clinicalzeros.gov/ct2/show/NCT04443881,0,0,0,0,0,0,Spain,0,anakinra|ml prefilled syringe [kineret],NA
NCT04443673,2020-08-20,2/28/2021,Interventional,Glycine Supplement for Severe COVID-19,Recruiting,N/A,Instituto Nacional de Enfermedades Respiratorias,NA,https://clinicalzeros.gov/ct2/show/NCT04443673,0,0,0,0,2,0,Mexico,0,glycine,NA
NCT04442789,2020-05-20,12/31/2021,Observational,Sequelae of Sars-CoV-2 Infections,Recruiting,NA,University of Giessen,NA,https://clinicalzeros.gov/ct2/show/NCT04442789,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04466683,2020-08-28,12/31/2021,Interventional,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04466683,0,0,0,0,1,1,United States,0,radiotherapy|high dose radiation 100 cgy,NA
NCT04446169,2020-06-27,9/1/2020,Observational,COVID-19 (SARS-CoV-2) in Urine and Semen,"Active, not recruiting",NA,University of Florence,NA,https://clinicalzeros.gov/ct2/show/NCT04446169,0,0,0,0,4,0,Italy,0,pcr|semen qualitative analysis|questionnaire|interleukin,NA
NCT04441710,2020-10-27,4/30/2022,Observational [Patient Registry],Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04441710,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04441632,2020-06-15,7/26/2020,Interventional,Effect of Positive Attitudes on Behavior and Wellness,Completed,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04441632,0,0,0,0,1,1,United States,0,positive feedback,NA
NCT04441385,2020-06-26,11/30/2020,Interventional,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,Recruiting,Phase 2,Hospital Universitario Infanta Leonor,NA,https://clinicalzeros.gov/ct2/show/NCT04441385,0,0,0,0,1,0,Spain,0,maraviroc|standard care,NA
NCT04440098,2020-04-22,5/11/2020,Observational,Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology,Completed,NA,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04440098,0,0,0,0,0,1,United States,0,"NA",NA
NCT04443257,2020-07-08,7/25/2021,Observational,REassessement After Hospitalization for Sars-COV-2 disordER,Enrolling by invitation,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04443257,0,0,0,0,3,0,France,0,assessment of the sequelae after hospitalization for sars-cov-2,NA
NCT04452682,2020-05-25,6/21/2020,Observational,The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice,Completed,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04452682,0,0,0,0,0,0,Egypt,0,covid 19 impact,NA
NCT04444557,2020-04-17,5/1/2020,Observational,Effect of COvid-19 on Mental Health in Syrian and Turkish Maintenance HemoDialysis Patients: COST-HD Study,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04444557,0,0,0,0,0,0,Turkey,0,beck depression inventory (bdi),NA
NCT04438993,2020-05-29,10/31/2020,Observational,The COVID-19 Disease and CARdiac Events Study,Recruiting,NA,NHS Lanarkshire,NA,https://clinicalzeros.gov/ct2/show/NCT04438993,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04462120,2020-06-16,6/18/2020,Observational,IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study,"Active, not recruiting",NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04462120,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04473274,2020-05-21,11/1/2020,Interventional,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,Phase 4,Samaritan Health Services,NA,https://clinicalzeros.gov/ct2/show/NCT04473274,0,0,0,0,2,1,United States,0,pioglitazone,NA
NCT04448405,2020-06-18,10/1/2020,Observational,Covid-19 Lockdown and Deviant Sexual Fantasies,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04448405,0,0,0,0,2,0,France,0,questionnaire,NA
NCT04468308,2020-09-08,3/31/2021,Observational,VRQOL in Cataract Patients During the COVID-19 Pandemic,Recruiting,NA,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04468308,0,0,0,0,1,0,Austria,0,questionnaire,NA
NCT04459533,2020-06-01,6/1/2020,Observational,Sparing in Neuromuscular Blockade in COVID 19 ICU,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04459533,0,0,0,0,0,0,France,0,tof protocol,NA
NCT04445506,2020-04-01,5/31/2020,Observational,Short Term Corticosteroids in SARS-CoV2 Patients,Completed,NA,The Miriam Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04445506,0,0,0,0,0,1,United States,0,dexamethasone,NA
NCT04445454,2020-06-12,9/30/2022,Interventional,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,Phase 1/Phase 2,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04445454,0,0,0,0,0,0,Belgium,0,mesenchymal stem cells,NA
NCT04445389,2020-06-17,3/17/2021,Interventional,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults",Recruiting,Phase 1/Phase 2,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04445389,0,0,0,1,2,0,"Korea, Republic of",0,gx-19|saline,NA
NCT04445311,2020-05-31,7/30/2020,Interventional,Ivermectin in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04445311,0,0,0,0,0,0,Egypt,0,ivermectin,NA
NCT04453384,2020-09-01,12/31/2020,Interventional,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,Recruiting,Phase 2,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04453384,0,0,0,0,2,0,France,0,xav-19|placebo,NA
NCT04444310,2020-06-15,6/18/2020,Observational [Patient Registry],Antibody Responses in Contacts of COVID-19 Patients,"Active, not recruiting",NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04444310,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04449978,2020-04-09,6/30/2022,Observational,TARGet Kids! COVID-19 Study of Children and Families,Recruiting,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04449978,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04449783,2020-06-25,8/25/2020,Observational,Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery,Recruiting,NA,Liverpool University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04449783,0,0,0,0,1,0,United Kingdom,0,pre-operative screening|telephone consult,NA
NCT04449042,2020-04-01,12/31/2025,Observational [Patient Registry],The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry,Recruiting,NA,Boston Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04449042,0,0,0,0,0,1,United States,0,airway management during sedation/general anesthesia|airway management during sedation|general anesthesia,NA
NCT04448769,2020-06-26,7/24/2020,Interventional,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Completed,N/A,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04448769,0,0,0,0,3,0,France,0,anti-sars-cov-2 igt seropositivity,NA
NCT04448054,2020-05-20,11/20/2021,Observational,"Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas",Recruiting,NA,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04448054,0,0,0,0,2,0,France,0,mri,NA
NCT04447235,2020-07-23,12/31/2020,Interventional,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,Recruiting,Phase 2,Instituto do Cancer do Estado de SÃ£o Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04447235,0,0,0,0,1,0,Brazil,0,placebo|ivermectin|losartan,NA
NCT04447469,2020-07-27,2/28/2021,Interventional,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,Recruiting,Phase 2/Phase 3,"Kiniksa Pharmaceuticals, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04447469,0,0,0,0,5,1,United States|Brazil|Chile|Peru|South Africa,0,mavrilimumab|placebo,NA
NCT04447404,2020-09-21,9/30/2021,Interventional,"DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury",Recruiting,Phase 2,Durect,NA,https://clinicalzeros.gov/ct2/show/NCT04447404,0,0,0,0,2,1,United States,0,dur-928|placebo,NA
NCT04447144,2020-06-01,8/1/2020,Observational,"Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome",Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04447144,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04446338,2020-05-13,6/30/2020,Observational,Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04446338,0,0,0,0,0,0,Germany,0,antibody test,NA
NCT04446377,2020-07-15,3/31/2021,Interventional,A Study of LAM-002A for the Prevention of Progression of COVID-19,Recruiting,Phase 2,"AI Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04446377,0,0,0,0,2,1,United States,0,apilimod dimesylate|placebo,NA
NCT04446286,2020-06-18,8/18/2020,Observational,Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04446286,0,0,0,0,2,0,France,0,"NA",NA
NCT04445870,2020-05-01,12/31/2020,Observational,Oncology Care Pathway's Modifications Impact During COVID-19 Pandemic : the ONCOCARE-COV Study,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04445870,0,0,0,0,1,0,France,0,data record,NA
NCT04466839,2020-07-02,12/18/2020,Observational,Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients,Completed,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04466839,0,0,0,0,2,0,France,0,questionnaire/interview|questionnaire|interview,NA
NCT04466306,2020-04-15,7/8/2020,Observational [Patient Registry],Pediatric Acute Kidney Injury in COVID-19,Enrolling by invitation,NA,Children's Healthcare of Atlanta,NA,https://clinicalzeros.gov/ct2/show/NCT04466306,0,0,0,0,0,1,United States|Canada|Israel|Japan|Serbia|Spain|United Kingdom,0,"NA",NA
NCT04445597,2020-05-07,12/31/2022,Interventional,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,Recruiting,N/A,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04445597,0,0,0,0,1,0,Belgium,0,sampling,NA
NCT04457817,2020-12-01,7/31/2021,Interventional,Compensatory Reserve Index (CRI) for Management of COVID-19,Enrolling by invitation,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04457817,0,0,0,0,3,1,United States,0,cri management,NA
NCT04445441,2020-04-24,9/3/2020,Observational,An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso,Completed,NA,Centre Muraz,NA,https://clinicalzeros.gov/ct2/show/NCT04445441,0,0,0,0,2,0,Burkina Faso,0,"NA",NA
NCT04445428,2020-07-15,9/30/2021,Interventional,OPV as Potential Protection Against COVID-19,Enrolling by invitation,Phase 4,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04445428,0,0,0,1,3,0,Guinea-Bissau,0,oral polio vaccine / information|information|oral polio vaccine,NA
NCT04445402,2020-04-30,5/1/2021,Observational [Patient Registry],Pediatrics HOT COVID-19 Database in NY Tristate,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04445402,0,0,0,0,0,1,United States,0,"NA",NA
NCT04445376,2020-07-03,9/10/2020,Interventional,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Completed,N/A,Government College University Faisalabad,NA,https://clinicalzeros.gov/ct2/show/NCT04445376,0,0,0,0,6,0,Pakistan,0,exercise,NA
NCT04445233,2020-04-29,6/30/2021,Observational,COVID-19 Household Transmission Study,"Active, not recruiting",NA,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04445233,0,0,0,0,1,1,United States,0,"NA",NA
NCT04445220,2020-11-19,2/28/2021,Interventional,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,Recruiting,Phase 1/Phase 2,"Sentien Biotechnologies, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04445220,0,0,0,0,4,1,United States,0,sbi-101,NA
NCT04444700,2020-07-04,11/30/2020,Interventional,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04444700,0,0,0,0,1,0,Brazil,0,anticoagulation,NA
NCT04444401,2020-06-15,6/15/2021,Observational,Registry on NEN Patients and COVID-19,Recruiting,NA,European Institute of Oncology,NA,https://clinicalzeros.gov/ct2/show/NCT04444401,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04446429,2020-09-15,12/24/2020,Interventional,Anti-Androgen Treatment for COVID-19,Completed,N/A,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04446429,0,0,0,0,7,0,Brazil,1,proxalutamide|standard care,NA
NCT04516486,2020-03-09,5/24/2020,Observational,Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients,"Active, not recruiting",NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04516486,0,0,0,0,0,0,France,0,retrospective metagenomics on clinical samples collected during hospitalization,NA
NCT04456361,2020-04-16,10/15/2020,Interventional,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",Early Phase 1,Instituto de Medicina Regenerativa,NA,https://clinicalzeros.gov/ct2/show/NCT04456361,0,0,0,0,1,0,Mexico,0,mesenchymal stem cells,NA
NCT04452487,2020-06-01,6/30/2021,Observational,Study of the Consequences of Infection on Compliance of Modalities of Decisions of Limitations and Stops of Treatments (COVID-19-LAT),Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04452487,0,0,0,0,0,0,France,0,decisions of limitations/stop processing|decisions of limitations|stop processing,NA
NCT04448145,2020-03-26,3/1/2021,Observational,Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04448145,0,0,0,0,0,1,United States,0,"NA",NA
NCT04448119,2020-10-16,3/31/2021,Interventional,Control of COVID-19 Outbreaks in Long Term Care,Recruiting,Phase 2,Appili Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04448119,0,0,0,0,2,0,Canada,0,favipiravir|placebo,NA
NCT04447638,2020-03-20,6/1/2020,Observational,Percutaneous Tracheostomy With COVID-19,Completed,NA,Ã‡anakkale Onsekiz Mart University,NA,https://clinicalzeros.gov/ct2/show/NCT04447638,0,0,0,0,1,0,Turkey,0,tracheostomy with aerosol box in covid-19 positive patients,NA
NCT04452422,2020-06-23,9/23/2020,Observational,Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04452422,0,0,0,0,0,0,France,0,"NA",NA
NCT04450017,2020-04-06,7/31/2020,Observational,Clinical Features of Severe Patients With COVID-19,Recruiting,NA,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04450017,0,0,0,0,0,0,Russian Federation,0,"the demographic, clinical, laboratory,/instrumental data|the demographic, clinical, laboratory,|data",NA
NCT04493307,2020-06-30,2/28/2021,Observational,The Evaluation of Hemostasis in Hospitalized COVID-19 Patients,Recruiting,NA,LifeBridge Health,NA,https://clinicalzeros.gov/ct2/show/NCT04493307,0,0,0,0,2,1,United States,0,phlebotomy,NA
NCT04453657,2021-02-28,9/30/2021,Interventional,"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19",Enrolling by invitation,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04453657,0,0,0,0,8,1,United States,0,familychildcare (provisional name of app),NA
NCT04458363,2020-07-04,9/1/2020,Interventional,Convalescent Plasma in Pediatric COVID-19,Completed,Early Phase 1,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04458363,0,0,0,0,1,1,United States,0,convalescent plasma|standard care,NA
NCT04452630,2020-06-23,7/23/2020,Observational,Cardiovascular Consequences After COVID-19,Recruiting,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04452630,0,0,0,0,0,0,France,0,infectious disease/cardiology clinical consultations|infectious disease|cardiology clinical consultations,NA
NCT04452617,2020-03-19,4/8/2020,Observational,Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19,Completed,NA,Institut Mutualiste Montsouris,NA,https://clinicalzeros.gov/ct2/show/NCT04452617,0,0,0,0,1,0,France,0,"NA",NA
NCT04452565,2020-10-15,12/31/2020,Interventional,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",Recruiting,Phase 2/Phase 3,"NeuroActiva, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04452565,0,0,0,0,4,1,United States,0,na-831|na-831/atazanavir|na-831/dexamethasone|atazanavir/dexamethasone|atazanavir|dexamethasone,NA
NCT04455815,2020-09-25,8/31/2021,Interventional,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,Recruiting,Phase 2/Phase 3,Cancer Research UK,NA,https://clinicalzeros.gov/ct2/show/NCT04455815,0,0,0,0,5,0,United Kingdom,0,camostat,NA
NCT04452318,2020-07-13,6/15/2021,Interventional,COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,Recruiting,Phase 3,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04452318,0,0,0,0,13,1,"United States|Moldova, Republic of|Romania",0,regn10933 / regn10987|placebo|regn10933|regn10987,NA
NCT04451317,2020-06-12,8/31/2021,Observational,Physical Activity Following the Containment Period Imposed by the COVID-19 Pandemic in Patients,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04451317,0,0,0,0,2,0,France,0,"questionnaire, phone call",NA
NCT04453527,2020-05-28,5/31/2021,Observational,The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19,Recruiting,NA,Portsmouth Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04453527,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04453501,2020-03-02,4/25/2020,Observational,Anti Infective Agents Impact in COVID-19 Pneumonia,Completed,NA,Centre d'Investigation Clinique et Technologique 805,NA,https://clinicalzeros.gov/ct2/show/NCT04453501,0,0,0,0,0,0,France,0,favorable outcome,NA
NCT04452773,2020-07-14,9/30/2020,Interventional,Clinical Trial to Evaluate the Efficacy of Food Supplement ManremycÂ® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,Recruiting,N/A,Reig Jofre Group,NA,https://clinicalzeros.gov/ct2/show/NCT04452773,0,0,0,0,2,0,Spain,0,manremyc|placebo,NA
NCT04449588,2020-07-23,8/7/2021,Interventional,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,Recruiting,Phase 2/Phase 3,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04449588,0,0,0,0,1,0,Bangladesh|China|India|Indonesia|Spain,0,"bdb-001 injection|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules",NA
NCT04451993,2020-06-25,9/1/2020,Observational,Physical Activity Level in Patients With OSAS During Covid-19 Pandemic,Completed,NA,Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04451993,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04451577,2020-06-01,6/1/2021,Observational,"Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection",Recruiting,NA,Istituto Clinico Humanitas,NA,https://clinicalzeros.gov/ct2/show/NCT04451577,0,0,0,0,0,0,Italy,0,no intervention,NA
NCT04450277,2020-04-01,5/31/2020,Observational [Patient Registry],Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic,Completed,NA,Khoo Teck Puat Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04450277,0,0,0,0,1,0,Singapore,0,emergency surgery,NA
NCT04449094,2020-02-28,3/30/2020,Observational,Emergence of the COVID 19 Epidemic in the City of Nice,Completed,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04449094,0,0,0,0,0,0,France,0,"NA",NA
NCT04449081,2020-04-25,6/10/2020,Observational,"Knowledge, Attitude and Practice of Dental Students About COVID-19",Completed,NA,Melaka Manipal Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04449081,0,0,0,0,1,0,Malaysia,0,"knowledge, attitude, practice, awareness, preference",NA
NCT04448704,2020-06-22,10/11/2020,Observational,Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak,Completed,NA,Yale-NUS College,NA,https://clinicalzeros.gov/ct2/show/NCT04448704,0,0,0,0,3,0,Singapore,0,"NA",NA
NCT04525742,2020-07-05,8/30/2020,Interventional,COVID-19 Pandemic and Parents of Disabled Children,Completed,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04525742,0,0,0,0,1,0,Turkey,0,difficulties lived by disabled children's parents in the period of covid-19 pandemic,NA
NCT04448756,2020-07-29,6/6/2021,Interventional,Study of M5049 in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia,Recruiting,Phase 2,EMD Serono,NA,https://clinicalzeros.gov/ct2/show/NCT04448756,0,0,0,0,7,1,United States|Brazil,0,m5049|placebo,NA
NCT04469621,2020-07-17,10/23/2020,Interventional,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,Completed,Phase 1,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04469621,0,0,0,0,9,0,Argentina|Brazil|Chile|Mexico|Russian Federation,0,sar443122|placebo,NA
NCT04464408,2020-07-23,12/31/2020,Interventional,Favipiravir Therapy in Adults With Mild COVID-19,Recruiting,Phase 2/Phase 3,King Abdullah International Medical Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04464408,0,0,0,0,1,0,Saudi Arabia,0,favipiravir|placebo,NA
NCT04464486,2020-04-21,3/31/2021,Interventional,Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,Enrolling by invitation,N/A,University of Utah,NA,https://clinicalzeros.gov/ct2/show/NCT04464486,0,0,0,0,0,1,United States,0,sch intervention,NA
NCT04463264,2020-06-26,11/15/2020,Interventional,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),Recruiting,Phase 2/Phase 3,Laboratorios Roemmers S.A.I.C.F.,NA,https://clinicalzeros.gov/ct2/show/NCT04463264,0,0,0,0,3,0,Argentina,0,nitazoxanide|placebo,NA
NCT04611243,2020-05-22,5/21/2022,Observational,"Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19",Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04611243,0,0,0,0,0,0,Hong Kong,0,kaletra/beta interferon|kaletra|beta interferon,NA
NCT04497779,2020-07-13,8/21/2021,Observational,Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma,Recruiting,NA,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04497779,0,0,0,0,1,1,United States,0,biospecimen collection|biospeciman collection|diagnostic laboratory biomarker analysis|electronic health record review|questionnaire,NA
NCT04474249,2020-06-25,12/31/2022,Observational,Follow-up of Critical COVID-19 Patients,Recruiting,NA,Uppsala University,NA,https://clinicalzeros.gov/ct2/show/NCT04474249,0,0,0,0,1,0,Sweden,0,"NA",NA
NCT04460664,2020-08-14,1/31/2021,Observational,Coagulation Changes Associated With COVID-19 Infection,Enrolling by invitation,NA,HemoSonics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04460664,0,0,0,0,1,1,United States,0,quantra system,NA
NCT04469153,2020-06-29,9/1/2020,Observational,Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04469153,0,0,0,0,0,0,France,0,no intervention|evaluation of the ferritin|glycosylated ferritin by standard approved serological tests,NA
NCT04463628,2020-05-15,11/30/2020,Observational,"Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic",Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04463628,0,0,0,0,0,0,France,0,questionnaire|interview,NA
NCT04460170,2020-07-01,2/1/2022,Observational [Patient Registry],COVID-19 Follow up Intensive Care Studies,Recruiting,NA,University Medical Center Groningen,NA,https://clinicalzeros.gov/ct2/show/NCT04460170,0,0,0,0,1,0,Netherlands,0,"NA",NA
NCT04457388,2020-03-25,6/15/2020,Interventional,Tele-Yoga Therapy for Chronic Pain,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04457388,0,0,0,0,2,0,United Kingdom,0,tele-yoga,NA
NCT04457349,2020-07-25,12/29/2020,Interventional,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Recruiting,N/A,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04457349,0,0,0,0,4,0,Egypt,0,therapeutic plasma exchange (tpe),NA
NCT04459455,2020-08-19,10/15/2020,Interventional,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,N/A,Stony Brook University,NA,https://clinicalzeros.gov/ct2/show/NCT04459455,0,0,0,0,2,1,United States,0,remain covid free ssi|contain covid anxiety ssi,NA
NCT04458298,2020-07-01,1/31/2021,Interventional,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,Recruiting,Phase 2,"Orpheris, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04458298,0,0,0,0,4,1,United States,0,op-101|placebo,NA
NCT04456933,2020-06-29,12/31/2021,Observational,Intracorporeal Anastomosis in Laparoscopic Left Colectomy. Cohort Comparative Study,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04456933,0,0,0,0,2,0,Spain,0,extracorporeal left hemicolectomy anastomosis|intracorporeal left hemicolectomy anastomosis,NA
NCT04452695,2020-03-10,8/3/2020,Observational,Acceptability of Telehealth Triage Using Robotic Systems in COVID-19,Completed,NA,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04452695,0,0,0,0,2,1,United States,0,doctor spot,NA
NCT04456595,2020-07-21,9/30/2021,Interventional,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,Recruiting,Phase 3,Butantan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04456595,0,0,0,1,3,0,Brazil,0,adsorbed covid-19 (inactivated) vaccine|placebo,NA
NCT04456556,2020-04-27,6/20/2020,Observational,Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19),Completed,NA,Minia University,NA,https://clinicalzeros.gov/ct2/show/NCT04456556,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04456452,2020-07-27,9/8/2020,Interventional,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,Phase 1,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04456452,0,0,0,0,5,1,United States,0,ampion|standard care,NA
NCT04456413,2020-11-06,11/30/2021,Interventional,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,Recruiting,Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04456413,0,0,0,0,2,1,United States,0,convalescent plasma|best supportive care,NA
NCT04456153,2020-07-22,5/31/2021,Interventional,Atovaquone for Treatment of COVID-19,Recruiting,Phase 2,University of Texas Southwestern Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04456153,0,0,0,0,4,1,United States,0,experimental group|placebo,NA
NCT04456101,2020-06-19,12/1/2020,Observational,"Study on the Recovery of Pulmonary Function, Chest CT, Hematologic, and Immune & Inflammatory Conditions in COVID-19 Rehabilitation Patients",Recruiting,NA,"Wuhan Union Hospital, China",NA,https://clinicalzeros.gov/ct2/show/NCT04456101,0,0,0,0,1,0,China,0,"NA",NA
NCT04456062,2020-08-04,3/31/2021,Interventional,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,Recruiting,N/A,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04456062,0,0,0,0,2,0,Canada,0,caring contacts,NA
NCT04456036,2020-07-01,12/31/2020,Observational [Patient Registry],Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care,Recruiting,NA,UniversitÃ  Politecnica delle Marche,NA,https://clinicalzeros.gov/ct2/show/NCT04456036,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04455308,2020-07-21,10/19/2020,Interventional,COVID-19 and Chilblains,Completed,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04455308,0,0,0,0,2,0,France,0,biological samples,NA
NCT04454333,2020-06-03,6/18/2020,Observational,COVID-19 in Pain Perspective,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04454333,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04453514,2020-07-21,10/31/2020,Interventional,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Recruiting,N/A,National University of Natural Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04453514,0,0,0,0,1,1,United States,0,trauma-informed yoga video recording,NA
NCT04453280,2020-05-18,6/3/2020,Observational,Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity),Completed,NA,Institute of Health Information and Statistics of the Czech Republic,NA,https://clinicalzeros.gov/ct2/show/NCT04453280,0,0,0,0,0,0,Czechia,0,quantitative analysis of anti-sars-cov-2-antibodies|rapid test,NA
NCT04482673,2020-07-31,12/31/2021,Interventional,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,Recruiting,Phase 4,Medical University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04482673,0,0,0,0,1,1,United States,0,vitamin d|placebo,NA
NCT04481516,2020-07-01,12/31/2020,Observational,Yoga in NHS Health Care Workers With COVID-19 Related Stress,Recruiting,NA,Doncaster And Bassetlaw Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04481516,0,0,0,0,0,0,United Kingdom,0,yoga,NA
NCT04461925,2020-05-02,5/2/2021,Interventional,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Recruiting,Phase 1/Phase 2,Institute of Cell Therapy,NA,https://clinicalzeros.gov/ct2/show/NCT04461925,0,0,0,0,0,0,Ukraine,0,mesenchymalÂ stem cells|antibiotics|hormones|anticoagulation|ðžxygen therapy,NA
NCT04460027,2020-06-22,11/30/2020,Interventional,W-SUDs for COVID-19,Completed,Phase 1,"Woebot Labs, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04460027,0,0,0,0,2,1,United States,0,woebot substance use disorder,NA
NCT04458519,2020-07-16,4/30/2021,Interventional,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Recruiting,N/A,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,https://clinicalzeros.gov/ct2/show/NCT04458519,0,0,0,0,3,0,Canada,0,probiorinse|saline,NA
NCT04458246,2020-07-31,12/31/2020,Interventional,Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04458246,0,0,0,0,0,0,Brazil,0,exercise,NA
NCT04457505,2020-05-08,5/31/2021,Observational [Patient Registry],One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19,Recruiting,NA,"Consorcio Centro de InvestigaciÃ³n BiomÃ©dica en Red, M.P.",NA,https://clinicalzeros.gov/ct2/show/NCT04457505,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04456075,2020-04-01,4/30/2022,Observational,Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19,Recruiting,NA,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04456075,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04455451,2020-08-06,12/31/2022,Observational,Intensive Care Therapy of Covid-19 Disease in Germany,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04455451,0,0,0,0,8,0,Germany,0,"NA",NA
NCT04455347,2020-06-15,6/30/2022,Observational [Patient Registry],Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked,Recruiting,NA,Imagine Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04455347,0,0,0,0,0,0,France,0,"NA",NA
NCT04716023,2019-08-23,8/22/2021,Observational,Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04716023,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04521088,2020-07-02,12/31/2020,Observational [Patient Registry],Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic,Recruiting,NA,Wissenschaftliches Institut Bethanien e.V,NA,https://clinicalzeros.gov/ct2/show/NCT04521088,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04485351,2020-07-31,8/31/2020,Observational,Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes,Recruiting,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04485351,0,0,0,0,0,0,France,0,no intervention,NA
NCT04453982,2020-06-21,2/28/2021,Observational,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b,Recruiting,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04453982,0,0,0,0,1,0,Canada,0,human milk donors,NA
NCT04453969,2020-05-24,1/31/2021,Observational,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a,Recruiting,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04453969,0,0,0,0,1,0,Canada,0,covid-19,NA
NCT04453566,2020-05-27,8/24/2020,Observational,"Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.",Recruiting,NA,Uskudar University,NA,https://clinicalzeros.gov/ct2/show/NCT04453566,0,0,0,0,1,0,Turkey,0,online survey,NA
NCT04453475,2020-07-01,7/31/2021,Interventional,Feasibility and Benefits of Digital Services During the COVID19 Pandemic,Recruiting,N/A,Jacobs University Bremen gGmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04453475,0,0,0,0,1,0,Germany,0,training session adressing information/health literacy|training session adressing information|health literacy,NA
NCT04452708,2020-06-11,6/10/2021,Observational,HFNC and NIV for COVID-19 Complicated by Respiratory Failure,Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04452708,0,0,0,0,0,0,Hong Kong,0,oxygen,NA
NCT04452435,2020-07-21,10/13/2020,Interventional,Safety and Efficacy of C21 in Subjects With COVID-19,Completed,Phase 2,Vicore Pharma AB,NA,https://clinicalzeros.gov/ct2/show/NCT04452435,0,0,0,0,4,0,India|United Kingdom,0,c21|placebo,NA
NCT04451889,2020-08-01,7/1/2021,Interventional,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,N/A,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04451889,0,0,0,0,1,0,Russian Federation,0,miniprobe alveoflex,NA
NCT04452669,2020-09-15,5/1/2021,Interventional,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,Recruiting,Phase 2,Aerogen Pharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04452669,0,0,0,0,3,1,United States,0,ventaprost (inhaled epoprostenol delivered via a dedicated delivery system),NA
NCT04467112,2020-07-30,10/31/2020,Observational,Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols,Recruiting,NA,Owlstone Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04467112,0,0,0,0,3,0,United Kingdom,0,breath biopsy face masks with removable filters/fitted pva strip|breath biopsy face masks with removable filters|fitted pva strip,NA
NCT04465604,2020-07-01,11/1/2020,Interventional,Hypertonic Saline for COVID-19 Symptoms,Recruiting,N/A,King Faisal Specialist Hospital & Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04465604,0,0,0,0,0,0,Saudi Arabia,0,wearing surgical face mask sprayed with hypertonic saline,NA
NCT04463849,2020-06-30,12/30/2020,Interventional,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,N/A,University of Milan,NA,https://clinicalzeros.gov/ct2/show/NCT04463849,0,0,0,0,0,0,Italy,0,stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by covid-19 infection,NA
NCT04461379,2020-07-21,1/1/2021,Interventional,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Active, not recruiting",Phase 3,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04461379,0,0,0,1,3,0,Mexico,0,bcg|placebo,NA
NCT04465656,2020-07-07,10/31/2020,Observational,Registry of the Evolution of Diagnosed and/or Hospitalized Patients for Pulmonary Embolism During the Covid-19 Pandemic,Recruiting,NA,"Hospital St. Joseph, Marseille, France",NA,https://clinicalzeros.gov/ct2/show/NCT04465656,0,0,0,0,1,0,France,0,serology test for covid-19,NA
NCT04460703,2020-07-03,7/8/2020,Interventional,"COVID-19 Vaccine Messaging, Part 1",Completed,N/A,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04460703,0,0,0,1,1,1,United States,0,control message|baseline message|personal freedom message|economic freedom message|self-interest message|community interest message|economic benefit message|guilt message|embarrassment message|anger message|trust in science message|not bravery message,NA
NCT04460651,2020-08-14,1/31/2021,Interventional,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,Recruiting,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,NA,https://clinicalzeros.gov/ct2/show/NCT04460651,0,0,0,0,1,0,Argentina,0,icosapent ethyl (ipe)|placebo,NA
NCT04460534,2020-05-07,7/31/2021,Interventional,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Recruiting,N/A,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,https://clinicalzeros.gov/ct2/show/NCT04460534,0,0,0,0,0,0,France,0,diagnostic,NA
NCT04459689,2020-03-15,3/31/2022,Observational [Patient Registry],COVID-19 in PID Survey,Recruiting,NA,Imagine Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04459689,0,0,0,0,0,0,France,0,"NA",NA
NCT04467918,2020-07-06,11/16/2020,Interventional,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Active, not recruiting",Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04467918,0,0,0,0,5,0,Brazil,0,cannabidiol|placebo,NA
NCT04466540,2020-05-12,1/28/2021,Interventional,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 4,Hospital AlemÃ£o Oswaldo Cruz,NA,https://clinicalzeros.gov/ct2/show/NCT04466540,0,0,0,0,1,0,Brazil,0,hydroxychloroquine|placebo,NA
NCT04465474,2020-05-01,4/30/2022,Observational [Patient Registry],"Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)",Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04465474,0,0,0,0,3,0,China|Hong Kong|Spain,0,non intervention,NA
NCT04457726,2020-07-01,3/31/2021,Interventional,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,Phase 1/Phase 2,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04457726,0,0,0,0,1,0,Singapore,0,sars-cov-2 specific t cells,NA
NCT04457570,2020-06-15,12/15/2020,Observational,Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04457570,0,0,0,0,0,0,France,0,mortality,NA
NCT04459403,2020-06-08,12/30/2020,Observational,Psychiatric Disturbances and COVID-19 Infection,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04459403,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04505761,2020-08-01,1/1/2021,Interventional,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19",Recruiting,N/A,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04505761,0,0,0,0,1,0,Netherlands,0,virtual reality,NA
NCT04470869,2020-06-12,4/12/2021,Interventional,Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04470869,0,0,0,0,0,0,France,0,phone call,NA
NCT04460274,2019-12-31,6/15/2020,Observational,Forecast Number of Covid-19 Cases Worldwide,Completed,NA,Turkish Ministry of Health Izmir Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04460274,0,0,0,0,1,0,Turkey,0,model building|model validation,NA
NCT04460183,2020-07-29,1/27/2021,Interventional,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,Recruiting,Phase 2/Phase 3,Thirty Respiratory Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04460183,0,0,0,0,4,0,United Kingdom,0,"resp301, a nitric oxide generating solution|standard care",NA
NCT04459676,2020-07-31,10/31/2020,Interventional,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,Recruiting,Phase 2,Angion Biomedica Corp,NA,https://clinicalzeros.gov/ct2/show/NCT04459676,0,0,0,0,3,0,Brazil,0,standard care|ang-3777|placebo,NA
NCT04459364,2020-06-01,7/7/2020,Observational [Patient Registry],The Prevalence of Pulmonary Hypertension in Patients With COVID-19.,Completed,NA,Attgeno AB,NA,https://clinicalzeros.gov/ct2/show/NCT04459364,0,0,0,0,1,0,Sweden,0,"NA",NA
NCT04459325,2020-06-01,7/20/2020,Interventional,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,Phase 3,AO GENERIUM,NA,https://clinicalzeros.gov/ct2/show/NCT04459325,0,0,0,0,1,0,Russian Federation,0,tigeraseâ®/best available care|best available therapy|tigeraseâ®,NA
NCT04459312,2020-06-01,7/10/2020,Observational,National Covid-19 Surveillance Physicians,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",NA,https://clinicalzeros.gov/ct2/show/NCT04459312,0,0,0,0,1,0,Germany,0,serology test,NA
NCT04459962,2020-06-29,1/7/2021,Interventional,Covid-19 Breath Test,Completed,N/A,Ancon Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04459962,0,0,0,0,1,0,United Kingdom,0,breath test/cheek swab|breath test|cheek swab,NA
NCT04463420,2020-08-15,11/15/2020,Interventional,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04463420,0,0,0,0,2,0,"Iran, Islamic Republic of",0,phr160 spray|placebo|standard care,NA
NCT04514627,2020-07-13,7/31/2021,Interventional,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,N/A,Olive View-UCLA Education & Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04514627,0,0,0,0,1,1,United States,0,auricular percutaneous neurostimulation,NA
NCT04461340,2020-08-15,10/30/2020,Interventional,Efficacy and Safety of Sirolimus in COVID-19 Infection,Recruiting,Phase 2,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04461340,0,0,0,0,3,0,Egypt,0,sirolimus,NA
NCT04460469,2020-07-01,9/30/2020,Observational,Anxiety Level and Oral Hygiene Practice in Dental Students During Covid-19 Pandemic,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04460469,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04460443,2020-08-01,8/1/2021,Interventional,Sofosbuvir in Treatment of COVID 19,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04460443,0,0,0,0,2,0,Egypt,0,sofosbuvir|sofosbuvir ledipsavir|daclatasvir,NA
NCT04468139,2020-06-20,7/20/2020,Interventional,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,Phase 4,"Ministry of Health, Saudi Arabia",NA,https://clinicalzeros.gov/ct2/show/NCT04468139,0,0,0,0,0,0,Saudi Arabia,0,quercetin|bromelain|zinc|vitamin c,NA
NCT04459520,2020-07-23,7/28/2020,Interventional,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04459520,0,0,0,0,2,1,United States,0,no intervention|unavailable covid test result - hypothetical scenario,NA
NCT04459390,2020-07-20,10/20/2020,Observational,Association of Comorbidities With COVID19,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04459390,0,0,0,0,1,0,Egypt,0,pcr,NA
NCT04522037,2020-06-01,9/30/2020,Observational,Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04522037,0,0,0,0,0,0,France,0,no intervention|compare the difference in respiratory rate between h0|h12 of the initiation of morphine between the control|interventional groups,NA
NCT04469179,2020-08-20,9/30/2020,Interventional,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19",Recruiting,Phase 1,"SAb Biotherapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04469179,0,0,0,0,1,1,United States,0,sab-185|saline,NA
NCT04479540,2020-05-26,5/26/2021,Interventional,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04479540,0,0,0,0,1,0,France,0,angiography scanner,NA
NCT04475484,2020-06-10,12/31/2020,Observational,Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04475484,0,0,0,0,0,0,France,0,online survey,NA
NCT04467931,2020-01-19,10/21/2020,Observational,ACEI or ARB and COVID-19 Severity and Mortality in US Veterans,"Active, not recruiting",NA,University of Utah,NA,https://clinicalzeros.gov/ct2/show/NCT04467931,0,0,0,0,1,1,United States,0,ace inhibitor/arb|non-acei/arb|ace inhibitor|arb|non-acei,NA
NCT04466462,2020-05-26,6/30/2020,Observational,Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel,Completed,NA,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04466462,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04466098,2020-07-30,12/1/2021,Interventional,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),Recruiting,Phase 2,"Masonic Cancer Center, University of Minnesota",NA,https://clinicalzeros.gov/ct2/show/NCT04466098,0,0,0,0,2,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04466085,2020-07-12,10/22/2020,Interventional,Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 2,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04466085,0,0,0,1,2,0,China,0,recombinant new coronavirus vaccine (cho cell) low-dose group|recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,NA
NCT04465058,2020-07-08,8/8/2020,Observational,Characteristics of Critically Ill COVID 19 Patients,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04465058,0,0,0,0,0,0,Egypt,0,covid-19,NA
NCT04463862,2020-06-04,9/4/2020,Observational [Patient Registry],COVID - AirPollution,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04463862,0,0,0,0,1,0,Belgium|France,0,"NA",NA
NCT04463758,2020-05-11,2/28/2022,Observational,Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04463758,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04463472,2020-06-29,9/28/2020,Interventional,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"Active, not recruiting",Phase 1/Phase 2,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04463472,0,0,0,1,3,0,Japan,0,ag0301-covid19,NA
NCT04468386,2020-07-07,3/30/2021,Observational,Specimen Collection Study Protocol,"Active, not recruiting",NA,Biomerica,NA,https://clinicalzeros.gov/ct2/show/NCT04468386,0,0,0,0,3,1,United States,0,"NA",NA
NCT04476914,2020-06-29,12/31/2020,Observational,Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU,Recruiting,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04476914,0,0,0,0,2,1,United States,0,"NA",NA
NCT04473053,2020-07-03,7/3/2021,Interventional,Rapid Experimental Medicine for COVID-19,Recruiting,Phase 2/Phase 3,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04473053,0,0,0,0,1,0,United Kingdom,0,standard care|nafamostat mesilate|td139,NA
NCT04460690,2020-07-13,7/31/2021,Interventional,"Rapid, Onsite COVID-19 Detection",Enrolling by invitation,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04460690,0,0,0,0,4,1,United States,0,rapid test,NA
NCT04460677,2020-08-12,3/31/2021,Interventional,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04460677,0,0,0,0,4,1,United States,0,emotional support plan|daily monitoring,NA
NCT04460638,2020-07-23,7/31/2022,Observational,SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04460638,0,0,0,0,2,0,France,0,saliva|clinical assessment,NA
NCT04460599,2020-03-08,7/30/2020,Observational,Neurological Features During COVID19,Recruiting,NA,Centre d'Investigation Clinique et Technologique 805,NA,https://clinicalzeros.gov/ct2/show/NCT04460599,0,0,0,0,1,0,France,0,observation,NA
NCT04460196,2020-07-08,9/18/2020,Observational [Patient Registry],Healthcare Renunciation During the Confinement Period in Connection With the COVID-19 Epidemic in Adult Emergency Departments,Completed,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04460196,0,0,0,0,2,0,France,0,questionnaire,NA
NCT04460014,2020-09-30,3/1/2021,Interventional,Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,Recruiting,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04460014,0,0,0,0,4,0,Sweden,0,simple cognitive task intervention|placebo,NA
NCT04471636,2020-09-18,2/28/2021,Interventional,Telemedicine in Outpatient Covid-19 Patients,Recruiting,N/A,Ludwig-Maximilians - University of Munich,NA,https://clinicalzeros.gov/ct2/show/NCT04471636,0,0,0,0,1,0,Germany,0,withings scanwatch,NA
NCT04466241,2020-11-27,3/26/2021,Interventional,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,Recruiting,Phase 2/Phase 3,French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS),NA,https://clinicalzeros.gov/ct2/show/NCT04466241,0,0,0,0,3,0,CÃ´te D'Ivoire,0,lopinavir/ritonavir 200 mg-50 mg oral tablet|telmisartan 40mg oral tablet|atorvastatin 20 mg oral tablet|lopinavir|ritonavir 200 mg-50 mg oral tablet,NA
NCT04470999,2020-04-15,9/30/2020,Interventional,Changes in Cellular Immune Profile During COVID-19 Infection,Recruiting,N/A,Seraph Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04470999,0,0,0,0,2,1,United States,0,leukapheresis,NA
NCT04470544,2020-07-28,9/15/2022,Interventional,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,Recruiting,Phase 2,Academic and Community Cancer Research United,NA,https://clinicalzeros.gov/ct2/show/NCT04470544,0,0,0,0,3,1,United States,0,camostat mesilate|standard care,NA
NCT04474236,2020-05-27,2/27/2021,Observational,Lung Ultrasound for COVID-19 Initial Triage and Monitoring,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04474236,0,0,0,0,0,0,France,0,thoracic lung ultrasound,NA
NCT04468802,2020-02-01,6/30/2020,Observational,Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04468802,0,0,0,0,1,0,Turkey,0,case fatality rate,NA
NCT04468412,2020-07-14,9/30/2021,Observational,Influence of COVID-19 on Vascular Endothelial Function,"Active, not recruiting",NA,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04468412,0,0,0,0,2,0,Netherlands,0,carotid artery reactivity testing,NA
NCT04468256,2020-07-26,7/31/2022,Observational,The Heart Hive COVID-19 Study,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04468256,0,0,0,0,1,0,United Kingdom,0,covid-19 experience surveys,NA
NCT04468217,2020-06-02,9/15/2020,Observational,Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR,Recruiting,NA,Neurognos,NA,https://clinicalzeros.gov/ct2/show/NCT04468217,0,0,0,0,0,0,Chile,0,"obtainment of nasopharyngeal, oropharyngeal, buccal, nasal/saliva samples|obtainment of nasopharyngeal, oropharyngeal, buccal, nasal|saliva",NA
NCT04468009,2020-06-25,1/19/2021,Interventional,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Recruiting,Phase 2,Hospital de Infecciosas Francisco Javier Muniz,NA,https://clinicalzeros.gov/ct2/show/NCT04468009,0,0,0,0,4,0,Argentina,0,convalescent plasma,NA
NCT04467840,2020-08-21,2/28/2021,Interventional,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,RedHill Biopharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04467840,0,0,0,0,20,0,Brazil|Colombia|Israel|Italy|Mexico|Poland|Russian Federation,0,opaganib|placebo,NA
NCT04467008,2020-07-15,8/15/2020,Observational,Covid-19 Rapid Diagnostic Tests on Blood Drop,Completed,NA,CMC Ambroise ParÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04467008,0,0,0,0,1,0,France,0,"NA",NA
NCT04466982,2020-07-02,8/31/2021,Observational,Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection,Recruiting,NA,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04466982,0,0,0,0,2,0,United Kingdom,0,"NA",NA
NCT04466800,2020-07-30,4/2/2021,Interventional,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04466800,0,0,0,0,4,0,France,0,intervention group_rehabilitation program,NA
NCT04466644,2020-06-08,8/24/2020,Observational,COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics),Completed,NA,Igenomix,NA,https://clinicalzeros.gov/ct2/show/NCT04466644,0,0,0,0,1,1,United States,0,elisa|pcr,NA
NCT04466605,2020-03-30,6/30/2020,Interventional,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04466605,0,0,0,0,0,0,India,0,tele-yoga|primary care,NA
NCT04466280,2020-07-15,11/15/2020,Interventional,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19",Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04466280,0,0,0,0,0,0,"Iran, Islamic Republic of",0,hydroxychloroquine|mucodentol|personal protective equipment,NA
NCT04465695,2020-07-14,6/30/2021,Interventional,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04465695,0,0,0,0,3,0,China,0,interferon|clofazimine,NA
NCT04465552,2020-07-10,6/30/2021,Observational,Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients,Recruiting,NA,Kansas City Heart Rhythm Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04465552,0,0,0,0,3,1,United States,0,patients received standard of care treatment during hospitalization,NA
NCT04471649,2020-06-15,10/31/2020,Observational,Hydroxy Chloroquine and Covid in RA Patients,Recruiting,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04471649,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04468646,2020-06-15,7/15/2020,Interventional,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,Phase 3,University of Health Sciences Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04468646,0,0,0,0,0,0,Pakistan,0,nk-1r antagonist,NA
NCT04465981,2020-07-31,12/31/2020,Observational,Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins,Recruiting,NA,INanoBio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04465981,0,0,0,0,1,1,United States,0,sampling,NA
NCT04463602,2020-07-25,1/25/2021,Interventional,Desidustat in the Management of COVID-19 Patients,"Active, not recruiting",Phase 2,Cadila Healthcare Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04463602,0,0,0,0,6,0,Mexico,0,desidustat|standard care,NA
NCT04475211,2020-08-10,8/31/2022,Observational,LILLE COVID RESEARCH NETWORK (Covid-19),Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04475211,0,0,0,0,1,0,France,0,"NA",NA
NCT04474496,2020-07-27,12/15/2020,Observational,Impact of COVID-19 on Marshallese Communities in the U.S.,Enrolling by invitation,NA,University of Arkansas,NA,https://clinicalzeros.gov/ct2/show/NCT04474496,0,0,0,0,3,1,United States,0,assessing impact of covid19,NA
NCT04463004,2020-09-02,8/31/2021,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Recruiting,Phase 2,Virginia Commonwealth University,NA,https://clinicalzeros.gov/ct2/show/NCT04463004,0,0,0,0,2,1,United States,0,mavrilimumab|placebo,NA
NCT04462627,2020-04-14,12/31/2021,Interventional,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04462627,0,0,0,0,1,0,Belgium,0,blood group determination|serology test|probiotic,NA
NCT04464395,2020-07-01,3/31/2021,Interventional,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Recruiting,Phase 1,"Corvus Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04464395,0,0,0,0,4,1,United States,0,cpi-006|standard care,NA
NCT04472052,2020-03-16,5/31/2020,Observational,Frequency of Perforated Appendicitis in Times of COVID-19,Completed,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04472052,0,0,0,0,0,0,Germany,0,appendectomy,NA
NCT04560231,2020-06-01,11/30/2020,Interventional,Remdesivir in COVID-19 Lahore General Hospital,Recruiting,Early Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560231,0,0,0,0,1,0,Pakistan,0,remdesivir,NA
NCT04560205,2020-05-01,12/30/2020,Interventional,Tocilizumab in COVID-19 Lahore General Hospital,Recruiting,Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560205,0,0,0,0,1,0,Pakistan,0,tocilizumab,NA
NCT04473365,2020-07-20,6/30/2021,Observational,Rapid Diagnostic Profiling of SARS-CoV-2 (COVID-19),Recruiting,NA,Mekelle University,NA,https://clinicalzeros.gov/ct2/show/NCT04473365,0,0,0,0,2,0,Ethiopia,0,"NA",NA
NCT04470531,2020-07-12,10/12/2020,Interventional,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://clinicalzeros.gov/ct2/show/NCT04470531,0,0,0,0,1,0,Bangladesh,0,trimoxazole,NA
NCT04468971,2020-09-29,9/30/2021,Interventional,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,Recruiting,Phase 1,"Cellenkos, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04468971,0,0,0,0,4,1,United States,0,ck0802|placebo,NA
NCT04469114,2020-09-16,3/1/2021,Interventional,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,"Active, not recruiting",Phase 2,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04469114,0,0,0,0,5,0,Brazil,0,tofacitinib|placebo,NA
NCT04474444,2019-03-23,3/23/2021,Observational,Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP),Recruiting,NA,University of Lincoln,NA,https://clinicalzeros.gov/ct2/show/NCT04474444,0,0,0,0,0,0,United Kingdom,0,attendance by ambulance crew,NA
NCT04472078,2020-06-10,6/26/2020,Observational [Patient Registry],"Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina",Completed,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04472078,0,0,0,0,1,0,Argentina,0,serology test|igg,NA
NCT04470739,2020-05-30,9/30/2020,Interventional,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04470739,0,0,0,0,0,0,Turkey,0,chest x-ray,NA
NCT04470323,2020-07-22,10/31/2020,Observational,Functional Exhaustion of T Cells in COVID19 Patients,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04470323,0,0,0,0,2,0,Egypt,0,flow cytometry,NA
NCT04560257,2020-05-01,12/30/2020,Interventional,High Flow Nasal Cannula HFNC In Covid-19 Patients,Recruiting,N/A,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560257,0,0,0,0,3,0,Pakistan,0,high flow nasal cannula,NA
NCT04481685,2020-07-20,7/31/2021,Interventional,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",Recruiting,Phase 2,University of Kansas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04481685,0,0,0,0,2,1,United States,0,ati-450|placebo,NA
NCT04496128,2020-04-13,12/31/2020,Observational,COVID19 Neurological Manifestation,Enrolling by invitation,NA,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04496128,0,0,0,0,2,1,United States,0,"NA",NA
NCT04496076,2020-04-02,12/31/2020,Observational,COVID-19 Brain Injury,Enrolling by invitation,NA,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04496076,0,0,0,0,2,1,United States,0,"NA",NA
NCT04495933,2020-07-13,10/31/2020,Interventional,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults",Recruiting,Phase 1,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04495933,0,0,0,1,1,0,Australia,0,mf59 adjuvanted sars-cov-2 sclamp vaccine|placebo,NA
NCT04478071,2020-08-22,8/1/2022,Interventional,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,"The University of Texas Health Science Center, Houston",NA,https://clinicalzeros.gov/ct2/show/NCT04478071,0,0,0,0,1,1,United States,0,vadadustat|placebo,NA
NCT04478019,2020-07-07,4/30/2021,Interventional,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Recruiting,Early Phase 1,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04478019,0,0,0,0,0,1,United States,0,povidone-iodine|0.12% chg oral rinse,NA
NCT04479488,2020-07-27,1/31/2021,Observational [Patient Registry],Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil),Recruiting,NA,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04479488,0,0,0,0,3,0,Brazil,0,hospital admission|non-hospitalization procedures,NA
NCT04476953,2020-08-03,7/31/2021,Interventional,COVID-FISETIN: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation,Enrolling by invitation,Phase 2,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04476953,0,0,0,0,1,1,United States,0,placebo|fisetin,NA
NCT04479358,2020-09-10,12/1/2020,Interventional,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,Recruiting,Phase 2,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04479358,0,0,0,0,1,1,United States,0,tocilizumab|standard care,NA
NCT04477993,2020-07-17,2/17/2021,Interventional,Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,Recruiting,Phase 2/Phase 3,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04477993,0,0,0,0,0,0,Brazil,0,ruxolitinib|placebo,NA
NCT04475185,2020-07-20,12/31/2020,Interventional,Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,Recruiting,N/A,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04475185,0,0,0,0,4,0,France,0,makair,NA
NCT04474340,2020-05-21,9/30/2020,Interventional,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,Recruiting,Phase 1,"Ministry of Health, Kuwait",NA,https://clinicalzeros.gov/ct2/show/NCT04474340,0,0,0,0,1,0,Kuwait,0,convalscent plasma,NA
NCT04474288,2020-07-16,7/31/2021,Observational,The COVID-19 PUI Reality Check (CPRC) Study,Recruiting,NA,Bassett Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04474288,0,0,0,0,1,1,United States,0,sars-cov-2 antibody testing,NA
NCT04474067,2020-06-28,3/31/2021,Observational,COVID-19 - Cytokine Storm,Recruiting,NA,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04474067,0,0,0,0,2,0,Israel,0,no intervention,NA
NCT04473157,2020-07-01,11/30/2020,Observational,COVID-19 in Patients With Anosmia in Egypt,Completed,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04473157,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04473131,2020-04-27,6/30/2022,Observational,Immune Profiling of COVID19-patients Admitted to ICU,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04473131,0,0,0,0,0,0,Qatar,0,no intervention,NA
NCT04473118,2020-07-11,9/30/2020,Observational,Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04473118,0,0,0,0,0,0,Qatar,0,questionnaire,NA
NCT04474457,2020-06-11,12/31/2020,Observational,Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age,"Active, not recruiting",NA,"Ministry of Health, Turkey",NA,https://clinicalzeros.gov/ct2/show/NCT04474457,0,0,0,0,2,0,Turkey,0,favipiravir,NA
NCT04494776,2020-05-21,11/3/2020,Observational,SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study,Recruiting,NA,Hospital do Rim e HipertensÃ£o,NA,https://clinicalzeros.gov/ct2/show/NCT04494776,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04471051,2020-04-30,4/30/2021,Observational,An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients,Recruiting,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04471051,0,0,0,0,0,1,United States,0,"NA",NA
NCT04470622,2020-07-20,6/30/2021,Interventional,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),Recruiting,Phase 2,Heron Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04470622,0,0,0,0,6,1,United States|Puerto Rico,0,aprepitant injectable emulsion|placebo,NA
NCT04470609,2020-07-10,11/30/2020,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,Enrolling by invitation,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04470609,0,0,0,1,0,0,China,0,inactivated sars-cov-2 vaccine|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|placebo|28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-,NA
NCT04470583,2020-10-09,11/30/2021,Observational,Evaluating Clinical Parameters of COVID-19 in Pregnancy,Recruiting,NA,Chelsea and Westminster NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04470583,0,0,0,0,2,0,United Kingdom,0,"NA",NA
NCT04469660,2020-05-18,8/30/2020,Observational,Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare Professionals in India,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04469660,0,0,0,0,0,0,India,0,"NA",NA
NCT04469647,2020-07-19,1/15/2021,Observational,COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH,Enrolling by invitation,NA,Johns Hopkins Aramco Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04469647,0,0,0,0,1,0,Saudi Arabia,0,serology test,NA
NCT04469634,2020-07-31,7/31/2021,Interventional,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,"Active, not recruiting",N/A,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04469634,0,0,0,0,2,0,Belgium,0,"assessing antibody responses, neutralizing capacity/memory b-cell function|assessing antibody responses, neutralizing capacity|memory b-cell function",NA
NCT04694638,2020-05-21,5/31/2021,Interventional,"Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection",Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04694638,0,0,0,0,0,1,United States,0,body position change,NA
NCT04537962,2020-06-11,9/30/2020,Interventional,"Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study",Enrolling by invitation,N/A,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04537962,0,0,0,0,0,0,Brazil,0,colgate periogard mouthwash|colgate peroxyl mouthwash|colgate total mouthwash|placebo,NA
NCT04510025,2020-05-13,5/1/2023,Observational,Capturing MultiORgan Effects of COVID-19,Recruiting,NA,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04510025,0,0,0,0,1,0,United Kingdom,0,magnetic resonance imaging,NA
NCT04488081,2020-07-31,7/24/2022,Interventional,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,Recruiting,Phase 2,QuantumLeap Healthcare Collaborative,NA,https://clinicalzeros.gov/ct2/show/NCT04488081,0,0,0,0,2,1,United States,0,remdesivir|cenicriviroc|icatibant|razuprotafib|apremilast,NA
NCT04479319,2020-12-31,6/30/2021,Observational,Decision Support System Algorithm for COVID-19 Diagnosis,Recruiting,NA,Ankara University,NA,https://clinicalzeros.gov/ct2/show/NCT04479319,0,0,0,0,1,0,Turkey,0,thorax ct,NA
NCT04484597,2020-03-15,8/15/2020,Observational,Predictors of COVID-19 Infection and Disease Progression,Recruiting,NA,Port Said University,NA,https://clinicalzeros.gov/ct2/show/NCT04484597,0,0,0,0,0,0,Egypt,0,pct,NA
NCT04478539,2020-06-01,6/1/2021,Interventional,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Recruiting,N/A,Zan Mitrev Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04478539,0,0,0,0,0,0,North Macedonia,0,extracorporeal blood purification using the oxirisâ® (an69st) hemofilter,NA
NCT04477954,2020-07-06,11/6/2020,Interventional,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Terminated,Phase 2,AsociaciÃ³n Argentina de Medicina HiperbÃ¡rica e InvestigaciÃ³n,"Investigators and Ethic Committee endorsed early suspension of the protocol because of
    superiority and safety. For the interim analysys, the statistical methodology presented by
    Pocock was followed.",https://clinicalzeros.gov/ct2/show/NCT04477954,0,0,0,0,2,0,Argentina,0,oxygen,NA
NCT04477902,2020-07-01,7/1/2022,Observational,Long-Term Experience and Health Effects of COVID-19,Recruiting,NA,Altura,NA,https://clinicalzeros.gov/ct2/show/NCT04477902,0,0,0,0,1,1,United States,0,none - observational,NA
NCT04476992,2020-07-24,7/17/2021,Interventional,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,"Active, not recruiting",Phase 1/Phase 2,"Federal State Budgetary Scientific Institution, Research Institute of Cardiology",NA,https://clinicalzeros.gov/ct2/show/NCT04476992,0,0,0,0,3,0,Russian Federation,0,nitric oxide|sessions,NA
NCT04476979,2020-07-16,3/31/2021,Interventional,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04476979,0,0,0,0,1,0,French Guiana,0,tocilizumab|dexamethasone,NA
NCT04476888,2020-04-26,9/15/2020,Interventional,Convalescent Plasma Treatment in COVID-19,Completed,N/A,Aga Khan University,NA,https://clinicalzeros.gov/ct2/show/NCT04476888,0,0,0,0,2,0,Pakistan,0,convalescent plasma|drugs/supportive care|drugs|supportive care,NA
NCT04476823,2020-03-15,5/31/2020,Observational,European Pathology Laboratories and COVID-19,Completed,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04476823,0,0,0,0,0,0,France,0,activity,NA
NCT04476745,2020-10-05,12/15/2020,Interventional,The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People,Enrolling by invitation,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04476745,0,0,0,0,2,0,Jordan,0,vitamin d,NA
NCT04476602,2020-04-27,12/31/2020,Observational,Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol,Recruiting,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04476602,0,0,0,0,1,1,United States,0,"NA",NA
NCT04475588,2020-05-01,7/8/2020,Interventional,Efficacy and Safety of Itolizumab in COVID-19 Complications,Completed,Phase 2,Biocon Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04475588,0,0,0,0,0,0,India,0,itolizumab|best supportive care|antibiotics|hydroxychloroquine / oxygen,NA
NCT04475302,2020-07-01,1/31/2021,Interventional,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Recruiting,Phase 3,"Tuberculosis Research Centre, India",NA,https://clinicalzeros.gov/ct2/show/NCT04475302,0,0,0,1,2,0,India,0,bcg,NA
NCT04475120,2020-04-15,7/2/2020,Interventional,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,Phase 2/Phase 3,University of Rome Tor Vergata,NA,https://clinicalzeros.gov/ct2/show/NCT04475120,0,0,0,0,0,0,Italy,0,liposomal,NA
NCT04477083,2020-07-15,8/15/2020,Interventional,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",N/A,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04477083,0,0,0,0,0,0,Egypt,0,hydroxychloroquine|supportive/symptomatic treatment|supportive care|symptomatic treatment,NA
NCT04522310,2020-05-20,10/7/2020,Observational,ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis,Recruiting,NA,Centre Hospitalier de Lens,NA,https://clinicalzeros.gov/ct2/show/NCT04522310,0,0,0,0,2,0,France,0,mr-pro-adm,NA
NCT04475913,2018-07-11,7/11/2020,Interventional,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,"Active, not recruiting",N/A,October University for Modern Sciences and Arts,NA,https://clinicalzeros.gov/ct2/show/NCT04475913,0,0,0,0,0,0,Egypt,0,dig axial|dig tilted|cig axial|cig tilted,NA
NCT04475107,2020-07-09,4/30/2021,Interventional,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,Recruiting,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04475107,0,0,0,0,3,0,"Korea, Republic of",0,pyronaridine-artesunate|placebo,NA
NCT04475068,2020-07-17,9/30/2020,Observational,Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection,Recruiting,NA,Hospital Nacional Edgardo Rebagliati Martins,NA,https://clinicalzeros.gov/ct2/show/NCT04475068,0,0,0,0,1,0,Peru,0,lateral position (left/right lateral decubitus)|lateral position (left|right lateral decubitus),NA
NCT04474301,2020-06-11,7/1/2021,Observational,Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04474301,0,0,0,0,0,1,United States,0,questionnaire,NA
NCT04473898,2020-06-19,10/19/2020,Interventional,Telerehabilitation After Coronavirus,Recruiting,N/A,KTO Karatay University,NA,https://clinicalzeros.gov/ct2/show/NCT04473898,0,0,0,0,1,0,Turkey,0,exercise|education,NA
NCT04473690,2020-12-30,5/6/2021,Interventional,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,Recruiting,Phase 1/Phase 2,"Kentucky BioProcessing, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04473690,0,0,0,1,11,1,United States,0,low dose of kbp-covid-19|high dose of kbp-covid-19|placebo,NA
NCT04483375,2020-07-24,12/25/2020,Interventional,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",Completed,Phase 1,Sinocelltech Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04483375,0,0,0,0,3,0,China,0,scta01|placebo,NA
NCT04482595,2020-11-11,8/31/2021,Interventional,BIO 300 Oral Suspension in Discharged COVID-19 Patients,Recruiting,Phase 2,Humanetics Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04482595,0,0,0,0,3,1,United States,0,bio 300 oral suspension|placebo,NA
NCT04473547,2020-07-15,8/30/2020,Observational,COVID 19 Preventive Measures Among Mansoura Nursing Students,Recruiting,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04473547,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04473300,2020-05-11,8/31/2020,Observational,Assessment of Lung Recruitablity of Acute Respiratory Distress Syndrome With SARS-CoV-2 Pneumonia by Electrical Impedance Tomography,Recruiting,NA,Osaka University,NA,https://clinicalzeros.gov/ct2/show/NCT04473300,0,0,0,0,0,0,Japan,0,"NA",NA
NCT04482387,2020-07-24,7/1/2021,Interventional,DigiVis: Self-testing Vision App for Telephone Consultations,Recruiting,N/A,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04482387,0,0,0,0,1,0,United Kingdom,0,digivis visual acuity app,NA
NCT04473248,2020-06-28,8/30/2020,Interventional,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Completed,N/A,Spartan Bioscience Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04473248,0,0,0,0,1,0,Canada,0,spartan covid-19 system,NA
NCT04473183,2020-07-21,1/31/2022,Observational,Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota,Recruiting,NA,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04473183,0,0,0,0,2,1,United States,0,specimen collection|survey,NA
NCT04473170,2020-04-04,5/20/2020,Interventional,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,Completed,Phase 1/Phase 2,Abu Dhabi Stem Cells Center,NA,https://clinicalzeros.gov/ct2/show/NCT04473170,0,0,0,0,0,0,United Arab Emirates,0,autologous non-hematopoietic peripheral blood stem cells (nhpbsc)|standard care,NA
NCT04472585,2020-11-14,8/15/2021,Interventional,Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04472585,0,0,0,0,1,0,Pakistan,0,ivermectin|injectable placebo|zinc|placebo empty capsule|oral ivermectin,NA
NCT04472494,2020-08-24,1/13/2021,Interventional,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,Recruiting,Phase 2,Bristol-Myers Squibb,NA,https://clinicalzeros.gov/ct2/show/NCT04472494,0,0,0,0,4,1,United States|Puerto Rico,0,abatacept|placebo,NA
NCT04472013,2020-08-12,12/31/2022,Observational,"Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19",Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04472013,0,0,0,0,3,0,Switzerland,0,data collection from lumbar puncture|data collection from blood draw|cns magnetic resonance imaging (mri) imaging|microscopy of defined brain regions on autopsy specimens,NA
NCT04471766,2020-07-20,6/30/2021,Interventional,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,Enrolling by invitation,N/A,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04471766,0,0,0,0,3,0,Guinea-Bissau,0,certified cloth face mask/preventive information|preventive information|certified cloth face mask,NA
NCT04475575,2020-04-06,6/30/2020,Interventional,Can the Electronic Nose Smell COVID-19 Antibodies?,Completed,N/A,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04475575,0,0,0,0,0,0,Netherlands,0,aeonose,NA
NCT04475562,2020-04-06,5/6/2020,Interventional,Can the Electronic Nose Smell COVID-19?,Completed,N/A,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04475562,0,0,0,0,0,0,Netherlands,0,aeonose,NA
NCT04500067,2020-05-07,9/15/2020,Interventional,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",Completed,Phase 3,Biopharma Plasma LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04500067,0,0,0,0,1,0,Ukraine,0,ivig,NA
NCT04480957,2020-08-04,12/31/2020,Interventional,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,Recruiting,Phase 1/Phase 2,"Arcturus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04480957,0,0,0,1,1,0,Singapore,0,arct-021 dose 1|arct-021 dose 2|arct-021 dose 3|arct-021 dose 4|arct-021 dose regimen 1|arct-021 dose regimen 2|placebo,NA
NCT04480515,2020-03-11,6/15/2020,Observational,Does COVID-19 Pandemic Reduce In-hospital Mortality?,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04480515,0,0,0,0,0,0,Turkey,0,in-hospital mortality rate,NA
NCT04479982,2020-09-24,12/31/2020,Observational,Microbial Infection and AMR in Hospitalized Patients With Covid 19,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04479982,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04483271,2020-10-02,12/15/2020,Interventional,The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm,Enrolling by invitation,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04483271,0,0,0,0,1,0,Jordan,0,300 mg of omega3-fa,NA
NCT04480398,2020-05-12,6/15/2020,Observational,Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,Completed,NA,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04480398,0,0,0,0,1,0,India,0,guduchi ghan vati,NA
NCT04477889,2020-06-20,12/31/2025,Observational,Methodist Health System COVID-19 Patient Registry,Recruiting,NA,Methodist Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04477889,0,0,0,0,1,1,United States,0,treatment for covid-19,NA
NCT04477473,2020-06-30,7/30/2020,Observational,Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group,Recruiting,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04477473,0,0,0,0,1,0,Switzerland,0,questionnaire,NA
NCT04480060,2020-03-10,6/30/2020,Observational,Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04480060,0,0,0,0,0,0,Turkey,0,pcr,NA
NCT04479137,2020-03-10,6/30/2020,Observational,Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04479137,0,0,0,0,1,0,Turkey,0,pcr,NA
NCT04480112,2020-06-02,5/31/2021,Interventional,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Enrolling by invitation,N/A,Boston University,NA,https://clinicalzeros.gov/ct2/show/NCT04480112,0,0,0,0,3,1,United States,0,technology based social interactions|no research related technology based social interactions,NA
NCT04495764,2020-07-20,1/31/2021,Observational,Registry of Sustained Immunity to COVID-19 Among ESKD Patients,"Active, not recruiting",NA,Davita Clinical Research,NA,https://clinicalzeros.gov/ct2/show/NCT04495764,0,0,0,0,5,1,United States,0,"NA",NA
NCT04479293,2020-07-01,10/30/2020,Observational,Post COVID-19 Functional Status in Egypt,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04479293,0,0,0,0,1,0,Egypt,0,post covid-19 functional satus scale,NA
NCT04479280,2020-07-20,8/16/2020,Observational,Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04479280,0,0,0,0,2,0,Egypt,0,"sonclot coagulation/platelet function analyzer scp1, sienco, usa|sonclot coagulation|platelet function analyzer scp1, sienco, usa",NA
NCT04479124,2020-03-10,6/30/2020,Observational,The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04479124,0,0,0,0,0,0,Turkey,0,pcr,NA
NCT04514900,2020-09-23,9/15/2021,Interventional,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,"Active, not recruiting",N/A,University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04514900,0,0,0,0,3,1,United States,0,video chat /personalized feedback|video chat / basic feedback|discussion board for social support /basic feedback|discussion board for social support/personalized feedback|video chat|personalized feedback|basic feedback|discussion board for social support,NA
NCT04488796,2020-09-07,12/31/2020,Interventional,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,Recruiting,N/A,"Western University, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04488796,0,0,0,0,4,0,Canada,0,assigned strategies: opt-in|assigned strategies: active choice|assigned strategies: enhanced active choice|choice of assignment: opt-in|choice of assignment: active choice|choice of assignment: enhanced active choice,NA
NCT04492891,2020-11-23,11/23/2025,Interventional,Cyclosporine For The Treatment Of COVID-19(+),Recruiting,Phase 2,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04492891,0,0,0,0,1,1,United States,0,cyclosporine|standard care,NA
NCT04487574,2020-07-25,10/29/2020,Interventional,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,Completed,Phase 3,RSV Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04487574,0,0,0,0,2,0,Russian Federation,0,xc221|placebo,NA
NCT04487444,2020-09-10,3/31/2021,Interventional,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,Recruiting,Phase 2,Rhode Island Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04487444,0,0,0,0,3,1,United States,0,thymalfasin,NA
NCT04487210,2020-10-07,1/30/2021,Interventional,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,"Active, not recruiting",Phase 1,Medigen Vaccine Biologics Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04487210,0,0,0,0,3,0,Taiwan,0,mvc-cov1901,NA
NCT04491214,2020-07-24,7/31/2020,Observational,Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19),Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04491214,0,0,0,0,1,0,France,0,quality of live assessment,NA
NCT04486521,2020-07-22,7/22/2021,Observational,Clinical Outcome of Anti-IL6 vs Anti-IL6 Corticosteroid Combination in Patients With SARS-CoV-2 Cytokine Release Syndrome,Recruiting,NA,King Faisal Specialist Hospital & Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04486521,0,0,0,0,0,0,Saudi Arabia,0,interleukin|corticosteroids,NA
NCT04486417,2020-06-01,7/22/2020,Observational,Feasibility of a Telematics Pre-operative Assessment in a Bariatric Surgery During Covid-19,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicalzeros.gov/ct2/show/NCT04486417,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04485429,2020-07-20,12/31/2020,Interventional,Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia,Recruiting,Phase 3,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04485429,0,0,0,0,0,0,Brazil,0,methylprednisolone|heparin,NA
NCT04484545,2020-04-01,6/1/2021,Observational,Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection,"Active, not recruiting",NA,Glasgow Royal Infirmary,NA,https://clinicalzeros.gov/ct2/show/NCT04484545,0,0,0,0,0,0,United Kingdom,0,prognostic score,NA
NCT04483960,2020-07-28,12/31/2021,Interventional,Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial,Recruiting,Phase 3,University of Melbourne,NA,https://clinicalzeros.gov/ct2/show/NCT04483960,0,0,0,0,2,0,Australia,0,nafamostat mesilate|convalescent plasma|enoxaparin|dalteparin|tinzaparin|aspirin,NA
NCT04483908,2020-04-10,5/30/2022,Observational,COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses,Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04483908,0,0,0,0,0,0,Switzerland,0,blood sample|fingertip tests for poc assays|saliva|collection of swabs,NA
NCT04483830,2020-06-05,8/6/2020,Interventional,Suloexide in the Treatment of Early Stages of COVID-19,Completed,Phase 2/Phase 3,Clinedem,NA,https://clinicalzeros.gov/ct2/show/NCT04483830,0,0,0,0,2,0,Mexico,0,sulodexide|placebo,NA
NCT04482699,2020-12-30,12/30/2021,Interventional,RAPA-501-Allo Off-the-Shelf Therapy of COVID-19,Recruiting,Phase 1/Phase 2,Rapa Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04482699,0,0,0,0,8,1,United States,0,rapa-501-allo off-the-shelf therapy of covid-19|placebo,NA
NCT04486001,2020-12-15,1/15/2022,Interventional,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,Recruiting,Phase 1,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04486001,0,0,0,0,4,1,United States,0,psc-04,NA
NCT04495543,2020-12-01,8/31/2021,Interventional,Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living',Recruiting,N/A,"St. Michael's Hospital, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04495543,0,0,0,0,1,0,Canada,0,brief skills for safer living,NA
NCT04482361,2020-08-06,12/22/2020,Observational [Patient Registry],SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES,Completed,NA,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04482361,0,0,0,0,1,0,Argentina,0,presence of specific anti-sars-cov-2 antibodies,NA
NCT04481620,2020-08-31,12/30/2020,Observational,"Development and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT",Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04481620,0,0,0,0,1,0,France,0,"NA",NA
NCT04481529,2020-07-29,12/15/2020,Observational,COVID-19 Serological Status of Hospital Staff Working or Not in the COVID-19 Sector,"Active, not recruiting",NA,"University Hospital, Limoges",NA,https://clinicalzeros.gov/ct2/show/NCT04481529,0,0,0,0,1,0,France,0,health questionnaire,NA
NCT04480580,2020-03-30,4/30/2020,Observational,Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery,Completed,NA,University of Cagliari,NA,https://clinicalzeros.gov/ct2/show/NCT04480580,0,0,0,0,0,0,Italy,0,sars-cov-2 ab,NA
NCT04480424,2020-09-17,4/30/2021,Interventional,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04480424,0,0,0,0,3,1,United States,0,gamunex-c|standard care,NA
NCT04480138,2020-08-11,4/15/2021,Interventional,Pegylated Interferon - Î±2b With SARSCoV- 2 (COVID-19),Recruiting,Phase 2,Cadila Healthcare Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04480138,0,0,0,0,3,0,Mexico,0,pegylated interferon-î±2b|standard care,NA
NCT04570462,2020-05-18,12/31/2020,Interventional,Mild Hypothermia for COVID-19 ARDS,Recruiting,N/A,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04570462,0,0,0,0,0,1,United States,0,hypothermia via cooling machine- arctic sun 5000,NA
NCT04492267,2020-07-07,1/7/2021,Observational,Inflammatory Bowel Disease (IBD) and Covid-19 Infection,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04492267,0,0,0,0,0,0,France,0,"NA",NA
NCT04490278,2020-09-29,7/30/2021,Interventional,CoV-PICS: A Virtual Post-ICU Clinic,Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04490278,0,0,0,0,3,1,United States,0,medical record review - inpatient treatment|online questionnaires,NA
NCT04506632,2020-06-02,4/2/2021,Observational,Burden for STaff Working in the NHS,Recruiting,NA,Sheffield Teaching Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04506632,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04488549,2020-05-20,6/10/2020,Observational,Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19),Completed,NA,Treviso Regional Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04488549,0,0,0,0,0,0,Italy,0,questionnaire,NA
NCT04488510,2020-05-06,5/6/2020,Observational,Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04488510,0,0,0,0,1,0,France,0,"NA",NA
NCT04487977,2020-04-22,9/30/2020,Observational,Survey on COVID-19 Airway Management,Recruiting,NA,Spanish Society of Anesthesia and Critical Care (SEDAR),NA,https://clinicalzeros.gov/ct2/show/NCT04487977,0,0,0,0,0,0,Spain,0,questionnaire,NA
NCT04487886,2020-11-18,2/28/2022,Interventional,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Recruiting,Phase 2,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04487886,0,0,0,0,2,1,United States,0,duvelisib|placebo,NA
NCT04487873,2020-07-23,12/18/2020,Observational,COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic,Recruiting,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04487873,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04487691,2020-12-08,6/1/2021,Interventional,Nebulized PL for Post-COVID-19 Syndrome,Recruiting,N/A,"Regenexx, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04487691,0,0,0,0,2,1,United States,0,nebulized platelet lysate|nebulized sterile saline,NA
NCT04486482,2020-07-31,3/31/2021,Interventional,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,Recruiting,N/A,Kaleido Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04486482,0,0,0,0,0,1,United States,0,kb109 / self supportive care (ssc)|self supportive care (ssc) alone|kb109|self supportive care (ssc),NA
NCT04486313,2020-08-13,12/30/2020,Interventional,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,Recruiting,Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04486313,0,0,0,0,4,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04485364,2020-04-14,4/14/2020,Observational,Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04485364,0,0,0,0,0,0,France,0,"NA",NA
NCT04485338,2020-08-01,12/31/2020,Observational,Chest Radiography in COVID-19 Patients,Recruiting,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicalzeros.gov/ct2/show/NCT04485338,0,0,0,0,1,0,Netherlands,0,"NA",NA
NCT04488575,2020-08-26,7/6/2021,Interventional,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,Recruiting,Phase 2,"Evelo Biosciences, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04488575,0,0,0,0,4,1,United States,0,edp1815|placebo,NA
NCT04570982,2020-07-30,10/30/2020,Observational,Clinical Protocol for Convalescent Plasma and Remdesivir Therapy in Nepal,Recruiting,NA,Nepal Health Research Council,NA,https://clinicalzeros.gov/ct2/show/NCT04570982,0,0,0,0,0,0,Nepal,0,convalescent plasma,NA
NCT04519437,2020-07-26,10/25/2021,Interventional,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","Active, not recruiting",Phase 1,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04519437,0,0,0,0,3,1,United States,0,regn10933 / regn10987|placebo|regn10933|regn10987,NA
NCT04487639,2020-07-10,7/31/2021,Interventional,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,Recruiting,N/A,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04487639,0,0,0,0,0,0,France,0,"sars-cov-2 research in nasopharyngeal swab, sperm/serologics|sars-cov-2 research in nasopharyngeal swab, sperm|serology test",NA
NCT04486729,2020-07-01,10/10/2020,Observational,Respiratory Mechanics and Gas Exchange Characteristics in Patient With SARS-CoV-2,Recruiting,NA,Sanatorio Anchorena San Martin,NA,https://clinicalzeros.gov/ct2/show/NCT04486729,0,0,0,0,0,0,Argentina,0,high peep with end inspiratory pause|low peep - fio2 high|high peep without end inspiratory pause|low peep - fio2 low,NA
NCT04500652,2020-06-27,8/30/2020,Observational,Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians in the Covid-19 Pandemic,Recruiting,NA,Dokuz Eylul University,NA,https://clinicalzeros.gov/ct2/show/NCT04500652,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04500600,2020-06-11,7/1/2021,Observational,Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04500600,0,0,0,0,0,1,United States,0,quality-of-life assessment|questionnaire,NA
NCT04485169,2020-04-01,7/31/2020,Interventional,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Completed,N/A,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04485169,0,0,0,0,1,0,Pakistan,0,therapeutic plasma exchange (tpe),NA
NCT04494386,2020-07-23,10/30/2020,Interventional,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Recruiting,Phase 1/Phase 2,"Restem, LLC.",NA,https://clinicalzeros.gov/ct2/show/NCT04494386,0,0,0,0,2,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04491227,2020-05-05,4/30/2022,Observational,Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection,Enrolling by invitation,NA,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04491227,0,0,0,0,0,1,United States|Bolivia|Canada|Chile|India|United Kingdom,0,"NA",NA
NCT04484207,2020-07-06,10/20/2020,Interventional,Addressing COVID-19 Mental Health Problems Among US Veterans,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04484207,0,0,0,0,2,1,United States,0,a short video intervention|a vignette intervention,NA
NCT04488588,2020-03-15,5/1/2020,Observational,Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04488588,0,0,0,0,0,0,Egypt,0,immunoglobulin,NA
NCT04488471,2020-06-30,6/30/2022,Observational,Impact of Isolation in Patients With IBD During the COVID-19 Crisis,Recruiting,NA,Sheffield Teaching Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04488471,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04487951,2020-07-01,11/1/2020,Observational,N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04487951,0,0,0,0,0,0,Egypt,0,"pro bnp , vitamin d",NA
NCT04487769,2020-06-01,8/31/2021,Observational,Lung Ultrasound in COVID-19 Patients,Recruiting,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicalzeros.gov/ct2/show/NCT04487769,0,0,0,0,2,0,Netherlands,0,"NA",NA
NCT04487197,2020-07-15,1/15/2021,Observational,"SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)",Recruiting,NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04487197,0,0,0,0,2,0,Italy,0,blood sample,NA
NCT04487171,2020-07-21,7/31/2021,Interventional,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04487171,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04487119,2020-08-12,8/20/2020,Observational,Hematology and Clinical Picture in Pediatric COVID-19 Infection,Completed,NA,Benha University,NA,https://clinicalzeros.gov/ct2/show/NCT04487119,0,0,0,0,4,0,Egypt,0,"NA",NA
NCT04483752,2020-06-08,2/8/2021,Interventional,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Recruiting,N/A,Centre Chirurgical Marie Lannelongue,NA,https://clinicalzeros.gov/ct2/show/NCT04483752,0,0,0,0,0,0,France,0,chest ct,NA
NCT04483622,2020-06-12,1/13/2021,Observational,Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients,Recruiting,NA,Sohag University,NA,https://clinicalzeros.gov/ct2/show/NCT04483622,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04482686,2020-12-09,5/31/2021,Interventional,Trial of Combination Therapy to Treat COVID-19 Infection,Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04482686,0,0,0,0,6,1,United States,0,ivermectin|doxycycline hcl|zinc|vitamin d|vitamin c,NA
NCT04482647,2020-06-17,7/1/2021,Interventional,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Recruiting,Phase 1,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04482647,0,0,0,0,3,1,United States,0,media intervention|meditation therapy|quality-of-life assessment|questionnaire|yoga,NA
NCT04482621,2020-09-14,5/31/2021,Interventional,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04482621,0,0,0,0,2,1,United States,0,decitabine|placebo,NA
NCT04482205,2020-03-16,5/31/2020,Observational,Covid -19 Pandemic: Economic Burden on Patients Operated for Traumatic Close Fractures,Completed,NA,Aga Khan University,NA,https://clinicalzeros.gov/ct2/show/NCT04482205,0,0,0,0,0,0,Pakistan,0,"NA",NA
NCT04481646,2020-06-12,6/30/2022,Observational [Patient Registry],Novel Face Mask Sampling for COVID-19: A Diagnostic and Public Health Tool,Recruiting,NA,University of Leicester,NA,https://clinicalzeros.gov/ct2/show/NCT04481646,0,0,0,0,0,0,United Kingdom,0,face mask sampling,NA
NCT04481633,2020-09-09,9/30/2021,Interventional,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04481633,0,0,0,0,2,0,France,0,covid 19 serology|covid 19 self-questionnaire,NA
NCT04492228,2020-09-01,12/31/2020,Interventional,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Recruiting,N/A,Ospedale Policlinico San Martino,NA,https://clinicalzeros.gov/ct2/show/NCT04492228,0,0,0,0,1,0,Italy,0,ketogenic diet,NA
NCT04494984,2020-07-27,11/23/2020,Interventional,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","Active, not recruiting",Phase 2/Phase 3,Inmunova S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04494984,0,0,0,0,2,0,Argentina,0,inm005|placebo,NA
NCT04490473,2020-07-24,3/24/2021,Interventional,Turkish of the SARS-CoV-2 Anxiety Scale,Recruiting,N/A,Eskisehir Osmangazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04490473,0,0,0,0,1,0,Turkey,0,survey,NA
NCT04489446,2020-08-19,12/31/2020,Interventional,Sildenafil in COVID-19,Recruiting,Phase 1/Phase 2,Universidad Nacional Andres Bello,NA,https://clinicalzeros.gov/ct2/show/NCT04489446,0,0,0,0,3,0,Chile,0,sildenafil|placebo,NA
NCT04496245,2020-08-24,6/30/2021,Interventional,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,Recruiting,Phase 3,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04496245,0,0,0,0,1,0,Australia,0,broncho-vaxomâ®,NA
NCT04494893,2020-04-24,12/31/2020,Observational,ImmuneRACE - Immune Response Action to COVID-19 Events,Recruiting,NA,Adaptive Biotechnologies,NA,https://clinicalzeros.gov/ct2/show/NCT04494893,0,0,0,0,0,1,United States,0,"NA",NA
NCT04494867,2020-08-19,12/31/2020,Interventional,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,Recruiting,N/A,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04494867,0,0,0,0,3,1,United States,0,core warming|standard care,NA
NCT04494646,2020-09-08,1/30/2021,Interventional,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),Recruiting,Phase 2/Phase 3,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04494646,0,0,0,0,3,1,United States,0,bardoxolone methyl|placebo,NA
NCT04493359,2020-07-25,2/14/2022,Interventional,Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,Recruiting,Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04493359,0,0,0,0,1,0,Brazil,0,renin-angiotensin system inhibitors,NA
NCT04596098,2020-04-30,6/30/2021,Observational,Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.,Recruiting,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04596098,0,0,0,0,1,0,France,0,blood sample,NA
NCT04501796,2020-08-31,10/31/2021,Interventional,A Trial of NT-I7 in COVID-19 (SPESELPIS),Recruiting,Phase 1,NeoImmuneTech,NA,https://clinicalzeros.gov/ct2/show/NCT04501796,0,0,0,0,0,1,United States,0,double-blind nt-i7|placebo,NA
NCT04499313,2020-08-02,11/15/2020,Interventional,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,Recruiting,Phase 3,Chattogram General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04499313,0,0,0,0,4,0,Bangladesh,0,dexamethasone|methylprednisolone,NA
NCT04498546,2020-07-20,8/30/2020,Observational [Patient Registry],Mask Usage and Exercise During the COVÄ°D-19 Pandemic,Recruiting,NA,KTO Karatay University,NA,https://clinicalzeros.gov/ct2/show/NCT04498546,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04497623,2020-07-28,8/13/2020,Interventional,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.",Completed,N/A,FundaciÃ³n Neumologica Colombiana,NA,https://clinicalzeros.gov/ct2/show/NCT04497623,0,0,0,0,1,0,Colombia,0,invasive mechanical ventilation using the unisabana-herons ventilator during 24 hours,NA
NCT04535791,2020-07-15,5/31/2021,Interventional,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04535791,0,0,0,0,0,0,Mexico,0,cholecalciferol,NA
NCT04492384,2020-06-11,1/14/2021,Observational,Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients,Completed,NA,Eurasian Association of Therapists,NA,https://clinicalzeros.gov/ct2/show/NCT04492384,0,0,0,0,3,0,Russian Federation,0,non-interventional,NA
NCT04491318,2020-07-01,7/25/2020,Observational,COVID-19 Quarantine on Musculoskeletal Status in Hemophilia,Recruiting,NA,InvestigaciÃ³n en Hemofilia y Fisioterapia,NA,https://clinicalzeros.gov/ct2/show/NCT04491318,0,0,0,0,0,0,Spain,0,observational,NA
NCT04491240,2020-07-20,10/1/2020,Interventional,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Completed,Phase 1/Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,https://clinicalzeros.gov/ct2/show/NCT04491240,0,0,0,0,4,0,Russian Federation,1,exo 1 inhalation|exo 2 inhalation|placebo,NA
NCT04491201,2020-07-27,9/27/2020,Observational,National Survey of the Impact of COVID-19 Pandemics,Recruiting,NA,Peking Union Medical College Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04491201,0,0,0,0,0,0,China,0,questionnaire,NA
NCT04490824,2020-10-01,10/31/2020,Interventional,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Recruiting,N/A,Institute of Progressive Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04490824,0,0,0,0,3,1,United States,0,kelea water|water without an elevated level of kelea,NA
NCT04551690,2020-04-15,7/15/2020,Observational,Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE),Completed,NA,"Hospital San Juan de Dios, Santiago",NA,https://clinicalzeros.gov/ct2/show/NCT04551690,0,0,0,0,0,0,Chile,0,"NA",NA
NCT04496141,2020-07-27,11/30/2020,Observational,Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19,"Active, not recruiting",NA,Hong Kong Sanatorium & Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04496141,0,0,0,0,0,0,Hong Kong,0,sars-cov-2 antibody immunoassays,NA
NCT04518514,2020-04-20,10/31/2020,Interventional,Telemedical Risk Assessment and Preoperative Evaluation (TAPE),Recruiting,N/A,RWTH Aachen University,NA,https://clinicalzeros.gov/ct2/show/NCT04518514,0,0,0,0,0,0,Germany,0,tape-software,NA
NCT04495907,2020-08-06,3/31/2021,Observational,COVID-19 Progression in End-Stage Kidney Disease,Recruiting,NA,Davita Clinical Research,NA,https://clinicalzeros.gov/ct2/show/NCT04495907,0,0,0,0,5,1,United States,0,"NA",NA
NCT04495842,2020-10-01,3/31/2021,Interventional,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,N/A,Franklin School of Integrative Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04495842,0,0,0,0,1,1,United States,0,essential oil blend|control blend,NA
NCT04501822,2020-07-19,7/19/2021,Observational,One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia,Recruiting,NA,Tomsk National Research Medical Center of the Russian Academy of Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04501822,0,0,0,0,0,0,Russian Federation,0,"evaluation of clinical, instrumental/laboratory diagnostics tests|evaluation of clinical, instrumental|laboratory diagnostics tests",NA
NCT04525378,2020-07-01,9/30/2020,Interventional,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Phase 1,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04525378,0,0,0,0,1,0,Brazil,0,mesenchymal stromal cell-based therapy,NA
NCT04505722,2020-09-07,3/10/2023,Interventional,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,"Active, not recruiting",Phase 3,Janssen Vaccines & Prevention B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04505722,0,0,0,0,10,1,United States|Argentina|Brazil|Chile|Colombia|Mexico|Peru|South Africa,0,ad26.cov2.s|placebo,NA
NCT04495101,2020-07-29,4/30/2021,Interventional,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04495101,0,0,0,0,2,0,Spain,0,prolastin|standard care,NA
NCT04505605,2020-05-14,11/30/2020,Observational,Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04505605,0,0,0,0,1,0,France,0,blood sample,NA
NCT04494399,2020-07-29,7/1/2022,Interventional,IFN Beta-1b and Ribavirin for Covid-19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04494399,0,0,0,0,0,0,Hong Kong,0,interferon|ribavirin,NA
NCT04494204,2020-08-07,12/1/2020,Interventional,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,Completed,Phase 2/Phase 3,Nutrin GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04494204,0,0,0,0,4,0,India,0,immunofree tablets/reginmune capsule|immunofree tablets|reginmune,NA
NCT04500366,2020-08-26,4/30/2021,Interventional,GERAS Frailty Rehabilitation at Home During COVID-19,Recruiting,N/A,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04500366,0,0,0,0,1,0,Canada,0,socialization|virtual group exercise|nutrition consult/protein supplementation|medication review|nutrition consult|protein supplementation,NA
NCT04499391,2020-12-04,7/31/2022,Interventional,COVID-19 Project ECHO in Nursing Homes,Recruiting,N/A,Milton S. Hershey Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04499391,0,0,0,0,3,1,United States,0,project echo,NA
NCT04493268,2020-03-07,7/20/2020,Observational,HYPONATREMIA IN COVID-19 PATIENTS,Completed,NA,Hospital Nacional Profesor Alejandro Posadas,NA,https://clinicalzeros.gov/ct2/show/NCT04493268,0,0,0,0,0,0,Argentina,0,"NA",NA
NCT04498299,2020-09-01,10/1/2020,Observational,Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness,Recruiting,NA,Hospital Beneficencia Espanola de Puebla,NA,https://clinicalzeros.gov/ct2/show/NCT04498299,0,0,0,0,0,0,Mexico,0,echocardiogram,NA
NCT04492527,2020-07-28,6/30/2021,Interventional,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,Recruiting,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04492527,0,0,0,0,1,0,Canada,0,telehealth,NA
NCT04492514,2020-05-20,5/31/2021,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Recruiting,Phase 2,University of Cincinnati,NA,https://clinicalzeros.gov/ct2/show/NCT04492514,0,0,0,0,0,1,United States,0,mavrilimumab|placebo,NA
NCT04492501,2020-04-01,7/20/2020,Interventional,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,Completed,N/A,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04492501,0,0,0,0,0,0,Pakistan,0,therapeutic plasma exchange (tpe)|convalescent plasma|tocilizumab|remdesivir|mesenchymal stem cells,NA
NCT04492410,2020-07-21,9/30/2020,Interventional,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),Recruiting,N/A,Centre Antoine Lacassagne,NA,https://clinicalzeros.gov/ct2/show/NCT04492410,0,0,0,0,0,0,France,0,serology test,NA
NCT04492371,2020-07-01,7/31/2021,Observational,COVID-19 Infection and Multiple Myeloma,Recruiting,NA,European Myeloma Network,NA,https://clinicalzeros.gov/ct2/show/NCT04492371,0,0,0,0,0,0,Austria|Belgium|Czechia|Germany|Greece|Italy|Netherlands|United Kingdom,0,"NA",NA
NCT04492358,2020-10-22,10/31/2021,Interventional,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,Phase 2/Phase 3,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04492358,0,0,0,0,1,0,Spain,0,colchicine|prednisone tablet|standard care,NA
NCT04491994,2020-04-10,5/31/2020,Interventional,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Completed,Phase 3,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04491994,0,0,0,0,1,0,Pakistan,1,hydroxychloroquine,NA
NCT04491292,2020-05-18,4/30/2021,Observational,Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04491292,0,0,0,0,0,1,United States,0,questionnaire,NA
NCT04490850,2020-07-15,7/15/2021,Interventional,COVID-19 Seroprevalence Study in French Guiana,Recruiting,N/A,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04490850,0,0,0,0,0,0,French Guiana,0,blood sample,NA
NCT04490174,2020-01-08,6/1/2022,Observational,Serological Surveillance for COVID-19 in Central North Carolina,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04490174,0,0,0,0,36,1,United States,0,"NA",NA
NCT04497454,2020-05-08,7/1/2021,Interventional,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04497454,0,0,0,0,0,0,Brazil,0,eit-group|ardsnet,NA
NCT04497402,2020-09-01,9/1/2021,Observational [Patient Registry],Sex-Informed Data in the COVID-19 Pandemic.,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicalzeros.gov/ct2/show/NCT04497402,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04497298,2020-08-10,11/30/2020,Interventional,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,Recruiting,Phase 1,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04497298,0,0,0,1,4,0,Belgium|France,0,placebo|two covid-19 vaccine candidate (tmv-083) administrations - low dose|two covid-19 vaccine candidate (tmv-083) administrations - high dose|one covid-19 vaccine candidate (tmv-083) administration - high dose,NA
NCT04498377,2021-01-26,9/30/2021,Interventional,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,Recruiting,Phase 2,Generon (Shanghai) Corporation Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04498377,0,0,0,0,5,1,United States,0,f-652|placebo,NA
NCT04497987,2020-08-02,3/8/2021,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,Recruiting,Phase 3,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04497987,0,0,0,0,14,1,United States,0,ly3819253|placebo|ly3832479,NA
NCT04498416,2020-04-27,7/31/2021,Observational,CoCo-20: a Longitudinal Follow-up Study of the French Paediatric Population During and After the Coronavirus Pandemic COVID-19,Recruiting,NA,Fondation Lenval,NA,https://clinicalzeros.gov/ct2/show/NCT04498416,0,0,0,0,3,0,France,0,quantitative/qualitative assessments of mental health|quantitative|qualitative assessments of mental health,NA
NCT04498507,2020-04-16,10/30/2020,Observational,Psychosocial Outcomes in Families of COVID-19 ICU Patients,Completed,NA,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04498507,0,0,0,0,1,0,Belgium,0,questionnaire,NA
NCT04497818,2020-06-16,7/16/2020,Observational,Correlation Fear of COVID-19 & Dental Treatment Anxiety,Completed,NA,Qassim University,NA,https://clinicalzeros.gov/ct2/show/NCT04497818,0,0,0,0,0,0,Saudi Arabia,0,cross sectional study using scientifically validated psychometric scales,NA
NCT04497649,2020-07-01,4/1/2021,Interventional,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04497649,0,0,0,0,2,0,Egypt,0,sofosbuvir|daclatasvir,NA
NCT04497636,2020-07-03,1/31/2021,Observational,Mental Health Impact of the COVID-19 Pandemic Among Migrants in Chile,Recruiting,NA,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04497636,0,0,0,0,0,0,Chile,0,"NA",NA
NCT04497441,2020-06-10,8/10/2020,Observational,Netizens' Perception of COVID-19 Information & Information Sources.,Recruiting,NA,Qassim University,NA,https://clinicalzeros.gov/ct2/show/NCT04497441,0,0,0,0,0,0,Saudi Arabia,0,questionnaire,NA
NCT04502056,2020-07-31,9/21/2020,Interventional,Covid-19 Messaging to Underserved Communities - 2nd Experiment,"Active, not recruiting",N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04502056,0,0,0,0,1,1,United States,0,acknowledgement racial injustice ama|african american sender acknowledgement|african american sender in informational videos.|racial inequality highlighted|ama acknowledgement drug pricing|white sender in acknowledgement|white sender in informational videos|no racial inequality highlighting|placebo videos,NA
NCT04501432,2020-07-14,10/24/2020,Observational,Cardiac Rehabilitation and Ongoing Physical Activity During COVID-19,Completed,NA,Ludwig Boltzmann Institute for Digital Health and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04501432,0,0,0,0,1,0,Austria,0,no intervention,NA
NCT04526054,2020-09-03,9/3/2021,Interventional,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04526054,0,0,0,0,1,0,France,0,ent exam|olfactometry|brain mri,NA
NCT04497467,2020-08-01,12/31/2020,Observational,Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic,Recruiting,NA,National Taiwan University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04497467,0,0,0,0,0,0,Taiwan,0,"NA",NA
NCT04497415,2020-10-21,11/30/2020,Interventional,The COVID-19 and Healthcare Workers: An Active Intervention,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04497415,0,0,0,0,4,1,United States,0,video-based intervention,NA
NCT04501952,2020-09-18,4/30/2021,Interventional,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,Recruiting,Phase 3,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04501952,0,0,0,0,8,1,United States|Denmark|Spain|United Kingdom,0,rdv|placebo,NA
NCT04510207,2020-07-16,3/16/2021,Interventional,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,Phase 3,China National Biotec Group Company Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04510207,0,0,0,1,6,0,Bahrain|Egypt|Jordan|United Arab Emirates,0,inactivated sars-cov-2 vaccine|placebo,NA
NCT04527471,2020-09-04,2/28/2021,Interventional,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"Active, not recruiting",Phase 2,Verona Pharma plc,NA,https://clinicalzeros.gov/ct2/show/NCT04527471,0,0,0,0,3,1,United States,0,ensifentrine|placebo,NA
NCT04506515,2020-04-09,4/19/2020,Observational,Psychological Impact of COVID-19 Pandemic in Healthcare Workers,Completed,NA,Hospital General Universitario de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04506515,0,0,0,0,0,0,Spain,0,psychological stress/adaptation at work score (psas)|psychological stress|adaptation at work score (psas),NA
NCT04505631,2020-06-10,6/30/2021,Observational,Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19,Recruiting,NA,Groupe Hospitalier de la Region de Mulhouse et Sud Alsace,NA,https://clinicalzeros.gov/ct2/show/NCT04505631,0,0,0,0,0,0,France,0,"NA",NA
NCT04513158,2020-08-14,8/1/2021,Interventional,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Norton Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04513158,0,0,0,0,2,1,United States,0,convalescent plasma,NA
NCT04503057,2020-05-01,5/1/2023,Observational [Patient Registry],Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Lund University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04503057,0,0,0,0,0,0,Sweden,0,"NA",NA
NCT04502433,2021-01-06,7/31/2021,Interventional,Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19),Recruiting,Phase 2,Chiesi Farmaceutici S.p.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04502433,0,0,0,0,1,0,United Kingdom,0,curosurfâ® (poractant alfa),NA
NCT04509713,2020-07-02,9/30/2020,Observational,Canine COVID-19 Detection,Recruiting,NA,ARCTEC,NA,https://clinicalzeros.gov/ct2/show/NCT04509713,0,0,0,0,0,0,United Kingdom,0,collection of odour samples,NA
NCT04505774,2020-09-04,3/31/2021,Interventional,Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4),Recruiting,Phase 4,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04505774,0,0,0,0,4,1,United States|Spain,0,theraputic heparin|heparin,NA
NCT04499300,2020-06-09,12/31/2020,Observational,Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age,Recruiting,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04499300,0,0,0,0,1,0,Belgium,0,data collection from medical files,NA
NCT04498286,2020-08-06,11/1/2021,Observational,COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients,Recruiting,NA,VU University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04498286,0,0,0,0,0,0,Netherlands,0,serology test,NA
NCT04498273,2020-09-07,9/30/2021,Interventional,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,Recruiting,Phase 3,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04498273,0,0,0,0,1,1,United States,0,apixaban 2.5 mg|apixaban 5mg|aspirin|placebo,NA
NCT04498247,2020-08-27,4/26/2022,Interventional,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","Active, not recruiting",Phase 1/Phase 2,Merck Sharp & Dohme Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04498247,0,0,0,1,9,1,United States|Austria|Belgium,0,v591|placebo,NA
NCT04498091,2020-03-15,7/1/2020,Observational,EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19,"Active, not recruiting",NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04498091,0,0,0,0,0,0,France,0,biological data|clinical data,NA
NCT04498065,2020-03-01,7/1/2020,Observational,MYocardial DOmmages Related to COVID-19,"Active, not recruiting",NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04498065,0,0,0,0,0,0,France,0,biological data|clinical data,NA
NCT04497272,2020-08-07,8/7/2021,Interventional,Assesment of the Metabolomic Signature in COVID-19 Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04497272,0,0,0,0,1,0,France,0,covid-19 patients,NA
NCT04497246,2020-05-29,12/31/2020,Observational,"Psychological Impact, Mental Health and Sleep Disorder Among Patients Hospitalized and Health Care Workers During the 2019 Coronavirus Outbreak (COVID-19)",Recruiting,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04497246,0,0,0,0,0,0,Belgium,0,questionnaire,NA
NCT04498442,2020-05-22,10/22/2020,Interventional,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,N/A,Beth Israel Deaconess Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04498442,0,0,0,0,3,1,United States,0,simha kriya|reading a book,NA
NCT04631380,2020-08-01,1/31/2021,Interventional,Prayer in Commbate to Corona Virus - Covid -19,Recruiting,N/A,Hospital do Coracao,NA,https://clinicalzeros.gov/ct2/show/NCT04631380,0,0,0,0,0,0,Brazil,0,prayer,NA
NCT04505592,2020-09-25,6/30/2021,Interventional,Tenecteplase in Patients With COVID-19,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04505592,0,0,0,0,3,1,United States,0,tenecteplase|placebo,NA
NCT04504240,2020-08-01,10/30/2020,Interventional,Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients,Recruiting,Phase 3,Chattogram General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04504240,0,0,0,0,1,0,Bangladesh,0,famotidine,NA
NCT04504877,2020-06-16,11/16/2020,Interventional,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,"Active, not recruiting",Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04504877,0,0,0,0,3,0,Brazil,0,cannabidiol,NA
NCT04504734,2020-11-27,2/1/2021,Interventional,Bucillamine in Treatment of Patients With COVID-19,Enrolling by invitation,Phase 3,"Revive Therapeutics, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04504734,0,0,0,0,11,1,United States,0,bucillamine|placebo,NA
NCT04515199,2020-07-01,1/31/2021,Observational [Patient Registry],Home Management of Adult Egyptian Mild COVID-19 Cases,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04515199,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04511650,2020-10-21,2/28/2021,Interventional,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,Phase 2,Aerpio Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04511650,0,0,0,0,7,1,United States,0,razuprotafib subcutaneous solution|placebo,NA
NCT04503525,2020-05-25,5/25/2021,Observational,Nutritional Assessment of Hospitalized Patients With COVID-19,Recruiting,NA,Lille Catholic University,NA,https://clinicalzeros.gov/ct2/show/NCT04503525,0,0,0,0,0,0,France,0,nutritional assessment,NA
NCT04503447,2020-08-01,9/9/2020,Observational,COVID-19 Seroprevalence Study in ITM Staff,Completed,NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04503447,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04502667,2020-07-15,2/28/2021,Interventional,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04502667,0,0,0,0,0,0,Mexico,0,cholecalciferol,NA
NCT04510441,2020-05-26,5/1/2022,Observational,Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04510441,0,0,0,0,0,0,United Kingdom,0,no intervention,NA
NCT04510194,2021-01-01,9/30/2021,Interventional,MET-COVID -- Outpatient Metformin Use for COVID-19,Recruiting,Phase 2/Phase 3,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04510194,0,0,0,0,5,1,United States,0,metformin|placebo,NA
NCT04502472,2020-06-06,12/31/2021,Interventional,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Recruiting,Phase 2/Phase 3,Inova Health Care Services,NA,https://clinicalzeros.gov/ct2/show/NCT04502472,0,0,0,0,0,1,United States,0,convalescent plasma,NA
NCT04509999,2020-10-26,9/30/2022,Interventional,Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,Recruiting,Phase 3,University of Florida,NA,https://clinicalzeros.gov/ct2/show/NCT04509999,0,0,0,0,5,1,United States,0,bicalutamide 150 mg oral tablet|placebo,NA
NCT04508920,2019-05-15,6/15/2021,Observational [Patient Registry],A Survey to Assess Effects of Covid-19 on Cardiovascular Patients,Recruiting,NA,"Centro en Insuficiencia Cardiaca, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04508920,0,0,0,0,0,0,Mexico,0,"survey|symptomatology, treatment. daily activities",NA
NCT04502342,2020-06-01,8/30/2020,Interventional,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,https://clinicalzeros.gov/ct2/show/NCT04502342,0,0,0,0,1,0,Guinea,0,hydroxychloroquine / azithromycin|cospherunate/azythromycine|cospherunate/phytomedicine/azythromycien|hydroxychloroquine|azithromycin|cospherunate|phytomedicine,NA
NCT04501445,2020-09-14,8/1/2021,Interventional,Psychological Symptoms and Families of COVID-19 Patients,Recruiting,N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04501445,0,0,0,0,2,1,United States,0,written summary of rounds,NA
NCT04500639,2020-07-23,12/31/2020,Observational,Over-the-counter Medications & COVID-19,Recruiting,NA,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04500639,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04508075,2020-08-10,1/31/2021,Interventional,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine",Recruiting,Phase 3,PT Bio Farma,NA,https://clinicalzeros.gov/ct2/show/NCT04508075,0,0,0,1,1,0,Indonesia,0,inactivated vaccine|placebo,NA
NCT04500418,2020-08-25,9/30/2021,Interventional,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,Phase 2,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04500418,0,0,0,0,2,0,Germany,0,cenicriviroc|placebo,NA
NCT04500132,2020-05-28,8/31/2021,Interventional,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,Recruiting,Phase 2,Enzychem Lifesciences Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04500132,0,0,0,0,1,0,"Korea, Republic of",0,ec-18|placebo,NA
NCT04507230,2020-08-07,10/31/2020,Observational,COVID-19 Associated Coagulopathy in Egypt,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04507230,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04575610,2020-11-30,3/31/2021,Interventional,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Recruiting,Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04575610,0,0,0,0,2,1,United States,0,pf-06650833|placebo,NA
NCT04507256,2020-08-18,10/25/2021,Interventional,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"Active, not recruiting",Phase 1,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04507256,0,0,0,0,4,0,United Kingdom,0,azd7442|placebo,NA
NCT04506528,2020-08-10,1/31/2023,Observational [Patient Registry],The C3I COVID-19 Project,Recruiting,NA,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04506528,0,0,0,0,3,1,United States,0,"NA",NA
NCT04534790,2020-07-24,12/31/2020,Interventional,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,Recruiting,N/A,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04534790,0,0,0,0,0,0,Mexico,0,radiotherapy,NA
NCT04506268,2020-09-09,10/13/2020,Interventional,COVID-19 SAFE Enrollment,"Active, not recruiting",N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04506268,0,0,0,0,5,1,United States,0,opt-out recruitment email|opt-in recruitment email,NA
NCT04506229,2020-08-20,8/31/2021,Observational,Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function,Recruiting,NA,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04506229,0,0,0,0,2,1,United States,0,whole exome sequencing,NA
NCT04505709,2020-08-01,8/1/2021,Observational [Patient Registry],"Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19",Enrolling by invitation,NA,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,https://clinicalzeros.gov/ct2/show/NCT04505709,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04508712,2020-08-10,8/31/2021,Observational [Patient Registry],Long-term Outcomes in Patients With COVID-19,Recruiting,NA,RenJi Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04508712,0,0,0,0,2,0,China,0,"NA",NA
NCT04511819,2020-08-28,6/30/2021,Interventional,Losmapimod Safety and Efficacy in COVID-19,Recruiting,Phase 3,Fulcrum Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04511819,0,0,0,0,13,1,United States|Brazil|Mexico,0,losmapimod|placebo,NA
NCT04508439,2020-06-20,8/30/2020,Interventional,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,N/A,Hospital Regional de Alta especialidad de Ixtapaluca,NA,https://clinicalzeros.gov/ct2/show/NCT04508439,0,0,0,0,0,0,Mexico,0,enoxaparin,NA
NCT04507893,2020-03-15,9/30/2020,Observational,Comparison Between Positive and Negative COVID-19 Pneumonia,Recruiting,NA,University of Palermo,NA,https://clinicalzeros.gov/ct2/show/NCT04507893,0,0,0,0,1,0,Italy,0,"clinical, laboratory/imaging characteristics of pneumonia|clinical, laboratory|imaging characteristics of pneumonia",NA
NCT04516915,2020-06-15,5/31/2021,Interventional,IMU-838 and Oseltamivir in the Treatment of COVID-19,Recruiting,Phase 2,University Hospitals Coventry and Warwickshire NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04516915,0,0,0,0,1,0,United Kingdom,0,imu-838|oseltamivir,NA
NCT04513470,2020-08-01,1/31/2021,Interventional,Allocetra-OTS in COVID-19,"Active, not recruiting",Phase 1,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04513470,0,0,0,0,1,0,Israel,0,allocetra-ots,NA
NCT04501991,2020-03-11,5/4/2020,Observational,Short-term Impact of COVID-19 Lockdown on Metabolic Control of Type 2 Diabetes,Completed,NA,University of Pisa,NA,https://clinicalzeros.gov/ct2/show/NCT04501991,0,0,0,0,0,0,Italy,0,antidiabetic treatment,NA
NCT04501783,2020-05-20,7/29/2020,Interventional,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,"Active, not recruiting",Phase 3,R-Pharm,NA,https://clinicalzeros.gov/ct2/show/NCT04501783,0,0,0,0,0,0,Russian Federation,0,favipiravir|standard care,NA
NCT04501458,2020-05-18,12/19/2020,Interventional,Western Kenya Integrated COVID-19 Response,Recruiting,N/A,Surgical Systems Research Group,NA,https://clinicalzeros.gov/ct2/show/NCT04501458,0,0,0,0,2,0,Kenya,0,"training of youth, community health assistants/community health workers.|training clinicians in basic critical care/the management of severe covid-19 cases|training of youth, community health assistants|community health workers.|training clinicians in basic critical care|the management of severe covid-19 cases",NA
NCT04504032,2020-09-02,4/30/2021,Interventional,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),Recruiting,Phase 2,Bill & Melinda Gates Medical Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04504032,0,0,0,0,6,1,United States|United Kingdom,0,rivaroxaban|placebo,NA
NCT04510012,2020-03-05,3/5/2021,Observational,Characterizing the Immune Response and Neuronal Damage in COVID-19,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04510012,0,0,0,0,0,0,Switzerland,0,"analysis of cytokine response, innate/adaptive immune response, complement activation,/serum neurofilaments as a marker of neurological damage.|analysis of cytokine response, innate|adaptive immune response, complement activation,|serum neurofilaments as a marker of neurological damage.",NA
NCT04508972,2020-07-01,10/1/2020,Observational,The VOICE-COVID-19,Recruiting,NA,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04508972,0,0,0,0,4,0,Canada,0,alexa amazon,NA
NCT04508959,2020-04-15,7/31/2021,Observational [Patient Registry],The McMaster Multi-Regional COVID-19 Hospital Case Registry,Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04508959,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04508868,2020-08-31,12/23/2020,Interventional,Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,Terminated,N/A,Uppsala University,"Study terminated due to changes in government restrictions. Collected data to be presented as a
    pilot study.",https://clinicalzeros.gov/ct2/show/NCT04508868,0,0,0,0,2,0,Sweden,0,behavioral|minimal attention control intervention,NA
NCT04508777,2020-09-09,12/31/2020,Observational,COVID SAFE: COVID-19 Screening Assessment for Exposure,Enrolling by invitation,NA,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04508777,0,0,0,0,2,1,United States,0,saliva,NA
NCT04508023,2020-08-13,3/3/2021,Interventional,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",Recruiting,Phase 3,"Janssen Research & Development, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04508023,0,0,0,0,6,1,United States,0,rivaroxaban|placebo|standard care,NA
NCT04511923,2020-12-23,12/31/2021,Interventional,Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,Recruiting,Phase 1/Phase 2,University College Hospital Galway,NA,https://clinicalzeros.gov/ct2/show/NCT04511923,0,0,0,0,1,0,Ireland,0,nebulised heparin,NA
NCT04581018,2020-08-13,10/30/2021,Interventional,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04581018,0,0,0,0,1,0,Hong Kong,0,health supplements,NA
NCT04527575,2020-07-27,9/28/2020,Interventional,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Active, not recruiting",Phase 1/Phase 2,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,https://clinicalzeros.gov/ct2/show/NCT04527575,0,0,0,1,1,0,Russian Federation,0,epivaccorona (epivaccorona vaccine based on peptide antigens for the prevention of covid-19)|placebo,NA
NCT04515147,2020-09-28,11/9/2021,Interventional,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","Active, not recruiting",Phase 2,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04515147,0,0,0,1,8,0,Panama|Peru,0,cvncov 6 î¼g|cvncov 12 î¼g|hepatitis a vaccine|pneumococcal vaccine|cvncov 12î¼g,NA
NCT04513964,2020-11-01,12/31/2020,Observational,Impact of COVID-19 on the Benefit of Cardiac Rehabilitation,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04513964,0,0,0,0,2,0,France,0,"NA",NA
NCT04514016,2020-08-12,3/31/2021,Observational,Cross Sectional CFAR HIV/COVID Study,Recruiting,NA,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04514016,0,0,0,0,0,1,United States,0,"NA",NA
NCT04514003,2020-07-01,12/31/2023,Observational,The Corona and COVID-19 Study in Telemark and Agder,Recruiting,NA,Sykehuset Telemark,NA,https://clinicalzeros.gov/ct2/show/NCT04514003,0,0,0,0,1,0,Norway,0,"NA",NA
NCT04517695,2020-08-01,2/1/2021,Observational,Blood Volume Assessment in COVID-19 ICU Patients - BVAC19,Recruiting,NA,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04517695,0,0,0,0,0,1,United States,0,bva-100,NA
NCT04513210,2020-10-10,10/30/2021,Observational,Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 Infection,Enrolling by invitation,NA,Jagiellonian University,NA,https://clinicalzeros.gov/ct2/show/NCT04513210,0,0,0,0,3,0,Poland,0,"NA",NA
NCT04512079,2020-09-08,3/31/2021,Interventional,FREEDOM COVID-19 Anticoagulation Strategy,Recruiting,Phase 4,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04512079,0,0,0,0,2,1,United States|Brazil|Colombia|India|Mexico,0,enoxaparin|apixaban,NA
NCT04512027,2020-09-15,9/19/2020,Interventional,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,Completed,N/A,Composite Interceptive Med Science,NA,https://clinicalzeros.gov/ct2/show/NCT04512027,0,0,0,0,3,0,India,0,prolectin-m; a (1-6)-alpha-d-mannopyranose class|standard care,NA
NCT04510662,2020-08-31,3/31/2021,Interventional,Telmisartan in Respiratory Failure Due to COVID-19,Recruiting,Phase 2,Hospital Regional de Alta Especialidad de Zumpango,NA,https://clinicalzeros.gov/ct2/show/NCT04510662,0,0,0,0,0,0,Mexico,0,telmisartan,NA
NCT04510493,2020-10-23,9/30/2023,Interventional,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Recruiting,Phase 3,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04510493,0,0,0,0,4,0,Switzerland,0,canakinumab|placebo,NA
NCT04509973,2020-08-27,9/17/2021,Interventional,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Recruiting,Phase 3,Scandinavian Critical Care Trials Group,NA,https://clinicalzeros.gov/ct2/show/NCT04509973,0,0,0,0,1,0,Denmark|India|Sweden|Switzerland,0,dexamethasone,NA
NCT04509947,2020-08-11,1/8/2021,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1,Janssen Pharmaceutical K.K.,NA,https://clinicalzeros.gov/ct2/show/NCT04509947,0,0,0,0,4,0,Japan,0,ad26.cov2.s|placebo,NA
NCT04605965,2020-06-09,6/30/2022,Observational [Patient Registry],WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19,Recruiting,NA,Tulane University,NA,https://clinicalzeros.gov/ct2/show/NCT04605965,0,0,0,0,1,1,United States,0,"NA",NA
NCT04522089,2020-08-24,11/20/2020,Interventional,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,Recruiting,Phase 1,Adimmune Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04522089,0,0,0,1,3,0,Taiwan,0,adimrsc-2f,NA
NCT04519216,2020-07-31,6/30/2021,Interventional,Breastfeeding Education in the Time of COVID-19,Recruiting,N/A,"University of California, Davis",NA,https://clinicalzeros.gov/ct2/show/NCT04519216,0,0,0,0,0,1,United States,0,telesimulation,NA
NCT04513847,2020-08-13,9/13/2020,Observational,PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis,Completed,NA,Dermatrials Research,NA,https://clinicalzeros.gov/ct2/show/NCT04513847,0,0,0,0,2,0,Canada,0,"NA",NA
NCT04513184,2020-07-14,3/30/2021,Interventional,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,Phase 2,Universidad Nacional Autonoma de Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04513184,0,0,0,0,3,0,Mexico,0,dexamethasone,NA
NCT04512300,2020-06-15,6/25/2020,Observational,Parental Attitude Toward Children Dental Treatment During COVID-19 Pandemic,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04512300,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04512118,2020-03-15,6/30/2020,Observational,CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04512118,0,0,0,0,0,0,France,0,pet-ct of 18f-fdg,NA
NCT04511949,2020-07-12,9/30/2020,Interventional,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,N/A,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,https://clinicalzeros.gov/ct2/show/NCT04511949,0,0,0,0,2,0,France,0,igm/igg rapid test|igg|igm antibodytest,NA
NCT04540120,2020-09-25,6/30/2021,Interventional,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,Recruiting,Phase 2,Olatec Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04540120,0,0,0,0,11,1,United States|Netherlands|Switzerland,0,dapansutrile capsules|placebo,NA
NCT04521010,2020-01-01,4/30/2020,Observational,Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic,Completed,NA,Poznan University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04521010,0,0,0,0,0,0,Poland,0,covid-19 pandemic,NA
NCT04516564,2020-09-30,3/31/2021,Interventional,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",Recruiting,Phase 1,Akeso,NA,https://clinicalzeros.gov/ct2/show/NCT04516564,0,0,0,0,2,0,New Zealand,0,ak119|placebo,NA
NCT04527614,2020-09-24,5/30/2021,Interventional,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Enrolling by invitation,N/A,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04527614,0,0,0,0,1,0,Belgium,0,qrt-pcr/serology|qrt-pcr|serology test,NA
NCT04523571,2020-07-28,9/30/2020,Interventional,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Active, not recruiting",Phase 1,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04523571,0,0,0,1,2,0,China,0,bnt162b1|placebo,NA
NCT04522830,2020-07-30,1/31/2021,Interventional,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,Recruiting,Phase 2,"Beech Tree Labs, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04522830,0,0,0,0,7,1,United States,0,btl-tml-covid|placebo,NA
NCT04522076,2020-04-06,5/1/2022,Observational,Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia,"Active, not recruiting",NA,National Medical Research Center for Therapy and Preventive Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04522076,0,0,0,0,0,0,Russian Federation,0,"NA",NA
NCT04519502,2020-06-23,3/31/2021,Observational,Maternal Morbidity and Mortality During the COVID-19 Pandemic,Recruiting,NA,The George Washington University Biostatistics Center,NA,https://clinicalzeros.gov/ct2/show/NCT04519502,0,0,0,0,1,1,United States,0,"NA",NA
NCT04519398,2020-08-18,2/17/2021,Observational,Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events,Recruiting,NA,Grigore T. Popa University of Medicine and Pharmacy,NA,https://clinicalzeros.gov/ct2/show/NCT04519398,0,0,0,0,0,0,Romania,0,complete thrombophilic profile testing by multiplex pcr,NA
NCT04519320,2020-05-18,8/18/2021,Interventional,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,Recruiting,N/A,Centre Hospitalier Universitaire de Besancon,NA,https://clinicalzeros.gov/ct2/show/NCT04519320,0,0,0,0,1,0,France,0,pulmonary function testing,NA
NCT04519307,2020-03-01,8/1/2020,Observational,Evaluation of Newborns Presenting With Suspected COVID 19,"Active, not recruiting",NA,Dr. Behcet Uz Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04519307,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04518735,2020-04-01,6/30/2020,Observational,Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study),Completed,NA,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,https://clinicalzeros.gov/ct2/show/NCT04518735,0,0,0,0,0,0,Spain,0,antithrombotic therapy (anticoagulant and/or antiplatelet) before admission for covid19|antithrombotic therapy (anticoagulant and|or antiplatelet) before admission for covid19,NA
NCT04519411,2020-05-21,12/31/2021,Interventional,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04519411,0,0,0,0,1,1,United States,0,transpulmonary pressure measurements,NA
NCT04519255,2020-07-01,12/31/2022,Observational,Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT,"Active, not recruiting",NA,"Fifth Affiliated Hospital, Sun Yat-Sen University",NA,https://clinicalzeros.gov/ct2/show/NCT04519255,0,0,0,0,1,0,China,0,"NA",NA
NCT04650178,2020-05-26,7/1/2021,Observational,Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04650178,0,0,0,0,0,1,United States,0,quality-of-life assessment|questionnaire,NA
NCT04581161,2020-08-28,10/31/2020,Interventional,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,N/A,Hill-Rom,NA,https://clinicalzeros.gov/ct2/show/NCT04581161,0,0,0,0,0,1,United States,0,life2000â® ventilator,NA
NCT04531735,2020-03-01,8/1/2020,Observational,Respiratory Syncytial Virus Infection May be More Dangerous in Neonate,"Active, not recruiting",NA,Dr. Behcet Uz Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04531735,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04531618,2020-08-13,12/31/2021,Interventional,Mother-infant Bonding During COVID-19,Recruiting,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04531618,0,0,0,0,1,1,United States,0,family nurture intervention (fni),NA
NCT04528641,2020-08-10,7/31/2021,Interventional,GRAd-COV2 Vaccine Against COVID-19,Recruiting,Phase 1,ReiThera Srl,NA,https://clinicalzeros.gov/ct2/show/NCT04528641,0,0,0,1,1,0,Italy,0,grad-cov2,NA
NCT04525911,2020-08-26,3/31/2021,Observational,Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital,Recruiting,NA,HÃ´pital EuropÃ©en Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04525911,0,0,0,0,1,0,France,0,serology test,NA
NCT04524520,2020-05-05,5/8/2021,Observational,"COVID19-OR (SARS-CoV-2): Observation,Risk & Recovery",Recruiting,NA,Western Sussex Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04524520,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04523831,2020-06-01,8/22/2020,Interventional,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Completed,Phase 3,Dhaka Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04523831,0,0,0,0,5,0,Bangladesh,1,ivermectin/doxycycline|standard care|ivermectin|doxycycline,NA
NCT04523181,2020-10-08,4/30/2021,Interventional,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,Recruiting,Phase 2,Golden Biotechnology Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04523181,0,0,0,0,4,1,United States|Argentina|Peru,0,antroquinonol|placebo,NA
NCT04522466,2020-04-03,5/28/2020,Interventional,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Terminated,Phase 3,Centre Hospitalier Universitaire de Saint Etienne,Stop of the study by competent authority (ANSM),https://clinicalzeros.gov/ct2/show/NCT04522466,0,0,0,0,1,0,France,0,hydroxychloroquine,NA
NCT04521322,2020-07-24,10/30/2020,Interventional,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,Recruiting,Phase 4,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicalzeros.gov/ct2/show/NCT04521322,0,0,0,0,1,0,Argentina,0,iota-carrageenan,NA
NCT04528368,2020-12-11,4/30/2021,Interventional,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,Phase 2,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04528368,0,0,0,0,1,0,Brazil,0,convalescent plasma,NA
NCT04529499,2020-08-20,3/31/2021,Interventional,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,"Active, not recruiting",Phase 3,Dr. Reddy's Laboratories Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04529499,0,0,0,0,2,0,Kuwait,0,avigan|placebo,NA
NCT04530448,2020-10-05,1/31/2021,Interventional,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Recruiting,Phase 4,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04530448,0,0,0,0,2,1,United States,0,sodium bicarbonate|standard care,NA
NCT04527497,2020-08-01,5/30/2021,Observational,Clinical Course and Treatment of COVID-19 Inpatients in Hospital,Recruiting,NA,Wissenschaftliches Institut Bethanien e.V,NA,https://clinicalzeros.gov/ct2/show/NCT04527497,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04525287,2020-02-20,8/20/2020,Observational,Prediction Models for Diagnosis and Prognosis of Severe COVID-19,Recruiting,NA,"Second Affiliated Hospital, School of Medicine, Zhejiang University",NA,https://clinicalzeros.gov/ct2/show/NCT04525287,0,0,0,0,0,0,China,0,"NA",NA
NCT04524598,2020-07-20,12/31/2020,Interventional,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Recruiting,N/A,"Limbix Health, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04524598,0,0,0,0,1,1,United States,0,limbix spark|psychoeducation,NA
NCT04523246,2020-09-01,7/1/2021,Interventional,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,Recruiting,Early Phase 1,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04523246,0,0,0,1,2,1,United States,0,"shingrix (zoster vaccine recombinant, adjuvanted)|saline",NA
NCT04517123,2020-09-01,12/31/2021,Interventional,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04517123,0,0,0,0,2,1,United States,0,prone positioning,NA
NCT04523090,2020-08-27,4/30/2021,Interventional,Catalysing the Containment of COVID-19,Recruiting,Phase 2/Phase 3,University of Cape Town,NA,https://clinicalzeros.gov/ct2/show/NCT04523090,0,0,0,0,2,0,South Africa,0,nitazoxanide|placebo,NA
NCT04523051,2020-04-01,4/1/2021,Observational,Rehabilitation After Admission in Intensive Care Unit for COVID-19,Recruiting,NA,Centre Hospitalier RÃ©gional Metz-Thionville,NA,https://clinicalzeros.gov/ct2/show/NCT04523051,0,0,0,0,1,0,France,0,"NA",NA
NCT04523012,2020-07-01,6/30/2021,Observational,COVID-19 and HIV Patients,Recruiting,NA,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,https://clinicalzeros.gov/ct2/show/NCT04523012,0,0,0,0,0,0,France,0,seroprevalence of sars-cov-2 infection in patients with hiv infection,NA
NCT04517097,2020-05-12,6/30/2020,Observational,Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic,Completed,NA,Centre Georges Francois Leclerc,NA,https://clinicalzeros.gov/ct2/show/NCT04517097,0,0,0,0,0,0,France,0,blood sample,NA
NCT04528667,2021-01-06,5/31/2021,Interventional,Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04528667,0,0,0,0,2,0,Brazil,0,sti-5656|placebo,NA
NCT04568031,2020-08-23,11/10/2021,Interventional,Study of AZD1222 for the Prevention of COVID-19 in Japan,"Active, not recruiting",Phase 1/Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04568031,0,0,0,1,3,0,Japan,0,azd1222|0.9% (w/v) saline|0.9% (w|v) saline,NA
NCT04552379,2020-12-01,4/30/2021,Interventional,The Containing Coronavirus Disease 19 (COVID-19) Trial,Recruiting,Phase 3,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04552379,0,0,0,0,1,0,Chile,0,peginterferon beta-1a,NA
NCT04535167,2020-09-09,7/5/2021,Interventional,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.",Recruiting,Phase 1,Pfizer,NA,https://clinicalzeros.gov/ct2/show/NCT04535167,0,0,0,0,3,1,United States,0,pf-07304814|placebo,NA
NCT04526912,2020-08-28,4/30/2021,Interventional,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,Recruiting,Phase 1,Viela Bio,NA,https://clinicalzeros.gov/ct2/show/NCT04526912,0,0,0,0,3,1,United States,0,vib7734|placebo,NA
NCT04525716,2020-03-01,8/31/2020,Observational,The Effect of Covid-19 on Patient Outcomes Among Operated Patients,Recruiting,NA,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04525716,0,0,0,0,0,0,Sweden,0,covid-19 infection status,NA
NCT04525443,2020-06-03,8/31/2020,Observational,Endothelial Function and COVID-19,Recruiting,NA,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04525443,0,0,0,0,0,1,United States|Spain,0,"NA",NA
NCT04524754,2020-07-11,9/11/2020,Observational,Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04524754,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04524507,2020-08-27,5/31/2021,Interventional,COVID-19 Antibody Plasma Research Study in Hospitalized Patients,Recruiting,Phase 2,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04524507,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04524234,2020-04-20,8/31/2020,Observational,Cardiac Dysfunction in Critically Ill Patients With COVID-19,Completed,NA,"Sahlgrenska University Hospital, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04524234,0,0,0,0,3,0,Sweden,0,echocardiography,NA
NCT04525417,2020-04-25,9/25/2020,Interventional,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Completed,N/A,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,NA,https://clinicalzeros.gov/ct2/show/NCT04525417,0,0,0,0,1,0,France,0,aaz covid-19 rapid test,NA
NCT04536935,2021-01-31,2/28/2021,Interventional,Mobile Mental Health Apps for Suicide Prevention,Enrolling by invitation,N/A,University of Washington,NA,https://clinicalzeros.gov/ct2/show/NCT04536935,0,0,0,0,2,1,United States,0,mobile mental health app - 1|mobile mental health app - 2|mobile mental health app - 3|mobile mental health app - 4,NA
NCT04526990,2020-09-15,12/30/2021,Interventional,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,Recruiting,Phase 3,CanSino Biologics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04526990,0,0,0,1,11,0,Mexico|Argentina|Chile|Pakistan|Russian Federation,0,adenovirus type 5 vector|placebo,NA
NCT04526977,2021-01-10,6/30/2021,Observational,Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).,Recruiting,NA,Asociacion para el Estudio de las Enfermedades Infecciosas,NA,https://clinicalzeros.gov/ct2/show/NCT04526977,0,0,0,0,1,0,Spain,0,immune response study,NA
NCT04531254,2020-08-10,10/31/2020,Observational,Back to School COVID-19 Simulation Study,"Active, not recruiting",NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04531254,0,0,0,0,0,0,Canada,0,behavior,NA
NCT04530409,2020-08-26,12/1/2020,Interventional,Timing of Corticosteroids in COVID-19,Recruiting,Phase 4,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04530409,0,0,0,0,2,0,Egypt,0,early-dexamethasone|dexamethasone,NA
NCT04527458,2020-02-24,8/2/2020,Observational,Case Fatalities in Hospitalised COVID-19 Patients in the UK,Completed,NA,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04527458,0,0,0,0,0,0,United Kingdom,0,patient characteristics|covid-19 treatments|differences in triage|surge capacity,NA
NCT04527432,2020-12-16,3/31/2022,Interventional,COVID-19 Health Professional Impact Study,Recruiting,N/A,The Royal Wolverhampton Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04527432,0,0,0,0,3,0,United Kingdom,0,questionnaire|sars-cov-2 antibody test,NA
NCT04527354,2020-09-08,11/30/2020,Interventional,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,"Active, not recruiting",Phase 2,PHARMENTERPRISES LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04527354,0,0,0,0,2,0,Russian Federation,0,treamid|placebo,NA
NCT04527315,2020-07-17,8/31/2023,Observational [Patient Registry],COVID-19 Survivorship Registry,Recruiting,NA,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04527315,0,0,0,0,1,1,United States,0,questionnaire,NA
NCT04527133,2020-06-11,8/11/2020,Interventional,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",N/A,Aviron LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04527133,0,0,0,0,0,0,Russian Federation,0,aprotinin,NA
NCT04527081,2020-08-31,11/9/2020,Interventional,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"Active, not recruiting",Phase 1/Phase 2,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04527081,0,0,0,1,4,0,Japan,0,ag0302-covid19,NA
NCT04559542,2020-09-10,11/30/2020,Observational,"Body Weight Regulation, Disordered Eating Behaviour, and Experiences of Sexual Harassment in Female Martial Art Athletes",Recruiting,NA,Norwegian School of Sport Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04559542,0,0,0,0,0,0,Norway,0,"NA",NA
NCT04537351,2020-08-24,3/31/2021,Interventional,The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19,Recruiting,Phase 1/Phase 2,Cynata Therapeutics Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04537351,0,0,0,0,2,0,Australia,0,cyp-001,NA
NCT04532411,2020-03-01,9/30/2020,Observational,COVID-19 Testing Sample Acquisition Throughput and Efficiency,"Active, not recruiting",NA,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04532411,0,0,0,0,0,1,United States,0,personal protective testing booth,NA
NCT04532372,2021-01-07,9/18/2022,Interventional,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,Recruiting,Phase 1/Phase 2,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04532372,0,0,0,0,2,1,United States,0,best available therapy|leflunomide|placebo,NA
NCT04531111,2020-07-07,8/31/2020,Observational,Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04531111,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04530604,2020-10-01,10/1/2021,Interventional,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Recruiting,Phase 1,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04530604,0,0,0,0,1,1,United States,0,defibrotide,NA
NCT04530435,2020-10-06,4/30/2021,Interventional,PEP Flute-selfcare in COVID-19,Recruiting,N/A,Bispebjerg Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04530435,0,0,0,0,2,0,Denmark,0,pep flute,NA
NCT04528901,2020-09-04,12/31/2022,Observational,Study of seroPREvalence Vis-Ã -vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital),Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04528901,0,0,0,0,2,0,France,0,"NA",NA
NCT04527601,2020-08-21,9/13/2020,Observational,Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments,Completed,NA,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04527601,0,0,0,0,3,0,Denmark,0,"NA",NA
NCT04527562,2020-07-14,11/15/2020,Interventional,Colchicine in Moderate Symptomatic COVID-19 Patients,Completed,N/A,Dhaka Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04527562,0,0,0,0,2,0,Bangladesh,0,colchicine|placebo,NA
NCT04730284,2020-08-25,9/30/2021,Interventional,Evaluation of a Synbiotic Formula in Patient With COVID-19,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04730284,0,0,0,0,0,0,Hong Kong,0,health supplements,NA
NCT04559074,2020-10-23,4/30/2021,Interventional,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Recruiting,Phase 4,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04559074,0,0,0,0,2,0,United Kingdom,0,amlodipine,NA
NCT04554992,2020-03-20,6/30/2022,Interventional,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),"Active, not recruiting",Phase 1,The Methodist Hospital System,NA,https://clinicalzeros.gov/ct2/show/NCT04554992,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04546841,2020-11-27,9/30/2021,Interventional,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,Recruiting,Phase 1,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04546841,0,0,0,1,1,0,Germany,0,multipeptide cocktail,NA
NCT04516928,2020-09-21,11/2/2020,Observational,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04516928,0,0,0,0,1,0,France,0,serology test|questionnaire,NA
NCT04516759,2020-08-12,3/31/2021,Interventional,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,Recruiting,Phase 2,St George Street Capital,NA,https://clinicalzeros.gov/ct2/show/NCT04516759,0,0,0,0,9,0,Czechia|Romania|United Kingdom,0,azd1656|placebo,NA
NCT04514874,2020-09-01,12/31/2020,Observational,Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04514874,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04544072,2020-05-01,12/1/2020,Observational,Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards,Recruiting,NA,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04544072,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04517630,2020-06-01,9/30/2020,Observational [Patient Registry],Renal Biomarkers in AKI and COVID-19,Recruiting,NA,Instituto Nacional de Enfermedades Respiratorias,NA,https://clinicalzeros.gov/ct2/show/NCT04517630,0,0,0,0,1,0,Mexico,0,"urinary ngal, timp-2, igfbp7, il-6, viral load/metabolomic|urinary ngal, timp-2, igfbp7, il-6, viral load|metabolomic",NA
NCT04536441,2020-04-01,5/30/2020,Interventional,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Completed,N/A,Universiti Tunku Abdul Rahman,NA,https://clinicalzeros.gov/ct2/show/NCT04536441,0,0,0,0,0,0,Malaysia,0,ultra brief online mindfulness-based intervention|control,NA
NCT04534400,2020-09-01,1/15/2021,Observational,Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04534400,0,0,0,0,1,0,France,0,thoracic ct-scan,NA
NCT04517136,2020-09-14,2/14/2021,Observational,Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04517136,0,0,0,0,3,0,France,0,assessment of work-related stress|saliva|cardiac/electrodermal recordings|emotional stimulation|cardiac|electrodermal recordings,NA
NCT04550351,2020-08-19,12/18/2020,Interventional,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04550351,0,0,0,1,3,0,China,0,biological/vaccine: recombinant new coronavirus vaccine (cho cell) low-dose group|biological/vaccine: recombinant new coronavirus vaccine (cho cells) high-dose group|biological/vaccine: recombinant new coronavirus vaccine (cho cells) placebo group|biological|vaccine: recombinant new coronavirus vaccine (cho cell) low-dose group|vaccine: recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,NA
NCT04542850,2020-11-15,6/15/2021,Interventional,"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19",Recruiting,N/A,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04542850,0,0,0,0,2,0,Bahrain,0,5-ala-phosphate / sfc (5-ala / sfc)|5-ala-phosphate|sfc (5-ala|sfc),NA
NCT04532931,2020-09-03,6/30/2021,Interventional,COVID-19 Treatment in South Africa,Recruiting,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04532931,0,0,0,0,4,0,South Africa,0,standard care|artesunate-amodiaquine|pyronaridine-artesunate|favipiravir/nitazoxanide|sofosbuvir/daclatasvir|favipiravir|nitazoxanide|sofosbuvir|daclatasvir,NA
NCT04531774,2020-08-28,6/1/2021,Interventional,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,N/A,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04531774,0,0,0,0,2,0,Switzerland,0,recharge|self study,NA
NCT04531501,2020-06-29,9/29/2020,Observational,COVID-19 Saliva Test Research Study,Recruiting,NA,Chronomics Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04531501,0,0,0,0,0,0,United Kingdom,0,saliva/nps test|saliva|nps test,NA
NCT04516837,2020-08-31,8/31/2021,Interventional,Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),Recruiting,Phase 2,Peking University People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04516837,0,0,0,0,2,0,China,0,eltrombopag|rhtpo,NA
NCT04516824,2020-03-19,7/13/2020,Observational,Experience of Orthopaedic and Spine Center Pakistan During COVID-19,Completed,NA,Ghurki Trust and Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04516824,0,0,0,0,0,0,Pakistan,0,orthopaedic surgical procedures,NA
NCT04547634,2020-07-01,11/30/2020,Interventional,Telerehabilitation in Oncology Patients,Enrolling by invitation,N/A,University of Malaga,NA,https://clinicalzeros.gov/ct2/show/NCT04547634,0,0,0,0,0,0,Spain,0,therapeutic exercise/education|therapeutic exercise|education,NA
NCT04531202,2020-03-02,9/30/2020,Observational [Patient Registry],CORE Study COVID-19,Recruiting,NA,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04531202,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04530500,2020-08-13,6/24/2023,Observational,COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression,Enrolling by invitation,NA,"University of California, Irvine",NA,https://clinicalzeros.gov/ct2/show/NCT04530500,0,0,0,0,1,1,United States,0,covid-19 androgen sensitivity test (covast),NA
NCT04530461,2020-06-01,11/30/2020,Observational,Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases,Recruiting,NA,Military Hospital of Tunis,NA,https://clinicalzeros.gov/ct2/show/NCT04530461,0,0,0,0,1,0,Tunisia,0,serology test,NA
NCT04530422,2020-04-15,7/8/2020,Interventional,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,Phase 3,Almaza Military Fever Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04530422,0,0,0,0,0,0,Egypt,0,sofosbuvir/ledipasvir|sofosbuvir|ledipasvir,NA
NCT04530370,2020-05-29,9/30/2020,Interventional,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,Early Phase 1,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04530370,0,0,0,0,0,0,Egypt,0,convalescent plasma,NA
NCT04530357,2020-09-19,11/25/2020,Interventional,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine",Completed,Phase 1/Phase 2,Research Institute for Biological Safety Problems,NA,https://clinicalzeros.gov/ct2/show/NCT04530357,0,0,0,1,7,0,Kazakhstan,0,qazcovid-inâ® - covid-19 inactivated vaccine|placebo,NA
NCT04530136,2020-11-30,8/15/2021,Interventional,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,Pharming Technologies B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04530136,0,0,0,0,2,1,United States,0,ruconest,NA
NCT04529447,2020-06-10,8/10/2020,Observational,Response of Korean Medicine Hospital to COVID-19,Completed,NA,Jaseng Hospital of Korean Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04529447,0,0,0,0,0,0,"Korea, Republic of",0,questionnaire,NA
NCT04529408,2020-08-26,8/26/2020,Observational,EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04529408,0,0,0,0,0,0,United Kingdom,0,earsats pulse oximeter probe,NA
NCT04539262,2020-09-14,3/31/2021,Interventional,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Recruiting,Phase 1/Phase 2,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04539262,0,0,0,0,6,1,United States,0,remdesivir|placebo,NA
NCT04541680,2020-10-29,3/31/2021,Interventional,Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04541680,0,0,0,0,1,0,France,0,nintedanib 150 mg [ofev]|placebo,NA
NCT04540419,2020-09-11,11/30/2020,Interventional,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Active, not recruiting",Phase 3,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04540419,0,0,0,1,2,0,Russian Federation,0,adenovirus type 5 vector|placebo,NA
NCT04530578,2020-06-01,10/30/2020,Interventional,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Recruiting,Phase 4,"Clinica San Camilo, Argentina",NA,https://clinicalzeros.gov/ct2/show/NCT04530578,0,0,0,0,1,0,Argentina,0,heparin|enoxaparin,NA
NCT04525820,2020-12-15,5/31/2021,Interventional,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study",Recruiting,N/A,"Cantonal Hosptal, Baselland",NA,https://clinicalzeros.gov/ct2/show/NCT04525820,0,0,0,0,2,0,Switzerland,0,single high dose vitamin d|placebo|treatment as usual vitamin d,NA
NCT04525404,2020-11-12,9/1/2021,Observational,MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients,Recruiting,NA,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04525404,0,0,0,0,2,0,Canada,0,"mri (heart, brain, lungs, liver)|bloodwork|cognitive testing|olfaction testing|spirometry|walk test",NA
NCT04539275,2020-11-16,6/20/2022,Interventional,COVID-19 (VA CURES-1),Recruiting,Phase 3,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04539275,0,0,0,0,6,1,United States,0,convalescent plasma|masked saline placebo,NA
NCT04537559,2020-03-01,7/31/2020,Observational,Impact of COVID-19 Outbreak on Non-COVID-19 Patients,Enrolling by invitation,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04537559,0,0,0,0,1,0,Switzerland,0,"NA",NA
NCT04536298,2020-12-28,4/30/2021,Interventional,Vitamin D and COVID-19 Trial,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04536298,0,0,0,0,2,1,United States,0,vitamin d|placebo,NA
NCT04536285,2020-05-01,8/31/2020,Observational,Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in Egypt,Completed,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04536285,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04519385,2020-03-01,7/1/2020,Interventional,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04519385,0,0,0,0,1,0,Egypt,0,tocilizumab|dexamethasone,NA
NCT04535700,2020-09-18,3/10/2021,Interventional,Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19,Recruiting,Phase 4,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04535700,0,0,0,0,1,0,Spain,0,pioglitazone 30 mg|standard care,NA
NCT04535453,2020-08-28,12/15/2021,Interventional,A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents,Recruiting,Phase 2,Janssen Vaccines & Prevention B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04535453,0,0,0,1,4,0,Canada|Germany|Netherlands|Spain|United Kingdom,0,ad26.cov2.s|placebo,NA
NCT04519372,2020-04-01,6/14/2020,Observational,SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting,"Active, not recruiting",NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04519372,0,0,0,0,1,0,Switzerland,0,testing for sars-cov-2,NA
NCT04518410,2020-08-19,12/31/2021,Interventional,ACTIV-2: A Study for Outpatients With COVID-19,Recruiting,Phase 2/Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04518410,0,0,0,0,51,1,United States|Puerto Rico,0,ly3819253|placebo,NA
NCT04517396,2020-08-18,8/31/2021,Interventional,FEnofibRate as a Metabolic INtervention for COVID-19,Enrolling by invitation,Phase 2,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04517396,0,0,0,0,5,1,United States,0,fenofibrate/fenofibric acid|placebo|standard care|fenofibrate|fenofibric acid,NA
NCT04516954,2020-08-01,11/30/2020,Interventional,Convalescent Plasma for COVID-19 Patients,Enrolling by invitation,Early Phase 1,Vinmec Research Institute of Stem Cell and Gene Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04516954,0,0,0,0,2,0,Vietnam,0,convalescent plasma,NA
NCT04516746,2020-08-28,3/23/2021,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",Recruiting,Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04516746,0,0,0,1,4,1,United States|Argentina|Chile|Colombia|France|Peru,0,azd1222|placebo,NA
NCT04612972,2020-09-10,12/31/2020,Interventional,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Adult Population In Peru",Recruiting,Phase 3,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04612972,0,0,0,1,0,0,Peru,0,inactivated sars cov 2 vaccine (vero cell). wuhan,NA
NCT04532294,2020-09-08,2/19/2021,Interventional,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",Recruiting,Phase 1,BeiGene,NA,https://clinicalzeros.gov/ct2/show/NCT04532294,0,0,0,0,4,0,Australia,0,bgb dxp593|placebo,NA
NCT04531345,2020-10-01,11/1/2020,Observational,Cytokine Status of Covid-19 Patients,Completed,NA,Istanbul Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04531345,0,0,0,0,1,0,Turkey,0,flow cytometry,NA
NCT04531319,2020-08-15,10/1/2020,Observational,Immune Cell Subgroups in Covid 19 Patients,Completed,NA,Istanbul Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04531319,0,0,0,0,1,0,Turkey,0,flow cytometry,NA
NCT04590352,2020-03-26,5/13/2020,Observational,Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients,Completed,NA,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04590352,0,0,0,0,1,0,Netherlands,0,nasopharyngeal/throat swab|collection of mucosal lining fluid|blood sample|nasopharyngeal|throat swab,NA
NCT04587921,2020-06-22,1/22/2021,Interventional,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04587921,0,0,0,0,0,0,Brazil,0,digital oximeter monitoring,NA
NCT04549636,2020-09-18,12/31/2021,Observational,COVID-19 Related Lung Ventilation and Perfusion Injury,Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04549636,0,0,0,0,1,0,Canada,0,v/q spect-ct|st. george's respiratory questionnaire (sgrq)|mmrc (modified medical research council) dyspnea scale|six-minute walk test (6mwt)|spirometry|plethysmography/dlco|airwave oscillometry|v|q spect-ct|plethysmography|dlco,NA
NCT04539834,2020-05-01,8/1/2020,Observational,Electrolyte State in Patients With COVID-19,"Active, not recruiting",NA,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04539834,0,0,0,0,0,0,Egypt,0,electrolytes,NA
NCT04537663,2020-08-25,11/30/2020,Interventional,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Recruiting,Phase 4,UMC Utrecht,NA,https://clinicalzeros.gov/ct2/show/NCT04537663,0,0,0,1,0,0,Netherlands,0,bacille calmette-guã©rin (bcg)|placebo,NA
NCT04535869,2020-12-30,1/1/2021,Interventional,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Recruiting,Phase 3,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04535869,0,0,0,0,2,0,Egypt,0,sofosbuvir 400 mg/daclatasvir 200mg|sofosbuvir 400 mg|daclatasvir 200mg,NA
NCT04535856,2020-11-14,1/14/2021,Interventional,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,Completed,Phase 1,Ina-Respond,NA,https://clinicalzeros.gov/ct2/show/NCT04535856,0,0,0,0,6,0,Indonesia,0,allogeneic mesenchymal stem cell|placebo,NA
NCT04537806,2020-12-18,10/31/2021,Interventional,A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Phase 3,Sage Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04537806,0,0,0,0,1,1,United States,0,brexanolone|placebo,NA
NCT04536051,2020-06-02,9/30/2021,Interventional,A Study of a Candidate COVID-19 Vaccine (COV003),Recruiting,Phase 3,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04536051,0,0,0,1,2,0,Brazil,0,chadox1 ncov-19 single dose / paracetamol|menacwy single dose / paracetamol|chadox1 ncov-19 two dose / paracetamol|menacwy prime/saline placebo boost / paracetamol|chadox1 ncov-19 single dose|paracetamol|menacwy single dose|chadox1 ncov-19 two dose|menacwy prime|saline placebo boost,NA
NCT04533399,2020-08-17,11/30/2021,Interventional,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,Recruiting,Phase 2,Novavax,NA,https://clinicalzeros.gov/ct2/show/NCT04533399,0,0,0,1,3,0,South Africa,0,sars-cov-2 rs/matrix-m1 adjuvant|placebo|sars-cov-2 rs|adjuvant,NA
NCT04532632,2020-09-01,10/1/2020,Observational [Patient Registry],Taste and Smell Impairment in Critically Ill COVID-19 Patients,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04532632,0,0,0,0,3,0,Turkey,0,"NA",NA
NCT04538456,2020-10-15,4/30/2021,Observational,Impact of COVID-19 on Lung Cancer Patients,Recruiting,NA,The Christie NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04538456,0,0,0,0,2,0,United Kingdom,0,questionnaire/optional interview|questionnaire|optional interview,NA
NCT04537650,2021-01-01,8/31/2021,Observational,Swallowing Impairment After COVID-19 Infection,Enrolling by invitation,NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04537650,0,0,0,0,3,1,United States|Canada,0,videofluoroscopic swallowing study (vfss),NA
NCT04578197,2020-08-18,6/30/2022,Observational,NeuroCovid - a Study of Intensive Care-requiring Covid-19 Patients,Recruiting,NA,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04578197,0,0,0,0,0,0,Sweden,0,"NA",NA
NCT04554264,2020-09-01,9/30/2021,Interventional,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04554264,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04537858,2020-06-18,8/20/2020,Interventional,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,"Active, not recruiting",N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04537858,0,0,0,0,0,0,Brazil,0,virtual reality therapy first|conventional therapy first,NA
NCT04535154,2020-03-31,6/1/2021,Observational,Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19,"Active, not recruiting",NA,"University Hospital, Akershus",NA,https://clinicalzeros.gov/ct2/show/NCT04535154,0,0,0,0,0,0,Norway,0,no intervention,NA
NCT04535128,2020-03-24,12/31/2020,Observational [Patient Registry],"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications",Recruiting,NA,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04535128,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04535063,2020-04-18,12/30/2020,Interventional,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicalzeros.gov/ct2/show/NCT04535063,0,0,0,0,1,0,Argentina,0,convalescent plasma,NA
NCT04545749,2020-09-25,12/31/2020,Interventional,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine",Recruiting,Phase 1,"United Biomedical Inc., Asia",NA,https://clinicalzeros.gov/ct2/show/NCT04545749,0,0,0,1,1,0,Taiwan,0,ub-612,NA
NCT04542044,2020-04-02,5/5/2020,Observational,Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia,Completed,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04542044,0,0,0,0,0,0,Switzerland,0,management strategy of outpatient with mild to moderate sars-cov-2 pneumonia,NA
NCT04534725,2020-12-17,12/31/2021,Interventional,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;,Recruiting,Phase 3,"Peter MacCallum Cancer Centre, Australia",NA,https://clinicalzeros.gov/ct2/show/NCT04534725,0,0,0,0,4,0,Australia,0,interferon alfa|selinexor|lenzilumab,NA
NCT04534569,2020-09-04,10/3/2020,Observational,Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF),Completed,NA,NMC Specialty Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04534569,0,0,0,0,6,0,United Arab Emirates,0,experts consensus,NA
NCT04690413,2020-09-01,12/31/2020,Interventional,NOWDx Test for the Detection of Antibodies to COVID-19,Enrolling by invitation,N/A,"NOWDiagnostics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04690413,0,0,0,0,0,1,United States,0,nowdx covid-19 test,NA
NCT04669925,2020-09-01,1/31/2021,Observational,COVID-19 Impact on the Lombardy Region's Emergency System,"Active, not recruiting",NA,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04669925,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04537208,2020-09-03,11/30/2021,Interventional,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",Phase 1/Phase 2,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04537208,0,0,0,1,5,1,United States,0,placebo|sars-cov-2 vaccine formulation 2 without adjuvant|sars-cov-2 vaccine formulation 1 with adjuvant 1|sars-cov-2 vaccine formulation 1 with adjuvant 2|sars-cov-2 vaccine formulation 2 with adjuvant 1|sars-cov-2 vaccine formulation 2 with adjuvant 2,NA
NCT04537117,2020-04-20,5/5/2020,Observational,"Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19",Completed,NA,Fayoum University,NA,https://clinicalzeros.gov/ct2/show/NCT04537117,0,0,0,0,0,0,Egypt,0,questionaire,NA
NCT04548934,2020-09-13,10/31/2020,Interventional,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Completed,N/A,Institute of Mountain Emergency Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04548934,0,0,0,0,1,0,Italy,0,personal protective equipment (ppe)|no personal protective equipment (ppe),NA
NCT04537949,2020-09-09,3/31/2021,Interventional,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,Recruiting,Phase 1/Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04537949,0,0,0,1,2,0,Germany,0,bnt162b3,NA
NCT04602260,2020-06-09,9/30/2021,Observational,Functional Recovery of Hospitalised Patients With COVID-19: The COREG Extension Study,Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04602260,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04577534,2020-08-14,12/31/2021,Interventional,COVID-19: Salvage TOcilizumab as a Rescue Measure,Recruiting,Phase 3,Turku University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04577534,0,0,0,0,1,0,Finland,0,iv tocillizumab (tcz),NA
NCT04558463,2020-04-16,9/30/2020,Interventional,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,Recruiting,Phase 3,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04558463,0,0,0,0,0,0,Indonesia,0,favipiravir|oseltamivir 75mg,NA
NCT04542941,2020-06-16,12/31/2020,Interventional,Assessment of Safety and Efficacy of CCP,Completed,N/A,Makerere University,NA,https://clinicalzeros.gov/ct2/show/NCT04542941,0,0,0,0,1,0,Uganda,0,convalescent plasma,NA
NCT04544878,2020-03-26,6/1/2021,Observational [Patient Registry],Pediatric Intensive Care and COVID-19,Recruiting,NA,Bicetre Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04544878,0,0,0,0,0,0,France,0,"NA",NA
NCT04544605,2020-09-07,9/30/2021,Observational,Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients,Recruiting,NA,Hong Kong Baptist University,NA,https://clinicalzeros.gov/ct2/show/NCT04544605,0,0,0,0,1,0,China,0,individualized-chinese herbal medicine,NA
NCT04542343,2020-11-01,9/30/2021,Interventional,COVID-19 Risk Reduction Among African American Parishioners,Recruiting,N/A,Charles Drew University of Medicine and Science,NA,https://clinicalzeros.gov/ct2/show/NCT04542343,0,0,0,0,1,1,United States,0,"change in knowledge, motivation, skills, resources",NA
NCT04535674,2020-10-09,2/28/2021,Interventional,Asunercept in Patients With Severe COVID-19,Recruiting,Phase 2,Apogenix AG,NA,https://clinicalzeros.gov/ct2/show/NCT04535674,0,0,0,0,4,0,Russian Federation|Spain,0,asunercept,NA
NCT04535297,2020-05-10,5/30/2020,Observational,Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke,Completed,NA,University of Haifa,NA,https://clinicalzeros.gov/ct2/show/NCT04535297,0,0,0,0,0,0,Israel,0,exposure,NA
NCT04534608,2020-05-11,6/30/2020,Observational,COVID-19 Child Health Investigation of Latent Disease in Hamburg,"Active, not recruiting",NA,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04534608,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04534595,2019-04-30,3/31/2021,Observational,Data Collection on the Model Schools Pediatric Health Initiative at 5 SBHC Sites: COVID-19 Questionnaire,Recruiting,NA,"St. Michael's Hospital, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04534595,0,0,0,0,0,0,Canada,0,covid-19,NA
NCT04542213,2020-08-01,9/30/2020,Interventional,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Recruiting,Phase 3,Hospital Regional de Alta Especialidad del Bajio,NA,https://clinicalzeros.gov/ct2/show/NCT04542213,0,0,0,0,0,0,Mexico,0,linagliptin|insulin,NA
NCT04540484,2020-08-26,9/24/2021,Observational,COVID-19 IgG Formation in Physicians at ALGH and Their Household Members,Recruiting,NA,Advocate Health Care,NA,https://clinicalzeros.gov/ct2/show/NCT04540484,0,0,0,0,1,1,United States,0,"NA",NA
NCT04539821,2020-10-01,3/31/2021,Interventional,Virtual Pain Care Management (COVID-19),Recruiting,N/A,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04539821,0,0,0,0,1,1,United States,0,vcpm,NA
NCT04539795,2020-11-01,9/30/2021,Interventional,COVID-19 Study of Safety and Tolerability of Alvelestat,Recruiting,Phase 1/Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04539795,0,0,0,0,1,1,United States,0,alvelestat|placebo,NA
NCT04538586,2020-05-01,12/1/2020,Observational,"Influence of the COVId-19 Pandemic on STRESS, and Screening Procedures (COVISTRESS Screening)",Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04538586,0,0,0,0,0,0,France,0,"NA",NA
NCT04569188,2020-05-15,8/15/2020,Interventional,Convalescent Plasma in COVID-19 Elderly Patients,Completed,Phase 2,Azienda Socio Sanitaria Territoriale di Mantova,NA,https://clinicalzeros.gov/ct2/show/NCT04569188,0,0,0,0,1,0,Italy,0,convalescent plasma,NA
NCT04546581,2020-10-08,7/31/2021,Interventional,Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),Recruiting,Phase 3,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04546581,0,0,0,0,3,1,United States|Denmark|Greece|Japan|Nigeria|Spain|United Kingdom,0,hyperimmune immunoglobulin to sars-cov-2 (hivig)|placebo|remdesivir,NA
NCT04544150,2020-06-01,9/1/2020,Observational,Gastrointestinal Manifestations Among Patients With COVID19,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04544150,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04543760,2020-10-01,3/31/2021,Interventional,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Recruiting,N/A,"Hospital St. Joseph, Marseille, France",NA,https://clinicalzeros.gov/ct2/show/NCT04543760,0,0,0,0,2,0,France,0,prone positioning|supine position,NA
NCT04542993,2020-09-08,9/30/2021,Interventional,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,Recruiting,Phase 2,Swedish Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04542993,0,0,0,0,1,1,United States,0,zinc picolinate|resveratrol|placebo,NA
NCT04542915,2020-09-29,10/31/2021,Observational,COVID-19-Related Health and Practices Among Dental Hygienists,"Active, not recruiting",NA,American Dental Association,NA,https://clinicalzeros.gov/ct2/show/NCT04542915,0,0,0,0,1,1,United States,0,no intervention,NA
NCT04542876,2020-05-01,7/31/2020,Interventional,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04542876,0,0,0,0,0,0,India,0,guduchi ghan vati,NA
NCT04542226,2020-03-31,7/15/2020,Observational,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Completed,NA,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04542226,0,0,0,0,6,0,Belarus|Russian Federation,1,polyoxidonium,NA
NCT04542200,2021-01-01,12/31/2022,Observational,Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment,Enrolling by invitation,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04542200,0,0,0,0,2,1,United States,0,serology test,NA
NCT04561154,2020-06-11,6/11/2021,Interventional,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Recruiting,N/A,Centre Hospitalier le Mans,NA,https://clinicalzeros.gov/ct2/show/NCT04561154,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04552483,2020-06-08,8/20/2020,Interventional,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Completed,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04552483,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04542967,2020-06-23,9/2/2020,Interventional,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Recruiting,Phase 2,Hospital Central Militar,NA,https://clinicalzeros.gov/ct2/show/NCT04542967,0,0,0,0,1,0,Mexico,0,biological,NA
NCT04542694,2020-05-21,8/10/2020,Interventional,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Completed,Phase 3,"Promomed, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04542694,0,0,0,0,3,0,Russian Federation,1,favipiravir|standard care,NA
NCT04542421,2020-07-01,7/1/2021,Interventional,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04542421,0,0,0,0,1,1,United States,0,lung ultrasound use in patients hospitalized with covid,NA
NCT04540939,2020-10-19,12/31/2021,Interventional,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Recruiting,N/A,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04540939,0,0,0,0,2,1,United States,0,mindfulness-based cognitive therapy|muscle relaxation therapy,NA
NCT04540185,2020-11-01,11/1/2022,Interventional,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,Enrolling by invitation,Phase 3,"NeuroActiva, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04540185,0,0,0,1,1,1,United States|New Zealand,0,oral polio vaccine|placebo|na-831|polio vaccine/na-831|polio vaccine,NA
NCT04545060,2020-08-27,1/31/2021,Interventional,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,Recruiting,Phase 2/Phase 3,"Vir Biotechnology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04545060,0,0,0,0,12,1,United States|Austria|Brazil|Canada|Chile|France|Peru|Spain|United Kingdom,0,vir-7831|placebo,NA
NCT04551339,2020-09-28,6/14/2021,Interventional,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,Enrolling by invitation,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04551339,0,0,0,0,2,1,United States,0,preservision areds formulation soft gels/tablets|multivitamin with 11mg of zinc|preservision areds formulation soft gels|tablets,NA
NCT04549922,2020-10-22,2/28/2021,Interventional,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,"Active, not recruiting",Phase 2,Hospital do Coracao,NA,https://clinicalzeros.gov/ct2/show/NCT04549922,0,0,0,0,2,0,Brazil,0,isis 721744|saline,NA
NCT04545541,2020-11-01,4/30/2022,Interventional,Nebulised Heparin in Patients With Severe COVID-19,Recruiting,Phase 2/Phase 3,Australian National University,NA,https://clinicalzeros.gov/ct2/show/NCT04545541,0,0,0,0,2,1,United States,0,nebulised unfractionated heparin (ufh),NA
NCT04544033,2020-09-15,12/31/2020,Observational,IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients,Recruiting,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04544033,0,0,0,0,1,0,Egypt,0,interleuken 6,NA
NCT04622748,2020-07-10,12/10/2020,Observational,Neurocognitive Functions of Recovered COVID-19 Patients,Recruiting,NA,"National Institute on Drug Dependence, China",NA,https://clinicalzeros.gov/ct2/show/NCT04622748,0,0,0,0,0,0,China,0,trier social stress test,NA
NCT04549337,2020-09-25,5/1/2021,Interventional,Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04549337,0,0,0,0,2,0,Denmark,0,exercise training,NA
NCT04554251,2020-09-01,12/1/2020,Observational,Global Impact of COVID-19 on Pulmonology Special Units,Enrolling by invitation,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04554251,0,0,0,0,0,0,Egypt,0,questionnaire,NA
NCT04548531,2020-09-10,4/30/2021,Interventional,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Enrolling by invitation,N/A,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04548531,0,0,0,0,1,1,United States,0,shared decision making,NA
NCT04546776,2020-09-08,6/30/2022,Observational,COVID-19 Persistence in Stool,Enrolling by invitation,NA,Quadram Institute Bioscience,NA,https://clinicalzeros.gov/ct2/show/NCT04546776,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04547660,2020-07-16,7/31/2021,Interventional,Convalescent Plasma for Severe COVID-19 Patients,Recruiting,Phase 3,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04547660,0,0,0,0,0,0,Brazil,0,convalescent plasma|best supportive care,NA
NCT04547283,2020-06-14,9/20/2020,Interventional,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Recruiting,N/A,Atrium Health,NA,https://clinicalzeros.gov/ct2/show/NCT04547283,0,0,0,0,0,1,United States,0,standard care|apps,NA
NCT04545047,2020-05-01,12/31/2021,Observational,Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19,"Active, not recruiting",NA,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04545047,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04544176,2020-01-01,6/30/2020,Observational,COVID-19 Risk From Attending Outpatient Appointments,"Active, not recruiting",NA,Nottingham University Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04544176,0,0,0,0,1,0,United Kingdom,0,observational,NA
NCT04661527,2020-04-22,12/30/2020,Interventional,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Recruiting,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicalzeros.gov/ct2/show/NCT04661527,0,0,0,0,1,0,Spain,0,sarilumab,NA
NCT04542447,2020-09-01,9/30/2020,Interventional,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,Recruiting,Phase 1,Natureceuticals Sdn Bhd,NA,https://clinicalzeros.gov/ct2/show/NCT04542447,0,0,0,0,1,0,India,0,nuvastatic,NA
NCT04542408,2020-11-12,5/31/2021,Interventional,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Recruiting,Phase 3,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04542408,0,0,0,0,2,0,Germany,0,anticoagulation agents (edoxaban and/or high dose lmwh)|low dose low molecular weight heparin/placebo|anticoagulation agents (edoxaban and|or high dose lmwh)|low dose low molecular weight heparin|placebo,NA
NCT04576351,2020-09-01,12/31/2023,Observational,The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19,Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04576351,0,0,0,0,0,0,Norway,0,observation,NA
NCT04569266,2020-08-07,11/7/2021,Interventional,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Recruiting,N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04569266,0,0,0,0,0,0,France,0,specific exercise rehabilitation treatment,NA
NCT04556565,2020-05-08,5/31/2021,Observational,MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain,Recruiting,NA,Hospital del Mar Research Institute (IMIM),NA,https://clinicalzeros.gov/ct2/show/NCT04556565,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04548908,2020-08-03,4/30/2021,Observational,Prevalence Of COVID-19 Among Health-workers in a French General Hospital,Recruiting,NA,Centre Hospitalier Sud Essonne,NA,https://clinicalzeros.gov/ct2/show/NCT04548908,0,0,0,0,0,0,France,0,pcr/serology,NA
NCT04542954,2020-03-01,8/31/2020,Observational [Patient Registry],Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East,Completed,NA,Hamid Al-Essa Organ Transplant Center,NA,https://clinicalzeros.gov/ct2/show/NCT04542954,0,0,0,0,0,0,Kuwait,0,optimized management of covid-19 positive kidney transplant recipients: single center experience from the middle east,NA
NCT04542330,2020-09-15,1/31/2022,Interventional,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Recruiting,Phase 3,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04542330,0,0,0,1,2,0,Denmark,0,bcg-denmark|saline,NA
NCT04541472,2020-05-01,12/1/2020,Observational,Influence of the COVId-19 Pandemic on the STRESS of Dental Surgeons (COVISTRESS - Dental Surgery),Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04541472,0,0,0,0,0,0,France,0,"NA",NA
NCT04550403,2020-07-30,5/30/2021,Observational,Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes,Recruiting,NA,Azienda Ospedaliero-Universitaria di Parma,NA,https://clinicalzeros.gov/ct2/show/NCT04550403,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04550325,2020-08-05,11/26/2020,Interventional,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",Completed,Phase 1/Phase 2,"Kamada, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04550325,0,0,0,0,1,0,Israel,0,kamada anti-sars-cov-2,NA
NCT04548895,2020-12-30,6/30/2021,Observational,Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19,Recruiting,NA,"Health Stream Analytics, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04548895,0,0,0,0,1,1,United States,0,observational measurement of biometric data. no change to health care provided.,NA
NCT04547140,2021-01-31,4/30/2021,Interventional,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04547140,0,0,0,0,3,1,United States|Brazil,0,liquid alpha1-proteinase inhibitor (human)|placebo|standard care,NA
NCT04547127,2020-04-29,2/28/2021,Interventional,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04547127,0,0,0,0,1,0,Spain,0,convalescent plasma|standard care,NA
NCT04546737,2020-09-08,7/31/2021,Interventional,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients",Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04546737,0,0,0,0,1,0,France,0,magnetic resonance spectroscopy (mrs).,NA
NCT04546191,2020-07-01,9/1/2020,Observational [Patient Registry],Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland,Completed,NA,Landspitali University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04546191,0,0,0,0,1,0,Iceland,0,"NA",NA
NCT04652505,2020-07-13,3/31/2021,Observational,"Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study",Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04652505,0,0,0,0,0,1,United States,0,questionnaire,NA
NCT04581915,2020-09-08,12/31/2021,Interventional,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,Recruiting,Phase 2/Phase 3,Wits Health Consortium (Pty) Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04581915,0,0,0,0,1,0,South Africa,0,triazavirin (riamilovir)|placebo,NA
NCT04587414,2019-03-06,10/31/2020,Interventional,eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19,"Active, not recruiting",N/A,UKK Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04587414,0,0,0,0,0,0,Finland,0,telehealth/counselling|telehealth|standard care|counselling,NA
NCT04560608,2020-03-15,1/31/2021,Observational [Patient Registry],"Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19",Recruiting,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04560608,0,0,0,0,1,0,France,0,"NA",NA
NCT04552340,2020-03-16,3/31/2023,Observational,"Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.",Recruiting,NA,Istituto Clinico Humanitas,NA,https://clinicalzeros.gov/ct2/show/NCT04552340,0,0,0,0,0,0,Italy,0,patient with sar-cov-2 infection,NA
NCT04549350,2020-05-19,8/18/2020,Observational,Sleep Quality Among HCWs,Completed,NA,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04549350,0,0,0,0,1,0,Egypt,0,psqi,NA
NCT04549831,2020-04-08,4/8/2021,Observational,Genetic Bases of COVID-19 Clinical Variability,Recruiting,NA,University of Siena,NA,https://clinicalzeros.gov/ct2/show/NCT04549831,0,0,0,0,1,0,Italy,0,massive parallel sequencing of host genome,NA
NCT04548544,2019-10-18,5/20/2020,Interventional,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,Completed,N/A,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04548544,0,0,0,0,0,1,United States,0,"training for awareness, resilience,/action (tara)|training for awareness, resilience,|action (tara)",NA
NCT04547218,2020-06-22,12/31/2020,Observational,Study on Incidence of Elective Surgery Postponed During COVID-19 Pandemic in Geriatric Population,Completed,NA,University of Malaya,NA,https://clinicalzeros.gov/ct2/show/NCT04547218,0,0,0,0,1,0,Malaysia,0,"NA",NA
NCT04547114,2020-09-14,12/31/2020,Observational,Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects,Recruiting,NA,Klinikum Bayreuth GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04547114,0,0,0,0,0,0,Germany,0,multicapillary column coupled ion mobility spectrometry,NA
NCT04641182,2020-07-06,8/16/2020,Observational [Patient Registry],Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure,Completed,NA,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04641182,0,0,0,0,0,0,Chile,0,prone positioning,NA
NCT04554979,2020-06-01,7/15/2020,Observational,COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04554979,0,0,0,0,1,0,Egypt,0,hydroxychloroquine,NA
NCT04569292,2020-01-01,4/30/2021,Observational,COVID-19 Infection in Cancer Pantients,Recruiting,NA,Ospedale Andrea Tortora di Pagani,NA,https://clinicalzeros.gov/ct2/show/NCT04569292,0,0,0,0,0,0,Italy,0,no intervention,NA
NCT04551781,2020-04-01,7/30/2020,Interventional,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04551781,0,0,0,0,0,0,Egypt,0,prednisone|control,NA
NCT04550312,2020-09-30,10/31/2020,Observational,The Impact of Lifestyle Changes on Non-COVID Deaths,Recruiting,NA,The First Affiliated Hospital with Nanjing Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04550312,0,0,0,0,0,0,China,0,"NA",NA
NCT04560881,2020-09-16,12/1/2021,Interventional,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Active, not recruiting",Phase 3,Laboratorio Elea Phoenix S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04560881,0,0,0,1,2,0,Argentina,0,inactivated sars-cov-2 vaccine|placebo/aluminum adjuvant of inactivated sars-cov-2 vaccine|placebo|aluminum adjuvant of inactivated sars-cov-2 vaccine,NA
NCT04595110,2020-03-25,4/25/2021,Observational,Hemostatic Profile in Patients Affected by COVID-19,Recruiting,NA,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04595110,0,0,0,0,0,0,Italy,0,observational,NA
NCT04557358,2020-07-01,12/31/2020,Observational,Impact in the Medical Care Among the Rheumatic Diseases Patients in a Tertiary Hospital in MÃ©xico During the COVID-19 Pandemic,Recruiting,NA,"National Institute of Medical Sciences and Nutrition, Salvador Zubiran",NA,https://clinicalzeros.gov/ct2/show/NCT04557358,0,0,0,0,0,0,Mexico,0,covid-19 survey|rapid-3|whoqol-bref|dass-21 instrument (depression/anxiety)|ier-r (posttraumatic stress)|dass-21 instrument (depression|anxiety),NA
NCT04556513,2020-09-18,12/31/2021,Observational,Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status,Recruiting,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04556513,0,0,0,0,2,0,France,0,paraclinical examination|clinical examination|semi-directive interview|quality of life questionnaires,NA
NCT04555213,2020-09-30,3/31/2021,Interventional,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,Recruiting,Phase 1,Noxopharm Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04555213,0,0,0,0,2,0,"Moldova, Republic of",0,nox66,NA
NCT04555954,2020-04-11,7/31/2020,Observational,Determining the Physical Activity Level of Healthy Adults During Pandemic,Completed,NA,Pamukkale University,NA,https://clinicalzeros.gov/ct2/show/NCT04555954,0,0,0,0,0,0,Turkey,0,surveys/questionnaires|survey|questionnaire,NA
NCT04555187,2020-06-08,12/31/2021,Observational,Cardiovascular Risk Stratification in Covid-19,"Active, not recruiting",NA,Oregon Health and Science University,NA,https://clinicalzeros.gov/ct2/show/NCT04555187,0,0,0,0,1,1,United States,0,"NA",NA
NCT04555148,2020-09-20,12/30/2020,Interventional,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),Recruiting,Phase 2,Green Cross Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04555148,0,0,0,0,0,0,"Korea, Republic of",0,gc5131|placebo,NA
NCT04581135,2020-05-01,4/30/2023,Observational [Patient Registry],Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04581135,0,0,0,0,0,0,Switzerland,0,covid-19,NA
NCT04570384,2020-10-15,5/28/2021,Interventional,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,Recruiting,Phase 2,"Asklepion Pharmaceuticals, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04570384,0,0,0,0,2,1,United States,0,l-citrulline|placebo,NA
NCT04550390,2020-09-15,10/15/2020,Observational,Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19.,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04550390,0,0,0,0,2,0,France,0,saliva,NA
NCT04570189,2020-10-01,1/31/2021,Observational,"Evaluating Auscul-X, a Touch Free Digital Stethoscope",Recruiting,NA,AusculSciences Canada Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04570189,0,0,0,0,1,0,Canada,0,auscul-x,NA
NCT04560855,2020-09-14,6/14/2021,Observational,Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home,Recruiting,NA,Withings,NA,https://clinicalzeros.gov/ct2/show/NCT04560855,0,0,0,0,0,0,France,0,connected devices measurements,NA
NCT04610502,2020-09-06,10/6/2020,Interventional,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,"Active, not recruiting",Phase 2,Caja Costarricense de Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04610502,0,0,0,0,1,0,Costa Rica,0,administration of equine immunoglobulin anti sars-cov-2,NA
NCT04600895,2020-11-30,8/31/2021,Interventional,The Prevent Severe COVID-19 (PRESECO) Study,Recruiting,Phase 3,Appili Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04600895,0,0,0,0,1,1,United States,0,favipiravir|placebo,NA
NCT04591158,2020-09-15,9/30/2021,Interventional,COVID-19 and Lung Ultrasound Utility,Recruiting,N/A,Bridge to Health Medical and Dental USA,NA,https://clinicalzeros.gov/ct2/show/NCT04591158,0,0,0,0,0,0,Canada,0,butterfly iq,NA
NCT04555109,2020-06-30,6/30/2021,Observational,Convalescent Plasma for COVID-19 Research Donor Study,Recruiting,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04555109,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04557046,2020-06-26,11/30/2021,Interventional,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04557046,0,0,0,0,3,1,United States,0,nasal|nasopharyngeal swab|throat swab|fingerstick|saliva,NA
NCT04585945,2020-08-04,3/31/2021,Observational,COVID-19 on Placental Gene Expression and Pathology,Recruiting,NA,Prisma Health-Upstate,NA,https://clinicalzeros.gov/ct2/show/NCT04585945,0,0,0,0,1,1,United States,0,positive for sars-cov-2 infection,NA
NCT04568564,2020-10-01,5/1/2021,Interventional,Telerehabilitation in Lung Surgery Patients,Recruiting,N/A,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04568564,0,0,0,0,2,0,Turkey,0,"breathing exercise, intensive spirometry use, supported cough, progressive mobilisation/ambulation|exercise booklet|breathing exercise, intensive spirometry use, supported cough, progressive mobilisation|ambulation",NA
NCT04559113,2020-05-01,12/30/2020,Interventional,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Recruiting,N/A,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04559113,0,0,0,0,1,0,Pakistan,0,methylprednisolone injectable product,NA
NCT04553705,2020-09-20,11/4/2020,Interventional,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Recruiting,Phase 2/Phase 3,Beni-Suef University,NA,https://clinicalzeros.gov/ct2/show/NCT04553705,0,0,0,0,1,0,Saudi Arabia,0,omega 3/nigella sativa oil|omega 3/nigella sativa oil/indian costus|omega 3/nigella sativa oil/quinine pills|omega 3/nigella sativa oil/anise seed capsule|omega 3/nigella sativa oil/deglycyrrhizinated licorice|active comparator|omega-3|nigella sativa oil|indian costus|quinine|anise|deglycyrrhizinated licorice,NA
NCT04553575,2020-09-25,9/30/2022,Observational [Patient Registry],CoViD-19 Patient in Reims University Hospital in March to April 2020,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04553575,0,0,0,0,1,0,France,0,serology test,NA
NCT04553055,2020-07-20,9/15/2020,Observational [Patient Registry],Antibiotic Misuse During COVID-19 Pandemic,Completed,NA,Beni-Suef University,NA,https://clinicalzeros.gov/ct2/show/NCT04553055,0,0,0,0,1,0,Egypt,0,online questionnaires,NA
NCT04552366,2020-09-29,12/31/2020,Interventional,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,"Active, not recruiting",Phase 1,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://clinicalzeros.gov/ct2/show/NCT04552366,0,0,0,1,2,0,China,0,ad5-ncov,NA
NCT04551911,2020-10-26,2/28/2021,Interventional,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,Recruiting,Phase 2,"OPKO Health, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04551911,0,0,0,0,3,1,United States,0,rayaldee 30mcg extended-release (er) capsule|placebo,NA
NCT04551547,2020-10-31,2/28/2021,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,Recruiting,Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04551547,0,0,0,1,2,0,China,0,"two doses of low dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of medium dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|placebo",NA
NCT04551378,2020-07-13,12/31/2021,Observational,The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04551378,0,0,0,0,0,1,United States,0,quality-of-life assessment|questionnaire,NA
NCT04565249,2020-10-22,8/31/2021,Interventional,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",Recruiting,Phase 2,"Pliant Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04565249,0,0,0,0,3,1,United States,0,pln-74809|placebo,NA
NCT04568018,2020-07-03,12/31/2020,Observational,Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,NA,Biosurf LLC.,NA,https://clinicalzeros.gov/ct2/show/NCT04568018,0,0,0,0,0,0,Russian Federation,0,surfactant,NA
NCT04567810,2020-09-18,12/14/2020,Interventional,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",Completed,Phase 1,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04567810,0,0,0,0,2,0,Australia,0,anti-sars-cov-2 igy|placebo,NA
NCT04563650,2020-09-18,5/31/2021,Interventional,COVID-19 Serology and Immunosenescence,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04563650,0,0,0,0,0,0,France,0,blood sample,NA
NCT04563065,2020-08-01,11/30/2020,Interventional,Active Pregnancy Against COVID-19,Recruiting,N/A,Universidad Politecnica de Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04563065,0,0,0,0,1,0,Spain,0,exercise program|healthy lifestyle advise,NA
NCT04558320,2020-07-02,4/1/2021,Observational,COVID-19 and Lactating Mothers,Recruiting,NA,University of Rochester,NA,https://clinicalzeros.gov/ct2/show/NCT04558320,0,0,0,0,0,1,United States,0,"NA",NA
NCT04558203,2020-09-22,10/25/2020,Observational [Patient Registry],"The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice",Recruiting,NA,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04558203,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04558125,2020-09-08,12/31/2021,Interventional,Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,"Active, not recruiting",Phase 4,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04558125,0,0,0,0,1,1,United States,0,tnkase,NA
NCT04563247,2020-07-01,10/30/2020,Observational,Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs,"Active, not recruiting",NA,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04563247,0,0,0,0,1,0,Pakistan,0,igg sars cov 2 antibodies,NA
NCT04558749,2020-10-01,4/30/2021,Observational,Anxiety and Depression Among Pregnant Women During COVID-19 Pandemic,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04558749,0,0,0,0,1,0,Egypt,0,state-trait anxiety inventory scale|edinburgh postnatal depression scale (edps),NA
NCT04558645,2020-09-18,12/18/2020,Observational,Evaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic,Completed,NA,Gazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04558645,0,0,0,0,3,0,Turkey,0,online survey,NA
NCT04558307,2020-06-03,6/1/2021,Observational,Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations,Enrolling by invitation,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04558307,0,0,0,0,0,1,United States,0,pilot a rapid sars-cov-2 testing strategy|community-driven messages to promote covid-19 testing,NA
NCT04558021,2020-10-08,1/30/2021,Interventional,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,Recruiting,Phase 3,Imuneks Farma ilac San. Tic. A.S.,NA,https://clinicalzeros.gov/ct2/show/NCT04558021,0,0,0,0,1,0,Turkey,0,niclosamide suspension|placebo,NA
NCT04556604,2020-04-10,8/14/2020,Observational,Surgical Consent During the COVID-19 Pandemic,Completed,NA,Medway Primary Care Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04556604,0,0,0,0,0,0,United Kingdom,0,educational meetings/visual prompts|education|visual prompts,NA
NCT04556318,2020-09-23,3/31/2021,Observational,Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19),Recruiting,NA,B. Braun Melsungen AG,NA,https://clinicalzeros.gov/ct2/show/NCT04556318,0,0,0,0,4,0,Germany,0,ion mobility spectrometry (ims),NA
NCT04714515,2020-02-20,3/30/2020,Observational,Montelukast - a Treatment Choice for COVID-19,Completed,NA,University of Sargodha,NA,https://clinicalzeros.gov/ct2/show/NCT04714515,0,0,0,0,0,0,China|Pakistan,0,montelukast|hydroxychloroquine|ivermectin,NA
NCT04560413,2020-06-01,7/25/2020,Observational,"Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients",Completed,NA,Fatih Sultan Mehmet Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560413,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04558411,2020-09-12,12/15/2020,Interventional,"Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04558411,0,0,0,0,0,1,United States,0,dialectical behavioral therapy (dbt) skills,NA
NCT04558385,2020-07-01,10/15/2020,Observational,Seroconversion in COVID-19 Recovered Population,"Active, not recruiting",NA,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04558385,0,0,0,0,1,0,Pakistan,0,igg sars cov2,NA
NCT04558372,2020-04-01,12/12/2020,Interventional,Genosvid Diagnostic Test for Early Detection of COVID-19,Completed,N/A,Gadjah Mada University,NA,https://clinicalzeros.gov/ct2/show/NCT04558372,0,0,0,0,3,0,Indonesia,0,exhaled breath sampling,NA
NCT04691609,2020-03-01,3/31/2023,Observational,Assiut University Registry for ACS Patients During COVID-19 Pandemic,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04691609,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04573270,2020-04-24,8/20/2020,Interventional,Mesenchymal Stem Cells for the Treatment of COVID-19,Completed,Phase 1,Thomas Advanced Medical LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04573270,0,0,0,0,0,1,United States,0,primepro|placebo,NA
NCT04559035,2020-09-24,12/31/2020,Interventional,Nasal Irrigation to Reduce COVID-19 Morbidity,Enrolling by invitation,N/A,Augusta University,NA,https://clinicalzeros.gov/ct2/show/NCT04559035,0,0,0,0,0,1,United States,0,nasal lavage,NA
NCT04578509,2020-10-19,4/30/2021,Observational,Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04578509,0,0,0,0,2,0,France,0,nasopharyngeal swab|saliva|data collection|axillary sweat sample,NA
NCT04569383,2020-10-05,5/31/2021,Interventional,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19",Recruiting,Phase 1,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04569383,0,0,0,1,1,0,Germany,0,mva-sars-2-s vaccinations (days 0/28)|mva-sars-2-s vaccinations (days 0|28),NA
NCT04568850,2020-07-01,11/30/2020,Observational,Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19 Exposed Population,"Active, not recruiting",NA,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04568850,0,0,0,0,1,0,Pakistan,0,plasma igg levels,NA
NCT04568421,2020-08-18,12/31/2021,Observational [Patient Registry],Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection,Recruiting,NA,Sociedad Argentina de Reumatologia,NA,https://clinicalzeros.gov/ct2/show/NCT04568421,0,0,0,0,0,0,Argentina,0,immunosuppressive agents,NA
NCT04568044,2020-09-16,12/31/2022,Observational,Evaluation of Humoral Immunity Following COVID-19 in Pregnancy,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04568044,0,0,0,0,0,0,United Kingdom,0,blood sample,NA
NCT04565379,2020-09-25,11/30/2020,Interventional,Clinical Trial to Investigate the Efficacy and Safety of NuSepinÂ® in COVID-19 Pneumonia Patients,Recruiting,Phase 2,Shaperon,NA,https://clinicalzeros.gov/ct2/show/NCT04565379,0,0,0,0,2,0,Romania,0,nusepinâ® 0.1 mg|nusepinâ® 0.2 mg|placebo,NA
NCT04563676,2020-09-22,3/31/2021,Interventional,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04563676,0,0,0,0,0,0,France,0,blood test,NA
NCT04563702,2020-09-21,12/10/2020,Interventional,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1,Vaxart,NA,https://clinicalzeros.gov/ct2/show/NCT04563702,0,0,0,1,2,1,United States,0,vxa-cov2-1,NA
NCT04563156,2020-06-23,6/30/2021,Observational,Follow-up and Rehabilitation of Survivors of Severe Coronavirus Disease 2019 (COVID-19) Infection,Enrolling by invitation,NA,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04563156,0,0,0,0,0,0,Brazil,0,lung function test,NA
NCT04609462,2020-08-11,6/30/2021,Interventional,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,Recruiting,N/A,Fundacion Clinica Valle del Lili,NA,https://clinicalzeros.gov/ct2/show/NCT04609462,0,0,0,0,1,0,Colombia,0,conventional oxygen therapy|high flow nasal cannula,NA
NCT04563208,2020-12-09,2/28/2021,Interventional,Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19,Recruiting,Phase 2,"University of Witwatersrand, South Africa",NA,https://clinicalzeros.gov/ct2/show/NCT04563208,0,0,0,0,3,0,South Africa,0,placebo|duact,NA
NCT04561102,2020-09-11,12/31/2020,Observational,Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From an Asymptomatic Population,Enrolling by invitation,NA,"Illumina, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04561102,0,0,0,0,0,1,United States,0,diagnostic test for detection of sars-cov-2,NA
NCT04561089,2020-07-13,12/31/2020,Observational,Evaluation of the COVIDSeq Test in Saliva Specimens From Illumina Personnel,Enrolling by invitation,NA,"Illumina, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04561089,0,0,0,0,0,1,United States,0,covidseq test,NA
NCT04561063,2020-12-08,7/31/2021,Interventional,COVID-19 Prophylaxis South Africa (COVER HCW),Recruiting,Phase 2,"University of Witwatersrand, South Africa",NA,https://clinicalzeros.gov/ct2/show/NCT04561063,0,0,0,0,2,0,South Africa,0,nitazoxanide|sofosbuvir/daclatasvir|sofosbuvir|daclatasvir,NA
NCT04559009,2020-10-15,12/31/2023,Observational [Patient Registry],COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry,Recruiting,NA,Atrium Health,NA,https://clinicalzeros.gov/ct2/show/NCT04559009,0,0,0,0,1,1,United States,0,"NA",NA
NCT04576728,2020-10-06,5/31/2021,Interventional,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,Recruiting,Phase 2,Biotest,NA,https://clinicalzeros.gov/ct2/show/NCT04576728,0,0,0,0,3,0,Brazil|France|Russian Federation|Spain,0,trimodulin|placebo,NA
NCT04701515,2020-06-10,12/31/2022,Observational,Cardiovascular Manifestations of COVID-19,Recruiting,NA,Methodist Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04701515,0,0,0,0,0,1,United States,0,chart review,NA
NCT04587323,2020-05-22,3/20/2023,Observational,VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease,Recruiting,NA,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04587323,0,0,0,0,0,1,United States,0,"NA",NA
NCT04581746,2020-11-25,12/31/2021,Interventional,Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Recruiting,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04581746,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04575571,2020-04-29,4/29/2025,Observational,MAVIPAN: My Life and the COVID-19 Pandemic,Recruiting,NA,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04575571,0,0,0,0,0,0,Canada,0,no intervention|qualitative interviews..,NA
NCT04574219,2020-11-03,10/31/2022,Interventional,Virtual Parental Presence on Induction,Recruiting,N/A,"Children's Hospital Medical Center, Cincinnati",NA,https://clinicalzeros.gov/ct2/show/NCT04574219,0,0,0,0,1,1,United States|Canada,0,use of facetime with child/parents during induction|use of facetime with child|parents during induction,NA
NCT04568876,2020-10-23,11/30/2021,Interventional,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,Recruiting,Phase 4,Epitech Group SpA,NA,https://clinicalzeros.gov/ct2/show/NCT04568876,0,0,0,0,2,0,Italy,0,"micronized/ultra-micronized palmitoylethanolamide (mpea/umpea, 300mg / 600mg) oral suspension|standard care|micronized|ultra-micronized palmitoylethanolamide (mpea|umpea, 300mg|600mg) oral suspension",NA
NCT04568551,2020-10-01,3/31/2021,Observational,"COVID-19-associated Anxiety of Pregnant Women for Anomalies, Stillbirth and Preterm Labor",Recruiting,NA,Martin-Luther-UniversitÃ¤t Halle-Wittenberg,NA,https://clinicalzeros.gov/ct2/show/NCT04568551,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04567836,2020-06-01,12/1/2020,Observational,Screening of Health-care Workers in an University Hospital for SARS-CoV-2,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04567836,0,0,0,0,2,0,Italy,0,investigation of the prevalence of test positivity,NA
NCT04566770,2020-09-24,8/21/2021,Interventional,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Recruiting,Phase 2,CanSino Biologics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04566770,0,0,0,1,1,0,China,0,adenovirus type 5 vector|recombinant novel coronavirus vaccine (adenovirus type 5 vector) -placebo,NA
NCT04567173,2020-09-21,6/30/2021,Interventional,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,Recruiting,Phase 2/Phase 3,University of the Philippines,NA,https://clinicalzeros.gov/ct2/show/NCT04567173,0,0,0,0,1,0,Philippines,0,convalescent plasma,NA
NCT04566965,2020-08-18,12/31/2022,Observational,Serology to Covid for Recording Exposures and Evaluating Needs,Recruiting,NA,"Children's Hospital Medical Center, Cincinnati",NA,https://clinicalzeros.gov/ct2/show/NCT04566965,0,0,0,0,0,1,United States,0,sars-cov-2,NA
NCT04565509,2020-11-20,6/30/2022,Interventional,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04565509,0,0,0,0,1,1,United States,0,general communication message|focused/targeted message|best message alone|best message / augmented message/implementation strategy|focused|targeted message|best message|augmented message|implementation strategy,NA
NCT04565197,2020-05-01,12/30/2020,Interventional,Convalescent Plasma Therapy for COVID-19 Patients,"Active, not recruiting",Early Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04565197,0,0,0,0,1,0,Pakistan,0,convalescent plasma,NA
NCT04565106,2020-04-15,5/31/2020,Observational,Automatic Oxygen Titration With O2maticÂ® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure,Completed,NA,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04565106,0,0,0,0,0,0,Denmark,0,closed-loop control of oxygen supplementation by o2matic,NA
NCT04564716,2020-09-28,3/28/2021,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04564716,0,0,0,1,3,0,Belarus,0,gam-covid-vac|placebo,NA
NCT04564287,2020-10-28,12/1/2021,Observational,An Observational Study of Neurologic Function After COVID-19 Infection,Enrolling by invitation,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04564287,0,0,0,0,36,1,United States,0,"NA",NA
NCT04569786,2020-10-29,2/15/2021,Interventional,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),"Active, not recruiting",Phase 1,Merck Sharp & Dohme Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04569786,0,0,0,1,9,1,United States,0,v590|placebo,NA
NCT04565080,2021-02-10,12/31/2021,Observational,Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD),Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04565080,0,0,0,0,88,1,United States,0,"NA",NA
NCT04565067,2021-02-10,12/31/2021,Observational,Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04565067,0,0,0,0,88,1,United States,0,"NA",NA
NCT04564274,2021-02-10,9/1/2021,Observational,COV2Base-A Rare Disease by COVID Study,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04564274,0,0,0,0,88,1,United States,0,"NA",NA
NCT04565782,2020-09-15,11/1/2020,Observational,Corona Virus Infection Among Liver Transplant Recipients,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04565782,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04565665,2020-07-29,4/30/2021,Interventional,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Recruiting,Phase 1,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04565665,0,0,0,0,2,1,United States,0,best available therapy|mesenchymalÂ stem cells,NA
NCT04563689,2020-06-18,10/22/2020,Interventional,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Completed,N/A,Dentaid SL,NA,https://clinicalzeros.gov/ct2/show/NCT04563689,0,0,0,0,1,0,Colombia,0,chx0.12/cpc0.05 oral rinse (perioaidactive control)|placebo|chx0.12|cpc0.05 oral rinse (perioaidactive control),NA
NCT04562285,2020-06-23,6/30/2021,Observational,Sustained Immunity to SARS-CoV-2,Recruiting,NA,Henry Ford Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04562285,0,0,0,0,0,1,United States,0,serologic immunoassays to sars-cov-2 antibodies,NA
NCT04562246,2020-08-14,8/31/2021,Observational,SARS-CoV-2 IgG and IgM Serologic Assays,Recruiting,NA,Henry Ford Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04562246,0,0,0,0,0,1,United States,0,serologic assays for antibodies to sars-cov-2,NA
NCT04561219,2020-04-19,10/2/2020,Interventional,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,Completed,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04561219,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04561193,2020-05-30,12/31/2020,Observational,Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19),Recruiting,NA,Methodist Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04561193,0,0,0,0,0,1,United States,0,observational,NA
NCT04561024,2020-03-01,10/30/2020,Observational,Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm,"Active, not recruiting",NA,"Ensemble Group Holdings, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04561024,0,0,0,0,1,0,Hong Kong,0,ai model,NA
NCT04560530,2020-03-01,7/30/2020,Observational,The Role of CT Chest Scan in the Pre-anesthetic Assessment of Suspected or Confirmed COVID -19 Patients,Completed,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04560530,0,0,0,0,0,0,Saudi Arabia,0,radiotherapy,NA
NCT04570488,2020-05-15,12/30/2020,Interventional,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,N/A,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04570488,0,0,0,0,1,1,United States,0,epic risk score display,NA
NCT04593940,2020-10-15,2/28/2021,Interventional,Immune Modulators for Treating COVID-19,Recruiting,Phase 3,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04593940,0,0,0,0,6,1,United States,0,infliximab|abatacept|remdesivir|cenicriviroc,NA
NCT04569877,2020-09-24,12/25/2022,Interventional,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Recruiting,Phase 2,University of Giessen,NA,https://clinicalzeros.gov/ct2/show/NCT04569877,0,0,0,0,1,0,Germany,0,molgramostim nebuliser solution|placebo,NA
NCT04569344,2020-01-01,3/31/2021,Observational,COVID-19 and Venous Thromboembolism Risk,Enrolling by invitation,NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04569344,0,0,0,0,3,1,United States,0,laboratory test positive for sars-cov-2 virus,NA
NCT04568005,2020-06-01,8/1/2020,Observational [Patient Registry],Evaluation of Lymphedema Patients Status During Covid-19 Pandemic,Completed,NA,Fatih Sultan Mehmet Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04568005,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04567953,2020-07-28,1/30/2021,Interventional,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",N/A,Paradigm Laboratories LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04567953,0,0,0,0,0,1,United States,0,saliva,NA
NCT04568122,2020-11-20,4/30/2021,Interventional,"Rapid Turnaround, Home-based Saliva Testing for COVID-19",Recruiting,N/A,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04568122,0,0,0,0,5,1,United States,0,saliva test kit,NA
NCT04611841,2020-07-21,12/31/2022,Observational,Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2,Enrolling by invitation,NA,Federal Research and Clinical Center of Physical-Chemical Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04611841,0,0,0,0,0,0,Russian Federation,0,"NA",NA
NCT04570254,2020-08-19,10/15/2020,Interventional,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,"Active, not recruiting",N/A,Unidad Temporal COVID-19 en Centro Citibanamex,NA,https://clinicalzeros.gov/ct2/show/NCT04570254,0,0,0,0,1,0,Mexico,0,vitamin c|vitamin e|melatonin|n-acetyl cysteine|pentoxifylline,NA
NCT04594291,2020-10-07,9/30/2023,Observational,MRI Changes of Acute Kidney Injury in COVID-19,Recruiting,NA,University Hospitals of Derby and Burton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04594291,0,0,0,0,0,0,United Kingdom,0,mri scans,NA
NCT04583410,2020-10-22,8/31/2021,Interventional,Efficacy of Nicotine in Preventing COVID-19 Infection in Caregivers,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04583410,0,0,0,0,3,0,France,0,nicotine patch|placebo patch,NA
NCT04575064,2020-06-29,3/31/2022,Interventional,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",Phase 2/Phase 3,"Klinikum Bremen-Mitte, gGmbH",NA,https://clinicalzeros.gov/ct2/show/NCT04575064,0,0,0,0,0,0,Germany,0,standard care|remdesivir,NA
NCT04576312,2020-06-29,12/31/2020,Interventional,Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19,"Active, not recruiting",Phase 1,UNION therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04576312,0,0,0,0,1,0,Denmark,0,uni911 inhalation,NA
NCT04576299,2020-09-01,10/30/2020,Observational,Health Care Workers' Perception of Patient Safety During COVID-19 Pandemic,"Active, not recruiting",NA,Universidad Miguel Hernandez de Elche,NA,https://clinicalzeros.gov/ct2/show/NCT04576299,0,0,0,0,0,0,Chile|Colombia|Ecuador|Spain,0,group 1,NA
NCT04573868,2020-03-01,6/30/2020,Observational [Patient Registry],"National Study ""AEC COVID-19""",Recruiting,NA,Hospitales Universitarios Virgen del RocÃ­o,NA,https://clinicalzeros.gov/ct2/show/NCT04573868,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04573634,2020-05-15,12/31/2023,Observational,A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition,Recruiting,NA,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04573634,0,0,0,0,1,1,United States,0,"NA",NA
NCT04573153,2020-09-21,1/31/2021,Interventional,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,Recruiting,Phase 2/Phase 3,ScandiBio Therapeutics AB,NA,https://clinicalzeros.gov/ct2/show/NCT04573153,0,0,0,0,1,0,Turkey,0,hydroxychloroquine / metabolic cofactor supplementation|hydroxychloroquine / sorbitol|hydroxychloroquine|metabolic cofactor supplementation|sorbitol,NA
NCT04575597,2020-10-19,6/11/2021,Interventional,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),Recruiting,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04575597,0,0,0,0,15,1,United States|Brazil|Canada|Chile|Colombia|France|Germany|Israel|Philippines|Russian Federation|South Africa|Spain|Ukraine|United Kingdom,0,molnupiravir|placebo,NA
NCT04575584,2020-10-19,5/17/2021,Interventional,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),Recruiting,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04575584,0,0,0,0,17,1,"United States|Brazil|Canada|Chile|Colombia|France|Israel|Korea, Republic of|Mexico|Philippines|Poland|Russian Federation|South Africa|Spain|Ukraine|United Kingdom",0,molnupiravir|placebo,NA
NCT04583189,2020-10-01,11/25/2020,Interventional,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Completed,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04583189,0,0,0,0,2,0,France,0,performance of the test antigenic/test rt-pcr|performance of the test antigenic|test rt-pcr,NA
NCT04572399,2020-10-30,12/28/2020,Interventional,UVA Light Device to Treat COVID-19,Completed,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04572399,0,0,0,0,3,1,United States,0,uv light treatment,NA
NCT04570202,2020-11-20,8/20/2021,Interventional,Health cAre woRkers exposeD to COVID-19,Recruiting,N/A,"University Hospital, Tours",NA,https://clinicalzeros.gov/ct2/show/NCT04570202,0,0,0,0,2,0,France,0,emdr,NA
NCT04568863,2020-06-20,10/30/2020,Interventional,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,Recruiting,Phase 2,Pharmamel S.L.,NA,https://clinicalzeros.gov/ct2/show/NCT04568863,0,0,0,0,0,0,Spain,0,melatonin intravenous|placebo,NA
NCT04568811,2020-09-26,10/25/2020,Interventional,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"Active, not recruiting",Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04568811,0,0,0,1,0,0,China,0,adenovirus type-5 vectored covid-19 vaccine,NA
NCT04568655,2020-02-01,7/1/2020,Observational,The Noninvasive Ventilation to COVID-19 Patients,Completed,NA,The First Affiliated Hospital of Guangzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04568655,0,0,0,0,0,0,China,0,noninvasive ventilation,NA
NCT04635605,2020-11-05,12/31/2021,Interventional,Methylene Blue Treatment of COVID-19,Recruiting,Phase 2,Fondazione Epatocentro Ticino,NA,https://clinicalzeros.gov/ct2/show/NCT04635605,0,0,0,0,1,0,Switzerland,0,methylene blue|control test,NA
NCT04661462,2020-09-30,9/30/2021,Observational,Health After Covid-19 in Tyrol,Recruiting,NA,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04661462,0,0,0,0,0,0,Austria,0,online survey,NA
NCT04629105,2020-07-24,8/31/2021,Interventional,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER),Recruiting,Phase 1,Longeveron LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04629105,0,0,0,0,0,1,United States,0,longeveron mesenchymal stem cells (lmscs)|placebo,NA
NCT04582344,2020-09-14,2/15/2021,Interventional,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),Recruiting,Phase 3,Health Institutes of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04582344,0,0,0,1,0,0,Turkey,0,coronavac|placebo,NA
NCT04579289,2020-06-15,9/1/2020,Observational,Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions,Completed,NA,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04579289,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04578210,2020-09-04,1/31/2021,Interventional,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,Recruiting,Phase 1/Phase 2,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicalzeros.gov/ct2/show/NCT04578210,0,0,0,0,1,0,Spain,0,t memory cells/nk cells|t memory cells|nk cells,NA
NCT04581577,2020-09-11,12/17/2020,Observational,Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders,Recruiting,NA,Royal Brompton & Harefield NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04581577,0,0,0,0,0,0,United Kingdom,0,semi-structured telephone questionnaire,NA
NCT04575532,2020-10-05,1/15/2021,Observational,Detection of COVID-19 Decompensation,Enrolling by invitation,NA,"physIQ, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04575532,0,0,0,0,0,1,United States,0,"use of the pinpointiq solution (physiq, inc.)",NA
NCT04577235,2020-06-05,8/5/2020,Interventional,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Completed,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04577235,0,0,0,0,0,0,Turkey,0,severity of lung involvement with covid-19.,NA
NCT04575168,2020-10-30,11/30/2020,Observational,Clinical Study Spartan COVID-19 V2 System,Recruiting,NA,Spartan Bioscience Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04575168,0,0,0,0,2,1,United States,0,spartan covid-19 test,NA
NCT04575038,2020-11-19,2/28/2021,Interventional,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,Recruiting,Phase 2,"Clear Creek Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04575038,0,0,0,0,8,1,United States,0,brequinar|placebo,NA
NCT04573062,2021-02-10,12/31/2024,Observational,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04573062,0,0,0,0,83,1,United States,0,"NA",NA
NCT04715295,2020-10-05,5/30/2021,Interventional,Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19,Recruiting,Phase 4,Yaounde Central Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04715295,0,0,0,0,0,0,Cameroon,0,doxycycline tablets|rivaroxaban 15mg tab|hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,NA
NCT04583449,2020-08-19,12/1/2020,Interventional,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,N/A,University of East London,NA,https://clinicalzeros.gov/ct2/show/NCT04583449,0,0,0,0,0,0,United Kingdom,0,mental imagery,NA
NCT04573361,2020-05-02,5/27/2020,Interventional,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Completed,N/A,Real Centro Universitario Maria Cristina,NA,https://clinicalzeros.gov/ct2/show/NCT04573361,0,0,0,0,0,0,Spain,0,chiropractic care (one visit)|chiropractic care (more than one visit),NA
NCT04573335,2020-06-01,7/15/2020,Observational,Diabetes Outcomes in COVID-19 Pandemic,Completed,NA,"Services Institute of Medical Sciences, Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04573335,0,0,0,0,0,0,Pakistan,0,"NA",NA
NCT04573322,2020-09-10,11/14/2021,Interventional,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,Recruiting,Phase 1/Phase 2,Diffusion Pharmaceuticals Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04573322,0,0,0,0,0,0,Romania,0,trans sodium crocetinate|saline,NA
NCT04572438,2020-08-01,4/1/2021,Observational,A Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy,Recruiting,NA,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04572438,0,0,0,0,0,0,United Kingdom,0,tracheostomy,NA
NCT04572412,2020-11-25,4/30/2021,Interventional,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia,Recruiting,N/A,Lancashire Teaching Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04572412,0,0,0,0,2,0,United Kingdom,0,radiotherapy,NA
NCT04570397,2020-12-18,5/31/2021,Interventional,Ravulizumab and COVID-19,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04570397,0,0,0,0,1,1,United States,0,ravulizumab,NA
NCT04569825,2020-08-01,9/30/2020,Interventional,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Recruiting,Early Phase 1,University Of Anbar,NA,https://clinicalzeros.gov/ct2/show/NCT04569825,0,0,0,0,0,0,Iraq,0,ophtamesone,NA
NCT04649086,2020-06-05,10/5/2021,Interventional,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection,Recruiting,N/A,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04649086,0,0,0,0,1,0,France,0,rehabilitation by eccentric exercises|rehabilitation by concentric exercises,NA
NCT04583319,2020-10-31,11/30/2020,Observational,"Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection",Recruiting,NA,Firalis SA,NA,https://clinicalzeros.gov/ct2/show/NCT04583319,0,0,0,0,1,0,Turkey,0,easycov poc,NA
NCT04603781,2020-12-04,12/31/2021,Interventional,CBD Oil for Reducing Emotional Impact of COVID-19,Recruiting,Phase 2/Phase 3,University of Texas at Austin,NA,https://clinicalzeros.gov/ct2/show/NCT04603781,0,0,0,0,2,1,United States,0,cbd isolate|full spectrum cbd oil|placebo oil,NA
NCT04594330,2020-06-01,12/31/2020,Interventional,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,Phase 2,Gadjah Mada University,NA,https://clinicalzeros.gov/ct2/show/NCT04594330,0,0,0,0,0,0,Indonesia,0,virgin coconut oil (vco)|placebo,NA
NCT04593641,2020-09-04,10/22/2020,Interventional,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","Active, not recruiting",Phase 1,Celltrion,NA,https://clinicalzeros.gov/ct2/show/NCT04593641,0,0,0,0,0,0,"Korea, Republic of",0,ct-p59,NA
NCT04597034,2020-10-02,12/30/2021,Interventional,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,Recruiting,N/A,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04597034,0,0,0,0,0,0,Mexico,0,an69-oxiris|an69-standard,NA
NCT04590170,2020-10-30,10/30/2022,Observational,French Cohort of COVID-19 Patients With Post-intensive Care Syndrome,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04590170,0,0,0,0,1,0,France,0,post-intensive care unit syndrome,NA
NCT04581291,2020-01-01,6/1/2020,Interventional,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,N/A,Istanbul Gelisim University,NA,https://clinicalzeros.gov/ct2/show/NCT04581291,0,0,0,0,0,0,Turkey,0,moderate intensity aerobic exercises,NA
NCT04583761,2020-10-12,2/28/2021,Observational,Tobacco and Nicotine Consumption and the Risk of Acquisition of Coronavirus Disease 2019 (COVID-19),"Active, not recruiting",NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04583761,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04581200,2021-01-25,7/31/2021,Interventional,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04581200,0,0,0,0,4,1,United States,0,lift,NA
NCT04724629,2021-01-05,3/31/2021,Interventional,Survival TRial Using CytoKines in COVID-19 (STRUCK Trial),Recruiting,Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04724629,0,0,0,0,0,0,Brazil,0,ixekizumab|aldesleukin|colchicine|standard care,NA
NCT04581954,2020-10-02,6/30/2021,Interventional,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Recruiting,Phase 1/Phase 2,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04581954,0,0,0,0,1,0,United Kingdom,0,ruxolitinib|fostamatinib|standard care,NA
NCT04583592,2020-11-09,2/28/2021,Interventional,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),Recruiting,Phase 2,Sagent Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04583592,0,0,0,0,14,1,United States,0,camostat mesilate|placebo,NA
NCT04582331,2020-09-10,4/30/2021,Observational,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis,Recruiting,NA,Sonde Health,NA,https://clinicalzeros.gov/ct2/show/NCT04582331,0,0,0,0,1,1,United States|India,0,smartphone-based voice/self-reported symptom collection|smartphone-based voice|self-reported symptom collection,NA
NCT04600999,2020-10-07,6/30/2021,Interventional,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,Recruiting,Phase 3,University of Pecs,NA,https://clinicalzeros.gov/ct2/show/NCT04600999,0,0,0,0,0,0,Hungary,0,favipiravir,NA
NCT04589936,2020-09-03,6/30/2021,Interventional,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Recruiting,N/A,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04589936,0,0,0,0,0,0,United Kingdom,0,prone positioning,NA
NCT04587258,2020-08-28,9/1/2022,Observational,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island,Recruiting,NA,Rhode Island Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04587258,0,0,0,0,0,1,United States,0,informational videos/social media campaigns encouraging cancer screening.|informational videos|social media campaigns encouraging cancer screening.,NA
NCT04586114,2020-03-01,5/31/2020,Observational,Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19,"Active, not recruiting",NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04586114,0,0,0,0,1,0,France,0,corticosteroids/derivatives|corticosteroids|derivatives,NA
NCT04584710,2020-10-13,1/31/2021,Interventional,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,Recruiting,Phase 2,Restorbio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04584710,0,0,0,0,2,1,United States,0,rtb101|placebo,NA
NCT04584606,2020-06-27,10/31/2020,Observational,Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04584606,0,0,0,0,0,0,Egypt,0,lab workup (on admission/regularly during follow up).|lab workup (on admission|regularly during follow up).,NA
NCT04584580,2020-08-01,10/31/2020,Interventional,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,Phase 4,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04584580,0,0,0,0,0,0,Egypt,0,low-molecular-weight heparin,NA
NCT04590430,2020-10-20,2/28/2021,Interventional,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults","Active, not recruiting",Phase 1,HiFiBiO Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04590430,0,0,0,0,2,1,United States,0,hfb30132a|placebo,NA
NCT04583293,2020-12-08,10/31/2022,Observational,Acute kIDnEy Injury in coviD-19,Recruiting,NA,University Hospitals of Derby and Burton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04583293,0,0,0,0,2,0,United Kingdom,0,no intervention,NA
NCT04582214,2020-09-28,1/1/2021,Interventional,Oscillation and Lung Expansion Therapy in Patients With COVID-19,Recruiting,N/A,Hill-Rom,NA,https://clinicalzeros.gov/ct2/show/NCT04582214,0,0,0,0,0,1,United States,0,metanebâ® system,NA
NCT04582201,2020-09-21,4/24/2021,Interventional,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,Recruiting,Phase 1,Agenus Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04582201,0,0,0,0,1,1,United States,0,agent-797,NA
NCT04581928,2020-10-10,12/10/2020,Observational,Patients Reactions Towards Their Diagnosis as Having COVID-19,Recruiting,NA,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04581928,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04581044,2020-09-17,10/23/2020,Observational,Impact of COVID-19 on Psoriasis Practice,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04581044,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04611399,2021-02-03,11/1/2021,Interventional,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04611399,0,0,0,0,1,0,Italy,0,vr for psychoeducation/relaxation|text material for psychoeducation/audio for relaxation techniques|vr for psychoeducation|relaxation|text material for psychoeducation|audio for relaxation techniques,NA
NCT04579640,2020-10-27,6/30/2021,Interventional,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,"Active, not recruiting",Phase 3,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04579640,0,0,0,0,2,0,United Kingdom,0,vitamin d,NA
NCT04579627,2020-05-14,6/8/2020,Observational,"Facial Hair, PPE and COVID-19",Completed,NA,Royal Cornwall Hospitals Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04579627,0,0,0,0,0,0,United Kingdom,0,questionnaire,NA
NCT04579588,2020-10-29,12/1/2022,Observational,Understanding Immunity to the Flu Vaccine in COVID-19 Patients,Enrolling by invitation,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04579588,0,0,0,0,2,1,United States,0,flu shot,NA
NCT04579549,2020-09-29,9/30/2021,Interventional,Repeat Testing for SARS-CoV-2,Enrolling by invitation,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04579549,0,0,0,0,2,1,United States,0,saliva assay,NA
NCT04579471,2020-07-01,12/31/2021,Observational,Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study,Recruiting,NA,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04579471,0,0,0,0,1,0,Belgium,0,sars-cov-2 igg,NA
NCT04579393,2020-01-27,1/31/2021,Interventional,Fostamatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04579393,0,0,0,0,10,1,United States,0,placebo|fostamatinib,NA
NCT04584567,2020-11-20,2/1/2021,Interventional,"OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 """,Recruiting,Phase 3,"General Administration of Military Health, Tunisia",NA,https://clinicalzeros.gov/ct2/show/NCT04584567,0,0,0,0,3,0,Tunisia,0,doxycyclin,NA
NCT04578132,2020-11-24,6/30/2021,Observational,Description of the Population With Genitourinary Tumors and COVID-19,Recruiting,NA,Spanish Oncology Genito-Urinary Group,NA,https://clinicalzeros.gov/ct2/show/NCT04578132,0,0,0,0,6,0,Spain,0,"NA",NA
NCT04623671,2020-11-15,4/30/2021,Interventional,Intravenous Infusion of CAP-1002 in Patients With COVID-19,Recruiting,Phase 2,Capricor Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04623671,0,0,0,0,2,1,United States,0,cap-1002|placebo,NA
NCT04594668,2020-04-24,4/24/2021,Interventional,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,Recruiting,Phase 2,University of Aarhus,NA,https://clinicalzeros.gov/ct2/show/NCT04594668,0,0,0,0,0,0,Denmark,0,senicapoc,NA
NCT04584684,2020-12-18,9/30/2022,Interventional,Mouth Rinses for Inactivation of COVID-19,Recruiting,Phase 2,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04584684,0,0,0,0,2,1,United States,0,1% w/v povidone-iodide|0.075% cetylpyridinium chloride|saline|1.5-2% w/v hydrogen peroxide|0.12% chlorhexidine gluconate|21% ethanol/essential oils|1% w|v povidone-iodide|1.5-2% w|v hydrogen peroxide|21% ethanol|essential oils,NA
NCT04583995,2020-09-28,1/31/2021,Interventional,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom",Recruiting,Phase 3,Novavax,NA,https://clinicalzeros.gov/ct2/show/NCT04583995,0,0,0,1,2,0,United Kingdom,0,sars-cov-2 rs/matrix m1-adjuvant|placebo|licensed seasonal influenza vaccine|sars-cov-2 rs|matrix m1-adjuvant,NA
NCT04583345,2020-06-01,12/1/2020,Observational,Physical Activity Levels of Hypertensive and Healthy Individuals Under Social Isolation During the COVID-19 Pandemic,Recruiting,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04583345,0,0,0,0,1,0,Turkey,0,questionnaire,NA
NCT04583306,2020-06-01,12/15/2020,Observational [Patient Registry],The Salivary Raman COVID-19 Fingerprint,Recruiting,NA,Fondazione Don Carlo Gnocchi Onlus,NA,https://clinicalzeros.gov/ct2/show/NCT04583306,0,0,0,0,0,0,Italy,0,"raman analysis of saliva, characterization of the raman database/building of the classification model|raman analysis of saliva, characterization of the raman database|building of the classification model",NA
NCT04584450,2020-09-02,12/31/2020,Observational,Investigation of Validity and Reliability of Post-COVID-19 Functional Status Scale,Completed,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04584450,0,0,0,0,1,0,Turkey,0,questionnaire,NA
NCT04583969,2020-10-19,12/31/2021,Interventional,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04583969,0,0,0,0,11,1,United States,0,remdesivir|lenzilumab|placebo,NA
NCT04586413,2020-10-07,10/31/2022,Observational,Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg),Recruiting,NA,Medialis Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04586413,0,0,0,0,1,0,United Kingdom,0,no intervention,NA
NCT04583956,2020-10-14,12/31/2021,Interventional,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04583956,0,0,0,0,12,1,United States,0,placebo|remdesivir|risankizumab,NA
NCT04582903,2021-02-10,8/31/2025,Observational,Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04582903,0,0,0,0,77,1,United States,0,"NA",NA
NCT04584658,2020-09-15,10/31/2021,Observational,Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study),Recruiting,NA,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04584658,0,0,0,0,2,0,United Kingdom,0,fibreoptic endoscopic evaluation of swallowing (fees)|videofluoroscopy|dysphagia handicap index (dhi)|voice symptom scale (voiss),NA
NCT04583982,2020-10-09,12/4/2020,Observational,ImmuneSenseâ„¢ COVID-19 Study,Completed,NA,Adaptive Biotechnologies,NA,https://clinicalzeros.gov/ct2/show/NCT04583982,0,0,0,0,2,1,United States,0,t-detectâ„¢ sars-cov-2 assay,NA
NCT04583865,2020-10-07,9/14/2021,Observational,Feasibility and Quality of TeleConsultation in Pediatric Anesthesia,"Active, not recruiting",NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04583865,0,0,0,0,0,0,France,0,teleconsultation,NA
NCT04583566,2020-10-04,10/3/2021,Observational [Patient Registry],"Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients",Recruiting,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04583566,0,0,0,0,1,0,Egypt,0,covid-19 diagnostic/assessment tests|covid-19 diagnostic|assessment tests,NA
NCT04582318,2020-11-08,6/30/2021,Interventional,"A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19",Recruiting,Phase 1/Phase 2,"NGM Biopharmaceuticals, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04582318,0,0,0,0,1,0,Australia,0,ngm621|placebo,NA
NCT04581889,2020-07-02,7/31/2021,Observational,Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in TÃ¼bingen Children,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04581889,0,0,0,0,1,0,Germany,0,diagnostic test,NA
NCT04581863,2020-11-30,2/21/2021,Interventional,COVID-19 Watch + COVID-19 Pulse,Recruiting,N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04581863,0,0,0,0,5,1,United States,0,pulse oximeter|covid watch,NA
NCT04581811,2020-11-10,5/31/2021,Interventional,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Recruiting,N/A,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04581811,0,0,0,0,1,1,United States,0,prolonged proned positioning|traditional proning arm,NA
NCT04581096,2020-10-02,2/15/2021,Observational [Patient Registry],Mapping COVID-19 Spread in a Tertiary Hospital,Recruiting,NA,Hospital General Universitario de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04581096,0,0,0,0,1,0,Spain,0,no intervention,NA
NCT04581083,2020-10-08,10/10/2020,Observational,"Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic",Completed,NA,Hunter College of City University of New York,NA,https://clinicalzeros.gov/ct2/show/NCT04581083,0,0,0,0,2,0,Bolivia,0,pcr|lamp|pool rt-pcr|pool lamp,NA
NCT04593069,2020-10-07,2/28/2021,Interventional,The COGCOV Study in ICU Patients,Recruiting,N/A,Ziekenhuis Oost-Limburg,NA,https://clinicalzeros.gov/ct2/show/NCT04593069,0,0,0,0,1,0,Belgium,0,neurocognitive assessment,NA
NCT04591613,2020-12-31,8/31/2022,Interventional,Late Clinical Events Associated With COVID-19 Infection,Recruiting,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04591613,0,0,0,0,1,0,France|French Guiana,0,questionnaire|biocollection|follow-up visit,NA
NCT04610541,2020-10-12,10/30/2021,Interventional,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,"Active, not recruiting",Phase 3,University of Pecs,NA,https://clinicalzeros.gov/ct2/show/NCT04610541,0,0,0,0,1,0,Hungary,0,remdesivir-hu,NA
NCT04592549,2020-12-04,9/30/2021,Interventional,"This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19",Recruiting,Phase 1,Ology Bioservices,NA,https://clinicalzeros.gov/ct2/show/NCT04592549,0,0,0,0,2,1,United States,0,adm03820|placebo,NA
NCT04605757,2020-07-30,4/30/2021,Observational,Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study,Recruiting,NA,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,NA,https://clinicalzeros.gov/ct2/show/NCT04605757,0,0,0,0,1,0,Italy,0,"clinical, functional/radiological lung involvement evolution|clinical, functional|radiological lung involvement evolution",NA
NCT04589949,2020-10-12,11/1/2022,Interventional,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,Phase 3,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04589949,0,0,0,0,0,0,Netherlands,0,convp|ffp,NA
NCT04589117,2020-05-27,8/2/2020,Interventional,Expressive Writing for COVID-19 Resilience for Parents,Completed,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04589117,0,0,0,0,0,1,United States,0,expressive writing,NA
NCT04589104,2020-05-26,8/17/2020,Interventional,Expressive Writing for COVID-19 Resilience,Completed,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04589104,0,0,0,0,0,1,United States,0,expressive writing,NA
NCT04586140,2020-11-09,4/30/2021,Observational,Operation of the GHPSJ Clinical Ethical Reflection Assistance Group During the COVID-19 Period,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04586140,0,0,0,0,1,0,France,0,"NA",NA
NCT04584593,2020-10-02,2/28/2022,Interventional,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04584593,0,0,0,0,2,0,France,0,sample,NA
NCT04588363,2020-11-19,11/30/2021,Observational,COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C,Recruiting,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04588363,0,0,0,0,15,1,United States,0,sars-cov-2 and/or mis-c exposure|sars-cov-2 and|or mis-c exposure,NA
NCT04720794,2020-09-25,10/20/2020,Interventional,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,Completed,N/A,Lucira Health Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04720794,0,0,0,0,1,1,United States,0,lucira covid-19 all-in-one test kit,NA
NCT04592354,2020-10-15,4/15/2021,Interventional,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,N/A,Terra Biological LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04592354,0,0,0,0,0,1,United States,0,oxaloacetate medical food/dietary supplement|oxaloacetate medical food|dietary supplement,NA
NCT04591600,2020-07-01,9/30/2020,Interventional,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,Completed,Phase 1/Phase 2,Alkarkh Health Directorate-Baghdad,NA,https://clinicalzeros.gov/ct2/show/NCT04591600,0,0,0,0,0,0,Iraq,0,ivermectin/doxycyline|standard care|ivermectin|doxycyline,NA
NCT04590053,2020-10-20,2/28/2021,Interventional,"Allocetra-OTS in COVID-19, Phase II",Recruiting,Phase 2,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04590053,0,0,0,0,2,0,Israel,0,allocetra-ots,NA
NCT04596579,2020-10-09,10/9/2021,Observational,SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida,Enrolling by invitation,NA,H. Lee Moffitt Cancer Center and Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04596579,0,0,0,0,1,1,United States,0,sars-cov-2 antibody analysis|weck-cel swab collection|web based questionnaire,NA
NCT04587219,2020-10-22,3/30/2021,Interventional,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","Active, not recruiting",Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04587219,0,0,0,1,5,0,Russian Federation,0,gam-covid-vac,NA
NCT04591717,2020-10-19,11/19/2021,Interventional,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04591717,0,0,0,1,4,1,United States,0,had5-s-fusion/n-etsd vaccine|had5-s-fusion|n-etsd vaccine,NA
NCT04593654,2020-03-01,8/15/2020,Observational,Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients,Completed,NA,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04593654,0,0,0,0,0,0,Sweden,0,tinzaparin/dalteparin|tinzaparin|dalteparin,NA
NCT04592055,2020-03-20,10/15/2020,Observational,The Effect of COVID-19 on Diabetes Mellitus,Recruiting,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04592055,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04591704,2020-03-20,10/15/2020,Observational,The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19,Recruiting,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04591704,0,0,0,0,0,0,Turkey,0,"hospitalisation, necessity of icu, mortality rate, lung involvement",NA
NCT04624503,2020-10-01,6/1/2021,Observational,Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19,Recruiting,NA,"Humanitas Hospital, Italy",NA,https://clinicalzeros.gov/ct2/show/NCT04624503,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04603664,2020-10-30,2/28/2021,Observational,Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04603664,0,0,0,0,1,0,Egypt,0,serum ngal/cystatin c|serum ngal|cystatin c,NA
NCT04595240,2020-05-01,10/15/2020,Observational,Semen Analysis Changes in Covid-19 Positivepatients,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04595240,0,0,0,0,0,0,Egypt,0,semen analysis,NA
NCT04648800,2020-07-07,12/31/2020,Interventional,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,Recruiting,Phase 3,University of Rzeszow,NA,https://clinicalzeros.gov/ct2/show/NCT04648800,0,0,0,1,0,0,Poland,0,bcg-10 vaccine|saline,NA
NCT04602000,2020-09-25,12/31/2020,Interventional,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,Recruiting,Phase 2/Phase 3,Celltrion,NA,https://clinicalzeros.gov/ct2/show/NCT04602000,0,0,0,0,0,0,"Korea, Republic of",0,ct-p59/placebo|ct-p59|placebo,NA
NCT04590794,2020-10-11,1/31/2021,Observational,SuPAR in Adult Patients With Covid-19,"Active, not recruiting",NA,University of Thessaly,NA,https://clinicalzeros.gov/ct2/show/NCT04590794,0,0,0,0,4,0,Greece,0,soluble urokinase plasminogen activator receptor,NA
NCT04590378,2020-03-01,11/1/2020,Observational,Pulmonary Embolism and COVID-19,Recruiting,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04590378,0,0,0,0,0,0,Turkey,0,intensive care unit admission ratio,NA
NCT04590586,2020-11-24,10/22/2021,Interventional,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Recruiting,Phase 3,Amgen,NA,https://clinicalzeros.gov/ct2/show/NCT04590586,0,0,0,0,5,1,United States|Argentina|South Africa|Ukraine,0,standard care|apremilast|apremilast placebo|lanadelumab|lanadelumab placebo|zilucoplan|zilucoplan placebo,NA
NCT04588909,2020-03-23,9/22/2020,Observational,Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy,"Active, not recruiting",NA,Sheri Kashmir Institute of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04588909,0,0,0,0,0,0,India,0,colorectal resections,NA
NCT04588480,2020-10-21,11/30/2021,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","Active, not recruiting",Phase 1/Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04588480,0,0,0,1,2,0,Japan,0,bnt162b2|placebo,NA
NCT04588792,2021-02-01,10/1/2021,Interventional,Furosemide as Supportive Therapy for COVID-19 Respiratory Failure,Recruiting,Phase 2/Phase 3,Queen's University,NA,https://clinicalzeros.gov/ct2/show/NCT04588792,0,0,0,0,4,0,Canada,0,nebulized furosemide|nebulized saline,NA
NCT04594343,2020-11-20,3/31/2021,Interventional,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,Recruiting,Phase 2,ETICA,NA,https://clinicalzeros.gov/ct2/show/NCT04594343,0,0,0,0,2,0,Brazil,0,disulfiram|placebo,NA
NCT04609371,2020-10-21,3/1/2021,Interventional,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Enrolling by invitation,N/A,"St. Mary's Research Center, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04609371,0,0,0,0,1,0,Canada,0,self-care tools|lay telephone coaching,NA
NCT04602312,2020-10-28,3/31/2021,Interventional,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),Recruiting,N/A,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04602312,0,0,0,0,2,0,Australia,0,meditation (1 x 20-minute guided audio training),NA
NCT04601090,2020-09-16,9/30/2022,Observational [Patient Registry],Survival Rates and Longterm Outcomes After COVID-19,Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04601090,0,0,0,0,1,0,Norway,0,icu treatment,NA
NCT04602286,2020-10-28,3/31/2021,Interventional,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),Recruiting,N/A,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04602286,0,0,0,0,2,0,Australia,0,meditation (1 x 20-minute guided audio training),NA
NCT04599998,2020-10-15,2/15/2021,Observational,Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia,Enrolling by invitation,NA,Koc University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04599998,0,0,0,0,0,0,Turkey,0,"spirometry, thoracic ct, cpet, 6 minute walking test, sf-36 questionnaire",NA
NCT04598594,2020-11-06,9/30/2021,Interventional,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04598594,0,0,0,0,6,0,France,0,"patch, nicotine|patch, placebo",NA
NCT04607941,2020-10-27,6/4/2021,Observational,"Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2 Responsible for COVID-19",Recruiting,NA,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04607941,0,0,0,0,1,0,France,0,questionnaire|phone interviews,NA
NCT04604977,2020-09-15,10/31/2021,Interventional,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04604977,0,0,0,0,0,0,Italy,0,mindfulness,NA
NCT04603924,2020-10-07,6/30/2021,Interventional,Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients,Recruiting,Phase 2/Phase 3,ANA Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04603924,0,0,0,0,2,1,United States,0,niclosamide|placebo,NA
NCT04597047,2020-08-20,10/31/2022,Interventional,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04597047,0,0,0,0,0,1,United States,0,capillary collection/testing|venous draw/testing|capillary collection|testing|venous draw,NA
NCT04596085,2020-09-16,11/30/2020,Interventional,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)",Recruiting,N/A,"The Herb, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04596085,0,0,0,0,4,0,India,0,investigational product - viracide|placebo,NA
NCT04600440,2020-04-25,12/31/2021,Interventional,Convalescent Plasma in the Treatment of Covid-19,Recruiting,N/A,Skane University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04600440,0,0,0,0,0,0,Sweden,0,convalescent plasma,NA
NCT04598581,2020-11-02,10/31/2021,Interventional,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19","Active, not recruiting",N/A,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04598581,0,0,0,0,3,0,Switzerland,0,radiotherapy|placebo,NA
NCT04596943,2020-10-15,12/31/2020,Observational,RGD PET/CT Imaging in COVID-19 Patients,Recruiting,NA,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04596943,0,0,0,0,0,0,Netherlands,0,[68ga]ga-dota-(rgd)2 pet/ct|[68ga]ga-dota-(rgd)2 pet|ct-scan,NA
NCT04596839,2020-09-04,2/28/2021,Interventional,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),Recruiting,N/A,Beximco Pharmaceuticals Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04596839,0,0,0,0,3,0,Bangladesh,0,remdesivir|standard care,NA
NCT04595773,2021-01-22,12/31/2023,Interventional,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)",Recruiting,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04595773,0,0,0,0,64,1,United States,0,exercise|education,NA
NCT04724681,2021-02-01,12/31/2021,Interventional,Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection,Recruiting,N/A,University Hospital Bispebjerg and Frederiksberg,NA,https://clinicalzeros.gov/ct2/show/NCT04724681,0,0,0,0,0,0,Denmark,0,ward css,NA
NCT04719208,2020-10-06,5/31/2021,Interventional,[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse,Recruiting,N/A,Augusta University,NA,https://clinicalzeros.gov/ct2/show/NCT04719208,0,0,0,0,0,1,United States,0,water (e) mouth rinse with the solution provided|chlorhexidine gluconate (a) mouth rinse with the solution provided|hydrogen peroxide (b) mouth rinse with the solution provided|betadine (c) mouth rinse with the solution provided|alcohol mouthwash (listerine) (d) mouth rinse with the solution provided,NA
NCT04625985,2020-07-14,12/31/2020,Interventional,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",Recruiting,Phase 2,Laboratorios Silanes S.A. de C.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04625985,0,0,0,0,0,0,Mexico,0,metformin glycinate|placebo,NA
NCT04618042,2020-11-13,7/31/2021,Interventional,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04618042,0,0,0,0,1,0,France,0,fx06|placebo of fx06,NA
NCT04609332,2020-11-10,8/31/2021,Observational [Patient Registry],Endothelial Damage and Angiogenesis Biomarkers During COVID-19,Recruiting,NA,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04609332,0,0,0,0,2,0,Chile,0,endothelial damage/angiogenic biomarkers|endothelial damage|angiogenic biomarkers,NA
NCT04608201,2020-12-09,12/31/2021,Interventional,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04608201,0,0,0,0,2,0,France,0,nicotine 7 mg/ 24h transdermal patch - 24 hour|placebo of nicotine transdermal patch|nicotine 7 mg|24h transdermal patch - 24 hour,NA
NCT04605952,2020-07-01,8/30/2020,Observational,Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive,Completed,NA,Tata Main Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04605952,0,0,0,0,0,0,India,0,repeat sars-cov-2 igg antibodies at 45-65 days,NA
NCT04603794,2020-10-01,11/30/2020,Interventional,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,Recruiting,Phase 4,Ohio State University,NA,https://clinicalzeros.gov/ct2/show/NCT04603794,0,0,0,0,0,1,United States,0,0.12% chlorhexidine gluconate mouth rinse|0.5% povidone iodine|1% hydrogen peroxide|0.9% normal saline,NA
NCT04603729,2020-05-30,6/30/2020,Interventional,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,Phase 3,Fatima Memorial Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04603729,0,0,0,0,0,0,Pakistan,0,dexamethasone 2 mg/ml|methylprednisolone injection|dexamethasone 2 mg|methylprednisolone,NA
NCT04604327,2020-10-26,5/31/2021,Interventional,Comparison of Two Different Doses of Bemiparin in COVID-19,Recruiting,Phase 3,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicalzeros.gov/ct2/show/NCT04604327,0,0,0,0,0,0,Spain,0,bemiparin sodium,NA
NCT04602871,2020-07-03,1/30/2021,Interventional,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Recruiting,N/A,Scentech Medical Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04602871,0,0,0,0,0,0,Israel,0,breath biopsy,NA
NCT04602832,2020-10-14,12/31/2020,Interventional,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,Enrolling by invitation,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04602832,0,0,0,0,1,0,Canada,0,enduring happiness/continued self-enhancement (enhance) for covid-19|enduring happiness|continued self-enhancement (enhance) for covid-19,NA
NCT04602481,2020-05-31,5/31/2022,Observational,COVID-19 in People With Primary Ciliary Dyskinesia,Recruiting,NA,University of Bern,NA,https://clinicalzeros.gov/ct2/show/NCT04602481,0,0,0,0,0,0,Switzerland,0,"NA",NA
NCT04602442,2020-10-01,8/1/2021,Interventional,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,Enrolling by invitation,Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,https://clinicalzeros.gov/ct2/show/NCT04602442,0,0,0,0,0,0,Russian Federation,0,exo 1 inhalation|exo 2 inhalation|placebo,NA
NCT04601077,2020-11-01,6/1/2021,Interventional,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans,Recruiting,Phase 1/Phase 2,Nitric Oxide Innovations LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04601077,0,0,0,0,1,1,United States,0,"nitric oxide lozenges, 30 mg|placebo",NA
NCT04610567,2020-10-27,3/15/2021,Interventional,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Recruiting,Phase 1/Phase 2,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04610567,0,0,0,0,2,0,Brazil,0,methotrexate-lde phase 1|methotrexate-lde phase 2|placebo-lde phase 2,NA
NCT04598620,2020-09-19,10/1/2021,Observational,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate,Recruiting,NA,Aalborg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04598620,0,0,0,0,1,0,Denmark,0,"NA",NA
NCT04598347,2020-08-08,1/8/2022,Observational [Patient Registry],Evaluation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19,Recruiting,NA,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,https://clinicalzeros.gov/ct2/show/NCT04598347,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04598256,2020-06-01,8/31/2020,Observational [Patient Registry],Endoscopic Procedures of Children in the Normalization Process of Covid-19 Pandemic,Completed,NA,Tepecik Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04598256,0,0,0,0,2,0,Turkey,0,endoscopic procedure,NA
NCT04603755,2020-10-26,4/30/2022,Observational,Electrical Impedance Tomography: Collapse in Dependent Areas as a Predictor of Response to Prone Position Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04603755,0,0,0,0,1,0,France,0,electrical impedance tomography,NA
NCT04604119,2020-05-01,5/30/2020,Observational [Patient Registry],Anxiety and Burnout in Anesthetists and Intensive Care Unit Nurses During Covid-19 Pandemic,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04604119,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04604080,2020-11-01,11/18/2020,Observational,Post-COVID-19 Epidemic Depression Assessment in Adults in South Punjab Pakistan,Completed,NA,Islamia University of Bahawalpur,NA,https://clinicalzeros.gov/ct2/show/NCT04604080,0,0,0,0,4,0,Pakistan,0,service of questionnaire,NA
NCT04603963,2020-06-01,10/10/2020,Interventional,Inspiratory Muscle Training in Patients With COVID-19,Terminated,N/A,Hospital Israelita Albert Einstein,There was a change in the institutional flow reducing the cases of covid 19,https://clinicalzeros.gov/ct2/show/NCT04603963,0,0,0,0,1,0,Brazil,0,power breathe,NA
NCT04603677,2020-07-08,7/30/2022,Observational,Northern Colorado COVID-19 Biobank,Enrolling by invitation,NA,Colorado State University,NA,https://clinicalzeros.gov/ct2/show/NCT04603677,0,0,0,0,0,1,United States,0,"NA",NA
NCT04632706,2020-09-22,2/28/2021,Interventional,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,Recruiting,Early Phase 1,MedinCell S.A,NA,https://clinicalzeros.gov/ct2/show/NCT04632706,0,0,0,0,0,0,United Kingdom,0,ivermectin|placebo,NA
NCT04609501,2020-06-01,6/30/2023,Observational [Patient Registry],"Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship","Active, not recruiting",NA,Hillel Yaffe Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04609501,0,0,0,0,0,0,Israel,0,"NA",NA
NCT04609423,2020-11-10,5/31/2021,Interventional,Cod Liver Oil for Covid-19 Prevention Study,Recruiting,Phase 4,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04609423,0,0,0,0,3,0,Norway,0,cod liver oil|corn oil (placebo),NA
NCT04615416,2020-05-01,1/31/2021,Interventional,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Recruiting,N/A,"Teachers College, Columbia University",NA,https://clinicalzeros.gov/ct2/show/NCT04615416,0,0,0,0,0,1,United States,0,emotion regulation training via telehealth,NA
NCT04613310,2020-09-25,12/31/2020,Interventional,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),Recruiting,N/A,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04613310,0,0,0,0,1,0,Switzerland,0,rapid diagnostic test vs pcr,NA
NCT04605172,2020-11-02,4/30/2021,Observational,Lockdown Impact on Spontaneous Premature Birth in a Level III NICU,Enrolling by invitation,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04605172,0,0,0,0,1,0,France,0,hospitalization for premature birth,NA
NCT04610801,2020-08-08,8/8/2021,Interventional,Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2,Recruiting,Phase 3,Larkin Community Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04610801,0,0,0,0,1,1,United States,0,nasal rinse,NA
NCT04602637,2019-12-15,12/15/2020,Observational,Training Load Management in Three Professional Tennis Players During COVID-19 Lockdown: a Case Series Study,"Active, not recruiting",NA,Kine Kinesiologia Deportiva y Funcional,NA,https://clinicalzeros.gov/ct2/show/NCT04602637,0,0,0,0,0,0,Argentina,0,training load,NA
NCT04602507,2020-12-07,3/31/2021,Interventional,Ivermectin in Adults With Severe COVID-19.,Recruiting,Phase 2,CES University,NA,https://clinicalzeros.gov/ct2/show/NCT04602507,0,0,0,0,1,0,Colombia,0,ivermectin|placebo,NA
NCT04601012,2020-09-20,10/20/2020,Observational,OCTA Study: Retinal Vascular Changes in Patients With SARS-CoV-2 Infection,Completed,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04601012,0,0,0,0,2,0,Italy,0,optical coherence tomography angiography,NA
NCT04599959,2020-10-26,1/20/2021,Interventional,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,Completed,N/A,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04599959,0,0,0,0,2,0,Mexico,0,sampling of sars-cov-2 rna from nasopharyngeal swab specimen/saliva collected via salivette cortisol|sampling of sars-cov-2 rna from nasopharyngeal swab specimen|saliva collected via salivette cortisol,NA
NCT04609839,2020-10-27,4/27/2023,Observational,FOLLOW-UP OF PATIENTS WITH COVID-19.,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04609839,0,0,0,0,0,0,France,0,follow-up of patients with covid-19,NA
NCT04609722,2020-07-01,2/1/2021,Interventional,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Recruiting,N/A,Adiyaman University Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04609722,0,0,0,0,2,0,Turkey,0,solution-focused support program,NA
NCT04608305,2020-10-28,5/1/2021,Interventional,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine",Recruiting,Phase 1/Phase 2,Israel Institute for Biological Research (IIBR),NA,https://clinicalzeros.gov/ct2/show/NCT04608305,0,0,0,1,2,0,Israel,0,"iibr-100, low dose (prime)|iibr-100 medium dose (prime)|iibr-100 high-dose (prime)|iibr-100 low-dose (prime-boost)|placebo",NA
NCT04605692,2020-03-09,5/20/2020,Observational,Evaluation of Occupational Burnout and Stress Among Dentists in Covid-19 Pandemic,Completed,NA,Akdeniz University,NA,https://clinicalzeros.gov/ct2/show/NCT04605692,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04605588,2020-12-02,4/30/2021,Interventional,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,Recruiting,Phase 2,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04605588,0,0,0,0,3,1,United States,0,nitazoxanide|placebo nitazoxanide|ribavirin|placebo ribavirin|hydroxychloroquine|placebo hydroxychloroquine,NA
NCT04604184,2020-11-03,3/20/2021,Interventional,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,Recruiting,Phase 2,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04604184,0,0,0,0,6,1,United States|Brazil|Chile|Mexico|Puerto Rico|Spain,0,bi 764198|placebo,NA
NCT04604704,2021-01-28,8/31/2021,Interventional,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Recruiting,Phase 2,AgelessRx,NA,https://clinicalzeros.gov/ct2/show/NCT04604704,0,0,0,0,3,1,United States,0,naltrexone|nad/|placebo|nad|NA,NA
NCT04606498,2020-12-18,12/31/2021,Observational,Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study,Recruiting,NA,Henry M. Jackson Foundation for the Advancement of Military Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04606498,0,0,0,0,6,1,United States,0,observational,NA
NCT04606784,2020-10-28,1/31/2021,Interventional,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,Recruiting,Phase 1,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04606784,0,0,0,0,1,1,United States,0,ampion|standard care,NA
NCT04606732,2020-09-20,12/31/2020,Observational [Patient Registry],CardioVascular Disease Progression and Prognosis in COVID-19,Recruiting,NA,University of Bologna,NA,https://clinicalzeros.gov/ct2/show/NCT04606732,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04606563,2020-10-09,6/30/2021,Interventional,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,Phase 3,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04606563,0,0,0,0,0,1,United States|Belgium|Canada|France|Japan|Spain,0,losartan,NA
NCT04605887,2021-01-18,11/30/2023,Interventional,Angiotensin 1-7 as a Therapy in the Treatment of COVID-19,Recruiting,Phase 2,Rambam Health Care Campus,NA,https://clinicalzeros.gov/ct2/show/NCT04605887,0,0,0,0,2,0,Israel,0,angiotensin,NA
NCT04701528,2020-11-15,3/25/2022,Interventional,Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients,Recruiting,Phase 2,Leiden University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04701528,0,0,0,0,0,0,Netherlands,0,voclosporin|tacrolimus,NA
NCT04653831,2020-11-08,11/30/2021,Interventional,Treatment With Pirfenidone for COVID-19 Related Severe ARDS,Recruiting,N/A,Soroka University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04653831,0,0,0,0,0,0,Israel,0,pirfenidone|standard care,NA
NCT04609774,2020-10-08,11/20/2020,Observational,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019,Completed,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04609774,0,0,0,0,2,0,Argentina,0,severe acute respiratory syndrome coronavirus 2 detection,NA
NCT04613050,2020-07-02,12/24/2021,Interventional,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04613050,0,0,0,0,1,0,Egypt,0,respiratory training|aerobic training,NA
NCT04618341,2020-03-30,6/30/2020,Observational,A Clinical Study of Online Active Play Program With Adolescents,Completed,NA,Revival Active,NA,https://clinicalzeros.gov/ct2/show/NCT04618341,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04613817,2020-12-03,6/30/2021,Observational [Patient Registry],Sero-prevalence COVID-19 Among Belgian Children,Recruiting,NA,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04613817,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04611802,2020-12-27,3/31/2021,Interventional,"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2",Recruiting,Phase 3,Novavax,NA,https://clinicalzeros.gov/ct2/show/NCT04611802,0,0,0,1,12,1,United States|Mexico|Puerto Rico,0,sars-cov-2 rs/matrix-m1 adjuvant|placebo|sars-cov-2 rs|adjuvant,NA
NCT04618835,2020-11-03,11/3/2021,Observational,Physical Activity a Vital Sign? 40 Steps to Safety Test for Patients With COVID-19,Recruiting,NA,Betsi Cadwaladr University Health Board,NA,https://clinicalzeros.gov/ct2/show/NCT04618835,0,0,0,0,0,0,United Kingdom,0,40-steps-test,NA
NCT04615975,2020-11-01,7/30/2021,Interventional,Ketogenic Diet as Protective Factor During COVID-19,Recruiting,N/A,University of Padova,NA,https://clinicalzeros.gov/ct2/show/NCT04615975,0,0,0,0,0,0,Italy,0,ketogenic diet with phytoextracts,NA
NCT04694664,2020-10-01,12/1/2020,Observational,COVID-19 Vaccine Confidence Among Pregnant Women and Mothers,Completed,NA,Pregistry,NA,https://clinicalzeros.gov/ct2/show/NCT04694664,0,0,0,0,0,1,United States,0,survey,NA
NCT04610515,2020-12-15,11/14/2022,Observational [Patient Registry],Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE),Recruiting,NA,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04610515,0,0,0,0,1,1,United States,0,"NA",NA
NCT04609969,2020-10-13,10/17/2020,Interventional,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Completed,N/A,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04609969,0,0,0,0,3,0,France,0,rt-qpcr test|covid-viroâ® test,NA
NCT04608266,2020-12-03,1/31/2022,Interventional,CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04608266,0,0,0,0,2,0,France,0,camostat mesylate|placebo,NA
NCT04608097,2020-10-28,1/15/2021,Interventional,Understanding Reactions to Emotional Material in the Media During COVID-19,Recruiting,N/A,Uppsala University,NA,https://clinicalzeros.gov/ct2/show/NCT04608097,0,0,0,0,2,0,Sweden,0,simple cognitive task intervention|placebo,NA
NCT04616976,2020-01-01,2/29/2020,Observational,COVID-19 With Convalescent Plasma,Completed,NA,"Southeast University, China",NA,https://clinicalzeros.gov/ct2/show/NCT04616976,0,0,0,0,0,0,China,0,convalescent plasma,NA
NCT04607928,2020-08-01,8/1/2021,Interventional,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Recruiting,Phase 2,Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge,NA,https://clinicalzeros.gov/ct2/show/NCT04607928,0,0,0,0,2,0,Spain,0,pirfenidone|placebo,NA
NCT04644705,2020-11-02,5/31/2021,Interventional,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,Recruiting,Phase 1,CharitÃ© Research Organisation GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04644705,0,0,0,0,0,0,Germany,0,niclosamide|placebo,NA
NCT04623177,2020-03-01,9/30/2020,Observational,Thromboprophylaxis for Patients in ICU With COVID-19,"Active, not recruiting",NA,Instituto de Investigacion Sanitaria La Fe,NA,https://clinicalzeros.gov/ct2/show/NCT04623177,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04615741,2020-11-01,2/28/2021,Interventional,Finding Wellness in the Pandemic,Recruiting,N/A,University of Lethbridge,NA,https://clinicalzeros.gov/ct2/show/NCT04615741,0,0,0,0,2,0,Canada,0,trauma informed yoga|trauma informed psychotherapy,NA
NCT04615390,2020-03-30,6/3/2021,Observational,Recovery Profiles in Patients With SARS-CoV-2 Outcomes Undergoing Rehabilitation,Recruiting,NA,University Hospital of Ferrara,NA,https://clinicalzeros.gov/ct2/show/NCT04615390,0,0,0,0,0,0,Italy,0,early rehabilitation|subacute rehabilitation|mindfulness training|personalized ambulatory training,NA
NCT04615052,2020-09-26,10/31/2021,Interventional,Home-based Exercise in COVID-19 Survivors,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04615052,0,0,0,0,0,0,Brazil,0,exercise training,NA
NCT04613739,2020-12-08,9/1/2021,Interventional,Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19,Recruiting,N/A,Harvard Pilgrim Health Care,NA,https://clinicalzeros.gov/ct2/show/NCT04613739,0,0,0,0,1,1,United States,0,insurance navigation,NA
NCT04613245,2020-05-01,1/30/2021,Observational [Patient Registry],Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04613245,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04611256,2020-08-01,11/30/2020,Interventional,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Recruiting,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,https://clinicalzeros.gov/ct2/show/NCT04611256,0,0,0,0,1,0,Mexico,0,msc|control,NA
NCT04611230,2020-11-05,9/24/2021,Observational,"A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois",Recruiting,NA,AbbVie,NA,https://clinicalzeros.gov/ct2/show/NCT04611230,0,0,0,0,1,1,United States,0,"NA",NA
NCT04647682,2020-11-01,6/30/2021,Observational,Physical Activity Program Implementation in Hospitalized Positive Covid-19 Older Adults,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04647682,0,0,0,0,2,0,France,0,physical activity program,NA
NCT04609085,2021-02-10,4/30/2023,Observational,SARS-COV2 Pandemic Serosurvey in a Rare Disease Population,Enrolling by invitation,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04609085,0,0,0,0,64,1,United States,0,"NA",NA
NCT04619693,2020-11-18,9/18/2021,Observational,Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04619693,0,0,0,0,3,0,France,0,"NA",NA
NCT04625036,2020-05-30,11/30/2020,Observational [Patient Registry],NO-mediated Vascular Function in Covid-19 Patient,Recruiting,NA,Istituti Clinici Scientifici Maugeri SpA,NA,https://clinicalzeros.gov/ct2/show/NCT04625036,0,0,0,0,0,0,Italy,0,single passive leg movement,NA
NCT04616846,2020-08-04,9/15/2021,Interventional,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,N/A,Centre Antoine Lacassagne,NA,https://clinicalzeros.gov/ct2/show/NCT04616846,0,0,0,0,0,0,France|Monaco,0,peripheral venous ultrasound,NA
NCT04615936,2020-07-10,5/31/2021,Interventional,Nasal Photodisinfection COVID Proof of Concept Study,Recruiting,N/A,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04615936,0,0,0,0,0,0,Canada,0,methylene-blue photodisinfection,NA
NCT04615728,2019-11-01,7/5/2020,Observational,MANAGEMENT OF APPENDICITIS DURING THE COVID-19 PANDEMIC,Completed,NA,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04615728,0,0,0,0,0,0,United Kingdom,0,laparoscopic/open appendicectomy|laparoscopic|open appendicectomy,NA
NCT04614883,2020-10-21,10/31/2021,Interventional,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04614883,0,0,0,0,0,0,France,0,volatile organic compounds analysis|canine odor detection of volatile organic compounds,NA
NCT04614025,2020-11-30,5/31/2021,Interventional,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,Recruiting,Phase 2,Pluristem Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04614025,0,0,0,0,0,0,Germany|Israel,0,plx-pad,NA
NCT04614012,2020-07-02,7/2/2022,Interventional,Hyperimmune Plasma for Patients With COVID-19,Recruiting,N/A,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04614012,0,0,0,0,0,0,Italy,0,treated with hyperimmune plasma,NA
NCT04613297,2020-10-19,10/31/2021,Interventional,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04613297,0,0,0,0,0,0,France,0,baseline/during hospitalization blood samples|baseline blood sample|baseline|during hospitalization blood samples,NA
NCT04632732,2020-10-26,10/7/2021,Observational [Patient Registry],Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).,Recruiting,NA,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04632732,0,0,0,0,1,0,Canada,0,covid-19 test|blood sample,NA
NCT04619368,2020-07-27,7/31/2022,Observational [Patient Registry],Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome Caused by COVID-19,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04619368,0,0,0,0,0,0,France,0,follow up calls,NA
NCT04618861,2020-10-13,11/2/2020,Observational,Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study,Completed,NA,Kafkas University,NA,https://clinicalzeros.gov/ct2/show/NCT04618861,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04615676,2020-04-27,7/17/2020,Observational [Patient Registry],Prospective Evaluation of the Predictive Criteria of Severity for Respiratory Infection Due to COVID-19 Virus,Completed,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04615676,0,0,0,0,1,0,France,0,follow-up phone call,NA
NCT04615195,2020-06-10,7/2/2020,Observational,Effect of COVID19-related COntainment in ChildreN,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04615195,0,0,0,0,0,0,France,0,cries 13 questionnaire,NA
NCT04615026,2020-11-04,6/30/2021,Observational [Patient Registry],Prevalence of Thrombosis in COVID-Patients,Recruiting,NA,University Hospital Augsburg,NA,https://clinicalzeros.gov/ct2/show/NCT04615026,0,0,0,0,0,0,Germany,0,duplex sonography,NA
NCT04615000,2020-10-29,11/1/2021,Observational [Patient Registry],SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort,Recruiting,NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04615000,0,0,0,0,0,0,Belgium,0,sars-cov-2 serological assessment (igg),NA
NCT04614948,2020-11-12,5/10/2022,Interventional,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,Recruiting,Phase 3,Janssen Vaccines & Prevention B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04614948,0,0,0,0,6,1,United States|Belgium|Brazil|Colombia|France|Germany|Philippines|South Africa|Spain|United Kingdom,0,ad26.cov2.s|placebo,NA
NCT04696679,2020-06-19,11/30/2020,Observational,Quality of Life of Very Preterm Children With Dysexecutive Disorders at Elementary School Age During the Confinement-deconfinement Period of Covid-19 Pandemic,Completed,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04696679,0,0,0,0,2,0,France,0,patient quality of life assessment|control group quality of life assessment,NA
NCT04639466,2020-12-11,11/10/2022,Interventional,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19",Recruiting,Phase 1,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04639466,0,0,0,1,4,1,United States,0,placebo|vaccine therapy,NA
NCT04632537,2020-12-07,11/30/2022,Interventional,BCG Vaccination to Prevent COVID-19,Recruiting,Phase 3,Henry M. Jackson Foundation for the Advancement of Military Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04632537,0,0,0,1,6,1,United States,0,ticeâ® bcg (for intravesical use) bcg live strain of the bcg (merck) vaccine|preservative-free saline,NA
NCT04629157,2020-11-05,11/19/2020,Interventional,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Recruiting,N/A,Alder Hey Children's NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04629157,0,0,0,0,0,0,United Kingdom,0,innova lateral flow device,NA
NCT04622826,2020-05-15,12/31/2020,Interventional,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,Recruiting,Phase 2,Azienda USL Toscana Nord Ovest,NA,https://clinicalzeros.gov/ct2/show/NCT04622826,0,0,0,0,0,0,Italy,0,immune plasma,NA
NCT04621214,2020-03-21,4/28/2020,Observational,Innovation of Audio-Visual Triage System in Combating the Spread of COVID-19 Infection and Its Efficacy: A Novel Strategy,Completed,NA,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04621214,0,0,0,0,0,0,Pakistan,0,audio-visual triage system (avt),NA
NCT04621123,2020-10-30,2/28/2021,Interventional,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Recruiting,Phase 2,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04621123,0,0,0,0,0,0,Spain,0,convalescent plasma|control,NA
NCT04620798,2020-09-14,12/31/2020,Interventional,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,"Active, not recruiting",N/A,Indiana University,NA,https://clinicalzeros.gov/ct2/show/NCT04620798,0,0,0,0,0,1,United States,0,immediate vs. delayed provision of antibody test results,NA
NCT04619407,2020-11-04,3/31/2021,Observational,"Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers",Recruiting,NA,University Medicine Greifswald,NA,https://clinicalzeros.gov/ct2/show/NCT04619407,0,0,0,0,0,0,Germany,0,nasopharyngeal swab|serum test,NA
NCT04619290,2020-10-12,11/30/2020,Interventional,Outpatient Treatment With CoVid-19 With Prexablu,Recruiting,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,https://clinicalzeros.gov/ct2/show/NCT04619290,0,0,0,0,1,0,Mexico,0,sublingual methylene blue|control patients,NA
NCT04617483,2020-10-31,11/28/2020,Interventional,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults",Recruiting,Phase 3,"Sinovac Biotech Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04617483,0,0,0,1,0,0,China,0,"two doses of commercial scale inactivated sars-cov-2 vaccine at the schedule of day 0,14|two doses of pilot scale inactivated sars-cov-2 vaccine at the schedule of day 0,14|two doses of pilot scale inactivated sars-cov-2 vaccine at the schedule of day 0,14 in elderly",NA
NCT04621058,2020-11-09,11/30/2021,Interventional,Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.,Recruiting,Phase 3,Bioaraba Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04621058,0,0,0,0,2,0,Spain,0,vitamin d|placebo,NA
NCT04627675,2020-12-30,5/31/2021,Interventional,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),Recruiting,Phase 1,Providence Health & Services,NA,https://clinicalzeros.gov/ct2/show/NCT04627675,0,0,0,1,1,1,United States,0,corvax|il-12 plasmid|cliniporator,NA
NCT04721444,2021-03-01,8/1/2022,Observational,Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19),Recruiting,NA,Royal Marsden NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04721444,0,0,0,0,1,0,United Kingdom,0,machine learning classification of parenchymal lung change cause|machine learning classification of recurrence/non-recurrence|machine learning classification of recurrence|non-recurrence,NA
NCT04645433,2020-03-15,5/15/2020,Observational,Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04645433,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04646525,2020-10-01,2/1/2021,Observational,The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs,Recruiting,NA,Selcuk University,NA,https://clinicalzeros.gov/ct2/show/NCT04646525,0,0,0,0,0,0,Turkey,0,physical examination,NA
NCT04623346,2020-03-11,11/1/2020,Observational,Orthopaedic Conservative Treatment in the Time of Covid-19 Pandemic,"Active, not recruiting",NA,Prof. Dr. Cemil TascÄ±oglu Education and Research Hospital Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04623346,0,0,0,0,1,0,Turkey,0,observation for study group,NA
NCT04666207,2020-05-25,1/31/2021,Observational,"Viral Shedding, Symptoms and Exposure of SARS-CoV-2 in Non-hospitalized Children With COVID-19",Recruiting,NA,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04666207,0,0,0,0,0,0,Denmark,0,pcr,NA
NCT04635618,2020-11-05,7/13/2021,Interventional,Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19,Enrolling by invitation,N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04635618,0,0,0,0,0,0,Brazil,0,cognitive behavioral brief-telepsychotherapy|brief interpersonal telepsychotherapy|telepsychoeducation,NA
NCT04632082,2020-11-05,7/13/2021,Interventional,Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19,Enrolling by invitation,N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04632082,0,0,0,0,1,0,Brazil,0,telepsychoeducation with personalized videos|telepsychoeducation without personalized videos,NA
NCT04657497,2020-11-09,5/31/2021,Interventional,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),Recruiting,Phase 3,Ono Pharmaceutical Co. Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04657497,0,0,0,0,0,0,Japan,0,foy-305|placebo,NA
NCT04625114,2020-11-04,10/1/2022,Interventional,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,Phase 2,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04625114,0,0,0,0,0,0,Belgium,0,camostat|placebo,NA
NCT04641481,2020-11-25,6/30/2021,Interventional,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,Recruiting,Phase 3,Bharat Biotech International Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04641481,0,0,0,1,1,0,India,0,bbv152|placebo,NA
NCT04621149,2020-11-15,3/31/2021,Interventional,An Outpatient Study Investigating Non-prescription Treatments for COVID-19,Recruiting,Phase 2,"Profact, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04621149,0,0,0,0,3,1,United States,0,"chlorine dioxide|zinc acetate|famotidine|placebo|lactoferrin, green tea extract",NA
NCT04621084,2020-04-01,12/31/2025,Observational,Influence of the COVId-19 Pandemic on STRESS and Eating Habits,Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04621084,0,0,0,0,0,0,France,0,eating habits,NA
NCT04621071,2021-01-05,3/31/2021,Interventional,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,Recruiting,N/A,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04621071,0,0,0,0,3,0,Canada,0,probiotics (2 strains 10x10^9 ufc)|placebo (potato starch/magnesium stearate)|placebo (potato starch|magnesium stearate),NA
NCT04619706,2020-12-14,8/14/2021,Interventional,Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19,Recruiting,Phase 2,"FSD Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04619706,0,0,0,0,2,1,United States,0,fsd201|placebo,NA
NCT04619680,2020-11-18,7/31/2021,Interventional,The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19,Recruiting,Phase 4,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04619680,0,0,0,0,2,1,United States,0,nintedanib|placebo,NA
NCT04619628,2020-12-11,6/30/2021,Interventional,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19",Recruiting,Phase 1,"Codagenix, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04619628,0,0,0,1,1,0,United Kingdom,0,covi-vac|placebo,NA
NCT04619576,2020-06-01,12/21/2025,Observational,Influence of the COVId-19 Pandemic on STRESS of Occupational Health Workers,Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04619576,0,0,0,0,0,0,France,0,occupational health workers,NA
NCT04623021,2020-09-25,12/12/2020,Interventional,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,Completed,Phase 2,Chong Kun Dang Pharmaceutical,NA,https://clinicalzeros.gov/ct2/show/NCT04623021,0,0,0,0,1,0,Russian Federation,0,nafamostat mesilate,NA
NCT04635943,2020-08-28,12/28/2020,Interventional,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Recruiting,Phase 2,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04635943,0,0,0,0,0,0,Peru,0,ivermectin|placebo,NA
NCT04678193,2020-12-24,6/30/2021,Observational [Patient Registry],COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy,Enrolling by invitation,NA,"Aventyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04678193,0,0,0,0,1,1,United States|India|Sweden,0,coromec registry with ecl-19,NA
NCT04631497,2020-07-01,12/31/2020,Observational,"Assessment of Stress, Depression and Anxiety in Healthcare Caring for Patients With COVID-19",Recruiting,NA,Jagiellonian University,NA,https://clinicalzeros.gov/ct2/show/NCT04631497,0,0,0,0,0,0,Poland,0,test,NA
NCT04637477,2020-08-01,12/31/2020,Interventional,Virtual Enhanced Lifestyle for Metabolic Syndrome (ELM) Proof-of-Concept Study,"Active, not recruiting",N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04637477,0,0,0,0,0,1,United States,0,virtual elm,NA
NCT04633772,2020-08-05,2/1/2021,Interventional,Use of Angiotensin-(1-7) in COVID-19,Recruiting,Phase 1/Phase 2,Erasme University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04633772,0,0,0,0,1,0,Brazil,0,angiotensin-(1-7)|placebo,NA
NCT04627194,2020-02-20,4/30/2020,Observational,Characteristics of COVID-19 Patients in Kazakhstan in Early 2020,"Active, not recruiting",NA,Semey State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04627194,0,0,0,0,0,0,Kazakhstan,0,"NA",NA
NCT04625075,2020-06-10,6/10/2021,Observational,Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (COVID-19),Recruiting,NA,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04625075,0,0,0,0,0,0,United Kingdom,0,cardiac mri|cardiac ct|electrocardiogram (ecg)|blood sample,NA
NCT04623697,2020-11-01,10/30/2023,Observational [Patient Registry],Covid-19 Infection and New Onset Type 1 Diabetes,Recruiting,NA,Hospital of South West Jutland,NA,https://clinicalzeros.gov/ct2/show/NCT04623697,0,0,0,0,0,0,Denmark,0,"NA",NA
NCT04623047,2020-04-02,2/1/2022,Observational,Using Smart Watches to Detect and Monitor COVID-19,Recruiting,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04623047,0,0,0,0,0,1,United States,0,"NA",NA
NCT04622865,2020-06-01,6/30/2021,Interventional,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,Recruiting,Phase 2,AB Science,NA,https://clinicalzeros.gov/ct2/show/NCT04622865,0,0,0,0,0,0,France,0,masitinib|isoquercetin|best supportive care,NA
NCT04622891,2020-04-01,7/30/2020,Interventional,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04622891,0,0,0,0,0,0,Egypt,0,clarithromycin 500mg|azithromycin|placebo,NA
NCT04621903,2020-10-08,10/27/2020,Interventional,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04621903,0,0,0,0,1,0,United Kingdom,0,shanshamani vati plus,NA
NCT04634903,2020-11-19,5/1/2021,Interventional,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19","Active, not recruiting",N/A,Stony Brook University,NA,https://clinicalzeros.gov/ct2/show/NCT04634903,0,0,0,0,2,1,United States,0,supportive therapy ssi|behavioral activation ssi|growth mindset ssi,NA
NCT04632368,2020-11-20,4/30/2021,Interventional,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04632368,0,0,0,0,1,1,United States,0,transcendental meditation,NA
NCT04628637,2020-04-16,10/1/2020,Observational,High GRP78 Levels in Covid-19 Infection: A Case-Control Study,Completed,NA,Kafkas University,NA,https://clinicalzeros.gov/ct2/show/NCT04628637,0,0,0,0,0,0,Turkey,0,serum protein level analysis,NA
NCT04628000,2020-10-27,10/14/2021,Observational,Baseline Vitamin D Deficiency and COVID-19 Disease Severity,Recruiting,NA,Parkview Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04628000,0,0,0,0,1,1,United States,0,vitamin d,NA
NCT04668170,2020-05-05,12/31/2021,Observational,Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04668170,0,0,0,0,0,0,France,0,blood sample|blood collection on their first consultation/10 to 14 days later|longitudinally|10 to 14 days later,NA
NCT04628195,2020-04-01,6/30/2020,Observational,Cardiac Performance in Mechanically Ventilated COVID-19 Patients,Completed,NA,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04628195,0,0,0,0,0,0,Chile,0,"NA",NA
NCT04626076,2020-08-13,6/30/2021,Observational [Patient Registry],International Registry of Healthcare Workers Exposed to COVID-19 Patients,Recruiting,NA,Certara,NA,https://clinicalzeros.gov/ct2/show/NCT04626076,0,0,0,0,0,0,Pakistan,0,comparative observational cohort study,NA
NCT04625972,2020-12-02,1/21/2022,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults",Recruiting,Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04625972,0,0,0,0,2,1,United States|United Kingdom,0,azd7442|placebo,NA
NCT04643964,2020-11-30,11/30/2020,Interventional,Brief Video Interventions for Depression,Recruiting,N/A,Ohio State University,NA,https://clinicalzeros.gov/ct2/show/NCT04643964,0,0,0,0,0,1,United States,0,entrã©e: cognitive skills|entrã©e: behavioral skills|entrã©e: interpersonal skills|sampler skills,NA
NCT04625296,2020-09-17,1/31/2021,Observational,Behaviour and Experience of Communities Healthcare Professionals Facing the SARS CoV-2 (COVID-19) Epidemic,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04625296,0,0,0,0,0,0,France,0,semi-directive interview|questionnaire : preparedness for caregiving scale,NA
NCT04625257,2020-10-24,3/31/2021,Observational,"COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)",Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04625257,0,0,0,0,1,0,Switzerland,0,saliva based assay: crude rna extraction|validation of the ngs method|validation of the lamp assays|validation of the poct antigen tests,NA
NCT04625725,2020-11-21,8/2/2021,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.",Recruiting,Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04625725,0,0,0,0,2,1,United States|Belgium|France|Spain|United Kingdom,0,azd7442|placebo,NA
NCT04636697,2020-11-19,12/31/2021,Interventional,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,Recruiting,Phase 2/Phase 3,Medicago,NA,https://clinicalzeros.gov/ct2/show/NCT04636697,0,0,0,1,4,1,United States|Canada,0,intramuscular injection|intramuscular vaccine,NA
NCT04633941,2020-06-01,7/30/2020,Observational,Impact of Social Distancing on Bariatric Versus Non-Surgical Obese Patients During COVID-19 Pandemic,Completed,NA,Singapore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04633941,0,0,0,0,1,0,Singapore,0,standard care,NA
NCT04643548,2020-10-13,6/13/2021,Observational,WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients,Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04643548,0,0,0,0,1,0,France,0,"NA",NA
NCT04629638,2020-08-01,11/15/2020,Observational,Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04629638,0,0,0,0,3,0,Turkey,0,"maternal attachment, edinburgh depression scoring/postpartum anxiety scale scores|maternal attachment, edinburgh depression scoring|postpartum anxiety scale scores",NA
NCT04629001,2020-09-01,9/1/2021,Observational [Patient Registry],Effect of Covid-19 on Outcomes of Pregnancy,"Active, not recruiting",NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04629001,0,0,0,0,0,0,Egypt,0,"covid-19 pcr , igm",NA
NCT04628208,2020-11-17,1/31/2021,Observational,Clinical Study Spartan COVID-19 V2 System (Canada Alternate),Recruiting,NA,Spartan Bioscience Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04628208,0,0,0,0,2,0,Canada,0,spartan covid-19 v2 system,NA
NCT04627623,2020-06-22,3/22/2021,Observational,Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration,Recruiting,NA,Medical University of Silesia,NA,https://clinicalzeros.gov/ct2/show/NCT04627623,0,0,0,0,1,0,Poland,0,igm/igg antibodies assay|igm|igg antibodies assay,NA
NCT04637867,2020-11-23,11/1/2021,Interventional,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04637867,0,0,0,0,1,0,France,0,"collection of blood, salivary/nasopharyngeal samples.|collection of blood, salivary|nasopharyngeal samples.",NA
NCT04636021,2020-08-01,12/31/2021,Observational [Patient Registry],Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era,Recruiting,NA,Pinnacle Health Cardiovascular Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04636021,0,0,0,0,0,1,United States,0,covid-19 testing,NA
NCT04635787,2020-11-05,9/30/2022,Observational,Vital Sensor Monitors for CV19 Detection,Enrolling by invitation,NA,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04635787,0,0,0,0,0,1,United States,0,anne one,NA
NCT04630054,2020-11-15,2/15/2021,Interventional,Face Masks to Reduce COVID-19 in Bangladesh,Recruiting,N/A,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04630054,0,0,0,0,1,0,Bangladesh,0,face mask|face mask awareness,NA
NCT04630015,2020-08-31,8/1/2023,Observational,Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth,Recruiting,NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04630015,0,0,0,0,1,1,United States,0,questionnaire,NA
NCT04629989,2020-11-13,2/15/2021,Interventional,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,Recruiting,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04629989,0,0,0,0,2,0,Belgium,0,standard oxygen delivery system|mask|surgical mask,NA
NCT04629222,2020-03-11,7/20/2020,Observational,Tracheobronchitis in Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04629222,0,0,0,0,0,0,France,0,"NA",NA
NCT04629183,2020-11-01,4/30/2021,Observational,Risk Stratification of COVID-19 Patients Discharged From the Emergency Department,Recruiting,NA,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,https://clinicalzeros.gov/ct2/show/NCT04629183,0,0,0,0,1,0,Italy,0,integrated clinical evaluation,NA
NCT04691947,2020-11-05,3/1/2021,Interventional,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,Recruiting,Phase 1,Health Institutes of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04691947,0,0,0,1,1,0,Turkey,0,erucov-vac|placebo,NA
NCT04657510,2020-11-14,12/1/2020,Observational,Femoral frACturEs and COVID-19.,Recruiting,NA,Istituto Ortopedico Galeazzi,NA,https://clinicalzeros.gov/ct2/show/NCT04657510,0,0,0,0,0,0,Italy,0,covid-19,NA
NCT04632602,2020-04-04,12/31/2020,Interventional,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04632602,0,0,0,0,0,0,France,0,physiological effects of awake prone position in covid 19 patients,NA
NCT04639375,2020-11-15,4/18/2021,Interventional,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),Recruiting,Phase 4,E-MO Biology Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04639375,0,0,0,1,4,1,United States,0,vaccinated with polio vaccine (ipv),NA
NCT04646044,2020-11-13,1/28/2021,Interventional,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,Recruiting,Phase 1,Nektar Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04646044,0,0,0,0,0,1,United States,0,bempegaldesleukin|standard care|placebo,NA
NCT04637828,2020-11-18,7/30/2021,Interventional,A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Genoscience Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04637828,0,0,0,0,0,0,France,0,gns561,NA
NCT04634422,2020-11-16,6/30/2021,Interventional,Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04634422,0,0,0,0,1,0,Denmark,0,plasma exchange/convalescent plasma|plasma|convalescent plasma,NA
NCT04632719,2020-11-08,12/29/2020,Interventional,The MentalPlusÂ® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04632719,0,0,0,0,0,0,Brazil,0,the use of the mentalplusâ® digital game for assessment/rehabilitation of cognitive function after remission of the symptoms of covid-19|the use of the mentalplusâ® digital game for assessment|rehabilitation of cognitive function after remission of the symptoms of covid-19,NA
NCT04631172,2020-05-01,9/30/2020,Observational [Patient Registry],Covid-19 Anxiety and Phobia Levels of the Parents,Completed,NA,Selcuk University,NA,https://clinicalzeros.gov/ct2/show/NCT04631172,0,0,0,0,1,0,Turkey,0,"coronavirus anxiety scale , covid-19 phobia scale",NA
NCT04646109,2020-05-11,9/2/2020,Interventional,Ivermectin for Severe COVID-19 Management,Completed,Phase 3,Afyonkarahisar Health Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04646109,0,0,0,0,1,0,Turkey,1,ivermectin,NA
NCT04633915,2020-11-26,8/31/2021,Observational,Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.,Recruiting,NA,"Saint Petersburg State University, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04633915,0,0,0,0,1,0,Russian Federation,0,"NA",NA
NCT04636034,2021-01-12,8/31/2021,Interventional,The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection,Recruiting,Phase 3,University Hospital Bispebjerg and Frederiksberg,NA,https://clinicalzeros.gov/ct2/show/NCT04636034,0,0,0,0,3,0,Denmark,0,"sphenopalatine ganglion block with local anesthetic|sphenopalatine ganglion block with placebo (isotone nacl)|""sham""-block with placebo (isotone nacl)",NA
NCT04669938,2020-12-04,3/31/2022,Observational,"Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease,COVID-19, in Hospitalized Patients",Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04669938,0,0,0,0,0,0,France,0,oropharyngeal/intestinal microbiota|host genotype|host immune factors|viral sequence|oropharyngeal|intestinal microbiota,NA
NCT04636333,2020-10-30,4/7/2021,Interventional,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Recruiting,Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04636333,0,0,0,1,2,0,China,0,"two doses of middle-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14|three doses of middle-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14, 28|two doses of high-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14|three doses of high-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14, 28|two doses of placebo at the schedule of day 0, 14 #middle-dose group#|three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|two doses of placebo at the schedule of day 0, 14 #high-dose group#|three doses of placebo at the schedule of day 0, 14, 28 #high-dose group#",NA
NCT04636086,2020-11-12,1/31/2021,Interventional,Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection,Recruiting,Phase 4,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04636086,0,0,0,0,0,0,Belgium,0,cholecalciferol|placebo,NA
NCT04635813,2020-03-10,9/30/2020,Observational,The Impact of COVID-19 Pandemic on Thyroid Surgery in Italy: Results From a Nation-wide Multicentric Study,Completed,NA,University of Cagliari,NA,https://clinicalzeros.gov/ct2/show/NCT04635813,0,0,0,0,0,0,Italy,0,thyroidectomy,NA
NCT04634799,2021-01-08,11/30/2021,Interventional,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Recruiting,Phase 1/Phase 2,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04634799,0,0,0,0,2,1,United States,0,tm5614|placebo,NA
NCT04634409,2020-10-29,1/22/2021,Interventional,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04634409,0,0,0,0,7,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo|vir-7831,NA
NCT04634318,2020-12-10,12/31/2021,Interventional,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID),Recruiting,N/A,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,https://clinicalzeros.gov/ct2/show/NCT04634318,0,0,0,0,4,0,France,0,respiratory rehabilitation program (rr).|respiratory tele-rehabilitation program (trr).,NA
NCT04649021,2020-12-04,12/31/2021,Interventional,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,Recruiting,Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04649021,0,0,0,1,1,0,China,0,bnt162b2|placebo,NA
NCT04651400,2020-10-19,1/31/2021,Observational,"Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection",Recruiting,NA,Octapharma,NA,https://clinicalzeros.gov/ct2/show/NCT04651400,0,0,0,0,0,0,Austria|France|Germany,0,antithrombin iii,NA
NCT04640233,2020-11-30,8/31/2021,Interventional,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Ð¡ov-2) Infection,Recruiting,Phase 2/Phase 3,Dr. Reddy's Laboratories Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04640233,0,0,0,1,1,0,India,0,gam-covid-vac|placebo,NA
NCT04637295,2021-01-27,6/30/2021,Observational,"Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19",Recruiting,NA,University of Nebraska,NA,https://clinicalzeros.gov/ct2/show/NCT04637295,0,0,0,0,1,1,United States,0,"NA",NA
NCT04644198,2021-02-01,12/1/2021,Interventional,Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica,Recruiting,Phase 2,The University of The West Indies,NA,https://clinicalzeros.gov/ct2/show/NCT04644198,0,0,0,0,2,0,Jamaica,0,convalescent plasma infusion,NA
NCT04644146,2020-12-01,6/1/2021,Observational,Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection),Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04644146,0,0,0,0,0,0,France,0,genetic,NA
NCT04643444,2021-01-31,1/31/2022,Observational,Police COVID-19 Serosurvey,Recruiting,NA,University of Bern,NA,https://clinicalzeros.gov/ct2/show/NCT04643444,0,0,0,0,2,0,Switzerland,0,blood sample|online survey,NA
NCT04642950,2020-12-17,4/30/2021,Interventional,A Phase II/III Study of Sargramostim,Recruiting,Phase 2/Phase 3,Nobelpharma,NA,https://clinicalzeros.gov/ct2/show/NCT04642950,0,0,0,0,1,0,Japan,0,sargramostim|placebo,NA
NCT04640402,2020-11-17,2/18/2021,Interventional,A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),Recruiting,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04640402,0,0,0,1,0,0,China,0,low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/two dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/two dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/three dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/two dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/two dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/three dose regimen|low-dose placebo (18-59 years)/two dose regimen|low-dose placebo (18-59 years)/three dose regimen|high-dose placebo (18-59 years)/two dose regimen|high-dose placebo (18-59 years)/three dose regimen|low-dose placebo (60-85 years)/two dose regimen|low-dose placebo (60-85 years)/three dose regimen|high-dose placebo (60-85 years)/two dose regimen|high-dose placebo (60-85 years)/three dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)|two dose regimen|three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)|low-dose placebo (18-59 years)|high-dose placebo (18-59 years)|low-dose placebo (60-85 years)|high-dose placebo (60-85 years),NA
NCT04640038,2020-12-18,12/31/2022,Interventional,Contrast Enhanced Ultrasound in COVID-19,Recruiting,Phase 3,Children's Hospital of Philadelphia,NA,https://clinicalzeros.gov/ct2/show/NCT04640038,0,0,0,0,2,1,United States,0,sulfur hexafluoride lipid-type a microspheres,NA
NCT04644159,2020-11-13,6/30/2022,Observational,"Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]",Recruiting,NA,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04644159,0,0,0,0,1,0,France,0,biological samples,NA
NCT04642703,2020-03-03,11/30/2020,Observational,Mortality in Patients With Severe COVID-19 Pneumonia Who Underwent Tracheostomy,Recruiting,NA,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04642703,0,0,0,0,1,0,Chile,0,"NA",NA
NCT04639349,2020-11-19,3/1/2021,Interventional,Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID,Recruiting,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04639349,0,0,0,0,0,0,Egypt,0,exercise|control,NA
NCT04638842,2020-12-24,6/1/2021,Interventional,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04638842,0,0,0,0,2,0,Mexico,0,online intervention grief covid-19,NA
NCT04638673,2020-11-19,6/30/2021,Interventional,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,Recruiting,Phase 2,Medical University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04638673,0,0,0,0,1,1,United States,0,soterix tavns model 0125-lte stimulator - active-active group|soterix tavns model 0125-lte stimulator - sham-active group,NA
NCT04640168,2020-11-24,4/30/2021,Interventional,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04640168,0,0,0,0,20,1,"United States|Japan|Korea, Republic of|Mexico|Singapore",0,baricitinib|dexamethasone|placebo|remdesivir,NA
NCT04689711,2020-12-07,8/31/2021,Observational,Prognostic Models for COVID-19 Care,Enrolling by invitation,NA,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04689711,0,0,0,0,0,1,United States,0,"NA",NA
NCT04637906,2020-11-18,2/18/2021,Interventional,Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2),Recruiting,N/A,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04637906,0,0,0,0,2,0,Italy,0,bioargininaâ®,NA
NCT04636320,2020-06-13,1/13/2021,Interventional,Prevalence of Myocardial Scars on CMR After COVID-19 Infection,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04636320,0,0,0,0,0,0,France,0,contrast-enhanced cmr|exercise test ecg|blood sample|resting 12 lead ecg|24 hour holter ecg,NA
NCT04636294,2020-08-01,12/30/2020,Observational,Borderline COVID-19 PCR Test Result,"Active, not recruiting",NA,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04636294,0,0,0,0,0,0,Belgium,0,pcr,NA
NCT04647994,2020-09-21,7/1/2021,Observational,Exploratory Study: COVID-19 and Pregnancy,Recruiting,NA,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04647994,0,0,0,0,1,0,Brazil,0,sars-cov-2 serology,NA
NCT04651790,2020-11-27,1/31/2022,Interventional,"Efficacy, Safety, and Immunogenicity of an Inactivated Vaccine Against COVID-19 in High Infection Risk Adults",Recruiting,Phase 3,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04651790,0,0,0,1,0,0,Chile,0,sars-cov-2 inactivated vaccine,NA
NCT04644172,2020-11-01,11/30/2023,Interventional,Improving Thinking in Everyday Life After Covid-19,Recruiting,Phase 1/Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04644172,0,0,0,0,0,1,United States,0,speed of processing training|instrumental activities of daily living shaping|transfer package from ci therapy|standard care,NA
NCT04645368,2020-07-01,4/30/2021,Observational,"Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19",Recruiting,NA,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04645368,0,0,0,0,0,0,Russian Federation,0,bovhyaluronidase azoxymer,NA
NCT04644120,2020-12-10,8/2/2021,Interventional,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 Moves Through the Body of Adult Participants Hospitalized With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 1,AbbVie,NA,https://clinicalzeros.gov/ct2/show/NCT04644120,0,0,0,0,2,1,United States|Israel|Netherlands|Puerto Rico,0,abbv-47d11|placebo for abbv-47d11,NA
NCT04642638,2020-11-30,9/30/2022,Interventional,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure",Recruiting,Phase 2/Phase 3,Inovio Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04642638,0,0,0,1,4,1,United States,0,ino-4800|cellectraâ® 2000|placebo,NA
NCT04641988,2020-02-01,3/1/2020,Observational,Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04641988,0,0,0,0,0,0,France,0,"NA",NA
NCT04653727,2021-01-06,5/31/2021,Observational,Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19,Recruiting,NA,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04653727,0,0,0,0,2,0,Germany,0,cross-sectional survey,NA
NCT04640194,2020-12-16,5/29/2022,Interventional,A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19,Recruiting,Phase 2/Phase 3,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04640194,0,0,0,0,6,0,Austria|Belgium|France|Germany|Italy|Netherlands|Portugal|Spain,0,alteplase|standard care,NA
NCT04640428,2020-05-26,2/27/2021,Observational,COVID-19 Stroke Apical Lung Examination Study,Recruiting,NA,King's College Hospital NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04640428,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04642040,2020-06-30,1/31/2021,Interventional,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Recruiting,N/A,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04642040,0,0,0,0,0,0,Turkey,0,pulmonary rehabilitation,NA
NCT04646655,2020-07-27,5/31/2021,Interventional,Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19,Recruiting,Phase 3,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04646655,0,0,0,0,0,0,Italy,0,enoxaparin,NA
NCT04642196,2020-05-02,10/10/2020,Observational,COVID-19 in Home Healthcare,Completed,NA,"University Hospital, Linkoeping",NA,https://clinicalzeros.gov/ct2/show/NCT04642196,0,0,0,0,0,0,Sweden,0,"NA",NA
NCT04641858,2020-12-03,2/28/2022,Interventional,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,Recruiting,Phase 4,University of Southern Denmark,NA,https://clinicalzeros.gov/ct2/show/NCT04641858,0,0,0,1,1,0,Cape Verde|Guinea-Bissau|Mozambique,0,bcg-denmark|saline,NA
NCT04644302,2020-02-01,7/31/2021,Observational,Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis,Recruiting,NA,University Hospital Hradec Kralove,NA,https://clinicalzeros.gov/ct2/show/NCT04644302,0,0,0,0,1,0,Czechia,0,microcirculation recording,NA
NCT04643691,2020-09-11,9/30/2022,Interventional,Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS,Recruiting,Phase 2,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04643691,0,0,0,0,0,0,France,0,losartan 50 mg/spironolactone 25 mg pillules oral use|losartan 50 mg|spironolactone 25 mg pillules oral use,NA
NCT04643678,2020-10-30,4/30/2021,Interventional,Anakinra in the Management of COVID-19 Infection,Recruiting,Phase 2/Phase 3,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04643678,0,0,0,0,1,0,Qatar,0,anakinra|standard care,NA
NCT04643561,2020-11-01,12/31/2020,Interventional,Using Travelan to Boost Immune Response in Vitro to COVID-19,"Active, not recruiting",Phase 1/Phase 2,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04643561,0,0,0,0,1,0,Israel,0,travelan otc,NA
NCT04646603,2021-01-28,4/1/2021,Interventional,MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients,Recruiting,Phase 1/Phase 2,MedRegen LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04646603,0,0,0,0,5,1,United States,0,mrg-001|placebo,NA
NCT04699851,2020-11-18,4/18/2021,Interventional,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens,Recruiting,N/A,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04699851,0,0,0,0,1,0,Canada,0,tailored recommendations|general recommendation,NA
NCT04649827,2020-04-02,6/30/2020,Observational,A Clinical Trial for Hospitalized Patients With COVID-19 in CearÃ¡: ResCOVID Study,Recruiting,NA,Escola de SaÃºde PÃºblica do CearÃ¡,NA,https://clinicalzeros.gov/ct2/show/NCT04649827,0,0,0,0,0,0,Brazil,0,clinical observation,NA
NCT04649515,2020-12-04,8/31/2021,Interventional,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans",Recruiting,Phase 3,Tychan Pte Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04649515,0,0,0,0,1,0,Singapore,0,ty027|saline,NA
NCT04668469,2020-06-08,9/15/2020,Interventional,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,N/A,Benha University,NA,https://clinicalzeros.gov/ct2/show/NCT04668469,0,0,0,0,0,0,Egypt,0,ivermectin|hydroxychloroquine|personal protective measures,NA
NCT04668339,2021-01-07,4/30/2022,Interventional,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,Recruiting,Phase 2,"Arcturus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04668339,0,0,0,1,1,1,United States|Singapore,0,"arct-021 single dose priming|arct-021 two lower dose priming|arct-021 two higher dose priming|placebo (two doses), priming|randomized booster|placebo booster",NA
NCT04667936,2020-03-01,12/15/2020,Observational,Evaluation of Sedation in COVID-19 ARDS,Recruiting,NA,Goethe University,NA,https://clinicalzeros.gov/ct2/show/NCT04667936,0,0,0,0,0,0,Germany,0,treatment group,NA
NCT04649931,2020-12-14,5/31/2021,Observational,Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease),Recruiting,NA,B. Braun Melsungen AG,NA,https://clinicalzeros.gov/ct2/show/NCT04649931,0,0,0,0,2,0,Germany,0,ion mobility spectrometry (ims),NA
NCT04663594,2020-12-04,3/31/2021,Interventional,Online Culture for Mental Health in People Aged 16-24,Recruiting,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04663594,0,0,0,0,1,0,United Kingdom,0,wofb|ashmolean website,NA
NCT04647747,2020-11-30,3/30/2021,Interventional,Silent Hypoxia and Awake Proning in COVID-19 Patients,Recruiting,N/A,Ostfold Hospital Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04647747,0,0,0,0,2,0,Norway,0,self measurement with pulse oximeter,NA
NCT04649918,2020-11-25,1/31/2021,Observational,Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19,Recruiting,NA,SchÃ¶n Klinik Berchtesgadener Land,NA,https://clinicalzeros.gov/ct2/show/NCT04649918,0,0,0,0,0,0,Germany,0,pulmonary rehabilitation,NA
NCT04646590,2020-12-16,4/30/2022,Interventional,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,Recruiting,Phase 3,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04646590,0,0,0,1,2,0,China|Ecuador|Indonesia|Pakistan|Uzbekistan,0,recombinant new coronavirus vaccine (cho cell) group|placebo,NA
NCT04655625,2020-11-23,5/27/2021,Interventional,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),Recruiting,Phase 2/Phase 3,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04655625,0,0,0,1,0,0,Japan,0,group a (ag0302-covid19)|group a (placebo)|group b (ag0302-covid19)|group b (placebo),NA
NCT04693975,2020-10-16,10/31/2022,Observational [Patient Registry],Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases,Recruiting,NA,Universidade Estadual de Londrina,NA,https://clinicalzeros.gov/ct2/show/NCT04693975,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04666558,2020-11-30,12/17/2021,Interventional,Heal-Me Personalized Online Nutrition and Exercise Routines,Recruiting,N/A,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04666558,0,0,0,0,0,0,Canada,0,exercise/nutrition|exercise|nutrition,NA
NCT04659135,2020-04-19,12/31/2022,Observational [Patient Registry],ASCO Survey on COVID-19 in Oncology (ASCO) Registry,Recruiting,NA,American Society of Clinical Oncology,NA,https://clinicalzeros.gov/ct2/show/NCT04659135,0,0,0,0,0,1,United States,0,"NA",NA
NCT04652102,2020-12-14,3/5/2021,Interventional,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19,Recruiting,Phase 2/Phase 3,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04652102,0,0,0,1,4,0,Belgium|Germany|Mexico|Netherlands|Peru|Spain,0,cvncov|placebo,NA
NCT04650035,2020-11-01,11/4/2020,Observational,The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak,Completed,NA,Yarmouk University,NA,https://clinicalzeros.gov/ct2/show/NCT04650035,0,0,0,0,1,0,Jordan,0,"NA",NA
NCT04649996,2020-09-01,10/31/2020,Observational,Variation in Acute Appendicitis During COVID-19 Pandemic in Italy,Completed,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04649996,0,0,0,0,1,0,Italy,0,appendectomy,NA
NCT04649840,2020-10-01,12/31/2021,Observational,Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients,Enrolling by invitation,NA,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,https://clinicalzeros.gov/ct2/show/NCT04649840,0,0,0,0,0,0,Belarus,0,humoral/cellular immunity|humoral|cellular immunity,NA
NCT04663737,2020-12-03,2/26/2021,Interventional,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19",Recruiting,Phase 2,"Senhwa Biosciences, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04663737,0,0,0,0,1,1,United States,0,silmitasertib|standard care,NA
NCT04668209,2021-01-01,3/31/2021,Interventional,Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,University of Arizona,NA,https://clinicalzeros.gov/ct2/show/NCT04668209,0,0,0,0,1,1,United States,0,silmitasertib,NA
NCT04650191,2020-03-01,6/30/2021,Observational [Patient Registry],Surfactant Protein Genetic Variants in COVID-19 Infection,Recruiting,NA,Milton S. Hershey Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04650191,0,0,0,0,0,1,United States,0,identification of genetic variants,NA
NCT04649736,2020-10-26,3/30/2021,Interventional,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Recruiting,N/A,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04649736,0,0,0,0,0,0,Peru,0,respiratory/psychological rehabilitation|respiratory|psychological rehabilitation,NA
NCT04649658,2020-03-01,6/1/2020,Observational,Pronation in COVID-19 Patients Undergoing Non Invasive Respiratory Support,Completed,NA,University of Modena and Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04649658,0,0,0,0,1,0,Italy,0,prone positioning,NA
NCT04649333,2020-06-15,8/31/2020,Observational,COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures,Completed,NA,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04649333,0,0,0,0,1,0,Austria,0,"NA",NA
NCT04649320,2020-11-23,12/31/2020,Observational,Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias,Recruiting,NA,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04649320,0,0,0,0,0,0,Austria,0,questionnaire,NA
NCT04649151,2020-12-09,6/30/2022,Interventional,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",Recruiting,Phase 2/Phase 3,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04649151,0,0,0,1,5,1,United States,0,mrna-1273|placebo,NA
NCT04703205,2020-09-16,3/31/2021,Interventional,Study in COvid-19 Patients With iveRmectin (CORVETTE-01),Recruiting,Phase 2,Kitasato University,NA,https://clinicalzeros.gov/ct2/show/NCT04703205,0,0,0,0,1,0,Japan,0,ivermectin 3 mg|placebo,NA
NCT04658979,2020-12-31,3/31/2021,Interventional,Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study,Recruiting,N/A,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,NA,https://clinicalzeros.gov/ct2/show/NCT04658979,0,0,0,0,1,0,Canada,0,pulmonary tele-rehabilitation,NA
NCT04659486,2020-09-24,4/30/2021,Interventional,Adolescents With COVID-19/MIS-C at HCFMUSP,Enrolling by invitation,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04659486,0,0,0,0,0,0,Brazil,0,home-based exercise training,NA
NCT04657809,2020-12-01,12/25/2020,Interventional,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,"Active, not recruiting",Phase 2,Deraya University,NA,https://clinicalzeros.gov/ct2/show/NCT04657809,0,0,0,0,1,0,Egypt,0,insulin film|fast dissolving film,NA
NCT04655586,2020-12-10,4/30/2021,Interventional,"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19",Recruiting,Phase 2/Phase 3,"ARCA Biopharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04655586,0,0,0,0,3,1,United States,0,rnapc2|heparin,NA
NCT04655521,2020-12-02,8/31/2021,Observational,Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2,Recruiting,NA,UniversitÃ¤t des Saarlandes,NA,https://clinicalzeros.gov/ct2/show/NCT04655521,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04654416,2020-03-20,8/7/2020,Observational,Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine,Completed,NA,ClÃ­nica MedellÃ­n - Grupo QuirÃ³nsalud,NA,https://clinicalzeros.gov/ct2/show/NCT04654416,0,0,0,0,0,0,Colombia,0,corticosteroid with/without colchicine|corticosteroid with|without colchicine,NA
NCT04652674,2020-09-28,6/30/2021,Interventional,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic: A Prospective Randomized Trial,Recruiting,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04652674,0,0,0,0,0,1,United States,0,telemedicine visit|in-person postoperative visit,NA
NCT04652648,2020-05-27,10/31/2020,Interventional,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,Phase 4,Bryn Mawr Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04652648,0,0,0,0,0,1,United States,0,hydroxychloroquine,NA
NCT04652518,2020-12-11,8/31/2021,Interventional,LYT-100 in Post-acute COVID-19 Respiratory Disease,Recruiting,Phase 2,PureTech,NA,https://clinicalzeros.gov/ct2/show/NCT04652518,0,0,0,0,5,1,United States|Romania,0,lyt-100|placebo,NA
NCT04651413,2020-11-24,3/31/2021,Observational,PCR Cycle Threshold Values and COVID-19 Outcomes,Recruiting,NA,University Hospitals of North Midlands NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04651413,0,0,0,0,1,0,United Kingdom,0,pcr value,NA
NCT04678687,2021-01-01,6/1/2021,Interventional,COVID-19 and Tissue Damage in Vital Organs,"Active, not recruiting",N/A,Dokuz Eylul University,NA,https://clinicalzeros.gov/ct2/show/NCT04678687,0,0,0,0,1,0,Turkey,0,"liver, lung, heart/kidney biopsy|liver, lung, heart|kidney biopsy",NA
NCT04652765,2021-02-28,1/31/2023,Interventional,Camostat With Bicalutamide for COVID-19,Recruiting,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,NA,https://clinicalzeros.gov/ct2/show/NCT04652765,0,0,0,0,1,1,United States,0,camostat mesilate|bicalutamide 150 mg,NA
NCT04687488,2020-07-23,11/9/2020,Interventional,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,Completed,N/A,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04687488,0,0,0,0,0,0,Belgium,0,fluorescein|particle measurement,NA
NCT04664049,2020-12-23,12/31/2022,Observational,The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection,Recruiting,NA,"National Research Institute of Chinese Medicine, Ministry of Health and Welfare",NA,https://clinicalzeros.gov/ct2/show/NCT04664049,0,0,0,0,1,0,Taiwan,0,nricm101,NA
NCT04667247,2020-12-03,4/1/2021,Interventional,Mushroom-based Product for COVID-19,Recruiting,Phase 1/Phase 2,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04667247,0,0,0,0,0,1,United States,0,fotv,NA
NCT04662021,2020-12-10,2/10/2021,Interventional,Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety,Enrolling by invitation,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04662021,0,0,0,0,1,0,Egypt,0,aerobic exercises,NA
NCT04656691,2021-01-04,5/31/2021,Interventional,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Enrolling by invitation,Phase 4,UnitedHealth Group,NA,https://clinicalzeros.gov/ct2/show/NCT04656691,0,0,0,0,1,1,United States,0,bamlanivimab,NA
NCT04656626,2020-07-07,7/21/2020,Interventional,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,Completed,N/A,Imam Abdulrahman Bin Faisal University,NA,https://clinicalzeros.gov/ct2/show/NCT04656626,0,0,0,0,2,0,Saudi Arabia,0,brief mindfulness based intervention|progressive muscle relaxation,NA
NCT04664023,2020-12-09,7/30/2022,Observational,"Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution",Recruiting,NA,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04664023,0,0,0,0,1,0,France,0,"blood collection at day 8, day 16, day 24, month 6/month 12 after first symptoms from sars-cov-2 infection|blood collection at day 8, day 16, day 24, month 6|month 12 after first symptoms from sars-cov-2 infection",NA
NCT04658433,2020-12-05,2/15/2021,Interventional,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,Recruiting,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04658433,0,0,0,0,0,0,Jordan,0,300 mg of omega3-fa,NA
NCT04657484,2020-12-08,12/7/2021,Interventional,Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease,Recruiting,N/A,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04657484,0,0,0,0,1,0,India,0,medium dose prednisolone|low dose prednisolone,NA
NCT04659239,2021-01-28,9/30/2021,Interventional,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19",Enrolling by invitation,Phase 3,Chinese Academy of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04659239,0,0,0,1,1,0,Brazil|Malaysia,0,inactivated sars-cov-2 vaccine|placebo,NA
NCT04655612,2020-12-01,7/1/2021,Observational,Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04655612,0,0,0,0,2,0,France,0,"NA",NA
NCT04654481,2020-12-31,2/28/2021,Interventional,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,Recruiting,N/A,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04654481,0,0,0,0,0,1,United States,0,hcfwo|standard care/monitoring|standard care|monitoring,NA
NCT04657471,2020-12-08,6/8/2021,Interventional,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Recruiting,N/A,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04657471,0,0,0,0,2,0,France,0,revised home-cov score,NA
NCT04657445,2020-11-17,5/31/2021,Observational,"EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY",Recruiting,NA,"University Hospital, Ioannina",NA,https://clinicalzeros.gov/ct2/show/NCT04657445,0,0,0,0,3,0,Greece,0,visual analogue scale,NA
NCT04653857,2020-04-01,4/30/2020,Observational,Cardiac Assessment After Covid-19 Disease in Elite Altheltic Population,"Active, not recruiting",NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04653857,0,0,0,0,1,0,France,0,"NA",NA
NCT04653844,2020-02-01,2/20/2021,Observational,RT-PCR Database Analysis for COVID-19 Infections and Re-infection,"Active, not recruiting",NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04653844,0,0,0,0,1,0,France,0,"NA",NA
NCT04699058,2020-07-17,12/31/2020,Observational,COVID-19 Sero-prevalence Health Care Workers Kinshasa,Recruiting,NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04699058,0,0,0,0,0,0,"Congo, The Democratic Republic of the",0,covid-antibody test,NA
NCT04665193,2020-11-23,4/30/2021,Interventional,An Approach to Screening for COVID-19 at Vancouver Airport,Recruiting,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04665193,0,0,0,0,0,0,Canada,0,rapid antigen test,NA
NCT04662684,2020-10-16,4/30/2021,Interventional,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,Recruiting,Phase 3,Science Valley Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04662684,0,0,0,0,0,0,Brazil,0,rivaroxaban 10 mg,NA
NCT04659941,2020-10-01,10/1/2021,Interventional,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04659941,0,0,0,1,0,0,Brazil,0,bcg,NA
NCT04659876,2020-03-22,9/1/2020,Observational,Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to COVID 19,Completed,NA,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04659876,0,0,0,0,0,0,Turkey,0,clinical features/laboratory values|clinical features|laboratory values,NA
NCT04659356,2020-09-01,12/1/2020,Observational,NOSOcomial COVID-19 in ICU (NOSOCOVID),Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04659356,0,0,0,0,0,0,France,0,patients admitted in intensive care units,NA
NCT04659187,2020-03-26,5/30/2021,Observational,CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany,Recruiting,NA,Asklepios proresearch,NA,https://clinicalzeros.gov/ct2/show/NCT04659187,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04661657,2020-12-28,12/31/2021,Observational [Patient Registry],COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04661657,0,0,0,0,1,1,United States,0,transthoracic echocardiogram (tte)|cardiovascular magnetic resonance (cmr) imaging,NA
NCT04664010,2020-02-06,1/14/2021,Interventional,Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19),"Active, not recruiting",N/A,Xi'an International Medical Center Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04664010,0,0,0,0,0,0,China,0,"alpha-interferon alpha, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste, fumigation/inhalation of vitamin c|alpha-interferon, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste/5% glucose|alpha-interferon, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste/high-dose vitamin c treatment|alpha-interferon alpha, abidol, ribavirin, buzhong yiqi plus|minus formula, huhuang detoxicity paste, baimu qingre jiedu paste, fumigation|inhalation of vitamin c|alpha-interferon, abidol, ribavirin, buzhong yiqi plus|minus formula, huhuang detoxicity paste, baimu qingre jiedu paste|5% glucose|high-dose vitamin c treatment",NA
NCT04661410,2020-12-01,12/1/2021,Interventional,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,Recruiting,N/A,Drexel University,NA,https://clinicalzeros.gov/ct2/show/NCT04661410,0,0,0,0,1,1,United States,0,reward re-training|supportive therapy,NA
NCT04659889,2020-12-31,6/30/2021,Observational,Clinical and Haematological Phenotypes in Long COVID,Recruiting,NA,HCA International Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04659889,0,0,0,0,0,0,United Kingdom,0,blood sampling (venesection),NA
NCT04659772,2020-12-31,12/31/2020,Interventional,A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection,Enrolling by invitation,Phase 2,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04659772,0,0,0,0,0,1,United States,0,clazakizumab|placebo,NA
NCT04659759,2020-11-17,12/31/2021,Observational,"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes",Recruiting,NA,Thomas Jefferson University,NA,https://clinicalzeros.gov/ct2/show/NCT04659759,0,0,0,0,1,1,United States,0,exposure|covid-19 vaccine,NA
NCT04659746,2020-12-09,2/28/2021,Interventional,MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay,Recruiting,N/A,Universidad AutÃ³noma de EncarnaciÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04659746,0,0,0,0,2,0,Paraguay,0,mejoracare,NA
NCT04657263,2020-11-01,5/1/2021,Observational,Impact of the COVID-19 Pandemic on Vaccination,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04657263,0,0,0,0,1,0,France,0,vaccine coverage assessment,NA
NCT04669912,2021-01-15,1/22/2021,Observational,COVID-19 Pandemic Lockdown Effect in Adolescents and Young Adults With Type 1 Diabetes: Positive Results of an Unpreceded Challenge for Telemedicine and Patient Self-management,Completed,NA,Centre Hospitalier Sud Francilien,NA,https://clinicalzeros.gov/ct2/show/NCT04669912,0,0,0,0,2,0,France,0,glucose control/sensor usage|glucose control|sensor usage,NA
NCT04663945,2020-12-11,6/1/2021,Interventional,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors,Recruiting,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04663945,0,0,0,0,3,1,United States,0,biobehavioral tele-rehabilitation sessions,NA
NCT04691895,2020-05-01,9/30/2020,Observational [Patient Registry],Gastrointestinal Symptoms in COVID-19,"Active, not recruiting",NA,University of Bologna,NA,https://clinicalzeros.gov/ct2/show/NCT04691895,0,0,0,0,1,0,Italy,0,sars-cov2 infection,NA
NCT04695457,2020-07-15,11/16/2020,Observational,Correlation Between the Incidence of COVID-19 in Nursing-homes and the Profile of Nursing Homes in the French Alps,Completed,NA,Centre Hospitalier Annecy Genevois,NA,https://clinicalzeros.gov/ct2/show/NCT04695457,0,0,0,0,0,0,France,0,"NA",NA
NCT04668625,2020-11-30,12/20/2020,Interventional,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Completed,N/A,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04668625,0,0,0,0,4,0,Spain,0,participate in a massive musical event,NA
NCT04673149,2020-12-23,7/31/2022,Interventional,GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19),Recruiting,Phase 1/Phase 2,"GeneOne Life Science, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04673149,0,0,0,1,2,0,"Korea, Republic of",0,gls-5310|placebo,NA
NCT04662671,2020-11-18,3/15/2021,Interventional,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Recruiting,Phase 1/Phase 2,KNOWBio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04662671,0,0,0,0,0,1,United States,0,rd-x19,NA
NCT04661930,2020-12-13,4/1/2021,Interventional,Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Recruiting,Phase 3,Hebrew University of Jerusalem,NA,https://clinicalzeros.gov/ct2/show/NCT04661930,0,0,0,0,0,0,Israel,0,tricorâ® 145mg tablets|standard care|placebo,NA
NCT04661839,2020-12-31,9/30/2021,Interventional,Phase 1 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered as a Single Dose or a Repeat Dose in Healthy Adults,Recruiting,Phase 1,Emergent BioSolutions,NA,https://clinicalzeros.gov/ct2/show/NCT04661839,0,0,0,0,0,1,United States,0,covid-higiv|placebo (saline),NA
NCT04668950,2020-12-22,7/31/2021,Interventional,Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2),Recruiting,Phase 3,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04668950,0,0,0,0,4,1,United States|Canada,0,fluvoxamine|placebo,NA
NCT04668937,2020-03-18,3/18/2020,Observational,ConsÃ©quences of the COVID-19 Lockdown Measures on the CHRU Nancy Pediatric Emergency Services,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04668937,0,0,0,0,0,0,France,0,"NA",NA
NCT04668196,2020-05-22,1/31/2021,Observational,Noninvasive Respiratory Support in COVID-19 (CATCOVID-AIR),Recruiting,NA,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04668196,0,0,0,0,0,0,Spain,0,high-flow nasal cannula treatment|continuous positive airway pressure (cpap) treatment|noninvasive ventilation treatment,NA
NCT04667923,2020-10-01,3/31/2021,Observational,Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome,Recruiting,NA,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04667923,0,0,0,0,1,0,Russian Federation,0,respiratory monitoring|respiratory muscles ultrasound|electro impedance tomography|capnography|arterial blood gas|quasistatic pressure-volume curve,NA
NCT04667780,2020-12-10,5/9/2021,Interventional,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Recruiting,Phase 3,Ayub Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04667780,0,0,0,0,0,0,Pakistan,0,colchicine|standard covid-19 care,NA
NCT04666753,2020-07-02,9/29/2020,Observational,Retrospective Study of ImmunoFormulation for COVID-19,Completed,NA,Fagron Iberica S.A.U.,NA,https://clinicalzeros.gov/ct2/show/NCT04666753,0,0,0,0,0,0,Spain,0,immunoformulation,NA
NCT04666493,2020-12-04,11/30/2021,Interventional,Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19,Recruiting,N/A,"Anagnostou, Evdokia, M.D.",NA,https://clinicalzeros.gov/ct2/show/NCT04666493,0,0,0,0,0,0,Canada,0,"cognitive behavior therapy (cbt), specifically using the facing your fears (fyf) curriculum",NA
NCT04666246,2020-03-01,2/1/2021,Observational,Inspiratory Effort in COVID-19,Recruiting,NA,University of Modena and Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04666246,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04666064,2020-12-10,6/30/2021,Observational,Validation of COVILUS Score in Patients Suspected of COVID-19 Infection in the Emergency Room,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04666064,0,0,0,0,0,0,France,0,covid19 rt-pcr|lung ultrasound,NA
NCT04663555,2021-02-02,3/31/2022,Interventional,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,Recruiting,Phase 4,Brno University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04663555,0,0,0,0,3,0,Czechia,0,dexamethasone,NA
NCT04710836,2020-12-03,8/31/2032,Observational,NoRCoRP Assessment Clinic,Recruiting,NA,Nottingham University Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04710836,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04668911,2020-12-13,12/12/2021,Observational,"Oral Health, Microbial Burden and COVID-19",Recruiting,NA,Eastman Dental Insitute and Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04668911,0,0,0,0,1,0,United Kingdom,0,swab,NA
NCT04665752,2021-02-10,6/30/2023,Observational,Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04665752,0,0,0,0,36,1,United States,0,"NA",NA
NCT04673331,2020-11-04,11/4/2021,Observational,"Physical Activity, Exercise Capacity and Coronavirus Phobia of Adult Cystic Fibrosis Patients During COVID-19 Pandemic",Recruiting,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04673331,0,0,0,0,0,0,Turkey,0,exercise,NA
NCT04678700,2021-03-01,6/1/2021,Interventional,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Recruiting,N/A,European University of Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04678700,0,0,0,0,1,0,Spain,0,chest physiotherapy post-covid19,NA
NCT04673279,2020-12-02,4/10/2021,Observational [Patient Registry],Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina,Recruiting,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04673279,0,0,0,0,0,0,Argentina,0,serology test,NA
NCT04667962,2020-12-23,9/30/2021,Observational,Impact of the Change in Hospital Service of Caregivers During COVID-19 Health Crisis on Operational Strain,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04667962,0,0,0,0,1,0,France,0,online survey,NA
NCT04667442,2020-12-01,3/31/2021,Observational,Investigational Performance Evaluation of the Nanomix eLabÂ® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects,Recruiting,NA,Nanomix,NA,https://clinicalzeros.gov/ct2/show/NCT04667442,0,0,0,0,1,1,United States,0,nanomix elabâ® covid-19 rapid antigen panel (non-interventional),NA
NCT04666441,2020-12-15,3/1/2021,Interventional,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,Recruiting,Phase 2,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04666441,0,0,0,0,1,1,United States,0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,NA
NCT04666025,2020-09-23,9/23/2022,Observational,SARS-CoV-2 Donor-Recipient Immunity Transfer,Recruiting,NA,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04666025,0,0,0,0,0,1,United States,0,biospecimen collection|biospeciman collection|diagnostic laboratory biomarker analysis|electronic health record review|questionnaire,NA
NCT04666012,2020-12-29,3/31/2021,Interventional,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,Recruiting,Phase 1/Phase 2,"Cellid Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04666012,0,0,0,1,1,0,"Korea, Republic of",0,adcld-cov19,NA
NCT04665258,2020-12-14,6/14/2021,Observational,COVID-19 Vaccine and Impact on Fertility Study,Recruiting,NA,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04665258,0,0,0,0,1,1,United States,0,"NA",NA
NCT04665245,2020-12-15,4/30/2021,Observational,Symptom-Based Markers for COVID-19 Transmission,Enrolling by invitation,NA,University of Iowa,NA,https://clinicalzeros.gov/ct2/show/NCT04665245,0,0,0,0,2,1,United States,0,"NA",NA
NCT04663659,2020-03-15,5/15/2020,Observational,The Effect of Diabetes Mellitus on Mortality of Patients With COVID-19,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04663659,0,0,0,0,1,0,Turkey,0,no intervention,NA
NCT04734886,2020-11-27,8/30/2021,Interventional,The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19,Recruiting,N/A,"Ã–rebro University, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04734886,0,0,0,0,0,0,Sweden,0,l. reuteri dsm 17938 / vitamin d|placebo / vitamin d|l. reuteri dsm 17938|vitamin d|placebo,NA
NCT04695743,2020-09-01,6/1/2022,Interventional,Group CST Using Zoom: A Proof of Concept Study,Recruiting,N/A,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04695743,0,0,0,0,0,0,United Kingdom,0,online cognitive stimulation therapy,NA
NCT04688840,2020-01-01,9/1/2020,Observational,Smartphone Application: A Possible Solution for Follow up of Patients With Hip Arthroplasty,Completed,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04688840,0,0,0,0,0,0,Egypt,0,hip arthropalsty,NA
NCT04695678,2020-07-01,1/31/2021,Observational,Epidemiological Multicohort Study of Latent COVID-19 Infections,"Active, not recruiting",NA,Wissenschaftliches Institut Bethanien e.V,NA,https://clinicalzeros.gov/ct2/show/NCT04695678,0,0,0,0,0,0,Germany,0,covid-19 nasal/pharyngeal swab|covid-19 nasal|pharyngeal swab,NA
NCT04678778,2019-03-19,2/17/2021,Interventional,Virtual Reality Study - COVID-19 Protocol,Recruiting,N/A,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04678778,0,0,0,0,1,1,United States,0,physical/cognitive activity|physical|cognitive activity,NA
NCT04671017,2020-12-16,2/15/2021,Interventional,"Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults","Active, not recruiting",Phase 1/Phase 2,Valneva Austria GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04671017,0,0,0,1,3,0,United Kingdom,0,vla2001,NA
NCT04674189,2020-12-23,6/30/2021,Interventional,A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19,Recruiting,Phase 3,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04674189,0,0,0,1,1,0,Germany,0,cvncov vaccine|placebo,NA
NCT04670328,2020-05-01,7/31/2020,Observational,Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity,Completed,NA,FMH College of Medicine and Dentistry,NA,https://clinicalzeros.gov/ct2/show/NCT04670328,0,0,0,0,0,0,Pakistan,0,not required,NA
NCT04670094,2020-12-30,12/31/2021,Observational,Comorbidities and Risk Score in COVID-19 Patients,"Active, not recruiting",NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04670094,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04669990,2020-11-19,10/31/2021,Observational,Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study,Recruiting,NA,Nepal Health Research Council,NA,https://clinicalzeros.gov/ct2/show/NCT04669990,0,0,0,0,0,0,Nepal,0,remdesivir,NA
NCT04669509,2020-04-01,10/1/2020,Observational,Effect of Liver Injury on Mortality in Coronavirus Disease-2019 Patients Admitted to Intensive Care Unit,Completed,NA,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04669509,0,0,0,0,0,0,Turkey,0,liver function tests,NA
NCT04669054,2020-12-01,5/30/2021,Observational,Hospital Interns Psychological State During the COVID-19,"Active, not recruiting",NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04669054,0,0,0,0,0,0,France,0,"NA",NA
NCT04668313,2020-09-29,12/30/2020,Observational [Patient Registry],COVID-19 Advanced Respiratory Physiology (CARP) Study,Recruiting,NA,NHS Greater Glasgow and Clyde,NA,https://clinicalzeros.gov/ct2/show/NCT04668313,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04694612,2021-01-01,3/31/2021,Interventional,Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal,Recruiting,Phase 3,Nepal Health Research Council,NA,https://clinicalzeros.gov/ct2/show/NCT04694612,0,0,0,0,0,0,Nepal,0,favipiravir|placebo|remdesivir,NA
NCT04679584,2020-11-16,12/31/2021,Observational,COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life,Recruiting,NA,University Hospital Schleswig-Holstein,NA,https://clinicalzeros.gov/ct2/show/NCT04679584,0,0,0,0,0,0,Germany,0,observation of different courses of sars-cov-2 infection in different phases (acute vs. post-acute)/settings|observation of different courses of sars-cov-2 infection in different phases (acute vs. post-acute)|settings,NA
NCT04676971,2020-12-11,7/7/2021,Interventional,Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia,Recruiting,Phase 2,"ImmuneMed, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04676971,0,0,0,0,2,0,Italy|Russian Federation,0,hzvsf-v13|placebo (normal saline solution),NA
NCT04674553,2020-11-10,12/10/2020,Observational,Effect of Obesity Among COVID-19 Patients in Critical Care Settings,Completed,NA,"Services Institute of Medical Sciences, Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04674553,0,0,0,0,0,0,Pakistan,0,"NA",NA
NCT04675281,2020-04-24,4/24/2021,Observational,Pathological Findings of Fatal COVID-19,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04675281,0,0,0,0,0,0,France,0,2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks,NA
NCT04672343,2020-10-19,4/30/2021,Observational,Prognostic Impact of the Nutritional Status of Individuals Aged 70 Years and Older With SARS-CoV-2,Recruiting,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04672343,0,0,0,0,0,0,France,0,data collection|querying the insee database,NA
NCT04674644,2020-10-16,10/23/2020,Interventional,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Completed,N/A,Suleyman Demirel University,NA,https://clinicalzeros.gov/ct2/show/NCT04674644,0,0,0,0,2,0,Turkey,1,the psychosocial effects of covid-19 pandemic on dental professionals,NA
NCT04713150,2020-10-05,9/30/2021,Observational,HEALthy Brain and Child Development Study - COVID-19 Supplement,Recruiting,NA,Boston Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713150,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04677283,2020-04-05,12/31/2020,Observational,"Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in ÃŽle-de-France.",Recruiting,NA,GÃ©rond'if,NA,https://clinicalzeros.gov/ct2/show/NCT04677283,0,0,0,0,0,0,France,0,"NA",NA
NCT04677270,2020-08-31,11/30/2020,Interventional,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Completed,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04677270,0,0,0,0,0,0,Sweden,0,digital problem solving tool,NA
NCT04682041,2020-12-22,6/30/2021,Interventional,Evaluating the Impact of EnteraGam In People With COVID-19,Recruiting,N/A,"Entera Health, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04682041,0,0,0,0,1,0,Spain,0,bovine plasma-derived immunoglobulin concentrate|standard care,NA
NCT04677660,2021-01-21,3/11/2022,Interventional,A Study of TAK-919 in Healthy Japanese Adults (COVID-19),Recruiting,Phase 1/Phase 2,Takeda,NA,https://clinicalzeros.gov/ct2/show/NCT04677660,0,0,0,0,3,0,Japan,0,tak-919|placebo,NA
NCT04689490,2020-08-01,12/31/2020,Observational,Prospective Study of Persistent Dyspnea in Recovered COVID-19 Patients,Recruiting,NA,Hospital ClÃ­nico Universitario de Valladolid,NA,https://clinicalzeros.gov/ct2/show/NCT04689490,0,0,0,0,0,0,Spain,0,cardiopulmonary exercise test,NA
NCT04690920,2020-07-23,12/10/2020,Interventional,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Completed,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04690920,0,0,0,0,0,0,Pakistan,0,tocilizumab,NA
NCT04680858,2020-07-01,1/31/2021,Interventional,Impact of Digital Communication Assist Tools in Endoscopic Team Communication During COVID-19,Enrolling by invitation,N/A,University of Ulm,NA,https://clinicalzeros.gov/ct2/show/NCT04680858,0,0,0,0,1,0,Germany,0,dect,NA
NCT04681040,2020-12-19,3/31/2022,Observational,Risk Stratification of COVID-19 Using Urine Biomarkers,Recruiting,NA,"National Center for Global Health and Medicine, Japan",NA,https://clinicalzeros.gov/ct2/show/NCT04681040,0,0,0,0,1,1,United States|Brazil|Denmark|Japan|Philippines,0,"NA",NA
NCT04678739,2020-08-15,1/30/2021,Interventional,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Recruiting,Phase 3,M Abdur Rahim Medical College and Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04678739,0,0,0,0,2,0,Bangladesh,0,remdesivir|tocilizumab,NA
NCT04694651,2020-12-15,1/30/2021,Observational [Patient Registry],Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04694651,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04679272,2020-12-01,1/30/2021,Observational,Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients,Enrolling by invitation,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04679272,0,0,0,0,2,0,France,0,"NA",NA
NCT04678024,2020-11-18,8/31/2021,Observational,Sensitivity Evaluation of Serological Tests for Covid-19,Enrolling by invitation,NA,Istituto Ortopedico Galeazzi,NA,https://clinicalzeros.gov/ct2/show/NCT04678024,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04676867,2021-01-11,2/28/2021,Interventional,Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19,Recruiting,Phase 2,DalCor Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04676867,0,0,0,0,1,0,Canada,0,dalcetrapib|placebo,NA
NCT04691908,2020-12-25,3/31/2021,Interventional,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine",Enrolling by invitation,Phase 3,Research Institute for Biological Safety Problems,NA,https://clinicalzeros.gov/ct2/show/NCT04691908,0,0,0,1,0,0,Kazakhstan,0,qazcovid-inâ®-vaccine against covid-19|placebo,NA
NCT04674410,2020-03-01,1/31/2021,Observational,Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients,"Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04674410,0,0,0,0,0,1,United States,0,antibiotic,NA
NCT04681430,2021-01-08,5/31/2021,Interventional,Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Recruiting,Phase 2,"Heinrich-Heine University, Duesseldorf",NA,https://clinicalzeros.gov/ct2/show/NCT04681430,0,0,0,0,3,0,Germany,0,convalescent plasma|camostat mesilate|placebo for camostat mesilate|standard care,NA
NCT04686721,2020-12-20,9/30/2021,Observational [Patient Registry],Observational Study for the Evaluation of Tracheal Stenosis in COVID-19 Patients,Recruiting,NA,Istituto Clinico Humanitas,NA,https://clinicalzeros.gov/ct2/show/NCT04686721,0,0,0,0,1,0,Italy,0,chest ct scan / baseline spirometry|chest ct|baseline spirometry,NA
NCT04680949,2020-12-23,9/20/2021,Interventional,suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19,Recruiting,Phase 3,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04680949,0,0,0,0,2,0,Greece|Italy,0,anakinra|placebo,NA
NCT04681755,2020-05-19,5/19/2021,Observational,Rehabilitation Required Due to Clinical Disorders After Severe Covid-19 Infection,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04681755,0,0,0,0,1,0,France,0,"NA",NA
NCT04681001,2020-12-20,5/30/2021,Interventional,"Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers",Recruiting,N/A,Marinomed Biotech AG,NA,https://clinicalzeros.gov/ct2/show/NCT04681001,0,0,0,0,1,0,Austria,0,nasal rinse,NA
NCT04679428,2020-05-07,5/7/2022,Observational,Immunological Characteristics of COVID-19 Patients,Recruiting,NA,The University Clinic of Pulmonary and Allergic Diseases Golnik,NA,https://clinicalzeros.gov/ct2/show/NCT04679428,0,0,0,0,0,0,Slovenia,0,"NA",NA
NCT04679415,2020-12-17,4/30/2021,Interventional,Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia,Recruiting,Phase 2,"ImmuneMed, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04679415,0,0,0,0,1,0,Indonesia,0,hzvsf-v13|placebo (normal saline solution),NA
NCT04685629,2020-05-07,5/22/2022,Observational,Covid-19 Long-term Revalidation Follow-up,Recruiting,NA,"University Hospital, Antwerp",NA,https://clinicalzeros.gov/ct2/show/NCT04685629,0,0,0,0,2,0,Belgium,0,25 post icu-patients|25 post non-icu patients,NA
NCT04685655,2020-01-07,12/31/2021,Interventional,RescuE pLAsma eXchange in Severe COVID-19,Recruiting,N/A,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04685655,0,0,0,0,1,0,Germany,0,therapeutic plasma exchange (tpe),NA
NCT04685603,2020-12-07,1/31/2021,Interventional,Dendritic Cell Vaccine to Prevent COVID-19,Recruiting,Phase 1,Indonesia-MoH,NA,https://clinicalzeros.gov/ct2/show/NCT04685603,0,0,0,1,1,0,Indonesia,0,av-covid-19,NA
NCT04685447,2020-03-16,4/20/2020,Interventional,Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients,Recruiting,N/A,Universita degli Studi di Genova,NA,https://clinicalzeros.gov/ct2/show/NCT04685447,0,0,0,0,1,0,Italy,0,expanded hemodialysis for covid19 maintenance hemodialysis patients|hemodialysis by protein-leaking dialyzer for covid19 maintenance hemodialysis patients,NA
NCT04685213,2020-08-18,8/18/2021,Interventional,Electrical Stimulation for Critically Ill Covid-19 Patients,Recruiting,Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04685213,0,0,0,0,0,1,United States,0,electrical stimulation|electrical stimulation - sham,NA
NCT04684433,2020-04-14,12/31/2020,Observational,Surgery in the Time of COVID-19 Pandemic,Recruiting,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04684433,0,0,0,0,1,0,Belgium,0,data extraction from medical files,NA
NCT04686578,2020-12-01,2/15/2021,Observational,The Effects of Covid-19 Pandemic on The Patients With Fibromyalgia,Recruiting,NA,Diskapi Yildirim Beyazit Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04686578,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04686565,2020-02-15,2/28/2021,Observational,Covid-19 Pandemic and Cerebral Palsy,Recruiting,NA,Diskapi Yildirim Beyazit Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04686565,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04684615,2021-02-10,7/31/2022,Observational,Mental Health Impact of the COVID-19 Pandemic on Amish and Mennonite Participants in AMBiGen,Enrolling by invitation,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04684615,0,0,0,0,28,1,United States,0,"NA",NA
NCT04682873,2020-05-15,6/1/2021,Interventional,A Clinical Study to Assess the Efficacy and Safety of AmizonÂ® Max in the Treatment of Moderate Covid-19,Recruiting,Phase 3,"Joint Stock Company ""Farmak""",NA,https://clinicalzeros.gov/ct2/show/NCT04682873,0,0,0,0,0,0,Ukraine,0,enisamium iodide|placebo,NA
NCT04682574,2020-11-02,12/30/2020,Interventional,Role of Mega Dose of Vitamin C in Critical COVID-19 Patients,Recruiting,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04682574,0,0,0,0,1,0,Pakistan,0,vitamin c,NA
NCT04682132,2020-05-26,12/31/2020,Observational,Polk COVID-19 and Flu Response,"Active, not recruiting",NA,Polk County Fire Rescue,NA,https://clinicalzeros.gov/ct2/show/NCT04682132,0,0,0,0,0,1,United States,0,"covid-19 antigen/antibody tests,/influenza rapid test|covid-19 antigen|antibody tests,|influenza rapid test",NA
NCT04682093,2020-03-09,1/31/2021,Observational,Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED,Enrolling by invitation,NA,European Society for Emergency Medicine (EUSEM) Research Network,NA,https://clinicalzeros.gov/ct2/show/NCT04682093,0,0,0,0,1,0,Croatia|Finland|France|Greece|Italy,0,"NA",NA
NCT04681950,2020-11-24,12/30/2020,Observational,Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program,Recruiting,NA,Biocerna LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04681950,0,0,0,0,0,1,United States,0,"NA",NA
NCT04681157,2020-04-03,4/3/2021,Observational,Retrospective Study on Anosmias and Ageusias Linked to Infection by Covid-19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04681157,0,0,0,0,1,0,France,0,"NA",NA
NCT04682912,2021-01-30,2/28/2021,Observational,Blood Types in Children With COVID-19,Recruiting,NA,Mersin Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04682912,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04686760,2020-11-15,1/15/2021,Interventional,Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients,Recruiting,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04686760,0,0,0,0,0,0,Pakistan,0,nitroglycerin,NA
NCT04689464,2020-12-01,2/28/2021,Observational,COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients,Recruiting,NA,AlFayhaa General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04689464,0,0,0,0,0,0,Iraq,0,"NA",NA
NCT04694482,2020-11-12,1/31/2021,Observational,The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04694482,0,0,0,0,1,0,Italy,0,psychometric scale administration,NA
NCT04689399,2020-12-26,12/29/2020,Interventional,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04689399,0,0,0,0,1,0,Denmark,0,"standard q covid-19 ag - test, produced by sd biosensor inc.",NA
NCT04686747,2021-01-31,3/1/2021,Observational,COVID - 19 and Advanced Gastro-intestinal Cancer Treatment,Enrolling by invitation,NA,S.M. Misericordia Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04686747,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04693026,2020-09-10,2/15/2021,Interventional,Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients,Recruiting,Phase 3,M Abdur Rahim Medical College and Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04693026,0,0,0,0,0,0,Bangladesh,0,remdesivir|baricitinib|tocilizumab,NA
NCT04691921,2021-01-04,1/18/2021,Observational,Current Pharmacological Practices in Severe COVID-19,Recruiting,NA,NMC Specialty Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04691921,0,0,0,0,3,0,India,0,current clinical practices of participating physicians,NA
NCT04686708,2019-03-11,9/11/2020,Observational,COVID-19 Pandemic and General Surgery Emergencies,Completed,NA,Gulhane Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04686708,0,0,0,0,0,0,Turkey,0,emergency general surgical admissions,NA
NCT04729140,2020-12-28,12/28/2021,Interventional,An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization,Recruiting,Phase 4,"Max Health, Subsero Health",NA,https://clinicalzeros.gov/ct2/show/NCT04729140,0,0,0,0,1,1,United States,0,ivermectin|doxycycline tablets|placebo,NA
NCT04715919,2021-01-15,6/1/2021,Observational,Long Term Outcomes of Coronavirus Disease-19 (COVID-19),Recruiting,NA,Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04715919,0,0,0,0,0,0,Turkey,0,chest computed tomography|pulmonary function tests|six minutes walk test|quality of life,NA
NCT04692129,2020-05-29,12/31/2021,Observational,Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04692129,0,0,0,0,1,0,Brazil|Mexico|Spain,0,"NA",NA
NCT04694573,2020-12-28,12/28/2021,Observational [Patient Registry],Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies,Recruiting,NA,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04694573,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04690816,2021-02-10,12/31/2024,Observational,Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04690816,0,0,0,0,24,1,United States,0,"NA",NA
NCT04706416,2020-11-14,1/15/2021,Interventional,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),"Active, not recruiting",Phase 1,Quantinosis.ai LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04706416,0,0,0,0,0,1,United States,0,n-acetyl glucosamine (nag),NA
NCT04699097,2020-07-01,9/1/2020,Observational,The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children,Completed,NA,Kayseri City Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04699097,0,0,0,0,0,0,Turkey,0,azithromycin,NA
NCT04697030,2020-09-15,10/15/2020,Observational,Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan,Completed,NA,Sialkott College of Physical Therapy,NA,https://clinicalzeros.gov/ct2/show/NCT04697030,0,0,0,0,0,0,Pakistan,0,"NA",NA
NCT04695379,2020-05-26,11/26/2022,Observational,Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection,Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04695379,0,0,0,0,0,0,France,0,"NA",NA
NCT04694014,2020-10-15,5/30/2021,Observational,Emotional Intelligence Skills Health Leaders Need During Covid-19,Enrolling by invitation,NA,African Wood Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04694014,0,0,0,0,0,0,Kenya,0,ei open ended pre-survey/semi structured interview|behavioral/cognitive assessment|geneva emotional competence test (geco)|ei open ended pre-survey|semi structured interview|behavioral|cognitive assessment,NA
NCT04693052,2020-12-10,2/1/2021,Observational,Attitudes Towards Receiving Mental Health Care Using Telehealth During the COVID-19 Pandemic,Enrolling by invitation,NA,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04693052,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04690387,2020-12-07,1/13/2021,Interventional,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","Active, not recruiting",Phase 1,"Aivita Biomedical, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04690387,0,0,0,1,1,0,Indonesia,0,av-covid-19|gm-csf,NA
NCT04695652,2020-12-30,6/30/2021,Interventional,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,Recruiting,Phase 2,Medigen Vaccine Biologics Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04695652,0,0,0,1,3,0,Taiwan|Vietnam,0,mvc-cov1901(s protein with adjuvant)|mvc-cov1901(saline),NA
NCT04699578,2020-12-28,12/31/2021,Observational,COVID-19 Infection and Fetal-neonatal Outcomes,Recruiting,NA,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04699578,0,0,0,0,0,0,Italy,0,covid-19 positive,NA
NCT04690114,2020-10-01,5/31/2021,Observational [Patient Registry],COVID-10 in the Pediatric Population: SARS-CoV-2 Seropositivity,Recruiting,NA,Shaare Zedek Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04690114,0,0,0,0,1,0,Israel,0,"NA",NA
NCT04688372,2020-10-01,2/15/2021,Observational,Hospital COVID-19 Surge and Associated Mortality Risk,"Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04688372,0,0,0,0,1,1,United States,0,surge index,NA
NCT04695158,2021-01-06,1/29/2021,Observational,Blood Sample Measurements and Physical Activity Levels in Type II Diabetes and/or COVID-19,Recruiting,NA,Izmir Bakircay University,NA,https://clinicalzeros.gov/ct2/show/NCT04695158,0,0,0,0,2,0,Turkey,0,covid-19 group (group i)|type ii diabetes mellitus/covid-19 group (group ii)|type ii diabetes mellitus|covid-19 group (group ii),NA
NCT04724538,2020-10-15,2/10/2021,Interventional,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Recruiting,Phase 1/Phase 2,National Medical Research Radiological Centre of the Ministry of Health of Russia,NA,https://clinicalzeros.gov/ct2/show/NCT04724538,0,0,0,0,0,0,Russian Federation,0,99mtc-pertechnetate|99mtc-pertechnetate aerosol,NA
NCT04707833,2020-11-26,12/1/2023,Interventional,Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04707833,0,0,0,0,0,0,France,0,serological testing for covid-19 infection,NA
NCT04694742,2020-09-01,3/31/2021,Observational,Ventilatory Efficiency in Critically Ill COVID-19 Patients,Recruiting,NA,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04694742,0,0,0,0,0,0,Italy,0,data collecting,NA
NCT04707820,2020-04-16,6/10/2021,Interventional,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04707820,0,0,0,0,0,0,France,0,elispot,NA
NCT04691934,2020-03-11,12/25/2020,Observational,Obstetric Anesthesia Experiences in COVID-19 Positive Patients,Completed,NA,Turkiye Yuksek Ihtisas Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04691934,0,0,0,0,0,0,Turkey,0,anesthesia management,NA
NCT04694768,2020-07-01,1/1/2021,Observational,Implementation of Rehabilitation Program for Post COVID-19,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04694768,0,0,0,0,0,0,Egypt,0,rehabilitation,NA
NCT04694716,2021-01-06,1/29/2021,Observational,Determination of Serum Trace Element and Physical Activity Levels in COVID-19,Recruiting,NA,Izmir Bakircay University,NA,https://clinicalzeros.gov/ct2/show/NCT04694716,0,0,0,0,2,0,Turkey,0,no intervention,NA
NCT04694703,2021-01-06,1/29/2021,Observational,"Changing of Trace Element, Homocysteine, Oxidative Stress Parameters and Physical Activity Levels in Covid-19",Recruiting,NA,Izmir Bakircay University,NA,https://clinicalzeros.gov/ct2/show/NCT04694703,0,0,0,0,2,0,Turkey,0,covid-19 group,NA
NCT04689724,2020-08-10,2/28/2021,Observational,Covid-19 Airway Management,Recruiting,NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04689724,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04689477,2020-05-25,12/31/2021,Observational [Patient Registry],Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04689477,0,0,0,0,0,0,Brazil|Mexico|Spain,0,vascular occlusion test,NA
NCT04689542,2021-01-01,8/1/2021,Interventional,Surgical Face Mask Effects in Patients With COVID-19,Recruiting,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04689542,0,0,0,0,2,0,Belgium,0,sit-to-stand test,NA
NCT04695301,2020-07-01,7/1/2021,Interventional,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Recruiting,N/A,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04695301,0,0,0,0,2,0,Brazil,0,rehabilitation protocol through a digital platform,NA
NCT04712344,2021-01-18,9/30/2021,Interventional,Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO),Recruiting,Phase 2,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicalzeros.gov/ct2/show/NCT04712344,0,0,0,0,2,0,Germany,0,convalescent plasma,NA
NCT04701489,2021-01-31,4/30/2021,Interventional,UNITE Study (UMN-GE) for COVID-19,Enrolling by invitation,N/A,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04701489,0,0,0,0,1,1,United States,0,splenic ultrasound,NA
NCT04701502,2020-11-09,2/24/2021,Interventional,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Recruiting,Phase 2,Catalysis SL,NA,https://clinicalzeros.gov/ct2/show/NCT04701502,0,0,0,0,1,0,Bulgaria,0,viusid|asbrip|standard care,NA
NCT04700137,2021-01-18,1/17/2022,Interventional,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era",Enrolling by invitation,N/A,"St. Luke's Health System, Boise, Idaho",NA,https://clinicalzeros.gov/ct2/show/NCT04700137,0,0,0,0,2,1,United States,0,caring contacts/introductory phone call (cc/)|caring contacts without an introductory phone call (cc)|caring contacts|introductory phone call (cc|),NA
NCT04698798,2021-01-31,5/31/2021,Interventional,Skeletal Muscle Wasting in SARS-CoV-2,Recruiting,N/A,Hasselt University,NA,https://clinicalzeros.gov/ct2/show/NCT04698798,0,0,0,0,1,0,Belgium,0,muscle biopsy,NA
NCT04698083,2020-07-22,10/15/2020,Observational,"Electrocardiographic QRS Axis Shift ,Rotation and COVÄ°D-19",Completed,NA,Ankara Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04698083,0,0,0,0,0,0,Turkey,0,"electrocardiography ,tomographic imaging",NA
NCT04697927,2020-12-30,12/31/2022,Observational,A Study of Risk Factors for the COVID-19 Virus Infection,Recruiting,NA,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04697927,0,0,0,0,2,1,United States,0,questionnaire,NA
NCT04698382,2020-08-01,4/1/2021,Observational,"Impact of COVID-19 on the Incidence, Characteristics, Management and Outcome of Sepsis","Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04698382,0,0,0,0,0,1,United States,0,"NA",NA
NCT04698044,2020-05-08,6/25/2020,Observational,Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period,Completed,NA,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",NA,https://clinicalzeros.gov/ct2/show/NCT04698044,0,0,0,0,1,0,Turkey,0,hospital anxiety depression scale,NA
NCT04700163,2021-01-11,6/15/2021,Interventional,RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers,Recruiting,Phase 1,Rockefeller University,NA,https://clinicalzeros.gov/ct2/show/NCT04700163,0,0,0,0,2,1,United States,0,c144-ls/c-135-ls|c144-ls|c-135-ls,NA
NCT04709003,2020-12-23,6/30/2022,Observational,Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI),Recruiting,NA,Clalit Health Services,NA,https://clinicalzeros.gov/ct2/show/NCT04709003,0,0,0,0,0,0,Israel,0,serologic test|respiratory swabs,NA
NCT04695756,2020-12-15,6/15/2021,Observational,Liver Transplantation and Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04695756,0,0,0,0,1,0,Argentina,0,covid-19 pandemic,NA
NCT04703608,2021-01-31,3/31/2022,Interventional,Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia,Recruiting,Phase 3,London School of Hygiene and Tropical Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04703608,0,0,0,0,2,0,Gambia,0,ivermectin|asp|placebo,NA
NCT04702945,2020-03-01,12/31/2022,Observational [Patient Registry],Canadian COVID-19 Emergency Department Registry,Recruiting,NA,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04702945,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04701996,2020-09-23,11/20/2021,Observational,Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo,Recruiting,NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04701996,0,0,0,0,1,0,"Congo, The Democratic Republic of the",0,serological surveillance,NA
NCT04699227,2020-04-23,4/30/2021,Interventional,Can RIC Prevent Deterioration to Critical Care in Covid19,Recruiting,N/A,University College London Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04699227,0,0,0,0,0,0,United Kingdom,0,cuff application with inflation|sham inflation,NA
NCT04703036,2021-01-11,12/31/2021,Interventional,"Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19",Recruiting,Early Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04703036,0,0,0,0,2,1,United States,0,glycine|n-acetylcysteine|alanine,NA
NCT04712357,2020-11-09,1/31/2022,Interventional,Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19,Recruiting,N/A,Universidade Federal do Ceara,NA,https://clinicalzeros.gov/ct2/show/NCT04712357,0,0,0,0,0,0,Brazil,0,vitamin c 500 mg oral tablet|tenofovir disoproxyl fumarate 300 mg oral tablet|tenofovir disoproxyl fumarate 300 mg/emtricitabine 200 mg oral tablet|tenofovir disoproxyl fumarate 300 mg|emtricitabine 200 mg oral tablet,NA
NCT04703907,2020-12-03,8/31/2021,Interventional,Auricular Stimulation for Relief of Stress and Anxiety,Recruiting,N/A,University Medicine Greifswald,NA,https://clinicalzeros.gov/ct2/show/NCT04703907,0,0,0,0,0,0,Germany,0,auricular stimulation,NA
NCT04703777,2020-04-04,4/4/2021,Observational,Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 Epidemic,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04703777,0,0,0,0,0,0,France,0,"NA",NA
NCT04707742,2020-06-15,11/18/2020,Interventional,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Completed,N/A,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,NA,https://clinicalzeros.gov/ct2/show/NCT04707742,0,0,0,0,0,0,Spain,0,betadineâ© bucal 100 mg/ml|oximenâ® 3%|clorhexidine dental phbâ©|vitis xtra forteâ©|distilled water|betadineâ© bucal 100 mg|methylprednisolone,NA
NCT04704466,2021-01-07,6/30/2021,Observational,Impact of Covid-19 Pandemic on Management of Head and Neck Cancers,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04704466,0,0,0,0,1,0,France,0,"NA",NA
NCT04705831,2020-12-30,1/31/2022,Interventional,Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection,Recruiting,Phase 4,IMMUNOe Research Centers,NA,https://clinicalzeros.gov/ct2/show/NCT04705831,0,0,0,0,0,1,United States,0,ruconest,NA
NCT04715243,2021-01-31,4/30/2021,Interventional,"Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients",Recruiting,N/A,Sultan Qaboos University,NA,https://clinicalzeros.gov/ct2/show/NCT04715243,0,0,0,0,1,0,Oman,0,high flow nasal cannula (hfnc)|helmet niv|face-mask niv,NA
NCT04713878,2020-05-08,6/30/2020,Interventional,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713878,0,0,0,0,1,0,Turkey,0,mesenchymal stem cells,NA
NCT04710771,2020-11-23,1/15/2021,Observational,Effect of Prone Positioning in Patients With COVID-19,Recruiting,NA,Sialkott College of Physical Therapy,NA,https://clinicalzeros.gov/ct2/show/NCT04710771,0,0,0,0,1,0,Pakistan,0,prone lying position|alternate nostril breathing,NA
NCT04704388,2020-06-01,1/31/2021,Observational,Study Project Comparing the Sequelae of SARS-CoV-2 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical Care,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04704388,0,0,0,0,0,0,France,0,"NA",NA
NCT04709744,2020-04-01,12/25/2020,Observational,Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic,Completed,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04709744,0,0,0,0,1,0,Egypt,0,vitamin d|elisa,NA
NCT04703452,2021-01-19,1/31/2022,Observational,poSt Covid-19 Infection centraL sENsitisaTion,Recruiting,NA,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04703452,0,0,0,0,1,0,Belgium,0,indicators of central sensitisation,NA
NCT04703270,2021-01-04,1/3/2023,Observational,Understanding COVID-19 Infection in Pregnant Women and Their Babies,Recruiting,NA,"St George's, University of London",NA,https://clinicalzeros.gov/ct2/show/NCT04703270,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04724616,2021-01-06,6/30/2021,Interventional,CARTOON: CoronAviRus (COVID-19) educaTional prOgram fOr childreN,Recruiting,N/A,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04724616,0,0,0,0,0,0,Austria,0,educational program (cartoon),NA
NCT04701944,2020-04-21,4/21/2021,Observational,Clinical Study of Pregnant Women With COVID-19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04701944,0,0,0,0,0,0,France,0,"NA",NA
NCT04701905,2020-04-30,4/30/2021,Observational,The Offer of Neurosurgery Care in the Grand Est of France During the Health Crisis Linked to Covid-19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04701905,0,0,0,0,0,0,France,0,"NA",NA
NCT04701892,2021-01-19,1/31/2023,Observational,poSt Covid-19 Infection centraL Sensitisation 2,Recruiting,NA,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04701892,0,0,0,0,1,0,Belgium,0,indicators of central sensitisation,NA
NCT04701710,2020-10-15,12/18/2020,Interventional,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,Completed,Phase 1/Phase 2,"Ministry of Public Health, Argentina",NA,https://clinicalzeros.gov/ct2/show/NCT04701710,0,0,0,0,1,0,Argentina,0,ivermectin / iota-carrageenan|ivermectin|iota-carrageenan,NA
NCT04713111,2020-05-04,11/30/2020,Interventional,Stress and Recovery in Frontline COVID-19 Workers,Completed,N/A,4YouandMe,NA,https://clinicalzeros.gov/ct2/show/NCT04713111,0,0,0,0,0,1,United States,0,lifestyle (meditation)|lifestyle (exercise),NA
NCT04712045,2020-08-01,12/12/2020,Interventional,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Completed,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04712045,0,0,0,0,0,0,United Kingdom,0,new ppe|old ppe,NA
NCT04708236,2021-01-31,5/31/2021,Interventional,A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia,Recruiting,Phase 1/Phase 2,"Oryn Therapeutics, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04708236,0,0,0,0,0,1,United States,0,ortd-1 low dose|ortd-1 mid dose|ortd-1 high dose|vehicle control,NA
NCT04706533,2020-03-23,6/30/2021,Observational,"Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19",Recruiting,NA,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04706533,0,0,0,0,0,1,United States,0,biomarkers of inflammation,NA
NCT04706260,2020-04-14,4/14/2021,Observational,Clinical Evolution and Becoming of Adult Patients Infected With Covid-19 Hospitalized at Strasbourg University Hospitals,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04706260,0,0,0,0,0,0,France,0,"NA",NA
NCT04708912,2020-12-15,1/20/2021,Observational,Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19),Recruiting,NA,Basaksehir Cam & Sakura Åžehir Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04708912,0,0,0,0,1,0,Turkey,0,observation,NA
NCT04706390,2021-01-12,1/12/2022,Observational,Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination,Recruiting,NA,University of Bergen,NA,https://clinicalzeros.gov/ct2/show/NCT04706390,0,0,0,0,0,0,Norway,0,covid-19 vaccine,NA
NCT04706325,2021-01-01,5/1/2021,Observational,COVID-19 RELATED KIDNEY DAMAGE,Recruiting,NA,Kocaeli Derince Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04706325,0,0,0,0,0,0,Turkey,0,acute kidney injury,NA
NCT04707534,2021-01-21,5/21/2021,Interventional,Dexamethasone for COVID-19,Recruiting,Phase 4,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04707534,0,0,0,0,1,1,United States,0,dexamethasone,NA
NCT04715438,2021-01-08,7/31/2021,Observational,Vaccination Against COVID-19 in Cancer,Recruiting,NA,University Medical Center Groningen,NA,https://clinicalzeros.gov/ct2/show/NCT04715438,0,0,0,0,1,0,Netherlands,0,"NA",NA
NCT04724720,2021-01-19,12/31/2021,Interventional,Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19,Recruiting,Phase 2,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04724720,0,0,0,0,0,1,United States,0,famotidine|placebo,NA
NCT04716985,2021-01-22,7/22/2021,Interventional,Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care,Recruiting,N/A,AGIR Ã  Dom,NA,https://clinicalzeros.gov/ct2/show/NCT04716985,0,0,0,0,2,0,France,0,molecular hydrogen|placebo magnesium,NA
NCT04720404,2020-06-23,2/28/2022,Interventional,Mindful Prevention of Psychopathology in Healthcare Workers During the COVID-19 Crisis (COVID-19 MindPreP),Recruiting,N/A,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04720404,0,0,0,0,0,0,Netherlands,0,mindfulness-based stress reduction|self-help mindfulness/compassion exercises|support as usual|self-help mindfulness|compassion exercises,NA
NCT04712448,2020-12-30,6/30/2021,Observational,Serum Prevalence of Dars-Cov-2 Antibodies in Pre-pandemic Blood Samples (SPARE),"Active, not recruiting",NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04712448,0,0,0,0,0,0,Italy,0,anti-covid test,NA
NCT04715607,2021-01-22,3/5/2021,Interventional,"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens",Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04715607,0,0,0,0,2,0,Denmark,0,sequence of testing.,NA
NCT04711954,2020-11-01,11/1/2021,Observational [Patient Registry],HIV/COV in Ukraine-NL,Recruiting,NA,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04711954,0,0,0,0,0,0,Netherlands|Ukraine,0,"NA",NA
NCT04711863,2021-01-16,5/31/2021,Interventional,Fluvoxamine for Adults With Mild to Moderate COVID-19,Recruiting,Phase 2,Asan Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04711863,0,0,0,0,1,0,"Korea, Republic of",0,fluvoxamine|placebo,NA
NCT04710394,2021-01-11,3/11/2022,Interventional,Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell,Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04710394,0,0,0,0,3,1,United States,0,smell training,NA
NCT04709302,2021-02-28,6/30/2022,Observational [Patient Registry],Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04709302,0,0,0,0,0,0,Nigeria|South Africa,0,covid-19|hiv|art,NA
NCT04709172,2021-01-05,4/5/2021,Interventional,Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia,Recruiting,Phase 4,Meiji Pharma Spain S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04709172,0,0,0,0,1,0,Spain,0,cefditoren pivoxil 400mg,NA
NCT04710329,2021-01-16,1/25/2021,Observational,High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients,"Active, not recruiting",NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04710329,0,0,0,0,3,0,Turkey,0,vitamin c,NA
NCT04709120,2021-01-11,3/31/2021,Observational [Patient Registry],Analysis of Health Status of Ð¡omorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection,Recruiting,NA,Eurasian Association of Therapists,NA,https://clinicalzeros.gov/ct2/show/NCT04709120,0,0,0,0,1,0,Russian Federation,0,"NA",NA
NCT04734912,2021-01-13,6/15/2021,Interventional,Evaluation of Transnasal Endoscopy During COVID-19 Pandemic,Recruiting,N/A,Johannes Gutenberg University Mainz,NA,https://clinicalzeros.gov/ct2/show/NCT04734912,0,0,0,0,0,0,Germany,0,gastroscopy in transnasal techique,NA
NCT04724434,2020-12-04,6/30/2021,Observational,Follow-up Study of COVID-19 Patients in the District Konstanz,Enrolling by invitation,NA,Hegau-Bodensee-Klinikum Singen,NA,https://clinicalzeros.gov/ct2/show/NCT04724434,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04716088,2020-11-18,12/2/2020,Observational,Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19,Completed,NA,The University Clinic of Pulmonary and Allergic Diseases Golnik,NA,https://clinicalzeros.gov/ct2/show/NCT04716088,0,0,0,0,1,0,Slovenia,0,rapid antigen test for sars cov2,NA
NCT04715477,2021-01-17,4/1/2021,Observational,Intensive Care Anxiety in SARS-CoV-2 Patients,Recruiting,NA,Derince Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04715477,0,0,0,0,0,0,Turkey,0,hospital anxiety depression measure,NA
NCT04715360,2020-12-29,11/29/2021,Interventional,Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy,Recruiting,Phase 1/Phase 2,Hayandra Peduli Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04715360,0,0,0,0,0,0,Indonesia,0,autologous activated platelet-rich plasma|avigan,NA
NCT04713488,2021-01-15,7/20/2021,Interventional,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","Active, not recruiting",Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04713488,0,0,0,1,2,0,Russian Federation,0,sputnik light,NA
NCT04723576,2020-12-03,2/28/2022,Interventional,Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19),Recruiting,N/A,RAND,NA,https://clinicalzeros.gov/ct2/show/NCT04723576,0,0,0,0,0,1,United States,0,stress first aid,NA
NCT04714333,2020-05-06,5/5/2021,Observational,Detection of Covid-19 by Volatile Organic Compounds in Exhaled Breath,Enrolling by invitation,NA,British Columbia Cancer Agency,NA,https://clinicalzeros.gov/ct2/show/NCT04714333,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04713852,2020-03-13,9/30/2020,Observational,Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients,Completed,NA,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713852,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04716556,2020-07-16,5/31/2021,Interventional,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,"Active, not recruiting",N/A,Istituto Superiore di SanitÃ ,NA,https://clinicalzeros.gov/ct2/show/NCT04716556,0,0,0,0,0,0,Italy,0,convalescent plasma,NA
NCT04724707,2020-09-11,12/31/2021,Observational [Patient Registry],Russian Cardiovascular Registry of COVID-19,Recruiting,NA,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,https://clinicalzeros.gov/ct2/show/NCT04724707,0,0,0,0,0,0,Russian Federation,0,"NA",NA
NCT04714125,2020-06-19,2/1/2021,Observational,Prognostic Value of Flow-mediated Dilation in Hospitalized COVID-19 Patients,Recruiting,NA,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04714125,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04718506,2021-01-12,6/12/2021,Interventional,Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention,Recruiting,N/A,Universidad de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04718506,0,0,0,0,0,0,Spain,0,exercise|controls,NA
NCT04714138,2021-01-05,2/20/2021,Observational,Remote Video Consultation for Quality of Life Assessment in Patients Hospitalised After COVID-19 Infection,Recruiting,NA,Groupe Hospitalier du Havre,NA,https://clinicalzeros.gov/ct2/show/NCT04714138,0,0,0,0,1,0,France,0,"NA",NA
NCT04714008,2020-12-01,12/31/2022,Observational,Covid-19 and ONline GAmbling,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04714008,0,0,0,0,0,0,France,0,"NA",NA
NCT04713540,2021-01-01,4/1/2021,Observational,Rehabilitation in Intensive Care Unit,Recruiting,NA,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713540,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04716998,2021-01-31,1/31/2022,Interventional,Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19,Recruiting,Phase 1/Phase 2,BonusBio Group Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04716998,0,0,0,0,1,0,Israel,0,mesencure,NA
NCT04716179,2021-01-18,5/18/2021,Interventional,Prospective Two-arm Study of Fertility in Men With COVID-19,Recruiting,N/A,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04716179,0,0,0,0,0,0,Russian Federation,0,"sperm test|hormone levels (testosterone, fsh, lh, prolactin)|sars-cov-2 ig g levels|testis pathology samples",NA
NCT04716465,2021-01-19,1/31/2023,Observational,Dysautonomia in Patients Post COVID-19 Infection,Recruiting,NA,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04716465,0,0,0,0,1,0,Belgium,0,dysautonomia,NA
NCT04726371,2021-01-08,10/31/2022,Interventional,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Recruiting,N/A,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04726371,0,0,0,0,0,1,United States,0,generic best practices|tailored best practices,NA
NCT04720235,2020-12-09,3/9/2021,Interventional,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,Recruiting,N/A,Lucira Health Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04720235,0,0,0,0,0,1,United States,0,lucira covid-19 all-in-one test kit,NA
NCT04719182,2020-09-01,1/1/2021,Observational,Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19,"Active, not recruiting",NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicalzeros.gov/ct2/show/NCT04719182,0,0,0,0,0,0,Netherlands,0,adjunctive therapies,NA
NCT04723459,2021-01-23,2/19/2021,Interventional,Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff,Recruiting,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04723459,0,0,0,0,1,0,Egypt,0,ivermectin impregnated mask,NA
NCT04718480,2020-11-27,8/31/2021,Interventional,Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients,Recruiting,Phase 2,SigmaDrugs Research Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04718480,0,0,0,0,0,0,Hungary,0,placebo|fluvoxamine,NA
NCT04716647,2020-10-09,12/12/2020,Interventional,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04716647,0,0,0,0,0,0,United Kingdom,0,ayurveda,NA
NCT04715997,2020-12-30,5/30/2021,Interventional,"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults",Recruiting,Phase 1/Phase 2,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04715997,0,0,0,1,0,0,"Korea, Republic of",0,gx-19n,NA
NCT04721236,2020-11-19,11/19/2021,Interventional,Early Use of Hyperimmune Plasma in COVID-19,Recruiting,N/A,IRCCS Policlinico S. Matteo,NA,https://clinicalzeros.gov/ct2/show/NCT04721236,0,0,0,0,0,0,Italy,0,convalescent plasma,NA
NCT04716426,2021-01-28,2/28/2021,Interventional,APTâ„¢ T3X on the COVID-19 Contamination Rate,Recruiting,N/A,University of Nove de Julho,NA,https://clinicalzeros.gov/ct2/show/NCT04716426,0,0,0,0,2,0,Brazil,0,tetracycline hydrochloride 3%|placebo,NA
NCT04719234,2020-06-15,12/1/2020,Interventional,Lung Ultrasonography in COVID-19 Pneumonia,Completed,N/A,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04719234,0,0,0,0,0,0,Turkey,0,lung ultrasonography,NA
NCT04718519,2020-06-22,10/11/2020,Observational,Individual and Institutional Resilience in Migrant Workers During the COVID-19 Pandemic,Completed,NA,Yale-NUS College,NA,https://clinicalzeros.gov/ct2/show/NCT04718519,0,0,0,0,0,0,Singapore,0,factors promoting resilience,NA
NCT04730427,2021-01-31,5/31/2021,Interventional,Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19,Recruiting,Phase 1,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04730427,0,0,0,0,0,0,"Korea, Republic of",0,gx-i7|gx-i7 vehicle,NA
NCT04717024,2020-09-15,12/31/2021,Observational,The Nanowear Wearable Covid-19 Observational and Analysis Trend,Recruiting,NA,Nanowear Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04717024,0,0,0,0,0,1,United States,0,observational study - no intervention,NA
NCT04717011,2021-01-31,7/31/2021,Observational,Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients,Recruiting,NA,Igenomix,NA,https://clinicalzeros.gov/ct2/show/NCT04717011,0,0,0,0,1,0,Spain,0,pcr test,NA
NCT04726111,2020-12-30,7/30/2021,Interventional,COVID-19 and Pregnancy: Placental and Immunological Impacts,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04726111,0,0,0,0,0,0,France,0,specimens specific for the study,NA
NCT04716569,2021-01-20,2/1/2021,Interventional,Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19,Recruiting,Phase 2/Phase 3,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04716569,0,0,0,0,1,0,Egypt,0,intranasal ivermectin spray,NA
NCT04729075,2021-01-19,1/19/2021,Observational [Patient Registry],"Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset",Completed,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04729075,0,0,0,0,0,1,United States,0,ards/covid19 treatments|ards|covid19 treatments,NA
NCT04728919,2021-01-15,1/15/2022,Observational,Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection,Recruiting,NA,Tampere University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04728919,0,0,0,0,0,0,Finland,0,"NA",NA
NCT04730661,2020-12-21,12/21/2021,Interventional,Efficacy of the Sit to Stand Test (STST) in the Decision to Hospitalize a Patient Consulting the Emergency Department for COVID 19 (Coronavirus Infectious Disease),Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04730661,0,0,0,0,0,0,France,0,sit to stand test,NA
NCT04725084,2020-07-01,12/15/2020,Observational,Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome,Completed,NA,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,https://clinicalzeros.gov/ct2/show/NCT04725084,0,0,0,0,0,0,France,0,use of high flow nasal cannula alone|use of non-invasive ventilation|use of continuous positive airway pressure,NA
NCT04723550,2021-01-05,11/5/2021,Interventional,COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes,Recruiting,N/A,Xuzhou No.1 Peoples Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04723550,0,0,0,0,1,0,China,0,hospital telemedicine management system|standard care,NA
NCT04726163,2021-01-29,6/14/2021,Interventional,Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection,Recruiting,N/A,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04726163,0,0,0,0,1,0,France,0,continuous blind glucose measurement device (free style pro),NA
NCT04717089,2020-02-10,1/31/2021,Observational,Extended Recovery During COVID-19: Multi-perspective Value-based Analysis,Recruiting,NA,Tuen Mun Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04717089,0,0,0,0,2,0,Hong Kong,0,overnight intensive recovery / extended recovery|overnight intensive recovery|extended recovery,NA
NCT04724642,2020-12-28,5/28/2021,Observational,"COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency",Recruiting,NA,Tel-Aviv Sourasky Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04724642,0,0,0,0,1,0,Israel,0,"NA",NA
NCT04723290,2020-06-20,10/31/2020,Interventional,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,Completed,N/A,Grand HÃ´pital de Charleroi,NA,https://clinicalzeros.gov/ct2/show/NCT04723290,0,0,0,0,1,0,Belgium,0,serological tests for sars cov-2,NA
NCT04727424,2021-01-19,2/1/2022,Interventional,Repurposed Approved Therapies for Outpatient Treatment of Patients With Early-Onset COVID-19 and Mild Symptoms,Recruiting,Phase 3,Cardresearch,NA,https://clinicalzeros.gov/ct2/show/NCT04727424,0,0,0,0,0,0,Brazil,0,fluvoxamine maleate 100 mg [luvox]|metformin extended release oral tablet|ivermectin|placebo,NA
NCT04726865,2020-10-01,12/20/2020,Observational,COVID-19 Pandemic and Medical Students,Completed,NA,University of Jordan,NA,https://clinicalzeros.gov/ct2/show/NCT04726865,0,0,0,0,0,0,Jordan,0,naser al-husban,NA
NCT04725097,2020-12-10,7/31/2021,Observational,A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04725097,0,0,0,0,0,1,United States|India|Spain|United Kingdom,0,"NA",NA
NCT04729491,2020-06-30,9/15/2020,Interventional,EAT-DUTA AndroCoV Trial,Completed,Phase 2/Phase 3,Corpometria Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04729491,0,0,0,0,0,0,Brazil,0,dutasteride 0.5 mg|azithromycin|nitazoxanide|placebo,NA
NCT04729452,2020-06-01,10/1/2023,Observational,Characterisation of the Immune Response to SARS-CoV-2,Recruiting,NA,Cwm Taf University Health Board (NHS),NA,https://clinicalzeros.gov/ct2/show/NCT04729452,0,0,0,0,0,0,United Kingdom,0,blood test,NA
NCT04727775,2020-11-25,1/25/2021,Interventional,Antiviral Drugs on the Treatment of SARS-CoV-2,Recruiting,Phase 1,Astana Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04727775,0,0,0,0,0,0,Kazakhstan,0,favipiravir|remdesivir,NA
NCT04727372,2021-01-23,2/23/2021,Observational [Patient Registry],Social Acceptability of COVID-19 Vaccines in Pakistan,Enrolling by invitation,NA,Islamia University of Bahawalpur,NA,https://clinicalzeros.gov/ct2/show/NCT04727372,0,0,0,0,0,0,Pakistan,0,questionnaire,NA
NCT04723524,2020-09-22,6/30/2021,Interventional,Jinhua Qinggan Granules in the Treatment of COVID-19,Recruiting,Phase 2,University of Karachi,NA,https://clinicalzeros.gov/ct2/show/NCT04723524,0,0,0,0,2,0,Pakistan,0,"jinhua qinggan (jhqg) granules, traditional chinese medicine|placebo",NA
NCT04738695,2021-02-01,3/31/2022,Observational,SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19),Recruiting,NA,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04738695,0,0,0,0,0,0,Belgium,0,point-of-care rapid anti-sars-cov-2 antibody test (orient gene biotech)/dry blood spot collection (euroimmun)|point-of-care rapid anti-sars-cov-2 antibody test (orient gene biotech)|dry blood spot collection (euroimmun),NA
NCT04727762,2021-02-04,3/1/2021,Observational,Use of the Mask and Current Pandemic,Recruiting,NA,University of Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04727762,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04729374,2021-01-27,12/31/2023,Observational,COVID-19 Vaccine Induced Adaptive Immune Responses,Recruiting,NA,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,NA,https://clinicalzeros.gov/ct2/show/NCT04729374,0,0,0,0,2,0,China,0,"NA",NA
NCT04726176,2021-01-30,7/1/2021,Observational,COVID-19 and the Brain,Recruiting,NA,Vrije Universiteit Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04726176,0,0,0,0,1,0,Belgium,0,exposure to covid-19,NA
NCT04726098,2021-01-15,6/30/2021,Interventional,Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Recruiting,Phase 4,Hospital Clinico Universitario de Santiago,NA,https://clinicalzeros.gov/ct2/show/NCT04726098,0,0,0,0,0,0,Spain,0,dexamethasone high dose|dexamethasone low dose,NA
NCT04727294,2021-01-22,6/30/2021,Observational,"MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey",Recruiting,NA,HealthTree Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04727294,0,0,0,0,0,1,United States,0,questionnaire,NA
NCT04728880,2021-01-26,3/31/2021,Observational,Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience,Recruiting,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04728880,0,0,0,0,0,0,Egypt,0,remdesivir,NA
NCT04728828,2021-01-25,2/15/2023,Observational,COVADIAL - Immunogenicity of COVID-19 Vaccine in Hemodialysis Patients,Recruiting,NA,Centre Hospitalier de Cornouaille,NA,https://clinicalzeros.gov/ct2/show/NCT04728828,0,0,0,0,0,0,France,0,serological covid-19 vaccine immunogenicity,NA
NCT04731116,2021-01-10,12/31/2021,Interventional,Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection,Recruiting,Phase 1/Phase 2,Rabin Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04731116,0,0,0,0,0,0,Israel,0,cannabidiol,NA
NCT04730401,2021-01-27,8/31/2021,Interventional,Convalescent Plasma in the Treatment of Covid-19,Recruiting,Phase 2,Helsinki University Central Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04730401,0,0,0,0,0,0,Finland,0,convalescent plasma|placebo,NA
NCT04733807,2021-01-28,7/31/2021,Observational,Antibodies Response to mRNA Vaccine Against Covid-19,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicalzeros.gov/ct2/show/NCT04733807,0,0,0,0,0,0,Italy,0,bnt162b2 mrna covid-19 vaccine,NA
NCT04732949,2021-01-12,6/1/2021,Interventional,Study to Assess Efficacy and Safety of Inhaled Interferon-Î² Therapy for COVID-19,Recruiting,Phase 3,Synairgen Research Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04732949,0,0,0,0,0,0,United Kingdom,0,sng001|placebo,NA
NCT04728594,2021-01-15,1/17/2021,Interventional,Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,N/A,Geisinger Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04728594,0,0,0,1,1,1,United States,0,social proof|reframing|scarcity message,NA
NCT04730934,2021-01-01,2/15/2021,Observational [Patient Registry],Effects of the COVID-19 Pandemic on Fibromyalgia Patients,Recruiting,NA,Kars State Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04730934,0,0,0,0,1,0,Turkey,0,"perceived stress scale|fibromyalgia impact questionnaire|the drugs used before/during the pandemic, the patient's job status, physical activity conditions, pain status|the drugs used before|during the pandemic, the patient's job status, physical activity conditions, pain status",NA
NCT04740320,2020-12-15,5/31/2021,Observational [Patient Registry],COVID-19 SARS-CoV-2 Screening Protocol,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04740320,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04732702,2020-10-29,1/31/2021,Observational,Effects of Contact Restrictions During the COVID-19 Pandemic on Newborns and Their Parents,Recruiting,NA,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04732702,0,0,0,0,1,0,Germany,0,no intervention,NA
NCT04733833,2021-01-26,6/30/2022,Interventional,A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19,Recruiting,Phase 2,Vascular Biogenics Ltd. operating as VBL Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04733833,0,0,0,0,0,0,Israel,0,vb-201 / standard of care|standard care|vb-201,NA
NCT04734873,2021-02-01,12/30/2021,Interventional,CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients,Recruiting,Phase 3,"Corvus Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04734873,0,0,0,0,0,1,United States|Argentina|Brazil|Canada|Colombia|France|Germany|Israel|Italy|Mexico|Peru|South Africa|Spain|Ukraine,0,cpi-006 2 mg/kg / soc|cpi-006 1 mg/kg / soc|placebo / soc|cpi-006 2 mg|kg|standard care|cpi-006 1 mg|placebo,NA
NCT04734171,2020-04-02,4/16/2020,Interventional,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak",Completed,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04734171,0,0,0,0,0,1,United States,0,digital social activity video intervention|informational sheet|stigma awareness video intervention,NA
NCT04732858,2020-03-01,8/31/2020,Observational,"Educational Interventions for Surgeons During COVID-19 Pandemic: Cross-sectional, E-survey","Active, not recruiting",NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04732858,0,0,0,0,0,0,France,0,cross sectional e-survey on surgeons exposed to any educational intervention,NA
NCT04732819,2021-01-04,4/19/2021,Interventional,Improving COVID-19 Vaccine Uptake in Nursing Homes,Recruiting,N/A,Brown University,NA,https://clinicalzeros.gov/ct2/show/NCT04732819,0,0,0,1,0,1,United States,0,high touch multi-pronged behavioral intervention,NA
NCT04740372,2020-11-20,6/30/2021,Observational,"Development of an International COVID-19 Specific Quality of Life Questionnaire, Phase III. The OSLO COVID-19 QLQ",Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04740372,0,0,0,0,0,0,Norway,0,no intervention. method study. psychometric testing,NA
NCT04740125,2020-05-01,7/31/2020,Observational,SURVEY ABOUT STRESS-COVID IN HEALTH CARE WORKERS IN NORTH AFRICA COUNTRY,Completed,NA,"General Administration of Military Health, Tunisia",NA,https://clinicalzeros.gov/ct2/show/NCT04740125,0,0,0,0,0,0,Tunisia,0,"NA",NA
NCT04734223,2020-04-01,12/31/2020,Observational,Neuroimaging Findings in Patients With COVID-19,Completed,NA,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04734223,0,0,0,0,1,0,Turkey,0,neuroimaging findings in patients with covid-19,NA
NCT04734678,2020-12-01,3/1/2021,Observational,Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04734678,0,0,0,0,0,0,Egypt,0,tocilizumab|infliximab,NA
NCT04733625,2020-09-15,12/17/2020,Interventional,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,N/A,Kasr El Aini Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04733625,0,0,0,0,0,0,Egypt,0,cholecalciferol|placebo,NA
NCT04738045,2020-11-01,2/1/2021,Interventional,Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients,"Active, not recruiting",Phase 4,October 6 University,NA,https://clinicalzeros.gov/ct2/show/NCT04738045,0,0,0,0,0,0,Egypt,0,remdesivir|lopinavir/ ritonavir/remdesivir combination|lopinavir|ritonavir|remdesivir combination,NA
NCT04734717,2021-01-12,4/12/2021,Interventional,Coordination and Locomotor Problems in Patients With Covid-19 Virus,Enrolling by invitation,N/A,Somogy Megyei Kaposi MÃ³r Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04734717,0,0,0,0,0,0,Hungary,0,neurology test,NA
NCT04741412,2020-06-03,5/31/2021,Observational [Patient Registry],"Pediatric SARS-CoV-2 Infections: Course of COVID-19, Immune Responses, Complications and Long-term Consequences",Recruiting,NA,University Hospital Erlangen,NA,https://clinicalzeros.gov/ct2/show/NCT04741412,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04739020,2021-01-18,6/30/2021,Interventional,Aerosols in PCR SARS-CoV-2 Positive and Negative Patients,Recruiting,N/A,Johann Wolfgang Goethe University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04739020,0,0,0,0,0,0,Germany,0,resp-aer-meter|spirometry|qualitative/quantitative virus pcr of respiratory secretions in patients with high aerosol concentrations|qualitative|quantitative virus pcr of respiratory secretions in patients with high aerosol concentrations,NA
NCT04738760,2020-12-01,4/1/2021,Observational,Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04738760,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04736901,2020-12-01,4/1/2021,Observational,Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04736901,0,0,0,0,1,0,Egypt,0,enoxaparin|rivaroxaban|apixaban,NA
NCT04736732,2021-01-01,1/1/2023,Observational,The IRCM POST-COVID-19 (IPCO) Clinic,Recruiting,NA,Institut de Recherches Cliniques de Montreal,NA,https://clinicalzeros.gov/ct2/show/NCT04736732,0,0,0,0,0,0,Canada,0,medical follow-up,NA
NCT04736524,2021-01-15,3/31/2022,Observational,Immune Response Following COVID-19 Vaccination,Recruiting,NA,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04736524,0,0,0,0,0,1,United States,0,rapid antibody test,NA
NCT04739410,2020-05-01,6/30/2020,Interventional,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,https://clinicalzeros.gov/ct2/show/NCT04739410,0,0,0,0,0,0,Pakistan,0,ivermectin,NA
NCT04738331,2021-02-01,5/20/2022,Observational,Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04738331,0,0,0,0,0,0,France,0,"NA",NA
NCT04738032,2020-08-26,1/7/2021,Observational,Stories for Change: Digital Storytelling Intervention for Diabetes Self-Management in the COVID-19 Pandemic,Completed,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04738032,0,0,0,0,0,1,United States,0,digital storytelling intervention,NA
NCT04741178,2020-03-20,1/2/2021,Observational,PAtterns and Extension in Sars-Cov-2 Related Interstitial Pneumonia: CT Analysis,Recruiting,NA,Morgagni Pierantoni Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04741178,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04739345,2020-12-01,4/1/2021,Observational,New Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04739345,0,0,0,0,0,0,Egypt,0,"NA",NA
